feel better live longer august interim update updates information corporate responsibility report published march inserted relevant sections report highlighted blue boxes similar style text responsibility great west road brentford middlesex tw gs uk tel corporate responsibility report contents downloaded full corporate responsibility report corporate responsibility gsk research practices message ceo emerging technologies corporate responsibility principles cloning technology stem cell research genetic research business case corporate responsibility collaborative research emerging technologies key issues animal research corporate responsibility governance human tissue research stakeholder engagement medical governance reporting clinical research benchmarking planning approval assurance internal audit informed consent corporate responsibility data summary posttrial treatment resources downloads clinical trials developing world public disclosure clinical research contribution global health patient safety cost disease patient safety governance framework role vaccines collecting reporting safety data performance treating ill health disease awareness prevention maintaining confidentiality research participants investing rd working healthcare professionals contributing scientific understanding training auditing preparing pandemic flu case studies qas qas access medicines ethical conduct approach contribution code conduct business ethics role others marketing ethics developing countries relationships healthcare professionals research development directtoconsumer advertising publicprivate partnerships training awareness product registrations leading example preferential pricing performance plans pricing middleincome countries monitoring compliance developed countries case studies pricing medicines qas intellectual property future response assurance recommendations case studies qas corporate responsibility report contents supply chain people responsibility supply chain culture behaviours human rights clause restructuring choosing suppliers consultation monitoring engagement communication supplier diversity diversity inclusion fair treatment suppliers training development maintaining quality reward recognition security supply health safety wellbeing counterfeiting health safety management case studies hazard assessment communication qas safety programmes health wellbeing programmes environmental sustainability health business continuity training awareness plan excellence performance targets journey sustainability case studies managing ehs sustainability qas ehss vision policy training awareness human rights audits compliance employees reward recognition suppliers management ehss communities environmental fundamentals society wastewater activities sensitive countries hazardous nonhazardous waste contaminated land public policy patient advocacy emissions air ehss business processes approach external affairs supplier performance public policy activity sustainability advocacy healthcare materials efficiency disease prevention climate change energy advocacy research practices water use advocacy patient safety product stewardship advocacy intellectual property packaging advocacy pricing competitiveness open transparent relations political contributions stakeholder engagement lobbying expenditures ehss reporting patient advocacy assurance transparency gsk response assurance understanding patients qas developing industry standards environmental metrics advocacy qas corporate responsibility report contents work communities community investment preventing disease eliminating lymphatic filariasis p ersonal hygiene sanitation education phase local programmes building community capacity combating hivaids positive action combating malaria africa malaria partnership local programmes responding disasters around world supporting science education plans corporate responsibility report august corporate responsibility report selected full report contents corporate responsibility gsk contribution health access medicines research practices ethical conduct supply chain environmental sustainability people human rights public policy patient advocacy work communities find corporate responsibility glaxosmithkline online wwwgskcomresponsibility home responsibility corporate responsibility gsk corporate responsibility report corporate responsibility gsk corporate responsibility cr central business aim operate way reflects values understand respond stakeholder views connect business decisions ethical social environmental concerns seek minimise negative impacts maximise benefits business read message ceo importance cr gsk every gsk employee responsible upholding values maintaining high ethical standards corporate responsibility principles define approach key responsibility issues provide guidance employees standards company committed communicate people underline commitment corporate responsibility update progress also engage external stakeholders including healthcare professionals investors patients non governmental organisations local communities suppliers identify key issues gain feedback approach corporate responsibility business makes valuable contribution society medicines vaccines produce improve peoples lives however know research development manufacture sale medicines vaccines raise ethical issues consequently pharmaceutical industry subject high level public scrutiny sometimes critical media coverage aim highest ethical standards regularly report progress essential maintaining good relationships stakeholders achieving goals strategic priorities ensuring future sustainability business also supports inclusion key sustainability indices ftsegood index dow jones sustainability index see scored industry investor benchmarks corporate responsibility principles define approach key responsibility issues provide guidance employees standards company committed read management structures processes advancing progress cr principles back top home responsibility corporate responsibility gsk corporate responsibility report corporate responsibility gsk corporate responsibility cr central business aim operate way reflects values understand respond stakeholder views connect business decisions ethical social environmental concerns seek minimise negative impacts maximise benefits business read message ceo importance cr gsk every gsk employee responsible upholding values maintaining high ethical standards corporate responsibility principles define approach key responsibility issues provide guidance employees standards company committed communicate people underline commitment corporate responsibility update progress also engage external stakeholders including healthcare professionals investors patients non governmental organisations local communities suppliers identify key issues gain feedback approach corporate responsibility business makes valuable contribution society medicines vaccines produce improve peoples lives however know research development manufacture sale medicines vaccines raise ethical issues consequently pharmaceutical industry subject high level public scrutiny sometimes critical media coverage aim highest ethical standards regularly report progress essential maintaining good relationships stakeholders achieving goals strategic priorities ensuring future sustainability business also supports inclusion key sustainability indices ftsegood index dow jones sustainability index see scored industry investor benchmarks corporate responsibility principles define approach key responsibility issues provide guidance employees standards company committed read management structures processes advancing progress cr principles back top home responsibility corporate responsibility gsk message ceo corporate responsibility report message ceo new mindset welcome gsks corporate responsibility report provides information activity performance want company forward looking innovative willing try new approaches partnerships company constantly looking new sustainable ways increase access medicines vaccines especially least able pay made significant progress helping address global healthcare challenges example past ten years donated one billion tablets programme eliminate lymphatic filariasis debilitating tropical disease doubling manufacturing capacity million tablets year commitment preferential pricing means offer aids malaria medicines notforprofit prices worlds poorest countries also supply vaccines organisations gavi unicef preferential prices typically per cent prices developed countries every success story examples could review performance believe time new mindset industry new contract society difficult economic times challenge think beyond shortterm performance must look longterm distracted economic problems needs developing world remain pressing begin four areas show going things differently first exploring flexible approach intellectual property rights incentivise much needed research medicines neglected tropical diseases severe lack research one option least developed country ldc patent pool would put relevant small molecule compounds process patents knowledge would allow others access develop produce new products secondly april reduce prices patented medicines poorest countries world ldcs higher per cent developed world price possible reduce prices ensuring cover manufacturing costs offer sustainable also recognise challenge middleincome countries wide disparity incomes ability pay intention work casebycase basis recognising one size fits solution improving access medicines countries thirdly seek partnerships open doors developing world research centre spain already know partnership achieve example successfully trialled malaria vaccine candidate partnership paths malaria vaccine initiative bill melinda gates foundation extend approach benefits huge fourthly working partners ngos reinvest per cent profit make selling medicines ldcs support strengthening healthcare infrastructure countries sales ldcs relatively low profit limited initially funding amount million annually action hope send signal multinational companies operating ldcs join us make meaningful change countries developing countries must transform gsk local company addressing local healthcare needs brazilian business leading way supplying vaccines sharing technical expertise help build local capacity forget significant healthcare challenges exist developed countries must work partnership create virtuous circle industry gets rewarded demonstrating genuine innovation healthcare payers get valueformoney medicines save highcost healthcare interventions patients get medicines need course access medicines issue counts want gsk recognised around world stakeholders company highest ethical standards made good progress committed stopping corporate political contributions decision report fully funding medical education patient groups payments physicians increase transparency provide reassurance stakeholders reflecting commitment animal welfare took voluntary decision end research great apes highestorder animals next humans time new mindset industry new contract society support pharmaceutical companies partners outside industry believe significant improvements human health really achieved andrew witty ceo back tophome responsibility corporate responsibility gsk message ceo corporate responsibility report message ceo new mindset welcome gsks corporate responsibility report provides information activity performance want company forward looking innovative willing try new approaches partnerships company constantly looking new sustainable ways increase access medicines vaccines especially least able pay made significant progress helping address global healthcare challenges example past ten years donated one billion tablets programme eliminate lymphatic filariasis debilitating tropical disease doubling manufacturing capacity million tablets year commitment preferential pricing means offer aids malaria medicines notforprofit prices worlds poorest countries also supply vaccines organisations gavi unicef preferential prices typically per cent prices developed countries every success story examples could review performance believe time new mindset industry new contract society difficult economic times challenge think beyond shortterm performance must look longterm distracted economic problems needs developing world remain pressing begin four areas show going things differently first exploring flexible approach intellectual property rights incentivise much needed research medicines neglected tropical diseases severe lack research one option least developed country ldc patent pool would put relevant small molecule compounds process patents knowledge would allow others access develop produce new products secondly april reduce prices patented medicines poorest countries world ldcs higher per cent developed world price possible reduce prices ensuring cover manufacturing costs offer sustainable also recognise challenge middleincome countries wide disparity incomes ability pay intention work casebycase basis recognising one size fits solution improving access medicines countries thirdly seek partnerships open doors developing world research centre spain already know partnership achieve example successfully trialled malaria vaccine candidate partnership paths malaria vaccine initiative bill melinda gates foundation extend approach benefits huge fourthly working partners ngos reinvest per cent profit make selling medicines ldcs support strengthening healthcare infrastructure countries sales ldcs relatively low profit limited initially funding amount million annually action hope send signal multinational companies operating ldcs join us make meaningful change countries developing countries must transform gsk local company addressing local healthcare needs brazilian business leading way supplying vaccines sharing technical expertise help build local capacity forget significant healthcare challenges exist developed countries must work partnership create virtuous circle industry gets rewarded demonstrating genuine innovation healthcare payers get valueformoney medicines save highcost healthcare interventions patients get medicines need course access medicines issue counts want gsk recognised around world stakeholders company highest ethical standards made good progress committed stopping corporate political contributions decision report fully funding medical education patient groups payments physicians increase transparency provide reassurance stakeholders reflecting commitment animal welfare took voluntary decision end research great apes highestorder animals next humans time new mindset industry new contract society support pharmaceutical companies partners outside industry believe significant improvements human health really achieved andrew witty ceo back top home responsibility corporate responsibility gsk message ceo corporate responsibility report message ceo new mindset welcome gsks corporate responsibility report provides information activity performance want company forward looking innovative willing try new approaches partnerships company constantly looking new sustainable ways increase access medicines vaccines especially least able pay made significant progress helping address global healthcare challenges example past ten years donated one billion tablets programme eliminate lymphatic filariasis debilitating tropical disease doubling manufacturing capacity million tablets year commitment preferential pricing means offer aids malaria medicines notforprofit prices worlds poorest countries also supply vaccines organisations gavi unicef preferential prices typically per cent prices developed countries every success story examples could review performance believe time new mindset industry new contract society difficult economic times challenge think beyond shortterm performance must look longterm distracted economic problems needs developing world remain pressing begin four areas show going things differently first exploring flexible approach intellectual property rights incentivise much needed research medicines neglected tropical diseases severe lack research one option least developed country ldc patent pool would put relevant small molecule compounds process patents knowledge would allow others access develop produce new products secondly april reduce prices patented medicines poorest countries world ldcs higher per cent developed world price possible reduce prices ensuring cover manufacturing costs offer sustainable also recognise challenge middleincome countries wide disparity incomes ability pay intention work casebycase basis recognising one size fits solution improving access medicines countries thirdly seek partnerships open doors developing world research centre spain already know partnership achieve example successfully trialled malaria vaccine candidate partnership paths malaria vaccine initiative bill melinda gates foundation extend approach benefits huge fourthly working partners ngos reinvest per cent profit make selling medicines ldcs support strengthening healthcare infrastructure countries sales ldcs relatively low profit limited initially funding amount million annually action hope send signal multinational companies operating ldcs join us make meaningful change countries developing countries must transform gsk local company addressing local healthcare needs brazilian business leading way supplying vaccines sharing technical expertise help build local capacity forget significant healthcare challenges exist developed countries must work partnership create virtuous circle industry gets rewarded demonstrating genuine innovation healthcare payers get valueformoney medicines save highcost healthcare interventions patients get medicines need course access medicines issue counts want gsk recognised around world stakeholders company highest ethical standards made good progress committed stopping corporate political contributions decision report fully funding medical education patient groups payments physicians increase transparency provide reassurance stakeholders reflecting commitment animal welfare took voluntary decision end research great apes highestorder animals next humans time new mindset industry new contract society support pharmaceutical companies partners outside industry believe significant improvements human health really achieved andrew witty ceo back top home responsibility corporate responsibility gsk corporate responsibility principles corporate responsibility report corporate responsibility principles corporate responsibility principles identify key responsibility issues provide guidance employees standards gsk committed employment practices treat employees respect dignity encourage diversity ensure fair treatment phases employment provide safe healthy working environment support employees perform full potential take responsibility performance reputation business read employment practices human rights committed upholding un universal declaration human rights oecd guidelines multinational enterprises core labour standards set international labour organization expect standards suppliers contractors business partners working gsks behalf read approach human rights access medicines continue research develop medicines treat diseases developing world find sustainable ways improve access medicines disadvantaged people seek partnerships support activity read approach access medicines leadership advocacy establish challenging standards corporate responsibility appropriate complexities specific needs business building external guidelines experience share best practice seek influence others remaining competitive order sustain business community investment make positive contribution communities operate invest health education programmes partnerships aim bring sustainable improvements underserved people developed developing world read work communities engagement stakeholders want understand concerns interest corporate responsibility issues engage range stakeholders communicate openly addressing cr issues ways aim meet needs different groups allowing us pursue legitimate business goals read stakeholder engagement standards ethical conduct expect employees meet high ethical standards aspects business conducting activities honesty integrity adhering cr principles complying applicable laws regulations read ethical conduct research innovation undertaking research innovating may explore apply new technologies constructively engage stakeholders concerns may arise ensure products subject rigorous scientific evaluation testing safety effectiveness quality comply exceed regulations legal standards applicable research development products read research practices products customers promote products line high ethical medical scientific standards comply applicable laws regulations read marketing ethics caring environment operate environmentally responsible manner systematic management environmental impacts measurement performance setting challenging performance targets improve efficiency activities minimise material energy use waste generated aim find opportunities use renewable materials recycle waste read environmental sustainability back tophome responsibility corporate responsibility gsk corporate responsibility principles corporate responsibility report corporate responsibility principles corporate responsibility principles identify key responsibility issues provide guidance employees standards gsk committed employment practices treat employees respect dignity encourage diversity ensure fair treatment phases employment provide safe healthy working environment support employees perform full potential take responsibility performance reputation business read employment practices human rights committed upholding un universal declaration human rights oecd guidelines multinational enterprises core labour standards set international labour organization expect standards suppliers contractors business partners working gsks behalf read approach human rights access medicines continue research develop medicines treat diseases developing world find sustainable ways improve access medicines disadvantaged people seek partnerships support activity read approach access medicines leadership advocacy establish challenging standards corporate responsibility appropriate complexities specific needs business building external guidelines experience share best practice seek influence others remaining competitive order sustain business community investment make positive contribution communities operate invest health education programmes partnerships aim bring sustainable improvements underserved people developed developing world read work communities engagement stakeholders want understand concerns interest corporate responsibility issues engage range stakeholders communicate openly addressing cr issues ways aim meet needs different groups allowing us pursue legitimate business goals read stakeholder engagement standards ethical conduct expect employees meet high ethical standards aspects business conducting activities honesty integrity adhering cr principles complying applicable laws regulations read ethical conduct research innovation undertaking research innovating may explore apply new technologies constructively engage stakeholders concerns may arise ensure products subject rigorous scientific evaluation testing safety effectiveness quality comply exceed regulations legal standards applicable research development products read research practices products customers promote products line high ethical medical scientific standards comply applicable laws regulations read marketing ethics caring environment operate environmentally responsible manner systematic management environmental impacts measurement performance setting challenging performance targets improve efficiency activities minimise material energy use waste generated aim find opportunities use renewable materials recycle waste read environmental sustainability back top home responsibility corporate responsibility gsk corporate responsibility principles corporate responsibility report corporate responsibility principles corporate responsibility principles identify key responsibility issues provide guidance employees standards gsk committed employment practices treat employees respect dignity encourage diversity ensure fair treatment phases employment provide safe healthy working environment support employees perform full potential take responsibility performance reputation business read employment practices human rights committed upholding un universal declaration human rights oecd guidelines multinational enterprises core labour standards set international labour organization expect standards suppliers contractors business partners working gsks behalf read approach human rights access medicines continue research develop medicines treat diseases developing world find sustainable ways improve access medicines disadvantaged people seek partnerships support activity read approach access medicines leadership advocacy establish challenging standards corporate responsibility appropriate complexities specific needs business building external guidelines experience share best practice seek influence others remaining competitive order sustain business community investment make positive contribution communities operate invest health education programmes partnerships aim bring sustainable improvements underserved people developed developing world read work communities engagement stakeholders want understand concerns interest corporate responsibility issues engage range stakeholders communicate openly addressing cr issues ways aim meet needs different groups allowing us pursue legitimate business goals read stakeholder engagement standards ethical conduct expect employees meet high ethical standards aspects business conducting activities honesty integrity adhering cr principles complying applicable laws regulations read ethical conduct research innovation undertaking research innovating may explore apply new technologies constructively engage stakeholders concerns may arise ensure products subject rigorous scientific evaluation testing safety effectiveness quality comply exceed regulations legal standards applicable research development products read research practices products customers promote products line high ethical medical scientific standards comply applicable laws regulations read marketing ethics caring environment operate environmentally responsible manner systematic management environmental impacts measurement performance setting challenging performance targets improve efficiency activities minimise material energy use waste generated aim find opportunities use renewable materials recycle waste read environmental sustainability back top home responsibility corporate responsibility gsk business case corporate responsibility corporate responsibility report business case corporate responsibility demonstrating practices responsible ethical benefits business following ways improved reputation greater trust gsk products ability attract retain motivate talented people becoming increasingly important fewer young people major markets choose sciencebased careers constructive engagement stakeholders helps us prevent avoidable conflict identify innovative approaches benefit gsk wider society greater access markets ability influence healthcare policy improved relationships regulators healthcare payers helping governments increase access medicines resolve healthcare challenges particularly important greater ability anticipate prepare legislative changes maintain competitive advantage helping maintain support intellectual property system finding innovative ways increase access medicines reduced costs efficient use resources increased environmental efficiency business strategy business performance development driven three strategic priorities supported corporate responsibility activities believe corporate responsibility managed part overall business strategy daytoday business operations reason separate corporate responsibility strategy gsk corporate responsibility strategic priorities established strategic priorities believe increase growth reduce risk improve longterm financial performance grow diversified global business deliver products value simplify operating model believe priorities enable us navigate coming years successfully retain leadingedge position company able meet patients healthcare providers needs future running business responsible way fundamental success inseparable strategic priorities want work way reflects values seeks understand respond stakeholder views connects business decisions ethical social environmental concerns way aim minimise negative impacts maximise positive benefits business back top home responsibility corporate responsibility gsk business case corporate responsibility corporate responsibility report business case corporate responsibility demonstrating practices responsible ethical benefits business following ways improved reputation greater trust gsk products ability attract retain motivate talented people becoming increasingly important fewer young people major markets choose sciencebased careers constructive engagement stakeholders helps us prevent avoidable conflict identify innovative approaches benefit gsk wider society greater access markets ability influence healthcare policy improved relationships regulators healthcare payers helping governments increase access medicines resolve healthcare challenges particularly important greater ability anticipate prepare legislative changes maintain competitive advantage helping maintain support intellectual property system finding innovative ways increase access medicines reduced costs efficient use resources increased environmental efficiency business strategy business performance development driven three strategic priorities supported corporate responsibility activities believe corporate responsibility managed part overall business strategy daytoday business operations reason separate corporate responsibility strategy gsk corporate responsibility strategic priorities established strategic priorities believe increase growth reduce risk improve longterm financial performance grow diversified global business deliver products value simplify operating model believe priorities enable us navigate coming years successfully retain leadingedge position company able meet patients healthcare providers needs future running business responsible way fundamental success inseparable strategic priorities want work way reflects values seeks understand respond stakeholder views connects business decisions ethical social environmental concerns way aim minimise negative impacts maximise positive benefits business back top home responsibility corporate responsibility gsk business case corporate responsibility corporate responsibility report business case corporate responsibility demonstrating practices responsible ethical benefits business following ways improved reputation greater trust gsk products ability attract retain motivate talented people becoming increasingly important fewer young people major markets choose sciencebased careers constructive engagement stakeholders helps us prevent avoidable conflict identify innovative approaches benefit gsk wider society greater access markets ability influence healthcare policy improved relationships regulators healthcare payers helping governments increase access medicines resolve healthcare challenges particularly important greater ability anticipate prepare legislative changes maintain competitive advantage helping maintain support intellectual property system finding innovative ways increase access medicines reduced costs efficient use resources increased environmental efficiency business strategy business performance development driven three strategic priorities supported corporate responsibility activities believe corporate responsibility managed part overall business strategy daytoday business operations reason separate corporate responsibility strategy gsk corporate responsibility strategic priorities established strategic priorities believe increase growth reduce risk improve longterm financial performance grow diversified global business deliver products value simplify operating model believe priorities enable us navigate coming years successfully retain leadingedge position company able meet patients healthcare providers needs future running business responsible way fundamental success inseparable strategic priorities want work way reflects values seeks understand respond stakeholder views connects business decisions ethical social environmental concerns way aim minimise negative impacts maximise positive benefits business back top home responsibility corporate responsibility gsk key issues corporate responsibility report key issues cr reporting focused material significant relevant issues business following factors influence materiality assessment business strategy risk management processes stakeholder interest including investor feedback changes business operations example types product produce locations operate existing proposed legislation public opinion press coverage identified following responsibility issues material gsk contribution core business makes health research development manufacture sale medicines vaccines increasing access medicines underserved communities ethical standards research development sales marketing environmental impact particularly climate change back top home responsibility corporate responsibility gsk key issues corporate responsibility report key issues cr reporting focused material significant relevant issues business following factors influence materiality assessment business strategy risk management processes stakeholder interest including investor feedback changes business operations example types product produce locations operate existing proposed legislation public opinion press coverage identified following responsibility issues material gsk contribution core business makes health research development manufacture sale medicines vaccines increasing access medicines underserved communities ethical standards research development sales marketing environmental impact particularly climate change back top home responsibility corporate responsibility gsk corporate responsibility governance corporate responsibility report corporate responsibility governance corporate responsibility committee crc nonexecutive directors provides highlevel guidance approach cr ceo members corporate executive team cet accountable responsible management business participate crc meetings committee members sir christopher gent chair dr stephanie burns dr daniel podolsky sir ian prosser tom de swaan committee meets three times year review policies progress cr principles committee reviews performance five cr principles annually access medicines standards ethical conduct research innovation employment practices community investment principles discussed least every two years committee reports findings board management corporate responsibility crc reviewed gsks activity number areas including access medicines community partnerships humanitarian donations employee volunteering sales marketing practices disclosure funding medical education patient advocacy groups product safety communication clinical trial results rd diseases developing world use animals research outsourcing research research emerging markets reduction employee numbers restructuring employee consultation requirements employment litigation us committee also reviews signs annual performance information published website annual cr highlights document augment gsk 's engagement stakeholder opinion march sophia tickell appointed external advisor corporate responsibility committee sophia executive director member leadership team sustainability think tank consultancy seeks enhance business engagement social environmental concerns sophia extensive experience constructively challenging companies increase understanding societal expectations develop strategies meet gained experience work journalist latin america work international development advocacy work oxfam recently direction investorled pharma futures dialogues aim better align societal shareholder value sophia attend meetings corporate responsibility committee advise company capacity read corporate responsibility committee corporate responsibility risks risk oversight compliance council rocc coordinates management significant business risks rocc also considers reputational corporate responsibility risks read risk management compliance gsk management structure cr covers diverse range issues gsk believe managed within business functions relevant subject experts work crossfunctional team made representatives key business areas oversees development implementation communication policies including responsibility elements across gsk members senior managers direct access corporate executive team small central cr team coordinate policy development reporting specifically respect cr communicate socially responsible investors stakeholders measuring performance established metrics key performance indicators track performance responsibility issues back tophome responsibility corporate responsibility gsk corporate responsibility governance corporate responsibility report corporate responsibility governance corporate responsibility committee crc nonexecutive directors provides highlevel guidance approach cr ceo members corporate executive team cet accountable responsible management business participate crc meetings committee members sir christopher gent chair dr stephanie burns dr daniel podolsky sir ian prosser tom de swaan committee meets three times year review policies progress cr principles committee reviews performance five cr principles annually access medicines standards ethical conduct research innovation employment practices community investment principles discussed least every two years committee reports findings board management corporate responsibility crc reviewed gsks activity number areas including access medicines community partnerships humanitarian donations employee volunteering sales marketing practices disclosure funding medical education patient advocacy groups product safety communication clinical trial results rd diseases developing world use animals research outsourcing research research emerging markets reduction employee numbers restructuring employee consultation requirements employment litigation us committee also reviews signs annual performance information published website annual cr highlights document augment gsk 's engagement stakeholder opinion march sophia tickell appointed external advisor corporate responsibility committee sophia executive director member leadership team sustainability think tank consultancy seeks enhance business engagement social environmental concerns sophia extensive experience constructively challenging companies increase understanding societal expectations develop strategies meet gained experience work journalist latin america work international development advocacy work oxfam recently direction investorled pharma futures dialogues aim better align societal shareholder value sophia attend meetings corporate responsibility committee advise company capacity read corporate responsibility committee corporate responsibility risks risk oversight compliance council rocc coordinates management significant business risks rocc also considers reputational corporate responsibility risks read risk management compliance gsk management structure cr covers diverse range issues gsk believe managed within business functions relevant subject experts work crossfunctional team made representatives key business areas oversees development implementation communication policies including responsibility elements across gsk members senior managers direct access corporate executive team small central cr team coordinate policy development reporting specifically respect cr communicate socially responsible investors stakeholders measuring performance established metrics key performance indicators track performance responsibility issues back top home responsibility corporate responsibility gsk corporate responsibility governance corporate responsibility report corporate responsibility governance corporate responsibility committee crc nonexecutive directors provides highlevel guidance approach cr ceo members corporate executive team cet accountable responsible management business participate crc meetings committee members sir christopher gent chair dr stephanie burns dr daniel podolsky sir ian prosser tom de swaan committee meets three times year review policies progress cr principles committee reviews performance five cr principles annually access medicines standards ethical conduct research innovation employment practices community investment principles discussed least every two years committee reports findings board management corporate responsibility crc reviewed gsks activity number areas including access medicines community partnerships humanitarian donations employee volunteering sales marketing practices disclosure funding medical education patient advocacy groups product safety communication clinical trial results rd diseases developing world use animals research outsourcing research research emerging markets reduction employee numbers restructuring employee consultation requirements employment litigation us committee also reviews signs annual performance information published website annual cr highlights document augment gsk 's engagement stakeholder opinion march sophia tickell appointed external advisor corporate responsibility committee sophia executive director member leadership team sustainability think tank consultancy seeks enhance business engagement social environmental concerns sophia extensive experience constructively challenging companies increase understanding societal expectations develop strategies meet gained experience work journalist latin america work international development advocacy work oxfam recently direction investorled pharma futures dialogues aim better align societal shareholder value sophia attend meetings corporate responsibility committee advise company capacity read corporate responsibility committee corporate responsibility risks risk oversight compliance council rocc coordinates management significant business risks rocc also considers reputational corporate responsibility risks read risk management compliance gsk management structure cr covers diverse range issues gsk believe managed within business functions relevant subject experts work crossfunctional team made representatives key business areas oversees development implementation communication policies including responsibility elements across gsk members senior managers direct access corporate executive team small central cr team coordinate policy development reporting specifically respect cr communicate socially responsible investors stakeholders measuring performance established metrics key performance indicators track performance responsibility issues back top home responsibility corporate responsibility gsk stakeholder engagement corporate responsibility report stakeholder engagement stakeholder engagement dialogue enables us connect views opinions societies operate helps us identify important issues shape responses interest shareholders wider society regular engagement means better informed emerging current issues changing societal expectations provides opportunity us voice approach responsibility issues obtain important feedback build trust discussion takes place normal course business example scientists regularly meet academics researchers pharmaceutical companies advisory boards medical conferences describe engage stakeholders give examples engagement stakeholder group provide information responding feedback receive find examples engagement stakeholders throughout website back top home responsibility corporate responsibility gsk stakeholder engagement corporate responsibility report stakeholder engagement stakeholder engagement dialogue enables us connect views opinions societies operate helps us identify important issues shape responses interest shareholders wider society regular engagement means better informed emerging current issues changing societal expectations provides opportunity us voice approach responsibility issues obtain important feedback build trust discussion takes place normal course business example scientists regularly meet academics researchers pharmaceutical companies advisory boards medical conferences describe engage stakeholders give examples engagement stakeholder group provide information responding feedback receive find examples engagement stakeholders throughout website back top home responsibility corporate responsibility gsk stakeholder engagement engage corporate responsibility report engage healthcare professionals engage healthcare professionals many ways including sales representatives running clinical trials read research ethics policies governing relationships healthcare professionals patients gsk researchers scientists meet patients part focus patient initiative engagement influences understanding diseases research priorities read case studywe also support work patient advocacy groups conduct market research via third parties understand patient needs governments regulators engage debate legislation seek influence policy decisions affect gsk also engage governments responsibilityrelated issues healthcare providers engage healthcare providers government affairs marketing access medicines activities investors meet regularly investors socially responsible investors read investor engagement activities employees seek feedback employees regular surveys also consult employees changes affect discuss business developments regional national consultation forums local communities interactions local communities managed individual gsk sites read financial practical support communities multilateral agencies engage multilateral agencies access public health initiatives nongovernmental organisations ngos engage international local ngos access education public health programmes part public policy work also engage regularly animal welfare organisations read animal research gsk scientific community academic partnerships important gsk part scientific debates involved number academic collaborations suppliers hold global regional supplier review meetings senior gsk managers address interact suppliers key issues read engagement suppliers peer companies engage peer companies membership pharmaceutical industry organisations example efpia phrma ifpma collaboration specific projects back top home responsibility corporate responsibility gsk stakeholder engagement engage corporate responsibility report engage healthcare professionals engage healthcare professionals many ways including sales representatives running clinical trials read research ethics policies governing relationships healthcare professionals patients gsk researchers scientists meet patients part focus patient initiative engagement influences understanding diseases research priorities read case studywe also support work patient advocacy groups conduct market research via third parties understand patient needs governments regulators engage debate legislation seek influence policy decisions affect gsk also engage governments responsibilityrelated issues healthcare providers engage healthcare providers government affairs marketing access medicines activities investors meet regularly investors socially responsible investors read investor engagement activities employees seek feedback employees regular surveys also consult employees changes affect discuss business developments regional national consultation forums local communities interactions local communities managed individual gsk sites read financial practical support communities multilateral agencies engage multilateral agencies access public health initiatives nongovernmental organisations ngos engage international local ngos access education public health programmes part public policy work also engage regularly animal welfare organisations read animal research gsk scientific community academic partnerships important gsk part scientific debates involved number academic collaborations suppliers hold global regional supplier review meetings senior gsk managers address interact suppliers key issues read engagement suppliers peer companies engage peer companies membership pharmaceutical industry organisations example efpia phrma ifpma collaboration specific projects back top home responsibility corporate responsibility gsk stakeholder engagement engage corporate responsibility report engage healthcare professionals engage healthcare professionals many ways including sales representatives running clinical trials read research ethics policies governing relationships healthcare professionals patients gsk researchers scientists meet patients part focus patient initiative engagement influences understanding diseases research priorities read case studywe also support work patient advocacy groups conduct market research via third parties understand patient needs governments regulators engage debate legislation seek influence policy decisions affect gsk also engage governments responsibilityrelated issues healthcare providers engage healthcare providers government affairs marketing access medicines activities investors meet regularly investors socially responsible investors read investor engagement activities employees seek feedback employees regular surveys also consult employees changes affect discuss business developments regional national consultation forums local communities interactions local communities managed individual gsk sites read financial practical support communities multilateral agencies engage multilateral agencies access public health initiatives nongovernmental organisations ngos engage international local ngos access education public health programmes part public policy work also engage regularly animal welfare organisations read animal research gsk scientific community academic partnerships important gsk part scientific debates involved number academic collaborations suppliers hold global regional supplier review meetings senior gsk managers address interact suppliers key issues read engagement suppliers peer companies engage peer companies membership pharmaceutical industry organisations example efpia phrma ifpma collaboration specific projects back top home responsibility corporate responsibility gsk stakeholder engagement engagement employees corporate responsibility report engagement employees important employees know commitment corporate responsibility understand responsibilities keep uptodate progress read approach embedding ethical culture gsk keep employees informed corporate responsibility mygsk intranet site spirit internal quarterly magazine feature articles responsibility issues read engage employees environment health safety issues least nine articles responsibility issues published spirit included articles environmental sustainability community investments efforts combat diseases developing world lymphatic filariasis year published four editions spirit distributing copies edition internally additionally year online version magazine introduced intranet offering access employees distributed corporate responsibility review spirit magazine directly corporate executive team gsk board senior managers site directors communications staff news articles icons intranet site used guide users directly review year published shorter cr highlights document direct people website raising awareness online cr report publicising website company intranet back top home responsibility corporate responsibility gsk stakeholder engagement engagement employees corporate responsibility report engagement employees important employees know commitment corporate responsibility understand responsibilities keep uptodate progress read approach embedding ethical culture gsk keep employees informed corporate responsibility mygsk intranet site spirit internal quarterly magazine feature articles responsibility issues read engage employees environment health safety issues least nine articles responsibility issues published spirit included articles environmental sustainability community investments efforts combat diseases developing world lymphatic filariasis year published four editions spirit distributing copies edition internally additionally year online version magazine introduced intranet offering access employees distributed corporate responsibility review spirit magazine directly corporate executive team gsk board senior managers site directors communications staff news articles icons intranet site used guide users directly review year published shorter cr highlights document direct people website raising awareness online cr report publicising website company intranet back top home responsibility corporate responsibility gsk stakeholder engagement engagement investors corporate responsibility report engagement investors held meetings investors discuss responsibility issues comprised onetoone meetings teleconferences socially responsible investment sri roadshow investor questions questions raised investors responsibility issues concerned access medicines clinical trial results disclosure clinical trials developing world patient safety operations sensitive countries read gsks position human rights sales marketing practices read marketing ethics gsk stem cell research animal research including genetic engineering animals environmental issues including climate change water pollution political contributions also disclose information greenhouse gas emissions carbon disclosure project cdp investor collaboration back top home responsibility corporate responsibility gsk stakeholder engagement engagement investors corporate responsibility report engagement investors held meetings investors discuss responsibility issues comprised onetoone meetings teleconferences socially responsible investment sri roadshow investor questions questions raised investors responsibility issues concerned access medicines clinical trial results disclosure clinical trials developing world patient safety operations sensitive countries read gsks position human rights sales marketing practices read marketing ethics gsk stem cell research animal research including genetic engineering animals environmental issues including climate change water pollution political contributions also disclose information greenhouse gas emissions carbon disclosure project cdp investor collaboration back top home responsibility corporate responsibility gsk stakeholder engagement engagement opinion leaders corporate responsibility report engagement opinion leaders ipsos mori survey gsk participated ipsos mori survey rates companies according cr experts ngos perception cr performance nearly threequarters people surveyed thought gsk took responsibilities seriously maintaining significant improvement made compared gsk seventhhighest rated company question companies three respondents spontaneously mentioned gsk leader corporate responsibility spontaneous mentions gsk last year back top home responsibility corporate responsibility gsk stakeholder engagement engagement opinion leaders corporate responsibility report engagement opinion leaders ipsos mori survey gsk participated ipsos mori survey rates companies according cr experts ngos perception cr performance nearly threequarters people surveyed thought gsk took responsibilities seriously maintaining significant improvement made compared gsk seventhhighest rated company question companies three respondents spontaneously mentioned gsk leader corporate responsibility spontaneous mentions gsk last year back top home responsibility corperate responsibility gsk stakeholder engagement engagement access medicines corporate responsibility report engagement access medicines engagement issues relating access medicines described access medicines section well engagement gsk conducted three formal stakeholder discussions get feedback approach different issues relating access medicines engaged influential individuals organisations expertise area including ngos government representatives journalists academics investors industry organisations topics covered increasing access hivaids medicines developing countries expanding rd diseases developing world increasing access medicines middleincome countries necessarily agree comments made participants sessions provided valuable feedback approach feedback gsks approach developing countries participants felt gsk moral responsibility make products accessible poor people access medicines also important gsks longterm business sustainability felt gsks approach increasing access developing countries rd preferential pricing voluntary licensing appropriate although participants would like gsk invest rd diseases developing world remove obstacles supply generic medicines countries participants urged gsk collaborate pharmaceutical companies address access issues developing countries felt industrywide approach could help address issues quickly effectively feedback gsks approach middleincome countries participants emphasised importance increasing access medicines middleincome countries mics still large numbers poor people encouraged gsk treat mics would highincome countries participants felt gsk clear strategy access mics would like gsk clearer approach objectives particular would like know regard mics significant commercial markets pointed chronic diseases growing problem mics suggested gsk take broad approach access encompasses medicines highprofile diseases hivaids malaria tb read findings session detail back top home responsibility corperate responsibility gsk stakeholder engagement engagement access medicines corporate responsibility report engagement access medicines engagement issues relating access medicines described access medicines section well engagement gsk conducted three formal stakeholder discussions get feedback approach different issues relating access medicines engaged influential individuals organisations expertise area including ngos government representatives journalists academics investors industry organisations topics covered increasing access hivaids medicines developing countries expanding rd diseases developing world increasing access medicines middleincome countries necessarily agree comments made participants sessions provided valuable feedback approach feedback gsks approach developing countries participants felt gsk moral responsibility make products accessible poor people access medicines also important gsks longterm business sustainability felt gsks approach increasing access developing countries rd preferential pricing voluntary licensing appropriate although participants would like gsk invest rd diseases developing world remove obstacles supply generic medicines countries participants urged gsk collaborate pharmaceutical companies address access issues developing countries felt industrywide approach could help address issues quickly effectively feedback gsks approach middleincome countries participants emphasised importance increasing access medicines middleincome countries mics still large numbers poor people encouraged gsk treat mics would highincome countries participants felt gsk clear strategy access mics would like gsk clearer approach objectives particular would like know regard mics significant commercial markets pointed chronic diseases growing problem mics suggested gsk take broad approach access encompasses medicines highprofile diseases hivaids malaria tb read findings session detail back top home responsibility cr gsk stakeholder engagement engagement ehs corporate responsibility report engagement ehss environment health safety sustainability stakeholder panel uk provided independent feedback performance since panel members represents customers suppliers regulators public interest groups investors two senior ehss representatives gsk regularly participate gsk managers attend discussions specific topics panel facilitated environment council independent charity panel met april october debate range issues including broad issue sustainability gsks position nanotechnology progress climate change process safety green chemistry programmes gsks plans complying eus registration evaluation authorisation chemicals reach legislation mass efficiency improvement pharmaceuticals environment using feedback stakeholder panel inform environment health safety sustainability programme panel also providing input new gsk sustainability council composed senior managers across gsk panel members provided feedback direction panel take effectiveness dialogue proposed panel broader geographic reach therefore added three new european panel members recruiting two panel finds gsk honest open discussions consider participation valuable however commented takes gsk long time demonstrate changes occur result suggestions feedback value feedback receive panel look ways speed response recommendations many sites also engage stakeholders locally ehss issues activities open days newsletters community projects back top home responsibility cr gsk stakeholder engagement engagement ehs corporate responsibility report engagement ehss environment health safety sustainability stakeholder panel uk provided independent feedback performance since panel members represents customers suppliers regulators public interest groups investors two senior ehss representatives gsk regularly participate gsk managers attend discussions specific topics panel facilitated environment council independent charity panel met april october debate range issues including broad issue sustainability gsks position nanotechnology progress climate change process safety green chemistry programmes gsks plans complying eus registration evaluation authorisation chemicals reach legislation mass efficiency improvement pharmaceuticals environment using feedback stakeholder panel inform environment health safety sustainability programme panel also providing input new gsk sustainability council composed senior managers across gsk panel members provided feedback direction panel take effectiveness dialogue proposed panel broader geographic reach therefore added three new european panel members recruiting two panel finds gsk honest open discussions consider participation valuable however commented takes gsk long time demonstrate changes occur result suggestions feedback value feedback receive panel look ways speed response recommendations many sites also engage stakeholders locally ehss issues activities open days newsletters community projects back top home responsibility corporate responsibility gsk reporting corporate responsibility report reporting welcome corporate responsibility report year reported activities performance online providing easy access information key issues plus ability build custom version report report report corporate responsibility activities performance annually website contains detailed account cr policies performance selected performance information also downloaded read use website also publish corporate responsibility highlights provides overview approach cr available print data relate worldwide operations calendar year except stated environmental data collected pharmaceutical consumer healthcare nutritionals manufacturing sites vaccines sites one yet operation pharmaceutical consumer healthcare rd sites including five whose environmental data included host sites nine small new warrant collection environmental data us uk headquarters buildings smaller offices distribution centres injury illness data collected pharmaceutical consumer healthcare nutritionals manufacturing sites vaccines sites one yet operation pharmaceutical consumer healthcare rd sites two considered new start reporting us uk headquarters sites offices sales groups one million hours worked smaller offices distribution centres data environment health safety sections independently assured sgs use external guidelines inform reporting relevant base report global reporting initiative gri guidelines produced gri index show elements guidelines covered report aid comparison company reports also joined un global compact provided index show reporting line global compact expectations brandnames appearing italics throughout report trademarks either owned andor licensed gsk associated companies contact welcome feedback information contained report please contact us corporate responsibility glaxosmithkline plc great west road brentford middlesex tw gs united kingdom csrcontactgskcom home responsibility corporate responsibility gsk reporting corporate responsibility report reporting welcome corporate responsibility report year reported activities performance online providing easy access information key issues plus ability build custom version report report report corporate responsibility activities performance annually website contains detailed account cr policies performance selected performance information also downloaded read use website also publish corporate responsibility highlights provides overview approach cr available print data relate worldwide operations calendar year except stated environmental data collected pharmaceutical consumer healthcare nutritionals manufacturing sites vaccines sites one yet operation pharmaceutical consumer healthcare rd sites including five whose environmental data included host sites nine small new warrant collection environmental data us uk headquarters buildings smaller offices distribution centres injury illness data collected pharmaceutical consumer healthcare nutritionals manufacturing sites vaccines sites one yet operation pharmaceutical consumer healthcare rd sites two considered new start reporting us uk headquarters sites offices sales groups one million hours worked smaller offices distribution centres data environment health safety sections independently assured sgs use external guidelines inform reporting relevant base report global reporting initiative gri guidelines produced gri index show elements guidelines covered report aid comparison company reports also joined un global compact provided index show reporting line global compact expectations brandnames appearing italics throughout report trademarks either owned andor licensed gsk associated companies contact welcome feedback information contained report please contact us corporate responsibility glaxosmithkline plc great west road brentford middlesex tw gs united kingdom csrcontactgskcom home responsibility corporate responsibility gsk reporting corporate responsibility report reporting welcome corporate responsibility report year reported activities performance online providing easy access information key issues plus ability build custom version report report report corporate responsibility activities performance annually website contains detailed account cr policies performance selected performance information also downloaded read use website also publish corporate responsibility highlights provides overview approach cr available print data relate worldwide operations calendar year except stated environmental data collected pharmaceutical consumer healthcare nutritionals manufacturing sites vaccines sites one yet operation pharmaceutical consumer healthcare rd sites including five whose environmental data included host sites nine small new warrant collection environmental data us uk headquarters buildings smaller offices distribution centres injury illness data collected pharmaceutical consumer healthcare nutritionals manufacturing sites vaccines sites one yet operation pharmaceutical consumer healthcare rd sites two considered new start reporting us uk headquarters sites offices sales groups one million hours worked smaller offices distribution centres data environment health safety sections independently assured sgs use external guidelines inform reporting relevant base report global reporting initiative gri guidelines produced gri index show elements guidelines covered report aid comparison company reports also joined un global compact provided index show reporting line global compact expectations brandnames appearing italics throughout report trademarks either owned andor licensed gsk associated companies contact welcome feedback information contained report please contact us corporate responsibility glaxosmithkline plc great west road brentford middlesex tw gs united kingdom csrcontactgskcom home responsibility corporate responsibility gsk benchmarking corporate responsibility report benchmarking gsk received following ratings benchmarking organisations indexes organisationaccess medicines index access medicines foundation innovest strategic value advisers rating gsk ranked highest index assessed companies contribution improving access medicines gsk clear overall leader top five eight categories assessed organisation dow jones sustainability index rating gsk continued member dow jones sustainability index covers top ten per cent sustainable companies sector gsk awarded silver class sector mover distinctions improving bronze class awarded classes awarded companies relative sector leader organisation ftsegood rating gsk included ftsegood index organisation global sustainable corporations innovest strategic value advisors rating gsk included list global sustainable corporations companies selected demonstrate capacity address sectorspecific environmental social governance risks opportunities organisation business community communitymark rating gsk one companies manufacturing company awarded new communitymark following independent assessment outstanding community investment mark endorsed uk government voluntary sector leaders given work local national level uk well larger international programmes organisation business community environment index rating gsk maintained position platinum league index assessed companies investor ratings organisation ceres rating gsk ranked th overall nd pharmaceutical sector ceress climate change governance ranking worlds largest companies organisation storebrand rating gsk achieved best class status leading environmental social performance storebrand assesses indicators including corporate governance marketing ethics standards business partners occupational health safety environmental risk management labour relations reporting organisation association chartered certified accountants acca rating gsk corporate responsibility report shortlisted acca award recognises transparency credibility reporting organisation pwc building public trust award rating gsk one three companies shortlisted people reporting award assesses extent publicly available information enables stakeholders organisation sustainability global reporters benchmark rating gsks report scored per cent versus per cent report improvements every category particularly accessibility assurance back tophome responsibility corporate responsibility gsk benchmarking corporate responsibility report benchmarking gsk received following ratings benchmarking organisations indexes organisationaccess medicines index access medicines foundation innovest strategic value advisers rating gsk ranked highest index assessed companies contribution improving access medicines gsk clear overall leader top five eight categories assessed organisation dow jones sustainability index rating gsk continued member dow jones sustainability index covers top ten per cent sustainable companies sector gsk awarded silver class sector mover distinctions improving bronze class awarded classes awarded companies relative sector leader organisation ftsegood rating gsk included ftsegood index organisation global sustainable corporations innovest strategic value advisors rating gsk included list global sustainable corporations companies selected demonstrate capacity address sectorspecific environmental social governance risks opportunities organisation business community communitymark rating gsk one companies manufacturing company awarded new communitymark following independent assessment outstanding community investment mark endorsed uk government voluntary sector leaders given work local national level uk well larger international programmes organisation business community environment index rating gsk maintained position platinum league index assessed companies investor ratings organisation ceres rating gsk ranked th overall nd pharmaceutical sector ceress climate change governance ranking worlds largest companies organisation storebrand rating gsk achieved best class status leading environmental social performance storebrand assesses indicators including corporate governance marketing ethics standards business partners occupational health safety environmental risk management labour relations reporting organisation association chartered certified accountants acca rating gsk corporate responsibility report shortlisted acca award recognises transparency credibility reporting organisation pwc building public trust award rating gsk one three companies shortlisted people reporting award assesses extent publicly available information enables stakeholders organisation sustainability global reporters benchmark rating gsks report scored per cent versus per cent report improvements every category particularly accessibility assurance back top home responsibility corporate responsibility gsk benchmarking corporate responsibility report benchmarking gsk received following ratings benchmarking organisations indexes organisationaccess medicines index access medicines foundation innovest strategic value advisers rating gsk ranked highest index assessed companies contribution improving access medicines gsk clear overall leader top five eight categories assessed organisation dow jones sustainability index rating gsk continued member dow jones sustainability index covers top ten per cent sustainable companies sector gsk awarded silver class sector mover distinctions improving bronze class awarded classes awarded companies relative sector leader organisation ftsegood rating gsk included ftsegood index organisation global sustainable corporations innovest strategic value advisors rating gsk included list global sustainable corporations companies selected demonstrate capacity address sectorspecific environmental social governance risks opportunities organisation business community communitymark rating gsk one companies manufacturing company awarded new communitymark following independent assessment outstanding community investment mark endorsed uk government voluntary sector leaders given work local national level uk well larger international programmes organisation business community environment index rating gsk maintained position platinum league index assessed companies investor ratings organisation ceres rating gsk ranked th overall nd pharmaceutical sector ceress climate change governance ranking worlds largest companies organisation storebrand rating gsk achieved best class status leading environmental social performance storebrand assesses indicators including corporate governance marketing ethics standards business partners occupational health safety environmental risk management labour relations reporting organisation association chartered certified accountants acca rating gsk corporate responsibility report shortlisted acca award recognises transparency credibility reporting organisation pwc building public trust award rating gsk one three companies shortlisted people reporting award assesses extent publicly available information enables stakeholders organisation sustainability global reporters benchmark rating gsks report scored per cent versus per cent report improvements every category particularly accessibility assurance back top home responsibility corporate responsibility gsk assurance internal audit corporate responsibility report assurance internal audit external assurance ehs activities information provide environment health safety activities gsk externally assured independent thirdparty assurers reporting environment health safety performance assured sgs external assurer assurance process includes verification key environment health safety data site visits telephone calls ehs professionals review systems processes collecting collating analysing interpreting data read ehs assurance statement sgs external assurance access medicines activities cr report information access medicines externally assured read responding recommendations made assurers access medicines activity reporting year conduct assurance cr report described ehs section plan conduct assurance one new section report every year section report subject external assurance internal audit assurance gsk developed assurance programme provides holistic assessment internal control processes risk management audit within company key part programme extensive independent internal audit schedule delivered four specialist audit groups audits assess compliance laws regulations company standards evaluate effectiveness risk management process identifying managing mitigating significant risks facing gsk global internal audit gia responsible evaluating financial operational controls ensure financial reporting integrity safeguard assets losses including fraud corporate environment health safety sustainability cehss responsible assessing management health safety risks environmental impacts global manufacturing supply audit risk management arm assesses quality supply risks relating manufacturing supply chain processes gsk commercial products global quality compliance gqc responsible assessing risks relating medicines vaccines medical devices throughout product development process including manufacture clinical trial material central assurance function responsible developing assurance programme ensuring gsk audit groups work together efficient effective way deliver audit schedule global internal audit audits three audit groups alignment institute internal auditors international standards professional practice internal auditing cehss arm gcq audit groups additional responsibilities auditing contract manufacturers key suppliers gsk gsk employs approximately fulltime internal auditors across four audit groups audits range duration two manweeks simple activities scope limited several months audit involving complex highly technical processes audit teams may also supplemented external experts specific technical skills use guest auditors within business audits conducted based level risk regularly assess level internal control number responsibility areas including animal research business continuity planning community investment conduct clinical trials employment practices environmental factors ethical conduct financial processes health safety information technology intellectual property interactions patient groups manufacturing supply chain standards patient safety sales marketing practices issues control deficiencies identified audit groups recommend processes improvement gsk managers develop corrective action plans eliminate causes noncompliance gaps internal controls audit groups track plans completion report results senior management audit committee audit group reports audit committee part assurance programme provides assessment whether adequate controls place manage significant risks significant audit results also reported audit committee earliest opportunity back tophome responsibility corporate responsibility gsk assurance internal audit corporate responsibility report assurance internal audit external assurance ehs activities information provide environment health safety activities gsk externally assured independent thirdparty assurers reporting environment health safety performance assured sgs external assurer assurance process includes verification key environment health safety data site visits telephone calls ehs professionals review systems processes collecting collating analysing interpreting data read ehs assurance statement sgs external assurance access medicines activities cr report information access medicines externally assured read responding recommendations made assurers access medicines activity reporting year conduct assurance cr report described ehs section plan conduct assurance one new section report every year section report subject external assurance internal audit assurance gsk developed assurance programme provides holistic assessment internal control processes risk management audit within company key part programme extensive independent internal audit schedule delivered four specialist audit groups audits assess compliance laws regulations company standards evaluate effectiveness risk management process identifying managing mitigating significant risks facing gsk global internal audit gia responsible evaluating financial operational controls ensure financial reporting integrity safeguard assets losses including fraud corporate environment health safety sustainability cehss responsible assessing management health safety risks environmental impacts global manufacturing supply audit risk management arm assesses quality supply risks relating manufacturing supply chain processes gsk commercial products global quality compliance gqc responsible assessing risks relating medicines vaccines medical devices throughout product development process including manufacture clinical trial material central assurance function responsible developing assurance programme ensuring gsk audit groups work together efficient effective way deliver audit schedule global internal audit audits three audit groups alignment institute internal auditors international standards professional practice internal auditing cehss arm gcq audit groups additional responsibilities auditing contract manufacturers key suppliers gsk gsk employs approximately fulltime internal auditors across four audit groups audits range duration two manweeks simple activities scope limited several months audit involving complex highly technical processes audit teams may also supplemented external experts specific technical skills use guest auditors within business audits conducted based level risk regularly assess level internal control number responsibility areas including animal research business continuity planning community investment conduct clinical trials employment practices environmental factors ethical conduct financial processes health safety information technology intellectual property interactions patient groups manufacturing supply chain standards patient safety sales marketing practices issues control deficiencies identified audit groups recommend processes improvement gsk managers develop corrective action plans eliminate causes noncompliance gaps internal controls audit groups track plans completion report results senior management audit committee audit group reports audit committee part assurance programme provides assessment whether adequate controls place manage significant risks significant audit results also reported audit committee earliest opportunity back top home responsibility corporate responsibility gsk assurance internal audit corporate responsibility report assurance internal audit external assurance ehs activities information provide environment health safety activities gsk externally assured independent thirdparty assurers reporting environment health safety performance assured sgs external assurer assurance process includes verification key environment health safety data site visits telephone calls ehs professionals review systems processes collecting collating analysing interpreting data read ehs assurance statement sgs external assurance access medicines activities cr report information access medicines externally assured read responding recommendations made assurers access medicines activity reporting year conduct assurance cr report described ehs section plan conduct assurance one new section report every year section report subject external assurance internal audit assurance gsk developed assurance programme provides holistic assessment internal control processes risk management audit within company key part programme extensive independent internal audit schedule delivered four specialist audit groups audits assess compliance laws regulations company standards evaluate effectiveness risk management process identifying managing mitigating significant risks facing gsk global internal audit gia responsible evaluating financial operational controls ensure financial reporting integrity safeguard assets losses including fraud corporate environment health safety sustainability cehss responsible assessing management health safety risks environmental impacts global manufacturing supply audit risk management arm assesses quality supply risks relating manufacturing supply chain processes gsk commercial products global quality compliance gqc responsible assessing risks relating medicines vaccines medical devices throughout product development process including manufacture clinical trial material central assurance function responsible developing assurance programme ensuring gsk audit groups work together efficient effective way deliver audit schedule global internal audit audits three audit groups alignment institute internal auditors international standards professional practice internal auditing cehss arm gcq audit groups additional responsibilities auditing contract manufacturers key suppliers gsk gsk employs approximately fulltime internal auditors across four audit groups audits range duration two manweeks simple activities scope limited several months audit involving complex highly technical processes audit teams may also supplemented external experts specific technical skills use guest auditors within business audits conducted based level risk regularly assess level internal control number responsibility areas including animal research business continuity planning community investment conduct clinical trials employment practices environmental factors ethical conduct financial processes health safety information technology intellectual property interactions patient groups manufacturing supply chain standards patient safety sales marketing practices issues control deficiencies identified audit groups recommend processes improvement gsk managers develop corrective action plans eliminate causes noncompliance gaps internal controls audit groups track plans completion report results senior management audit committee audit group reports audit committee part assurance programme provides assessment whether adequate controls place manage significant risks significant audit results also reported audit committee earliest opportunity back top home responsibility corporate responsibility gsk corporate responsibility data summary corporate responsibility report corporate responsibility data summary metric access medicines number countries supplied gsk preferentially priced arvs number combivir epivir tablets shipped millions number generic arvs supplied licence gsk millions gsk combivir notforprofit price per day voluntary licences granted generic manufacturers gsk arvs cumulative total value products donated gsk patient assistance program us millions cost wholesale price wac research development expenditure rd billions gsk animal research facilities accredited association assessment accreditation laboratory animal care cumulative total number trials published gsk clinical study register cumulative total ethical conduct number employees completing certification gsk code conduct number contacts ethics compliance channels employment women management grades ethnic diversity people colour us ethnic diversity ethnic minorities uk lost time injury illness rate cases per hours worked environment number contract manufacturers audited energy consumption million gigajoules water consumption million cubic metres ozone depletion potential metered dose inhalers tonnes cfc equivalent ozone depletion potential production tonnes cfc equivalent ozone depletion potential refrigeration ancillary uses tonnes cfc equivalent volatile organic compound emissions thousand tonnes global warming potential energy sources thousand tonnes co equivalent hazardous waste disposed thousand tonnes community investment total community investment expenditure millions cost wholesale price wac value humanitarian product donations including albendazole millions cost wholesale price wac number albendazole tablets donated prevention lymphatic filariasis millions includes arvs sold notforprofit discounted prices unable collect data number patients treated includes freight delivery costs mdecins sans frontires pricing report lists average cost generic equivalents eight currently force restated figures reflect value cost average cost goods rather wholesale acquisition price wac first year valued donations way believe accurate reflection true cost gsk therefore transparent figures remain wac covers per cent animals housed gskowned laboratories includes contacts line managers compliance officers confidential integrity helplines offsite post office box us data include inhalers made asia climate change impact calculated co equivalent using greenhouse gas protocol developed world resources institute world business council sustainable development year review co factors update data years appropriate greatest changes generally updated factors electricity back tophome responsibility corporate responsibility gsk corporate responsibility data summary corporate responsibility report corporate responsibility data summary metric access medicines number countries supplied gsk preferentially priced arvs number combivir epivir tablets shipped millions number generic arvs supplied licence gsk millions gsk combivir notforprofit price per day voluntary licences granted generic manufacturers gsk arvs cumulative total value products donated gsk patient assistance program us millions cost wholesale price wac research development expenditure rd billions gsk animal research facilities accredited association assessment accreditation laboratory animal care cumulative total number trials published gsk clinical study register cumulative total ethical conduct number employees completing certification gsk code conduct number contacts ethics compliance channels employment women management grades ethnic diversity people colour us ethnic diversity ethnic minorities uk lost time injury illness rate cases per hours worked environment number contract manufacturers audited energy consumption million gigajoules water consumption million cubic metres ozone depletion potential metered dose inhalers tonnes cfc equivalent ozone depletion potential production tonnes cfc equivalent ozone depletion potential refrigeration ancillary uses tonnes cfc equivalent volatile organic compound emissions thousand tonnes global warming potential energy sources thousand tonnes co equivalent hazardous waste disposed thousand tonnes community investment total community investment expenditure millions cost wholesale price wac value humanitarian product donations including albendazole millions cost wholesale price wac number albendazole tablets donated prevention lymphatic filariasis millions includes arvs sold notforprofit discounted prices unable collect data number patients treated includes freight delivery costs mdecins sans frontires pricing report lists average cost generic equivalents eight currently force restated figures reflect value cost average cost goods rather wholesale acquisition price wac first year valued donations way believe accurate reflection true cost gsk therefore transparent figures remain wac covers per cent animals housed gskowned laboratories includes contacts line managers compliance officers confidential integrity helplines offsite post office box us data include inhalers made asia climate change impact calculated co equivalent using greenhouse gas protocol depvaegleo pe odf world resources institute world business council sustainable development year review co factors update data years appropriate greatest changes generally updated factors electricity back tophome responsibility corporate responsibility gsk corporate responsibility data summary corporate responsibility report corporate responsibility data summary metric access medicines number countries supplied gsk preferentially priced arvs number combivir epivir tablets shipped millions number generic arvs supplied licence gsk millions gsk combivir notforprofit price per day voluntary licences granted generic manufacturers gsk arvs cumulative total value products donated gsk patient assistance program us millions cost wholesale price wac research development expenditure rd billions gsk animal research facilities accredited association assessment accreditation laboratory animal care cumulative total number trials published gsk clinical study register cumulative total ethical conduct number employees completing certification gsk code conduct number contacts ethics compliance channels employment women management grades ethnic diversity people colour us ethnic diversity ethnic minorities uk lost time injury illness rate cases per hours worked environment number contract manufacturers audited energy consumption million gigajoules water consumption million cubic metres ozone depletion potential metered dose inhalers tonnes cfc equivalent ozone depletion potential production tonnes cfc equivalent ozone depletion potential refrigeration ancillary uses tonnes cfc equivalent volatile organic compound emissions thousand tonnes global warming potential energy sources thousand tonnes co equivalent hazardous waste disposed thousand tonnes community investment total community investment expenditure millions cost wholesale price wac value humanitarian product donations including albendazole millions cost wholesale price wac number albendazole tablets donated prevention lymphatic filariasis millions includes arvs sold notforprofit discounted prices unable collect data number patients treated includes freight delivery costs mdecins sans frontires pricing report lists average cost generic equivalents eight currently force restated figures reflect value cost average cost goods rather wholesale acquisition price wac first year valued donations way believe accurate reflection true cost gsk therefore transparent figures remain wac covers per cent animals housed gskowned laboratories includes contacts line managers compliance officers confidential integrity helplines offsite post office box us data include inhalers made asia climate change impact calculated co equivalent using greenhouse gas protocol developed world resources institute world business council sustainable development year review co factors update data years appropriate greatest changes generally updated factors electricity back top home responsibility corporate responsibility gsk corporate responsibility data summary corporate responsibility report corporate responsibility data summary metric access medicines number countries supplied gsk preferentially priced arvs number combivir epivir tablets shipped millions number generic arvs supplied licence gsk millions gsk combivir notforprofit price per day voluntary licences granted generic manufacturers gsk arvs cumulative total value products donated gsk patient assistance program us millions cost wholesale price wac research development expenditure rd billions gsk animal research facilities accredited association assessment accreditation laboratory animal care cumulative total number trials published gsk clinical study register cumulative total ethical conduct number employees completing certification gsk code conduct number contacts ethics compliance channels employment women management grades ethnic diversity people colour us ethnic diversity ethnic minorities uk lost time injury illness rate cases per hours worked environment number contract manufacturers audited energy consumption million gigajoules water consumption million cubic metres ozone depletion potential metered dose inhalers tonnes cfc equivalent ozone depletion potential production tonnes cfc equivalent ozone depletion potential refrigeration ancillary uses tonnes cfc equivalent volatile organic compound emissions thousand tonnes global warming potential energy sources thousand tonnes co equivalent hazardous waste disposed thousand tonnes community investment total community investment expenditure millions cost wholesale price wac value humanitarian product donations including albendazole millions cost wholesale price wac number albendazole tablets donated prevention lymphatic filariasis millions includes arvs sold notforprofit discounted prices unable collect data number patients treated includes freight delivery costs mdecins sans frontires pricing report lists average cost generic equivalents eight currently force restated figures reflect value cost average cost goods rather wholesale acquisition price wac first year valued donations way believe accurate reflection true cost gsk therefore transparent figures remain wac covers per cent animals housed gskowned laboratories includes contacts line managers compliance officers confidential integrity helplines offsite post office box us data include inhalers made asia climate change impact calculated co equivalent using greenhouse gas protocol developed world resources institute world business council sustainable development year review co factors update data years appropriate greatest changes generally updated factors electricity back top home responsibility corporate responsibility gsk resources downloads corporate responsibility report resources downloads reporting corporate responsibility report commitment transparency access corporate responsibility highlights pdf kb gri index pdf kb global compact index pdf kb corporate responsibility data summary environmental metrics archive reports additional resources access medicines briefing paper access medicines pdf kb findings stakeholder engagement sessions gsk access hiv medicines workshop pdf kb gsk ddw workshop findings pdf kb gsk mic workshop findings pdf kb ethical conduct gsk code conduct pdf kb employee guide business conduct pdf mb gsk european promotion medicines code practice pdf kb human rights human rights statement pdf kb public policy patient advocacy public policy position statements details relationships patient groups back top home responsibility corporate responsibility gsk resources downloads corporate responsibility report resources downloads reporting corporate responsibility report commitment transparency access corporate responsibility highlights pdf kb gri index pdf kb global compact index pdf kb corporate responsibility data summary environmental metrics archive reports additional resources access medicines briefing paper access medicines pdf kb findings stakeholder engagement sessions gsk access hiv medicines workshop pdf kb gsk ddw workshop findings pdf kb gsk mic workshop findings pdf kb ethical conduct gsk code conduct pdf kb employee guide business conduct pdf mb gsk european promotion medicines code practice pdf kb human rights human rights statement pdf kb public policy patient advocacy public policy position statements details relationships patient groups back top home responsibility contribution global health corporate responsibility report contribution global health respond societys healthcare needs important responsibility issue gsk also central commercial success ill health disease continue place huge burden society aids epidemic africa asia health needs ageing population developed world huge global growth chronic diseases diabetes emerging diseases pandemic flu pose potentially serious threats ill health also expensive increase healthcare costs reduce economic productivity business makes significant contribution society bringing products market address medical needs patients around world make contribution four key areas preventing disease one worlds largest producers vaccines diseases prevalent developed developing countries also prevent disease community investment disease awareness work overthe counter products treating ill health many products treat diseases place high burden society investing rd pipeline includes new medicines vaccines needed developing developed countries contributing scientific understanding participate partnerships advance scientific knowledge lay ground future medical advances believe business makes significant contribution society looking ways accelerate research neglected diseases sharing research resources findings organisations expanding partnerships governments ngos pharmaceutical companies also want partner others support delivery healthcare services well medicines products beneficial accessible affordable healthcare payers patients read efforts increase access key products developing developed countries support healthcare programmes community investment back top home responsibility contribution global health corporate responsibility report contribution global health respond societys healthcare needs important responsibility issue gsk also central commercial success ill health disease continue place huge burden society aids epidemic africa asia health needs ageing population developed world huge global growth chronic diseases diabetes emerging diseases pandemic flu pose potentially serious threats ill health also expensive increase healthcare costs reduce economic productivity business makes significant contribution society bringing products market address medical needs patients around world make contribution four key areas preventing disease one worlds largest producers vaccines diseases prevalent developed developing countries also prevent disease community investment disease awareness work overthe counter products treating ill health many products treat diseases place high burden society investing rd pipeline includes new medicines vaccines needed developing developed countries contributing scientific understanding participate partnerships advance scientific knowledge lay ground future medical advances believe business makes significant contribution society looking ways accelerate research neglected diseases sharing research resources findings organisations expanding partnerships governments ngos pharmaceutical companies also want partner others support delivery healthcare services well medicines products beneficial accessible affordable healthcare payers patients read efforts increase access key products developing developed countries support healthcare programmes community investment back top home responsibility contribution global health cost disease corporate responsibility report cost disease ill health expensive individual society often result poverty also important cause poverty patients mean loss quality life loss earnings shortened life expectancy place great burden families instance need care sick relatives reduce attendance school work governments employers taxpayers mean increased healthcare costs loss workforce productivity africa parts asia aids serious effect social economic development undermining progress towards millennium development goals poverty reduction efforts world bank estimates deaths working age adults hivaids may subtract one per cent year gdp economic growth subsaharan african countries south africa hivaids may depress gdp much per cent next decade malaria estimated cost african nations least billion year lost economic output economic cost tbrelated deaths including hiv coinfection sub saharan africa estimated billion read research diseases developing world efforts help people countries access essential medicines vaccines according us governments centers disease control prevention cdc costs chronic disease us alone include billion year direct indirect costs due diabetes billion annual medical care costs arthritis total costs including medical care lost productivity almost billion billion projected cost heart disease stroke read working partnership us combat chronic disease role vaccines preventing disease wwwwhointtradeglossarystoryenindexhtml rollback malaria httprbmwhointglobaladvocacyprhtml httpwwwwhointmediacentrenewsreleasesprenindexhtml wwwcdcgovnccdphpoverviewhtm back top home responsibility contribution global health cost disease corporate responsibility report cost disease ill health expensive individual society often result poverty also important cause poverty patients mean loss quality life loss earnings shortened life expectancy place great burden families instance need care sick relatives reduce attendance school work governments employers taxpayers mean increased healthcare costs loss workforce productivity africa parts asia aids serious effect social economic development undermining progress towards millennium development goals poverty reduction efforts world bank estimates deaths working age adults hivaids may subtract one per cent year gdp economic growth subsaharan african countries south africa hivaids may depress gdp much per cent next decade malaria estimated cost african nations least billion year lost economic output economic cost tbrelated deaths including hiv coinfection sub saharan africa estimated billion read research diseases developing world efforts help people countries access essential medicines vaccines according us governments centers disease control prevention cdc costs chronic disease us alone include billion year direct indirect costs due diabetes billion annual medical care costs arthritis total costs including medical care lost productivity almost billion billion projected cost heart disease stroke read working partnership us combat chronic disease role vaccines preventing disease wwwwhointtradeglossarystoryenindexhtml rollback malaria httprbmwhointglobaladvocacyprhtml httpwwwwhointmediacentrenewsreleasesprenindexhtml wwwcdcgovnccdphpoverviewhtm back top home responsibility contribution global health role vaccines corporate responsibility report role vaccines vaccines play major role preventing eliminating disease immunisation acknowledged world health organization among cost effective health investments immunisation programmes make substantial contribution aims united nations millennium development goals economic growth estimated least three million deaths prevented children saved disability due vaccines every year number deaths africa measles fell per cent due better coverage routine immunisation programmes targeted campaigns ensure children second chance vaccinated despite progress vaccines underused estimated lives two million children could saved year existing vaccines made accessible need require sustained financing development innovative vaccination programmes gsk among worlds top vaccine providers vaccines approved marketing rd pipeline onethird target diseases particularly prevalent developing world gsk vaccines included immunisation campaigns countries worldwide scientists work vaccine research gsk believe vaccine pipeline largest industry remain committed researching developing vaccines three infectious disease priorities tuberculosis hiv malaria together path malaria vaccine initiative demonstrated phase trials significant protection malaria infants young children gsks rtss candidate vaccine read malaria vaccine supplied billion vaccine doses nearly per cent shipped use developing countries read tiered pricing system vaccines vaccine portfolio addresses medical needs developing developed countries portfolio covers leading causes childhood mortality defined world health organization vaccine range includes products protect following diseases cervical cancer pneumococcal disease chickenpox polio diphtheria rotavirus hepatitis b rubella measles seasonal influenza meningitis tetanus mumps typhoid pandemic influenza whooping cough pertussis ehreth j global value vaccination vaccine progress global measles control mortality reduction wwwwhointwerwerpdf back top home responsibility contribution global health role vaccines corporate responsibility report role vaccines vaccines play major role preventing eliminating disease immunisation acknowledged world health organization among cost effective health investments immunisation programmes make substantial contribution aims united nations millennium development goals economic growth estimated least three million deaths prevented children saved disability due vaccines every year number deaths africa measles fell per cent due better coverage routine immunisation programmes targeted campaigns ensure children second chance vaccinated despite progress vaccines underused estimated lives two million children could saved year existing vaccines made accessible need require sustained financing development innovative vaccination programmes gsk among worlds top vaccine providers vaccines approved marketing rd pipeline onethird target diseases particularly prevalent developing world gsk vaccines included immunisation campaigns countries worldwide scientists work vaccine research gsk believe vaccine pipeline largest industry remain committed researching developing vaccines three infectious disease priorities tuberculosis hiv malaria together path malaria vaccine initiative demonstrated phase trials significant protection malaria infants young children gsks rtss candidate vaccine read malaria vaccine supplied billion vaccine doses nearly per cent shipped use developing countries read tiered pricing system vaccines vaccine portfolio addresses medical needs developing developed countries portfolio covers leading causes childhood mortality defined world health organization vaccine range includes products protect following diseases cervical cancer pneumococcal disease chickenpox polio diphtheria rotavirus hepatitis b rubella measles seasonal influenza meningitis tetanus mumps typhoid pandemic influenza whooping cough pertussis ehreth j global value vaccination vaccine progress global measles control mortality reduction wwwwhointwerwerpdf back top home responsibility contribution global health role vaccines corporate responsibility report role vaccines vaccines play major role preventing eliminating disease immunisation acknowledged world health organization among cost effective health investments immunisation programmes make substantial contribution aims united nations millennium development goals economic growth estimated least three million deaths prevented children saved disability due vaccines every year number deaths africa measles fell per cent due better coverage routine immunisation programmes targeted campaigns ensure children second chance vaccinated despite progress vaccines underused estimated lives two million children could saved year existing vaccines made accessible need require sustained financing development innovative vaccination programmes gsk among worlds top vaccine providers vaccines approved marketing rd pipeline onethird target diseases particularly prevalent developing world gsk vaccines included immunisation campaigns countries worldwide scientists work vaccine research gsk believe vaccine pipeline largest industry remain committed researching developing vaccines three infectious disease priorities tuberculosis hiv malaria together path malaria vaccine initiative demonstrated phase trials significant protection malaria infants young children gsks rtss candidate vaccine read malaria vaccine supplied billion vaccine doses nearly per cent shipped use developing countries read tiered pricing system vaccines vaccine portfolio addresses medical needs developing developed countries portfolio covers leading causes childhood mortality defined world health organization vaccine range includes products protect following diseases cervical cancer pneumococcal disease chickenpox polio diphtheria rotavirus hepatitis b rubella measles seasonal influenza meningitis tetanus mumps typhoid pandemic influenza whooping cough pertussis ehreth j global value vaccination vaccine progress global measles control mortality reduction wwwwhointwerwerpdf back top home responsibility contribution global health treating ill health corporate responsibility report treating ill health help treat ill health developing medicines consumer healthcare products also working governments employers us find innovative ways reduce impact chronic diseases pharmaceutical products target diseases following areas antibacterials antibiotics antimalarials infections malaria antivirals hivaids herpes hepatitis b influenza cardiovascular heart failure hypertension deep vein thrombosis central nervous system migraine epilepsy anxiety depression parkinsons disease smoking cessation anaesthesia analgesia antiemetics dermatology eczema dermatitis psoriasis metabolic diabetes osteoporosis obesity oncology breast cervical lung ovarian cancer nonhodgkins lymphoma leukaemia idiopathic thrombocytopaenic purpura respiratory immunoinflammation asthma chronic obstructive pulmonary disease rhinitis post operative ileus urogenital prostatic hypertrophy overactive bladder also make vaccines prevent serious diseases products help improve health number ways prolonging life antiretrovirals arvs combivir help patients control effects hiv infection many years sell arvs least developed countries countries sub saharan africa notforprofit prices read efforts increase access medicines preventing complications many diseases diabetes progressive patients receive right treatment suffer severe complications example every day us diabetes cause estimated lower limb amputations cases blindness people experiencing kidney failure avandia diabetes treatment helps patients control symptoms delays progression disease prevents complications avandia used seven million people worldwide improving quality life many medicines asthma diabetes help patients chronic diseases live full productive lives gsk preventative treatments asthma seretideadvair control symptoms asthma prevent asthma attacks curing infection produce antibiotics treat respiratory tract infections donate antibiotics help relief efforts disaster areas paracetamol paracetamol widely used lowcost medicine treating adult child pain fever listed one world health organizations essential medicines gsk produces ten billion tablets year overthecounter paracetomol product panadol available countries includes low middleincome countries provide affordable lowcost singledose packs medical guidelines across globe recommend paracetamol medicine panadol firstline oral painkiller chronic diseases osteoarthritis due efficacy safety profile cost effectiveness also firstchoice treatment conditions headache backache childrens fever paracetamol recommended treatment symptoms dengue fever debilitating life threatening disease transmitted mosquitoes tropical subtropical regions billion people risk infection twofifths worlds population countries read efforts increase awareness dengue fever correct treatment back tophome responsibility contribution global health treating ill health corporate responsibility report treating ill health help treat ill health developing medicines consumer healthcare products also working governments employers us find innovative ways reduce impact chronic diseases pharmaceutical products target diseases following areas antibacterials antibiotics antimalarials infections malaria antivirals hivaids herpes hepatitis b influenza cardiovascular heart failure hypertension deep vein thrombosis central nervous system migraine epilepsy anxiety depression parkinsons disease smoking cessation anaesthesia analgesia antiemetics dermatology eczema dermatitis psoriasis metabolic diabetes osteoporosis obesity oncology breast cervical lung ovarian cancer nonhodgkins lymphoma leukaemia idiopathic thrombocytopaenic purpura respiratory immunoinflammation asthma chronic obstructive pulmonary disease rhinitis post operative ileus urogenital prostatic hypertrophy overactive bladder also make vaccines prevent serious diseases products help improve health number ways prolonging life antiretrovirals arvs combivir help patients control effects hiv infection many years sell arvs least developed countries countries sub saharan africa notforprofit prices read efforts increase access medicines preventing complications many diseases diabetes progressive patients receive right treatment suffer severe complications example every day us diabetes cause estimated lower limb amputations cases blindness people experiencing kidney failure avandia diabetes treatment helps patients control symptoms delays progression disease prevents complications avandia used seven million people worldwide improving quality life many medicines asthma diabetes help patients chronic diseases live full productive lives gsk preventative treatments asthma seretideadvair control symptoms asthma prevent asthma attacks curing infection produce antibiotics treat respiratory tract infections donate antibiotics help relief efforts disaster areas paracetamol paracetamol widely used lowcost medicine treating adult child pain fever listed one world health organizations essential medicines gsk produces ten billion tablets year overthecounter paracetomol product panadol available countries includes low middleincome countries provide affordable lowcost singledose packs medical guidelines across globe recommend paracetamol medicine panadol firstline oral painkiller chronic diseases osteoarthritis due efficacy safety profile cost effectiveness also firstchoice treatment conditions headache backache childrens fever paracetamol recommended treatment symptoms dengue fever debilitating life threatening disease transmitted mosquitoes tropical subtropical regions billion people risk infection twofifths worlds population countries read efforts increase awareness dengue fever correct treatment back top home responsibility contribution global health treating ill health corporate responsibility report treating ill health help treat ill health developing medicines consumer healthcare products also working governments employers us find innovative ways reduce impact chronic diseases pharmaceutical products target diseases following areas antibacterials antibiotics antimalarials infections malaria antivirals hivaids herpes hepatitis b influenza cardiovascular heart failure hypertension deep vein thrombosis central nervous system migraine epilepsy anxiety depression parkinsons disease smoking cessation anaesthesia analgesia antiemetics dermatology eczema dermatitis psoriasis metabolic diabetes osteoporosis obesity oncology breast cervical lung ovarian cancer nonhodgkins lymphoma leukaemia idiopathic thrombocytopaenic purpura respiratory immunoinflammation asthma chronic obstructive pulmonary disease rhinitis post operative ileus urogenital prostatic hypertrophy overactive bladder also make vaccines prevent serious diseases products help improve health number ways prolonging life antiretrovirals arvs combivir help patients control effects hiv infection many years sell arvs least developed countries countries sub saharan africa notforprofit prices read efforts increase access medicines preventing complications many diseases diabetes progressive patients receive right treatment suffer severe complications example every day us diabetes cause estimated lower limb amputations cases blindness people experiencing kidney failure avandia diabetes treatment helps patients control symptoms delays progression disease prevents complications avandia used seven million people worldwide improving quality life many medicines asthma diabetes help patients chronic diseases live full productive lives gsk preventative treatments asthma seretideadvair control symptoms asthma prevent asthma attacks curing infection produce antibiotics treat respiratory tract infections donate antibiotics help relief efforts disaster areas paracetamol paracetamol widely used lowcost medicine treating adult child pain fever listed one world health organizations essential medicines gsk produces ten billion tablets year overthecounter paracetomol product panadol available countries includes low middleincome countries provide affordable lowcost singledose packs medical guidelines across globe recommend paracetamol medicine panadol firstline oral painkiller chronic diseases osteoarthritis due efficacy safety profile cost effectiveness also firstchoice treatment conditions headache backache childrens fever paracetamol recommended treatment symptoms dengue fever debilitating life threatening disease transmitted mosquitoes tropical subtropical regions billion people risk infection twofifths worlds population countries read efforts increase awareness dengue fever correct treatment back top home responsibility contribution global health treating ill health partnering combat chronic disease corporate responsibility report partnering combat chronic diseases healthcare costs many countries concern patients healthcare payers pharmaceutical industry alike increase prevalence many chronic diseases asthma diabetes heart disease major contributing factor working governments employers find new ways address problem chronic diseases reducing healthcare costs approach known triple solution three focus areas prevention addressing causes chronic diseases obesity smoking poor diet lack exercise intervention properly managing chronic diseases prevent complications avoid hospitalisation costs reduce time away work innovation developing new treatments costly unmet medical needs alzheimers disease stroke working employers communities us healthcare major source expenditure government employers consumers expenditures us healthcare exceeded trillion additionally absence work due ill health significant cost often goes unrecognised work closely state local public health agencies large number employers across us help create health management programmes remove barriers healthcare access reduce healthcare costs improve health organisation worked ten states five municipalities employers help address diseases put great burden healthcare budgets encourage employers provide preventative services workers example regular health screening detect early signs disease awareness campaigns initiatives help employees adopt healthy lifestyle develop disease management programmes help employees control symptoms stick treatment regimens initiate comprehensive wellness initiatives obesity smoking leading products smoking leading cause death disease united states direct indirect costs associated overweight obese estimated exceed billion per year us approximately nine per cent annual medical expenditures may advise employers create new incentives better health management example reducing copay element prescription medicine charges increase total amount employers pay pharmaceuticals short term however improving patient medication adherence rates prevent costly complications time away work longer term help lower overall healthcare costs diabetes ten city challenge day us diabetes causes estimated lower limb amputations people lose sight however right treatment many complications prevented diabetes ten city challenge supported gsk partnership city governments private employers ten cities american pharmacist association apha foundation pharmacistpsag iet olfp employees diabetes manage condition nutrition medication adopting healthy lifestyle aims prevent serious sideeffects reduce associated healthcare costs key features include lower copays portion prescription costs paid patient making medicines affordable making likely patients adhere prescribed treatment regimen regular meetings patients pharmacists discuss symptoms identify potential complications early possible help participants set achieve nutrition exercise weight loss goals including printed materials meetings pharmacist coaches share challenges findings resources employers outside ten cities dedicated website programme based apha foundations asheville project helped reduce healthcare costs participating employees per cent cut absenteeism per cent average pilot project based asheville project launched japan run team showa university pilot involve diabetes asthma patients twoyear period community health centres donated st cecilias health centre new orleans ninth ward part city saw great devastation hurricane katrina money used fund clinics community diabetes outreach program helped exceed us national average percentage diabetics receiving regular tests controlling symptoms read efforts raise awareness prevent disease back tophome responsibility contribution global health treating ill health partnering combat chronic disease corporate responsibility report partnering combat chronic diseases healthcare costs many countries concern patients healthcare payers pharmaceutical industry alike increase prevalence many chronic diseases asthma diabetes heart disease major contributing factor working governments employers find new ways address problem chronic diseases reducing healthcare costs approach known triple solution three focus areas prevention addressing causes chronic diseases obesity smoking poor diet lack exercise intervention properly managing chronic diseases prevent complications avoid hospitalisation costs reduce time away work innovation developing new treatments costly unmet medical needs alzheimers disease stroke working employers communities us healthcare major source expenditure government employers consumers expenditures us healthcare exceeded trillion additionally absence work due ill health significant cost often goes unrecognised work closely state local public health agencies large number employers across us help create health management programmes remove barriers healthcare access reduce healthcare costs improve health organisation worked ten states five municipalities employers help address diseases put great burden healthcare budgets encourage employers provide preventative services workers example regular health screening detect early signs disease awareness campaigns initiatives help employees adopt healthy lifestyle develop disease management programmes help employees control symptoms stick treatment regimens initiate comprehensive wellness initiatives obesity smoking leading products smoking leading cause death disease united states direct indirect costs associated overweight obese estimated exceed billion per year us approximately nine per cent annual medical expenditures may advise employers create new incentives better health management example reducing copay element prescription medicine charges increase total amount employers pay pharmaceuticals short term however improving patient medication adherence rates prevent costly complications time away work longer term help lower overall healthcare costs diabetes ten city challenge day us diabetes causes estimated lower limb amputations people lose sight however right treatment many complications prevented diabetes ten city challenge supported gsk partnership city governments private employers ten cities american pharmacist association apha foundation pharmacists helps employees diabetes manage condition nutrition medication adopting healthy lifestyle aims prevent serious sideeffects reduce associated healthcare costs key features include lower copays portion prescription costs paid patient making medicines affordable making likely patients adhere prescribed treatment regimen regular meetings patients pharmacists discuss symptoms identify potential complications early possible help participants set achieve nutrition exercise weight loss goals including printed materials meetings pharmacist coaches share challenges findings resources employers outside ten cities dedicated website programme based apha foundations asheville project helped reduce healthcare costs participating employees per cent cut absenteeism per cent average pilot project based asheville project launched japan run team showa university pilot involve diabetes asthma patients twoyear period community health centres donated st cecilias health centre new orleans ninth ward part city saw great devastation hurricane katrina money used fund clinics community diabetes outreach program helped exceed us national average percentage diabetics receiving regular tests controlling symptoms read efforts raise awareness prevent disease back top home responsibility contribution global health treating ill health partnering combat chronic disease corporate responsibility report partnering combat chronic diseases healthcare costs many countries concern patients healthcare payers pharmaceutical industry alike increase prevalence many chronic diseases asthma diabetes heart disease major contributing factor working governments employers find new ways address problem chronic diseases reducing healthcare costs approach known triple solution three focus areas prevention addressing causes chronic diseases obesity smoking poor diet lack exercise intervention properly managing chronic diseases prevent complications avoid hospitalisation costs reduce time away work innovation developing new treatments costly unmet medical needs alzheimers disease stroke working employers communities us healthcare major source expenditure government employers consumers expenditures us healthcare exceeded trillion additionally absence work due ill health significant cost often goes unrecognised work closely state local public health agencies large number employers across us help create health management programmes remove barriers healthcare access reduce healthcare costs improve health organisation worked ten states five municipalities employers help address diseases put great burden healthcare budgets encourage employers provide preventative services workers example regular health screening detect early signs disease awareness campaigns initiatives help employees adopt healthy lifestyle develop disease management programmes help employees control symptoms stick treatment regimens initiate comprehensive wellness initiatives obesity smoking leading products smoking leading cause death disease united states direct indirect costs associated overweight obese estimated exceed billion per year us approximately nine per cent annual medical expenditures may advise employers create new incentives better health management example reducing copay element prescription medicine charges increase total amount employers pay pharmaceuticals short term however improving patient medication adherence rates prevent costly complications time away work longer term help lower overall healthcare costs diabetes ten city challenge day us diabetes causes estimated lower limb amputations people lose sight however right treatment many complications prevented diabetes ten city challenge supported gsk partnership city governments private employers ten cities american pharmacist association apha foundation pharmacists helps employees diabetes manage condition nutrition medication adopting healthy lifestyle aims prevent serious sideeffects reduce associated healthcare costs key features include lower copays portion prescription costs paid patient making medicines affordable making likely patients adhere prescribed treatment regimen regular meetings patients pharmacists discuss symptoms identify potential complications early possible help participants set achieve nutrition exercise weight loss goals including printed materials meetings pharmacist coaches share challenges findings resources employers outside ten cities dedicated website programme based apha foundations asheville project helped reduce healthcare costs participating employees per cent cut absenteeism per cent average pilot project based asheville project launched japan run team showa university pilot involve diabetes asthma patients twoyear period community health centres donated st cecilias health centre new orleans ninth ward part city saw great devastation hurricane katrina money used fund clinics community diabetes outreach program helped exceed us national average percentage diabetics receiving regular tests controlling symptoms read efforts raise awareness prevent disease back top home responsibility contribution global health disease awareness prevention corporate responsibility report disease awareness prevention one worlds largest producers vaccines play vital role preventing disease also develop overthecounter products help people stop smoking lose weight maintain good oral health help raise awareness among healthcare professionals public work patient groups disease awareness campaigns take place coincide launch new product market positive impact public health create commercial benefits gsk read efforts raise awareness prevent disease home responsibility contribution global health disease awareness prevention corporate responsibility report disease awareness prevention one worlds largest producers vaccines play vital role preventing disease also develop overthecounter products help people stop smoking lose weight maintain good oral health help raise awareness among healthcare professionals public work patient groups disease awareness campaigns take place coincide launch new product market positive impact public health create commercial benefits gsk read efforts raise awareness prevent disease home responsibility contribution global health disease awareness prevention raising awareness disease corporate responsibility report raising awareness disease ran range disease awareness campaigns including pandemic flu world health organization considers world closer another flu pandemic time since last outbreak held workshop journalists european influenza congress portugal highlight threat pandemic flu journalists play important role raising government awareness health issues influencing health policy workshop participants spent two hours talking independent experts discussing key subjects learn past pandemics personal economic impacts outbreak role vaccines governments prepare read gsks flu products efforts help prepare pandemic flu cervical cancer vaccine cervarix helps prevent infection cancercausing types human papillomavirus hpv commonly lead cervical cancer year launched cervarix europe research region showed two per cent women knew link hpv cervical cancer since run disease awareness campaigns across many countries highlight link educate people importance screening help prevent cervical cancer campaigns target healthcare professionals media policy makers women press articles educational events healthcare professionals support cervical cancer patient groups activities european cervical cancer prevention week rotavirus rotarix vaccine rotavirus leading cause gastroenteritis infection rotavirus associated million clinic visits two million hospitalisations deaths worldwide among children five every year launch rotarix mexico latin american countries preceded widespread disease awareness campaign achieve gsk educated journalists gastroenteritis infection caused rotavirus causes prevent detect symptoms early rotavirus quickly become fatal child becomes dehydrated receive treatment educational materials discuss vaccination give guidance prompt detection treatment methods chronic diseases us us healthy communities programme offered free health screenings communities across country aims educate people chronic diseases encourage take better control health people manage chronic diseases may develop complications leading greater health problems announced findings nationwide health screenings people conducted part programme although approximately per cent participants reported health excellent tests indicated many good health example nearly half participants type diabetes showed poor glucose control nearly third asthmatics screened poor control condition individuals poorly controlled diabetes asthma twothirds visited primary care physician past year gsk partnered national association chronic disease directors nacdd webmd health information site help people become engaged managing health part triple solution approach encourage people assess risk chronic diseases using health check tool provides advice five biggest health risks dengue fever paracetamol recommended effective symptomatic treatment dengue fever debilitating disease transmitted mosquitoes tropical subtropical regions people know correct treatment dengue fever especially children people often use feverreducers aspirin exacerbate bleeding symptom dengue fever also seek medical treatment late increases risk serious complications death panadol gsks overthecounter paracetamol brand strong presence regions dengue fever prevalent notably asia africa middle east central south america gsk position take lead driving global awareness among healthcare professionals public dengue fever threat initiated sponsored dengue fever public awareness campaign highrisk areas including caribbean southeast asia worked collaboration organisations unicef pan america health organization also engage locally respected campaign ambassadors campaigns increase awareness television radio pr activities well roadside banners posters hospitals public health centres pharmacies drugstores local media picked activities helping raise awareness health professionals targeted raise awareness provide information help diagnosis treatment free panadol samples distributed hospitals campaign run costa rica contributed per cent reduction dengue fever cases reported board health campaign run number cases increased per cent gsk activated campaign collaboration board health end ' save lives ' campaign contributed per cent reduction dengue cases similarly panadol campaign contributed decreases southeast asian dengue cases especially indonesia dengue fever fatality rate dropped per cent previous year gsk planning continue campaign beyond parashar ud et al global illness deaths caused rotavirus disease children emerg infect dis data file back tophome responsibility contribution global health disease awareness prevention raising awareness disease corporate responsibility report raising awareness disease ran range disease awareness campaigns including pandemic flu world health organization considers world closer another flu pandemic time since last outbreak held workshop journalists european influenza congress portugal highlight threat pandemic flu journalists play important role raising government awareness health issues influencing health policy workshop participants spent two hours talking independent experts discussing key subjects learn past pandemics personal economic impacts outbreak role vaccines governments prepare read gsks flu products efforts help prepare pandemic flu cervical cancer vaccine cervarix helps prevent infection cancercausing types human papillomavirus hpv commonly lead cervical cancer year launched cervarix europe research region showed two per cent women knew link hpv cervical cancer since run disease awareness campaigns across many countries highlight link educate people importance screening help prevent cervical cancer campaigns target healthcare professionals media policy makers women press articles educational events healthcare professionals support cervical cancer patient groups activities european cervical cancer prevention week rotavirus rotarix vaccine rotavirus leading cause gastroenteritis infection rotavirus associated million clinic visits two million hospitalisations deaths worldwide among children five every year launch rotarix mexico latin american countries preceded widespread disease awareness campaign achieve gsk educated journalists gastroenteritis infection caused rotavirus causes prevent detect symptoms early rotavirus quickly become fatal child becomes dehydrated receive treatment educational materials discuss vaccination give guidance prompt detection treatment methods chronic diseases us us healthy communities programme offered free health screenings communities across country aims educate people chronic diseases encourage take better control health people manage chronic diseases may develop complications leading greater health problems announced findings nationwide health screenings people conducted part programme although approximately per cent participants reported health excellent tests indicated many good health example nearly half participants type diabetes showed poor glucose control nearly third asthmatics screened poor control condition individuals poorly controlled diabetes asthma twothirds visited primary care physician past year gsk partnered national association chronic disease directors nacdd webmd health information site help people become engaged managing health part triple solution approach encourage people assess risk chronic diseases using health check tool provides advice five biggest health risks dengue fever paracetamol recommended effective symptomatic treatment dengue fever debilitating disease transmitted mosquitoes tropical subtropical regions people know correct treatment dengue fever especially children people often use feverreducers aspirin exacerbate bleeding symptom dengue fever also seek medical treatment late increases risk serious complications death panadol gsks overthecounter paracetamol brand strong presence regions dengue fever prevalent notably asia africa middle east central south america gsk position take lead driving global awareness among healthcare professionals public dengue fever threat initiated sponsored dengue fever public awareness campaign highrisk areas including caribbean southeast asia worked collaboration organisations unicef pan america health organization also engage locally respected campaign ambassadors campaigns increase awareness television radio pr activities well roadside banners posters hospitals public health centres pharmacies drugstores local media picked activities helping raise awareness health professionals targeted raise awareness provide information help diagnosis treatment free panadol samples distributed hospitals campaign run costa rica contributed per cent reduction dengue fever cases reported board health campaign run number cases increased per cent gsk activated campaign collaboration board health end ' save lives ' campaign contributed per cent reduction dengue cases similarly panadol campaign contributed decreases southeast asian dengue cases especially indonesia dengue fever fatality rate dropped per cent previous year gsk planning continue campaign beyond parashar ud et al global illness deaths caused rotavirus disease children emerg infect dis data file back top home responsibility contribution global health disease awareness prevention raising awareness disease corporate responsibility report raising awareness disease ran range disease awareness campaigns including pandemic flu world health organization considers world closer another flu pandemic time since last outbreak held workshop journalists european influenza congress portugal highlight threat pandemic flu journalists play important role raising government awareness health issues influencing health policy workshop participants spent two hours talking independent experts discussing key subjects learn past pandemics personal economic impacts outbreak role vaccines governments prepare read gsks flu products efforts help prepare pandemic flu cervical cancer vaccine cervarix helps prevent infection cancercausing types human papillomavirus hpv commonly lead cervical cancer year launched cervarix europe research region showed two per cent women knew link hpv cervical cancer since run disease awareness campaigns across many countries highlight link educate people importance screening help prevent cervical cancer campaigns target healthcare professionals media policy makers women press articles educational events healthcare professionals support cervical cancer patient groups activities european cervical cancer prevention week rotavirus rotarix vaccine rotavirus leading cause gastroenteritis infection rotavirus associated million clinic visits two million hospitalisations deaths worldwide among children five every year launch rotarix mexico latin american countries preceded widespread disease awareness campaign achieve gsk educated journalists gastroenteritis infection caused rotavirus causes prevent detect symptoms early rotavirus quickly become fatal child becomes dehydrated receive treatment educational materials discuss vaccination give guidance prompt detection treatment methods chronic diseases us us healthy communities programme offered free health screenings communities across country aims educate people chronic diseases encourage take better control health people manage chronic diseases may develop complications leading greater health problems announced findings nationwide health screenings people conducted part programme although approximately per cent participants reported health excellent tests indicated many good health example nearly half participants type diabetes showed poor glucose control nearly third asthmatics screened poor control condition individuals poorly controlled diabetes asthma twothirds visited primary care physician past year gsk partnered national association chronic disease directors nacdd webmd health information site help people become engaged managing health part triple solution approach encourage people assess risk chronic diseases using health check tool provides advice five biggest health risks dengue fever paracetamol recommended effective symptomatic treatment dengue fever debilitating disease transmitted mosquitoes tropical subtropical regions people know correct treatment dengue fever especially children people often use feverreducers aspirin exacerbate bleeding symptom dengue fever also seek medical treatment late increases risk serious complications death panadol gsks overthecounter paracetamol brand strong presence regions dengue fever prevalent notably asia africa middle east central south america gsk position take lead driving global awareness among healthcare professionals public dengue fever threat initiated sponsored dengue fever public awareness campaign highrisk areas including caribbean southeast asia worked collaboration organisations unicef pan america health organization also engage locally respected campaign ambassadors campaigns increase awareness television radio pr activities well roadside banners posters hospitals public health centres pharmacies drugstores local media picked activities helping raise awareness health professionals targeted raise awareness provide information help diagnosis treatment free panadol samples distributed hospitals campaign run costa rica contributed per cent reduction dengue fever cases reported board health campaign run number cases increased per cent gsk activated campaign collaboration board health end ' save lives ' campaign contributed per cent reduction dengue cases similarly panadol campaign contributed decreases southeast asian dengue cases especially indonesia dengue fever fatality rate dropped per cent previous year gsk planning continue campaign beyond parashar ud et al global illness deaths caused rotavirus disease children emerg infect dis data file back top home responsibility contribution global health disease awareness prevention preventing disease corporate responsibility report preventing disease vaccines vaccines make significant contribution health recognised one successful ways preventing disease vaccines second clean drinking water reducing impact infectious diseases gsk one largest suppliers vaccines leading supplier childhood vaccines unicef vaccines designed eradicate control disease individual level prevent disease limit severity highly cost effective benefit society individuals vaccines widespread endorsement supranational organisations including united nations world bank proposes governments make immunisation priority healthcare investment immunisation programmes successfully eradicated smallpox worldwide made significant progress towards elimination polio even global eradication possible diseases reduced low levels vaccination maintained high levels example haemophilus influenzae type b vaccines used bacterial meningitis caused virus dramatically reduced majority cervical cancers preventable vaccination human papillomavirus hpv combined cervical screening gsks vaccine hpv cervarix available high middle lowincome countries around world committed working accelerate global access vaccine cervarix chosen vaccine national immunisation programme nip uk largest human papillomavirus immunisation programme world date since nip launch september per cent girls aged vaccinated consumer healthcare products smoking cessation smoking major public health problem contributing around five million premature deaths worldwide every year nicotine replacement therapies nrt significantly increase smokers chance stopping gsk created first overthecounter nrt market range nicotine replacement brands including niquitin cqnicoderm commit lozenge nicorette helped million people stop smoking since estimate around per cent smokers currently access nrt aim increase figure per cent launching nicotine replacement brands new markets poverty major barrier nrt purchase especially emerging markets provide smoking cessation education counselling support brazilian government part efforts help low income smokers trying stop smoking supported petition submitted new york commissioner health asking us food drug administration fda allow overthecounter nrt products sold wherever cigarettes sold permit sale smaller packs fewer doses would much lower prices fda currently allow sale smaller oneday affordable pack sizes uk support national health services stop smoking clinics provide clinics educational materials run online telephone support smokers also help train nhs nurses pharmacists stop smoking advisers preventing obesity obesity major cause ill health disease diabetes alli overthecounter weightloss treatment helps people lose weight combined lowfat reduced calorie diet alli marketed us since received positive opinion nonprescription product european medicines agency emea committee medicinal products human use january european commission granted nonprescription licence product since launch us six million starter packs alli sold helping millions people lose weight read case study ensure alli marketed responsibly oral healthcare important people maintain good oral health prevent gum disease tooth decay oral healthcare products include toothpastes mouth washes denture cleaners facility weybridge uk makes global brands aquafresh sensodyne largest oral healthcare research centre europe employees facility regularly visit oral healthcare conferences publish articles journals promote importance using oral healthcare products cosponsor innovation oral care awards international association dental research run award scheme recognises innovative research preventing mouth infections improving oral healthcare diagnostics community investment also invest community activities focus disease prevention example participate global alliance eliminate lymphatic filariasis leading cause disability tropical countries phase handwashing programme helps prevent spread diarrhoearelated disease children developing countries back tophome responsibility contribution global health disease awareness prevention preventing disease corporate responsibility report preventing disease vaccines vaccines make significant contribution health recognised one successful ways preventing disease vaccines second clean drinking water reducing impact infectious diseases gsk one largest suppliers vaccines leading supplier childhood vaccines unicef vaccines designed eradicate control disease individual level prevent disease limit severity highly cost effective benefit society individuals vaccines widespread endorsement supranational organisations including united nations world bank proposes governments make immunisation priority healthcare investment immunisation programmes successfully eradicated smallpox worldwide made significant progress towards elimination polio even global eradication possible diseases reduced low levels vaccination maintained high levels example haemophilus influenzae type b vaccines used bacterial meningitis caused virus dramatically reduced majority cervical cancers preventable vaccination human papillomavirus hpv combined cervical screening gsks vaccine hpv cervarix available high middle lowincome countries around world committed working accelerate global access vaccine cervarix chosen vaccine national immunisation programme nip uk largest human papillomavirus immunisation programme world date since nip launch september per cent girls aged vaccinated consumer healthcare products smoking cessation smoking major public health problem contributing around five million premature deaths worldwide every year nicotine replacement therapies nrt significantly increase smokers chance stopping gsk created first overthecounter nrt market range nicotine replacement brands including niquitin cqnicoderm commit lozenge nicorette helped million people stop smoking since estimate around per cent smokers currently access nrt aim increase figure per cent launching nicotine replacement brands new markets poverty major barrier nrt purchase especially emerging markets provide smoking cessation education counselling support brazilian government part efforts help low income smokers trying stop smoking supported petition submitted new york commissioner health asking us food drug administration fda allow overthecounter nrt products sold wherever cigarettes sold permit sale smaller packs fewer doses would much lower prices fda currently allow sale smaller oneday affordable pack sizes uk support national health services stop smoking clinics provide clinics educational materials run online telephone support smokers also help train nhs nurses pharmacists stop smoking advisers preventing obesity obesity major cause ill health disease diabetes alli overthecounter weightloss treatment helps people lose weight combined lowfat reduced calorie diet alli marketed us since received positive opinion nonprescription product european medicines agency emea committee medicinal products human use january european commission granted nonprescription licence product since launch us six million starter packs alli sold helping millions people lose weight read case study ensure alli marketed responsibly oral healthcare important people maintain good oral health prevent gum disease tooth decay oral healthcare products include toothpastes mouth washes denture cleaners facility weybridge uk makes global brands aquafresh sensodyne largest oral healthcare research centre europe employees facility regularly visit oral healthcare conferences publish articles journals promote importance using oral healthcare products cosponsor innovation oral care awards international association dental research run award scheme recognises innovative research preventing mouth infections improving oral healthcare diagnostics community investment also invest community activities focus disease prevention example participate global alliance eliminate lymphatic filariasis leading cause disability tropical countries phase handwashing programme helps prevent spread diarrhoearelated disease children developing countries back top home responsibility contribution global health disease awareness prevention preventing disease corporate responsibility report preventing disease vaccines vaccines make significant contribution health recognised one successful ways preventing disease vaccines second clean drinking water reducing impact infectious diseases gsk one largest suppliers vaccines leading supplier childhood vaccines unicef vaccines designed eradicate control disease individual level prevent disease limit severity highly cost effective benefit society individuals vaccines widespread endorsement supranational organisations including united nations world bank proposes governments make immunisation priority healthcare investment immunisation programmes successfully eradicated smallpox worldwide made significant progress towards elimination polio even global eradication possible diseases reduced low levels vaccination maintained high levels example haemophilus influenzae type b vaccines used bacterial meningitis caused virus dramatically reduced majority cervical cancers preventable vaccination human papillomavirus hpv combined cervical screening gsks vaccine hpv cervarix available high middle lowincome countries around world committed working accelerate global access vaccine cervarix chosen vaccine national immunisation programme nip uk largest human papillomavirus immunisation programme world date since nip launch september per cent girls aged vaccinated consumer healthcare products smoking cessation smoking major public health problem contributing around five million premature deaths worldwide every year nicotine replacement therapies nrt significantly increase smokers chance stopping gsk created first overthecounter nrt market range nicotine replacement brands including niquitin cqnicoderm commit lozenge nicorette helped million people stop smoking since estimate around per cent smokers currently access nrt aim increase figure per cent launching nicotine replacement brands new markets poverty major barrier nrt purchase especially emerging markets provide smoking cessation education counselling support brazilian government part efforts help low income smokers trying stop smoking supported petition submitted new york commissioner health asking us food drug administration fda allow overthecounter nrt products sold wherever cigarettes sold permit sale smaller packs fewer doses would much lower prices fda currently allow sale smaller oneday affordable pack sizes uk support national health services stop smoking clinics provide clinics educational materials run online telephone support smokers also help train nhs nurses pharmacists stop smoking advisers preventing obesity obesity major cause ill health disease diabetes alli overthecounter weightloss treatment helps people lose weight combined lowfat reduced calorie diet alli marketed us since received positive opinion nonprescription product european medicines agency emea committee medicinal products human use january european commission granted nonprescription licence product since launch us six million starter packs alli sold helping millions people lose weight read case study ensure alli marketed responsibly oral healthcare important people maintain good oral health prevent gum disease tooth decay oral healthcare products include toothpastes mouth washes denture cleaners facility weybridge uk makes global brands aquafresh sensodyne largest oral healthcare research centre europe employees facility regularly visit oral healthcare conferences publish articles journals promote importance using oral healthcare products cosponsor innovation oral care awards international association dental research run award scheme recognises innovative research preventing mouth infections improving oral healthcare diagnostics community investment also invest community activities focus disease prevention example participate global alliance eliminate lymphatic filariasis leading cause disability tropical countries phase handwashing programme helps prevent spread diarrhoearelated disease children developing countries back top home responsibility contribution global health investing rd corporate responsibility report investing rd despite advances healthcare still many diseases cure treatments could improved continued research innovation essential investment rd new medicines vaccines core business spent billion rd per cent expenditure pharmaceutical rd remainder vaccine consumer healthcare rd nearly prescription medicines vaccines clinical development detailed rd annual report current latestage pipeline includes products targeting diseases including many forms cancer infections respiratory diseases autoimmune disorders metabolic cardiovascular disease psychiatric disorders neurological diseases nine new products approved first time made six first submissions new products product line extensions example reflecting strong focus oncology december filed us licence pazopanib treatment advanced renal cell carcinoma read ensure high ethical standards rd activity expanding research capabilities improving productivity one strategic priorities improve rd productivity rd organisation restructured support changes described rd section annual report early conducted review involving external experts identify therapy areas recent advances science mean probability finding new treatments based outcomes review refocused earlystage research activities following areas biopharmaceuticals immunoinflammatory diseases infectious diseases metabolic pathways neurosciences oncology ophthalmology respiratory diseases rd china chinese rd centre opened employees moved stateof theart facilities shanghai centre investigating neurodegenerative disorders alzheimers disease parkinsons disease multiple sclerosis centre already progressing early pipeline target validation candidate selection intend develop centre lead facility global discovery development activities neurodegenerative disorders costs conducting research china lower markets however lower costs primary reason opening facility china offers huge pool scientific talent recruitment roadshow reached phd graduates ten top universities rd china conducted gsks global quality ethical standards rd policies monitoring procedures global apply operations china investing new areas science investing technologies providing new opportunities medical intervention including stem cell technology believe stem cell science great potential aid discovery new medicines improving screening identification development new compounds using stem cells could also help us develop medicines safer effective read collaboration harvard stem cell institute participation stem cells safer medicines publicprivate partnership external collaborations gsk monopoly best science expanding collaborations external partners business development activities access innovations outside organisation external collaborations underway complement internal discovery performance units immunoinflammation centre excellence drug discovery announced fiveyear research partnership immune disease institute idi boston us partnership combine idis world class immunological expertise gsks pharmaceutical capabilities also signed first agreement university cambridge develop compound potential treating obesity addictive disorders university contribute knowhow expertise bear financial risk compensated programme successful gsk provide operational support access inhouse clinical research imaging facilities background preclinical data drug cambridge university dedicate team academic experts neuroscience metabolic disorders importantly agreement allows academic scientists freedom publish results work incubator projects acquired pharmaceutical company sirtris leader research sirtuins recently discovered class enzymes believed involved ageing process combination specialist knowledge within sirtris gsks development capabilities provide best possible chance validating new approach diseases metabolism ageing read investment new technology annual report back tophome responsibility contribution global health investing rd corporate responsibility report investing rd despite advances healthcare still many diseases cure treatments could improved continued research innovation essential investment rd new medicines vaccines core business spent billion rd per cent expenditure pharmaceutical rd remainder vaccine consumer healthcare rd nearly prescription medicines vaccines clinical development detailed rd annual report current latestage pipeline includes products targeting diseases including many forms cancer infections respiratory diseases autoimmune disorders metabolic cardiovascular disease psychiatric disorders neurological diseases nine new products approved first time made six first submissions new products product line extensions example reflecting strong focus oncology december filed us licence pazopanib treatment advanced renal cell carcinoma read ensure high ethical standards rd activity expanding research capabilities improving productivity one strategic priorities improve rd productivity rd organisation restructured support changes described rd section annual report early conducted review involving external experts identify therapy areas recent advances science mean probability finding new treatments based outcomes review refocused earlystage research activities following areas biopharmaceuticals immunoinflammatory diseases infectious diseases metabolic pathways neurosciences oncology ophthalmology respiratory diseases rd china chinese rd centre opened employees moved stateof theart facilities shanghai centre investigating neurodegenerative disorders alzheimers disease parkinsons disease multiple sclerosis centre already progressing early pipeline target validation candidate selection intend develop centre lead facility global discovery development activities neurodegenerative disorders costs conducting research china lower markets however lower costs primary reason opening facility china offers huge pool scientific talent recruitment roadshow reached phd graduates ten top universities rd china conducted gsks global quality ethical standards rd policies monitoring procedures global apply operations china investing new areas science investing technologies providing new opportunities medical intervention including stem cell technology believe stem cell science great potential aid discovery new medicines improving screening identification development new compounds using stem cells could also help us develop medicines safer effective read collaboration harvard stem cell institute participation stem cells safer medicines publicprivate partnership external collaborations gsk monopoly best science expanding collaborations external partners business development activities access innovations outside organisation external collaborations underway complement internal discovery performance units immunoinflammation centre excellence drug discovery announced fiveyear research partnership immune disease institute idi boston us partnership combine idis world class immunological expertise gsks pharmaceutical capabilities also signed first agreement university cambridge develop compound potential treating obesity addictive disorders university contribute knowhow expertise bear financial risk compensated programme successful gsk provide operational support access inhouse clinical research imaging facilities background preclinical data drug cambridge university dedicate team academic experts neuroscience metabolic disorders importantly agreement allows academic scientists freedom publish results work incubator projects acquired pharmaceutical company sirtris leader research sirtuins recently discovered class enzymes believed involved ageing process combination specialist knowledge within sirtris gsks development capabilities provide best possible chance validating new approach diseases metabolism ageing read investment new technology annual report back top home responsibility contribution global health investing rd corporate responsibility report investing rd despite advances healthcare still many diseases cure treatments could improved continued research innovation essential investment rd new medicines vaccines core business spent billion rd per cent expenditure pharmaceutical rd remainder vaccine consumer healthcare rd nearly prescription medicines vaccines clinical development detailed rd annual report current latestage pipeline includes products targeting diseases including many forms cancer infections respiratory diseases autoimmune disorders metabolic cardiovascular disease psychiatric disorders neurological diseases nine new products approved first time made six first submissions new products product line extensions example reflecting strong focus oncology december filed us licence pazopanib treatment advanced renal cell carcinoma read ensure high ethical standards rd activity expanding research capabilities improving productivity one strategic priorities improve rd productivity rd organisation restructured support changes described rd section annual report early conducted review involving external experts identify therapy areas recent advances science mean probability finding new treatments based outcomes review refocused earlystage research activities following areas biopharmaceuticals immunoinflammatory diseases infectious diseases metabolic pathways neurosciences oncology ophthalmology respiratory diseases rd china chinese rd centre opened employees moved stateof theart facilities shanghai centre investigating neurodegenerative disorders alzheimers disease parkinsons disease multiple sclerosis centre already progressing early pipeline target validation candidate selection intend develop centre lead facility global discovery development activities neurodegenerative disorders costs conducting research china lower markets however lower costs primary reason opening facility china offers huge pool scientific talent recruitment roadshow reached phd graduates ten top universities rd china conducted gsks global quality ethical standards rd policies monitoring procedures global apply operations china investing new areas science investing technologies providing new opportunities medical intervention including stem cell technology believe stem cell science great potential aid discovery new medicines improving screening identification development new compounds using stem cells could also help us develop medicines safer effective read collaboration harvard stem cell institute participation stem cells safer medicines publicprivate partnership external collaborations gsk monopoly best science expanding collaborations external partners business development activities access innovations outside organisation external collaborations underway complement internal discovery performance units immunoinflammation centre excellence drug discovery announced fiveyear research partnership immune disease institute idi boston us partnership combine idis world class immunological expertise gsks pharmaceutical capabilities also signed first agreement university cambridge develop compound potential treating obesity addictive disorders university contribute knowhow expertise bear financial risk compensated programme successful gsk provide operational support access inhouse clinical research imaging facilities background preclinical data drug cambridge university dedicate team academic experts neuroscience metabolic disorders importantly agreement allows academic scientists freedom publish results work incubator projects acquired pharmaceutical company sirtris leader research sirtuins recently discovered class enzymes believed involved ageing process combination specialist knowledge within sirtris gsks development capabilities provide best possible chance validating new approach diseases metabolism ageing read investment new technology annual report back top home responsibility contribution global health contributing scientific understanding corporate responsibility report contributing scientific understanding fund basic medical research conducted outside gsk increase understanding human body impact disease often foundation future advances diagnosis treatment prevention disease often research conducted partnership others using new technologies examples include open innovation december announced joint million investment wellcome trust generate chemical probes proteins involved epigenetic signalling make available researchers without restriction partnership part new commitment promote openness research collaborations gsk pharmaceutical companies traditionally kept research data confidential publicprivate partnership led structural genomics consortium involve national institutes healths chemical genomics centre washington us university oxford initiative could offer new model future interactions academia industry collaborating accelerate drug development renewed support university dundees division signal transduction therapy dstt collaboration medical research council consortium pharmaceutical companies aim dstt accelerate development drugs treat diseases cancer diabetes rheumatoid arthritis targeting kinase phosphatase enzymes collaboration provide million dstt gsk working path malaria vaccine initiative mvi since develop paediatric vaccine malaria rtssas december partnership announced study results showed rtssas provides infants young children significant protection malaria pending national regulatory approvals phase lll studies start seven countries across africa early patient safety gsk team wall street journal technology innovation award healthcare team developed new software system helps screen novel drug candidates potential safety issues system known molecular clinical safety intelligence mcsi helps gsk researchers screen prioritise novel drug candidates potential adverse medical reactions much earlier stage prior clinical trials software enables direct translation safety knowledge human clinical experience earlystage drug discovery first time read patient safety gsk back top home responsibility contribution global health contributing scientific understanding corporate responsibility report contributing scientific understanding fund basic medical research conducted outside gsk increase understanding human body impact disease often foundation future advances diagnosis treatment prevention disease often research conducted partnership others using new technologies examples include open innovation december announced joint million investment wellcome trust generate chemical probes proteins involved epigenetic signalling make available researchers without restriction partnership part new commitment promote openness research collaborations gsk pharmaceutical companies traditionally kept research data confidential publicprivate partnership led structural genomics consortium involve national institutes healths chemical genomics centre washington us university oxford initiative could offer new model future interactions academia industry collaborating accelerate drug development renewed support university dundees division signal transduction therapy dstt collaboration medical research council consortium pharmaceutical companies aim dstt accelerate development drugs treat diseases cancer diabetes rheumatoid arthritis targeting kinase phosphatase enzymes collaboration provide million dstt gsk working path malaria vaccine initiative mvi since develop paediatric vaccine malaria rtssas december partnership announced study results showed rtssas provides infants young children significant protection malaria pending national regulatory approvals phase lll studies start seven countries across africa early patient safety gsk team wall street journal technology innovation award healthcare team developed new software system helps screen novel drug candidates potential safety issues system known molecular clinical safety intelligence mcsi helps gsk researchers screen prioritise novel drug candidates potential adverse medical reactions much earlier stage prior clinical trials software enables direct translation safety knowledge human clinical experience earlystage drug discovery first time read patient safety gsk back top home responsibility contribution global health contributing scientific understanding academic collaborations corporate responsibility report academic collaborations invest research capabilities universities fund leadingedge academic research projects support science students academic collaborations ukbased company providing support million support benefits academic institutions increased funding technology transfer access research facilities expertise contributes better scientific understanding capability countries operate benefits gsk enabling us tap rd expertise activity outside company expands potential recruitment pool better trained scientists support included academic discovery performance unit new initiative combine best academic thinking gsks industry expertise new agreement university cambridge develop novel agent therapeutic potential treating obesity addictive disorders alliances leading universities help accelerate drug discovery example established research agreements trinity college dublin university manchester collaboration agencies including uk engineering physical sciences research council epsrc wellcome trust fund projects mutual interest training gsk laboratories undergraduates intellectual property rights relating academic collaborations typically held gsk partner institutions free use outcome collaboration future research university also receives percentage financial returns derived new intellectual property back top home responsibility contribution global health contributing scientific understanding academic collaborations corporate responsibility report academic collaborations invest research capabilities universities fund leadingedge academic research projects support science students academic collaborations ukbased company providing support million support benefits academic institutions increased funding technology transfer access research facilities expertise contributes better scientific understanding capability countries operate benefits gsk enabling us tap rd expertise activity outside company expands potential recruitment pool better trained scientists support included academic discovery performance unit new initiative combine best academic thinking gsks industry expertise new agreement university cambridge develop novel agent therapeutic potential treating obesity addictive disorders alliances leading universities help accelerate drug discovery example established research agreements trinity college dublin university manchester collaboration agencies including uk engineering physical sciences research council epsrc wellcome trust fund projects mutual interest training gsk laboratories undergraduates intellectual property rights relating academic collaborations typically held gsk partner institutions free use outcome collaboration future research university also receives percentage financial returns derived new intellectual property back top home responsibility contribution global health pandemic flu responding hn outbreak corporate responsibility report pandemic flu responding hn outbreak updated august preparing influenza pandemic flu many years researching developing pre pandemic pandemic vaccines antivirals face masks well existing antibiotics portfolio preparations meant able respond rapidly new influenza hn strain emerged mexico late april world health organizations decision june move pandemic alert level sent particularly strong message governments stakeholders involved pandemic preparedness ensure adequate robust plans place respond new strain hn known swine flu collaborative global response involving governments international organisations businesses needed reduce impact hn gsk committed supporting governments health authorities around world respond challenge gsks contribution offer three key products combat pandemic flu hn pandemic vaccine actiprotect face mask relenza antiviral invested us billion expand capacity manufacture products believe global community take steps protect populations including without resources protect read efforts help facilitate access relenza pandemic flu vaccine developing countries prevention treatment products prevention vaccines immediately received hn swine flu virus strain late may began production vaccine help protect people hn unable begin production vaccine needs based strain acting full scale production manufacturing facilities canada germany working make vaccine available quickly possible expect produce several hundred million doses hn vaccine delivered september onwards date gsk received orders million doses vaccine made antigen stimulates immune response virus adjuvant helps boost immune response use adjuvant help increase effectiveness vaccine also mean less antigen needed produce amount vaccine addition clinical studies hn avian influenza strain adjuvanted vaccine demonstrated potential provide protection even influenza strain drifts changes slightly delivery vaccine depends gaining approval regulator discussion authorities around world ensure regulatory process proceeds quickly possible gsk received european licence pandemic vaccine based mockup dossier containing data hn avian flu anticipate provisional licence speed registration hn vaccine quickly supplement data dossier data actual hn pandemic strain currently discussions regulatory authorities develop appropriate clinical development plans vaccine number people studied initial trials limited need provide governments vaccine quickly possible additional studies ongoing monitoring therefore conducted vaccine launched gsk rapidly share results immunogenicity post marketing safety effectiveness studies international community face masks gsk developed actiprotect face mask coated antiviral agent provides physical barrier prevents wearer inhaling virus particles kills flu virus within one minute contact actiprotect tested pandemic hn strain however mask shown inactivate influenza virus strains tested including previous strains hn hn hn hn hn influenza b strain currently limited manufacturing capacity actiprotect therefore invested increasing existing manufacturing capacity also seeking additional manufacturing capability discussion companies treatment relenza zanamivir antiviral shortens duration flu helping sufferers feel better sooner gsk working governments supply relenza use pandemic since global spread avian flu hn began clinical tests show hn also sensitive relenza following outbreak hn strain contacted governments around world establish demand relenza ensure equitable distribution existing supplies put place series measures raise production levels result expect increase annual production capacity relenza million treatment courses end threefold increase previous maximum annual capacity million treatment courses relenza registered countries currently contracts place supply governments supporting access pandemic flu products many developing country governments lack resources protect populations hn concerned ability mount effective rapid response gsk committed facilitating access relenza pandemic flu vaccine countries strongly endorse principles set gates foundation help guide global allocation pandemic vaccines support message global community take steps necessary protect populations including without resources protect committed donate million doses hn vaccine million treatment courses relenza use developing countries ensure vaccine available developing countries subject yield existing contractual commitments also allocated per cent hn vaccine production capacity canadian manufacturing site developing countries ten per cent new increased relenza production capacity also allocated developing countries commitments include two donations operate tieredpricing policy pandemic vaccine relenza based world bank classification countries gavi eligibility vaccine line commitments set march make branded medicines affordable world 's poorest people relenza continue available notforprofit prices least developed countries remain committed engaging voluntary licence discussions companies willing manufacture supply zanamivircontaining products active ingredient relenza use developing countries example granted voluntary licence chinese manufacturer simcere manufacture sell products containing zanamivir china number countries including world 's least developed countries ensuring business continuity taken steps ensure flu pandemic continue supply essential pharmaceuticals vaccines influenza serious diseases patients need read business continuity plans lerouxroels et al antigen sparing crossreactive immunity adjuvanted rhn prototype pandemic influenza vaccine randomised controlled trial lancet lerouxroels et al broad clade crossreactive immunity induced adjuvant systemed clade rhn pandemic influenza vaccine plos one e doijounalpone baras et al crossprotection lethal hn challenge ferrets adjuvanted pandemic influenza vaccine plos one e back tophome responsibility contribution global health pandemic flu responding hn outbreak corporate responsibility report pandemic flu responding hn outbreak updated august preparing influenza pandemic flu many years researching developing pre pandemic pandemic vaccines antivirals face masks well existing antibiotics portfolio preparations meant able respond rapidly new influenza hn strain emerged mexico late april world health organizations decision june move pandemic alert level sent particularly strong message governments stakeholders involved pandemic preparedness ensure adequate robust plans place respond new strain hn known swine flu collaborative global response involving governments international organisations businesses needed reduce impact hn gsk committed supporting governments health authorities around world respond challenge gsks contribution offer three key products combat pandemic flu hn pandemic vaccine actiprotect face mask relenza antiviral invested us billion expand capacity manufacture products believe global community take steps protect populations including without resources protect read efforts help facilitate access relenza pandemic flu vaccine developing countries prevention treatment products prevention vaccines immediately received hn swine flu virus strain late may began production vaccine help protect people hn unable begin production vaccine needs based strain acting full scale production manufacturing facilities canada germany working make vaccine available quickly possible expect produce several hundred million doses hn vaccine delivered september onwards date gsk received orders million doses vaccine made antigen stimulates immune response virus adjuvant helps boost immune response use adjuvant help increase effectiveness vaccine also mean less antigen needed produce amount vaccine addition clinical studies hn avian influenza strain adjuvanted vaccine demonstrated potential provide protection even influenza strain drifts changes slightly delivery vaccine depends gaining approval regulator discussion authorities around world ensure regulatory process proceeds quickly possible gsk received european licence pandemic vaccine based mockup dossier containing data hn avian flu anticipate provisional licence speed registration hn vaccine quickly supplement data dossier data actual hn pandemic strain currently discussions regulatory authorities develop appropriate clinical development plans vaccine number people studied initial trials limited need provide governments vaccine quickly possible additional studies ongoing monitoring therefore conducted vaccine launched gsk rapidly share results immunogenicity post marketing safety effectiveness studies international community face masks gsk developed actiprotect face mask coated antiviral agent provides physical barrier prevents wearer inhaling virus particles kills flu virus within one minute contact actiprotect tested pandemic hn strain however mask shown inactivate influenza virus strains tested including previous strains hn hn hn hn hn influenza b strain currently limited manufacturing capacity actiprotect therefore invested increasing existing manufacturing capacity also seeking additional manufacturing capability discussion companies treatment relenza zanamivir antiviral shortens duration flu helping sufferers feel better sooner gsk working governments supply relenza use pandemic since global spread avian flu hn began clinical tests show hn also sensitive relenza following outbreak hn strain contacted governments around world establish demand relenza ensure equitable distribution existing supplies put place series measures raise production levels result expect increase annual production capacity relenza million treatment courses end threefold increase previous maximum annual capacity million treatment courses relenza registered countries currently contracts place supply governments supporting access pandemic flu products many developing country governments lack resources protect populations hn concerned ability mount effective rapid response gsk committed facilitating access relenza pandemic flu vaccine countries strongly endorse principles set gates foundation help guide global allocation pandemic vaccines support message global community take steps necessary protect populations including without resources protect committed donate million doses hn vaccine million treatment courses relenza use developing countries ensure vaccine available developing countries subject yield existing contractual commitments also allocated per cent hn vaccine production capacity canadian manufacturing site developing countries ten per cent new increased relenza production capacity also allocated developing countries commitments include two donations operate tieredpricing policy pandemic vaccine relenza based world bank classification countries gavi eligibility vaccine line commitments set march make branded medicines affordable world 's poorest people relenza continue available notforprofit prices least developed countries remain committed engaging voluntary licence discussions companies willing manufacture supply zanamivircontaining products active ingredient relenza use developing countries example granted voluntary licence chinese manufacturer simcere manufacture sell products containing zanamivir china number countries including world 's least developed countries ensuring business continuity taken steps ensure flu pandemic continue supply essential pharmaceuticals vaccines influenza serious diseases patients need read business continuity plans lerouxroels et al antigen sparing crossreactive immunity adjuvanted rhn prototype pandemic influenza vaccine randomised controlled trial lancet lerouxroels et al broad clade crossreactive immunity induced adjuvant systemed clade rhn pandemic influenza vaccine plos one e doijounalpone baras et al crossprotection lethal hn challenge ferrets adjuvanted pandemic influenza vaccine plos one e back tophome responsibility contribution global health pandemic flu responding hn outbreak corporate responsibility report pandemic flu responding hn outbreak updated august preparing influenza pandemic flu many years researching developing pre pandemic pandemic vaccines antivirals face masks well existing antibiotics portfolio preparations meant able respond rapidly new influenza hn strain emerged mexico late april world health organizations decision june move pandemic alert level sent particularly strong message governments stakeholders involved pandemic preparedness ensure adequate robust plans place respond new strain hn known swine flu collaborative global response involving governments international organisations businesses needed reduce impact hn gsk committed supporting governments health authorities around world respond challenge gsks contribution offer three key products combat pandemic flu hn pandemic vaccine actiprotect face mask relenza antiviral invested us billion expand capacity manufacture products believe global community take steps protect populations including without resources protect read efforts help facilitate access relenza pandemic flu vaccine developing countries prevention treatment products prevention vaccines immediately received hn swine flu virus strain late may began production vaccine help protect people hn unable begin production vaccine needs based strain acting full scale production manufacturing facilities canada germany working make vaccine available quickly possible expect produce several hundred million doses hn vaccine delivered september onwards date gsk received orders million doses vaccine made antigen stimulates immune response virus adjuvant helps boost immune response use adjuvant help increase effectiveness vaccine also mean less antigen needed produce amount vaccine addition clinical studies hn avian influenza strain adjuvanted vaccine demonstrated potential provide protection even influenza strain drifts changes slightly delivery vaccine depends gaining approval regulator discussion authorities around world ensure regulatory process proceeds quickly possible gsk received european licence pandemic vaccine based mockup dossier containing data hn avian flu anticipate provisional licence speed registration hn vaccine quickly supplement data dossier data actual hn pandemic strain currently discussions regulatory authorities develop appropriate clinical development plans vaccine number people studied initial trials limited need provide governments vaccine quickly possible additional studies ongoing monitoring therefore conducted vaccine launched gsk rapidly share results immunogenicity post marketing safety effectiveness studies international community face masks gsk developed actiprotect face mask coated antiviral agent provides physical barrier prevents wearer inhaling virus particles kills flu virus within one minute contact actiprotect tested pandemic hn strain however mask shown inactivate influenza virus strains tested including previous strains hn hn hn hn hn influenza b strain currently limited manufacturing capacity actiprotect therefore invested increasing existing manufacturing capacity also seeking additional manufacturing capability discussion companies treatment relenza zanamivir antiviral shortens duration flu helping sufferers feel better sooner gsk working governments supply relenza use pandemic since global spread avian flu hn began clinical tests show hn also sensitive relenza following outbreak hn strain contacted governments around world establish demand relenza ensure equitable distribution existing supplies put place series measures raise production levels result expect increase annual production capacity relenza million treatment courses end threefold increase previous maximum annual capacity million treatment courses relenza registered countries currently contracts place supply governments supporting access pandemic flu products many developing country governments lack resources protect populations hn concerned ability mount effective rapid response gsk committed facilitating access relenza pandemic flu vaccine countries strongly endorse principles set gates foundation help guide global allocation pandemic vaccines support message global community take steps necessary protect populations including without resources protect committed donate million doses hn vaccine million treatment courses relenza use developing countries ensure vaccine available developing countries subject yield existing contractual commitments also allocated per cent hn vaccine production capacity canadian manufacturing site developing countries ten per cent new increased relenza production capacity also allocated developing countries commitments include two donations operate tieredpricing policy pandemic vaccine relenza based world bank classification countries gavi eligibility vaccine line commitments set march make branded medicines affordable world 's poorest people relenza continue available notforprofit prices least developed countries remain committed engaging voluntary licence discussions companies willing manufacture supply zanamivircontaining products active ingredient relenza use developing countries example granted voluntary licence chinese manufacturer simcere manufacture sell products containing zanamivir china number countries including world 's least developed countries ensuring business continuity taken steps ensure flu pandemic continue supply essential pharmaceuticals vaccines influenza serious diseases patients need read business continuity plans lerouxroels et al antigen sparing crossreactive immunity adjuvanted rhn prototype pandemic influenza vaccine randomised controlled trial lancet lerouxroels et al broad clade crossreactive immunity induced adjuvant systemed clade rhn pandemic influenza vaccine plos one e doijounalpone baras et al crossprotection lethal hn challenge ferrets adjuvanted pandemic influenza vaccine plos one e back top home responsibility contribution global health pandemic flu responding hn outbreak corporate responsibility report pandemic flu responding hn outbreak updated august preparing influenza pandemic flu many years researching developing pre pandemic pandemic vaccines antivirals face masks well existing antibiotics portfolio preparations meant able respond rapidly new influenza hn strain emerged mexico late april world health organizations decision june move pandemic alert level sent particularly strong message governments stakeholders involved pandemic preparedness ensure adequate robust plans place respond new strain hn known swine flu collaborative global response involving governments international organisations businesses needed reduce impact hn gsk committed supporting governments health authorities around world respond challenge gsks contribution offer three key products combat pandemic flu hn pandemic vaccine actiprotect face mask relenza antiviral invested us billion expand capacity manufacture products believe global community take steps protect populations including without resources protect read efforts help facilitate access relenza pandemic flu vaccine developing countries prevention treatment products prevention vaccines immediately received hn swine flu virus strain late may began production vaccine help protect people hn unable begin production vaccine needs based strain acting full scale production manufacturing facilities canada germany working make vaccine available quickly possible expect produce several hundred million doses hn vaccine delivered september onwards date gsk received orders million doses vaccine made antigen stimulates immune response virus adjuvant helps boost immune response use adjuvant help increase effectiveness vaccine also mean less antigen needed produce amount vaccine addition clinical studies hn avian influenza strain adjuvanted vaccine demonstrated potential provide protection even influenza strain drifts changes slightly delivery vaccine depends gaining approval regulator discussion authorities around world ensure regulatory process proceeds quickly possible gsk received european licence pandemic vaccine based mockup dossier containing data hn avian flu anticipate provisional licence speed registration hn vaccine quickly supplement data dossier data actual hn pandemic strain currently discussions regulatory authorities develop appropriate clinical development plans vaccine number people studied initial trials limited need provide governments vaccine quickly possible additional studies ongoing monitoring therefore conducted vaccine launched gsk rapidly share results immunogenicity post marketing safety effectiveness studies international community face masks gsk developed actiprotect face mask coated antiviral agent provides physical barrier prevents wearer inhaling virus particles kills flu virus within one minute contact actiprotect tested pandemic hn strain however mask shown inactivate influenza virus strains tested including previous strains hn hn hn hn hn influenza b strain currently limited manufacturing capacity actiprotect therefore invested increasing existing manufacturing capacity also seeking additional manufacturing capability discussion companies treatment relenza zanamivir antiviral shortens duration flu helping sufferers feel better sooner gsk working governments supply relenza use pandemic since global spread avian flu hn began clinical tests show hn also sensitive relenza following outbreak hn strain contacted governments around world establish demand relenza ensure equitable distribution existing supplies put place series measures raise production levels result expect increase annual production capacity relenza million treatment courses end threefold increase previous maximum annual capacity million treatment courses relenza registered countries currently contracts place supply governments supporting access pandemic flu products many developing country governments lack resources protect populations hn concerned ability mount effective rapid response gsk committed facilitating access relenza pandemic flu vaccine countries strongly endorse principles set gates foundation help guide global allocation pandemic vaccines support message global community take steps necessary protect populations including without resources protect committed donate million doses hn vaccine million treatment courses relenza use developing countries ensure vaccine available developing countries subject yield existing contractual commitments also allocated per cent hn vaccine production capacity canadian manufacturing site developing countries ten per cent new increased relenza production capacity also allocated developing countries commitments include two donations operate tieredpricing policy pandemic vaccine relenza based world bank classification countries gavi eligibility vaccine line commitments set march make branded medicines affordable world 's poorest people relenza continue available notforprofit prices least developed countries remain committed engaging voluntary licence discussions companies willing manufacture supply zanamivircontaining products active ingredient relenza use developing countries example granted voluntary licence chinese manufacturer simcere manufacture sell products containing zanamivir china number countries including world 's least developed countries ensuring business continuity taken steps ensure flu pandemic continue supply essential pharmaceuticals vaccines influenza serious diseases patients need read business continuity plans lerouxroels et al antigen sparing crossreactive immunity adjuvanted rhn prototype pandemic influenza vaccine randomised controlled trial lancet lerouxroels et al broad clade crossreactive immunity induced adjuvant systemed clade rhn pandemic influenza vaccine plos one e doijounalpone baras et al crossprotection lethal hn challenge ferrets adjuvanted pandemic influenza vaccine plos one e back top home responsibility contribution global health qas corporate responsibility report qas respond questions raised stakeholders goal cure disease find treatments ongoing chronic use ideally want cure disease antibiotics help treat diseases caused bacterial infection antiparasitic medicines help prevent treat prevalent diseases lymphatic filariasis malaria unfortunately known cure diseases medicines help reduce symptoms may need taken long periods medicines still valuable may enable patient normal lifestyle example remaining work looking family many cases continuing research find cure ideally want prevent disease occurring first place vaccines important role factors consider prioritising rd efforts three main interrelated factors science patient need commercial potential assess scientific opportunities determine advances scientific disease understanding may lead innovative new ways treat prevent disease used outcome systematic therapy area review looking scientific understanding therapy areas refocus research effort continually evaluate scientific information obtain compounds help us predict whether developed effective welltolerated medicines assessing patient need fundamental rd gsk ranges looking medicines treat diseases current effective treatments development medicines improve existing treatments terms safety efficacy ease use assessment commercial potential possible new treatments includes product would differentiated competitors size potential market new treatment range conditions may suitable treating better able meet patient needs likely product commercially successful however always possible achieve return investment example developing treatments diseases prevalent developing world cases commercial potential limited patient need high may seek ways share costs risks associated drug development researching drugs treat serious diseases pipeline product range includes products major causes mortality morbidity disease product launches included promacta treatment idiopathic thrombocytopenic purpura volibris pulmonary arterial hypertension topselling products treat asthma chronic obstructive pulmonary disease epilepsy bipolar disorder diabetes herpes migraine vaccines portfolio includes vaccines prevent influenza hepatitis rotavirus human papillomavirus infection cause cervical cancer also make vaccines prevent many childhood illnesses measles rubella measure rd productivity ultimate measure productivity delivery new medicines meet patients needs gsk launched three products based new chemical biological entities six new vaccines number product line extensions benefit patients target sustain latestage pipeline around key assets however given research development take longer ten years measure productivity number ways rd process including number compounds pipeline emerging risks benefits compounds success progressing compounds pipeline clinical trial phases l lll market registration speed progress pipeline indication efficiency rd processes true research productivity falling large pharmaceutical companies gsk managing investment pharmaceutical rd risen number new medicines gaining regulatory approval remained relatively constant decreased believe many reasons including increasing focus rd chronic degenerative diseases alzheimers scientifically challenging require longer clinical trials increased failure rates significant investment industry new technologies help deliver innovative medicines longer term example systems biology tools genomewide association scans new vitro vivo models sophisticated imaging equipment extensive requirements regulators healthcare payers including need conduct larger clinical studies evaluate longterm outcome treatment medicine well higher hurdles approval effectiveness existing treatments conditions demonstrating improved safety efficacy new treatment increasingly difficult approach focus meeting patients needs increasing effectiveness efficiency rd example established discovery performance units dpu within established centres excellence drug discovery dpus small groups scientists focused specific disease molecular pathway structured efficient possible organisations combine entrepreneurial approach small company resources reach larger organisation back tophome responsibility contribution global health qas corporate responsibility report qas respond questions raised stakeholders goal cure disease find treatments ongoing chronic use ideally want cure disease antibiotics help treat diseases caused bacterial infection antiparasitic medicines help prevent treat prevalent diseases lymphatic filariasis malaria unfortunately known cure diseases medicines help reduce symptoms may need taken long periods medicines still valuable may enable patient normal lifestyle example remaining work looking family many cases continuing research find cure ideally want prevent disease occurring first place vaccines important role factors consider prioritising rd efforts three main interrelated factors science patient need commercial potential assess scientific opportunities determine advances scientific disease understanding may lead innovative new ways treat prevent disease used outcome systematic therapy area review looking scientific understanding therapy areas refocus research effort continually evaluate scientific information obtain compounds help us predict whether developed effective welltolerated medicines assessing patient need fundamental rd gsk ranges looking medicines treat diseases current effective treatments development medicines improve existing treatments terms safety efficacy ease use assessment commercial potential possible new treatments includes product would differentiated competitors size potential market new treatment range conditions may suitable treating better able meet patient needs likely product commercially successful however always possible achieve return investment example developing treatments diseases prevalent developing world cases commercial potential limited patient need high may seek ways share costs risks associated drug development researching drugs treat serious diseases pipeline product range includes products major causes mortality morbidity disease product launches included promacta treatment idiopathic thrombocytopenic purpura volibris pulmonary arterial hypertension topselling products treat asthma chronic obstructive pulmonary disease epilepsy bipolar disorder diabetes herpes migraine vaccines portfolio includes vaccines prevent influenza hepatitis rotavirus human papillomavirus infection cause cervical cancer also make vaccines prevent many childhood illnesses measles rubella measure rd productivity ultimate measure productivity delivery new medicines meet patients needs gsk launched three products based new chemical biological entities six new vaccines number product line extensions benefit patients target sustain latestage pipeline around key assets however given research development take longer ten years measure productivity number ways rd process including number compounds pipeline emerging risks benefits compounds success progressing compounds pipeline clinical trial phases l lll market registration speed progress pipeline indication efficiency rd processes true research productivity falling large pharmaceutical companies gsk managing investment pharmaceutical rd risen number new medicines gaining regulatory approval remained relatively constant decreased believe many reasons including increasing focus rd chronic degenerative diseases alzheimers scientifically challenging require longer clinical trials increased failure rates significant investment industry new technologies help deliver innovative medicines longer term example systems biology tools genomewide association scans new vitro vivo models sophisticated imaging equipment extensive requirements regulators healthcare payers including need conduct larger clinical studies evaluate longterm outcome treatment medicine well higher hurdles approval effectiveness existing treatments conditions demonstrating improved safety efficacy new treatment increasingly difficult approach focus meeting patients needs increasing effectiveness efficiency rd example established discovery performance units dpu within established centres excellence drug discovery dpus small groups scientists focused specific disease molecular pathway structured efficient possible organisations combine entrepreneurial approach small company resources reach larger organisation back top home responsibility contribution global health qas corporate responsibility report qas respond questions raised stakeholders goal cure disease find treatments ongoing chronic use ideally want cure disease antibiotics help treat diseases caused bacterial infection antiparasitic medicines help prevent treat prevalent diseases lymphatic filariasis malaria unfortunately known cure diseases medicines help reduce symptoms may need taken long periods medicines still valuable may enable patient normal lifestyle example remaining work looking family many cases continuing research find cure ideally want prevent disease occurring first place vaccines important role factors consider prioritising rd efforts three main interrelated factors science patient need commercial potential assess scientific opportunities determine advances scientific disease understanding may lead innovative new ways treat prevent disease used outcome systematic therapy area review looking scientific understanding therapy areas refocus research effort continually evaluate scientific information obtain compounds help us predict whether developed effective welltolerated medicines assessing patient need fundamental rd gsk ranges looking medicines treat diseases current effective treatments development medicines improve existing treatments terms safety efficacy ease use assessment commercial potential possible new treatments includes product would differentiated competitors size potential market new treatment range conditions may suitable treating better able meet patient needs likely product commercially successful however always possible achieve return investment example developing treatments diseases prevalent developing world cases commercial potential limited patient need high may seek ways share costs risks associated drug development researching drugs treat serious diseases pipeline product range includes products major causes mortality morbidity disease product launches included promacta treatment idiopathic thrombocytopenic purpura volibris pulmonary arterial hypertension topselling products treat asthma chronic obstructive pulmonary disease epilepsy bipolar disorder diabetes herpes migraine vaccines portfolio includes vaccines prevent influenza hepatitis rotavirus human papillomavirus infection cause cervical cancer also make vaccines prevent many childhood illnesses measles rubella measure rd productivity ultimate measure productivity delivery new medicines meet patients needs gsk launched three products based new chemical biological entities six new vaccines number product line extensions benefit patients target sustain latestage pipeline around key assets however given research development take longer ten years measure productivity number ways rd process including number compounds pipeline emerging risks benefits compounds success progressing compounds pipeline clinical trial phases l lll market registration speed progress pipeline indication efficiency rd processes true research productivity falling large pharmaceutical companies gsk managing investment pharmaceutical rd risen number new medicines gaining regulatory approval remained relatively constant decreased believe many reasons including increasing focus rd chronic degenerative diseases alzheimers scientifically challenging require longer clinical trials increased failure rates significant investment industry new technologies help deliver innovative medicines longer term example systems biology tools genomewide association scans new vitro vivo models sophisticated imaging equipment extensive requirements regulators healthcare payers including need conduct larger clinical studies evaluate longterm outcome treatment medicine well higher hurdles approval effectiveness existing treatments conditions demonstrating improved safety efficacy new treatment increasingly difficult approach focus meeting patients needs increasing effectiveness efficiency rd example established discovery performance units dpu within established centres excellence drug discovery dpus small groups scientists focused specific disease molecular pathway structured efficient possible organisations combine entrepreneurial approach small company resources reach larger organisation back top home responsibility access medicines corporate responsibility report access medicines access healthcare one worlds pressing social challenges every year millions people developing countries die curable infectious diseases access basic healthcare services including essential medicines millions unnecessarily exposed threat ill health inadequate ineffective disease prevention strategies number complex factors prevent access medicines often limited prospect commercial return rd neglected diseases unified registration system medicines makes registration process costly complex time consuming many developing countries distribution network medicines healthcare infrastructure treat patients prescribe medicines however problems must excuse inaction rather indicate action needed last decade pharmaceutical industry helped address healthcare challenges developing world researching new medicines making available affordable despite progress scale healthcare crisis means industry must take proactive approach identified four key areas strengthen approach flexible intellectual property flexible pricing recognising achieve partnerships alone looking move supplier medicines partner delivering solutions read plans areas abbas hussain president emerging markets gsk leads access efforts also reviewed corporate executive team gsks senior team corporate responsibility committee board increasing access medicines important business ethical reputational commercial reasons morally right thing valued shareholders employees stakeholders aligned corporate mission contributes gsks reputation ability attract retain talented employees business objective increase proportion worlds population access medicines currently around per cent successful pharmaceutical companies future serve bigger proportion worlds population business relies intellectual property ip rights system encourages medical innovation progress taking measures counter claims ip major barrier access looking ways improve availability affordability help increase access maintaining support intellectual property rights key business areas access problem confined developing world example us many people suffer unnecessary ill health healthcare insurance community investment programmes provide additional resource addressing healthcare challenges around world support underserved communities funding education practical support donations always looking refine improve contribution improving access medicines anpdag ien ceo andrew witty announced number new approaches pursuing believe pharmaceutical industry huge role play need take much leadership role historically always reacted problems future want us proactive genuinely finding new ways increase research increase access eradicate disease andrew witty ceo speech carter center atlanta december highlights announced new approaches increase flexibility pricing least developed countries intellectual property relating neglected diseases identified industry leader first access medicines index successful results reported phase clinical trials rtss malaria vaccine candidate african children entered new rd partnership drugs neglected diseases initiative notforprofit prices antiretrovirals reduced positive opinion received european medicines agency pneumococcal vaccine million antiretroviral tablets supplied developing countries including million tablets supplied generic manufacturers licensed gsk billion vaccines shipped almost per cent went developing world restructured commercial operations reflect needs patients business opportunities emerging markets entered new partnerships acquisitions develop relevant product portfoliohome responsibility access medicines corporate responsibility report access medicines access healthcare one worlds pressing social challenges every year millions people developing countries die curable infectious diseases access basic healthcare services including essential medicines millions unnecessarily exposed threat ill health inadequate ineffective disease prevention strategies number complex factors prevent access medicines often limited prospect commercial return rd neglected diseases unified registration system medicines makes registration process costly complex time consuming many developing countries distribution network medicines healthcare infrastructure treat patients prescribe medicines however problems must excuse inaction rather indicate action needed last decade pharmaceutical industry helped address healthcare challenges developing world researching new medicines making available affordable despite progress scale healthcare crisis means industry must take proactive approach identified four key areas strengthen approach flexible intellectual property flexible pricing recognising achieve partnerships alone looking move supplier medicines partner delivering solutions read plans areas abbas hussain president emerging markets gsk leads access efforts also reviewed corporate executive team gsks senior team corporate responsibility committee board increasing access medicines important business ethical reputational commercial reasons morally right thing valued shareholders employees stakeholders aligned corporate mission contributes gsks reputation ability attract retain talented employees business objective increase proportion worlds population access medicines currently around per cent successful pharmaceutical companies future serve bigger proportion worlds population business relies intellectual property ip rights system encourages medical innovation progress taking measures counter claims ip major barrier access looking ways improve availability affordability help increase access maintaining support intellectual property rights key business areas access problem confined developing world example us many people suffer unnecessary ill health healthcare insurance community investment programmes provide additional resource addressing healthcare challenges around world support underserved communities funding education practical support donations always looking refine improve contribution improving access medicines ceo andrew witty announced number new approaches pursuing believe pharmaceutical industry huge role play need take much leadership role historically always reacted problems future want us proactive genuinely finding new ways increase research increase access eradicate disease andrew witty ceo speech carter center atlanta december highlights announced new approaches increase flexibility pricing least developed countries intellectual property relating neglected diseases identified industry leader first access medicines index successful results reported phase clinical trials rtss malaria vaccine candidate african children entered new rd partnership drugs neglected diseases initiative notforprofit prices antiretrovirals reduced positive opinion received european medicines agency pneumococcal vaccine million antiretroviral tablets supplied developing countries including million tablets supplied generic manufacturers licensed gsk billion vaccines shipped almost per cent went developing world restructured commercial operations reflect needs patients business opportunities emerging markets entered new partnerships acquisitions develop relevant product portfolio home responsibility access medicines corporate responsibility report access medicines access healthcare one worlds pressing social challenges every year millions people developing countries die curable infectious diseases access basic healthcare services including essential medicines millions unnecessarily exposed threat ill health inadequate ineffective disease prevention strategies number complex factors prevent access medicines often limited prospect commercial return rd neglected diseases unified registration system medicines makes registration process costly complex time consuming many developing countries distribution network medicines healthcare infrastructure treat patients prescribe medicines however problems must excuse inaction rather indicate action needed last decade pharmaceutical industry helped address healthcare challenges developing world researching new medicines making available affordable despite progress scale healthcare crisis means industry must take proactive approach identified four key areas strengthen approach flexible intellectual property flexible pricing recognising achieve partnerships alone looking move supplier medicines partner delivering solutions read plans areas abbas hussain president emerging markets gsk leads access efforts also reviewed corporate executive team gsks senior team corporate responsibility committee board increasing access medicines important business ethical reputational commercial reasons morally right thing valued shareholders employees stakeholders aligned corporate mission contributes gsks reputation ability attract retain talented employees business objective increase proportion worlds population access medicines currently around per cent successful pharmaceutical companies future serve bigger proportion worlds population business relies intellectual property ip rights system encourages medical innovation progress taking measures counter claims ip major barrier access looking ways improve availability affordability help increase access maintaining support intellectual property rights key business areas access problem confined developing world example us many people suffer unnecessary ill health healthcare insurance community investment programmes provide additional resource addressing healthcare challenges around world support underserved communities funding education practical support donations always looking refine improve contribution improving access medicines ceo andrew witty announced number new approaches pursuing believe pharmaceutical industry huge role play need take much leadership role historically always reacted problems future want us proactive genuinely finding new ways increase research increase access eradicate disease andrew witty ceo speech carter center atlanta december highlights announced new approaches increase flexibility pricing least developed countries intellectual property relating neglected diseases identified industry leader first access medicines index successful results reported phase clinical trials rtss malaria vaccine candidate african children entered new rd partnership drugs neglected diseases initiative notforprofit prices antiretrovirals reduced positive opinion received european medicines agency pneumococcal vaccine million antiretroviral tablets supplied developing countries including million tablets supplied generic manufacturers licensed gsk billion vaccines shipped almost per cent went developing world restructured commercial operations reflect needs patients business opportunities emerging markets entered new partnerships acquisitions develop relevant product portfolio home responsibility access medicines approach contribution corporate responsibility report approach contribution gsk committed playing full part addressing healthcare challenges around world core business activity developing launching new medicines vaccines makes significant contribution recognise scale challenges requires coordinated approach looking expand research partnerships governments ngos companies support intellectual property rights essential encourage innovation want find ways use intellectual property flexibly speed development medicines neglected diseases without compromising sustainability business much difference activities rd pricing working partnerships make significant barriers access remain developing countries key among barriers lack healthcare infrastructure physical human although health service provider want work others deliver healthcare include investing infrastructure seek new opportunities area already making contribution strengthening infrastructure example donated equipment stateoftheart laboratory lagos state university college medicine professor clement adebamowo chairman national health research ethics committee nigeria said new laboratory would help nigeria regain lost ground health research reclaim position reputable partner education health research playing part address global healthcare challenges individually partnership right thing also makes good business sense work address global healthcare challenges action four areas improving affordability preferential pricing medicines tiered pricing vaccines worlds poorest countries exploring new business models middleincome countries providing discount cards developed countries investing research development targets diseases affecting developing world working partnerships research new medicines help deliver healthcare services undertaking community investment activities partnerships foster effective healthcare recognise developing world particular poses many healthcare challenges requires longterm commitment fundamental approach need ensure contribution sustainable built way business duty try ensure products used clinically appropriate way countries available particularly important case communicable diseases inappropriate use products speed development resistance treatment activities undertaken partnership organisations relevant specialist knowledge governments international agencies charities private sector organisations academic institutions gsk ranked top first access medicines index published june index rates companies performance according eight criteria management influence research development patenting capacity pricing drug donations philanthropy retain concerns methodology used report pleased multifaceted efforts make medicines available recognised index testament innovative sustainable approach many gsk employees contribute efforts help address healthcare challenges developing world home responsibility access medicines approach contribution corporate responsibility report approach contribution gsk committed playing full part addressing healthcare challenges around world core business activity developing launching new medicines vaccines makes significant contribution recognise scale challenges requires coordinated approach looking expand research partnerships governments ngos companies support intellectual property rights essential encourage innovation want find ways use intellectual property flexibly speed development medicines neglected diseases without compromising sustainability business much difference activities rd pricing working partnerships make significant barriers access remain developing countries key among barriers lack healthcare infrastructure physical human although health service provider want work others deliver healthcare include investing infrastructure seek new opportunities area already making contribution strengthening infrastructure example donated equipment stateoftheart laboratory lagos state university college medicine professor clement adebamowo chairman national health research ethics committee nigeria said new laboratory would help nigeria regain lost ground health research reclaim position reputable partner education health research playing part address global healthcare challenges individually partnership right thing also makes good business sense work address global healthcare challenges action four areas improving affordability preferential pricing medicines tiered pricing vaccines worlds poorest countries exploring new business models middleincome countries providing discount cards developed countries investing research development targets diseases affecting developing world working partnerships research new medicines help deliver healthcare services undertaking community investment activities partnerships foster effective healthcare recognise developing world particular poses many healthcare challenges requires longterm commitment fundamental approach need ensure contribution sustainable built way business duty try ensure products used clinically appropriate way countries available particularly important case communicable diseases inappropriate use products speed development resistance treatment activities undertaken partnership organisations relevant specialist knowledge governments international agencies charities private sector organisations academic institutions gsk ranked top first access medicines index published june index rates companies performance according eight criteria management influence research development patenting capacity pricing drug donations philanthropy retain concerns methodology used report pleased multifaceted efforts make medicines available recognised index testament innovative sustainable approach many gsk employees contribute efforts help address healthcare challenges developing world home responsibility access medicines approach contribution corporate responsibility report approach contribution gsk committed playing full part addressing healthcare challenges around world core business activity developing launching new medicines vaccines makes significant contribution recognise scale challenges requires coordinated approach looking expand research partnerships governments ngos companies support intellectual property rights essential encourage innovation want find ways use intellectual property flexibly speed development medicines neglected diseases without compromising sustainability business much difference activities rd pricing working partnerships make significant barriers access remain developing countries key among barriers lack healthcare infrastructure physical human although health service provider want work others deliver healthcare include investing infrastructure seek new opportunities area already making contribution strengthening infrastructure example donated equipment stateoftheart laboratory lagos state university college medicine professor clement adebamowo chairman national health research ethics committee nigeria said new laboratory would help nigeria regain lost ground health research reclaim position reputable partner education health research playing part address global healthcare challenges individually partnership right thing also makes good business sense work address global healthcare challenges action four areas improving affordability preferential pricing medicines tiered pricing vaccines worlds poorest countries exploring new business models middleincome countries providing discount cards developed countries investing research development targets diseases affecting developing world working partnerships research new medicines help deliver healthcare services undertaking community investment activities partnerships foster effective healthcare recognise developing world particular poses many healthcare challenges requires longterm commitment fundamental approach need ensure contribution sustainable built way business duty try ensure products used clinically appropriate way countries available particularly important case communicable diseases inappropriate use products speed development resistance treatment activities undertaken partnership organisations relevant specialist knowledge governments international agencies charities private sector organisations academic institutions gsk ranked top first access medicines index published june index rates companies performance according eight criteria management influence research development patenting capacity pricing drug donations philanthropy retain concerns methodology used report pleased multifaceted efforts make medicines available recognised index testament innovative sustainable approach many gsk employees contribute efforts help address healthcare challenges developing world home responsibility access medicines role others corporate responsibility report role others improving access healthcare developing countries complex challenge believe holistic approach embracing prevention treatment well fundamentally strengthening health systems work require stakeholders including pharmaceutical industry work together increase resources dedicated improving healthcare systems pharmaceutical companies including gsk must make medicines affordable possible people worlds poorest countries sustainable manner must invest research diseases developing world new prevention tools treatments urgently needed companies must look ways use intellectual property rights flexibly maximise rd resources neglected diseases rather suppliers medicines must also support governments efforts strengthen health systems developing innovative ways deliver medicines people need wealthy nations must give new funding coming global fund fight aids tb malaria bill melinda gates foundation pepfar us presidents emergency plan aids relief unitaid others funds still inadequate need predictable sustainable resources needed fund research strengthen health systems purchase medicines support disease prevention discourage migration trained healthcare workers developing countries current global financial crisis must divert resources away assisting developing countries developing countries must show genuine political commitment prioritising healthcare national budgets addressing stigma improving affordability removing import tariffs medicines part approach middleincome countries must accept responsibilities seek lowest prices offered worlds poorest countries countries provide environment encourages innovation support intellectual property ip rights avoid measures widespread compulsory licensing may negatively impact investment rd innovation supportive environment ip generally encourage companies flexible ip less defensive countries also address risk product diversion patients poor countries wealthier ones lobby governments policy makers advocate sustainable approach improving healthcare developing world approach must support innovation critical improving access longer term work area included urging g continue making healthcare developing world major agenda item supporting development pilot advance market commitment pneumococcal vaccine engaging work whos intergovernmental working group igwg public health innovation intellectual property working uk government global health issues development department international developments dfids medicines transparency alliance meta review good practice framework pharmaceutical companies playing leading role pharma futures industry dialogue exploring links sustainable pharmaceutical business models improved health outcomes middleincome markets including china india brazil discussing ip innovation funding ngos foundations stakeholders attending executive board meetings world health assembly meeting un secretary general ban ki moon discuss priorities addressing hivaids contributing design affordable medicines facility malaria playing leading role major global health initiatives example gsk sits boards gavi alliance roll back malaria participating board meetings global fund fight aids tb malaria supporting development quality assurance standards contributing development un human rights guidelines pharmaceutical companies relation access medicines engaging negotiations wto doha round seek sustainable proinnovation outcomes addressing hivaids eu neighbouring countries european commissions bremen process engaging intergovernmental meeting pandemic influenza preparedness contributed report prepared paul hunt un special rapporteur right health report gsks approach access medicines number senior executives including former ceo dr jp garnier chairman sir christopher gent interviewed expect report published first half read malaria advocacyhome responsibility access medicines role others corporate responsibility report role others improving access healthcare developing countries complex challenge believe holistic approach embracing prevention treatment well fundamentally strengthening health systems work require stakeholders including pharmaceutical industry work together increase resources dedicated improving healthcare systems pharmaceutical companies including gsk must make medicines affordable possible people worlds poorest countries sustainable manner must invest research diseases developing world new prevention tools treatments urgently needed companies must look ways use intellectual property rights flexibly maximise rd resources neglected diseases rather suppliers medicines must also support governments efforts strengthen health systems developing innovative ways deliver medicines people need wealthy nations must give new funding coming global fund fight aids tb malaria bill melinda gates foundation pepfar us presidents emergency plan aids relief unitaid others funds still inadequate need predictable sustainable resources needed fund research strengthen health systems purchase medicines support disease prevention discourage migration trained healthcare workers developing countries current global financial crisis must divert resources away assisting developing countries developing countries must show genuine political commitment prioritising healthcare national budgets addressing stigma improving affordability removing import tariffs medicines part approach middleincome countries must accept responsibilities seek lowest prices offered worlds poorest countries countries provide environment encourages innovation support intellectual property ip rights avoid measures widespread compulsory licensing may negatively impact investment rd innovation supportive environment ip generally encourage companies flexible ip less defensive countries also address risk product diversion patients poor countries wealthier ones lobby governments policy makers advocate sustainable approach improving healthcare developing world approach must support innovation critical improving access longer term work area included urging g continue making healthcare developing world major agenda item supporting development pilot advance market commitment pneumococcal vaccine engaging work whos intergovernmental working group igwg public health innovation intellectual property working uk government global health issues development department international developments dfids medicines transparency alliance meta review good practice framework pharmaceutical companies playing leading role pharma futures industry dialogue exploring links sustainable pharmaceutical business models improved health outcomes middleincome markets including china india brazil discussing ip innovation funding ngos foundations stakeholders attending executive board meetings world health assembly meeting un secretary general ban ki moon discuss priorities addressing hivaids contributing design affordable medicines facility malaria playing leading role major global health initiatives example gsk sits boards gavi alliance roll back malaria participating board meetings global fund fight aids tb malaria supporting development quality assurance standards contributing development un human rights guidelines pharmaceutical companies relation access medicines engaging negotiations wto doha round seek sustainable proinnovation outcomes addressing hivaids eu neighbouring countries european commissions bremen process engaging intergovernmental meeting pandemic influenza preparedness contributed report prepared paul hunt un special rapporteur right health report gsks approach access medicines number senior executives including former ceo dr jp garnier chairman sir christopher gent interviewed expect report published first half read malaria advocacy home responsibility access medicines role others corporate responsibility report role others improving access healthcare developing countries complex challenge believe holistic approach embracing prevention treatment well fundamentally strengthening health systems work require stakeholders including pharmaceutical industry work together increase resources dedicated improving healthcare systems pharmaceutical companies including gsk must make medicines affordable possible people worlds poorest countries sustainable manner must invest research diseases developing world new prevention tools treatments urgently needed companies must look ways use intellectual property rights flexibly maximise rd resources neglected diseases rather suppliers medicines must also support governments efforts strengthen health systems developing innovative ways deliver medicines people need wealthy nations must give new funding coming global fund fight aids tb malaria bill melinda gates foundation pepfar us presidents emergency plan aids relief unitaid others funds still inadequate need predictable sustainable resources needed fund research strengthen health systems purchase medicines support disease prevention discourage migration trained healthcare workers developing countries current global financial crisis must divert resources away assisting developing countries developing countries must show genuine political commitment prioritising healthcare national budgets addressing stigma improving affordability removing import tariffs medicines part approach middleincome countries must accept responsibilities seek lowest prices offered worlds poorest countries countries provide environment encourages innovation support intellectual property ip rights avoid measures widespread compulsory licensing may negatively impact investment rd innovation supportive environment ip generally encourage companies flexible ip less defensive countries also address risk product diversion patients poor countries wealthier ones lobby governments policy makers advocate sustainable approach improving healthcare developing world approach must support innovation critical improving access longer term work area included urging g continue making healthcare developing world major agenda item supporting development pilot advance market commitment pneumococcal vaccine engaging work whos intergovernmental working group igwg public health innovation intellectual property working uk government global health issues development department international developments dfids medicines transparency alliance meta review good practice framework pharmaceutical companies playing leading role pharma futures industry dialogue exploring links sustainable pharmaceutical business models improved health outcomes middleincome markets including china india brazil discussing ip innovation funding ngos foundations stakeholders attending executive board meetings world health assembly meeting un secretary general ban ki moon discuss priorities addressing hivaids contributing design affordable medicines facility malaria playing leading role major global health initiatives example gsk sits boards gavi alliance roll back malaria participating board meetings global fund fight aids tb malaria supporting development quality assurance standards contributing development un human rights guidelines pharmaceutical companies relation access medicines engaging negotiations wto doha round seek sustainable proinnovation outcomes addressing hivaids eu neighbouring countries european commissions bremen process engaging intergovernmental meeting pandemic influenza preparedness contributed report prepared paul hunt un special rapporteur right health report gsks approach access medicines number senior executives including former ceo dr jp garnier chairman sir christopher gent interviewed expect report published first half read malaria advocacy home responsibility access medicines developing countries corporate responsibility report developing countries poverty underlying cause healthcare crisis many parts developing world worlds poorest countries millions people reliable access food clean water never mind adequate healthcare services healthcare crisis developing world complex holistic approach work improve situation must involve comprehensive programme prevention health education screening diagnosis treatment community care support increasing access medicines also plays vital part areas gsk seeks opportunities make contribution significant additional funding national international sources must mobilised really make difference recommends minimum spend health per person per year provide basic health services yet average spend subsaharan africa according uks department international development african region suffers per cent global burden disease three per cent worlds health workers pharmaceutical industry must look form partnerships help deliver healthcare services political needed aid development build healthcare infrastructure gsk make important contribution researching new treatments vaccines diseases affecting developing countries registering products countries needed offering preferential pricing arrangements medicines tiered pricing vaccines needed seeking innovative partnerships help improve healthcare developing world granting voluntary licences allow companies manufacture medicines investing projects support healthcare delivery underserved communities diseases disproportionately affecting developing countries malaria kills million people year mostly children five years old around two billion people worldwide infected tb million people die disease year new treatments tb developed last years unaids estimates hivaidsrelated illnesses killed two million people million people worldwide living hiv worldwide woman dies cervical cancer every two minutes per cent developing world rotavirus infection causes deaths year mostly children two years age per cent deaths occur lowincome countries home responsibility access medicines developing countries corporate responsibility report developing countries poverty underlying cause healthcare crisis many parts developing world worlds poorest countries millions people reliable access food clean water never mind adequate healthcare services healthcare crisis developing world complex holistic approach work improve situation must involve comprehensive programme prevention health education screening diagnosis treatment community care support increasing access medicines also plays vital part areas gsk seeks opportunities make contribution significant additional funding national international sources must mobilised really make difference recommends minimum spend health per person per year provide basic health services yet average spend subsaharan africa according uks department international development african region suffers per cent global burden disease three per cent worlds health workers pharmaceutical industry must look form partnerships help deliver healthcare services political needed aid development build healthcare infrastructure gsk make important contribution researching new treatments vaccines diseases affecting developing countries registering products countries needed offering preferential pricing arrangements medicines tiered pricing vaccines needed seeking innovative partnerships help improve healthcare developing world granting voluntary licences allow companies manufacture medicines investing projects support healthcare delivery underserved communities diseases disproportionately affecting developing countries malaria kills million people year mostly children five years old around two billion people worldwide infected tb million people die disease year new treatments tb developed last years unaids estimates hivaidsrelated illnesses killed two million people million people worldwide living hiv worldwide woman dies cervical cancer every two minutes per cent developing world rotavirus infection causes deaths year mostly children two years age per cent deaths occur lowincome countries home responsibility access medicine developing countries research development corporate responsibility report research development diseases affecting developing countries effective treatments cases treatments exist become less effective due drug resistance sometimes treatments suitable example difficult administer areas poor healthcare infrastructure expensive researchbased company aim make major contribution health developing countries researching developing affordable new vaccines treatments infectious diseases currently conducting rd diseases particular relevance developing world bacterial meningitis chlamydia dengue fever hepatitis e hivaids leishmaniasis malaria pandemic flu pneumococcal disease chagas disease human african trypanosomiasis tb information rd pipeline see annual report biomedical rd costly risky time consuming activity develop one successful medicine vaccine typically take years average including costs failures costs around billion every compounds tested estimated five reach clinical trials one reaches market whats different rd medicines developing world gsk scientists working treatment projects diseases developing world ddw make access medicines priority right start rd process researching new ddw treatment emphasise factors heat humidity resistance product must able survive hot climate may refrigeration facilities ease use must easy use settings limited healthcare facilities example onceaday tablets taken home preferable injectable medicine must administered hospital clinic affordability price one important factors look molecules formulations straightforward manufacture therefore inexpensive produce diseases disproportionately affect developing world market exists developed countries hivaids still pursue business model accept rd costs risks involved expectation market wealthy countries subsidise poorer ones diseases developing world market exists pursue new ways working one solution publicprivate partnership ppp model businesses public sector work together model enables collaborators achieve together would alone also exploring ways share knowledge organisations help facilitate speed discovery development new medicines flexible intellectual property aim encourage pharmaceutical companies follow suit believe gsk currently company researching new vaccines treatments three whos priority infectious diseases malaria tb hivaids also extensive portfolio rd projects diseases developing world industry leader research hivaids treatment currently evaluating multiple secondgeneration integrase inhibitors clinical development also look new treatments neglected diseases typically collaboration external partners example engage ongoing rd programmes leishmaniasis chagas disease human african trypanosomiasis african sleeping sickness created dedicated group focus diseases developing world fully integrated pharmaceutical rd organisation group prioritises projects based socioeconomic public health benefit rather commercial returns addition scientists based uk us includes drug discovery centre tres cantos rd site spain scientists focus primarily malaria tb half scientists funded ppps medicines malaria venture tb alliance group focused developing world diseases also active vaccines organisation belgium looking ways expand tres cantos site global centre excellence encouraging investment collaboration governments ngos companies overriding objective ensure gsk makes best possible contribution improving health affected neglected diseases developing world achieved pursuing approach lead extensive effective sustainable pipeline diseases developing world ddw increasing partnerships external ddw communities cover neglected diseases diverse expertise research tools novel targets developable drug candidates worldwide talent pool including strong links best academic groups spreading ddw remits learning developing countries emerging markets sharing training activities science forums researchers upcoming scientists countries avoiding brain drain downsides strengthening current rd partnerships organisations medicines malaria venture mmv tb alliance drugs neglected diseases initiative dndi international aids vaccine initiative iavi path malaria vaccine initiative mvi aeras global tb vaccine foundation well seeking new partnerships read positions statements clinical trials developing world paediatric medicines briefing treatment children living hiv developing countries tufts center study drug development pharmaceutical industry profile washington dc phrma march home responsibility access medicine developing countries research development corporate responsibility report research development diseases affecting developing countries effective treatments cases treatments exist become less effective due drug resistance sometimes treatments suitable example difficult administer areas poor healthcare infrastructure expensive researchbased company aim make major contribution health developing countries researching developing affordable new vaccines treatments infectious diseases currently conducting rd diseases particular relevance developing world bacterial meningitis chlamydia dengue fever hepatitis e hivaids leishmaniasis malaria pandemic flu pneumococcal disease chagas disease human african trypanosomiasis tb information rd pipeline see annual report biomedical rd costly risky time consuming activity develop one successful medicine vaccine typically take years average including costs failures costs around billion every compounds tested estimated five reach clinical trials one reaches market whats different rd medicines developing world gsk scientists working treatment projects diseases developing world ddw make access medicines priority right start rd process researching new ddw treatment emphasise factors heat humidity resistance product must able survive hot climate may refrigeration facilities ease use must easy use settings limited healthcare facilities example onceaday tablets taken home preferable injectable medicine must administered hospital clinic affordability price one important factors look molecules formulations straightforward manufacture therefore inexpensive produce diseases disproportionately affect developing world market exists developed countries hivaids still pursue business model accept rd costs risks involved expectation market wealthy countries subsidise poorer ones diseases developing world market exists pursue new ways working one solution publicprivate partnership ppp model businesses public sector work together model enables collaborators achieve together would alone also exploring ways share knowledge organisations help facilitate speed discovery development new medicines flexible intellectual property aim encourage pharmaceutical companies follow suit believe gsk currently company researching new vaccines treatments three whos priority infectious diseases malaria tb hivaids also extensive portfolio rd projects diseases developing world industry leader research hivaids treatment currently evaluating multiple secondgeneration integrase inhibitors clinical development also look new treatments neglected diseases typically collaboration external partners example engage ongoing rd programmes leishmaniasis chagas disease human african trypanosomiasis african sleeping sickness created dedicated group focus diseases developing world fully integrated pharmaceutical rd organisation group prioritises projects based socioeconomic public health benefit rather commercial returns addition scientists based uk us includes drug discovery centre tres cantos rd site spain scientists focus primarily malaria tb half scientists funded ppps medicines malaria venture tb alliance group focused developing world diseases also active vaccines organisation belgium looking ways expand tres cantos site global centre excellence encouraging investment collaboration governments ngos companies overriding objective ensure gsk makes best possible contribution improving health affected neglected diseases developing world achieved pursuing approach lead extensive effective sustainable pipeline diseases developing world ddw increasing partnerships external ddw communities cover neglected diseases diverse expertise research tools novel targets developable drug candidates worldwide talent pool including strong links best academic groups spreading ddw remits learning developing countries emerging markets sharing training activities science forums researchers upcoming scientists countries avoiding brain drain downsides strengthening current rd partnerships organisations medicines malaria venture mmv tb alliance drugs neglected diseases initiative dndi international aids vaccine initiative iavi path malaria vaccine initiative mvi aeras global tb vaccine foundation well seeking new partnerships read positions statements clinical trials developing world paediatric medicines briefing treatment children living hiv developing countries tufts center study drug development pharmaceutical industry profile washington dc phrma march home responsibility access medicine developing countries research development corporate responsibility report research development diseases affecting developing countries effective treatments cases treatments exist become less effective due drug resistance sometimes treatments suitable example difficult administer areas poor healthcare infrastructure expensive researchbased company aim make major contribution health developing countries researching developing affordable new vaccines treatments infectious diseases currently conducting rd diseases particular relevance developing world bacterial meningitis chlamydia dengue fever hepatitis e hivaids leishmaniasis malaria pandemic flu pneumococcal disease chagas disease human african trypanosomiasis tb information rd pipeline see annual report biomedical rd costly risky time consuming activity develop one successful medicine vaccine typically take years average including costs failures costs around billion every compounds tested estimated five reach clinical trials one reaches market whats different rd medicines developing world gsk scientists working treatment projects diseases developing world ddw make access medicines priority right start rd process researching new ddw treatment emphasise factors heat humidity resistance product must able survive hot climate may refrigeration facilities ease use must easy use settings limited healthcare facilities example onceaday tablets taken home preferable injectable medicine must administered hospital clinic affordability price one important factors look molecules formulations straightforward manufacture therefore inexpensive produce diseases disproportionately affect developing world market exists developed countries hivaids still pursue business model accept rd costs risks involved expectation market wealthy countries subsidise poorer ones diseases developing world market exists pursue new ways working one solution publicprivate partnership ppp model businesses public sector work together model enables collaborators achieve together would alone also exploring ways share knowledge organisations help facilitate speed discovery development new medicines flexible intellectual property aim encourage pharmaceutical companies follow suit believe gsk currently company researching new vaccines treatments three whos priority infectious diseases malaria tb hivaids also extensive portfolio rd projects diseases developing world industry leader research hivaids treatment currently evaluating multiple secondgeneration integrase inhibitors clinical development also look new treatments neglected diseases typically collaboration external partners example engage ongoing rd programmes leishmaniasis chagas disease human african trypanosomiasis african sleeping sickness created dedicated group focus diseases developing world fully integrated pharmaceutical rd organisation group prioritises projects based socioeconomic public health benefit rather commercial returns addition scientists based uk us includes drug discovery centre tres cantos rd site spain scientists focus primarily malaria tb half scientists funded ppps medicines malaria venture tb alliance group focused developing world diseases also active vaccines organisation belgium looking ways expand tres cantos site global centre excellence encouraging investment collaboration governments ngos companies overriding objective ensure gsk makes best possible contribution improving health affected neglected diseases developing world achieved pursuing approach lead extensive effective sustainable pipeline diseases developing world ddw increasing partnerships external ddw communities cover neglected diseases diverse expertise research tools novel targets developable drug candidates worldwide talent pool including strong links best academic groups spreading ddw remits learning developing countries emerging markets sharing training activities science forums researchers upcoming scientists countries avoiding brain drain downsides strengthening current rd partnerships organisations medicines malaria venture mmv tb alliance drugs neglected diseases initiative dndi international aids vaccine initiative iavi path malaria vaccine initiative mvi aeras global tb vaccine foundation well seeking new partnerships read positions statements clinical trials developing world paediatric medicines briefing treatment children living hiv developing countries tufts center study drug development pharmaceutical industry profile washington dc phrma march home responsibility access medicine developing countries research development malaria corporate responsibility report malaria working malaria vaccine years invested million resources date currently developing candidate malaria vaccine rtss partnership path malaria vaccine initiative mvi contributed million results two separate phase trials confirmed findings earlier studies candidate vaccine provides infants young children vulnerable groups significant protection malaria children aged five months rtssas vaccine reduced risk clinical episodes malaria per cent eightmonth period trial among infants months received three doses modified rtssas vaccine risk first infection malaria reduced per cent six month period trials also showed rtssas vaccine interfere efficacy vaccines administered existing african national immunisation programmes means countries malaria prevalent vaccine could delivered current immunisation schedule infants called expanded program immunization epi christian loucq mvi director commented significance trial results saying closer ever developing malaria vaccine children africa commence largescale phase lll vaccine efficacy trials seven african countries across sites trials confirm safety efficacy candidate vaccine could filed registration introduced early children five months age take longer establish efficacy infants epi age six weeks old due complexity enrolment trials earliest vaccine could fully available following approval use infants read malaria vaccine case study update august phase iii trial rtss malaria vaccine candidate started bagamoyo tanzania may work malaria treatments includes tafenoquine potential new treatment radical cure p vivax malaria developed partnership medicines malaria venture mmv well causing acute infection red blood cells p vivax causes dormant infection liver cells parasites reactivate resulting reappearance parasites blood recurrence malaria radical cure implies complete elimination malaria parasites body including dormant liver stages tafenoquine offers potential one two day treatment course could replace primaquine standard care p vivax radical cure initial study commencing focus understanding safety tafenoquine subjects inherited glucosephosphate dehydrogenase gpd deficiency tafenoquine novel inclusion mmvs portfolio given activity liver stages malaria hypnozoites essential part fight p vivax infections malaria elimination agenda moves forwards need increasing array tools parasite said dr timothy wells chief scientific officer medicines malaria venture mmv gsk worked successfully number malaria projects past together hope develop radical cure p vivax malaria pyridones new class compounds potential highly effective drugsensitive drugresistant strains p falciparum p vivax malaria pyridone gsk pdaegvee lo opf ed partnership mmv entered first time human clinical trials early backup programme included gskmmv agreement well advanced candidate development expected mid isoquine new aminoquinoline compound first time human clinical trial completed based advice mmv expert scientific advisory committee following discussions three partners gsk university liverpool mmv isoquine project terminated time evidence provided demonstrate adequate therapeutic blood exposures achieved acceptable oral dosage bejon p lusingu j olotu et al efficacy rtssase clinical malaria month old children n engl j med abdulla oberholzer r juma et al safety immunogenicity rtssasd malaria vaccine infants n engl j med gsk press release issued february dacart lapdap reported corporate responsibility report early gsk medicines malaria venture mmv received data two phase lll clinical trials assessing use artemisininbased combination therapy dacart developing together one trial primarily designed establish efficacy dacart versus coartem currently first line antimalarial therapy many endemic countries second trial designed establish efficacy dacart versus lapdap chlorproguanil dapsone another antimalarial product gsk developed partnership including world health organization uks department international development key safety finding trials patients glucosephosphate dehydrogenase gpd deficiency found risk anaemia taking either dacart lapdap consequently given haematological profile dacart fact per cent population sub saharan africa gpd deficient gsk mmv decided terminate development dacart reasons gsk also decided withdraw lapdap market disappointment highlights highly risky complex nature pharmaceutical research development however gsk remains committed working partners mmv seek solutions patients suffering devastating diseasehome responsibility access medicine developing countries research development malaria corporate responsibility report malaria working malaria vaccine years invested million resources date currently developing candidate malaria vaccine rtss partnership path malaria vaccine initiative mvi contributed million results two separate phase trials confirmed findings earlier studies candidate vaccine provides infants young children vulnerable groups significant protection malaria children aged five months rtssas vaccine reduced risk clinical episodes malaria per cent eightmonth period trial among infants months received three doses modified rtssas vaccine risk first infection malaria reduced per cent six month period trials also showed rtssas vaccine interfere efficacy vaccines administered existing african national immunisation programmes means countries malaria prevalent vaccine could delivered current immunisation schedule infants called expanded program immunization epi christian loucq mvi director commented significance trial results saying closer ever developing malaria vaccine children africa commence largescale phase lll vaccine efficacy trials seven african countries across sites trials confirm safety efficacy candidate vaccine could filed registration introduced early children five months age take longer establish efficacy infants epi age six weeks old due complexity enrolment trials earliest vaccine could fully available following approval use infants read malaria vaccine case study update august phase iii trial rtss malaria vaccine candidate started bagamoyo tanzania may work malaria treatments includes tafenoquine potential new treatment radical cure p vivax malaria developed partnership medicines malaria venture mmv well causing acute infection red blood cells p vivax causes dormant infection liver cells parasites reactivate resulting reappearance parasites blood recurrence malaria radical cure implies complete elimination malaria parasites body including dormant liver stages tafenoquine offers potential one two day treatment course could replace primaquine standard care p vivax radical cure initial study commencing focus understanding safety tafenoquine subjects inherited glucosephosphate dehydrogenase gpd deficiency tafenoquine novel inclusion mmvs portfolio given activity liver stages malaria hypnozoites essential part fight p vivax infections malaria elimination agenda moves forwards need increasing array tools parasite said dr timothy wells chief scientific officer medicines malaria venture mmv gsk worked successfully number malaria projects past together hope develop radical cure p vivax malaria pyridones new class compounds potential highly effective drugsensitive drugresistant strains p falciparum p vivax malaria pyridone gsk developed partnership mmv entered first time human clinical trials early backup programme included gskmmv agreement well advanced candidate development expected mid isoquine new aminoquinoline compound first time human clinical trial completed based advice mmv expert scientific advisory committee following discussions three partners gsk university liverpool mmv isoquine project terminated time evidence provided demonstrate adequate therapeutic blood exposures achieved acceptable oral dosage bejon p lusingu j olotu et al efficacy rtssase clinical malaria month old children n engl j med abdulla oberholzer r juma et al safety immunogenicity rtssasd malaria vaccine infants n engl j med gsk press release issued february dacart lapdap reported corporate responsibility report early gsk medicines malaria venture mmv received data two phase lll clinical trials assessing use artemisininbased combination therapy dacart developing together one trial primarily designed establish efficacy dacart versus coartem currently first line antimalarial therapy many endemic countries second trial designed establish efficacy dacart versus lapdap chlorproguanil dapsone another antimalarial product gsk developed partnership including world health organization uks department international development key safety finding trials patients glucosephosphate dehydrogenase gpd deficiency found risk anaemia taking either dacart lapdap consequently given haematological profile dacart fact per cent population sub saharan africa gpd deficient gsk mmv decided terminate development dacart reasons gsk also decided withdraw lapdap market disappointment highlights highly risky complex nature pharmaceutical research development however gsk remains committed working partners mmv seek solutions patients suffering devastating disease home responsibility access medicine developing countries research development tuberculosis corporate responsibility report tuberculosis tuberculosis medicines research conducted partnership global alliance tb drug development tb alliance january announced renewal three years joint research programme tb alliance speaking time announcement dr mel spigelman tb alliance director research development said encouraged success pioneering work gsk nearly doubled number tb drug discovery projects pipeline collaboration advancing tb alliances mission develop revolutionary faster better tb treatment regimens exploring npaegwe w aofy attack disease lead tb project mycobacterium gyrase inhibitors expects select candidate development mid tb partnership projects way include research biomarkers currently effectiveness new tb drug determined months completion treatment biomarkers enable us predict early stage patients responding could significantly speed tb research mtbf tb candidate vaccine developed aeras global tb vaccine foundation early results positive suggesting vaccine safe produces strong immune reaction adults tb endemic regions trials planned infants tb endemic regionshome responsibility access medicine developing countries research development tuberculosis corporate responsibility report tuberculosis tuberculosis medicines research conducted partnership global alliance tb drug development tb alliance january announced renewal three years joint research programme tb alliance speaking time announcement dr mel spigelman tb alliance director research development said encouraged success pioneering work gsk nearly doubled number tb drug discovery projects pipeline collaboration advancing tb alliances mission develop revolutionary faster better tb treatment regimens exploring new ways attack disease lead tb project mycobacterium gyrase inhibitors expects select candidate development mid tb partnership projects way include research biomarkers currently effectiveness new tb drug determined months completion treatment biomarkers enable us predict early stage patients responding could significantly speed tb research mtbf tb candidate vaccine developed aeras global tb vaccine foundation early results positive suggesting vaccine safe produces strong immune reaction adults tb endemic regions trials planned infants tb endemic regions home responsibility access medicine developing countries research development tuberculosis corporate responsibility report tuberculosis tuberculosis medicines research conducted partnership global alliance tb drug development tb alliance january announced renewal three years joint research programme tb alliance speaking time announcement dr mel spigelman tb alliance director research development said encouraged success pioneering work gsk nearly doubled number tb drug discovery projects pipeline collaboration advancing tb alliances mission develop revolutionary faster better tb treatment regimens exploring new ways attack disease lead tb project mycobacterium gyrase inhibitors expects select candidate development mid tb partnership projects way include research biomarkers currently effectiveness new tb drug determined months completion treatment biomarkers enable us predict early stage patients responding could significantly speed tb research mtbf tb candidate vaccine developed aeras global tb vaccine foundation early results positive suggesting vaccine safe produces strong immune reaction adults tb endemic regions trials planned infants tb endemic regions home responsibility access medicine developing countries research development hivaids corporate responsibility report hivaids involved aids vaccine research two decades gsk also committed development new molecules target unmet medical needs hiv pressing need variety new antihiv drugs novel mechanisms action vaccines pursuing three separate vaccine strategies successful aids vaccine might combine several approaches recombinant measles vector measles vaccine one powerful providing lifelong protection disease working pasteur institute paris develop aids vaccine fusing genes hiv virus onto measles vaccine fco candidate vaccine advance phase lll trials hivinfected subjects extramural collaborative discovery rd programme aims identify hiv envelopebased protein vaccine capable producing broadly neutralising antibodies hiv infection addition continue collaborate international aids vaccine initiative iavi evaluating modifications joint programme treatments gsk committed development new molecules target unmet medical needs hiv pressing need variety new antihiv drugs novel mechanisms action integrase inhibitors represent important new class compounds treatment hiv increasingly clear secondgeneration integrase inhibitors needed address issues drug resistance dosing complexity currently number secondgeneration integrase inhibitors early stages clinical development february announced licence agreement idenix pharmaceuticals inc granting gsk exclusive worldwide rights idx novel nonnucleoside reverse transcriptase inhibitor nnrti phase clinical development developed idenix treatment hivaids new nnrtis needed address increasing prevalence viral resistance side effects associated drug class date idx demonstrated high potency low milligram doses high barrier drug resistance favourable riskbenefit profile convenience onceaday administration million children living hiv worldwide nearly per cent subsaharan africa committed improving treatment children living hivaids developing products designed use children developing scored tablets simplify treatment scored tablets enable antiretrovirals arvs broken two smaller doses simplifies treatment children unicef stated access tablet form arvs could improve treatment options children able swallow tablets tablets often easier store distribute also less complicated administer liquid formulations currently available particularly two three medicines combined one pill gained approval european commission new scored tablets epivir combivir ziagen enable children kilograms weight benefit solid dosage form received approvals epivir ziagen scored tablets us food drug administration february fda approved scored version combivir new tablets make treatment easier children example child weighing kilograms take half tablet combivir morning second half evening combination another arv instead requiring ml epivir solution twice day plus ml retrovir solution three timpaeges da oifl also committed support four paediatric clinical studies resourcepoor countries determine best ways expand access hivaids treatment international hiv collaborative research trials crt programme resourcepoor settings supporting clinical trials sponsored external organisations uks medical research council us national institutes health nih end trials way three planned involving approximately patients nineteen trials conducted sites africa crts focus predominantly public healthrelated issues developing world prevention mothertochild hiv transmission paediatric treatments strategies hivtb coinfection gsk donates study antiretrovirals andor financial support also provides scientific input countries hiv crt studies conducted include african countries asia latin america countries south africa india uganda thailand zimbabwe cambodia kenya vietnam botswana brazil zambia haiti tanzania peru malawi argentina ethiopia mali nigeriahome responsibility access medicine developing countries research development hivaids corporate responsibility report hivaids involved aids vaccine research two decades gsk also committed development new molecules target unmet medical needs hiv pressing need variety new antihiv drugs novel mechanisms action vaccines pursuing three separate vaccine strategies successful aids vaccine might combine several approaches recombinant measles vector measles vaccine one powerful providing lifelong protection disease working pasteur institute paris develop aids vaccine fusing genes hiv virus onto measles vaccine fco candidate vaccine advance phase lll trials hivinfected subjects extramural collaborative discovery rd programme aims identify hiv envelopebased protein vaccine capable producing broadly neutralising antibodies hiv infection addition continue collaborate international aids vaccine initiative iavi evaluating modifications joint programme treatments gsk committed development new molecules target unmet medical needs hiv pressing need variety new antihiv drugs novel mechanisms action integrase inhibitors represent important new class compounds treatment hiv increasingly clear secondgeneration integrase inhibitors needed address issues drug resistance dosing complexity currently number secondgeneration integrase inhibitors early stages clinical development february announced licence agreement idenix pharmaceuticals inc granting gsk exclusive worldwide rights idx novel nonnucleoside reverse transcriptase inhibitor nnrti phase clinical development developed idenix treatment hivaids new nnrtis needed address increasing prevalence viral resistance side effects associated drug class date idx demonstrated high potency low milligram doses high barrier drug resistance favourable riskbenefit profile convenience onceaday administration million children living hiv worldwide nearly per cent subsaharan africa committed improving treatment children living hivaids developing products designed use children developing scored tablets simplify treatment scored tablets enable antiretrovirals arvs broken two smaller doses simplifies treatment children unicef stated access tablet form arvs could improve treatment options children able swallow tablets tablets often easier store distribute also less complicated administer liquid formulations currently available particularly two three medicines combined one pill gained approval european commission new scored tablets epivir combivir ziagen enable children kilograms weight benefit solid dosage form received approvals epivir ziagen scored tablets us food drug administration february fda approved scored version combivir new tablets make treatment easier children example child weighing kilograms take half tablet combivir morning second half evening combination another arv instead requiring ml epivir solution twice day plus ml retrovir solution three times daily also committed support four paediatric clinical studies resourcepoor countries determine best ways expand access hivaids treatment international hiv collaborative research trials crt programme resourcepoor settings supporting clinical trials sponsored external organisations uks medical research council us national institutes health nih end trials way three planned involving approximately patients nineteen trials conducted sites africa crts focus predominantly public healthrelated issues developing world prevention mothertochild hiv transmission paediatric treatments strategies hivtb coinfection gsk donates study antiretrovirals andor financial support also provides scientific input countries hiv crt studies conducted include african countries asia latin america countries south africa india uganda thailand zimbabwe cambodia kenya vietnam botswana brazil zambia haiti tanzania peru malawi argentina ethiopia mali nigeria home responsibility access medicine developing countries research development hivaids corporate responsibility report hivaids involved aids vaccine research two decades gsk also committed development new molecules target unmet medical needs hiv pressing need variety new antihiv drugs novel mechanisms action vaccines pursuing three separate vaccine strategies successful aids vaccine might combine several approaches recombinant measles vector measles vaccine one powerful providing lifelong protection disease working pasteur institute paris develop aids vaccine fusing genes hiv virus onto measles vaccine fco candidate vaccine advance phase lll trials hivinfected subjects extramural collaborative discovery rd programme aims identify hiv envelopebased protein vaccine capable producing broadly neutralising antibodies hiv infection addition continue collaborate international aids vaccine initiative iavi evaluating modifications joint programme treatments gsk committed development new molecules target unmet medical needs hiv pressing need variety new antihiv drugs novel mechanisms action integrase inhibitors represent important new class compounds treatment hiv increasingly clear secondgeneration integrase inhibitors needed address issues drug resistance dosing complexity currently number secondgeneration integrase inhibitors early stages clinical development february announced licence agreement idenix pharmaceuticals inc granting gsk exclusive worldwide rights idx novel nonnucleoside reverse transcriptase inhibitor nnrti phase clinical development developed idenix treatment hivaids new nnrtis needed address increasing prevalence viral resistance side effects associated drug class date idx demonstrated high potency low milligram doses high barrier drug resistance favourable riskbenefit profile convenience onceaday administration million children living hiv worldwide nearly per cent subsaharan africa committed improving treatment children living hivaids developing products designed use children developing scored tablets simplify treatment scored tablets enable antiretrovirals arvs broken two smaller doses simplifies treatment children unicef stated access tablet form arvs could improve treatment options children able swallow tablets tablets often easier store distribute also less complicated administer liquid formulations currently available particularly two three medicines combined one pill gained approval european commission new scored tablets epivir combivir ziagen enable children kilograms weight benefit solid dosage form received approvals epivir ziagen scored tablets us food drug administration february fda approved scored version combivir new tablets make treatment easier children example child weighing kilograms take half tablet combivir morning second half evening combination another arv instead requiring ml epivir solution twice day plus ml retrovir solution three times daily also committed support four paediatric clinical studies resourcepoor countries determine best ways expand access hivaids treatment international hiv collaborative research trials crt programme resourcepoor settings supporting clinical trials sponsored external organisations uks medical research council us national institutes health nih end trials way three planned involving approximately patients nineteen trials conducted sites africa crts focus predominantly public healthrelated issues developing world prevention mothertochild hiv transmission paediatric treatments strategies hivtb coinfection gsk donates study antiretrovirals andor financial support also provides scientific input countries hiv crt studies conducted include african countries asia latin america countries south africa india uganda thailand zimbabwe cambodia kenya vietnam botswana brazil zambia haiti tanzania peru malawi argentina ethiopia mali nigeria home responsibility access medicine developing countries research development visceral leishmaniasis corporate responsibility report visceral leishmaniasis vl sitamaquine oral onceaday candidate treatment visceral leishmaniasis vl potentially fatal disease spread parasites data two phase proofofconcept studies kenya india encouraging overall day course per cent patients remained cured six months sitamaquine generally well tolerated patients studies however concerns regarding renal adverse events seen subjects appear treatment related interpretation data complicated particular vl associated renal impairment proceeding phase lll trials set phase llb study compare safety tolerability day course sitamaquine intravenous amphotericin b early results showed comparable efficacy previous studies despite shorter course sitamaquine much better tolerated amphotericin small number patients mild reversible renal side effects currently reviewing utility sitamaquine potential treatment vl regulatory authorities external stakeholders wasunna rashid jr mbui j et al phase ii doseincreasing study sitamaquine treatment visceral leishmaniasis kenya j trop med hyg jha tk sundar thakur cp et al phase ii doseranging study sitamaquine treatment visceral leishmaniasis india j trop med hyg prasad ls sen ganguly renal involvement kalaazar indian j med res jan dutra martinelli r de carvalho em et al renal involvement visceral leishmaniasis j kidney dis home responsibility access medicine developing countries research development visceral leishmaniasis corporate responsibility report visceral leishmaniasis vl sitamaquine oral onceaday candidate treatment visceral leishmaniasis vl potentially fatal disease spread parasites data two phase proofofconcept studies kenya india encouraging overall day course per cent patients remained cured six months sitamaquine generally well tolerated patients studies however concerns regarding renal adverse events seen subjects appear treatment related interpretation data complicated particular vl associated renal impairment proceeding phase lll trials set phase llb study compare safety tolerability day course sitamaquine intravenous amphotericin b early results showed comparable efficacy previous studies despite shorter course sitamaquine much better tolerated amphotericin small number patients mild reversible renal side effects currently reviewing utility sitamaquine potential treatment vl regulatory authorities external stakeholders wasunna rashid jr mbui j et al phase ii doseincreasing study sitamaquine treatment visceral leishmaniasis kenya j trop med hyg jha tk sundar thakur cp et al phase ii doseranging study sitamaquine treatment visceral leishmaniasis india j trop med hyg prasad ls sen ganguly renal involvement kalaazar indian j med res jan dutra martinelli r de carvalho em et al renal involvement visceral leishmaniasis j kidney dis home responsibility access medicine developing countries research development pneumococcal disease corporate responsibility report pneumococcal disease pneumococcal disease global health issue year streptococcus pneumoniae infections estimated kill one million children five years age worldwide distinct strains serotypes pneumococcus cause vast majority invasive disease young children january european medicines agencys committee medicinal products human use issued positive opinion recommended approval gsks paediatric pneumococcal candidate vaccine synflorix paediatric vaccine proposed indicated active immunisation invasive pneumococcal disease middle ear infections acute otitis media caused spneumoniae infants children six weeks two years european marketing authorisation vaccine expected granted first half submitted file potentially lifesaving candidate vaccine world health organization prequalification early prequalification service provided facilitate access medicines less affluent countries also discussions global alliance vaccines immunization accelerate availability funding pneumococcal vaccination pilot advance market commitment amc mechanism amcs new approach public health funding designed stimulate development manufacture vaccines developing countries donors commit money guarantee price vaccines developed thus creating potential viable future market home responsibility access medicine developing countries research development pneumococcal disease corporate responsibility report pneumococcal disease pneumococcal disease global health issue year streptococcus pneumoniae infections estimated kill one million children five years age worldwide distinct strains serotypes pneumococcus cause vast majority invasive disease young children january european medicines agencys committee medicinal products human use issued positive opinion recommended approval gsks paediatric pneumococcal candidate vaccine synflorix paediatric vaccine proposed indicated active immunisation invasive pneumococcal disease middle ear infections acute otitis media caused spneumoniae infants children six weeks two years european marketing authorisation vaccine expected granted first half submitted file potentially lifesaving candidate vaccine world health organization prequalification early prequalification service provided facilitate access medicines less affluent countries also discussions global alliance vaccines immunization accelerate availability funding pneumococcal vaccination pilot advance market commitment amc mechanism amcs new approach public health funding designed stimulate development manufacture vaccines developing countries donors commit money guarantee price vaccines developed thus creating potential viable future market home responsibility access medicine developing countries research development neglected diseases corporate responsibility report neglected diseases march announced collaborative research effort notforprofit organisation drugs neglected diseases initiative dndi targeting neglected tropical diseases disproportionately affect developing world research focus compounds may activity neglected diseases including visceral leishmaniasis kala azar human african trypanosomiasis sleeping sickness chagas disease collaboration established initial period two years may extended focus identifying developing compounds existing gsk programmes leverage expertise researchers gsk tres cantos facility along leading academic centres like london school hygiene tropical medicine collaboration formed specifically address unmet patient needs current treatments diseases significant drawbacks difficulty administration severe side effects length treatment cost emerging parasitic resistance home responsibility access medicine developing countries research development neglected diseases corporate responsibility report neglected diseases march announced collaborative research effort notforprofit organisation drugs neglected diseases initiative dndi targeting neglected tropical diseases disproportionately affect developing world research focus compounds may activity neglected diseases including visceral leishmaniasis kala azar human african trypanosomiasis sleeping sickness chagas disease collaboration established initial period two years may extended focus identifying developing compounds existing gsk programmes leverage expertise researchers gsk tres cantos facility along leading academic centres like london school hygiene tropical medicine collaboration formed specifically address unmet patient needs current treatments diseases significant drawbacks difficulty administration severe side effects length treatment cost emerging parasitic resistance home responsibility access medicine developing countries research development plans corporate responsibility report plans plan conduct largescale phase lll malaria vaccine efficacy trial seven african countries commence study focusing understanding safety tafenoquine subjects inherited glucosephosphate dehydrogenase gpd deficiency select candidate lead tb project mycobacterium gyrase inhibitors development mid initiate trails candidate tb vaccines infants continue clinical development multiple secondgeneration integrase inhibitors hivaids enter first time human clinical trials pyridone antimalarial developed partnership mmv achieved january select back candidate development mid review utility sitamaquine potential treatment vl regulatory authorities external stakeholders pandemic flu happens influenza pandemic could devastating effect particularly poorest countries least resources capacity prepare gsk active global preparations related pandemic flu read helping countries prepare pandemic flu home responsibility access medicine developing countries research development plans corporate responsibility report plans plan conduct largescale phase lll malaria vaccine efficacy trial seven african countries commence study focusing understanding safety tafenoquine subjects inherited glucosephosphate dehydrogenase gpd deficiency select candidate lead tb project mycobacterium gyrase inhibitors development mid initiate trails candidate tb vaccines infants continue clinical development multiple secondgeneration integrase inhibitors hivaids enter first time human clinical trials pyridone antimalarial developed partnership mmv achieved january select back candidate development mid review utility sitamaquine potential treatment vl regulatory authorities external stakeholders pandemic flu happens influenza pandemic could devastating effect particularly poorest countries least resources capacity prepare gsk active global preparations related pandemic flu read helping countries prepare pandemic flu home responsibility access medicine developing countries publicprivate partnerships corporate responsibility report publicprivate partnerships gsk must remain profitable sustain business provide funds enable us continue develop new medicines vaccines often limited prospect commercial return rd diseases developing world publicprivate partnership ppps enable rd diseases making work commercially viable sharing risks costs involved ppps speed rd process enable partners could ppp companies gsk provide rd technology manufacturing distribution expertise academic institutions may also provide research disease area knowledge public sector partners governments organisations bill melinda gates foundation help fund development delivery costs ensure medicines vaccines get people need funds usually channelled organisations medicines malaria venture mmv also help coordinate global rd activity ppps work many different ways example partnerships centred around dedicated diseases developing world discovery centre tres cantos global vaccines business headquartered belgium gsk provides facilities medicinal drug discovery meets running costs scientists tres cantos half subsidised partner organisations mmv global alliance tb drug development compounds move clinical development gsk provides clinical regulatory manufacturing expertise resources global rd supply network partners help fund cost running clinical trials address issues access distribution reduces costs development gets new products patients faster research programmes overseen joint steering committees representatives gsk partners terms agreements new treatments resulting ppps made available disease endemic countries affordable prices accelerating access initiative accelerating access initiative aai publicprivate partnership accelerate access care treatment hivaids gsk founder member aai formed may aai partnership unaids world bank unicef unfpa nine researchbased pharmaceutical companies abbott laboratories boehringer ingelheim bristolmyers squibb gilead sciences glaxosmithkline johnson johnson merck co inc pfizer roche objectives aai accelerate sustained access increase use appropriate good quality interventions preventiontreatment hivaids ensure care treatment reach significantly greater numbers people need new alliances involving committed governments private industry un development assistance agencies nongovernmental organisations people living hivaids report accelerating access initiative suggests december around patients developing countries receiving least one arv treatment supplied nine rd based pharmaceutical companies aai two years since december total number patients developing countries receiving treatment aai companies increased per cent africa alone patients treated least one arv supplied aai companies increase per cent two years resulted fold increase number people treated medicines supplied aai companies africa since establishment aai may home responsibility access medicine developing countries publicprivate partnerships corporate responsibility report publicprivate partnerships gsk must remain profitable sustain business provide funds enable us continue develop new medicines vaccines often limited prospect commercial return rd diseases developing world publicprivate partnership ppps enable rd diseases making work commercially viable sharing risks costs involved ppps speed rd process enable partners could ppp companies gsk provide rd technology manufacturing distribution expertise academic institutions may also provide research disease area knowledge public sector partners governments organisations bill melinda gates foundation help fund development delivery costs ensure medicines vaccines get people need funds usually channelled organisations medicines malaria venture mmv also help coordinate global rd activity ppps work many different ways example partnerships centred around dedicated diseases developing world discovery centre tres cantos global vaccines business headquartered belgium gsk provides facilities medicinal drug discovery meets running costs scientists tres cantos half subsidised partner organisations mmv global alliance tb drug development compounds move clinical development gsk provides clinical regulatory manufacturing expertise resources global rd supply network partners help fund cost running clinical trials address issues access distribution reduces costs development gets new products patients faster research programmes overseen joint steering committees representatives gsk partners terms agreements new treatments resulting ppps made available disease endemic countries affordable prices accelerating access initiative accelerating access initiative aai publicprivate partnership accelerate access care treatment hivaids gsk founder member aai formed may aai partnership unaids world bank unicef unfpa nine researchbased pharmaceutical companies abbott laboratories boehringer ingelheim bristolmyers squibb gilead sciences glaxosmithkline johnson johnson merck co inc pfizer roche objectives aai accelerate sustained access increase use appropriate good quality interventions preventiontreatment hivaids ensure care treatment reach significantly greater numbers people need new alliances involving committed governments private industry un development assistance agencies nongovernmental organisations people living hivaids report accelerating access initiative suggests december around patients developing countries receiving least one arv treatment supplied nine rd based pharmaceutical companies aai two years since december total number patients developing countries receiving treatment aai companies increased per cent africa alone patients treated least one arv supplied aai companies increase per cent two years resulted fold increase number people treated medicines supplied aai companies africa since establishment aai may home responsibility access medicine developing countries publicprivate partnerships corporate responsibility report publicprivate partnerships gsk must remain profitable sustain business provide funds enable us continue develop new medicines vaccines often limited prospect commercial return rd diseases developing world publicprivate partnership ppps enable rd diseases making work commercially viable sharing risks costs involved ppps speed rd process enable partners could ppp companies gsk provide rd technology manufacturing distribution expertise academic institutions may also provide research disease area knowledge public sector partners governments organisations bill melinda gates foundation help fund development delivery costs ensure medicines vaccines get people need funds usually channelled organisations medicines malaria venture mmv also help coordinate global rd activity ppps work many different ways example partnerships centred around dedicated diseases developing world discovery centre tres cantos global vaccines business headquartered belgium gsk provides facilities medicinal drug discovery meets running costs scientists tres cantos half subsidised partner organisations mmv global alliance tb drug development compounds move clinical development gsk provides clinical regulatory manufacturing expertise resources global rd supply network partners help fund cost running clinical trials address issues access distribution reduces costs development gets new products patients faster research programmes overseen joint steering committees representatives gsk partners terms agreements new treatments resulting ppps made available disease endemic countries affordable prices accelerating access initiative accelerating access initiative aai publicprivate partnership accelerate access care treatment hivaids gsk founder member aai formed may aai partnership unaids world bank unicef unfpa nine researchbased pharmaceutical companies abbott laboratories boehringer ingelheim bristolmyers squibb gilead sciences glaxosmithkline johnson johnson merck co inc pfizer roche objectives aai accelerate sustained access increase use appropriate good quality interventions preventiontreatment hivaids ensure care treatment reach significantly greater numbers people need new alliances involving committed governments private industry un development assistance agencies nongovernmental organisations people living hivaids report accelerating access initiative suggests december around patients developing countries receiving least one arv treatment supplied nine rd based pharmaceutical companies aai two years since december total number patients developing countries receiving treatment aai companies increased per cent africa alone patients treated least one arv supplied aai companies increase per cent two years resulted fold increase number people treated medicines supplied aai companies africa since establishment aai may home responsibility access medicine developing countries product registrations corporate responsibility report product registrations approach performance plans rapid product registration important ensure new medicines reach patients quickly possible regulatory process complex costly time consuming little regulatory harmonisation around world distinct submission required virtually every country companies prioritise regulatory resources led concerns pharmaceutical companies enough register essential medicines developing countries prevents countries taking advantage preferential pricing offers prioritise registration medicines based commercial considerations well prevalence disease use mechanisms european medicines agency emea article help facilitate product registration developing countries article allows agency 's committee medicinal products human use chmp give opinions cooperation world health organization medicinal products human use intended exclusively markets outside eu medicines treat malaria leishmaniasis positive opinion obtained via article used support registration process developing countries conducting regulatory reviews regularly review registration status key antiretrovirals arvs prioritise registration based needs arvs helps make epivir retrovir combivir ziagen available widely necessary possible screening vaccination could prevent many thousands women getting cervical cancer working register vaccine human papillomavirus hpv cervarix widely possible women better protected disease available high middle low income countries around world gsk committed accelerate global access vaccine read position cervical cancer prevention home responsibility access medicine developing countries product registrations corporate responsibility report product registrations approach performance plans rapid product registration important ensure new medicines reach patients quickly possible regulatory process complex costly time consuming little regulatory harmonisation around world distinct submission required virtually every country companies prioritise regulatory resources led concerns pharmaceutical companies enough register essential medicines developing countries prevents countries taking advantage preferential pricing offers prioritise registration medicines based commercial considerations well prevalence disease use mechanisms european medicines agency emea article help facilitate product registration developing countries article allows agency 's committee medicinal products human use chmp give opinions cooperation world health organization medicinal products human use intended exclusively markets outside eu medicines treat malaria leishmaniasis positive opinion obtained via article used support registration process developing countries conducting regulatory reviews regularly review registration status key antiretrovirals arvs prioritise registration based needs arvs helps make epivir retrovir combivir ziagen available widely necessary possible screening vaccination could prevent many thousands women getting cervical cancer working register vaccine human papillomavirus hpv cervarix widely possible women better protected disease available high middle low income countries around world gsk committed accelerate global access vaccine read position cervical cancer prevention home responsibility access medicine developing countries product registrations corporate responsibility report product registrations approach performance plans cervical cancer rotavirus october submitted cervarix vaccine helps prevent infection hpv world health organization prequalification products prequalification status may used un agencies gavi alliance well mass vaccination programmes across developing world submitting cervarix prequalification early possible working eliminate historical year delay new vaccines become available developing countries anticipate prequalification first half early received prequalification status rotavirus vaccine rotarix concluded deal brazilian government institute fiocruz supply enough rotarix protect every baby brazil rotavirus next five years includes technology transfer agreement fiocruz produce rotarix domestic market manufacture rotarix gsk contract export developing countries similar existing arrangements brazil oral polio vaccine haemophilus influenzae type b hib vaccine measles mumps rubella vaccine results approach rotarix brazil impressive hivaids gsk produces packs arvs specifically designed distributed developing countries access packs combivir epivir tablets epivir solution trizivir registered least countries means products available sale target countries including countries formal regulatory approval processes secondline arv ziagen formally registered tablet form countries oral solution target countries ziagen access packs registered countries process seeking registration others flu support government preparations global flu pandemic registered relenza countries relenza antiviral medicine help treat influenza home responsibility access medicine developing countries product registrations corporate responsibility report product registrations approach performance plans cervical cancer rotavirus october submitted cervarix vaccine helps prevent infection hpv world health organization prequalification products prequalification status may used un agencies gavi alliance well mass vaccination programmes across developing world submitting cervarix prequalification early possible working eliminate historical year delay new vaccines become available developing countries anticipate prequalification first half early received prequalification status rotavirus vaccine rotarix concluded deal brazilian government institute fiocruz supply enough rotarix protect every baby brazil rotavirus next five years includes technology transfer agreement fiocruz produce rotarix domestic market manufacture rotarix gsk contract export developing countries similar existing arrangements brazil oral polio vaccine haemophilus influenzae type b hib vaccine measles mumps rubella vaccine results approach rotarix brazil impressive hivaids gsk produces packs arvs specifically designed distributed developing countries access packs combivir epivir tablets epivir solution trizivir registered least countries means products available sale target countries including countries formal regulatory approval processes secondline arv ziagen formally registered tablet form countries oral solution target countries ziagen access packs registered countries process seeking registration others flu support government preparations global flu pandemic registered relenza countries relenza antiviral medicine help treat influenza home responsibility access medicine developing countries preferential pricing corporate responsibility report preferential pricing approach performance plans pricing one factor impacts access medicines vaccines developing countries price medicines preferentially developing countries use tiered pricing system wealthier middle income markets peoples ability pay medicines varies significantly however price one aspect affordability ability pay provision allocation resources primarily governments poverty reduction billion people live day virtually nothing affordable early announced new strategic approach pricing least developed countries ldcs april reduce prices patented medicines ldcs higher per cent price developed world maximum price possible go reduce prices aggressively ensuring cover manufacturing costs offer sustainable price reductions april products formulations across least developed countries average price reduction per cent also reinvest per cent profits ldcs back projects partnering organisations ngos widen access strengthen healthcare infrastructure ldcs sales ldcs relatively low per cent profit limited initially around million year however action hope send signal multinational companies operating ldcs join us contribute making difference many developing countries healthcare crisis dominated social economic impacts hivaids tb malaria gsk antiretrovirals arvs treat hivaids antimalarial treatments portfolio committed increasing access providing medicines least developed countries subsaharan africa notforprofit prices see key facts box negotiate preferential prices hivaids medicines middleincome countries casebycase basis read extending product portfolio developing world vaccines tiered pricing model vaccines make significant contribution public health helping prevent many potentially fatal infectious diseases immunisation acknowledged world health organization among costeffective health investments make vaccine portfolio available preferential prices developing countries using tiered pricing system prices linked gross national incomes defined world bank well size order length particular supply contract developing world prices little tenth developed countries work multinational organisations gavi unicef pan american health organization governments nongovernmental organisations provide appropriate affordable vaccines developing countries typically supply vaccines gavi unicef per cent developed world prices organisations selling vaccines large volumes longerterm contracts able significantly reduce price individual dose includes basic polio vaccines well specially developed combination vaccines target several diseases billion vaccine doses shipped per cent went developing world many vaccines included government vaccination programmes middleincome countries example rotarix rotavirus vaccine included government vaccination programmes new born babies brazil el salvador mexico panama venezuela supplied millionp adgoe se sof vaccine vast majority went developing middleincome countries addition tiered pricing looking innovative ways increase access vaccines poorer countries one option explored cervarix vaccine human papillomavirus partner major international nongovernmental organisation partnership able use organisations distribution networks increase supply vaccine developing countries deaths cervical cancer occur preventing product diversion product diversion notforprofit medicines illegally shipped back sale wealthier countries denies treatment patients poorer countries antidiversion measures include specially designed access packs arvs red rather white tablets epivir combivir enter voluntary licences know manufacturer ensure product diversion occur defined un httpwwwunorgspecialrepohrllsldclisthtm notforprofit nfp prices medicines key facts gsk offered preferential pricing antiretrovirals since formal notforprofit nfp pricing since nfp prices sustainable make profit cover costs means sustain supply highquality products long needed notforprofit prices apply gsks antiretrovirals malaria treatments nfp prices available least developed countries subsaharan africa total countries addition pepfar projects eligible global fund projects bring number countries eligible customers include public sector customers nfp organisations well private employers subsaharan africa providing treatment uninsured staff combivir leading combination arv available day nfp prices include insurance freight costs unlike prices quoted generic companies applicable orders size dependent large order quantitieshome responsibility access medicine developing countries preferential pricing corporate responsibility report preferential pricing approach performance plans pricing one factor impacts access medicines vaccines developing countries price medicines preferentially developing countries use tiered pricing system wealthier middle income markets peoples ability pay medicines varies significantly however price one aspect affordability ability pay provision allocation resources primarily governments poverty reduction billion people live day virtually nothing affordable early announced new strategic approach pricing least developed countries ldcs april reduce prices patented medicines ldcs higher per cent price developed world maximum price possible go reduce prices aggressively ensuring cover manufacturing costs offer sustainable price reductions april products formulations across least developed countries average price reduction per cent also reinvest per cent profits ldcs back projects partnering organisations ngos widen access strengthen healthcare infrastructure ldcs sales ldcs relatively low per cent profit limited initially around million year however action hope send signal multinational companies operating ldcs join us contribute making difference many developing countries healthcare crisis dominated social economic impacts hivaids tb malaria gsk antiretrovirals arvs treat hivaids antimalarial treatments portfolio committed increasing access providing medicines least developed countries subsaharan africa notforprofit prices see key facts box negotiate preferential prices hivaids medicines middleincome countries casebycase basis read extending product portfolio developing world vaccines tiered pricing model vaccines make significant contribution public health helping prevent many potentially fatal infectious diseases immunisation acknowledged world health organization among costeffective health investments make vaccine portfolio available preferential prices developing countries using tiered pricing system prices linked gross national incomes defined world bank well size order length particular supply contract developing world prices little tenth developed countries work multinational organisations gavi unicef pan american health organization governments nongovernmental organisations provide appropriate affordable vaccines developing countries typically supply vaccines gavi unicef per cent developed world prices organisations selling vaccines large volumes longerterm contracts able significantly reduce price individual dose includes basic polio vaccines well specially developed combination vaccines target several diseases billion vaccine doses shipped per cent went developing world many vaccines included government vaccination programmes middleincome countries example rotarix rotavirus vaccine included government vaccination programmes new born babies brazil el salvador mexico panama venezuela supplied million doses vaccine vast majority went developing middleincome countries addition tiered pricing looking innovative ways increase access vaccines poorer countries one option explored cervarix vaccine human papillomavirus partner major international nongovernmental organisation partnership able use organisations distribution networks increase supply vaccine developing countries deaths cervical cancer occur preventing product diversion product diversion notforprofit medicines illegally shipped back sale wealthier countries denies treatment patients poorer countries antidiversion measures include specially designed access packs arvs red rather white tablets epivir combivir enter voluntary licences know manufacturer ensure product diversion occur defined un httpwwwunorgspecialrepohrllsldclisthtm notforprofit nfp prices medicines key facts gsk offered preferential pricing antiretrovirals since formal notforprofit nfp pricing since nfp prices sustainable make profit cover costs means sustain supply highquality products long needed notforprofit prices apply gsks antiretrovirals malaria treatments nfp prices available least developed countries subsaharan africa total countries addition pepfar projects eligible global fund projects bring number countries eligible customers include public sector customers nfp organisations well private employers subsaharan africa providing treatment uninsured staff combivir leading combination arv available day nfp prices include insurance freight costs unlike prices quoted generic companies applicable orders size dependent large order quantities home responsibility access medicine developing countries preferential pricing corporate responsibility report preferential pricing approach performance plans pricing one factor impacts access medicines vaccines developing countries price medicines preferentially developing countries use tiered pricing system wealthier middle income markets peoples ability pay medicines varies significantly however price one aspect affordability ability pay provision allocation resources primarily governments poverty reduction billion people live day virtually nothing affordable early announced new strategic approach pricing least developed countries ldcs april reduce prices patented medicines ldcs higher per cent price developed world maximum price possible go reduce prices aggressively ensuring cover manufacturing costs offer sustainable price reductions april products formulations across least developed countries average price reduction per cent also reinvest per cent profits ldcs back projects partnering organisations ngos widen access strengthen healthcare infrastructure ldcs sales ldcs relatively low per cent profit limited initially around million year however action hope send signal multinational companies operating ldcs join us contribute making difference many developing countries healthcare crisis dominated social economic impacts hivaids tb malaria gsk antiretrovirals arvs treat hivaids antimalarial treatments portfolio committed increasing access providing medicines least developed countries subsaharan africa notforprofit prices see key facts box negotiate preferential prices hivaids medicines middleincome countries casebycase basis read extending product portfolio developing world vaccines tiered pricing model vaccines make significant contribution public health helping prevent many potentially fatal infectious diseases immunisation acknowledged world health organization among costeffective health investments make vaccine portfolio available preferential prices developing countries using tiered pricing system prices linked gross national incomes defined world bank well size order length particular supply contract developing world prices little tenth developed countries work multinational organisations gavi unicef pan american health organization governments nongovernmental organisations provide appropriate affordable vaccines developing countries typically supply vaccines gavi unicef per cent developed world prices organisations selling vaccines large volumes longerterm contracts able significantly reduce price individual dose includes basic polio vaccines well specially developed combination vaccines target several diseases billion vaccine doses shipped per cent went developing world many vaccines included government vaccination programmes middleincome countries example rotarix rotavirus vaccine included government vaccination programmes new born babies brazil el salvador mexico panama venezuela supplied million doses vaccine vast majority went developing middleincome countries addition tiered pricing looking innovative ways increase access vaccines poorer countries one option explored cervarix vaccine human papillomavirus partner major international nongovernmental organisation partnership able use organisations distribution networks increase supply vaccine developing countries deaths cervical cancer occur preventing product diversion product diversion notforprofit medicines illegally shipped back sale wealthier countries denies treatment patients poorer countries antidiversion measures include specially designed access packs arvs red rather white tablets epivir combivir enter voluntary licences know manufacturer ensure product diversion occur defined un httpwwwunorgspecialrepohrllsldclisthtm notforprofit nfp prices medicines key facts gsk offered preferential pricing antiretrovirals since formal notforprofit nfp pricing since nfp prices sustainable make profit cover costs means sustain supply highquality products long needed notforprofit prices apply gsks antiretrovirals malaria treatments nfp prices available least developed countries subsaharan africa total countries addition pepfar projects eligible global fund projects bring number countries eligible customers include public sector customers nfp organisations well private employers subsaharan africa providing treatment uninsured staff combivir leading combination arv available day nfp prices include insurance freight costs unlike prices quoted generic companies applicable orders size dependent large order quantities home responsibility access medicine developing countries preferential pricing corporate responsibility report preferential pricing approach performance plans offer antiretrovirals arvs antimalarials notforprofit nfp prices public sector customers notforprofit organisations countries least developed countries subsaharan africa february announced significant new price reductions arvs offered nfp basis countries reduction fifth time reduced prices part pioneering preferential pricing policy originally introduced combivir leading arv sells per patient per year least developed countries compared significant reduction almost per cent ziagen oral solution abacavir recommended world health organization use firstline secondline regimens within resourcelimited settings particularly children number factors enabled us implement price changes including improvements efficiencies manufacturing supply reductions costs active ingredients number tablets shipped shipped million tablets nfp combivir million tablets nfp epivir developing world compared million million respectively decline supply arvs outweighed growth volumes licensees licensees supplied million tablets versions epivir combivir african countries supply combivir epivir tablets gsk includes preferentially priced tablets supplied gsk tablets supplied licensees gsk supplied arvs nfp prices countries compared continue look new customers nfp arvs countries regularly review nfp prices however may well licensees able produce firstline arvs lower costs continue increase share business patients receiving treatment difficult estimate number patients treated result preferential pricing agreements since control healthcare provision however estimates three million people developing world treated arvs end increase one million year report accelerating access initiative aai suggests december around page patients developing countries receiving least one arv treatment supplied nine rdbased pharmaceutical companies aai two years since december total number patients developing countries receiving treatment aai companies increased per cent africa alone patients treated least one arv supplied aai companies increase per cent two years resulted fold increase number people treated medicines supplied aai companies africa since establishment aai may read gsk vaccine contributed elimination hib mengingitishome responsibility access medicine developing countries preferential pricing corporate responsibility report preferential pricing approach performance plans offer antiretrovirals arvs antimalarials notforprofit nfp prices public sector customers notforprofit organisations countries least developed countries subsaharan africa february announced significant new price reductions arvs offered nfp basis countries reduction fifth time reduced prices part pioneering preferential pricing policy originally introduced combivir leading arv sells per patient per year least developed countries compared significant reduction almost per cent ziagen oral solution abacavir recommended world health organization use firstline secondline regimens within resourcelimited settings particularly children number factors enabled us implement price changes including improvements efficiencies manufacturing supply reductions costs active ingredients number tablets shipped shipped million tablets nfp combivir million tablets nfp epivir developing world compared million million respectively decline supply arvs outweighed growth volumes licensees licensees supplied million tablets versions epivir combivir african countries supply combivir epivir tablets gsk includes preferentially priced tablets supplied gsk tablets supplied licensees gsk supplied arvs nfp prices countries compared continue look new customers nfp arvs countries regularly review nfp prices however may well licensees able produce firstline arvs lower costs continue increase share business patients receiving treatment difficult estimate number patients treated result preferential pricing agreements since control healthcare provision however estimates three million people developing world treated arvs end increase one million year report accelerating access initiative aai suggests december around patients developing countries receiving least one arv treatment supplied nine rdbased pharmaceutical companies aai two years since december total number patients developing countries receiving treatment aai companies increased per cent africa alone patients treated least one arv supplied aai companies increase per cent two years resulted fold increase number people treated medicines supplied aai companies africa since establishment aai may read gsk vaccine contributed elimination hib mengingitis home responsibility access medicine developing countries preferential pricing corporate responsibility report preferential pricing approach performance plans offer antiretrovirals arvs antimalarials notforprofit nfp prices public sector customers notforprofit organisations countries least developed countries subsaharan africa february announced significant new price reductions arvs offered nfp basis countries reduction fifth time reduced prices part pioneering preferential pricing policy originally introduced combivir leading arv sells per patient per year least developed countries compared significant reduction almost per cent ziagen oral solution abacavir recommended world health organization use firstline secondline regimens within resourcelimited settings particularly children number factors enabled us implement price changes including improvements efficiencies manufacturing supply reductions costs active ingredients number tablets shipped shipped million tablets nfp combivir million tablets nfp epivir developing world compared million million respectively decline supply arvs outweighed growth volumes licensees licensees supplied million tablets versions epivir combivir african countries supply combivir epivir tablets gsk includes preferentially priced tablets supplied gsk tablets supplied licensees gsk supplied arvs nfp prices countries compared continue look new customers nfp arvs countries regularly review nfp prices however may well licensees able produce firstline arvs lower costs continue increase share business patients receiving treatment difficult estimate number patients treated result preferential pricing agreements since control healthcare provision however estimates three million people developing world treated arvs end increase one million year report accelerating access initiative aai suggests december around patients developing countries receiving least one arv treatment supplied nine rdbased pharmaceutical companies aai two years since december total number patients developing countries receiving treatment aai companies increased per cent africa alone patients treated least one arv supplied aai companies increase per cent two years resulted fold increase number people treated medicines supplied aai companies africa since establishment aai may read gsk vaccine contributed elimination hib mengingitis home responsibility access medicine developing countries pricing middleincome countries corporate responsibility report pricing middleincome countries approach performance plans middleincome countries mics brazil china thailand indonesia lowincome countries india economically developed worlds poorest countries often large affluent middle class therefore provide greater commercial opportunities worlds poorest countries according report accounting firm pricewaterhousecoopers growing wealth brazil china india indonesia mexico russia turkey means could account per cent global pharmaceutical market however many middle income countries also large numbers people living extreme poverty healthcare demands often outstrip available resources challenges made worse increasing incidence chronic diseases asthma diabetes reflect situation restructured commercial organisation split old international division created two new regions emerging markets asia pacific enable us respond commercial opportunities reflecting healthcare environment individual needs increasing access medicines middleincome countries within responsible commercial framework complex clear one universal one size fits solution complexity key aspect pharma futures dialogue explored links sustainable pharmaceutical business models improved health outcomes middleincome markets including china india brazil vital identify best approaches gsk address complex challenges challenges include low government healthcare spend relative gross domestic product gdp low one per cent gdp compared average nine per cent eu poor healthcare infrastructure including hospitals clinics doctors nurses high level income inequality within countries complicate pricing considerations affordability medicines vaccines taxes markups medicines vaccines stigma discrimination associated certain diseases use traditional medicines remote rural populations recognise many middleincome countries need assistance however believe different approach needed one take worlds poorest countries offer supply medicines notforprofit prices vaccines highly preferential prices worlds poorest countries sustainable continue make adequate return wealthier markets many middleincome countries also growing commercial markets gsk represent important source future business industry response markets must therefore balance commercial objectives global commitment work governments stakeholders support efforts deliver medicines vaccines many needy people possible approach combines longestablished practices voluntary licences tiered pricing vaccines preferential pricing hivaids malaria medicines innovative strategies focus different socioeconomic groups within individual micshome responsibility access medicine developing countries pricing middleincome countries corporate responsibility report pricing middleincome countries approach performance plans middleincome countries mics brazil china thailand indonesia lowincome countries india economically developed worlds poorest countries often large affluent middle class therefore provide greater commercial opportunities worlds poorest countries according report accounting firm pricewaterhousecoopers growing wealth brazil china india indonesia mexico russia turkey means could account per cent global pharmaceutical market however many middle income countries also large numbers people living extreme poverty healthcare demands often outstrip available resources challenges made worse increasing incidence chronic diseases asthma diabetes reflect situation restructured commercial organisation split old international division created two new regions emerging markets asia pacific enable us respond commercial opportunities reflecting healthcare environment individual needs increasing access medicines middleincome countries within responsible commercial framework complex clear one universal one size fits solution complexity key aspect pharma futures dialogue explored links sustainable pharmaceutical business models improved health outcomes middleincome markets including china india brazil vital identify best approaches gsk address complex challenges challenges include low government healthcare spend relative gross domestic product gdp low one per cent gdp compared average nine per cent eu poor healthcare infrastructure including hospitals clinics doctors nurses high level income inequality within countries complicate pricing considerations affordability medicines vaccines taxes markups medicines vaccines stigma discrimination associated certain diseases use traditional medicines remote rural populations recognise many middleincome countries need assistance however believe different approach needed one take worlds poorest countries offer supply medicines notforprofit prices vaccines highly preferential prices worlds poorest countries sustainable continue make adequate return wealthier markets many middleincome countries also growing commercial markets gsk represent important source future business industry response markets must therefore balance commercial objectives global commitment work governments stakeholders support efforts deliver medicines vaccines many needy people possible approach combines longestablished practices voluntary licences tiered pricing vaccines preferential pricing hivaids malaria medicines innovative strategies focus different socioeconomic groups within individual mics home responsibility access medicine developing countries pricing middleincome countries corporate responsibility report pricing middleincome countries approach performance plans middleincome countries mics brazil china thailand indonesia lowincome countries india economically developed worlds poorest countries often large affluent middle class therefore provide greater commercial opportunities worlds poorest countries according report accounting firm pricewaterhousecoopers growing wealth brazil china india indonesia mexico russia turkey means could account per cent global pharmaceutical market however many middle income countries also large numbers people living extreme poverty healthcare demands often outstrip available resources challenges made worse increasing incidence chronic diseases asthma diabetes reflect situation restructured commercial organisation split old international division created two new regions emerging markets asia pacific enable us respond commercial opportunities reflecting healthcare environment individual needs increasing access medicines middleincome countries within responsible commercial framework complex clear one universal one size fits solution complexity key aspect pharma futures dialogue explored links sustainable pharmaceutical business models improved health outcomes middleincome markets including china india brazil vital identify best approaches gsk address complex challenges challenges include low government healthcare spend relative gross domestic product gdp low one per cent gdp compared average nine per cent eu poor healthcare infrastructure including hospitals clinics doctors nurses high level income inequality within countries complicate pricing considerations affordability medicines vaccines taxes markups medicines vaccines stigma discrimination associated certain diseases use traditional medicines remote rural populations recognise many middleincome countries need assistance however believe different approach needed one take worlds poorest countries offer supply medicines notforprofit prices vaccines highly preferential prices worlds poorest countries sustainable continue make adequate return wealthier markets many middleincome countries also growing commercial markets gsk represent important source future business industry response markets must therefore balance commercial objectives global commitment work governments stakeholders support efforts deliver medicines vaccines many needy people possible approach combines longestablished practices voluntary licences tiered pricing vaccines preferential pricing hivaids malaria medicines innovative strategies focus different socioeconomic groups within individual mics home responsibility access medicine developing countries pricing middleincome countries corporate responsibility report pricing middleincome countries approach performance plans approach pricing middleincome markets constantly evolving ongoing pricing pilot programmes informing evolution comprise mixture longestablished practices new approaches intend formalise communicate pricing policies middleincome countries longestablished practices tiered pricing vaccines vaccines available gavieligible middleincome countries mics including indonesia sri lanka cuba highly discounted prices many vaccines also included government vaccination programmes middleincome countries preferential pricing hivaids malaria medicines negotiate preferential pricing arrangements hivaids medicines antimalarials middle income countries casebycase basis done bilaterally dialogue governments believe approach appropriate burden disease resources available address burden vary significantly country country within countries arrangements combine viable sustainable commercial return gsk improved affordability healthcare systems concerned novel approaches developing flexible responsive approach accessing private public sector markets mics strategy focuses different socioeconomic groups within individual mics uses standard classifications socioeconomic groups group wealthiest section society e poorest typically company gsk makes disproportionate share sales people ab group sales tailing quite sharply cd group usually unable compete lowcost generic medicines sales e group believe productive way us align commercial accessibility goals make products readily available cd segment market free government funding poorest segment population exploring options projects including tiered pricing models within well countries including enable products priced differently private public health sectors gauging relationship price volume selected products targeted mics example may able reduce price products orders sufficiently high volume products local sourcing manufacturing arrangements designed address cost issues early draw definitive conclusions pilot projects results pilots commercially sensitive pilots investigating relationship price volume volume targets achieved analysis confounded unexpected factors reduced demand diabetes medicine avandia however clear simple universal solutions learned projects continue investigate approaches establish pilots initial pilots proved inconclusive example exploring options withincountry tiered pricing vaccines clear pricing decisions assessed vacuum factors market dynamics including new product introductions competitors react price changes taken account also evident every programme suitable every middleincome country pilots therefore helping inform approach middleincome countries confident successful elements incorporated longterm commercial strategy plan report cervarix price reduction philippines vietnam indonesia south africa gsk works partnership stakeholders optimise availability vaccine human papillonnavirus improving access treatment requires many stakeholders working together develop better infrastructure distribution channels adequate funding better disease awareness education appropriate market dynamics gsk committed ensuring pricing barrier access developing world reduced prices philippines vietnam indonesia south africa example philippines reduced price cervarix per cent south africa price reduction order per cent gsk long track record tiered pricing vaccines available governmentled programmes charge reduced prices countries lower levels income reduction price cervarix number countries demonstration commitment increasing access vaccineshome responsibility access medicine developing countries pricing middleincome countries corporate responsibility report pricing middleincome countries approach performance plans approach pricing middleincome markets constantly evolving ongoing pricing pilot programmes informing evolution comprise mixture longestablished practices new approaches intend formalise communicate pricing policies middleincome countries longestablished practices tiered pricing vaccines vaccines available gavieligible middleincome countries mics including indonesia sri lanka cuba highly discounted prices many vaccines also included government vaccination programmes middleincome countries preferential pricing hivaids malaria medicines negotiate preferential pricing arrangements hivaids medicines antimalarials middle income countries casebycase basis done bilaterally dialogue governments believe approach appropriate burden disease resources available address burden vary significantly country country within countries arrangements combine viable sustainable commercial return gsk improved affordability healthcare systems concerned novel approaches developing flexible responsive approach accessing private public sector markets mics strategy focuses different socioeconomic groups within individual mics uses standard classifications socioeconomic groups group wealthiest section society e poorest typically company gsk makes disproportionate share sales people ab group sales tailing quite sharply cd group usually unable compete lowcost generic medicines sales e group believe productive way us align commercial accessibility goals make products readily available cd segment market free government funding poorest segment population exploring options projects including tiered pricing models within well countries including enable products priced differently private public health sectors gauging relationship price volume selected products targeted mics example may able reduce price products orders sufficiently high volume products local sourcing manufacturing arrangements designed address cost issues early draw definitive conclusions pilot projects results pilots commercially sensitive pilots investigating relationship price volume volume targets achieved analysis confounded unexpected factors reduced demand diabetes medicine avandia however clear simple universal solutions learned projects continue investigate approaches establish pilots initial pilots proved inconclusive example exploring options withincountry tiered pricing vaccines clear pricing decisions assessed vacuum factors market dynamics including new product introductions competitors react price changes taken account also evident every programme suitable every middleincome country pilots therefore helping inform approach middleincome countries confident successful elements incorporated longterm commercial strategy plan report cervarix price reduction philippines vietnam indonesia south africa gsk works partnership stakeholders optimise availability vaccine human papillonnavirus improving access treatment requires many stakeholders working together develop better infrastructure distribution channels adequate funding better disease awareness education appropriate market dynamics gsk committed ensuring pricing barrier access developing world reduced prices philippines vietnam indonesia south africa example philippines reduced price cervarix per cent south africa price reduction order per cent gsk long track record tiered pricing vaccines available governmentled programmes charge reduced prices countries lower levels income reduction price cervarix number countries demonstration commitment increasing access vaccines home responsibility access medicine developing countries pricing middleincome countries corporate responsibility report pricing middleincome countries approach performance plans approach pricing middleincome markets constantly evolving ongoing pricing pilot programmes informing evolution comprise mixture longestablished practices new approaches intend formalise communicate pricing policies middleincome countries longestablished practices tiered pricing vaccines vaccines available gavieligible middleincome countries mics including indonesia sri lanka cuba highly discounted prices many vaccines also included government vaccination programmes middleincome countries preferential pricing hivaids malaria medicines negotiate preferential pricing arrangements hivaids medicines antimalarials middle income countries casebycase basis done bilaterally dialogue governments believe approach appropriate burden disease resources available address burden vary significantly country country within countries arrangements combine viable sustainable commercial return gsk improved affordability healthcare systems concerned novel approaches developing flexible responsive approach accessing private public sector markets mics strategy focuses different socioeconomic groups within individual mics uses standard classifications socioeconomic groups group wealthiest section society e poorest typically company gsk makes disproportionate share sales people ab group sales tailing quite sharply cd group usually unable compete lowcost generic medicines sales e group believe productive way us align commercial accessibility goals make products readily available cd segment market free government funding poorest segment population exploring options projects including tiered pricing models within well countries including enable products priced differently private public health sectors gauging relationship price volume selected products targeted mics example may able reduce price products orders sufficiently high volume products local sourcing manufacturing arrangements designed address cost issues early draw definitive conclusions pilot projects results pilots commercially sensitive pilots investigating relationship price volume volume targets achieved analysis confounded unexpected factors reduced demand diabetes medicine avandia however clear simple universal solutions learned projects continue investigate approaches establish pilots initial pilots proved inconclusive example exploring options withincountry tiered pricing vaccines clear pricing decisions assessed vacuum factors market dynamics including new product introductions competitors react price changes taken account also evident every programme suitable every middleincome country pilots therefore helping inform approach middleincome countries confident successful elements incorporated longterm commercial strategy plan report cervarix price reduction philippines vietnam indonesia south africa gsk works partnership stakeholders optimise availability vaccine human papillonnavirus improving access treatment requires many stakeholders working together develop better infrastructure distribution channels adequate funding better disease awareness education appropriate market dynamics gsk committed ensuring pricing barrier access developing world reduced prices philippines vietnam indonesia south africa example philippines reduced price cervarix per cent south africa price reduction order per cent gsk long track record tiered pricing vaccines available governmentled programmes charge reduced prices countries lower levels income reduction price cervarix number countries demonstration commitment increasing access vaccines home responsibility access medicine developing countries voluntary licensing corporate responsibility report voluntary licensing approach performance voluntary licences granted patent holders allow generics company manufacture sell products people assume generics always cheaper branded products seen many key solution access crisis developing world pharmaceutical companies increasing pressure grant licences however generics always cheaper success voluntary licence depend right licensees chosen particularly true treatment chronic disease like hivaids sustainable supply goodquality antiretrovirals arvs key believe voluntary licences universal solution tackling hivaids disease general cases local manufacture arvs make little difference affordability access patients point endorsed real barriers access lack healthcare infrastructure resources pay medicines regardless come however funding world bank international donors meant voluntary licences role play efforts tackle hivaids epidemic subsaharan africa helping increase availability medicines contribute better security supply decision grant voluntary licence depends number factors including case hivaids severity epidemic country local healthcare provision economic manufacturing environment discuss voluntary licences potential partners casebycase basis need sure manufacturer provide longterm supply goodquality medicines implement safeguards prevent diversion medicines wealthier markets continue consider role voluntary licensing helping increase access medicines middle income countries without undermining commercial business compulsory licences compulsory licences issued governments involve intellectual property rights taken away rights holder compulsory licences one flexibilities world trade organizations trips agreement intellectual property used humanitarian purposes however widespread use compulsory licences undermine intellectual property framework counter productive long term rd new treatments especially commercial markets exist hivaids depends protection intellectual property home responsibility access medicine developing countries voluntary licensing corporate responsibility report voluntary licensing approach performance voluntary licences granted patent holders allow generics company manufacture sell products people assume generics always cheaper branded products seen many key solution access crisis developing world pharmaceutical companies increasing pressure grant licences however generics always cheaper success voluntary licence depend right licensees chosen particularly true treatment chronic disease like hivaids sustainable supply goodquality antiretrovirals arvs key believe voluntary licences universal solution tackling hivaids disease general cases local manufacture arvs make little difference affordability access patients point endorsed real barriers access lack healthcare infrastructure resources pay medicines regardless come however funding world bank international donors meant voluntary licences role play efforts tackle hivaids epidemic subsaharan africa helping increase availability medicines contribute better security supply decision grant voluntary licence depends number factors including case hivaids severity epidemic country local healthcare provision economic manufacturing environment discuss voluntary licences potential partners casebycase basis need sure manufacturer provide longterm supply goodquality medicines implement safeguards prevent diversion medicines wealthier markets continue consider role voluntary licensing helping increase access medicines middle income countries without undermining commercial business compulsory licences compulsory licences issued governments involve intellectual property rights taken away rights holder compulsory licences one flexibilities world trade organizations trips agreement intellectual property used humanitarian purposes however widespread use compulsory licences undermine intellectual property framework counter productive long term rd new treatments especially commercial markets exist hivaids depends protection intellectual property home responsibility access medicine developing countries voluntary licensing corporate responsibility report voluntary licensing approach performance granted first voluntary licence vl negotiated eight licensing agreements arvs africa vls cover individual countries trade blocs others cover sub saharan africa update august july agreed royalty free voluntary licence enable aspen produce arv abacavir takes total number licensing agreements arvs africa nine offer grant licences abacavir open licensees august gave consent enable canadian company apotex manufacture generic fixed dose combination arv containing two molecules gsk patent rights treatment hivaids rwanda consent granted canadas access medicines regime reflects wto f agreement enables governments authorise production certain patented medicines export gsk agreed waive royalties basis apotexs triple combination generic arv supplied notforprofit basis licensees supplied million tablets versions epivir combivir africa represents per cent growth per cent welcome trend gives customers subsaharan africa greater choice contributes better security supply granted vl simcere chinese manufacturer granting right manufacture sell zanamivir relenza containing products china sell number countries including least developed countries zanamivir antiviral help treat influenza vl driven specific concern help ensure sufficient supplies event global flu pandemic collaboration local manufacture significantly reduces disease burden rotavirus brazil pursue initiatives high public health impact commercially viable example seen implementation universal mss vaccination umv programmes brazil rotavirus gsk brazilian vaccine manufacturer fiocruz longstanding partnership production vaccines diseases causing high mortality morbidity polio haemophilus influenzae type b hib measles mumps rubella recently rotavirus partnership gsk fiocruz supports brazils requirements universal mass vaccination rotavirus rotarix vaccine despite incomplete coverage vaccination programme significantly improved public health per cent reduction hospitalisation due acute diarrhoea aetiology per cent reduction rotavirusrelated hospitalisations reduction diarrhoea outbreaks due rotavirus paulo per cent per cent reduction proportion cases gastroenteritis caused rotavirus per cent per cent rotavirus vaccine expected lead avoided deaths per cent reduction pmagileli f avoided cases per cent reduction brazilian ministry health statisticshome responsibility access medicine developing countries voluntary licensing corporate responsibility report voluntary licensing approach performance granted first voluntary licence vl negotiated eight licensing agreements arvs africa vls cover individual countries trade blocs others cover sub saharan africa update august july agreed royalty free voluntary licence enable aspen produce arv abacavir takes total number licensing agreements arvs africa nine offer grant licences abacavir open licensees august gave consent enable canadian company apotex manufacture generic fixed dose combination arv containing two molecules gsk patent rights treatment hivaids rwanda consent granted canadas access medicines regime reflects wto f agreement enables governments authorise production certain patented medicines export gsk agreed waive royalties basis apotexs triple combination generic arv supplied notforprofit basis licensees supplied million tablets versions epivir combivir africa represents per cent growth per cent welcome trend gives customers subsaharan africa greater choice contributes better security supply granted vl simcere chinese manufacturer granting right manufacture sell zanamivir relenza containing products china sell number countries including least developed countries zanamivir antiviral help treat influenza vl driven specific concern help ensure sufficient supplies event global flu pandemic collaboration local manufacture significantly reduces disease burden rotavirus brazil pursue initiatives high public health impact commercially viable example seen implementation universal mss vaccination umv programmes brazil rotavirus gsk brazilian vaccine manufacturer fiocruz longstanding partnership production vaccines diseases causing high mortality morbidity polio haemophilus influenzae type b hib measles mumps rubella recently rotavirus partnership gsk fiocruz supports brazils requirements universal mass vaccination rotavirus rotarix vaccine despite incomplete coverage vaccination programme significantly improved public health per cent reduction hospitalisation due acute diarrhoea aetiology per cent reduction rotavirusrelated hospitalisations reduction diarrhoea outbreaks due rotavirus paulo per cent per cent reduction proportion cases gastroenteritis caused rotavirus per cent per cent rotavirus vaccine expected lead avoided deaths per cent reduction million avoided cases per cent reduction brazilian ministry health statistics home responsibility access medicine developing countries voluntary licensing corporate responsibility report voluntary licensing approach performance granted first voluntary licence vl negotiated eight licensing agreements arvs africa vls cover individual countries trade blocs others cover sub saharan africa update august july agreed royalty free voluntary licence enable aspen produce arv abacavir takes total number licensing agreements arvs africa nine offer grant licences abacavir open licensees august gave consent enable canadian company apotex manufacture generic fixed dose combination arv containing two molecules gsk patent rights treatment hivaids rwanda consent granted canadas access medicines regime reflects wto f agreement enables governments authorise production certain patented medicines export gsk agreed waive royalties basis apotexs triple combination generic arv supplied notforprofit basis licensees supplied million tablets versions epivir combivir africa represents per cent growth per cent welcome trend gives customers subsaharan africa greater choice contributes better security supply granted vl simcere chinese manufacturer granting right manufacture sell zanamivir relenza containing products china sell number countries including least developed countries zanamivir antiviral help treat influenza vl driven specific concern help ensure sufficient supplies event global flu pandemic collaboration local manufacture significantly reduces disease burden rotavirus brazil pursue initiatives high public health impact commercially viable example seen implementation universal mss vaccination umv programmes brazil rotavirus gsk brazilian vaccine manufacturer fiocruz longstanding partnership production vaccines diseases causing high mortality morbidity polio haemophilus influenzae type b hib measles mumps rubella recently rotavirus partnership gsk fiocruz supports brazils requirements universal mass vaccination rotavirus rotarix vaccine despite incomplete coverage vaccination programme significantly improved public health per cent reduction hospitalisation due acute diarrhoea aetiology per cent reduction rotavirusrelated hospitalisations reduction diarrhoea outbreaks due rotavirus paulo per cent per cent reduction proportion cases gastroenteritis caused rotavirus per cent per cent rotavirus vaccine expected lead avoided deaths per cent reduction million avoided cases per cent reduction brazilian ministry health statistics home responsibility access medicine developed countries corporate responsibility report developed countries approach performance access medicines issue developing world even developed countries patients afford medicines need particular problem us many people health insurance limited public health provision developed patient assistance programs paps discount savings cards us introduced discount cards middleincome countries programmes us patient assistance programs paps discount savings cards provide prescription medicines uninsured patients us free minimal cost gsk operates several programmes including commitment access covers cancer treatments bridges access covers medicines outpatients patients registered trough one phone call patient advocate receive medicine local pharmacy mail order gsk access provides extra help lowincome senior disabled patients enrolled medicare part programme provides free medicines eligible patients spent prescription medicines current year whose income per cent per cent federal poverty level federal poverty level single person couple family four member together rx access industry programme gives uninsured us citizens per cent discounts medicines gsk seven pharmaceutical companies programme open people earn four times federal poverty level nearly two million americans enrolled together rx access also working governments employers us find new ways address problem chronic diseases reducing healthcare costs discount cards countries gsk introduced discount cards lithuania ukraine enable lowincome patients chronic diseases asthma obtain prescription medicines discount price home responsibility access medicine developed countries corporate responsibility report developed countries approach performance access medicines issue developing world even developed countries patients afford medicines need particular problem us many people health insurance limited public health provision developed patient assistance programs paps discount savings cards us introduced discount cards middleincome countries programmes us patient assistance programs paps discount savings cards provide prescription medicines uninsured patients us free minimal cost gsk operates several programmes including commitment access covers cancer treatments bridges access covers medicines outpatients patients registered trough one phone call patient advocate receive medicine local pharmacy mail order gsk access provides extra help lowincome senior disabled patients enrolled medicare part programme provides free medicines eligible patients spent prescription medicines current year whose income per cent per cent federal poverty level federal poverty level single person couple family four member together rx access industry programme gives uninsured us citizens per cent discounts medicines gsk seven pharmaceutical companies programme open people earn four times federal poverty level nearly two million americans enrolled together rx access also working governments employers us find new ways address problem chronic diseases reducing healthcare costs discount cards countries gsk introduced discount cards lithuania ukraine enable lowincome patients chronic diseases asthma obtain prescription medicines discount price home responsibility access medicine developed countries corporate responsibility report developed countries approach performance programmes us patients received gsk medicines worth million us programmes value medicines calculated using average cost goods rather wholesale acquisition cost wac used previous years new approach valuing medicines accurately reflects true cost gsk therefore transparent believe first pharmaceutical company adopt practice number patients using largest patient assistance programmes declined eight per cent compared due decline sales avandia generic substitution coreg paxil may also increase number people without insurance delaying visits doctor year patients received day prescriptions gsk medicines together rx access programme giving patients discounts million since inception together rx access given nearly two million patients savings totalling million across wide range products discount cards countries lithuania orange card gives senior citizens disabled discount per cent patient copayment gsk prescription medicines far patients applied orange card pharmacies per cent pharmacies lithuania registered participate total discount given orange card ukraine gives significant discounts asthma chronic obstructive pulmonary disease patients need financial support purchasing seretide inhaled treatment asthma chronic obstructive pulmonary disease patients received eorange cards pharmacies registered participate programme total discount given gsk products home responsibility access medicine developed countries corporate responsibility report developed countries approach performance programmes us patients received gsk medicines worth million us programmes value medicines calculated using average cost goods rather wholesale acquisition cost wac used previous years new approach valuing medicines accurately reflects true cost gsk therefore transparent believe first pharmaceutical company adopt practice number patients using largest patient assistance programmes declined eight per cent compared due decline sales avandia generic substitution coreg paxil may also increase number people without insurance delaying visits doctor year patients received day prescriptions gsk medicines together rx access programme giving patients discounts million since inception together rx access given nearly two million patients savings totalling million across wide range products discount cards countries lithuania orange card gives senior citizens disabled discount per cent patient copayment gsk prescription medicines far patients applied orange card pharmacies per cent pharmacies lithuania registered participate total discount given orange card ukraine gives significant discounts asthma chronic obstructive pulmonary disease patients need financial support purchasing seretide inhaled treatment asthma chronic obstructive pulmonary disease patients received eorange cards pharmacies registered participate programme total discount given gsk products home responsibility access medicines pricing medicines corporate responsibility report pricing medicines prices newly approved medicines determined countrybycountry basis countries prices negotiated directly governments payers example sickness funds private health insurers others manufacturers free set prices subject kinds government controls pharmaceutical rd lengthy expensive process develop one successful medicine vaccine take average ten twelve years typically costs around billion every product reaches market thousands make research process seek ensure price new products reflects clinical value patients terms improved therapy better safety fewer side effects high risks associated rd need fair return investment affordability customers ultimately national price regulation often amount balancing act managing public healthcare budgets enabling patient access rewarding innovation rd investment sell medicines wholesalers pharmacies directly patients intermediaries often add price markups pharmaceutical products addition duties tariffs may imposed imported products affects price paid end customer example national health services hospitals patients tufts center study drug development home responsibility access medicines pricing medicines corporate responsibility report pricing medicines prices newly approved medicines determined countrybycountry basis countries prices negotiated directly governments payers example sickness funds private health insurers others manufacturers free set prices subject kinds government controls pharmaceutical rd lengthy expensive process develop one successful medicine vaccine take average ten twelve years typically costs around billion every product reaches market thousands make research process seek ensure price new products reflects clinical value patients terms improved therapy better safety fewer side effects high risks associated rd need fair return investment affordability customers ultimately national price regulation often amount balancing act managing public healthcare budgets enabling patient access rewarding innovation rd investment sell medicines wholesalers pharmacies directly patients intermediaries often add price markups pharmaceutical products addition duties tariffs may imposed imported products affects price paid end customer example national health services hospitals patients tufts center study drug development home responsibility access medicines intellectual property corporate responsibility report intellectual property intellectual property ip refers creations human mind laws countries stop creations used others include patents copyrights trademarks international level ip protected world trade organizations wto trade related aspects intellectual property rights agreement commonly known trips patents ip rights play vital role encouraging innovation needed develop new treatments many serious lifethreatening diseases invest considerable time money develop new pharmaceutical product average billion years per product every compounds tested estimated five reach clinical trials one reaches market new product could immediately copied sold others would able continue fund new research would discourage innovation limit research newer better medicines vaccines relation healthcare crisis developing world intellectual property specifically patents criticised two broad reasons opponents claim marketdriven ipbased rd system led misprioritisation rd resources means rd prioritisation based developed world market opportunities rather unmet medical need led rd deficit diseases developing world ip acted barrier access two facets firstly patents led monopoly pricing prevented generic competition able drive prices secondly patents acted barrier followon innovation development fixeddose combinations believe concerns overstated recognise need seek new approaches ip help tackle healthcare crisis believe ip system compatible rd diseases developing world gsk others industry expanded research neglected diseases recent years november international trade association ifpma published data showed number medicine vaccine projects undertaken companies product development partnerships increased november believe patents minor issue preventing people developing world getting access medicines little patent protection many vital medicines treatments malaria tuberculosis diarrhoeal diseases kill millions people year per cent medicines world health organizations essential medicines list patent protected anywhere world yet says onethird worlds population regular access drugs africa parts asia figure rises twothirds population poverty biggest barrier effective healthcare developing world usually associated poorly developed healthcare infrastructure little access doctors hospitals significant barriers stand way access medicines developing world must tackled shared responsibility sectors global society however traditionally allowed access intellectual property controlled situations exploring ways flexible intellectual property relates neglected diseases ips primary objective incentivise reward research however number neglected tropical diseases leprose cholera serious lack research variety complex reasons need explore address gap including use ip one approach might patent pool encourage research neglected tropical diseases gsk placing granted patents pending applications relating approximately patent families pool help others develop potential medicines neglected diseases addition providing access patent filings gsk set mechanism enable third parties request access intellectual property knowhow medicines may help researchers develop new medicines neglected tropical diseases aim pool must encourage research would otherwise happen hope something new comes research full benefits must go directly ldcs pool voluntary foster atmosphere cooperation encourage others join pool one mechanism exploring achieve aims also consider new ways stimulating research continue defend ip robustly outside pool business sustained rewarded discovery development innovative medicines however poorest countries plan much flexible develop work area throughout intellectual property laws help prevent distribution counterfeit products present serious health risk patients tufts center study drug development pharmaceutical industry profile washington dc phrma march wwwifpmaorgnewsnewsreleasedetailaspxnidhome responsibility access medicines intellectual property corporate responsibility report intellectual property intellectual property ip refers creations human mind laws countries stop creations used others include patents copyrights trademarks international level ip protected world trade organizations wto trade related aspects intellectual property rights agreement commonly known trips patents ip rights play vital role encouraging innovation needed develop new treatments many serious lifethreatening diseases invest considerable time money develop new pharmaceutical product average billion years per product every compounds tested estimated five reach clinical trials one reaches market new product could immediately copied sold others would able continue fund new research would discourage innovation limit research newer better medicines vaccines relation healthcare crisis developing world intellectual property specifically patents criticised two broad reasons opponents claim marketdriven ipbased rd system led misprioritisation rd resources means rd prioritisation based developed world market opportunities rather unmet medical need led rd deficit diseases developing world ip acted barrier access two facets firstly patents led monopoly pricing prevented generic competition able drive prices secondly patents acted barrier followon innovation development fixeddose combinations believe concerns overstated recognise need seek new approaches ip help tackle healthcare crisis believe ip system compatible rd diseases developing world gsk others industry expanded research neglected diseases recent years november international trade association ifpma published data showed number medicine vaccine projects undertaken companies product development partnerships increased november believe patents minor issue preventing people developing world getting access medicines little patent protection many vital medicines treatments malaria tuberculosis diarrhoeal diseases kill millions people year per cent medicines world health organizations essential medicines list patent protected anywhere world yet says onethird worlds population regular access drugs africa parts asia figure rises twothirds population poverty biggest barrier effective healthcare developing world usually associated poorly developed healthcare infrastructure little access doctors hospitals significant barriers stand way access medicines developing world must tackled shared responsibility sectors global society however traditionally allowed access intellectual property controlled situations exploring ways flexible intellectual property relates neglected diseases ips primary objective incentivise reward research however number neglected tropical diseases leprose cholera serious lack research variety complex reasons need explore address gap including use ip one approach might patent pool encourage research neglected tropical diseases gsk placing granted patents pending applications relating approximately patent families pool help others develop potential medicines neglected diseases addition providing access patent filings gsk set mechanism enable third parties request access intellectual property knowhow medicines may help researchers develop new medicines neglected tropical diseases aim pool must encourage research would otherwise happen hope something new comes research full benefits must go directly ldcs pool voluntary foster atmosphere cooperation encourage others join pool one mechanism exploring achieve aims also consider new ways stimulating research continue defend ip robustly outside pool business sustained rewarded discovery development innovative medicines however poorest countries plan much flexible develop work area throughout intellectual property laws help prevent distribution counterfeit products present serious health risk patients tufts center study drug development pharmaceutical industry profile washington dc phrma march wwwifpmaorgnewsnewsreleasedetailaspxnid home responsibility access medicines intellectual property corporate responsibility report intellectual property intellectual property ip refers creations human mind laws countries stop creations used others include patents copyrights trademarks international level ip protected world trade organizations wto trade related aspects intellectual property rights agreement commonly known trips patents ip rights play vital role encouraging innovation needed develop new treatments many serious lifethreatening diseases invest considerable time money develop new pharmaceutical product average billion years per product every compounds tested estimated five reach clinical trials one reaches market new product could immediately copied sold others would able continue fund new research would discourage innovation limit research newer better medicines vaccines relation healthcare crisis developing world intellectual property specifically patents criticised two broad reasons opponents claim marketdriven ipbased rd system led misprioritisation rd resources means rd prioritisation based developed world market opportunities rather unmet medical need led rd deficit diseases developing world ip acted barrier access two facets firstly patents led monopoly pricing prevented generic competition able drive prices secondly patents acted barrier followon innovation development fixeddose combinations believe concerns overstated recognise need seek new approaches ip help tackle healthcare crisis believe ip system compatible rd diseases developing world gsk others industry expanded research neglected diseases recent years november international trade association ifpma published data showed number medicine vaccine projects undertaken companies product development partnerships increased november believe patents minor issue preventing people developing world getting access medicines little patent protection many vital medicines treatments malaria tuberculosis diarrhoeal diseases kill millions people year per cent medicines world health organizations essential medicines list patent protected anywhere world yet says onethird worlds population regular access drugs africa parts asia figure rises twothirds population poverty biggest barrier effective healthcare developing world usually associated poorly developed healthcare infrastructure little access doctors hospitals significant barriers stand way access medicines developing world must tackled shared responsibility sectors global society however traditionally allowed access intellectual property controlled situations exploring ways flexible intellectual property relates neglected diseases ips primary objective incentivise reward research however number neglected tropical diseases leprose cholera serious lack research variety complex reasons need explore address gap including use ip one approach might patent pool encourage research neglected tropical diseases gsk placing granted patents pending applications relating approximately patent families pool help others develop potential medicines neglected diseases addition providing access patent filings gsk set mechanism enable third parties request access intellectual property knowhow medicines may help researchers develop new medicines neglected tropical diseases aim pool must encourage research would otherwise happen hope something new comes research full benefits must go directly ldcs pool voluntary foster atmosphere cooperation encourage others join pool one mechanism exploring achieve aims also consider new ways stimulating research continue defend ip robustly outside pool business sustained rewarded discovery development innovative medicines however poorest countries plan much flexible develop work area throughout intellectual property laws help prevent distribution counterfeit products present serious health risk patients tufts center study drug development pharmaceutical industry profile washington dc phrma march wwwifpmaorgnewsnewsreleasedetailaspxnid home responsibility access medicines intellectual property wto trips agreement corporate responsibility report wto trips agreement intellectual property ip rights protected globally world trade organizations wto trade related aspects intellectual property rights agreement trips trips agreement signed wto member countries covers types ip including patents copyright trademarks sets minimum standards ip rights wto member countries agreement covers areas business society including software music arts designed encourage innovation business sectors developing countries given extra time comply trips countries example india introduce patents pharmaceuticals least developed countries world example rwanda gambia comply agreement pharmaceuticals sectors patents trips access medicines concerns patents trips agreement restrict access medicines people developing countries making difficult obtain cheap generic versions important drugs used treat hivaids however trips agreement contains number public health safeguards clarified wto concerns trips access medicines addressed wto ministerial conference doha wto ministers confirmed ip protection important development new medicines restrict members rights protect public health also agreed trips agreement could implemented interpreted way supports public health promotes access medicines understanding captured doha declaration trips public health doha declaration confirmed rights member countries use flexibilities trips compulsory licences protect public health priorities compulsory licensing allows governments issue licence patented product manufactured without consent patent owner wto members agreed modify trips provisions relating compulsory licensing august countries unable produce pharmaceuticals domestically import patented products made compulsory licences abroad provision confirmed amendment trips agreement wto december gsk supports doha declaration agreement compulsory licensing committed playing key role access crisis home responsibility access medicines intellectual property wto trips agreement corporate responsibility report wto trips agreement intellectual property ip rights protected globally world trade organizations wto trade related aspects intellectual property rights agreement trips trips agreement signed wto member countries covers types ip including patents copyright trademarks sets minimum standards ip rights wto member countries agreement covers areas business society including software music arts designed encourage innovation business sectors developing countries given extra time comply trips countries example india introduce patents pharmaceuticals least developed countries world example rwanda gambia comply agreement pharmaceuticals sectors patents trips access medicines concerns patents trips agreement restrict access medicines people developing countries making difficult obtain cheap generic versions important drugs used treat hivaids however trips agreement contains number public health safeguards clarified wto concerns trips access medicines addressed wto ministerial conference doha wto ministers confirmed ip protection important development new medicines restrict members rights protect public health also agreed trips agreement could implemented interpreted way supports public health promotes access medicines understanding captured doha declaration trips public health doha declaration confirmed rights member countries use flexibilities trips compulsory licences protect public health priorities compulsory licensing allows governments issue licence patented product manufactured without consent patent owner wto members agreed modify trips provisions relating compulsory licensing august countries unable produce pharmaceuticals domestically import patented products made compulsory licences abroad provision confirmed amendment trips agreement wto december gsk supports doha declaration agreement compulsory licensing committed playing key role access crisis home responsibility access medicines intellectual property intellectual property rights brief corporate responsibility report intellectual property rights brief patents patent gives inventor new product exclusive rights manufacture use sell import product process used make rights granted set period generally years term patent runs lengthy research development rd period often five eight years patent remains product marketed countries extended patent term compensate long rd process patents granted condition inventor publishes full description invention would allow someone else manufacture product helps build scientific understanding encourage research innovation trademarks trademark brand name word phrase symbol design combination identifies distinguishes product company owner trademark prevent use third party trademarks enable customers tell products competitors provide reassurance quality origin product therefore vital part marketing data exclusivity sell new product must prove effective safe use products rigorously tested clinical trials medical research results research submitted governments confidential basis data exclusivity means governments use disclose data fixed period ensures companies benefit research free example demonstrate safety efficacy generic copies products interest facilitating timely market access need avoid repetitive animal testing human clinical trials competitors may refer data expiration period exclusivity home responsibility access medicines intellectual property intellectual property rights brief corporate responsibility report intellectual property rights brief patents patent gives inventor new product exclusive rights manufacture use sell import product process used make rights granted set period generally years term patent runs lengthy research development rd period often five eight years patent remains product marketed countries extended patent term compensate long rd process patents granted condition inventor publishes full description invention would allow someone else manufacture product helps build scientific understanding encourage research innovation trademarks trademark brand name word phrase symbol design combination identifies distinguishes product company owner trademark prevent use third party trademarks enable customers tell products competitors provide reassurance quality origin product therefore vital part marketing data exclusivity sell new product must prove effective safe use products rigorously tested clinical trials medical research results research submitted governments confidential basis data exclusivity means governments use disclose data fixed period ensures companies benefit research free example demonstrate safety efficacy generic copies products interest facilitating timely market access need avoid repetitive animal testing human clinical trials competitors may refer data expiration period exclusivity home responsibility access medicines future corporate responsibility report future increasing access medicines global challenge encouraging progress made areas significant problems remain new issues likely emerge example continued need significant scaleup treatment hivaids subsaharan africa resource poor settings potential global flu pandemic healthcare needs poor people middleincome countries growing impact noncommunicable diseases diabetes poor rich countries death million children year vaccinepreventable diseases implement programmes number areas help address challenges intellectual property explore ways flexible intellectual property rights relate neglected diseases including exploring idea patent pools believe could speed development new medicines encourage pharmaceutical companies adopt similar approach update august march launched ldc neglected tropical disease patent pool website enables interested stakeholders access list gsks patent filings small molecule pharmaceuticals treatment neglected tropical diseases ntds organisations apply licences areas developing treatments request licences research develop treatment ntd using gsk patented technology small molecules currently developing get help problems arising research development small molecule therapeutics treat ntds least developed countries july us biotechnology group alnylam became first company follow gsk contribute patents pool pricing improve transparency pricing policies implement new pricing policies least developed countries continue evolve new approaches increase affordability middle income countries update august april implemented price reductions patented products least developed countries ldcs commitment gsk patented products countries cost less per cent price referenced developed countries reduced prices seven patented brands individual product lines formulations average per cent countries prices reduced immediately due regulatory processes needing obtain government authorisation however price reduction process initiated also cut prices nonldc markets east africa francophone west africa reduce risk products would diverted ldcs sold wealthier countries thereby reducing availability ldcs research evaluate opportunities expand tres cantos diseases developing world research centre worldclass global centre excellence encouraging partnerships governments ngos pharmaceutical companies update august appointed leadership team working partners extend capacity scope tres cantos facility creating open collaborative way working providing facilities support network needed visiting scientists form drug discovery project teams gsk scientists healthcare services seek partner governments stakeholders help strengthen healthcare infrastructure services update august reinvestment initiative gsk support governments five ldcs addressing priority healthcare challenges remove barriers quality healthcare strengthen health infrastructure achieved targeted partnerships increase access essential medicines basic healthcare services work begin end four ldcs one gsk regions east africa southern africa anglophone west africa francophone west central africa expanding maternal child health activities specific focus children five integrated management childhood illness programme one additional ldc piloting new child family wellness cfw model cfw micro franchising model involves building network micro pharmacies clinics improve access essential medicines basic healthcare prevention services children families work use business models maintain standards readily scalable achieve economies scale gsk currently working ngo healthstore foundation implemented model kenya run viability studies least two ldcs east africa select one country implement initiative july announced new commitments fight hivaids subsaharan africa special focus care treatment children include million seed funding support public private partnership research development new hivaids medicines children commitment seek collaborations companies develop fixeddosed antiretroviral combinations creations positive action children fund working main industry associations new initiatives increase rd improve access first outcome activity announcement january grant million international federation pharmaceutical manufacturers associations ifpma special programme research training tropical diseases tdr cosponsored unicef undp world bank grant support tdrs development new medicines combat diseases disproportionately affect poor people living developing countries activities include plans establish pilot industry consortium focus developing new targets molecules prevent interrupt disease progression diseases developing world update august april announced intention combine gsk pfizer hiv businesses create new company dedicated discovery delivery hiv treatments combining businesses create specialist unit sustainable broader scope either companys individual business new company particularly look improve treatments formulations children living hiv continue offer hiv medicines notforprofit prices worlds poorest countries issue new voluntary licences diversify production expand capacity markets new company responsible delivering commitments announced gsk july home responsibility access medicines future corporate responsibility report future increasing access medicines global challenge encouraging progress made areas significant problems remain new issues likely emerge example continued need significant scaleup treatment hivaids subsaharan africa resource poor settings potential global flu pandemic healthcare needs poor people middleincome countries growing impact noncommunicable diseases diabetes poor rich countries death million children year vaccinepreventable diseases implement programmes number areas help address challenges intellectual property explore ways flexible intellectual property rights relate neglected diseases including exploring idea patent pools believe could speed development new medicines encourage pharmaceutical companies adopt similar approach update august march launched ldc neglected tropical disease patent pool website enables interested stakeholders access list gsks patent filings small molecule pharmaceuticals treatment neglected tropical diseases ntds organisations apply licences areas developing treatments request licences research develop treatment ntd using gsk patented technology small molecules currently developing get help problems arising research development small molecule therapeutics treat ntds least developed countries july us biotechnology group alnylam became first company follow gsk contribute patents pool pricing improve transparency pricing policies implement new pricing policies least developed countries continue evolve new approaches increase affordability middle income countries update august april implemented price reductions patented products least developed countries ldcs commitment gsk patented products countries cost less per cent price referenced developed countries reduced prices seven patented brands individual product lines formulations average per cent countries prices reduced immediately due regulatory processes needing obtain government authorisation however price reduction process initiated also cut prices nonldc markets east africa francophone west africa reduce risk products would diverted ldcs sold wealthier countries thereby reducing availability ldcs research evaluate opportunities expand tres cantos diseases developing world research centre worldclass global centre excellence encouraging partnerships governments ngos pharmaceutical companies update august appointed leadership team working partners extend capacity scope tres cantos facility creating open collaborative way working providing facilities support network needed visiting scientists form drug discovery project teams gsk scientists healthcare services seek partner governments stakeholders help strengthen healthcare infrastructure services update august reinvestment initiative gsk support governments five ldcs addressing priority healthcare challenges remove barriers quality healthcare strengthen health infrastructure achieved targeted partnerships increase access essential medicines basic healthcare services work begin end four ldcs one gsk regions east africa southern africa anglophone west africa francophone west central africa expanding maternal child health activities specific focus children five integrated management childhood illness programme one additional ldc piloting new child family wellness cfw model cfw micro franchising model involves building network micro pharmacies clinics improve access essential medicines basic healthcare prevention services children families work use business models maintain standards readily scalable achieve economies scale gsk currently working ngo healthstore foundation implemented model kenya run viability studies least two ldcs east africa select one country implement initiative july announced new commitments fight hivaids subsaharan africa special focus care treatment children include million seed funding support public private partnership research development new hivaids medicines children commitment seek collaborations companies develop fixeddosed antiretroviral combinations creations positive action children fund working main industry associations new initiatives increase rd improve access first outcome activity announcement january grant million international federation pharmaceutical manufacturers associations ifpma special programme research training tropical diseases tdr cosponsored unicef undp world bank grant support tdrs development new medicines combat diseases disproportionately affect poor people living developing countries activities include plans establish pilot industry consortium focus developing new targets molecules prevent interrupt disease progression diseases developing world update august april announced intention combine gsk pfizer hiv businesses create new company dedicated discovery delivery hiv treatments combining businesses create specialist unit sustainable broader scope either companys individual business new company particularly look improve treatments formulations children living hiv continue offer hiv medicines notforprofit prices worlds poorest countries issue new voluntary licences diversify production expand capacity markets new company responsible delivering commitments announced gsk july home responsibility access medicines future corporate responsibility report future increasing access medicines global challenge encouraging progress made areas significant problems remain new issues likely emerge example continued need significant scaleup treatment hivaids subsaharan africa resource poor settings potential global flu pandemic healthcare needs poor people middleincome countries growing impact noncommunicable diseases diabetes poor rich countries death million children year vaccinepreventable diseases implement programmes number areas help address challenges intellectual property explore ways flexible intellectual property rights relate neglected diseases including exploring idea patent pools believe could speed development new medicines encourage pharmaceutical companies adopt similar approach update august march launched ldc neglected tropical disease patent pool website enables interested stakeholders access list gsks patent filings small molecule pharmaceuticals treatment neglected tropical diseases ntds organisations apply licences areas developing treatments request licences research develop treatment ntd using gsk patented technology small molecules currently developing get help problems arising research development small molecule therapeutics treat ntds least developed countries july us biotechnology group alnylam became first company follow gsk contribute patents pool pricing improve transparency pricing policies implement new pricing policies least developed countries continue evolve new approaches increase affordability middle income countries update august april implemented price reductions patented products least developed countries ldcs commitment gsk patented products countries cost less per cent price referenced developed countries reduced prices seven patented brands individual product lines formulations average per cent countries prices reduced immediately due regulatory processes needing obtain government authorisation however price reduction process initiated also cut prices nonldc markets east africa francophone west africa reduce risk products would diverted ldcs sold wealthier countries thereby reducing availability ldcs research evaluate opportunities expand tres cantos diseases developing world research centre worldclass global centre excellence encouraging partnerships governments ngos pharmaceutical companies update august appointed leadership team working partners extend capacity scope tres cantos facility creating open collaborative way working providing facilities support network needed visiting scientists form drug discovery project teams gsk scientists healthcare services seek partner governments stakeholders help strengthen healthcare infrastructure services update august reinvestment initiative gsk support governments five ldcs addressing priority healthcare challenges remove barriers quality healthcare strengthen health infrastructure achieved targeted partnerships increase access essential medicines basic healthcare services work begin end four ldcs one gsk regions east africa southern africa anglophone west africa francophone west central africa expanding maternal child health activities specific focus children five integrated management childhood illness programme one additional ldc piloting new child family wellness cfw model cfw micro franchising model involves building network micro pharmacies clinics improve access essential medicines basic healthcare prevention services children families work use business models maintain standards readily scalable achieve economies scale gsk currently working ngo healthstore foundation implemented model kenya run viability studies least two ldcs east africa select one country implement initiative july announced new commitments fight hivaids subsaharan africa special focus care treatment children include million seed funding support public private partnership research development new hivaids medicines children commitment seek collaborations companies develop fixeddosed antiretroviral combinations creations positive action children fund working main industry associations new initiatives increase rd improve access first outcome activity announcement january grant million international federation pharmaceutical manufacturers associations ifpma special programme research training tropical diseases tdr cosponsored unicef undp world bank grant support tdrs development new medicines combat diseases disproportionately affect poor people living developing countries activities include plans establish pilot industry consortium focus developing new targets molecules prevent interrupt disease progression diseases developing world update august april announced intention combine gsk pfizer hiv businesses create new company dedicated discovery delivery hiv treatments combining businesses create specialist unit sustainable broader scope either companys individual business new company particularly look improve treatments formulations children living hiv continue offer hiv medicines notforprofit prices worlds poorest countries issue new voluntary licences diversify production expand capacity markets new company responsible delivering commitments announced gsk july home responsibility access medicines future corporate responsibility report future increasing access medicines global challenge encouraging progress made areas significant problems remain new issues likely emerge example continued need significant scaleup treatment hivaids subsaharan africa resource poor settings potential global flu pandemic healthcare needs poor people middleincome countries growing impact noncommunicable diseases diabetes poor rich countries death million children year vaccinepreventable diseases implement programmes number areas help address challenges intellectual property explore ways flexible intellectual property rights relate neglected diseases including exploring idea patent pools believe could speed development new medicines encourage pharmaceutical companies adopt similar approach update august march launched ldc neglected tropical disease patent pool website enables interested stakeholders access list gsks patent filings small molecule pharmaceuticals treatment neglected tropical diseases ntds organisations apply licences areas developing treatments request licences research develop treatment ntd using gsk patented technology small molecules currently developing get help problems arising research development small molecule therapeutics treat ntds least developed countries july us biotechnology group alnylam became first company follow gsk contribute patents pool pricing improve transparency pricing policies implement new pricing policies least developed countries continue evolve new approaches increase affordability middle income countries update august april implemented price reductions patented products least developed countries ldcs commitment gsk patented products countries cost less per cent price referenced developed countries reduced prices seven patented brands individual product lines formulations average per cent countries prices reduced immediately due regulatory processes needing obtain government authorisation however price reduction process initiated also cut prices nonldc markets east africa francophone west africa reduce risk products would diverted ldcs sold wealthier countries thereby reducing availability ldcs research evaluate opportunities expand tres cantos diseases developing world research centre worldclass global centre excellence encouraging partnerships governments ngos pharmaceutical companies update august appointed leadership team working partners extend capacity scope tres cantos facility creating open collaborative way working providing facilities support network needed visiting scientists form drug discovery project teams gsk scientists healthcare services seek partner governments stakeholders help strengthen healthcare infrastructure services update august reinvestment initiative gsk support governments five ldcs addressing priority healthcare challenges remove barriers quality healthcare strengthen health infrastructure achieved targeted partnerships increase access essential medicines basic healthcare services work begin end four ldcs one gsk regions east africa southern africa anglophone west africa francophone west central africa expanding maternal child health activities specific focus children five integrated management childhood illness programme one additional ldc piloting new child family wellness cfw model cfw micro franchising model involves building network micro pharmacies clinics improve access essential medicines basic healthcare prevention services children families work use business models maintain standards readily scalable achieve economies scale gsk currently working ngo healthstore foundation implemented model kenya run viability studies least two ldcs east africa select one country implement initiative july announced new commitments fight hivaids subsaharan africa special focus care treatment children include million seed funding support public private partnership research development new hivaids medicines children commitment seek collaborations companies develop fixeddosed antiretroviral combinations creations positive action children fund working main industry associations new initiatives increase rd improve access first outcome activity announcement january grant million international federation pharmaceutical manufacturers associations ifpma special programme research training tropical diseases tdr cosponsored unicef undp world bank grant support tdrs development new medicines combat diseases disproportionately affect poor people living developing countries activities include plans establish pilot industry consortium focus developing new targets molecules prevent interrupt disease progression diseases developing world update august april announced intention combine gsk pfizer hiv businesses create new company dedicated discovery delivery hiv treatments combining businesses create specialist unit sustainable broader scope either companys individual business new company particularly look improve treatments formulations children living hiv continue offer hiv medicines notforprofit prices worlds poorest countries issue new voluntary licences diversify production expand capacity markets new company responsible delivering commitments announced gsk july home responsibility access medicines response assurance recommendations corporate responsibility report response assurance recommendations bureau veritas assured access medicines section cr report see details pages made recommendations could improve reporting access medicines four key areas report challenges responded vision gsk could enhance communicate overall vision strategy access medicines demonstrate holistic longterm approach articulate business case provide context explain integrated overall business strategy gsk response june gsk published facing challenge summarised approach contribution improving access medicines principles underlying approach andrew witty assumed position ceo gsk instigated review approach access medicines major speech harvard university february andrew witty set approach improving access medicines developing world initiatives implement governance gsk provide greater detail governance accountability management structures access medicines relationship external stakeholders gsk response abbas hussain president emerging markets gsk leads access efforts also reviewed corporate executive team gsks senior management team corporate responsibility committee board continued engage stakeholders access issues including atm index participating development report gsks approach paul hunt un special rapporteur right health transparency gsk provides significant information case studies also consider provide greater transparency impacts access medicines initiatives put context relation overall operating model gsk response assessing impacts access medicines programme challenge report data number tablets shipped preferential pricing programmes voluntary licence agreements difficult translate figures numbers patients receiving treatment involved healthcare delivery medicines also used combination medicines supplied pharmaceutical companies simply converting shipments patient numbers would misleading accelerating access initiative aai publicprivate partnership working combat hivaids calculates treatment rates using medicines supplied nine rdbased pharmaceutical companies involved partnership estimated december around patients developing countries receiving least one arv treatment supplied companies able generate robust data impact programmes seek example october significant data lymphatic filariasis lf elimination programme published public library science plos journal neglected tropical diseases study found ten years since gsks commitment lf elimination programme prevented million children acquiring lf stopped million infected people progressing debilitating stages result fastestgrowing drug administration programme public health history delivering study calls best buy public health measuring performance linked transparency gsk consider provide relevant indicators demonstrate implementation longterm strategy promote comparisons across industry gsk response welcome comparisons across industry performance access mpeadgiec ine osf however since approaches differ significantly companies making meaningful comparisons challenge right one company may right another method ranking companies approach access medicines developed access medicines index gsk ranked top first access medicines index published index rates companies according performance eight criteria management influence research development patenting capacity pricing drug donations philanthropy pleased efforts make medicines available recognised index additionally asked paul hunt un special rapporteur right health contribute report preparing gsks approach access medicines cooperated fully number senior executives including former ceo dr jp garnier chairman sir christopher gent interviewed expect report published first half wwwplosntdsorgarticleinfodoijournalpntdhome responsibility access medicines response assurance recommendations corporate responsibility report response assurance recommendations bureau veritas assured access medicines section cr report see details pages made recommendations could improve reporting access medicines four key areas report challenges responded vision gsk could enhance communicate overall vision strategy access medicines demonstrate holistic longterm approach articulate business case provide context explain integrated overall business strategy gsk response june gsk published facing challenge summarised approach contribution improving access medicines principles underlying approach andrew witty assumed position ceo gsk instigated review approach access medicines major speech harvard university february andrew witty set approach improving access medicines developing world initiatives implement governance gsk provide greater detail governance accountability management structures access medicines relationship external stakeholders gsk response abbas hussain president emerging markets gsk leads access efforts also reviewed corporate executive team gsks senior management team corporate responsibility committee board continued engage stakeholders access issues including atm index participating development report gsks approach paul hunt un special rapporteur right health transparency gsk provides significant information case studies also consider provide greater transparency impacts access medicines initiatives put context relation overall operating model gsk response assessing impacts access medicines programme challenge report data number tablets shipped preferential pricing programmes voluntary licence agreements difficult translate figures numbers patients receiving treatment involved healthcare delivery medicines also used combination medicines supplied pharmaceutical companies simply converting shipments patient numbers would misleading accelerating access initiative aai publicprivate partnership working combat hivaids calculates treatment rates using medicines supplied nine rdbased pharmaceutical companies involved partnership estimated december around patients developing countries receiving least one arv treatment supplied companies able generate robust data impact programmes seek example october significant data lymphatic filariasis lf elimination programme published public library science plos journal neglected tropical diseases study found ten years since gsks commitment lf elimination programme prevented million children acquiring lf stopped million infected people progressing debilitating stages result fastestgrowing drug administration programme public health history delivering study calls best buy public health measuring performance linked transparency gsk consider provide relevant indicators demonstrate implementation longterm strategy promote comparisons across industry gsk response welcome comparisons across industry performance access medicines however since approaches differ significantly companies making meaningful comparisons challenge right one company may right another method ranking companies approach access medicines developed access medicines index gsk ranked top first access medicines index published index rates companies according performance eight criteria management influence research development patenting capacity pricing drug donations philanthropy pleased efforts make medicines available recognised index additionally asked paul hunt un special rapporteur right health contribute report preparing gsks approach access medicines cooperated fully number senior executives including former ceo dr jp garnier chairman sir christopher gent interviewed expect report published first half wwwplosntdsorgarticleinfodoijournalpntd home responsibility access medicines response assurance recommendations corporate responsibility report response assurance recommendations bureau veritas assured access medicines section cr report see details pages made recommendations could improve reporting access medicines four key areas report challenges responded vision gsk could enhance communicate overall vision strategy access medicines demonstrate holistic longterm approach articulate business case provide context explain integrated overall business strategy gsk response june gsk published facing challenge summarised approach contribution improving access medicines principles underlying approach andrew witty assumed position ceo gsk instigated review approach access medicines major speech harvard university february andrew witty set approach improving access medicines developing world initiatives implement governance gsk provide greater detail governance accountability management structures access medicines relationship external stakeholders gsk response abbas hussain president emerging markets gsk leads access efforts also reviewed corporate executive team gsks senior management team corporate responsibility committee board continued engage stakeholders access issues including atm index participating development report gsks approach paul hunt un special rapporteur right health transparency gsk provides significant information case studies also consider provide greater transparency impacts access medicines initiatives put context relation overall operating model gsk response assessing impacts access medicines programme challenge report data number tablets shipped preferential pricing programmes voluntary licence agreements difficult translate figures numbers patients receiving treatment involved healthcare delivery medicines also used combination medicines supplied pharmaceutical companies simply converting shipments patient numbers would misleading accelerating access initiative aai publicprivate partnership working combat hivaids calculates treatment rates using medicines supplied nine rdbased pharmaceutical companies involved partnership estimated december around patients developing countries receiving least one arv treatment supplied companies able generate robust data impact programmes seek example october significant data lymphatic filariasis lf elimination programme published public library science plos journal neglected tropical diseases study found ten years since gsks commitment lf elimination programme prevented million children acquiring lf stopped million infected people progressing debilitating stages result fastestgrowing drug administration programme public health history delivering study calls best buy public health measuring performance linked transparency gsk consider provide relevant indicators demonstrate implementation longterm strategy promote comparisons across industry gsk response welcome comparisons across industry performance access medicines however since approaches differ significantly companies making meaningful comparisons challenge right one company may right another method ranking companies approach access medicines developed access medicines index gsk ranked top first access medicines index published index rates companies according performance eight criteria management influence research development patenting capacity pricing drug donations philanthropy pleased efforts make medicines available recognised index additionally asked paul hunt un special rapporteur right health contribute report preparing gsks approach access medicines cooperated fully number senior executives including former ceo dr jp garnier chairman sir christopher gent interviewed expect report published first half wwwplosntdsorgarticleinfodoijournalpntd home responsibility access medicines case studies corporate responsibility report case studies potential malaria vaccine malaria kills one million people year worldwide makes millions sick children living subsaharan africa international community urgently needs safe effective vaccine control disease vaccine even partially effective profile necessary component comprehensive malaria control programme could potentially save hundreds thousands lives year malaria vaccine candidate rtss clinically advanced malaria vaccine candidate world since discovery gsk scientists gsk invested million resources progressing rtss phase lll trials full set clinical trials successful vaccine candidate take years involve volunteers cost million vaccine candidates survive rigorous process one reason pharmaceutical research development expensive creating malaria vaccine young children pregnant women one important vaccinedevelopment challenges today exception january gsk mvi path malaria vaccine initiative support bill melinda gates foundation entered publicprivate partnership develop rtssbased vaccine infants children living malaria endemic regions subsaharan africa clinical development rtss conducted clinical trial partnership committee collaboration leading african research institutes northern academic partners mvi gsk support malaria clinical trial alliance date gsk invested million resources develop vaccine december new england journal medicine published results two separate studies demonstrating malaria vaccine candidate provides infants children significant protection malaria infants data showed first time vaccine candidate administered part existing african immunisation programmes children aged five seventeen months candidate rtssas reduced risk clinical episodes per cent eightmonth followup period rtss entering pivotal phase lll studies worlds largest malaria vaccine trial date involving participants centres africa places trials limited healthcare infrastructure partners therefore helped set clinics seven african countries training doctors nurses laboratory staff hope infrastructure remain long trials completed update august phase iii trial rtss malaria vaccine candidate started bagamoyo tanzania may children need vaccine among poorest world price barrier access work supply organisations gavi unicef ensure price set right level also committed working international community mobilise resources fund vaccine infrastructure needed deliver abdulla oberholzer r juma et al safety immunogenicity rtssasd malaria vaccine infants n engl j med bejon p lusingu j olotu et al efficacy rtssase clinical malaria month old children n engl j med extending product portfolio developing world low middle income countries july gsk entered partnership south african pharmaceuticals company aspen line aim grow diversified business operate way adapted patient needs low middleincome markets aspens product portfolio covers broad range therapy areas relevant disease profile developing countries including analgesics pain relief antihypertensives high blood pressure bronchodilators treatment asthma antibacterials antigout agents antiinflammatory agents antidepressants antifungal agents antihistamines treatment allergies decongestants gastrointestinal agents dermatologicals treat skin conditions gaining access aspens current portfolio future pipeline gsk distributing products medicines needed low middleincome countries longterm nature collaboration initially beyond tenyear period also underlines gsks philosophy investing meaningful sustainable manner developing world january announced agreement ucb sa acquire current marketed product portfolio across certain territories africa middle east asia pacific latin america result agreement gsk acquire several leading pharmaceutical brands number disease areas include keppra treatment epilepsy xyzal zyrtec treatment allergic rhinitis aspen partnership ucb deal sit alongside recent acquisition bristol myers squibbs mature pharmaceuticals businesses egypt pakistan two associated manufacturing facilities together deals provide gsk access renewable highquality competitively priced pipeline branded pharmaceuticals products complements existing portfolio products help drive patient access low middleincome markets gsk vaccine eliminates hib meningitis public concern uganda national fouryear immunisation programme using gsks tritanrixhb hib vaccine eliminated hib meningitis public health concern uganda according global alliance vaccines immunisations gavi hib meningitis dangerous inflammation lining brain spinal cord gavi publicprivate partnership includes world health organization world bank supported bill melinda gates foundation others says use tritanrixhb hib reduced number incidences disease ugandan children zero news follows similar results bangladesh kenya chile gambia well britain us vaccine shown cut number cases hib meningitis least per cent three tofive year period julian loblevyt executive director gavi says results extremely positive applaud true success controlling deadly disease often claimed many lives says though developed countries largely eliminated disease hib vaccine distribution slow poorer parts world due financial logistical problems well limited awareness disease uganda government obtained gavi support use million doses vaccines giving protection hib diphtheria pertussis tetanus hepatitis b according study published bulletin world health organization vaccination programme uganda preventing almost cases severe hib disease child deaths every year introduction hib vaccine completely changed epidemiology bacterial meningitis uganda says adeodata kekitiinwa paediatrician kampala 's mulago hospital coauthored study hib kills children age five every year linked around three million cases illnesses result longterm effects deafness paralysis mental retardation learning disabilities gavi says every child hib meningitis developing country thought five ten others hibrelated pneumonia also preventable vaccination gsk press release march home responsibility access medicines case studies corporate responsibility report case studies potential malaria vaccine malaria kills one million people year worldwide makes millions sick children living subsaharan africa international community urgently needs safe effective vaccine control disease vaccine even partially effective profile necessary component comprehensive malaria control programme could potentially save hundreds thousands lives year malaria vaccine candidate rtss clinically advanced malaria vaccine candidate world since discovery gsk scientists gsk invested million resources progressing rtss phase lll trials full set clinical trials successful vaccine candidate take years involve volunteers cost million vaccine candidates survive rigorous process one reason pharmaceutical research development expensive creating malaria vaccine young children pregnant women one important vaccinedevelopment challenges today exception january gsk mvi path malaria vaccine initiative support bill melinda gates foundation entered publicprivate partnership develop rtssbased vaccine infants children living malaria endemic regions subsaharan africa clinical development rtss conducted clinical trial partnership committee collaboration leading african research institutes northern academic partners mvi gsk support malaria clinical trial alliance date gsk invested million resources develop vaccine december new england journal medicine published results two separate studies demonstrating malaria vaccine candidate provides infants children significant protection malaria infants data showed first time vaccine candidate administered part existing african immunisation programmes children aged five seventeen months candidate rtssas reduced risk clinical episodes per cent eightmonth followup period rtss entering pivotal phase lll studies worlds largest malaria vaccine trial date involving participants centres africa places trials limited healthcare infrastructure partners therefore helped set clinics seven african countries training doctors nurses laboratory staff hope infrastructure remain long trials completed update august phase iii trial rtss malaria vaccine candidate started bagamoyo tanzania may children need vaccine among poorest world price barrier access work supply organisations gavi unicef ensure price set right level also committed working international community mobilise resources fund vaccine infrastructure needed deliver abdulla oberholzer r juma et al safety immunogenicity rtssasd malaria vaccine infants n engl j med bejon p lusingu j olotu et al efficacy rtssase clinical malaria month old children n engl j med extending product portfolio developing world low middle income countries july gsk entered partnership south african pharmaceuticals company aspen line aim grow diversified business operate way adapted patient needs low middleincome markets aspens product portfolio covers broad range therapy areas relevant disease profile developing countries including analgesics pain relief antihypertensives high blood pressure bronchodilators treatment asthma antibacterials antigout agents antiinflammatory agents antidepressants antifungal agents antihistamines treatment allergies decongestants gastrointestinal agents dermatologicals treat skin conditions gaining access aspens current portfolio future pipeline gsk distributing products medicines needed low middleincome countries longterm nature collaboration initially beyond tenyear period also underlines gsks philosophy investing meaningful sustainable manner developing world january announced agreement ucb sa acquire current marketed product portfolio across certain territories africa middle east asia pacific latin america result agreement gsk acquire several leading pharmaceutical brands number disease areas include keppra treatment epilepsy xyzal zyrtec treatment allergic rhinitis aspen partnership ucb deal sit alongside recent acquisition bristol myers squibbs mature pharmaceuticals businesses egypt pakistan two associated manufacturing facilities together deals provide gsk access renewable highquality competitively priced pipeline branded pharmaceuticals products complements existing portfolio products help drive patient access low middleincome markets gsk vaccine eliminates hib meningitis public concern uganda national fouryear immunisation programme using gsks tritanrixhb hib vaccine eliminated hib meningitis public health concern uganda according global alliance vaccines immunisations gavi hib meningitis dangerous inflammation lining brain spinal cord gavi publicprivate partnership includes world health organization world bank supported bill melinda gates foundation others says use tritanrixhb hib reduced number incidences disease ugandan children zero news follows similar results bangladesh kenya chile gambia well britain us vaccine shown cut number cases hib meningitis least per cent three tofive year period julian loblevyt executive director gavi says results extremely positive applaud true success controlling deadly disease often claimed many lives says though developed countries largely eliminated disease hib vaccine distribution slow poorer parts world due financial logistical problems well limited awareness disease uganda government obtained gavi support use million doses vaccines giving protection hib diphtheria pertussis tetanus hepatitis b according study published bulletin world health organization vaccination programme uganda preventing almost cases severe hib disease child deaths every year introduction hib vaccine completely changed epidemiology bacterial meningitis uganda says adeodata kekitiinwa paediatrician kampala 's mulago hospital coauthored study hib kills children age five every year linked around three million cases illnesses result longterm effects deafness paralysis mental retardation learning disabilities gavi says every child hib meningitis developing country thought five ten others hibrelated pneumonia also preventable vaccination gsk press release march home responsibility access medicines case studies corporate responsibility report case studies potential malaria vaccine malaria kills one million people year worldwide makes millions sick children living subsaharan africa international community urgently needs safe effective vaccine control disease vaccine even partially effective profile necessary component comprehensive malaria control programme could potentially save hundreds thousands lives year malaria vaccine candidate rtss clinically advanced malaria vaccine candidate world since discovery gsk scientists gsk invested million resources progressing rtss phase lll trials full set clinical trials successful vaccine candidate take years involve volunteers cost million vaccine candidates survive rigorous process one reason pharmaceutical research development expensive creating malaria vaccine young children pregnant women one important vaccinedevelopment challenges today exception january gsk mvi path malaria vaccine initiative support bill melinda gates foundation entered publicprivate partnership develop rtssbased vaccine infants children living malaria endemic regions subsaharan africa clinical development rtss conducted clinical trial partnership committee collaboration leading african research institutes northern academic partners mvi gsk support malaria clinical trial alliance date gsk invested million resources develop vaccine december new england journal medicine published results two separate studies demonstrating malaria vaccine candidate provides infants children significant protection malaria infants data showed first time vaccine candidate administered part existing african immunisation programmes children aged five seventeen months candidate rtssas reduced risk clinical episodes per cent eightmonth followup period rtss entering pivotal phase lll studies worlds largest malaria vaccine trial date involving participants centres africa places trials limited healthcare infrastructure partners therefore helped set clinics seven african countries training doctors nurses laboratory staff hope infrastructure remain long trials completed update august phase iii trial rtss malaria vaccine candidate started bagamoyo tanzania may children need vaccine among poorest world price barrier access work supply organisations gavi unicef ensure price set right level also committed working international community mobilise resources fund vaccine infrastructure needed deliver abdulla oberholzer r juma et al safety immunogenicity rtssasd malaria vaccine infants n engl j med bejon p lusingu j olotu et al efficacy rtssase clinical malaria month old children n engl j med extending product portfolio developing world low middle income countries july gsk entered partnership south african pharmaceuticals company aspen line aim grow diversified business operate way adapted patient needs low middleincome markets aspens product portfolio covers broad range therapy areas relevant disease profile developing countries including analgesics pain relief antihypertensives high blood pressure bronchodilators treatment asthma antibacterials antigout agents antiinflammatory agents antidepressants antifungal agents antihistamines treatment allergies decongestants gastrointestinal agents dermatologicals treat skin conditions gaining access aspens current portfolio future pipeline gsk distributing products medicines needed low middleincome countries longterm nature collaboration initially beyond tenyear period also underlines gsks philosophy investing meaningful sustainable manner developing world january announced agreement ucb sa acquire current marketed product portfolio across certain territories africa middle east asia pacific latin america result agreement gsk acquire several leading pharmaceutical brands number disease areas include keppra treatment epilepsy xyzal zyrtec treatment allergic rhinitis aspen partnership ucb deal sit alongside recent acquisition bristol myers squibbs mature pharmaceuticals businesses egypt pakistan two associated manufacturing facilities together deals provide gsk access renewable highquality competitively priced pipeline branded pharmaceuticals products complements existing portfolio products help drive patient access low middleincome markets gsk vaccine eliminates hib meningitis public concern uganda national fouryear immunisation programme using gsks tritanrixhb hib vaccine eliminated hib meningitis public health concern uganda according global alliance vaccines immunisations gavi hib meningitis dangerous inflammation lining brain spinal cord gavi publicprivate partnership includes world health organization world bank supported bill melinda gates foundation others says use tritanrixhb hib reduced number incidences disease ugandan children zero news follows similar results bangladesh kenya chile gambia well britain us vaccine shown cut number cases hib meningitis least per cent three tofive year period julian loblevyt executive director gavi says results extremely positive applaud true success controlling deadly disease often claimed many lives says though developed countries largely eliminated disease hib vaccine distribution slow poorer parts world due financial logistical problems well limited awareness disease uganda government obtained gavi support use million doses vaccines giving protection hib diphtheria pertussis tetanus hepatitis b according study published bulletin world health organization vaccination programme uganda preventing almost cases severe hib disease child deaths every year introduction hib vaccine completely changed epidemiology bacterial meningitis uganda says adeodata kekitiinwa paediatrician kampala 's mulago hospital coauthored study hib kills children age five every year linked around three million cases illnesses result longterm effects deafness paralysis mental retardation learning disabilities gavi says every child hib meningitis developing country thought five ten others hibrelated pneumonia also preventable vaccination gsk press release march home responsibility access medicines case studies corporate responsibility report case studies potential malaria vaccine malaria kills one million people year worldwide makes millions sick children living subsaharan africa international community urgently needs safe effective vaccine control disease vaccine even partially effective profile necessary component comprehensive malaria control programme could potentially save hundreds thousands lives year malaria vaccine candidate rtss clinically advanced malaria vaccine candidate world since discovery gsk scientists gsk invested million resources progressing rtss phase lll trials full set clinical trials successful vaccine candidate take years involve volunteers cost million vaccine candidates survive rigorous process one reason pharmaceutical research development expensive creating malaria vaccine young children pregnant women one important vaccinedevelopment challenges today exception january gsk mvi path malaria vaccine initiative support bill melinda gates foundation entered publicprivate partnership develop rtssbased vaccine infants children living malaria endemic regions subsaharan africa clinical development rtss conducted clinical trial partnership committee collaboration leading african research institutes northern academic partners mvi gsk support malaria clinical trial alliance date gsk invested million resources develop vaccine december new england journal medicine published results two separate studies demonstrating malaria vaccine candidate provides infants children significant protection malaria infants data showed first time vaccine candidate administered part existing african immunisation programmes children aged five seventeen months candidate rtssas reduced risk clinical episodes per cent eightmonth followup period rtss entering pivotal phase lll studies worlds largest malaria vaccine trial date involving participants centres africa places trials limited healthcare infrastructure partners therefore helped set clinics seven african countries training doctors nurses laboratory staff hope infrastructure remain long trials completed update august phase iii trial rtss malaria vaccine candidate started bagamoyo tanzania may children need vaccine among poorest world price barrier access work supply organisations gavi unicef ensure price set right level also committed working international community mobilise resources fund vaccine infrastructure needed deliver abdulla oberholzer r juma et al safety immunogenicity rtssasd malaria vaccine infants n engl j med bejon p lusingu j olotu et al efficacy rtssase clinical malaria month old children n engl j med extending product portfolio developing world low middle income countries july gsk entered partnership south african pharmaceuticals company aspen line aim grow diversified business operate way adapted patient needs low middleincome markets aspens product portfolio covers broad range therapy areas relevant disease profile developing countries including analgesics pain relief antihypertensives high blood pressure bronchodilators treatment asthma antibacterials antigout agents antiinflammatory agents antidepressants antifungal agents antihistamines treatment allergies decongestants gastrointestinal agents dermatologicals treat skin conditions gaining access aspens current portfolio future pipeline gsk distributing products medicines needed low middleincome countries longterm nature collaboration initially beyond tenyear period also underlines gsks philosophy investing meaningful sustainable manner developing world january announced agreement ucb sa acquire current marketed product portfolio across certain territories africa middle east asia pacific latin america result agreement gsk acquire several leading pharmaceutical brands number disease areas include keppra treatment epilepsy xyzal zyrtec treatment allergic rhinitis aspen partnership ucb deal sit alongside recent acquisition bristol myers squibbs mature pharmaceuticals businesses egypt pakistan two associated manufacturing facilities together deals provide gsk access renewable highquality competitively priced pipeline branded pharmaceuticals products complements existing portfolio products help drive patient access low middleincome markets gsk vaccine eliminates hib meningitis public concern uganda national fouryear immunisation programme using gsks tritanrixhb hib vaccine eliminated hib meningitis public health concern uganda according global alliance vaccines immunisations gavi hib meningitis dangerous inflammation lining brain spinal cord gavi publicprivate partnership includes world health organization world bank supported bill melinda gates foundation others says use tritanrixhb hib reduced number incidences disease ugandan children zero news follows similar results bangladesh kenya chile gambia well britain us vaccine shown cut number cases hib meningitis least per cent three tofive year period julian loblevyt executive director gavi says results extremely positive applaud true success controlling deadly disease often claimed many lives says though developed countries largely eliminated disease hib vaccine distribution slow poorer parts world due financial logistical problems well limited awareness disease uganda government obtained gavi support use million doses vaccines giving protection hib diphtheria pertussis tetanus hepatitis b according study published bulletin world health organization vaccination programme uganda preventing almost cases severe hib disease child deaths every year introduction hib vaccine completely changed epidemiology bacterial meningitis uganda says adeodata kekitiinwa paediatrician kampala 's mulago hospital coauthored study hib kills children age five every year linked around three million cases illnesses result longterm effects deafness paralysis mental retardation learning disabilities gavi says every child hib meningitis developing country thought five ten others hibrelated pneumonia also preventable vaccination gsk press release march home responsibility access medicines qas corporate responsibility report qas respond questions raised stakeholders arent access programmes drop ocean given scale healthcare crisis developing world global healthcare crisis extensive complex programmes single organisation insufficient political effective investment extra resources required support healthcare development build infrastructure gsk wider pharmaceutical industry mandate expertise resources address problem alone without global partnership address issues efforts individual stakeholder inadequate primary responsibility dealing crisis lies governments call international agencies ngos support gsk committed playing full part partnerships organisations seeking new ways make contribution focus access programmes specific areas think make real difference example research develop medicines vaccines particularly needed developing countries make available lower prices preferential pricing arrangements voluntary licences also working identify ways support strengthening healthcare systems expanding pricing policies flexible intellectual property investing healthcare infrastructure medicines expensive wouldnt responsible thing could cut price medicines improving affordability medicines important taking steps area however kevin de cock head hivaids said work countries obvious quickly elephant room current price drugs real obstacle fragility health systems particularly africa therefore unless action taken address underlying problems poverty healthcare infrastructure reducing prices alone solve problem price products level enables us continue fund rd discover medicines vaccines future also need make enough profit gsk remains attractive prospect investors want make difference cutting prices far would mean undermine long term profitability therefore sustainability business getting balance right isnt easy pricing pilots conducting recent years taught us easy solutions believe new pricing policies announced help improve affordability worlds poorest continue learn refine approach roll policies people hivaids receiving treatment developing world important progress area three million people developing world receiving treatment lifesaving antiretrovirals led decline deaths caused aids despite increase number people living hiv however much core issue many people developing countries access effective healthcare services therefore unable access medicines due poverty many clinics patients unable pay even cheapest basic generic medicines access issue complex multifaceted pricing medicines important believe many significant barriers factors play part inadequate healthcare resources lack clinics hospitals poor distribution networks low numbers trained healthcare providers high levels patient illiteracy significant stigma discrimination lack political inadequate prioritisation health government budgets announced per cent profits make selling medicines least developed countries reinvested projects strengthen infrastructure widen access dont donate aids products worlds poorest common many stakeholders including oxfam believe donations arvs offer solution aids pandemic healthcare problems developing world generally widespread crisis one requires longterm commitment treatment commitment assured donations director general margaret chan said health systems tap root better health donated drugs world wont good without infrastructure delivery limited circumstances donations may appropriate example disease elimination efforts global alliance eliminate lf past donated arvs support unicef prevention mothertochild transmission programmes continue support collaborative clinical trials assess appropriate use arvs resource poor settings doesnt gsk extend notforprofit prices middleincome countries middleincome countries automatically eligible notforprofit prices offered least developed countries ldcs subsaharan africa however access medicines reduced prices middle income countries secure preferential prices bilateral discussions gsk looking ways make process easier focusing preferential prices countries need greatest resources limited widely accepted terms support improving healthcare services ldcs defined un subsaharan africa conducting pricing pilots middleincome countries recent years taught us easy solutions however continue develop policies middleincome countries flexible price therefore closely reflect countrys ability pay dont allow middleincome countries buy arvs generic manufacturers granted eight voluntary licences arvs african generic companies arrangements supply number middleincome countries africa middleincome countries generally economically developed least developed countries often large affluent middleclass countries also large numbers people living extreme poverty healthcare demands often outstrip available resources recognise many middleincome countries need assistance however believe different approach needed one take worlds poorest countries continue refine approach offer supply products notforprofit prices worlds poorest countries sustainable continue make adequate return wealthier markets many middleincome countries also growing commercial markets gsk represent important source future business industry response markets must therefore one balances commercial objectives global commitment work governments stakeholders ensure medicines vaccines reach many possible need believe governments middleincome countries improve access increasing investment disease prevention healthcare eliminating taxation tariffs medicines creating environment allows strong private healthcare sector coexist public healthcare provision working governments find creative ways meet goals dont pharmaceutical companies work together increase access medicines working main industry associations new initiatives increase rd improve access continue seek new opportunities work collaboration stakeholders including companieshome responsibility access medicines qas corporate responsibility report qas respond questions raised stakeholders arent access programmes drop ocean given scale healthcare crisis developing world global healthcare crisis extensive complex programmes single organisation insufficient political effective investment extra resources required support healthcare development build infrastructure gsk wider pharmaceutical industry mandate expertise resources address problem alone without global partnership address issues efforts individual stakeholder inadequate primary responsibility dealing crisis lies governments call international agencies ngos support gsk committed playing full part partnerships organisations seeking new ways make contribution focus access programmes specific areas think make real difference example research develop medicines vaccines particularly needed developing countries make available lower prices preferential pricing arrangements voluntary licences also working identify ways support strengthening healthcare systems expanding pricing policies flexible intellectual property investing healthcare infrastructure medicines expensive wouldnt responsible thing could cut price medicines improving affordability medicines important taking steps area however kevin de cock head hivaids said work countries obvious quickly elephant room current price drugs real obstacle fragility health systems particularly africa therefore unless action taken address underlying problems poverty healthcare infrastructure reducing prices alone solve problem price products level enables us continue fund rd discover medicines vaccines future also need make enough profit gsk remains attractive prospect investors want make difference cutting prices far would mean undermine long term profitability therefore sustainability business getting balance right isnt easy pricing pilots conducting recent years taught us easy solutions believe new pricing policies announced help improve affordability worlds poorest continue learn refine approach roll policies people hivaids receiving treatment developing world important progress area three million people developing world receiving treatment lifesaving antiretrovirals led decline deaths caused aids despite increase number people living hiv however much core issue many people developing countries access effective healthcare services therefore unable access medicines due poverty many clinics patients unable pay even cheapest basic generic medicines access issue complex multifaceted pricing medicines important believe many significant barriers factors play part inadequate healthcare resources lack clinics hospitals poor distribution networks low numbers trained healthcare providers high levels patient illiteracy significant stigma discrimination lack political inadequate prioritisation health government budgets announced per cent profits make selling medicines least developed countries reinvested projects strengthen infrastructure widen access dont donate aids products worlds poorest common many stakeholders including oxfam believe donations arvs offer solution aids pandemic healthcare problems developing world generally widespread crisis one requires longterm commitment treatment commitment assured donations director general margaret chan said health systems tap root better health donated drugs world wont good without infrastructure delivery limited circumstances donations may appropriate example disease elimination efforts global alliance eliminate lf past donated arvs support unicef prevention mothertochild transmission programmes continue support collaborative clinical trials assess appropriate use arvs resource poor settings doesnt gsk extend notforprofit prices middleincome countries middleincome countries automatically eligible notforprofit prices offered least developed countries ldcs subsaharan africa however access medicines reduced prices middle income countries secure preferential prices bilateral discussions gsk looking ways make process easier focusing preferential prices countries need greatest resources limited widely accepted terms support improving healthcare services ldcs defined un subsaharan africa conducting pricing pilots middleincome countries recent years taught us easy solutions however continue develop policies middleincome countries flexible price therefore closely reflect countrys ability pay dont allow middleincome countries buy arvs generic manufacturers granted eight voluntary licences arvs african generic companies arrangements supply number middleincome countries africa middleincome countries generally economically developed least developed countries often large affluent middleclass countries also large numbers people living extreme poverty healthcare demands often outstrip available resources recognise many middleincome countries need assistance however believe different approach needed one take worlds poorest countries continue refine approach offer supply products notforprofit prices worlds poorest countries sustainable continue make adequate return wealthier markets many middleincome countries also growing commercial markets gsk represent important source future business industry response markets must therefore one balances commercial objectives global commitment work governments stakeholders ensure medicines vaccines reach many possible need believe governments middleincome countries improve access increasing investment disease prevention healthcare eliminating taxation tariffs medicines creating environment allows strong private healthcare sector coexist public healthcare provision working governments find creative ways meet goals dont pharmaceutical companies work together increase access medicines working main industry associations new initiatives increase rd improve access continue seek new opportunities work collaboration stakeholders including companies home responsibility access medicines qas corporate responsibility report qas respond questions raised stakeholders arent access programmes drop ocean given scale healthcare crisis developing world global healthcare crisis extensive complex programmes single organisation insufficient political effective investment extra resources required support healthcare development build infrastructure gsk wider pharmaceutical industry mandate expertise resources address problem alone without global partnership address issues efforts individual stakeholder inadequate primary responsibility dealing crisis lies governments call international agencies ngos support gsk committed playing full part partnerships organisations seeking new ways make contribution focus access programmes specific areas think make real difference example research develop medicines vaccines particularly needed developing countries make available lower prices preferential pricing arrangements voluntary licences also working identify ways support strengthening healthcare systems expanding pricing policies flexible intellectual property investing healthcare infrastructure medicines expensive wouldnt responsible thing could cut price medicines improving affordability medicines important taking steps area however kevin de cock head hivaids said work countries obvious quickly elephant room current price drugs real obstacle fragility health systems particularly africa therefore unless action taken address underlying problems poverty healthcare infrastructure reducing prices alone solve problem price products level enables us continue fund rd discover medicines vaccines future also need make enough profit gsk remains attractive prospect investors want make difference cutting prices far would mean undermine long term profitability therefore sustainability business getting balance right isnt easy pricing pilots conducting recent years taught us easy solutions believe new pricing policies announced help improve affordability worlds poorest continue learn refine approach roll policies people hivaids receiving treatment developing world important progress area three million people developing world receiving treatment lifesaving antiretrovirals led decline deaths caused aids despite increase number people living hiv however much core issue many people developing countries access effective healthcare services therefore unable access medicines due poverty many clinics patients unable pay even cheapest basic generic medicines access issue complex multifaceted pricing medicines important believe many significant barriers factors play part inadequate healthcare resources lack clinics hospitals poor distribution networks low numbers trained healthcare providers high levels patient illiteracy significant stigma discrimination lack political inadequate prioritisation health government budgets announced per cent profits make selling medicines least developed countries reinvested projects strengthen infrastructure widen access dont donate aids products worlds poorest common many stakeholders including oxfam believe donations arvs offer solution aids pandemic healthcare problems developing world generally widespread crisis one requires longterm commitment treatment commitment assured donations director general margaret chan said health systems tap root better health donated drugs world wont good without infrastructure delivery limited circumstances donations may appropriate example disease elimination efforts global alliance eliminate lf past donated arvs support unicef prevention mothertochild transmission programmes continue support collaborative clinical trials assess appropriate use arvs resource poor settings doesnt gsk extend notforprofit prices middleincome countries middleincome countries automatically eligible notforprofit prices offered least developed countries ldcs subsaharan africa however access medicines reduced prices middle income countries secure preferential prices bilateral discussions gsk looking ways make process easier focusing preferential prices countries need greatest resources limited widely accepted terms support improving healthcare services ldcs defined un subsaharan africa conducting pricing pilots middleincome countries recent years taught us easy solutions however continue develop policies middleincome countries flexible price therefore closely reflect countrys ability pay dont allow middleincome countries buy arvs generic manufacturers granted eight voluntary licences arvs african generic companies arrangements supply number middleincome countries africa middleincome countries generally economically developed least developed countries often large affluent middleclass countries also large numbers people living extreme poverty healthcare demands often outstrip available resources recognise many middleincome countries need assistance however believe different approach needed one take worlds poorest countries continue refine approach offer supply products notforprofit prices worlds poorest countries sustainable continue make adequate return wealthier markets many middleincome countries also growing commercial markets gsk represent important source future business industry response markets must therefore one balances commercial objectives global commitment work governments stakeholders ensure medicines vaccines reach many possible need believe governments middleincome countries improve access increasing investment disease prevention healthcare eliminating taxation tariffs medicines creating environment allows strong private healthcare sector coexist public healthcare provision working governments find creative ways meet goals dont pharmaceutical companies work together increase access medicines working main industry associations new initiatives increase rd improve access continue seek new opportunities work collaboration stakeholders including companies home responsibility access medicines qas corporate responsibility report qas respond questions raised stakeholders arent access programmes drop ocean given scale healthcare crisis developing world global healthcare crisis extensive complex programmes single organisation insufficient political effective investment extra resources required support healthcare development build infrastructure gsk wider pharmaceutical industry mandate expertise resources address problem alone without global partnership address issues efforts individual stakeholder inadequate primary responsibility dealing crisis lies governments call international agencies ngos support gsk committed playing full part partnerships organisations seeking new ways make contribution focus access programmes specific areas think make real difference example research develop medicines vaccines particularly needed developing countries make available lower prices preferential pricing arrangements voluntary licences also working identify ways support strengthening healthcare systems expanding pricing policies flexible intellectual property investing healthcare infrastructure medicines expensive wouldnt responsible thing could cut price medicines improving affordability medicines important taking steps area however kevin de cock head hivaids said work countries obvious quickly elephant room current price drugs real obstacle fragility health systems particularly africa therefore unless action taken address underlying problems poverty healthcare infrastructure reducing prices alone solve problem price products level enables us continue fund rd discover medicines vaccines future also need make enough profit gsk remains attractive prospect investors want make difference cutting prices far would mean undermine long term profitability therefore sustainability business getting balance right isnt easy pricing pilots conducting recent years taught us easy solutions believe new pricing policies announced help improve affordability worlds poorest continue learn refine approach roll policies people hivaids receiving treatment developing world important progress area three million people developing world receiving treatment lifesaving antiretrovirals led decline deaths caused aids despite increase number people living hiv however much core issue many people developing countries access effective healthcare services therefore unable access medicines due poverty many clinics patients unable pay even cheapest basic generic medicines access issue complex multifaceted pricing medicines important believe many significant barriers factors play part inadequate healthcare resources lack clinics hospitals poor distribution networks low numbers trained healthcare providers high levels patient illiteracy significant stigma discrimination lack political inadequate prioritisation health government budgets announced per cent profits make selling medicines least developed countries reinvested projects strengthen infrastructure widen access dont donate aids products worlds poorest common many stakeholders including oxfam believe donations arvs offer solution aids pandemic healthcare problems developing world generally widespread crisis one requires longterm commitment treatment commitment assured donations director general margaret chan said health systems tap root better health donated drugs world wont good without infrastructure delivery limited circumstances donations may appropriate example disease elimination efforts global alliance eliminate lf past donated arvs support unicef prevention mothertochild transmission programmes continue support collaborative clinical trials assess appropriate use arvs resource poor settings doesnt gsk extend notforprofit prices middleincome countries middleincome countries automatically eligible notforprofit prices offered least developed countries ldcs subsaharan africa however access medicines reduced prices middle income countries secure preferential prices bilateral discussions gsk looking ways make process easier focusing preferential prices countries need greatest resources limited widely accepted terms support improving healthcare services ldcs defined un subsaharan africa conducting pricing pilots middleincome countries recent years taught us easy solutions however continue develop policies middleincome countries flexible price therefore closely reflect countrys ability pay dont allow middleincome countries buy arvs generic manufacturers granted eight voluntary licences arvs african generic companies arrangements supply number middleincome countries africa middleincome countries generally economically developed least developed countries often large affluent middleclass countries also large numbers people living extreme poverty healthcare demands often outstrip available resources recognise many middleincome countries need assistance however believe different approach needed one take worlds poorest countries continue refine approach offer supply products notforprofit prices worlds poorest countries sustainable continue make adequate return wealthier markets many middleincome countries also growing commercial markets gsk represent important source future business industry response markets must therefore one balances commercial objectives global commitment work governments stakeholders ensure medicines vaccines reach many possible need believe governments middleincome countries improve access increasing investment disease prevention healthcare eliminating taxation tariffs medicines creating environment allows strong private healthcare sector coexist public healthcare provision working governments find creative ways meet goals dont pharmaceutical companies work together increase access medicines working main industry associations new initiatives increase rd improve access continue seek new opportunities work collaboration stakeholders including companies home responsibility research practices corporate responsibility report research practices committed focusing patient everything rd pipeline central ability meet patients needs high ethical standards rd key protecting participants clinical research ensuring quality research maximising benefits minimising risks products high ethical standards also essential us obtain regulatory approval new medicines patients doctors put trust research programmes products aim make medicines safe possible evaluating risks benefits every stage initial research clinical trials new product approved sale committed high levels transparency results clinical research use number reporting channels evaluate efficacy safety medicines use medicines make informed decisions use also recognise biomedical research raise ethical concerns including use emerging technologies cloning use stem cells animal research storage use human tissue protection personal information research participants participate discussions research practices regularly engage academic scientists regulators policy makers stakeholders related issues home responsibility research practices corporate responsibility report research practices committed focusing patient everything rd pipeline central ability meet patients needs high ethical standards rd key protecting participants clinical research ensuring quality research maximising benefits minimising risks products high ethical standards also essential us obtain regulatory approval new medicines patients doctors put trust research programmes products aim make medicines safe possible evaluating risks benefits every stage initial research clinical trials new product approved sale committed high levels transparency results clinical research use number reporting channels evaluate efficacy safety medicines use medicines make informed decisions use also recognise biomedical research raise ethical concerns including use emerging technologies cloning use stem cells animal research storage use human tissue protection personal information research participants participate discussions research practices regularly engage academic scientists regulators policy makers stakeholders related issues home responsibility research practices emerging technologies corporate responsibility report emerging technologies research capabilities expanding development technologies related areas research stem cell genetic research advances helping expand boundaries scientific understanding technologies hold hope new ways treat serious diseases well better ways evaluate risks benefits medicines develop example advances genetic research beginning enable identification patients likely experience side effect medicine use emerging technologies research involved collaborative research technologies recognise research using emerging technologies give rise ethical concerns outline involvement approach use cloning technologies use stem cells genetic research collaborative research emerging technologies use transgenic animals home responsibility research practices emerging technologies corporate responsibility report emerging technologies research capabilities expanding development technologies related areas research stem cell genetic research advances helping expand boundaries scientific understanding technologies hold hope new ways treat serious diseases well better ways evaluate risks benefits medicines develop example advances genetic research beginning enable identification patients likely experience side effect medicine use emerging technologies research involved collaborative research technologies recognise research using emerging technologies give rise ethical concerns outline involvement approach use cloning technologies use stem cells genetic research collaborative research emerging technologies use transgenic animals home responsibility research practices emerging technologies cloning technology stem cell research corporate responsibility report cloning technologies stem cell research cloning technologies gsk uses cloning technologies replicate molecules cells research technologies provided better ways evaluate compounds enabling greater insight risks benefits potential medicines helping create better medicines patients technology fundamental component medicine discovery development gsk clone animals use cloning technologies intention reproducing entire human beings see medical research case read position statement cloning technologies stem cell research stem cell research recognise importance clear approach stem cell research standards apply area research updated published approach stem cell research sets standards apply using stem cells including using embryonic foetal stem cells began fiveyear collaboration harvard stem cell institute hsci includes million investment support research harvard university number affiliated hospitals areas neuroscience heart disease cancer diabetes musculoskeletal diseases obesity collaboration overseen joint steering committee made hsci gsk scientists managers also founding member stem cells safer medicine scsm initiative uk scsm aims develop bank human cell lines used early medicine discovery provide early identification elimination potential toxicity issues clinical testing number public sector organisations contributing initiative including department health department innovation universities skills scottish government medical research council biotechnology biological sciences research council independent ethics review board established review scsm ethics policy read collaborating research emerging technologies home responsibility research practices emerging technologies cloning technology stem cell research corporate responsibility report cloning technologies stem cell research cloning technologies gsk uses cloning technologies replicate molecules cells research technologies provided better ways evaluate compounds enabling greater insight risks benefits potential medicines helping create better medicines patients technology fundamental component medicine discovery development gsk clone animals use cloning technologies intention reproducing entire human beings see medical research case read position statement cloning technologies stem cell research stem cell research recognise importance clear approach stem cell research standards apply area research updated published approach stem cell research sets standards apply using stem cells including using embryonic foetal stem cells began fiveyear collaboration harvard stem cell institute hsci includes million investment support research harvard university number affiliated hospitals areas neuroscience heart disease cancer diabetes musculoskeletal diseases obesity collaboration overseen joint steering committee made hsci gsk scientists managers also founding member stem cells safer medicine scsm initiative uk scsm aims develop bank human cell lines used early medicine discovery provide early identification elimination potential toxicity issues clinical testing number public sector organisations contributing initiative including department health department innovation universities skills scottish government medical research council biotechnology biological sciences research council independent ethics review board established review scsm ethics policy read collaborating research emerging technologies home responsibility research practices emerging technologies genetic research corporate responsibility report genetic research genetic variation underpins many aspects human health people get certain diseases others age diseases manifest fast progress last year genes identified common human diseases cumulative history genetics research diseases genetic risk factors identified include diabetes heart disease obesity several cancers asthma number autoimmune disorders gsk researchers led contributed substantially several findings discoveries others come offer promise development innovative new medicines individual differences genes also affect people respond medicines differences genes explain patients experience adverse responses certain medicines others enjoy benefits without effects individuals require greater doses medicines others achieve level efficacy groups individuals respond well treatment others gsk scientists using emerging genetic information study medicines differentiated suit groups patients different genetic characteristics successful genetics research requires close collaboration organisations different areas expertise engaged number research projects involving academic partners regulatory agencies pharmaceutical companies read involvement serious adverse events consortium saec collaboration recognise people concerns applications standards genetic research aim address concerns transparent conduct genetic research genetic analysis gsk clinical trials undertaken seeking obtaining informed consent patient procedure includes providing information purpose scope research access genetic research data believe pharmaceutical industry shares responsibility governments helping identify develop policy genetic research refer guidance national international groups inform genetic research activities european medicines evaluation agency us food drug administration council international organisations medical sciences home responsibility research practices emerging technologies genetic research corporate responsibility report genetic research genetic variation underpins many aspects human health people get certain diseases others age diseases manifest fast progress last year genes identified common human diseases cumulative history genetics research diseases genetic risk factors identified include diabetes heart disease obesity several cancers asthma number autoimmune disorders gsk researchers led contributed substantially several findings discoveries others come offer promise development innovative new medicines individual differences genes also affect people respond medicines differences genes explain patients experience adverse responses certain medicines others enjoy benefits without effects individuals require greater doses medicines others achieve level efficacy groups individuals respond well treatment others gsk scientists using emerging genetic information study medicines differentiated suit groups patients different genetic characteristics successful genetics research requires close collaboration organisations different areas expertise engaged number research projects involving academic partners regulatory agencies pharmaceutical companies read involvement serious adverse events consortium saec collaboration recognise people concerns applications standards genetic research aim address concerns transparent conduct genetic research genetic analysis gsk clinical trials undertaken seeking obtaining informed consent patient procedure includes providing information purpose scope research access genetic research data believe pharmaceutical industry shares responsibility governments helping identify develop policy genetic research refer guidance national international groups inform genetic research activities european medicines evaluation agency us food drug administration council international organisations medical sciences home responsibility research practices emerging technologies collaborative research emerging technologies corporate responsibility report collaborative research emerging technologies new scientific knowledge technologies developed application medicine discovery development collaborative research combines resources expertise knowhow several partners benefit research often realised making results widely available research community example active participant innovative medicines initiative imi publicprivate partnership set european commission pharmaceutical industry european federation pharmaceutical industries associations efpia imi support stimulate collaborative research europe involving pharmaceutical companies smaller bioscience companies academia regulators patient groups aim removing barriers discovery development new medicines read investment rd new technologies partnerships academic collaborations home responsibility research practices emerging technologies collaborative research emerging technologies corporate responsibility report collaborative research emerging technologies new scientific knowledge technologies developed application medicine discovery development collaborative research combines resources expertise knowhow several partners benefit research often realised making results widely available research community example active participant innovative medicines initiative imi publicprivate partnership set european commission pharmaceutical industry european federation pharmaceutical industries associations efpia imi support stimulate collaborative research europe involving pharmaceutical companies smaller bioscience companies academia regulators patient groups aim removing barriers discovery development new medicines read investment rd new technologies partnerships academic collaborations home responsibility research practices animal research corporate responsibility report animal research approach performance plans animal studies remain small vital part researchthey method demonstrate effects potential new medicine living body used humans addition research animals provide vital information causes diseases diseases may develop safety regulations require us test new medicines animals tested clinical trials using humans vaccines tested animals time new batch produced nonmedicinal consumer health products ingredients example dietary supplements tested animals unless specific demand regulatory authority determine study needed support safe use gsk conduct animal testing nutritional healthcare products products classified cosmetics example toothpastes marketed european union animals necessary research committed acting ethically providing animals health wellbeing practising good animal welfare approach gsk animal research laboratories europe asia us animal research conducted external contractors behalf representing around six per cent total animal use estimate animal research accounts around five per cent gsk research expenditure almost animals used gsk rodents mainly rats mice also use rabbits dogs non human primates fish ferrets chickens pigs cats sheep goats together account one per cent listed order magnitude use ultimately gsk would like see important benefits research achieved applied humans without need animals research believe achieved foreseeable future goal use animals scientifically necessary use scientifically feasible minimise pain distress therefore gsk remains committed rs rs key aspect animal welfare covered biomedical community refers three rs rs rs replacing research using animals nonanimal alternatives species lowest possible order phylogenetically reducing number animals used experiments still obtaining information larger study refining techniques minimise pain distress maximise welfare animals scientists always try devise experiments require animals possible researchers work others design experiment obtain necessary information smallest number animals possible least effect individual animals implement rs using advanced scientific methods training raising awareness sharing encouraging best practice example use ultrasound imaging heart disease rats forum discussion global principles animal housing read recent gsk advances replacing reducing refining animal use addition encourage rs culture gsk regular training staff involved care use animals review study designs ethical panel considers rs whether alternatives animal studies possible prior approval studies refining techniques minimise pain distress maximise welfare animals internal rs website champions advances refinement reduction replacement animal use medicine discovery development promotes application across rd news bulletin advances rs updated rolling basis easily accessible rs website internal animal welfare awards employees made outstanding advances implementing rs nonhuman primates policy requires studies involving animals must use lowest possible order phylogenetically animal appropriate research study occasionally nonhuman primates may animals anatomy andor physiology disease similar humans sometimes human nonhuman primates affected respond potential medicine vaccine instance new medicine may based molecule produced primates including humans would destroyed immune systems species therefore use nonhuman primates species lower neurophysiological sensitivity appropriate two common nonhuman primates species used research macaques marmosets animal research carry less per cent involves nonhuman primates transgenic genetically modified animals genetically modified animals also known transgenic animals genetically adapted scientists create new characteristics transgenic animals per cent used biomedical research mice transgenic strains animals developed answer specific compound diseaserelated questions part medicine discovery process example transgenic mice model alzheimers disease fundamental biological research new compound development target validation use transgenic models mice sometimes replace need studies higher order animals gsk worldwide standards recognising differences countryspecific regulations gsk achieves worldwide standards using core principles care laboratory animals principles establish basis animal work conducted onbehalf gsk addition gsk facilities external laboratories conducting research behalf must follow legal regulatory requirements uk regulations responsibility home office europe animal research comes directive eec us covered animal welfare act also continue seek voluntary accreditation recognised agencies association assessment accreditation laboratory animal care international aaalaci communicating approach people hold strong views animal research testing believe important explain need animal research testing transparent many laboratories host visits schools colleges animal welfare organisations others engage regularly animal welfare organisations investors well contributing debate media protest accept right lawful protest animal research part free society condemn use violence intimidation opposed animal use welcome shift away extremism informed debatehome responsibility research practices animal research corporate responsibility report animal research approach performance plans animal studies remain small vital part researchthey method demonstrate effects potential new medicine living body used humans addition research animals provide vital information causes diseases diseases may develop safety regulations require us test new medicines animals tested clinical trials using humans vaccines tested animals time new batch produced nonmedicinal consumer health products ingredients example dietary supplements tested animals unless specific demand regulatory authority determine study needed support safe use gsk conduct animal testing nutritional healthcare products products classified cosmetics example toothpastes marketed european union animals necessary research committed acting ethically providing animals health wellbeing practising good animal welfare approach gsk animal research laboratories europe asia us animal research conducted external contractors behalf representing around six per cent total animal use estimate animal research accounts around five per cent gsk research expenditure almost animals used gsk rodents mainly rats mice also use rabbits dogs non human primates fish ferrets chickens pigs cats sheep goats together account one per cent listed order magnitude use ultimately gsk would like see important benefits research achieved applied humans without need animals research believe achieved foreseeable future goal use animals scientifically necessary use scientifically feasible minimise pain distress therefore gsk remains committed rs rs key aspect animal welfare covered biomedical community refers three rs rs rs replacing research using animals nonanimal alternatives species lowest possible order phylogenetically reducing number animals used experiments still obtaining information larger study refining techniques minimise pain distress maximise welfare animals scientists always try devise experiments require animals possible researchers work others design experiment obtain necessary information smallest number animals possible least effect individual animals implement rs using advanced scientific methods training raising awareness sharing encouraging best practice example use ultrasound imaging heart disease rats forum discussion global principles animal housing read recent gsk advances replacing reducing refining animal use addition encourage rs culture gsk regular training staff involved care use animals review study designs ethical panel considers rs whether alternatives animal studies possible prior approval studies refining techniques minimise pain distress maximise welfare animals internal rs website champions advances refinement reduction replacement animal use medicine discovery development promotes application across rd news bulletin advances rs updated rolling basis easily accessible rs website internal animal welfare awards employees made outstanding advances implementing rs nonhuman primates policy requires studies involving animals must use lowest possible order phylogenetically animal appropriate research study occasionally nonhuman primates may animals anatomy andor physiology disease similar humans sometimes human nonhuman primates affected respond potential medicine vaccine instance new medicine may based molecule produced primates including humans would destroyed immune systems species therefore use nonhuman primates species lower neurophysiological sensitivity appropriate two common nonhuman primates species used research macaques marmosets animal research carry less per cent involves nonhuman primates transgenic genetically modified animals genetically modified animals also known transgenic animals genetically adapted scientists create new characteristics transgenic animals per cent used biomedical research mice transgenic strains animals developed answer specific compound diseaserelated questions part medicine discovery process example transgenic mice model alzheimers disease fundamental biological research new compound development target validation use transgenic models mice sometimes replace need studies higher order animals gsk worldwide standards recognising differences countryspecific regulations gsk achieves worldwide standards using core principles care laboratory animals principles establish basis animal work conducted onbehalf gsk addition gsk facilities external laboratories conducting research behalf must follow legal regulatory requirements uk regulations responsibility home office europe animal research comes directive eec us covered animal welfare act also continue seek voluntary accreditation recognised agencies association assessment accreditation laboratory animal care international aaalaci communicating approach people hold strong views animal research testing believe important explain need animal research testing transparent many laboratories host visits schools colleges animal welfare organisations others engage regularly animal welfare organisations investors well contributing debate media protest accept right lawful protest animal research part free society condemn use violence intimidation opposed animal use welcome shift away extremism informed debate home responsibility research practices animal research corporate responsibility report animal research approach performance plans animal studies remain small vital part researchthey method demonstrate effects potential new medicine living body used humans addition research animals provide vital information causes diseases diseases may develop safety regulations require us test new medicines animals tested clinical trials using humans vaccines tested animals time new batch produced nonmedicinal consumer health products ingredients example dietary supplements tested animals unless specific demand regulatory authority determine study needed support safe use gsk conduct animal testing nutritional healthcare products products classified cosmetics example toothpastes marketed european union animals necessary research committed acting ethically providing animals health wellbeing practising good animal welfare approach gsk animal research laboratories europe asia us animal research conducted external contractors behalf representing around six per cent total animal use estimate animal research accounts around five per cent gsk research expenditure almost animals used gsk rodents mainly rats mice also use rabbits dogs non human primates fish ferrets chickens pigs cats sheep goats together account one per cent listed order magnitude use ultimately gsk would like see important benefits research achieved applied humans without need animals research believe achieved foreseeable future goal use animals scientifically necessary use scientifically feasible minimise pain distress therefore gsk remains committed rs rs key aspect animal welfare covered biomedical community refers three rs rs rs replacing research using animals nonanimal alternatives species lowest possible order phylogenetically reducing number animals used experiments still obtaining information larger study refining techniques minimise pain distress maximise welfare animals scientists always try devise experiments require animals possible researchers work others design experiment obtain necessary information smallest number animals possible least effect individual animals implement rs using advanced scientific methods training raising awareness sharing encouraging best practice example use ultrasound imaging heart disease rats forum discussion global principles animal housing read recent gsk advances replacing reducing refining animal use addition encourage rs culture gsk regular training staff involved care use animals review study designs ethical panel considers rs whether alternatives animal studies possible prior approval studies refining techniques minimise pain distress maximise welfare animals internal rs website champions advances refinement reduction replacement animal use medicine discovery development promotes application across rd news bulletin advances rs updated rolling basis easily accessible rs website internal animal welfare awards employees made outstanding advances implementing rs nonhuman primates policy requires studies involving animals must use lowest possible order phylogenetically animal appropriate research study occasionally nonhuman primates may animals anatomy andor physiology disease similar humans sometimes human nonhuman primates affected respond potential medicine vaccine instance new medicine may based molecule produced primates including humans would destroyed immune systems species therefore use nonhuman primates species lower neurophysiological sensitivity appropriate two common nonhuman primates species used research macaques marmosets animal research carry less per cent involves nonhuman primates transgenic genetically modified animals genetically modified animals also known transgenic animals genetically adapted scientists create new characteristics transgenic animals per cent used biomedical research mice transgenic strains animals developed answer specific compound diseaserelated questions part medicine discovery process example transgenic mice model alzheimers disease fundamental biological research new compound development target validation use transgenic models mice sometimes replace need studies higher order animals gsk worldwide standards recognising differences countryspecific regulations gsk achieves worldwide standards using core principles care laboratory animals principles establish basis animal work conducted onbehalf gsk addition gsk facilities external laboratories conducting research behalf must follow legal regulatory requirements uk regulations responsibility home office europe animal research comes directive eec us covered animal welfare act also continue seek voluntary accreditation recognised agencies association assessment accreditation laboratory animal care international aaalaci communicating approach people hold strong views animal research testing believe important explain need animal research testing transparent many laboratories host visits schools colleges animal welfare organisations others engage regularly animal welfare organisations investors well contributing debate media protest accept right lawful protest animal research part free society condemn use violence intimidation opposed animal use welcome shift away extremism informed debate home responsibility research practices animal research corporate responsibility report animal research approach performance plans animal studies remain small vital part researchthey method demonstrate effects potential new medicine living body used humans addition research animals provide vital information causes diseases diseases may develop safety regulations require us test new medicines animals tested clinical trials using humans vaccines tested animals time new batch produced nonmedicinal consumer health products ingredients example dietary supplements tested animals unless specific demand regulatory authority determine study needed support safe use gsk conduct animal testing nutritional healthcare products products classified cosmetics example toothpastes marketed european union animals necessary research committed acting ethically providing animals health wellbeing practising good animal welfare approach gsk animal research laboratories europe asia us animal research conducted external contractors behalf representing around six per cent total animal use estimate animal research accounts around five per cent gsk research expenditure almost animals used gsk rodents mainly rats mice also use rabbits dogs non human primates fish ferrets chickens pigs cats sheep goats together account one per cent listed order magnitude use ultimately gsk would like see important benefits research achieved applied humans without need animals research believe achieved foreseeable future goal use animals scientifically necessary use scientifically feasible minimise pain distress therefore gsk remains committed rs rs key aspect animal welfare covered biomedical community refers three rs rs rs replacing research using animals nonanimal alternatives species lowest possible order phylogenetically reducing number animals used experiments still obtaining information larger study refining techniques minimise pain distress maximise welfare animals scientists always try devise experiments require animals possible researchers work others design experiment obtain necessary information smallest number animals possible least effect individual animals implement rs using advanced scientific methods training raising awareness sharing encouraging best practice example use ultrasound imaging heart disease rats forum discussion global principles animal housing read recent gsk advances replacing reducing refining animal use addition encourage rs culture gsk regular training staff involved care use animals review study designs ethical panel considers rs whether alternatives animal studies possible prior approval studies refining techniques minimise pain distress maximise welfare animals internal rs website champions advances refinement reduction replacement animal use medicine discovery development promotes application across rd news bulletin advances rs updated rolling basis easily accessible rs website internal animal welfare awards employees made outstanding advances implementing rs nonhuman primates policy requires studies involving animals must use lowest possible order phylogenetically animal appropriate research study occasionally nonhuman primates may animals anatomy andor physiology disease similar humans sometimes human nonhuman primates affected respond potential medicine vaccine instance new medicine may based molecule produced primates including humans would destroyed immune systems species therefore use nonhuman primates species lower neurophysiological sensitivity appropriate two common nonhuman primates species used research macaques marmosets animal research carry less per cent involves nonhuman primates transgenic genetically modified animals genetically modified animals also known transgenic animals genetically adapted scientists create new characteristics transgenic animals per cent used biomedical research mice transgenic strains animals developed answer specific compound diseaserelated questions part medicine discovery process example transgenic mice model alzheimers disease fundamental biological research new compound development target validation use transgenic models mice sometimes replace need studies higher order animals gsk worldwide standards recognising differences countryspecific regulations gsk achieves worldwide standards using core principles care laboratory animals principles establish basis animal work conducted onbehalf gsk addition gsk facilities external laboratories conducting research behalf must follow legal regulatory requirements uk regulations responsibility home office europe animal research comes directive eec us covered animal welfare act also continue seek voluntary accreditation recognised agencies association assessment accreditation laboratory animal care international aaalaci communicating approach people hold strong views animal research testing believe important explain need animal research testing transparent many laboratories host visits schools colleges animal welfare organisations others engage regularly animal welfare organisations investors well contributing debate media protest accept right lawful protest animal research part free society condemn use violence intimidation opposed animal use welcome shift away extremism informed debate home responsibility research practices animal research corporate responsibility report animal research approach performance plans rs great apes family comprises gorillas chimpanzees orangutans bonobos one species ape pan troglodytes also known common chimpanzee used biomedical research three decades great apes used biomedical research took voluntary decision longer carry research great apes read position statements use nonhuman primates great apes research well ban use great apes recent gsk advances replacing reducing refining animal use include implementing polio vaccine test bulk manufacturing stage uses transgenic mice instead nonhuman primates mice genetically altered make susceptible polio virus decreasing number animals needed vaccine testing example included vitro non animal test regulatory submission new vaccine human papillomavirus cervarix means many markets new batches cervarix need tested animals developing transgenic mouse model mimics accelerated form alzheimers disease replace primates primary model disorder fundamental biological research compound development target validation carried using mouse model facilitating greater understanding disorder potential future therapies implementing new technology collect blood samples animal studies approach enables analysis carried much smaller blood samples traditional techniques enables quality data obtained using fewer animals working governments change regulatory requirements fewer animals required routine testing proposal reduce animal testing originating gsks vaccines business submitted european vaccine manufacturers association later presented european directorate quality medicines developing vitro alternatives safety tests check potential impact pharmaceutical process materials workers skin eyes animals used evaluation dermal eye irritation worker safety purposes since donating collection information commonly used blood collection methods uk national centre rs ncrs donation founding part ncrs blood sampling website uk site used many laboratory staff choose appropriate technique humane efficient sampling blood internal animal welfare award recognises work demonstrably beyond high standards care experimental design implementation expected gsk employees involved animal experimentation receive award contribution tangible benefits terms one rs make difference animal experimentation conducted gsk animals routinely cared recent recipients internal animal welfare award team uk implementing bloodspot technology preclinical toxicokinetic tk studies using technology meant researchers needed significantly smaller volumes blood therefore meant fewer animals needed tk studies member neuroscience department developing assessing alternative method administering medicines rats replaces previous method required restraint dosing allows us train rats drink test substance directly syringe team italy developed innovative nicotine selfadministration animal model pharmacological treatments aimed smoking cessation resulted per cent reduction number animals needed per study number animals absolute number animals used laboratories nine per cent lower rd activity tripled period estimate proportion total gsk animal research conducted external contractors lower per cent compared per cent animals used gsk per cent mice rats guinea pigs rodents rabbits others include animals used external contractors behalf animals used external contractors behalf rodents rabbits change rd activity compared change number animals used gsk data include animal research conducted external contractors behalf rd activity combines rd budget vaccine sales two main drivers animal use started separately estimating external animal use recorded external animal use representing total animal use range external interactions may involve gsk directly indirectly animal use diverse reported regulators third parties refer data estimate aaalaci accreditation animal laboratories belgium italy spain uk vast majority us accredited association assessment accreditation laboratory animal care international aaalaci private nonprofit organisation promotes humane treatment animals science voluntary accreditation assessment programmes achieve aaalaci accreditation organisation must go rigorous assessment association reviews facilities workers animal care maintain accreditation annual updates onsite reviews triannual basis required site visits conducted members aaalac council trained professional staff accreditation covers per cent animals housed gskowned laboratories working extend accreditation animal facilities plans gsk committed rs current initiative includes review animal models across business look types studies performed ensure suitable model used appropriate numbers animals involved rd leadership team review outcomes analysis make recommendations initiatives beyondhome responsibility research practices animal research corporate responsibility report animal research approach performance plans rs great apes family comprises gorillas chimpanzees orangutans bonobos one species ape pan troglodytes also known common chimpanzee used biomedical research three decades great apes used biomedical research took voluntary decision longer carry research great apes read position statements use nonhuman primates great apes research well ban use great apes recent gsk advances replacing reducing refining animal use include implementing polio vaccine test bulk manufacturing stage uses transgenic mice instead nonhuman primates mice genetically altered make susceptible polio virus decreasing number animals needed vaccine testing example included vitro non animal test regulatory submission new vaccine human papillomavirus cervarix means many markets new batches cervarix need tested animals developing transgenic mouse model mimics accelerated form alzheimers disease replace primates primary model disorder fundamental biological research compound development target validation carried using mouse model facilitating greater understanding disorder potential future therapies implementing new technology collect blood samples animal studies approach enables analysis carried much smaller blood samples traditional techniques enables quality data obtained using fewer animals working governments change regulatory requirements fewer animals required routine testing proposal reduce animal testing originating gsks vaccines business submitted european vaccine manufacturers association later presented european directorate quality medicines developing vitro alternatives safety tests check potential impact pharmaceutical process materials workers skin eyes animals used evaluation dermal eye irritation worker safety purposes since donating collection information commonly used blood collection methods uk national centre rs ncrs donation founding part ncrs blood sampling website uk site used many laboratory staff choose appropriate technique humane efficient sampling blood internal animal welfare award recognises work demonstrably beyond high standards care experimental design implementation expected gsk employees involved animal experimentation receive award contribution tangible benefits terms one rs make difference animal experimentation conducted gsk animals routinely cared recent recipients internal animal welfare award team uk implementing bloodspot technology preclinical toxicokinetic tk studies using technology meant researchers needed significantly smaller volumes blood therefore meant fewer animals needed tk studies member neuroscience department developing assessing alternative method administering medicines rats replaces previous method required restraint dosing allows us train rats drink test substance directly syringe team italy developed innovative nicotine selfadministration animal model pharmacological treatments aimed smoking cessation resulted per cent reduction number animals needed per study number animals absolute number animals used laboratories nine per cent lower rd activity tripled period estimate proportion total gsk animal research conducted external contractors lower per cent compared per cent animals used gsk per cent mice rats guinea pigs rodents rabbits others include animals used external contractors behalf animals used external contractors behalf rodents rabbits change rd activity compared change number animals used gsk data include animal research conducted external contractors behalf rd activity combines rd budget vaccine sales two main drivers animal use started separately estimating external animal use recorded external animal use representing total animal use range external interactions may involve gsk directly indirectly animal use diverse reported regulators third parties refer data estimate aaalaci accreditation animal laboratories belgium italy spain uk vast majority us accredited association assessment accreditation laboratory animal care international aaalaci private nonprofit organisation promotes humane treatment animals scpiaegnec e voluntary accreditation assessment programmes achieve aaalaci accreditation organisation must go rigorous assessment association reviews facilities workers animal care maintain accreditation annual updates onsite reviews triannual basis required site visits conducted members aaalac council trained professional staff accreditation covers per cent animals housed gskowned laboratories working extend accreditation animal facilities plans gsk committed rs current initiative includes review animal models across business look types studies performed ensure suitable model used appropriate numbers animals involved rd leadership team review outcomes analysis make recommendations initiatives beyondhome responsibility research practices animal research corporate responsibility report animal research approach performance plans rs great apes family comprises gorillas chimpanzees orangutans bonobos one species ape pan troglodytes also known common chimpanzee used biomedical research three decades great apes used biomedical research took voluntary decision longer carry research great apes read position statements use nonhuman primates great apes research well ban use great apes recent gsk advances replacing reducing refining animal use include implementing polio vaccine test bulk manufacturing stage uses transgenic mice instead nonhuman primates mice genetically altered make susceptible polio virus decreasing number animals needed vaccine testing example included vitro non animal test regulatory submission new vaccine human papillomavirus cervarix means many markets new batches cervarix need tested animals developing transgenic mouse model mimics accelerated form alzheimers disease replace primates primary model disorder fundamental biological research compound development target validation carried using mouse model facilitating greater understanding disorder potential future therapies implementing new technology collect blood samples animal studies approach enables analysis carried much smaller blood samples traditional techniques enables quality data obtained using fewer animals working governments change regulatory requirements fewer animals required routine testing proposal reduce animal testing originating gsks vaccines business submitted european vaccine manufacturers association later presented european directorate quality medicines developing vitro alternatives safety tests check potential impact pharmaceutical process materials workers skin eyes animals used evaluation dermal eye irritation worker safety purposes since donating collection information commonly used blood collection methods uk national centre rs ncrs donation founding part ncrs blood sampling website uk site used many laboratory staff choose appropriate technique humane efficient sampling blood internal animal welfare award recognises work demonstrably beyond high standards care experimental design implementation expected gsk employees involved animal experimentation receive award contribution tangible benefits terms one rs make difference animal experimentation conducted gsk animals routinely cared recent recipients internal animal welfare award team uk implementing bloodspot technology preclinical toxicokinetic tk studies using technology meant researchers needed significantly smaller volumes blood therefore meant fewer animals needed tk studies member neuroscience department developing assessing alternative method administering medicines rats replaces previous method required restraint dosing allows us train rats drink test substance directly syringe team italy developed innovative nicotine selfadministration animal model pharmacological treatments aimed smoking cessation resulted per cent reduction number animals needed per study number animals absolute number animals used laboratories nine per cent lower rd activity tripled period estimate proportion total gsk animal research conducted external contractors lower per cent compared per cent animals used gsk per cent mice rats guinea pigs rodents rabbits others include animals used external contractors behalf animals used external contractors behalf rodents rabbits change rd activity compared change number animals used gsk data include animal research conducted external contractors behalf rd activity combines rd budget vaccine sales two main drivers animal use started separately estimating external animal use recorded external animal use representing total animal use range external interactions may involve gsk directly indirectly animal use diverse reported regulators third parties refer data estimate aaalaci accreditation animal laboratories belgium italy spain uk vast majority us accredited association assessment accreditation laboratory animal care international aaalaci private nonprofit organisation promotes humane treatment animals science voluntary accreditation assessment programmes achieve aaalaci accreditation organisation must go rigorous assessment association reviews facilities workers animal care maintain accreditation annual updates onsite reviews triannual basis required site visits conducted members aaalac council trained professional staff accreditation covers per cent animals housed gskowned laboratories working extend accreditation animal facilities plans gsk committed rs current initiative includes review animal models across business look types studies performed ensure suitable model used appropriate numbers animals involved rd leadership team review outcomes analysis make recommendations initiatives beyond home responsibility research practices animal research corporate responsibility report animal research approach performance plans rs great apes family comprises gorillas chimpanzees orangutans bonobos one species ape pan troglodytes also known common chimpanzee used biomedical research three decades great apes used biomedical research took voluntary decision longer carry research great apes read position statements use nonhuman primates great apes research well ban use great apes recent gsk advances replacing reducing refining animal use include implementing polio vaccine test bulk manufacturing stage uses transgenic mice instead nonhuman primates mice genetically altered make susceptible polio virus decreasing number animals needed vaccine testing example included vitro non animal test regulatory submission new vaccine human papillomavirus cervarix means many markets new batches cervarix need tested animals developing transgenic mouse model mimics accelerated form alzheimers disease replace primates primary model disorder fundamental biological research compound development target validation carried using mouse model facilitating greater understanding disorder potential future therapies implementing new technology collect blood samples animal studies approach enables analysis carried much smaller blood samples traditional techniques enables quality data obtained using fewer animals working governments change regulatory requirements fewer animals required routine testing proposal reduce animal testing originating gsks vaccines business submitted european vaccine manufacturers association later presented european directorate quality medicines developing vitro alternatives safety tests check potential impact pharmaceutical process materials workers skin eyes animals used evaluation dermal eye irritation worker safety purposes since donating collection information commonly used blood collection methods uk national centre rs ncrs donation founding part ncrs blood sampling website uk site used many laboratory staff choose appropriate technique humane efficient sampling blood internal animal welfare award recognises work demonstrably beyond high standards care experimental design implementation expected gsk employees involved animal experimentation receive award contribution tangible benefits terms one rs make difference animal experimentation conducted gsk animals routinely cared recent recipients internal animal welfare award team uk implementing bloodspot technology preclinical toxicokinetic tk studies using technology meant researchers needed significantly smaller volumes blood therefore meant fewer animals needed tk studies member neuroscience department developing assessing alternative method administering medicines rats replaces previous method required restraint dosing allows us train rats drink test substance directly syringe team italy developed innovative nicotine selfadministration animal model pharmacological treatments aimed smoking cessation resulted per cent reduction number animals needed per study number animals absolute number animals used laboratories nine per cent lower rd activity tripled period estimate proportion total gsk animal research conducted external contractors lower per cent compared per cent animals used gsk per cent mice rats guinea pigs rodents rabbits others include animals used external contractors behalf animals used external contractors behalf rodents rabbits change rd activity compared change number animals used gsk data include animal research conducted external contractors behalf rd activity combines rd budget vaccine sales two main drivers animal use started separately estimating external animal use recorded external animal use representing total animal use range external interactions may involve gsk directly indirectly animal use diverse reported regulators third parties refer data estimate aaalaci accreditation animal laboratories belgium italy spain uk vast majority us accredited association assessment accreditation laboratory animal care international aaalaci private nonprofit organisation promotes humane treatment animals science voluntary accreditation assessment programmes achieve aaalaci accreditation organisation must go rigorous assessment association reviews facilities workers animal care maintain accreditation annual updates onsite reviews triannual basis required site visits conducted members aaalac council trained professional staff accreditation covers per cent animals housed gskowned laboratories working extend accreditation animal facilities plans gsk committed rs current initiative includes review animal models across business look types studies performed ensure suitable model used appropriate numbers animals involved rd leadership team review outcomes analysis make recommendations initiatives beyond home responsibility research practices human tissue research corporate responsibility report human tissue research research using human tissue human biological samples fundamental discovery development safety monitoring gsk medicines vital research conducted manner respects rights research participants meets legal ethical obligations uk human tissue act makes consent fundamental legal requirement collection use storage human tissue uk introduced following events alder hey hospital bristol royal infirmary human tissue taken used stored without consent introduced policy applies principles uk human tissue act global basis research conducted sponsored supported funded gsk ensure stringent ethical requirements uk law applied wherever research conducted using human biological samples home responsibility research practices human tissue research corporate responsibility report human tissue research research using human tissue human biological samples fundamental discovery development safety monitoring gsk medicines vital research conducted manner respects rights research participants meets legal ethical obligations uk human tissue act makes consent fundamental legal requirement collection use storage human tissue uk introduced following events alder hey hospital bristol royal infirmary human tissue taken used stored without consent introduced policy applies principles uk human tissue act global basis research conducted sponsored supported funded gsk ensure stringent ethical requirements uk law applied wherever research conducted using human biological samples home responsibility research practices medical governance corporate responsibility report medical governance gsk committed highest standards ethical medical practice supports mission improve quality human life enabling people feel better live longer medical governance gsk system principles policies accountabilities ensures apply generally recognised principles good medical science medical integrity ethics standards provides framework embed following principles patient safety fundamental operating principle gsk ahead commercial interests clinical research conducted objective scientific ethical manner protects informs patients promotional practices information provide products ethical accurate balanced medicines used appropriately benefit minimise risks patientss medical governance across gsk encompasses principles policies accountabilities three areas framework medical governance across businesses chief medical officer senior physician gsk responsibility authority establishing effective medical governance system corporate executive team members responsible performance compliance system within areas responsibility medical governance executive committee establishes policy medical governance subject approval corporate executive team also ensures medical governance systems operating effectively regional medical directors together regional presidents countryterritory medical directors ensure policies systems medical governance understood complied countries responsibility read patient safety governance framework home responsibility research practices medical governance corporate responsibility report medical governance gsk committed highest standards ethical medical practice supports mission improve quality human life enabling people feel better live longer medical governance gsk system principles policies accountabilities ensures apply generally recognised principles good medical science medical integrity ethics standards provides framework embed following principles patient safety fundamental operating principle gsk ahead commercial interests clinical research conducted objective scientific ethical manner protects informs patients promotional practices information provide products ethical accurate balanced medicines used appropriately benefit minimise risks patientss medical governance across gsk encompasses principles policies accountabilities three areas framework medical governance across businesses chief medical officer senior physician gsk responsibility authority establishing effective medical governance system corporate executive team members responsible performance compliance system within areas responsibility medical governance executive committee establishes policy medical governance subject approval corporate executive team also ensures medical governance systems operating effectively regional medical directors together regional presidents countryterritory medical directors ensure policies systems medical governance understood complied countries responsibility read patient safety governance framework home responsibility research practices clinical research corporate responsibility report clinical research carry series clinical trials evaluate investigational medicines potential become new medicines effect potential medicine often compared marketed medicines cases inactive substance placebo successful clinical trial programmes usually three four phases safety evaluated throughout clinical trials process rigorous procedures assurance processes ensure clinical trials medicines conducted according good clinical practice gcp guidelines developed international conference harmonisation ich principles contained world medical association declaration helsinki ethical principles medical research involving human subjects gsksponsored clinical trials conducted ethical standards irrespective whether take place developed developing countries safety participate clinical trials paramount importance informed consent procedure ensures volunteers informed aspects trial relevant decision participate gsk employees involved conducting trials receive training regulatory requirements gsk policies trials subject audit internal audit department regulators home responsibility research practices clinical research corporate responsibility report clinical research carry series clinical trials evaluate investigational medicines potential become new medicines effect potential medicine often compared marketed medicines cases inactive substance placebo successful clinical trial programmes usually three four phases safety evaluated throughout clinical trials process rigorous procedures assurance processes ensure clinical trials medicines conducted according good clinical practice gcp guidelines developed international conference harmonisation ich principles contained world medical association declaration helsinki ethical principles medical research involving human subjects gsksponsored clinical trials conducted ethical standards irrespective whether take place developed developing countries safety participate clinical trials paramount importance informed consent procedure ensures volunteers informed aspects trial relevant decision participate gsk employees involved conducting trials receive training regulatory requirements gsk policies trials subject audit internal audit department regulators home responsibility research practices clinical research planning approval corporate responsibility report planning approval protocol developed clinical trial protocols set purpose research explain trial conducted results analysed including details dosage duration treatment number participants required protocol also defines measurements used evaluate safety efficacy medicine appropriate procedures participants wish withdraw study trial protocols reviewed government regulatory agencies relevant countries required protocols reviewed independent ethical review committee lay people medical professionals scientists committee also reviews approves information provided process seeking informed consent ethics committees power reject stop clinical trial home responsibility research practices clinical research planning approval corporate responsibility report planning approval protocol developed clinical trial protocols set purpose research explain trial conducted results analysed including details dosage duration treatment number participants required protocol also defines measurements used evaluate safety efficacy medicine appropriate procedures participants wish withdraw study trial protocols reviewed government regulatory agencies relevant countries required protocols reviewed independent ethical review committee lay people medical professionals scientists committee also reviews approves information provided process seeking informed consent ethics committees power reject stop clinical trial home responsibility research practices clinical research informed consent corporate responsibility report informed consent informed consent means potential clinical trial participant voluntarily confirms willingness participate informed aspects trial relevant decision participate documented means written signed dated informed consent form informed consent clinical trial involves reading signing consent form two essential elements process communicate information answer questions signed documentation informed consent information written communicated nontechnical style lay person understand includes summary clinical trial including purpose treatment procedures schedule potential risks benefits alternatives participation provisions data protection explains participants ' rights including voluntary participation right end participation researchers health professionals know written document alone may ensure someone understands participation means therefore research team discusses person trial 's purpose procedures risks potential benefits participants ' rights person decides participate team continue update new information may affect willingness continue trial even trial person given opportunities ask questions raise concerns thus informed consent ongoing interactive process may special cases obtaining someones informed consent possible emergency research scenarios children age legal consent circumstances consent sought someone allowed provide local laws regulations situations someone read able speak understand local language impartial witness present informed consent process confirm writing information informed consent form accurately explained potential participant able ask questions gave consent voluntarily home responsibility research practices clinical research informed consent corporate responsibility report informed consent informed consent means potential clinical trial participant voluntarily confirms willingness participate informed aspects trial relevant decision participate documented means written signed dated informed consent form informed consent clinical trial involves reading signing consent form two essential elements process communicate information answer questions signed documentation informed consent information written communicated nontechnical style lay person understand includes summary clinical trial including purpose treatment procedures schedule potential risks benefits alternatives participation provisions data protection explains participants ' rights including voluntary participation right end participation researchers health professionals know written document alone may ensure someone understands participation means therefore research team discusses person trial 's purpose procedures risks potential benefits participants ' rights person decides participate team continue update new information may affect willingness continue trial even trial person given opportunities ask questions raise concerns thus informed consent ongoing interactive process may special cases obtaining someones informed consent possible emergency research scenarios children age legal consent circumstances consent sought someone allowed provide local laws regulations situations someone read able speak understand local language impartial witness present informed consent process confirm writing information informed consent form accurately explained potential participant able ask questions gave consent voluntarily home responsibility research practices clinical research posttrial treatment corporate responsibility report posttrial treatment general responsible funding nationally licensed medicines trial responsibility governments providers part national healthcare systems however beginning trials diseases conditions continue completion trial must assured healthcare system able provide take responsibility continued care patients exceptional circumstances nationally licensed medicines may funded gsk trial made available trial participants derived measurable medical benefit continue fund medicine funded normal healthcare infrastructure patient longer derives medical benefit may circumstances compelling medical rationale patients continue receive investigational medicine clinical trial case posttrial treatment may provided clinical trial expanded access programmes enable appropriate oversight reporting adverse events circumstances gsk fund investigational medicine long patient benefits compound approved licensed country read public policy clinical trials developing world home responsibility research practices clinical research posttrial treatment corporate responsibility report posttrial treatment general responsible funding nationally licensed medicines trial responsibility governments providers part national healthcare systems however beginning trials diseases conditions continue completion trial must assured healthcare system able provide take responsibility continued care patients exceptional circumstances nationally licensed medicines may funded gsk trial made available trial participants derived measurable medical benefit continue fund medicine funded normal healthcare infrastructure patient longer derives medical benefit may circumstances compelling medical rationale patients continue receive investigational medicine clinical trial case posttrial treatment may provided clinical trial expanded access programmes enable appropriate oversight reporting adverse events circumstances gsk fund investigational medicine long patient benefits compound approved licensed country read public policy clinical trials developing world home responsibility research practices clinical research clinical trials developing world corporate responsibility report clinical trials developing world gsk clinical trials wherever carried conducted high standard gsk conduct clinical trials countries know outset intent pursue registration make product available use country additional steps may needed ensure trials least developed countries conducted according good clinical practice gcp guidelines example matching objectives informed consent local culture may necessary instance involving local leaders andor family members circumstances capacity may provided help develop certain skill competence general upgrading performance ability facilitate prospective conduct clinical research activity gsk also broader community read posttrial treatment read position statement clinical trials developing world home responsibility research practices clinical research clinical trials developing world corporate responsibility report clinical trials developing world gsk clinical trials wherever carried conducted high standard gsk conduct clinical trials countries know outset intent pursue registration make product available use country additional steps may needed ensure trials least developed countries conducted according good clinical practice gcp guidelines example matching objectives informed consent local culture may necessary instance involving local leaders andor family members circumstances capacity may provided help develop certain skill competence general upgrading performance ability facilitate prospective conduct clinical research activity gsk also broader community read posttrial treatment read position statement clinical trials developing world home responsibility research practices public disclosure clinical research corporate responsibility report public disclosure clinical research approach performance plans pharmaceutical companies legally required disclose relevant data clinical trials appropriate regulatory authorities seeking approval new medicine approval sponsors continuing obligation provide regulatory authorities updated safety information clinical trials read patient safety safety efficacy information provided doctors prescribing information approved regulators public disclosure research fundamental advancing medical science informing prescribers patients scientific findings relating medicines clinical trial register launched designed supplement prescribing information publications scientific literature contains data relating marketed medicines serves resource researchers medical professionals public use alongside locally approved prescribing information improved clinical study register launched replaced previous register also includes protocol summaries enhanced searching capabilities read case study new register helping improve access clinical trials information read position statement disclosure clinical trial information home responsibility research practices public disclosure clinical research corporate responsibility report public disclosure clinical research approach performance plans pharmaceutical companies legally required disclose relevant data clinical trials appropriate regulatory authorities seeking approval new medicine approval sponsors continuing obligation provide regulatory authorities updated safety information clinical trials read patient safety safety efficacy information provided doctors prescribing information approved regulators public disclosure research fundamental advancing medical science informing prescribers patients scientific findings relating medicines clinical trial register launched designed supplement prescribing information publications scientific literature contains data relating marketed medicines serves resource researchers medical professionals public use alongside locally approved prescribing information improved clinical study register launched replaced previous register also includes protocol summaries enhanced searching capabilities read case study new register helping improve access clinical trials information read position statement disclosure clinical trial information home responsibility research practices public disclosure clinical research corporate responsibility report public disclosure clinical research approach performance plans end protocol summaries gsk actively recruiting clinical trials clinicaltrialsgov total registry clinical trials conducted around world provides information trial 's purpose may participate locations contact details information end clinical trial summaries clinical study register includes clinical trials major marketed products completed since formation gsk completed likely inform medical judgement objective disclose trial results summaries new products register within months product reaching market aim disclose results trials completed product approved marketing within one year trial completion met objective update august internal audit subsequently shown results small number trials posted register within months product reaching market following audit results studies posted register july improving procedures collecting posting trial results expect meet objective new clinical study register replaced previous register also provides protocol summaries enhanced search capabilities users number summaries gsk clinical trials gsk clinical study register cumulative total important steps build gsks commitment transparency clinical research taken committed january posting information types gsks clinical research evaluates medicines gsk clinical study register adding gsks observational research metaanalyses studies terminated compounds current commitment posting information related clinical trials phase llv marketed medicines addition adding names investigators participate clinical research ensuring clinical research either published manuscripts peer reviewed journals studies published providing context interpretation via gsk clinical study register supplement result summary posted ensure studies made publicly available irrespective whether results perceived positive negative medicines progress meeting commitment monitored external audiences gsk clinical study register include protocols plans research studies initiated summaries results references publications following completionhome responsibility research practices public disclosure clinical research corporate responsibility report public disclosure clinical research approach performance plans end protocol summaries gsk actively recruiting clinical trials clinicaltrialsgov total registry clinical trials conducted around world provides information trial 's purpose may participate locations contact details information end clinical trial summaries clinical study register includes clinical trials major marketed products completed since formation gsk completed likely inform medical judgement objective disclose trial results summaries new products register within months product reaching market aim disclose results trials completed product approved marketing within one year trial completion met objective update august internal audit subsequently shown results small number trials posted register within months product reaching market following audit results studies posted register july improving procedures collecting posting trial results expect meet objective new clinical study register replaced previous register also provides protocol summaries enhanced search capabilities users number summaries gsk clinical trials gsk clinical study register cumulative total important steps build gsks commitment transparency clinical research taken committed january posting information types gsks clinical research evaluates medicines gsk clinical study register adding gsks observational research metaanalyses studies terminated compounds current commitment posting information related clinical trials phase llv marketed medicines addition adding names investigators participate clinical research ensuring clinical research either published manuscripts peer reviewed journals studies published providing context interpretation via gsk clinical study register supplement result summary posted ensure studies made publicly available irrespective whether results perceived positive negative medicines progress meeting commitment monitored external audiences gsk clinical study register include protocols plans research studies initiated summaries results references publications following completion home responsibility research practices public disclosure clinical research corporate responsibility report public disclosure clinical research approach performance plans end protocol summaries gsk actively recruiting clinical trials clinicaltrialsgov total registry clinical trials conducted around world provides information trial 's purpose may participate locations contact details information end clinical trial summaries clinical study register includes clinical trials major marketed products completed since formation gsk completed likely inform medical judgement objective disclose trial results summaries new products register within months product reaching market aim disclose results trials completed product approved marketing within one year trial completion met objective update august internal audit subsequently shown results small number trials posted register within months product reaching market following audit results studies posted register july improving procedures collecting posting trial results expect meet objective new clinical study register replaced previous register also provides protocol summaries enhanced search capabilities users number summaries gsk clinical trials gsk clinical study register cumulative total important steps build gsks commitment transparency clinical research taken committed january posting information types gsks clinical research evaluates medicines gsk clinical study register adding gsks observational research metaanalyses studies terminated compounds current commitment posting information related clinical trials phase llv marketed medicines addition adding names investigators participate clinical research ensuring clinical research either published manuscripts peer reviewed journals studies published providing context interpretation via gsk clinical study register supplement result summary posted ensure studies made publicly available irrespective whether results perceived positive negative medicines progress meeting commitment monitored external audiences gsk clinical study register include protocols plans research studies initiated summaries results references publications following completion home responsibility research practices patient safety corporate responsibility report patient safety ensuring safety medicines medical devices critically important health wellbeing patients success business medicines potential risks well benefits although everyone takes medicine experience side effects important identify evaluate minimise safety concerns ensure overall benefits medicine outweigh risks strive serve patient interest promptly detecting potential safety issues products communicating regulators appropriate decisions made actions taken product safety assessed clinical trials product approved marketing sometimes adverse events potential safety issues occur approval product used large numbers patients policies governance framework place help us detect act adverse events dedicated team scientists healthcare professionals across world monitors communicates safety issues regulatory authorities also investing genetic research help predict individual patients respond medicine future help healthcare providers prescribe safer effective medicines read patient safety governance framework collect report safety data home responsibility research practices patient safety corporate responsibility report patient safety ensuring safety medicines medical devices critically important health wellbeing patients success business medicines potential risks well benefits although everyone takes medicine experience side effects important identify evaluate minimise safety concerns ensure overall benefits medicine outweigh risks strive serve patient interest promptly detecting potential safety issues products communicating regulators appropriate decisions made actions taken product safety assessed clinical trials product approved marketing sometimes adverse events potential safety issues occur approval product used large numbers patients policies governance framework place help us detect act adverse events dedicated team scientists healthcare professionals across world monitors communicates safety issues regulatory authorities also investing genetic research help predict individual patients respond medicine future help healthcare providers prescribe safer effective medicines read patient safety governance framework collect report safety data home responsibility research practices patient safety patient safety governance framework corporate responsibility report patient safety governance framework global safety board gsb makes decisions product safety issues board led chief medical officer composed senior physicians scientists role oversee safety investigational marketed medicines approve first administration investigational medicines humans define doses duration treatments considered safe approve progression investigational medicines pivotal trials trials provide primary data regulatory approval based assess issues related patient safety arise product development marketing three central departments responsible recording investigating evaluating adverse events reporting relevant regulatory authorities example us food drug administration fda european medicines evaluation agency emea global clinical safety pharmacovigilance team gcsp part gsk research development responsible safety evaluation pharmaceuticals devices gsk biologicals clinical safety pharmacovigilance department part vaccines business responsible safety evaluation gsk vaccines consumer healthcare product safety group part consumer healthcare business responsible safety evaluation consumer healthcare products require gsk staff immediately report issues relating safety quality medicines read expectations employee guide business conduct read medical governance benefitrisk management assess balance benefits risks particular medicine throughout lifecycle early development clinical trials product market evaluate document available safety information build detailed benefitrisk profile product use information develop benefitrisk management plan identifies ways improve products benefits minimise risks review update plans regularly clinical development period product approved marketing back top home responsibility research practices patient safety patient safety governance framework corporate responsibility report patient safety governance framework global safety board gsb makes decisions product safety issues board led chief medical officer composed senior physicians scientists role oversee safety investigational marketed medicines approve first administration investigational medicines humans define doses duration treatments considered safe approve progression investigational medicines pivotal trials trials provide primary data regulatory approval based assess issues related patient safety arise product development marketing three central departments responsible recording investigating evaluating adverse events reporting relevant regulatory authorities example us food drug administration fda european medicines evaluation agency emea global clinical safety pharmacovigilance team gcsp part gsk research development responsible safety evaluation pharmaceuticals devices gsk biologicals clinical safety pharmacovigilance department part vaccines business responsible safety evaluation gsk vaccines consumer healthcare product safety group part consumer healthcare business responsible safety evaluation consumer healthcare products require gsk staff immediately report issues relating safety quality medicines read expectations employee guide business conduct read medical governance benefitrisk management assess balance benefits risks particular medicine throughout lifecycle early development clinical trials product market evaluate document available safety information build detailed benefitrisk profile product use information develop benefitrisk management plan identifies ways improve products benefits minimise risks review update plans regularly clinical development period product approved marketing back top home responsibility research practices patient safety collecting reporting safety data corporate responsibility report collecting reporting safety data receive information adverse events several sources including unsolicited reports health professionals patients postmarketing trials observational studies investigators submit clinical study reports regulatory authorities medical scientific literature newspapers media gsk employee responsible reporting adverse event become aware adverse events occur recorded global safety database clinical trial database investigated clinical pharmacovigilance teams report potential safety issues regulatory authorities regular basis country manager responsible ensuring collection safety information reporting relevant central safety department local regulatory authority part management certification process managers acknowledged compliance policy adverse event reporting specifies gsk employee responsible reporting adverse event become aware conduct work added adverse event reporting button front mygsk intranet site make easier employees report adverse event may learn regulators countries also publishing information adverse events internet example data products marketed uk available via medicines healthcare products regulatory agency safety data also available canada us food drug administration made information database accessible public publishing quarterly report potential safety issues investigating research diabetes product avandia continued new fda required cardiovascular outcome study designed initiated also combined fda advisory committee review respiratory products containing longacting beta agonists read questions raised avandia read questions safety products containing longacting beta agonists read medical governance read position statement pharmacovigilance responding adverse events adverse events affect benefitrisk profile product corrective actions may needed minimise risk include carrying clinical trials modifying prescribing information communications physicians healthcare providers establishing specific methods minimise risk products subject limited distribution programmes prescription specialist doctors certain cases may appropriate stop clinical trial withdraw product market global labelling committees review approve prescribing information products ensure updated appropriate home responsibility research practices patient safety collecting reporting safety data corporate responsibility report collecting reporting safety data receive information adverse events several sources including unsolicited reports health professionals patients postmarketing trials observational studies investigators submit clinical study reports regulatory authorities medical scientific literature newspapers media gsk employee responsible reporting adverse event become aware adverse events occur recorded global safety database clinical trial database investigated clinical pharmacovigilance teams report potential safety issues regulatory authorities regular basis country manager responsible ensuring collection safety information reporting relevant central safety department local regulatory authority part management certification process managers acknowledged compliance policy adverse event reporting specifies gsk employee responsible reporting adverse event become aware conduct work added adverse event reporting button front mygsk intranet site make easier employees report adverse event may learn regulators countries also publishing information adverse events internet example data products marketed uk available via medicines healthcare products regulatory agency safety data also available canada us food drug administration made information database accessible public publishing quarterly report potential safety issues investigating research diabetes product avandia continued new fda required cardiovascular outcome study designed initiated also combined fda advisory committee review respiratory products containing longacting beta agonists read questions raised avandia read questions safety products containing longacting beta agonists read medical governance read position statement pharmacovigilance responding adverse events adverse events affect benefitrisk profile product corrective actions may needed minimise risk include carrying clinical trials modifying prescribing information communications physicians healthcare providers establishing specific methods minimise risk products subject limited distribution programmes prescription specialist doctors certain cases may appropriate stop clinical trial withdraw product market global labelling committees review approve prescribing information products ensure updated appropriate home responsibility research practices patient safety collecting reporting safety data corporate responsibility report collecting reporting safety data receive information adverse events several sources including unsolicited reports health professionals patients postmarketing trials observational studies investigators submit clinical study reports regulatory authorities medical scientific literature newspapers media gsk employee responsible reporting adverse event become aware adverse events occur recorded global safety database clinical trial database investigated clinical pharmacovigilance teams report potential safety issues regulatory authorities regular basis country manager responsible ensuring collection safety information reporting relevant central safety department local regulatory authority part management certification process managers acknowledged compliance policy adverse event reporting specifies gsk employee responsible reporting adverse event become aware conduct work added adverse event reporting button front mygsk intranet site make easier employees report adverse event may learn regulators countries also publishing information adverse events internet example data products marketed uk available via medicines healthcare products regulatory agency safety data also available canada us food drug administration made information database accessible public publishing quarterly report potential safety issues investigating research diabetes product avandia continued new fda required cardiovascular outcome study designed initiated also combined fda advisory committee review respiratory products containing longacting beta agonists read questions raised avandia read questions safety products containing longacting beta agonists read medical governance read position statement pharmacovigilance responding adverse events adverse events affect benefitrisk profile product corrective actions may needed minimise risk include carrying clinical trials modifying prescribing information communications physicians healthcare providers establishing specific methods minimise risk products subject limited distribution programmes prescription specialist doctors certain cases may appropriate stop clinical trial withdraw product market global labelling committees review approve prescribing information products ensure updated appropriate home responsibility research practices patient safety collecting reporting safety data responding questions avandia corporate responsibility report responding questions avandia avandia leading treatment type diabetes metaanalysis published new england journal medicine gsks metaanalysis submitted fda regulators centre debate whether avandia may associated increased risk myocardial infarction death cardiovascular causes following fda advisory committee meeting fda approved updated prescribing information avandia including new text existing boxed warning november updated prescribing information summarised data fda metaanalysis myocardial ischemic events suggested risk associated avandia three longterm clinical trials comparing avandia placebo oral antidiabetes medicines confirm exclude risk revised prescribing information included entirety available data risk myocardial ischemia inconclusive research involving avandia continued including cardiovascular outcome study called record results available addition gsk worked design fdarequired cardiovascular outcome study avandia called tide study begin update august results cardiovascular outcome study record published june record large prospective randomized controlled study initiated designed compare cardiovascular outcomes patients avandia added metformin sulfonylurea metformin sulfonylurea study showed combined endpoint cardiovascular hospitalization cardiovascular death includes heart attack congestive heart failure stroke statistically different two groups average years therapy tide study started planned medicines avandia included carry risks well benefits type diabetes chronic relentlessly progressive lifethreatening disease physicians often need prescribe two three medicines help patients maintain blood sugar levels array treatment options important gsk believes important avandia available support effective treatment type diabetes nissen k wolski effect rosiglitazone risk myocardial infarction death cardiovascular causes n engl j med cobitz et al retrospective evaluation congestive heart failure myocardial ischemia events patients type diabetes mellitus enrolled shortterm doubleblind randomized clinical studies rosiglitazone pharmacoepidemiology drug safety p home et al rosiglitazone evaluated cardiovascular outcomes interim analysis n engl j med ii kahn et al glycemic durability rosiglitazone metformin glyburide monotherapy n engl j med iii dream diabetes reduction assessment ramipril rosiglitazone medication trial investigators effect rosiglitazone frequency diabetes patients impaired glucose tolerance impaired fasting glucose randomised controlled trial lancet p home et al rosiglitazone evaluated cardiovascular outcomes oral agent combination therapy type diabetes record multicentre randomised openlabel trial lancet back top home responsibility research practices patient safety collecting reporting safety data responding questions avandia corporate responsibility report responding questions avandia avandia leading treatment type diabetes metaanalysis published new england journal medicine gsks metaanalysis submitted fda regulators centre debate whether avandia may associated increased risk myocardial infarction death cardiovascular causes following fda advisory committee meeting fda approved updated prescribing information avandia including new text existing boxed warning november updated prescribing information summarised data fda metaanalysis myocardial ischemic events suggested risk associated avandia three longterm clinical trials comparing avandia placebo oral antidiabetes medicines confirm exclude risk revised prescribing information included entirety available data risk myocardial ischemia inconclusive research involving avandia continued including cardiovascular outcome study called record results available addition gsk worked design fdarequired cardiovascular outcome study avandia called tide study begin update august results cardiovascular outcome study record published june record large prospective randomized controlled study initiated designed compare cardiovascular outcomes patients avandia added metformin sulfonylurea metformin sulfonylurea study showed combined endpoint cardiovascular hospitalization cardiovascular death includes heart attack congestive heart failure stroke statistically different two groups average years therapy tide study started planned medicines avandia included carry risks well benefits type diabetes chronic relentlessly progressive lifethreatening disease physicians often need prescribe two three medicines help patients maintain blood sugar levels array treatment options important gsk believes important avandia available support effective treatment type diabetes nissen k wolski effect rosiglitazone risk myocardial infarction death cardiovascular causes n engl j med cobitz et al retrospective evaluation congestive heart failure myocardial ischemia events patients type diabetes mellitus enrolled shortterm doubleblind randomized clinical studies rosiglitazone pharmacoepidemiology drug safety p home et al rosiglitazone evaluated cardiovascular outcomes interim analysis n engl j med ii kahn et al glycemic durability rosiglitazone metformin glyburide monotherapy n engl j med iii dream diabetes reduction assessment ramipril rosiglitazone medication trial investigators effect rosiglitazone frequency diabetes patients impaired glucose tolerance impaired fasting glucose randomised controlled trial lancet p home et al rosiglitazone evaluated cardiovascular outcomes oral agent combination therapy type diabetes record multicentre randomised openlabel trial lancet back top home responsibility research practices patient safety collecting reporting safety data responding questions avandia corporate responsibility report responding questions avandia avandia leading treatment type diabetes metaanalysis published new england journal medicine gsks metaanalysis submitted fda regulators centre debate whether avandia may associated increased risk myocardial infarction death cardiovascular causes following fda advisory committee meeting fda approved updated prescribing information avandia including new text existing boxed warning november updated prescribing information summarised data fda metaanalysis myocardial ischemic events suggested risk associated avandia three longterm clinical trials comparing avandia placebo oral antidiabetes medicines confirm exclude risk revised prescribing information included entirety available data risk myocardial ischemia inconclusive research involving avandia continued including cardiovascular outcome study called record results available addition gsk worked design fdarequired cardiovascular outcome study avandia called tide study begin update august results cardiovascular outcome study record published june record large prospective randomized controlled study initiated designed compare cardiovascular outcomes patients avandia added metformin sulfonylurea metformin sulfonylurea study showed combined endpoint cardiovascular hospitalization cardiovascular death includes heart attack congestive heart failure stroke statistically different two groups average years therapy tide study started planned medicines avandia included carry risks well benefits type diabetes chronic relentlessly progressive lifethreatening disease physicians often need prescribe two three medicines help patients maintain blood sugar levels array treatment options important gsk believes important avandia available support effective treatment type diabetes nissen k wolski effect rosiglitazone risk myocardial infarction death cardiovascular causes n engl j med cobitz et al retrospective evaluation congestive heart failure myocardial ischemia events patients type diabetes mellitus enrolled shortterm doubleblind randomized clinical studies rosiglitazone pharmacoepidemiology drug safety p home et al rosiglitazone evaluated cardiovascular outcomes interim analysis n engl j med ii kahn et al glycemic durability rosiglitazone metformin glyburide monotherapy n engl j med iii dream diabetes reduction assessment ramipril rosiglitazone medication trial investigators effect rosiglitazone frequency diabetes patients impaired glucose tolerance impaired fasting glucose randomised controlled trial lancet p home et al rosiglitazone evaluated cardiovascular outcomes oral agent combination therapy type diabetes record multicentre randomised openlabel trial lancet back top home responsibility research practices patient safety collecting reporting safety data questions safety products containing long acting beta agonists corporate responsibility report questions safety products containing longacting beta agonists longacting beta agonists known labas daily controller medicines relieve help prevent airway constriction airway constriction one two main components asthma labas treat main component asthma inflammation treated another type daily controller medicine called inhaled corticosteroid ics labas including gsks product serevent used alone treatment persistent asthma leading treatment guidelines recommend labas used appropriate patients asthma combination ics gsk makes two products containing laba salmeterol seretideadvair combination salmeterol ics fluticasone serevent contains salmeterol alone december combined advisory committee us food drug administration reviewed benefitrisk profile medicines containing labas children adults asthma review included labacontaining products indicated use treating asthma gsks products addressed lingering concerns labas may increase risk asthmarelated death current product labels prominently warn advisory committee makes recommendations fda makes final decision actions required seretideadvair committee unanimously voted benefits seretideadvair outweigh risks patients years older committee also voted favour positive benefitrisk profile younger patients although individual votes mixed serevent committee found benefits outweigh risks treatment asthma concerns expressed potential serevent used alone treatment asthma contrary current prescribing information way would make benefitrisk profile unfavourable contrast seretideadvair combination therapy laba ics combination use assured although gsk acknowledges concerns use serevent without ics best interests asthma patients favour option allowing dual therapy using separate inhalers use separate inhalers important treatment option asthma patients need alternative ics fluticasone ics contained seretideadvair flexibility ics doses beyond available combination product also important asthma patients receive favourable reimbursement separate inhalers gsk believes appropriate labelling proactive communication risks using laba alone potential misuse serevent monotherapy acceptably reduced dual therapy using separate inhalers remains available asthma patients need september advisory committee meeting gsk submitted proposed label change fda serevent clarify use asthma patients must combination ics line prescribing information countries serevent marketed awaiting outcome fdas consideration gsks proposed label change advisory committees review actively cooperate agency reaching appropriate resolution best interests asthma patients home responsibility research practices patient safety collecting reporting safety data questions safety products containing long acting beta agonists corporate responsibility report questions safety products containing longacting beta agonists longacting beta agonists known labas daily controller medicines relieve help prevent airway constriction airway constriction one two main components asthma labas treat main component asthma inflammation treated another type daily controller medicine called inhaled corticosteroid ics labas including gsks product serevent used alone treatment persistent asthma leading treatment guidelines recommend labas used appropriate patients asthma combination ics gsk makes two products containing laba salmeterol seretideadvair combination salmeterol ics fluticasone serevent contains salmeterol alone december combined advisory committee us food drug administration reviewed benefitrisk profile medicines containing labas children adults asthma review included labacontaining products indicated use treating asthma gsks products addressed lingering concerns labas may increase risk asthmarelated death current product labels prominently warn advisory committee makes recommendations fda makes final decision actions required seretideadvair committee unanimously voted benefits seretideadvair outweigh risks patients years older committee also voted favour positive benefitrisk profile younger patients although individual votes mixed serevent committee found benefits outweigh risks treatment asthma concerns expressed potential serevent used alone treatment asthma contrary current prescribing information way would make benefitrisk profile unfavourable contrast seretideadvair combination therapy laba ics combination use assured although gsk acknowledges concerns use serevent without ics best interests asthma patients favour option allowing dual therapy using separate inhalers use separate inhalers important treatment option asthma patients need alternative ics fluticasone ics contained seretideadvair flexibility ics doses beyond available combination product also important asthma patients receive favourable reimbursement separate inhalers gsk believes appropriate labelling proactive communication risks using laba alone potential misuse serevent monotherapy acceptably reduced dual therapy using separate inhalers remains available asthma patients need september advisory committee meeting gsk submitted proposed label change fda serevent clarify use asthma patients must combination ics line prescribing information countries serevent marketed awaiting outcome fdas consideration gsks proposed label change advisory committees review actively cooperate agency reaching appropriate resolution best interests asthma patients home responsibility research practices patient safety performance corporate responsibility report performance continued improve patient safety systems safety databases monitoring processes examples include established two clinical toxicities strategy panels comprising internal external experts provide expert safety input throughout medicine development process expert panels four areas cardiovascular hepatic renal haematological implemented clinical trials signal detection ctsd tool review completed study data partnership lincoln technologies enhanced ability identify explore safety signals clinical trials system bio award launched prototype molecular clinical safety programme mcsp mcsp tool seeks better inform decisionmaking medicine development integrating chemistry preclinical human safety data enabling us look patterns across different types safety information october gsk team wall street journal technology innovation award healthcare developing system entry selected independent panel judges reviewed applications awards working others work government officials industry partners policy makers efforts build enhanced safety system example gsk industry lead benefitrisk project consortium european commissions publicprivate partnership innovative medicines initiative aims develop methodologies enhance assessment benefitrisk profile new medicines gsk key partner among us food drug administration pharmaceutical companies academia us explore development new system detection adverse events benefits medicines using large healthcare system databases read collaborative research emerging technologies serious adverse events consortium cofounded serious adverse events consortium saec collaboration involving partners saec working improve patient safety identifying genetic variants predict adverse events druginduced liver injury rare serious severe skin rash called stevens johnson syndrome gsk scientists cochair saec scientific management committee seat board directors home responsibility research practices patient safety performance corporate responsibility report performance continued improve patient safety systems safety databases monitoring processes examples include established two clinical toxicities strategy panels comprising internal external experts provide expert safety input throughout medicine development process expert panels four areas cardiovascular hepatic renal haematological implemented clinical trials signal detection ctsd tool review completed study data partnership lincoln technologies enhanced ability identify explore safety signals clinical trials system bio award launched prototype molecular clinical safety programme mcsp mcsp tool seeks better inform decisionmaking medicine development integrating chemistry preclinical human safety data enabling us look patterns across different types safety information october gsk team wall street journal technology innovation award healthcare developing system entry selected independent panel judges reviewed applications awards working others work government officials industry partners policy makers efforts build enhanced safety system example gsk industry lead benefitrisk project consortium european commissions publicprivate partnership innovative medicines initiative aims develop methodologies enhance assessment benefitrisk profile new medicines gsk key partner among us food drug administration pharmaceutical companies academia us explore development new system detection adverse events benefits medicines using large healthcare system databases read collaborative research emerging technologies serious adverse events consortium cofounded serious adverse events consortium saec collaboration involving partners saec working improve patient safety identifying genetic variants predict adverse events druginduced liver injury rare serious severe skin rash called stevens johnson syndrome gsk scientists cochair saec scientific management committee seat board directors home responsibility research practices maintaining confidentiality research participants corporate responsibility report maintaining confidentiality research participants vital medical information collected research protected maintain confidentiality participants rigorous procedures control use research data research activities conducted according fundamental ethical legal principles including consent ethics committee approval use variety procedures protect confidentiality research participants data including data coding data encryption restricted access research databases third parties handling research data behalf required comply relevant data protection legislation standards collect information individuals relevant research study includes medical information health status medical conditions including occasions genetic data treatment conditions ethnic origin means vast majority instances collect store information directly identify individuals initials names addresses personal id numbers information identify individuals used specific instances required law regulations safety monitoring pharmacovigilance retain medical research data using minimum amount identifying information duration reasonably necessary meet regulatory legal research needs home responsibility research practices maintaining confidentiality research participants corporate responsibility report maintaining confidentiality research participants vital medical information collected research protected maintain confidentiality participants rigorous procedures control use research data research activities conducted according fundamental ethical legal principles including consent ethics committee approval use variety procedures protect confidentiality research participants data including data coding data encryption restricted access research databases third parties handling research data behalf required comply relevant data protection legislation standards collect information individuals relevant research study includes medical information health status medical conditions including occasions genetic data treatment conditions ethnic origin means vast majority instances collect store information directly identify individuals initials names addresses personal id numbers information identify individuals used specific instances required law regulations safety monitoring pharmacovigilance retain medical research data using minimum amount identifying information duration reasonably necessary meet regulatory legal research needs home responsibility research practices working healthcare professionals corporate responsibility report working healthcare professionals policies governing interactions gsk rd staff healthcare practitioners require clinical trial investigators must selected solely qualifications conduct good quality clinical n research history using using gsk products must taken account deciding whether include exclude particular trial payments practitioners governed contracts compensation reflects fair market value n work performed payments offered made influence judgement whether enrol maintain participant n clinical study gifts healthcare professionals involved research projects gsk permitted n phrma code interactions healthcare professionals also prohibits noneducational gifts healthcare professionals involved research gsk policies prohibited gifts healthcare professionals involved research since also committing disclose research payments made healthcare professionals institutions start payments us healthcare professionals institutions conduct clinical trials starting thereafter extended payments types research healthcare professionals institutions outside us read policies monitoring systems govern relationships healthcare professionals home responsibility research practices working healthcare professionals corporate responsibility report working healthcare professionals policies governing interactions gsk rd staff healthcare practitioners require clinical trial investigators must selected solely qualifications conduct good quality clinical n research history using using gsk products must taken account deciding whether include exclude particular trial payments practitioners governed contracts compensation reflects fair market value n work performed payments offered made influence judgement whether enrol maintain participant n clinical study gifts healthcare professionals involved research projects gsk permitted n phrma code interactions healthcare professionals also prohibits noneducational gifts healthcare professionals involved research gsk policies prohibited gifts healthcare professionals involved research since also committing disclose research payments made healthcare professionals institutions start payments us healthcare professionals institutions conduct clinical trials starting thereafter extended payments types research healthcare professionals institutions outside us read policies monitoring systems govern relationships healthcare professionals home responsibility research practices training auditing corporate responsibility report training auditing approach performance training clinical trials employees involved designing conducting recording reporting gsksponsored clinical research studies trained good clinical practice gcp guidelines developed international conference harmonisation ich employees must completed required training undertaking roles keep detailed training records routinely requested regulatory authorities undertaking inspection gsk clinical research trials auditing clinical trials gsks internal audit department audits conduct clinical trials audits cover gsk systems processes well external clinical research organisations investigators performing clinical research behalf trials selected audit based risk risk factors include complexity study patient population location study previous audit history unusual findings conduct study results reported quarterly rd compliance board annually risk oversight compliance council audit committee gsks board directors read corporate governance section annual report members global safety board gsb receive individual audit reports safetyrelated findings concerns issues identified fully investigated appropriate corrective action taken gsk staff corrective actions may include development new training programmes retraining individuals concerned severe cases appropriate disciplinary action taken including dismissal external investigators gsk may retrain investigator stop working investigator trial data noncompliant investigative sites excluded analysis regulatory authorities also carry inspections gsk investigators use conduct clinical trials home responsibility research practices training auditing corporate responsibility report training auditing approach performance training clinical trials employees involved designing conducting recording reporting gsksponsored clinical research studies trained good clinical practice gcp guidelines developed international conference harmonisation ich employees must completed required training undertaking roles keep detailed training records routinely requested regulatory authorities undertaking inspection gsk clinical research trials auditing clinical trials gsks internal audit department audits conduct clinical trials audits cover gsk systems processes well external clinical research organisations investigators performing clinical research behalf trials selected audit based risk risk factors include complexity study patient population location study previous audit history unusual findings conduct study results reported quarterly rd compliance board annually risk oversight compliance council audit committee gsks board directors read corporate governance section annual report members global safety board gsb receive individual audit reports safetyrelated findings concerns issues identified fully investigated appropriate corrective action taken gsk staff corrective actions may include development new training programmes retraining individuals concerned severe cases appropriate disciplinary action taken including dismissal external investigators gsk may retrain investigator stop working investigator trial data noncompliant investigative sites excluded analysis regulatory authorities also carry inspections gsk investigators use conduct clinical trials home responsibility research practices training auditing corporate responsibility report training auditing approach performance training clinical trials training activities related good clinical practice gcp training activity represents successful completion elearning module instructorled course related gcp one employees contractors auditing clinical trials conducted audits included audits investigator sites conducting gsksponsored trials represents approximately five per cent investigator sites participating pivotal clinical trials audits internal gsk systems processes used managing clinical trials data audits clinical research organisations carrying clinical trials gsks behalf audits gsk local operating companies involved clinical research activities win addition investigations conducted response suspected irregularities investigator sites issues identified investigator sites included insufficient oversight clinical trial activities investigators oversight covers areas investigator responsibility including knowledge protocol design appropriate documented delegation tasks skilled personnel availability meet sponsor representatives regular intervals study additional training investigators implementation internal controls helping reduce frequency significance issue inspections investigators clinical research organisations independent ethics committeesinstitutional review boards sponsors clinical trials also carried regulatory authorities ensure safety trial participants quality data trials conducted according good clinical practice inspections gsk investigators used gsk conduct clinical trials food drug administration fda conducted routine post marketing adverse drug experience inspection inspection involved review gsks processes receiving capturing tracking adverse drug experience information gsk products well reporting data fda course inspection inspector focused gsks compliance regulatory requirements new drug application nda annual reports periodic adverse drug experience reports result inspection gsk received warning letter agency march fda determined products certain required reports submitted gsk included required information clinical studies timely basis fda letter acknowledges information captured periodic reports many cases submitted agency reports communications addition information start clinical trials omitted reports available wwwclinicaltrialsgov clinical trial results also posted publicly gsks clinical study register acknowledge seriousness issues raised warning letter corrective steps taken underway make sure periodic reports filed completely promptly inspection gsk initiated review applicable processes reporting systems made continue progress updating procedures improving compliance area reporting including additional training ensure procedures followed across product lines gsk works continuously monitor necessary enhance compliance systems procedures home responsibility research practices training auditing corporate responsibility report training auditing approach performance training clinical trials training activities related good clinical practice gcp training activity represents successful completion elearning module instructorled course related gcp one employees contractors auditing clinical trials conducted audits included audits investigator sites conducting gsksponsored trials represents approximately five per cent investigator sites participating pivotal clinical trials audits internal gsk systems processes used managing clinical trials data audits clinical research organisations carrying clinical trials gsks behalf audits gsk local operating companies involved clinical research activities win addition investigations conducted response suspected irregularities investigator sites issues identified investigator sites included insufficient oversight clinical trial activities investigators oversight covers areas investigator responsibility including knowledge protocol design appropriate documented delegation tasks skilled personnel availability meet sponsor representatives regular intervals study additional training investigators implementation internal controls helping reduce frequency significance issue inspections investigators clinical research organisations independent ethics committeesinstitutional review boards sponsors clinical trials also carried regulatory authorities ensure safety trial participants quality data trials conducted according good clinical practice inspections gsk investigators used gsk conduct clinical trials food drug administration fda conducted routine post marketing adverse drug experience inspection inspection involved review gsks processes receiving capturing tracking adverse drug experience information gsk products well reporting data fda course inspection inspector focused gsks compliance regulatory requirements new drug application nda annual reports periodic adverse drug experience reports result inspection gsk received warning letter agency march fda determined products certain required reports submitted gsk included required information clinical studies timely basis fda letter acknowledges information captured periodic reports many cases submitted agency reports communications addition information start clinical trials omitted reports available wwwclinicaltrialsgov clinical trial results also posted publicly gsks clinical study register acknowledge seriousness issues raised warning letter corrective steps taken underway make sure periodic reports filed completely promptly inspection gsk initiated review applicable processes reporting systems made continue progress updating procedures improving compliance area reporting including additional training ensure procedures followed across product lines gsk works continuously monitor necessary enhance compliance systems procedures home responsibility research practices training auditing corporate responsibility report training auditing approach performance training clinical trials training activities related good clinical practice gcp training activity represents successful completion elearning module instructorled course related gcp one employees contractors auditing clinical trials conducted audits included audits investigator sites conducting gsksponsored trials represents approximately five per cent investigator sites participating pivotal clinical trials audits internal gsk systems processes used managing clinical trials data audits clinical research organisations carrying clinical trials gsks behalf audits gsk local operating companies involved clinical research activities win addition investigations conducted response suspected irregularities investigator sites issues identified investigator sites included insufficient oversight clinical trial activities investigators oversight covers areas investigator responsibility including knowledge protocol design appropriate documented delegation tasks skilled personnel availability meet sponsor representatives regular intervals study additional training investigators implementation internal controls helping reduce frequency significance issue inspections investigators clinical research organisations independent ethics committeesinstitutional review boards sponsors clinical trials also carried regulatory authorities ensure safety trial participants quality data trials conducted according good clinical practice inspections gsk investigators used gsk conduct clinical trials food drug administration fda conducted routine post marketing adverse drug experience inspection inspection involved review gsks processes receiving capturing tracking adverse drug experience information gsk products well reporting data fda course inspection inspector focused gsks compliance regulatory requirements new drug application nda annual reports periodic adverse drug experience reports result inspection gsk received warning letter agency march fda determined products certain required reports submitted gsk included required information clinical studies timely basis fda letter acknowledges information captured periodic reports many cases submitted agency reports communications addition information start clinical trials omitted reports available wwwclinicaltrialsgov clinical trial results also posted publicly gsks clinical study register acknowledge seriousness issues raised warning letter corrective steps taken underway make sure periodic reports filed completely promptly inspection gsk initiated review applicable processes reporting systems made continue progress updating procedures improving compliance area reporting including additional training ensure procedures followed across product lines gsk works continuously monitor necessary enhance compliance systems procedures home responsibility research practices case studies corporate responsibility report case studies focus patient programme focus patient programme helps rd employees understand patient needs inspires help improve lives patients held seminars patients visited gsk sites help rd employees understand realities living illness seminars included discussions breast cancer cystic fibrosis hivaids inflammatory bowel disease schizophrenia epilepsy meningitis hepatitis c pulmonary hypertension idiopathic pulmonary fibrosis migraine headaches attendees seminars also held lunchtime sessions develop ideas actions one session prompted organisation seminar site verona italy providing insight local scientists developing medicines sleep disorders depression another idea led patient empowered project improve patients experience gsk clinical trials patientfocused study design simplified patientdirected communications inform employees patients helping work rd regular monthly bulletins highlight key medicines pipeline meet needs patients helps motivate employees reminding importance work survey rd employees showed respondents felt increase patient focus across businesses greater application patient focus work processes development medicines clinical study register important results studies evaluate medicines public domain enables information used help inform medical judgement advance medical science traditionally publication scientific medical journals sought well recognised limitations studies published researchers possible publish study peer reviewed journal posting summary study internet initiated enables studies tracked publication studies publicly disclosed identified researchers called account posting results study completed means results public domain whether study accepted publication gsk provides online clinical study register contains results trials covering gsk products dating back company formed launched pleased site success latest figures show site receiving visitors month took steps build commitment transparency clinical research help people quickly find information need launched revised version clinical study register includes improved user interface making easier users find information disease area medicine adding observational research metaanalyses evaluate medicines studies terminated compounds register adds current commitment postprotocol summaries summary results gsks clinical trials phases llv marketed medicines however disclosure research protocols results online seen supplement replacement need publish studies peer reviewed journals believe level ppaugeb lic disclosure achieved posting results register alone achieved papers published peer reviewed journals fully explain study places results context gsk aims publish clinical research medicines comprehensive papers peer reviewed journals studies published provide context interpretation via registerhome responsibility research practices case studies corporate responsibility report case studies focus patient programme focus patient programme helps rd employees understand patient needs inspires help improve lives patients held seminars patients visited gsk sites help rd employees understand realities living illness seminars included discussions breast cancer cystic fibrosis hivaids inflammatory bowel disease schizophrenia epilepsy meningitis hepatitis c pulmonary hypertension idiopathic pulmonary fibrosis migraine headaches attendees seminars also held lunchtime sessions develop ideas actions one session prompted organisation seminar site verona italy providing insight local scientists developing medicines sleep disorders depression another idea led patient empowered project improve patients experience gsk clinical trials patientfocused study design simplified patientdirected communications inform employees patients helping work rd regular monthly bulletins highlight key medicines pipeline meet needs patients helps motivate employees reminding importance work survey rd employees showed respondents felt increase patient focus across businesses greater application patient focus work processes development medicines clinical study register important results studies evaluate medicines public domain enables information used help inform medical judgement advance medical science traditionally publication scientific medical journals sought well recognised limitations studies published researchers possible publish study peer reviewed journal posting summary study internet initiated enables studies tracked publication studies publicly disclosed identified researchers called account posting results study completed means results public domain whether study accepted publication gsk provides online clinical study register contains results trials covering gsk products dating back company formed launched pleased site success latest figures show site receiving visitors month took steps build commitment transparency clinical research help people quickly find information need launched revised version clinical study register includes improved user interface making easier users find information disease area medicine adding observational research metaanalyses evaluate medicines studies terminated compounds register adds current commitment postprotocol summaries summary results gsks clinical trials phases llv marketed medicines however disclosure research protocols results online seen supplement replacement need publish studies peer reviewed journals believe level public disclosure achieved posting results register alone achieved papers published peer reviewed journals fully explain study places results context gsk aims publish clinical research medicines comprehensive papers peer reviewed journals studies published provide context interpretation via register home responsibility research practices case studies corporate responsibility report case studies focus patient programme focus patient programme helps rd employees understand patient needs inspires help improve lives patients held seminars patients visited gsk sites help rd employees understand realities living illness seminars included discussions breast cancer cystic fibrosis hivaids inflammatory bowel disease schizophrenia epilepsy meningitis hepatitis c pulmonary hypertension idiopathic pulmonary fibrosis migraine headaches attendees seminars also held lunchtime sessions develop ideas actions one session prompted organisation seminar site verona italy providing insight local scientists developing medicines sleep disorders depression another idea led patient empowered project improve patients experience gsk clinical trials patientfocused study design simplified patientdirected communications inform employees patients helping work rd regular monthly bulletins highlight key medicines pipeline meet needs patients helps motivate employees reminding importance work survey rd employees showed respondents felt increase patient focus across businesses greater application patient focus work processes development medicines clinical study register important results studies evaluate medicines public domain enables information used help inform medical judgement advance medical science traditionally publication scientific medical journals sought well recognised limitations studies published researchers possible publish study peer reviewed journal posting summary study internet initiated enables studies tracked publication studies publicly disclosed identified researchers called account posting results study completed means results public domain whether study accepted publication gsk provides online clinical study register contains results trials covering gsk products dating back company formed launched pleased site success latest figures show site receiving visitors month took steps build commitment transparency clinical research help people quickly find information need launched revised version clinical study register includes improved user interface making easier users find information disease area medicine adding observational research metaanalyses evaluate medicines studies terminated compounds register adds current commitment postprotocol summaries summary results gsks clinical trials phases llv marketed medicines however disclosure research protocols results online seen supplement replacement need publish studies peer reviewed journals believe level public disclosure achieved posting results register alone achieved papers published peer reviewed journals fully explain study places results context gsk aims publish clinical research medicines comprehensive papers peer reviewed journals studies published provide context interpretation via register home responsibility research practices qas corporate responsibility report qas respond questions raised stakeholders assured risks healthy volunteers take experimental medicines first time minimised clinical trial take place new compound must undergo series stringent laboratory tests tests involve use animals human tissue predict effects investigational medicine human body including potential side effects basis predictions establish dosing levels sufficient margin safety andor appropriate monitoring procedures preclinical data laboratory tests proposal design first time human clinical trial reviewed gsk committee known global safety board experienced senior physicians experts independent project team regulatory authorities independent ethics committees must approve trial go ahead clinical trials designed minimise risk example initially give volunteers low dose investigational medicine increase dosing gradually carefully sequenced among subgroups cautious approach trials investigational medicine tested humans first time conducted clinical units rapid access hospital emergency care clinical trial volunteers provided information study including potential risks opportunity discuss risks researchers deciding whether participate known informed consent plan enter research collaborations ensure organisations partner meet research animal welfare standards recognise working collaboration organisations brings certain risks developing routine safeguards ensure partners work according core principles gsk including govern use animals research checks applied evaluating whether enter collaboration subsequently ongoing basis within framework established govern collaboration typically joint steering committee gsks willingness enter continue collaboration depends adequate assurance shared commitment core principles gsk opening rd facility china affect research standards cost reduction exercise opened new rd facility china focusing rd neurodegenerative disorders better therapies desperately needed alzheimers disease parkinsons disease multiple sclerosis costs conducting research china currently relativity lower markets however lower costs reason behind decision set new facility new centre enables us benefit accessing vast talent pool knowledge life sciences china increase focus depth important disease areas rd china conducted accordance gsks global quality ethical standards rd policies monitoring procedures apply operations china committed significant regional local resource ensuring operations china comply chinese government requirements gsks global standards home responsibility research practices qas corporate responsibility report qas respond questions raised stakeholders assured risks healthy volunteers take experimental medicines first time minimised clinical trial take place new compound must undergo series stringent laboratory tests tests involve use animals human tissue predict effects investigational medicine human body including potential side effects basis predictions establish dosing levels sufficient margin safety andor appropriate monitoring procedures preclinical data laboratory tests proposal design first time human clinical trial reviewed gsk committee known global safety board experienced senior physicians experts independent project team regulatory authorities independent ethics committees must approve trial go ahead clinical trials designed minimise risk example initially give volunteers low dose investigational medicine increase dosing gradually carefully sequenced among subgroups cautious approach trials investigational medicine tested humans first time conducted clinical units rapid access hospital emergency care clinical trial volunteers provided information study including potential risks opportunity discuss risks researchers deciding whether participate known informed consent plan enter research collaborations ensure organisations partner meet research animal welfare standards recognise working collaboration organisations brings certain risks developing routine safeguards ensure partners work according core principles gsk including govern use animals research checks applied evaluating whether enter collaboration subsequently ongoing basis within framework established govern collaboration typically joint steering committee gsks willingness enter continue collaboration depends adequate assurance shared commitment core principles gsk opening rd facility china affect research standards cost reduction exercise opened new rd facility china focusing rd neurodegenerative disorders better therapies desperately needed alzheimers disease parkinsons disease multiple sclerosis costs conducting research china currently relativity lower markets however lower costs reason behind decision set new facility new centre enables us benefit accessing vast talent pool knowledge life sciences china increase focus depth important disease areas rd china conducted accordance gsks global quality ethical standards rd policies monitoring procedures apply operations china committed significant regional local resource ensuring operations china comply chinese government requirements gsks global standards home responsibility research practices qas corporate responsibility report qas respond questions raised stakeholders assured risks healthy volunteers take experimental medicines first time minimised clinical trial take place new compound must undergo series stringent laboratory tests tests involve use animals human tissue predict effects investigational medicine human body including potential side effects basis predictions establish dosing levels sufficient margin safety andor appropriate monitoring procedures preclinical data laboratory tests proposal design first time human clinical trial reviewed gsk committee known global safety board experienced senior physicians experts independent project team regulatory authorities independent ethics committees must approve trial go ahead clinical trials designed minimise risk example initially give volunteers low dose investigational medicine increase dosing gradually carefully sequenced among subgroups cautious approach trials investigational medicine tested humans first time conducted clinical units rapid access hospital emergency care clinical trial volunteers provided information study including potential risks opportunity discuss risks researchers deciding whether participate known informed consent plan enter research collaborations ensure organisations partner meet research animal welfare standards recognise working collaboration organisations brings certain risks developing routine safeguards ensure partners work according core principles gsk including govern use animals research checks applied evaluating whether enter collaboration subsequently ongoing basis within framework established govern collaboration typically joint steering committee gsks willingness enter continue collaboration depends adequate assurance shared commitment core principles gsk opening rd facility china affect research standards cost reduction exercise opened new rd facility china focusing rd neurodegenerative disorders better therapies desperately needed alzheimers disease parkinsons disease multiple sclerosis costs conducting research china currently relativity lower markets however lower costs reason behind decision set new facility new centre enables us benefit accessing vast talent pool knowledge life sciences china increase focus depth important disease areas rd china conducted accordance gsks global quality ethical standards rd policies monitoring procedures apply operations china committed significant regional local resource ensuring operations china comply chinese government requirements gsks global standards home responsibility ethical conduct corporate responsibility report ethical conduct committed creating strong ethical culture gsk putting appropriate policies place recruiting right people equipping tools make ethical decisions putting patients first core principle ethical pharmaceutical company profit without principle short lived failure uphold high standards ethical conduct carries significant business risk erosion trust gsk products including among regulators doctors patients fines litigation resulting serious financial legal consequences damage gsks reputation code conduct sets fundamental standards employees employee guide business conduct builds code explains employees must meet requirements provides guidance including specific examples constitutes unethical behaviour strong policies codes practice good training essential elements approach however guarantee employees meet standards internal compliance systems designed identify address breaches codes fully investigate suspected breaches take appropriate disciplinary action including dismissal appropriate clear policies procedures prevent corrupt anticompetitive behaviour maintaining high ethical standards marketing also vital relevant patient safety essential marketing practices help doctors prescribe medicines patients best interests policies prohibit kickbacks bribery inducements doctors promotion unapproved uses medicines maintaining high ethical standards stages rd product approved marketing key part commitment put patient first ethical compass employee guide business conduct includes ethical compass helps employees deal ethical issues difficult resolve faced situation encourage people ask questions legal ethical consistent gsk policy code conduct consistent gsks mission spirit explain family friends would comfortable appeared newspaper encourage employees seek additional guidance keep asking questions certain making right choice back top home responsibility ethical conduct corporate responsibility report ethical conduct committed creating strong ethical culture gsk putting appropriate policies place recruiting right people equipping tools make ethical decisions putting patients first core principle ethical pharmaceutical company profit without principle short lived failure uphold high standards ethical conduct carries significant business risk erosion trust gsk products including among regulators doctors patients fines litigation resulting serious financial legal consequences damage gsks reputation code conduct sets fundamental standards employees employee guide business conduct builds code explains employees must meet requirements provides guidance including specific examples constitutes unethical behaviour strong policies codes practice good training essential elements approach however guarantee employees meet standards internal compliance systems designed identify address breaches codes fully investigate suspected breaches take appropriate disciplinary action including dismissal appropriate clear policies procedures prevent corrupt anticompetitive behaviour maintaining high ethical standards marketing also vital relevant patient safety essential marketing practices help doctors prescribe medicines patients best interests policies prohibit kickbacks bribery inducements doctors promotion unapproved uses medicines maintaining high ethical standards stages rd product approved marketing key part commitment put patient first ethical compass employee guide business conduct includes ethical compass helps employees deal ethical issues difficult resolve faced situation encourage people ask questions legal ethical consistent gsk policy code conduct consistent gsks mission spirit explain family friends would comfortable appeared newspaper encourage employees seek additional guidance keep asking questions certain making right choice back top home responsibility ethical conduct code conduct business ethics corporate responsibility report code conduct business ethics code conduct gsk code conduct sets standards expect employees contractors contains following key requirements conduct business honesty integrity professional manner protects gsks good public image reputation build relationships customers vendors suppliers fellow employees based trust treat individuals respect dignity conducting business become familiar comply legal requirements gsk policy procedures avoid activities could involve lead involvement unlawful practice harm gsks reputation image avoid actual potential conflicts interest gsk appearance thereof transactions read full code conduct employee guide business conduct builds code explains employees must meet requirements business ethics corrupt anticompetitive behaviour undermines fair competition inhibits economic development bad economies business people employee guide business conduct contains policies guidance ensure operate within letter spirit law maintain high standards ethical business behaviour anticompetitive behaviour committed free open competition succeed company high quality competitiveness products talent commitment employees policy anticompetitive behaviour covers issues mergers abuse monopoly powers resale price maintenance predatory pricing restrictive agreements practices sets standards behaviour expect employees agents preventing corruption policy anticorruption forbids payments inducements political candidates legislators political parties party officials government officials employees whether local national including officials employees governmentowned enterprises public international organisations also separate policies political contributions donations acceptance gifts entertainment employees sample questions employee guide business conduct question received order unusual volume combination pharmaceuticals new customer location noted political instability shipment location another country customer said bother including usual consumer use information problem answer enough red flags need get advice gsk legal department information indicates material might shipped prohibited country used improper even terrorist activity need know customer get advice question vendor offers sell gsk product manager mailing list names individuals treated depression concerns purchase list answer yes many countries including us eu established strict laws protecting healthcare information identifies individual written authorisation individual usually required gsk receive information back tophome responsibility ethical conduct code conduct business ethics corporate responsibility report code conduct business ethics code conduct gsk code conduct sets standards expect employees contractors contains following key requirements conduct business honesty integrity professional manner protects gsks good public image reputation build relationships customers vendors suppliers fellow employees based trust treat individuals respect dignity conducting business become familiar comply legal requirements gsk policy procedures avoid activities could involve lead involvement unlawful practice harm gsks reputation image avoid actual potential conflicts interest gsk appearance thereof transactions read full code conduct employee guide business conduct builds code explains employees must meet requirements business ethics corrupt anticompetitive behaviour undermines fair competition inhibits economic development bad economies business people employee guide business conduct contains policies guidance ensure operate within letter spirit law maintain high standards ethical business behaviour anticompetitive behaviour committed free open competition succeed company high quality competitiveness products talent commitment employees policy anticompetitive behaviour covers issues mergers abuse monopoly powers resale price maintenance predatory pricing restrictive agreements practices sets standards behaviour expect employees agents preventing corruption policy anticorruption forbids payments inducements political candidates legislators political parties party officials government officials employees whether local national including officials employees governmentowned enterprises public international organisations also separate policies political contributions donations acceptance gifts entertainment employees sample questions employee guide business conduct question received order unusual volume combination pharmaceuticals new customer location noted political instability shipment location another country customer said bother including usual consumer use information problem answer enough red flags need get advice gsk legal department information indicates material might shipped prohibited country used improper even terrorist activity need know customer get advice question vendor offers sell gsk product manager mailing list names individuals treated depression concerns purchase list answer yes many countries including us eu established strict laws protecting healthcare information identifies individual written authorisation individual usually required gsk receive information back top home responsibility ethical conduct code conduct business ethics corporate responsibility report code conduct business ethics code conduct gsk code conduct sets standards expect employees contractors contains following key requirements conduct business honesty integrity professional manner protects gsks good public image reputation build relationships customers vendors suppliers fellow employees based trust treat individuals respect dignity conducting business become familiar comply legal requirements gsk policy procedures avoid activities could involve lead involvement unlawful practice harm gsks reputation image avoid actual potential conflicts interest gsk appearance thereof transactions read full code conduct employee guide business conduct builds code explains employees must meet requirements business ethics corrupt anticompetitive behaviour undermines fair competition inhibits economic development bad economies business people employee guide business conduct contains policies guidance ensure operate within letter spirit law maintain high standards ethical business behaviour anticompetitive behaviour committed free open competition succeed company high quality competitiveness products talent commitment employees policy anticompetitive behaviour covers issues mergers abuse monopoly powers resale price maintenance predatory pricing restrictive agreements practices sets standards behaviour expect employees agents preventing corruption policy anticorruption forbids payments inducements political candidates legislators political parties party officials government officials employees whether local national including officials employees governmentowned enterprises public international organisations also separate policies political contributions donations acceptance gifts entertainment employees sample questions employee guide business conduct question received order unusual volume combination pharmaceuticals new customer location noted political instability shipment location another country customer said bother including usual consumer use information problem answer enough red flags need get advice gsk legal department information indicates material might shipped prohibited country used improper even terrorist activity need know customer get advice question vendor offers sell gsk product manager mailing list names individuals treated depression concerns purchase list answer yes many countries including us eu established strict laws protecting healthcare information identifies individual written authorisation individual usually required gsk receive information back top home responsibility ethical conduct marketing ethics corporate responsibility report marketing ethics market prescription medicines vaccines doctors hospitals governments countries us also advertise medicines directly consumers specialist sales representatives meet regularly doctors pharmacists inform medicines approved uses believe sales representatives play important role providing uptodate information doctors products benefits risks patients however recognise marketing pharmaceutical products raises challenging issues particular people concerned marketing pharmaceutical companies exerts undue influence doctors sales representatives always give doctors full information potential sideeffects promotion unapproved uses medicines may occurring regional marketing codes forbid practices unethical conduct provide regular training sales teams understand codes conduct monitoring assess compliance marketing codes practice sale promotion pharmaceutical products highly regulated governments medical agencies developed marketing codes policies provide training sales representatives ensure understand behave ethically comply law many countries codes policies go beyond legal requirements products sold countries around world first priority product country patient safety systems processes collect analyse report safety concerns products marketing codes practice apply employees agents commit us promotional practices ethical responsible principled patientcentred prohibit kickbacks bribery inducements doctors promotion unapproved uses medicines company policies supported regional marketing practices codes apply standards reflect differences market structures national healthcare systems regulations new us phrma code interactions healthcare professionals hcps came effect january fully aligned sales marketing practices requirements code cases gsk gone beyond requirements code including phasing prohibition giving non educational items us reinforcing cap payments made individual usbased hcp working consultant company example participating advisory board speaking gsksponsored meetings updated commercial practice policies cpps available first quarter gsk initiating review internal regional codes relating sales promotion pharmaceutical products review intend align legally culturally appropriate gsks regional codes alignment lead gsk develop detailed global principles guiding sales marketing gsk pharmaceutical products world helping strengthen industry codes gsk supports efforts strengthen marketing standards across pharmaceutical industry benefits us creating level playing field countries operate helps improve reputation pharmaceutical industry whole took active role working us pharmaceutical industry association phrma develop changes code interactions healthcare professionals gsk certify compliance code first quarter code guide sale marketing gsk pharmaceutical products us marketing codes practice summary full accurate information information provided approved uses medicine must based valid scientific evidence must accurate balanced fair objective unambiguous date promotional items healthcare professionals branded promotional items must given occasionally must relevant practice medicine nominal value less uk longer distribute noneducational items us line us phrma code items given inducement prescribe medicines medical professionals retained consultants gsk appropriate hospitality meetings entertainment permitted hospitality travel costs food may provided meetings educational professional purpose level hospitality must appropriate occasion must provided relevant healthcare professionals spouses children office personnel guests decisions grants medical education reviewed qualified medical scientific personnel back tophome responsibility ethical conduct marketing ethics corporate responsibility report marketing ethics market prescription medicines vaccines doctors hospitals governments countries us also advertise medicines directly consumers specialist sales representatives meet regularly doctors pharmacists inform medicines approved uses believe sales representatives play important role providing uptodate information doctors products benefits risks patients however recognise marketing pharmaceutical products raises challenging issues particular people concerned marketing pharmaceutical companies exerts undue influence doctors sales representatives always give doctors full information potential sideeffects promotion unapproved uses medicines may occurring regional marketing codes forbid practices unethical conduct provide regular training sales teams understand codes conduct monitoring assess compliance marketing codes practice sale promotion pharmaceutical products highly regulated governments medical agencies developed marketing codes policies provide training sales representatives ensure understand behave ethically comply law many countries codes policies go beyond legal requirements products sold countries around world first priority product country patient safety systems processes collect analyse report safety concerns products marketing codes practice apply employees agents commit us promotional practices ethical responsible principled patientcentred prohibit kickbacks bribery inducements doctors promotion unapproved uses medicines company policies supported regional marketing practices codes apply standards reflect differences market structures national healthcare systems regulations new us phrma code interactions healthcare professionals hcps came effect january fully aligned sales marketing practices requirements code cases gsk gone beyond requirements code including phasing prohibition giving non educational items us reinforcing cap payments made individual usbased hcp working consultant company example participating advisory board speaking gsksponsored meetings updated commercial practice policies cpps available first quarter gsk initiating review internal regional codes relating sales promotion pharmaceutical products review intend align legally culturally appropriate gsks regional codes alignment lead gsk develop detailed global principles guiding sales marketing gsk pharmaceutical products world helping strengthen industry codes gsk supports efforts strengthen marketing standards across pharmaceutical industry benefits us creating level playing field countries operate helps improve reputation pharmaceutical industry whole took active role working us pharmaceutical industry association phrma develop changes code interactions healthcare professionals gsk certify compliance code first quarter code guide sale marketing gsk pharmaceutical products us marketing codes practice summary full accurate information information provided approved uses medicine must based valid scientific evidence must accurate balanced fair objective unambiguous date promotional items healthcare professionals branded promotional items must given occasionally must relevant practice medicine nominal value less uk longer distribute noneducational items us line us phrma code items given inducement prescribe medicines medical professionals retained consultants gsk appropriate hospitality meetings entertainment permitted hospitality travel costs food may provided meetings educational professional purpose level hospitality must appropriate occasion must provided relevant healthcare professionals spouses children office personnel guests decisions grants medical education reviewed qualified medical scientific personnel back top home responsibility ethical conduct marketing ethics corporate responsibility report marketing ethics market prescription medicines vaccines doctors hospitals governments countries us also advertise medicines directly consumers specialist sales representatives meet regularly doctors pharmacists inform medicines approved uses believe sales representatives play important role providing uptodate information doctors products benefits risks patients however recognise marketing pharmaceutical products raises challenging issues particular people concerned marketing pharmaceutical companies exerts undue influence doctors sales representatives always give doctors full information potential sideeffects promotion unapproved uses medicines may occurring regional marketing codes forbid practices unethical conduct provide regular training sales teams understand codes conduct monitoring assess compliance marketing codes practice sale promotion pharmaceutical products highly regulated governments medical agencies developed marketing codes policies provide training sales representatives ensure understand behave ethically comply law many countries codes policies go beyond legal requirements products sold countries around world first priority product country patient safety systems processes collect analyse report safety concerns products marketing codes practice apply employees agents commit us promotional practices ethical responsible principled patientcentred prohibit kickbacks bribery inducements doctors promotion unapproved uses medicines company policies supported regional marketing practices codes apply standards reflect differences market structures national healthcare systems regulations new us phrma code interactions healthcare professionals hcps came effect january fully aligned sales marketing practices requirements code cases gsk gone beyond requirements code including phasing prohibition giving non educational items us reinforcing cap payments made individual usbased hcp working consultant company example participating advisory board speaking gsksponsored meetings updated commercial practice policies cpps available first quarter gsk initiating review internal regional codes relating sales promotion pharmaceutical products review intend align legally culturally appropriate gsks regional codes alignment lead gsk develop detailed global principles guiding sales marketing gsk pharmaceutical products world helping strengthen industry codes gsk supports efforts strengthen marketing standards across pharmaceutical industry benefits us creating level playing field countries operate helps improve reputation pharmaceutical industry whole took active role working us pharmaceutical industry association phrma develop changes code interactions healthcare professionals gsk certify compliance code first quarter code guide sale marketing gsk pharmaceutical products us marketing codes practice summary full accurate information information provided approved uses medicine must based valid scientific evidence must accurate balanced fair objective unambiguous date promotional items healthcare professionals branded promotional items must given occasionally must relevant practice medicine nominal value less uk longer distribute noneducational items us line us phrma code items given inducement prescribe medicines medical professionals retained consultants gsk appropriate hospitality meetings entertainment permitted hospitality travel costs food may provided meetings educational professional purpose level hospitality must appropriate occasion must provided relevant healthcare professionals spouses children office personnel guests decisions grants medical education reviewed qualified medical scientific personnel back top home responsibility ethical conduct marketing ethics relationships healthcare professionals corporate responsibility report relationships healthcare professionals approach performance plans well marketing codes detailed policies monitoring systems governing relationship healthcare professionals following areas medical education programmes provide funding enable physicians pharmacists nurses healthcare professionals attend education courses conferences therapeutic areas relevant gsk consider part marketing policies state content education programme choice faculty independently approved sponsoring speakers provide sponsorship healthcare professionals attend conferences present research results speak healthcare issues speakers must declare speech funded gsk advisory services engage healthcare professionals understand unmet medical needs developments science treatments helps us understand current future markets products engagement may take form convening advisory panels conducting broader market research read engage healthcare professionals conduct medical research behalf policies processes vary region comply local laws industry practices meet exceed codes relationships healthcare professionals following industry organisations pharmaceutical research manufacturers america phrma european federation pharmaceutical industries associations efpia international federation pharmaceutical manufacturers associations ifpma japan pharmaceuticals manufacturers association jpma policies processes restricted us include limit payments healthcare professionals speaker advisory fees year individual physician majority us healthcare professional consultants receive fees total less per year state reporting system expenditure healthcare professionals line legislation several us states system help us investigate situations excessive meals gifts may provided gsk requirement gsk funding grants healthcarerelated group including patient advocacy groups physician associations exceed per cent groups annual income speaker evaluation process covering healthcare professionals sponsored gsk requires regional medical scientists evaluate highfrequency speakers provide feedback healthcare professionals effectiveness compliance gsk speaker programmes policy process monitor questions posed doctors medical information department offlabel uses products number type referrals made individual representatives helps ensure representatives promoting offlabel uses questions doctors offlabel uses products must referred medical information department back top home responsibility ethical conduct marketing ethics relationships healthcare professionals corporate responsibility report relationships healthcare professionals approach performance plans well marketing codes detailed policies monitoring systems governing relationship healthcare professionals following areas medical education programmes provide funding enable physicians pharmacists nurses healthcare professionals attend education courses conferences therapeutic areas relevant gsk consider part marketing policies state content education programme choice faculty independently approved sponsoring speakers provide sponsorship healthcare professionals attend conferences present research results speak healthcare issues speakers must declare speech funded gsk advisory services engage healthcare professionals understand unmet medical needs developments science treatments helps us understand current future markets products engagement may take form convening advisory panels conducting broader market research read engage healthcare professionals conduct medical research behalf policies processes vary region comply local laws industry practices meet exceed codes relationships healthcare professionals following industry organisations pharmaceutical research manufacturers america phrma european federation pharmaceutical industries associations efpia international federation pharmaceutical manufacturers associations ifpma japan pharmaceuticals manufacturers association jpma policies processes restricted us include limit payments healthcare professionals speaker advisory fees year individual physician majority us healthcare professional consultants receive fees total less per year state reporting system expenditure healthcare professionals line legislation several us states system help us investigate situations excessive meals gifts may provided gsk requirement gsk funding grants healthcarerelated group including patient advocacy groups physician associations exceed per cent groups annual income speaker evaluation process covering healthcare professionals sponsored gsk requires regional medical scientists evaluate highfrequency speakers provide feedback healthcare professionals effectiveness compliance gsk speaker programmes policy process monitor questions posed doctors medical information department offlabel uses products number type referrals made individual representatives helps ensure representatives promoting offlabel uses questions doctors offlabel uses products must referred medical information department back top home responsibility ethical conduct marketing ethics relationships healthcare professionals corporate responsibility report relationships healthcare professionals approach performance plans well marketing codes detailed policies monitoring systems governing relationship healthcare professionals following areas medical education programmes provide funding enable physicians pharmacists nurses healthcare professionals attend education courses conferences therapeutic areas relevant gsk consider part marketing policies state content education programme choice faculty independently approved sponsoring speakers provide sponsorship healthcare professionals attend conferences present research results speak healthcare issues speakers must declare speech funded gsk advisory services engage healthcare professionals understand unmet medical needs developments science treatments helps us understand current future markets products engagement may take form convening advisory panels conducting broader market research read engage healthcare professionals conduct medical research behalf policies processes vary region comply local laws industry practices meet exceed codes relationships healthcare professionals following industry organisations pharmaceutical research manufacturers america phrma european federation pharmaceutical industries associations efpia international federation pharmaceutical manufacturers associations ifpma japan pharmaceuticals manufacturers association jpma policies processes restricted us include limit payments healthcare professionals speaker advisory fees year individual physician majority us healthcare professional consultants receive fees total less per year state reporting system expenditure healthcare professionals line legislation several us states system help us investigate situations excessive meals gifts may provided gsk requirement gsk funding grants healthcarerelated group including patient advocacy groups physician associations exceed per cent groups annual income speaker evaluation process covering healthcare professionals sponsored gsk requires regional medical scientists evaluate highfrequency speakers provide feedback healthcare professionals effectiveness compliance gsk speaker programmes policy process monitor questions posed doctors medical information department offlabel uses products number type referrals made individual representatives helps ensure representatives promoting offlabel uses questions doctors offlabel uses products must referred medical information department back top home responsibility ethical conduct marketing ethics relationships healthcare professionals corporate responsibility report relationships healthcare professionals approach performance plans united states make payments healthcare professionals consultancy work participating advisory board speaking gsksponsored meetings majority us hcp consultants receive fees total less per year however reinforced cap payments hcps us year individual physician interest physicians work receive excessive funding gsk ensures work gsk detract time spend patients conducting research could reduce professional credibility value gsk sources current medical expertise europe changed european code practice interactions healthcare professionals response new code promotion published european federation pharmaceutical industries associations made following changes refinements code use consultants gsk employees responsible selecting consultants must expertise evaluate whether consultant suitable meet identified business need real value gsk consultant required declare consultancy arrangements speaking publicly related issue samples product samples given limited numbers limited time reference local standards purposes familiarisation replaces previous limits less restrictive specify quantity timeframe grants donations introduced new policy grants financial donations health organisations involved grant donation used receive service return new policy states grants donations may given health organisation response unsolicited request purposes healthcare research must offered given understanding recipient prescribe recommend products must documented published externally meet requirement amount grant recipient published gsks website permitted health organisations rather individuals phase lv clinical studies studies conducted medicine approved marketing clarified principles behind studies clearly setting terms gsk collaborative studies studies must commissioned inducement prescribe supply recommend medicines must clear scientific andor educational purpose must contract institution undertaking research trial protocol must reviewed approved ethical committee available gsk rd medical personnel must approve supervise studies results distributed investigators asia pacific japan emerging markets gsk continues active ifpma code compliance network many senior country managers supportive leading industry change part strengthening local codes nigeria gsk received best compliant company award issued nafdac regulatory authority award first kind aims encourage compliance among companies nigeria encourage nigerians buy companies deemed compliant nafdac australia january gsk australia stopped distributing brand reminders healthcare professionals including pens notepads exception new brand launches aligns behaviour community expectations interact customers plans publish grants donations made us europe australia initiative move states victoria operating model take effect august delivering improved control around samples accountability security supporting aim achieve highest levels professional standards field sales force longer distribute samples directly healthcare professionals instead orders taken medical representatives samples delivered direct surgeries central warehouse gsks international promotion marketing code applicable emerging markets asia pacific regions subject regular twoyear review last revision incorporated major structural change align structure content ifpma code indeed goes many cases back tophome responsibility ethical conduct marketing ethics relationships healthcare professionals corporate responsibility report relationships healthcare professionals approach performance plans united states make payments healthcare professionals consultancy work participating advisory board speaking gsksponsored meetings majority us hcp consultants receive fees total less per year however reinforced cap payments hcps us year individual physician interest physicians work receive excessive funding gsk ensures work gsk detract time spend patients conducting research could reduce professional credibility value gsk sources current medical expertise europe changed european code practice interactions healthcare professionals response new code promotion published european federation pharmaceutical industries associations made following changes refinements code use consultants gsk employees responsible selecting consultants must expertise evaluate whether consultant suitable meet identified business need real value gsk consultant required declare consultancy arrangements speaking publicly related issue samples product samples given limited numbers limited time reference local standards purposes familiarisation replaces previous limits less restrictive specify quantity timeframe grants donations introduced new policy grants financial donations health organisations involved grant donation used receive service return new policy states grants donations may given health organisation response unsolicited request purposes healthcare research must offered given understanding recipient prescribe recommend products must documented published externally meet requirement amount grant recipient published gsks website permitted health organisations rather individuals phase lv clinical studies studies conducted medicine approved marketing clarified principles behind studies clearly setting terms gsk collaborative studies studies must commissioned inducement prescribe supply recommend medicines must clear scientific andor educational purpose must contract institution undertaking research trial protocol must reviewed approved ethical committee available gsk rd medical personnel must approve supervise studies results distributed investigators asia pacific japan emerging markets gsk continues active ifpma code compliance network many senior country managers supportive leading industry change part strengthening local codes nigeria gsk received best compliant company award issued nafdac regulatory authority award first kind aims encourage compliance among companies nigeria encourage nigerians buy companies deemed compliant nafdac australia january gsk australia stopped distributing brand reminders healthcare professionals including pens notepads exception new brand launches aligns behaviour community expectations interact customers plans publish grants donations made us europe australia initiative move states victoria operating model take effect august delivering improved control around samples accountability security supporting aim achieve highest levels professional standards field sales force longer distribute samples directly healthcare professionals instead orders taken medical representatives samples delivered direct surgeries central warehouse gsks international promotion marketing code applicable emerging markets asia pacific regions subject regular twoyear review last revision incorporated major structural change align structure content ifpma code indeed goes many cases back top home responsibility ethical conduct marketing ethics relationships healthcare professionals corporate responsibility report relationships healthcare professionals approach performance plans united states make payments healthcare professionals consultancy work participating advisory board speaking gsksponsored meetings majority us hcp consultants receive fees total less per year however reinforced cap payments hcps us year individual physician interest physicians work receive excessive funding gsk ensures work gsk detract time spend patients conducting research could reduce professional credibility value gsk sources current medical expertise europe changed european code practice interactions healthcare professionals response new code promotion published european federation pharmaceutical industries associations made following changes refinements code use consultants gsk employees responsible selecting consultants must expertise evaluate whether consultant suitable meet identified business need real value gsk consultant required declare consultancy arrangements speaking publicly related issue samples product samples given limited numbers limited time reference local standards purposes familiarisation replaces previous limits less restrictive specify quantity timeframe grants donations introduced new policy grants financial donations health organisations involved grant donation used receive service return new policy states grants donations may given health organisation response unsolicited request purposes healthcare research must offered given understanding recipient prescribe recommend products must documented published externally meet requirement amount grant recipient published gsks website permitted health organisations rather individuals phase lv clinical studies studies conducted medicine approved marketing clarified principles behind studies clearly setting terms gsk collaborative studies studies must commissioned inducement prescribe supply recommend medicines must clear scientific andor educational purpose must contract institution undertaking research trial protocol must reviewed approved ethical committee available gsk rd medical personnel must approve supervise studies results distributed investigators asia pacific japan emerging markets gsk continues active ifpma code compliance network many senior country managers supportive leading industry change part strengthening local codes nigeria gsk received best compliant company award issued nafdac regulatory authority award first kind aims encourage compliance among companies nigeria encourage nigerians buy companies deemed compliant nafdac australia january gsk australia stopped distributing brand reminders healthcare professionals including pens notepads exception new brand launches aligns behaviour community expectations interact customers plans publish grants donations made us europe australia initiative move states victoria operating model take effect august delivering improved control around samples accountability security supporting aim achieve highest levels professional standards field sales force longer distribute samples directly healthcare professionals instead orders taken medical representatives samples delivered direct surgeries central warehouse gsks international promotion marketing code applicable emerging markets asia pacific regions subject regular twoyear review last revision incorporated major structural change align structure content ifpma code indeed goes many cases back top home responsibility ethical conduct marketing ethics directtoconsumer advertising corporate responsibility report directtoconsumer advertising approach performance us legal advertise prescription medicines consumers tv print advertisements known directtoconsumer dtc advertising new zealand bangladesh korea also allow limited dtc advertising dtc advertising prescription medicines permitted markets promoting use prescription medicines directly consumers raise concerns critics believe encourages people request unnecessary treatment adding burden healthcare systems believe responsible pharmaceutical advertising useful source health information patients helps increase knowledge conditions educates patients treatment options countries us dtc advertising common industry practice would competitive disadvantage promote products way patients must still consult physicians condition appropriateness prescription medicine obtain consent receiving medicines prescription medicines us dtc communications policy based phrma guiding principles direct consumer advertisements prescription medicines detailed approval process dtc advertising includes review legal regulatory medical specialists appropriate us marketing employees received training dtc policy dtc television advertisements including audio visual components submitted us food drug administration fda review least days advance broadcast members public healthcare professionals send comments complaints dtc advertising phrmas office accountability reports comments responses companies fda fda amendments act imposes restrictions dtc advertising gives fda ability require submission dtc television advertisements days prior dissemination imposes new standard presentation safety information broadcast advertisements companies responsible false misleading dtc advertisements fined implemented provisions dtc advertising line acts requirements fund diseaseawareness campaigns designed increase understanding specific disease linked promotion gsk products also governed dtc policy disease awareness campaigns include television print advertisements direct mail mention specific gsk products make people aware treatments available condition encourage see doctor campaign materials branded indicate produced gsk overthecounter medicines consumer healthcare products advertising overthecounter medicines oral healthcare nutritional products governed national regulations codes practice advertising overthecounter medicines also promoted pharmacists doctors dentists sales teams belong consumer healthcare products association us comply code advertising practices nonprescription medicines gsk consumer healthcare advertising reviewed copy review committees larger markets medical legal personnel smaller markets publication ensure meets standards advertising children guidelines advertising children prohibit advertising designed appeal targeted children legally mandated minimum age example comply guidelines uk buy advertising space childrens media supply vending machines primary schools sports star sponsorship important brands lucozade sport guidelines state people set appropriate example used sponsorship appeal solely children age principles dtc advertising us policy requires dtc advertising dedicate appropriate amount time educating healthcare professionals prior initiating dtc promotion new medicine new therapeutic indication approved medicine designed educate consumers medicine condition prescribed accurate supported evidence include information risks benefits treatments provide information treatment options diet lifestyle changes referenced prescribing information product targeted audience least per cent adults back tophome responsibility ethical conduct marketing ethics directtoconsumer advertising corporate responsibility report directtoconsumer advertising approach performance us legal advertise prescription medicines consumers tv print advertisements known directtoconsumer dtc advertising new zealand bangladesh korea also allow limited dtc advertising dtc advertising prescription medicines permitted markets promoting use prescription medicines directly consumers raise concerns critics believe encourages people request unnecessary treatment adding burden healthcare systems believe responsible pharmaceutical advertising useful source health information patients helps increase knowledge conditions educates patients treatment options countries us dtc advertising common industry practice would competitive disadvantage promote products way patients must still consult physicians condition appropriateness prescription medicine obtain consent receiving medicines prescription medicines us dtc communications policy based phrma guiding principles direct consumer advertisements prescription medicines detailed approval process dtc advertising includes review legal regulatory medical specialists appropriate us marketing employees received training dtc policy dtc television advertisements including audio visual components submitted us food drug administration fda review least days advance broadcast members public healthcare professionals send comments complaints dtc advertising phrmas office accountability reports comments responses companies fda fda amendments act imposes restrictions dtc advertising gives fda ability require submission dtc television advertisements days prior dissemination imposes new standard presentation safety information broadcast advertisements companies responsible false misleading dtc advertisements fined implemented provisions dtc advertising line acts requirements fund diseaseawareness campaigns designed increase understanding specific disease linked promotion gsk products also governed dtc policy disease awareness campaigns include television print advertisements direct mail mention specific gsk products make people aware treatments available condition encourage see doctor campaign materials branded indicate produced gsk overthecounter medicines consumer healthcare products advertising overthecounter medicines oral healthcare nutritional products governed national regulations codes practice advertising overthecounter medicines also promoted pharmacists doctors dentists sales teams belong consumer healthcare products association us comply code advertising practices nonprescription medicines gsk consumer healthcare advertising reviewed copy review committees larger markets medical legal personnel smaller markets publication ensure meets standards advertising children guidelines advertising children prohibit advertising designed appeal targeted children legally mandated minimum age example comply guidelines uk buy advertising space childrens media supply vending machines primary schools sports star sponsorship important brands lucozade sport guidelines state people set appropriate example used sponsorship appeal solely children age principles dtc advertising us policy requires dtc advertising dedicate appropriate amount time educating healthcare professionals prior initiating dtc promotion new medicine new therapeutic indication approved medicine designed educate consumers medicine condition prescribed accurate supported evidence include information risks benefits treatments provide information treatment options diet lifestyle changes referenced prescribing information product targeted audience least per cent adults back top home responsibility ethical conduct marketing ethics directtoconsumer advertising corporate responsibility report directtoconsumer advertising approach performance us legal advertise prescription medicines consumers tv print advertisements known directtoconsumer dtc advertising new zealand bangladesh korea also allow limited dtc advertising dtc advertising prescription medicines permitted markets promoting use prescription medicines directly consumers raise concerns critics believe encourages people request unnecessary treatment adding burden healthcare systems believe responsible pharmaceutical advertising useful source health information patients helps increase knowledge conditions educates patients treatment options countries us dtc advertising common industry practice would competitive disadvantage promote products way patients must still consult physicians condition appropriateness prescription medicine obtain consent receiving medicines prescription medicines us dtc communications policy based phrma guiding principles direct consumer advertisements prescription medicines detailed approval process dtc advertising includes review legal regulatory medical specialists appropriate us marketing employees received training dtc policy dtc television advertisements including audio visual components submitted us food drug administration fda review least days advance broadcast members public healthcare professionals send comments complaints dtc advertising phrmas office accountability reports comments responses companies fda fda amendments act imposes restrictions dtc advertising gives fda ability require submission dtc television advertisements days prior dissemination imposes new standard presentation safety information broadcast advertisements companies responsible false misleading dtc advertisements fined implemented provisions dtc advertising line acts requirements fund diseaseawareness campaigns designed increase understanding specific disease linked promotion gsk products also governed dtc policy disease awareness campaigns include television print advertisements direct mail mention specific gsk products make people aware treatments available condition encourage see doctor campaign materials branded indicate produced gsk overthecounter medicines consumer healthcare products advertising overthecounter medicines oral healthcare nutritional products governed national regulations codes practice advertising overthecounter medicines also promoted pharmacists doctors dentists sales teams belong consumer healthcare products association us comply code advertising practices nonprescription medicines gsk consumer healthcare advertising reviewed copy review committees larger markets medical legal personnel smaller markets publication ensure meets standards advertising children guidelines advertising children prohibit advertising designed appeal targeted children legally mandated minimum age example comply guidelines uk buy advertising space childrens media supply vending machines primary schools sports star sponsorship important brands lucozade sport guidelines state people set appropriate example used sponsorship appeal solely children age principles dtc advertising us policy requires dtc advertising dedicate appropriate amount time educating healthcare professionals prior initiating dtc promotion new medicine new therapeutic indication approved medicine designed educate consumers medicine condition prescribed accurate supported evidence include information risks benefits treatments provide information treatment options diet lifestyle changes referenced prescribing information product targeted audience least per cent adults back top home responsibility ethical conduct marketing ethics directtoconsumer advertising corporate responsibility report directtoconsumer advertising approach performance problems gsk us dtc advertising identified fda receive comments phrma office accountability relating gsk dtc print advertisements february gsk received letter us food drug administration division drug marketing advertising communications saying television advertisement presented misleading suggestion superiority drug therapies overstated efficacy gsks product avodart advertisement aired march september longer use time letter received continuing make every effort ensure future advertisements incorporate directions provided us fda back top home responsibility ethical conduct marketing ethics directtoconsumer advertising corporate responsibility report directtoconsumer advertising approach performance problems gsk us dtc advertising identified fda receive comments phrma office accountability relating gsk dtc print advertisements february gsk received letter us food drug administration division drug marketing advertising communications saying television advertisement presented misleading suggestion superiority drug therapies overstated efficacy gsks product avodart advertisement aired march september longer use time letter received continuing make every effort ensure future advertisements incorporate directions provided us fda back top home responsibility ethical conduct training awareness corporate responsibility report training awareness training awareness programmes help employees understand importance ethical conduct apply policies practice new employees uk us complete induction training code conduct available intranet site annual management certification programme requires managers confirm comply ethics policies programme covers managers worldwide managers access three elearning modules ethical leadership specialised training provided employees working rd manufacturing sales marketing additional regulatory requirements corporate ethics compliance intranet contains links company policies ethics compliance training new recruits ethical decisionmaking model ethics quiz contact details compliance officers free phone numbers global confidential reporting line well phone line available languages used reporting concerns employees may relating compliance policies code conduct also integrity helpline based us provides advice callers within outside company code conduct issues well reporting channel training employees working sales marketing includes induction training testing marketing code practice detailed training sales representatives medicines promote diseases designed treat regular refresher courses held least year regular management updates europe emerging markets asia pacific us types unethical conduct detected disciplinary actions taken ethics training practice ethics training helps employees make right decisions apply policies practice example new employees encouraged ask following questions making decision legal ethical consistent gsk policy code conduct consistent gsks mission spirit explain family friends would comfortable appeared newspaper also run ethical decisionmaking training established employees leaders training employees explore ethical dilemmas may face work receive guidance help understand appropriate response one example ethical dilemma arrive office large gift basket filled expensive chocolates gourmet treats desk estimate value enclosed note consultant thanks choosing us consulting partner look forward working keep gift since already chose consultant gift cant considered influenced decision b call owner explain gift certainly thoughtful accept gsk policies accept item tell returning gift basket look forward working firm c put goodies office coffee station everyone enjoy best solution return gift answer b back tophome responsibility ethical conduct training awareness corporate responsibility report training awareness training awareness programmes help employees understand importance ethical conduct apply policies practice new employees uk us complete induction training code conduct available intranet site annual management certification programme requires managers confirm comply ethics policies programme covers managers worldwide managers access three elearning modules ethical leadership specialised training provided employees working rd manufacturing sales marketing additional regulatory requirements corporate ethics compliance intranet contains links company policies ethics compliance training new recruits ethical decisionmaking model ethics quiz contact details compliance officers free phone numbers global confidential reporting line well phone line available languages used reporting concerns employees may relating compliance policies code conduct also integrity helpline based us provides advice callers within outside company code conduct issues well reporting channel training employees working sales marketing includes induction training testing marketing code practice detailed training sales representatives medicines promote diseases designed treat regular refresher courses held least year regular management updates europe emerging markets asia pacific us types unethical conduct detected disciplinary actions taken ethics training practice ethics training helps employees make right decisions apply policies practice example new employees encouraged ask following questions making decision legal ethical consistent gsk policy code conduct consistent gsks mission spirit explain family friends would comfortable appeared newspaper also run ethical decisionmaking training established employees leaders training employees explore ethical dilemmas may face work receive guidance help understand appropriate response one example ethical dilemma arrive office large gift basket filled expensive chocolates gourmet treats desk estimate value enclosed note consultant thanks choosing us consulting partner look forward working keep gift since already chose consultant gift cant considered influenced decision b call owner explain gift certainly thoughtful accept gsk policies accept item tell returning gift basket look forward working firm c put goodies office coffee station everyone enjoy best solution return gift answer b back top home responsibility ethical conduct training awareness corporate responsibility report training awareness training awareness programmes help employees understand importance ethical conduct apply policies practice new employees uk us complete induction training code conduct available intranet site annual management certification programme requires managers confirm comply ethics policies programme covers managers worldwide managers access three elearning modules ethical leadership specialised training provided employees working rd manufacturing sales marketing additional regulatory requirements corporate ethics compliance intranet contains links company policies ethics compliance training new recruits ethical decisionmaking model ethics quiz contact details compliance officers free phone numbers global confidential reporting line well phone line available languages used reporting concerns employees may relating compliance policies code conduct also integrity helpline based us provides advice callers within outside company code conduct issues well reporting channel training employees working sales marketing includes induction training testing marketing code practice detailed training sales representatives medicines promote diseases designed treat regular refresher courses held least year regular management updates europe emerging markets asia pacific us types unethical conduct detected disciplinary actions taken ethics training practice ethics training helps employees make right decisions apply policies practice example new employees encouraged ask following questions making decision legal ethical consistent gsk policy code conduct consistent gsks mission spirit explain family friends would comfortable appeared newspaper also run ethical decisionmaking training established employees leaders training employees explore ethical dilemmas may face work receive guidance help understand appropriate response one example ethical dilemma arrive office large gift basket filled expensive chocolates gourmet treats desk estimate value enclosed note consultant thanks choosing us consulting partner look forward working keep gift since already chose consultant gift cant considered influenced decision b call owner explain gift certainly thoughtful accept gsk policies accept item tell returning gift basket look forward working firm c put goodies office coffee station everyone enjoy best solution return gift answer b back top home responsibility ethical conduct training awareness leading example corporate responsibility report leading example senior managers expected lead example complying company policies supporting staff reinforced annually formal management certification business ethics managers confirm understanding compliance company policies contained employee guide business conduct management certification promotes awareness gsks ethical standards company policies emphasises importance company policies thousands gsk employees course daily activities must comply law company policies conduct company transactions full certification statement understand gsk committed principle performance integrity particular ensuring activities comply applicable laws received copy access gsk code conduct polgsk gsk corporate policies corporate policy index accessible corporate ethics compliance community read understand employee guide business conduct accessible corporate ethics compliance community complied applicable laws regulations gsk corporate local policies procedures understand responsibility promptly report actual suspected violations law regulations gsk corporate local policies procedures reported actual potential compliance issues aware concerning legal requirements company policies following statements also applicable supervisors personnel management responsibility people supervision received copies access gsk code conduct applicable gsk policies informed responsibilities put place appropriate measures ensure people supervision comply applicable laws regulations gsk corporate local policies procedures working behalf gsk new hire employees supervision completed scheduled complete gsk corporate ethics compliance new hire training program gsk induction corporate ethics compliance community read understood shall comply fully policies procedures specified learning activity back top home responsibility ethical conduct training awareness leading example corporate responsibility report leading example senior managers expected lead example complying company policies supporting staff reinforced annually formal management certification business ethics managers confirm understanding compliance company policies contained employee guide business conduct management certification promotes awareness gsks ethical standards company policies emphasises importance company policies thousands gsk employees course daily activities must comply law company policies conduct company transactions full certification statement understand gsk committed principle performance integrity particular ensuring activities comply applicable laws received copy access gsk code conduct polgsk gsk corporate policies corporate policy index accessible corporate ethics compliance community read understand employee guide business conduct accessible corporate ethics compliance community complied applicable laws regulations gsk corporate local policies procedures understand responsibility promptly report actual suspected violations law regulations gsk corporate local policies procedures reported actual potential compliance issues aware concerning legal requirements company policies following statements also applicable supervisors personnel management responsibility people supervision received copies access gsk code conduct applicable gsk policies informed responsibilities put place appropriate measures ensure people supervision comply applicable laws regulations gsk corporate local policies procedures working behalf gsk new hire employees supervision completed scheduled complete gsk corporate ethics compliance new hire training program gsk induction corporate ethics compliance community read understood shall comply fully policies procedures specified learning activity back top home responsibility ethical conduct training awareness performance corporate responsibility report performance plans global gsk intends ethics integrity part therefore following key ethics integrity principles messages provided business training groups across company integration regular training courses gsk unwavering commitment conducting business integrity full compliance law every gsk employee personally professionally responsible helping gsk maintain organisational integrity good reputation profits without principles short lived faced difficult ethical situations reference ethical decisionmaking model legal consistent company policy consistent gsk values code conduct explain family friends would comfortable printed newspaper benefit people involved training describes gsk employees obtain assistance manager corporate ethics compliance web community human resources legal compliance officers champions integrity helpline based us training awareness activity included managers completed selfcertification process launched training new general managers site directors compliance responsibilities well wider monitoring compliance arrangements gsk added performing leading integrity training induction programme focuses ethical decision making code conduct raised awareness global confidential reporting line extensive poster campaign awareness programmes intranet confidential reporting phone line available countries languages target set ethical leadership objectives top managers put hold transition new ceo planning implement track assess ethical measures executive level company united states employees contractors completed compliance refresher training new hire training completed people launched redesigned training curriculum new us pharmaceuticals field sales employees curriculum integrates training ethical commercial practices sales training rather providing standalone modules integrate compliance training range sales training programmes added ethics section employee manual commercial policies expands policies provide information helps people make right decisions commercial interactions japan promotion compliance team trained employees gsk promotional code including entire sales force marketing employees clinical trial monitors employees interact healthcare professionals employees took course submitted letter pledged compliance standards law back tophome responsibility ethical conduct training awareness performance corporate responsibility report performance plans global gsk intends ethics integrity part therefore following key ethics integrity principles messages provided business training groups across company integration regular training courses gsk unwavering commitment conducting business integrity full compliance law every gsk employee personally professionally responsible helping gsk maintain organisational integrity good reputation profits without principles short lived faced difficult ethical situations reference ethical decisionmaking model legal consistent company policy consistent gsk values code conduct explain family friends would comfortable printed newspaper benefit people involved training describes gsk employees obtain assistance manager corporate ethics compliance web community human resources legal compliance officers champions integrity helpline based us training awareness activity included managers completed selfcertification process launched training new general managers site directors compliance responsibilities well wider monitoring compliance arrangements gsk added performing leading integrity training induction programme focuses ethical decision making code conduct raised awareness global confidential reporting line extensive poster campaign awareness programmes intranet confidential reporting phone line available countries languages target set ethical leadership objectives top managers put hold transition new ceo planning implement track assess ethical measures executive level company united states employees contractors completed compliance refresher training new hire training completed people launched redesigned training curriculum new us pharmaceuticals field sales employees curriculum integrates training ethical commercial practices sales training rather providing standalone modules integrate compliance training range sales training programmes added ethics section employee manual commercial policies expands policies provide information helps people make right decisions commercial interactions japan promotion compliance team trained employees gsk promotional code including entire sales force marketing employees clinical trial monitors employees interact healthcare professionals employees took course submitted letter pledged compliance standards law back top home responsibility ethical conduct training awareness performance corporate responsibility report performance plans global gsk intends ethics integrity part therefore following key ethics integrity principles messages provided business training groups across company integration regular training courses gsk unwavering commitment conducting business integrity full compliance law every gsk employee personally professionally responsible helping gsk maintain organisational integrity good reputation profits without principles short lived faced difficult ethical situations reference ethical decisionmaking model legal consistent company policy consistent gsk values code conduct explain family friends would comfortable printed newspaper benefit people involved training describes gsk employees obtain assistance manager corporate ethics compliance web community human resources legal compliance officers champions integrity helpline based us training awareness activity included managers completed selfcertification process launched training new general managers site directors compliance responsibilities well wider monitoring compliance arrangements gsk added performing leading integrity training induction programme focuses ethical decision making code conduct raised awareness global confidential reporting line extensive poster campaign awareness programmes intranet confidential reporting phone line available countries languages target set ethical leadership objectives top managers put hold transition new ceo planning implement track assess ethical measures executive level company united states employees contractors completed compliance refresher training new hire training completed people launched redesigned training curriculum new us pharmaceuticals field sales employees curriculum integrates training ethical commercial practices sales training rather providing standalone modules integrate compliance training range sales training programmes added ethics section employee manual commercial policies expands policies provide information helps people make right decisions commercial interactions japan promotion compliance team trained employees gsk promotional code including entire sales force marketing employees clinical trial monitors employees interact healthcare professionals employees took course submitted letter pledged compliance standards law back top home responsibility ethical conduct monitoring compliance corporate responsibility report monitoring compliance approach performance plans managers accountable managing risks noncompliance policies areas responsibility overseen seek advice corporate ethics compliance department promotes effective compliance programmes addresses compliance issues reports problems progress senior management board dedicated compliance officer business units rd manufacturing vaccines pharma europe pharmaceuticals emerging markets pharmaceuticals asia pacific japan consumer healthcare corporate us pharmaceuticals additional compliance representatives markets compliance officers senior managers direct access leadership teams gsk functions source expertise anyone question ethics gsk policies corporate compliance officer reports directly ceo develop gsks internal infrastructure new fulltime compliance director positions also established latin america middle eastnorth africa asia pacific china demonstrates ongoing commitment provide dedicated focused support senior management teams globally previously support via 'champion ' roles fulfilled individuals additional functional responsibilities beyond ethics compliance risk management risk oversight compliance council rocc includes several corporate executive team cet members oversees risk management internal control activities rocc supported gsks corporate assurance department corporate ethics compliance department gsks corporate compliance officer chairs rocc regularly reports significant risks cet audit committee board information risk management see corporate governance section annual report monitoring sales marketing sales representatives supervised managers regularly monitor educational events visits doctors expenses use riskbased approach determine frequency checks different districts individual sales representatives us sales representatives receive inquiries physicians offlabel uses gsk products must notify medical information department responds inquiry via medical information letter sales representatives must solicit offlabel questions physicians frequent medical information letter requests sales representative indicate employee prompting questions promoting offlabel uses gsk products monitor requests medical information letters internal audit department regularly audits sales marketing practices globally monitoring payments healthcare professionals organisations payments recorded monitored different ways different countries example us introduced state reporting system expenditure healthcare professionals line legislation several us states japan payments individual healthcare professionals medical institutions monitored quarterly basis results reported promotion compliance officers internal audit department systems help us identify situations excessive meals gifts may provided gsk reporting channels employees encouraged seek help ethical issues report concerns suspected cases misconduct line manager corporate ethics compliance department compliance officer compliance champion gsks human resources legal departments global confidential reporting line integrity helpline us us employees also report concerns offsite post office box via email reporting channels promoted employee guide business conduct gsk intranet training addressing misconduct corporate ethics compliance department monitors tracks allegations suspected legal ethical policy infractions ensures allegations appropriately investigated disciplinary action including dismissal taken necessary serious violations policies reported audit committee board back tophome responsibility ethical conduct monitoring compliance corporate responsibility report monitoring compliance approach performance plans managers accountable managing risks noncompliance policies areas responsibility overseen seek advice corporate ethics compliance department promotes effective compliance programmes addresses compliance issues reports problems progress senior management board dedicated compliance officer business units rd manufacturing vaccines pharma europe pharmaceuticals emerging markets pharmaceuticals asia pacific japan consumer healthcare corporate us pharmaceuticals additional compliance representatives markets compliance officers senior managers direct access leadership teams gsk functions source expertise anyone question ethics gsk policies corporate compliance officer reports directly ceo develop gsks internal infrastructure new fulltime compliance director positions also established latin america middle eastnorth africa asia pacific china demonstrates ongoing commitment provide dedicated focused support senior management teams globally previously support via 'champion ' roles fulfilled individuals additional functional responsibilities beyond ethics compliance risk management risk oversight compliance council rocc includes several corporate executive team cet members oversees risk management internal control activities rocc supported gsks corporate assurance department corporate ethics compliance department gsks corporate compliance officer chairs rocc regularly reports significant risks cet audit committee board information risk management see corporate governance section annual report monitoring sales marketing sales representatives supervised managers regularly monitor educational events visits doctors expenses use riskbased approach determine frequency checks different districts individual sales representatives us sales representatives receive inquiries physicians offlabel uses gsk products must notify medical information department responds inquiry via medical information letter sales representatives must solicit offlabel questions physicians frequent medical information letter requests sales representative indicate employee prompting questions promoting offlabel uses gsk products monitor requests medical information letters internal audit department regularly audits sales marketing practices globally monitoring payments healthcare professionals organisations payments recorded monitored different ways different countries example us introduced state reporting system expenditure healthcare professionals line legislation several us states japan payments individual healthcare professionals medical institutions monitored quarterly basis results reported promotion compliance officers internal audit department systems help us identify situations excessive meals gifts may provided gsk reporting channels employees encouraged seek help ethical issues report concerns suspected cases misconduct line manager corporate ethics compliance department compliance officer compliance champion gsks human resources legal departments global confidential reporting line integrity helpline us us employees also report concerns offsite post office box via email reporting channels promoted employee guide business conduct gsk intranet training addressing misconduct corporate ethics compliance department monitors tracks allegations suspected legal ethical policy infractions ensures allegations appropriately investigated disciplinary action including dismissal taken necessary serious violations policies reported audit committee board back top home responsibility ethical conduct monitoring compliance corporate responsibility report monitoring compliance approach performance plans managers accountable managing risks noncompliance policies areas responsibility overseen seek advice corporate ethics compliance department promotes effective compliance programmes addresses compliance issues reports problems progress senior management board dedicated compliance officer business units rd manufacturing vaccines pharma europe pharmaceuticals emerging markets pharmaceuticals asia pacific japan consumer healthcare corporate us pharmaceuticals additional compliance representatives markets compliance officers senior managers direct access leadership teams gsk functions source expertise anyone question ethics gsk policies corporate compliance officer reports directly ceo develop gsks internal infrastructure new fulltime compliance director positions also established latin america middle eastnorth africa asia pacific china demonstrates ongoing commitment provide dedicated focused support senior management teams globally previously support via 'champion ' roles fulfilled individuals additional functional responsibilities beyond ethics compliance risk management risk oversight compliance council rocc includes several corporate executive team cet members oversees risk management internal control activities rocc supported gsks corporate assurance department corporate ethics compliance department gsks corporate compliance officer chairs rocc regularly reports significant risks cet audit committee board information risk management see corporate governance section annual report monitoring sales marketing sales representatives supervised managers regularly monitor educational events visits doctors expenses use riskbased approach determine frequency checks different districts individual sales representatives us sales representatives receive inquiries physicians offlabel uses gsk products must notify medical information department responds inquiry via medical information letter sales representatives must solicit offlabel questions physicians frequent medical information letter requests sales representative indicate employee prompting questions promoting offlabel uses gsk products monitor requests medical information letters internal audit department regularly audits sales marketing practices globally monitoring payments healthcare professionals organisations payments recorded monitored different ways different countries example us introduced state reporting system expenditure healthcare professionals line legislation several us states japan payments individual healthcare professionals medical institutions monitored quarterly basis results reported promotion compliance officers internal audit department systems help us identify situations excessive meals gifts may provided gsk reporting channels employees encouraged seek help ethical issues report concerns suspected cases misconduct line manager corporate ethics compliance department compliance officer compliance champion gsks human resources legal departments global confidential reporting line integrity helpline us us employees also report concerns offsite post office box via email reporting channels promoted employee guide business conduct gsk intranet training addressing misconduct corporate ethics compliance department monitors tracks allegations suspected legal ethical policy infractions ensures allegations appropriately investigated disciplinary action including dismissal taken necessary serious violations policies reported audit committee board back top home responsibility ethical conduct monitoring compliance corporate responsibility report monitoring compliance approach performance plans reviewing compliance risk management strategy conducted review corporate ethics strategy based results review took steps following areas embed ethical culture gsk recruitment included questions ethics integrity recruitment process gsk managers interview guide carried extensive preemployment checks ensure recruit people share gsks values training extended ethics compliance induction training new employees worldwide provided extra training guidance employees committing minor breaches prevent committing serious breaches future global confidential reporting line extended independently managed reporting line countries operate many countries employees call native language undertook extensive intranet poster campaign raise awareness service senior management developed new training awareness programmes site directors general managers key representatives gsk countries locations work included individual briefings executive team new appointees compliance responsibilities policies streamlined administration corporate policies procedures involved reducing number policies procedures half requiring employees need detailed awareness policies procedures specific role financial fraud established new fraud risk assessment tool help us prevent financial fraud finance leadership team regularly review financial fraud cases progress meeting strategy review objectives reviewed twice year gsk audit committee board plan enhance global confidential reporting phone line facility internet reporting introduced selected countries languages supplier evolves technology number languages available addressing misconduct employees disciplined policy violations dismissed agreed leave company voluntarily known separations disciplinary actions included documented warnings instances financial penalties disciplinary actions included cases employees breaching sales marketing codes cases resulted dismissals separations company cases resulted documented warnings addition appropriate discipline employees staying company received retraining increased monitoring cases retraining also extended employees colleagues prevent making similar mistakes main types violations year included marketing promotional activities good manufacturinggood distribution practices falsification documents travel expenses claims code conduct issues back tophome responsibility ethical conduct monitoring compliance corporate responsibility report monitoring compliance approach performance plans reviewing compliance risk management strategy conducted review corporate ethics strategy based results review took steps following areas embed ethical culture gsk recruitment included questions ethics integrity recruitment process gsk managers interview guide carried extensive preemployment checks ensure recruit people share gsks values training extended ethics compliance induction training new employees worldwide provided extra training guidance employees committing minor breaches prevent committing serious breaches future global confidential reporting line extended independently managed reporting line countries operate many countries employees call native language undertook extensive intranet poster campaign raise awareness service senior management developed new training awareness programmes site directors general managers key representatives gsk countries locations work included individual briefings executive team new appointees compliance responsibilities policies streamlined administration corporate policies procedures involved reducing number policies procedures half requiring employees need detailed awareness policies procedures specific role financial fraud established new fraud risk assessment tool help us prevent financial fraud finance leadership team regularly review financial fraud cases progress meeting strategy review objectives reviewed twice year gsk audit committee board plan enhance global confidential reporting phone line facility internet reporting introduced selected countries languages supplier evolves technology number languages available addressing misconduct employees disciplined policy violations dismissed agreed leave company voluntarily known separations disciplinary actions included documented warnings instances financial penalties disciplinary actions included cases employees breaching sales marketing codes cases resulted dismissals separations company cases resulted documented warnings addition appropriate discipline employees staying company received retraining increased monitoring cases retraining also extended employees colleagues prevent making similar mistakes main types violations year included marketing promotional activities good manufacturinggood distribution practices falsification documents travel expenses claims code conduct issues back top home responsibility ethical conduct monitoring compliance corporate responsibility report monitoring compliance approach performance plans reviewing compliance risk management strategy conducted review corporate ethics strategy based results review took steps following areas embed ethical culture gsk recruitment included questions ethics integrity recruitment process gsk managers interview guide carried extensive preemployment checks ensure recruit people share gsks values training extended ethics compliance induction training new employees worldwide provided extra training guidance employees committing minor breaches prevent committing serious breaches future global confidential reporting line extended independently managed reporting line countries operate many countries employees call native language undertook extensive intranet poster campaign raise awareness service senior management developed new training awareness programmes site directors general managers key representatives gsk countries locations work included individual briefings executive team new appointees compliance responsibilities policies streamlined administration corporate policies procedures involved reducing number policies procedures half requiring employees need detailed awareness policies procedures specific role financial fraud established new fraud risk assessment tool help us prevent financial fraud finance leadership team regularly review financial fraud cases progress meeting strategy review objectives reviewed twice year gsk audit committee board plan enhance global confidential reporting phone line facility internet reporting introduced selected countries languages supplier evolves technology number languages available addressing misconduct employees disciplined policy violations dismissed agreed leave company voluntarily known separations disciplinary actions included documented warnings instances financial penalties disciplinary actions included cases employees breaching sales marketing codes cases resulted dismissals separations company cases resulted documented warnings addition appropriate discipline employees staying company received retraining increased monitoring cases retraining also extended employees colleagues prevent making similar mistakes main types violations year included marketing promotional activities good manufacturinggood distribution practices falsification documents travel expenses claims code conduct issues back top home responsibility ethical conduct case studies corporate responsibility report case studies suitability gsks approved speaker list well ensuring employees comply policies vital people working behalf meet highest ethical standards us pharmaceuticals compliance department received information gsk integrity helpline healthcare professional hcp engaged speak gsks behalf allegedly failed comply company policies promotional programmes two consecutive days gsk reviewed materials one programmes question identified number issues policy violations person suspended gsk speaker pending completion followup investigation investigation removed hcp approved speaker list responsible marketing weight loss treatment nearly twothirds us adults either clinically obese seriously overweight causing dramatic increase lifethreatening medical conditions heart disease diabetes adding strain healthcare system even small amount weight loss greatly reduce risk developing associated medical problems gsks overthecounter weight loss product alli orlistat mg helps overweight adults lose weight preventing per cent dietary fat absorbed gut helps people lose per cent weight diet exercise alone alli launched us june since sold six million starter packs alli received positive opinion european medicines agency emea committee medicinal products human use january european commission granted nonprescription licence product vital alli marketed responsibly used right way need educate physicians dieticians pharmacists ensure alli sold appropriately patients receive right information treatment marketing emphasises using alli requires lifestyle changes including exercise lowfat diet produce right results without unwanted side effects safety efficacy profile orlistat well documented established data clinical studies set website wwwmyallicom provide support alli users enables people set targets track weight loss post success stories includes ready alli quiz asks potential users confirm commitment moderating diet taking exercise reading label carefully site also includes alli circles online moderated forum users share experiences help stay focused weight loss targets forum gives us valuable feedback patients effectiveness product monitor site reports adverse effects reported fda inappropriate content donated dress success dfs mark oneyear anniversary us launch alli dfs international nonprofit organisation provides business clothing career support disadvantaged women encourage alli users volunteer dfs donate clothing becomes big lose weight dfs far received pieces clothing alli users anderson j orlistat management overweight individuals obesity review potential mg overthecounter dosage expert opin pharmacother alli summary product characteristics spc jacob togerson j orlistat treatment beneficial primary care tertiary settings obesity reviews back top home responsibility ethical conduct case studies corporate responsibility report case studies suitability gsks approved speaker list well ensuring employees comply policies vital people working behalf meet highest ethical standards us pharmaceuticals compliance department received information gsk integrity helpline healthcare professional hcp engaged speak gsks behalf allegedly failed comply company policies promotional programmes two consecutive days gsk reviewed materials one programmes question identified number issues policy violations person suspended gsk speaker pending completion followup investigation investigation removed hcp approved speaker list responsible marketing weight loss treatment nearly twothirds us adults either clinically obese seriously overweight causing dramatic increase lifethreatening medical conditions heart disease diabetes adding strain healthcare system even small amount weight loss greatly reduce risk developing associated medical problems gsks overthecounter weight loss product alli orlistat mg helps overweight adults lose weight preventing per cent dietary fat absorbed gut helps people lose per cent weight diet exercise alone alli launched us june since sold six million starter packs alli received positive opinion european medicines agency emea committee medicinal products human use january european commission granted nonprescription licence product vital alli marketed responsibly used right way need educate physicians dieticians pharmacists ensure alli sold appropriately patients receive right information treatment marketing emphasises using alli requires lifestyle changes including exercise lowfat diet produce right results without unwanted side effects safety efficacy profile orlistat well documented established data clinical studies set website wwwmyallicom provide support alli users enables people set targets track weight loss post success stories includes ready alli quiz asks potential users confirm commitment moderating diet taking exercise reading label carefully site also includes alli circles online moderated forum users share experiences help stay focused weight loss targets forum gives us valuable feedback patients effectiveness product monitor site reports adverse effects reported fda inappropriate content donated dress success dfs mark oneyear anniversary us launch alli dfs international nonprofit organisation provides business clothing career support disadvantaged women encourage alli users volunteer dfs donate clothing becomes big lose weight dfs far received pieces clothing alli users anderson j orlistat management overweight individuals obesity review potential mg overthecounter dosage expert opin pharmacother alli summary product characteristics spc jacob togerson j orlistat treatment beneficial primary care tertiary settings obesity reviews back top home responsibility ethical conduct case studies corporate responsibility report case studies suitability gsks approved speaker list well ensuring employees comply policies vital people working behalf meet highest ethical standards us pharmaceuticals compliance department received information gsk integrity helpline healthcare professional hcp engaged speak gsks behalf allegedly failed comply company policies promotional programmes two consecutive days gsk reviewed materials one programmes question identified number issues policy violations person suspended gsk speaker pending completion followup investigation investigation removed hcp approved speaker list responsible marketing weight loss treatment nearly twothirds us adults either clinically obese seriously overweight causing dramatic increase lifethreatening medical conditions heart disease diabetes adding strain healthcare system even small amount weight loss greatly reduce risk developing associated medical problems gsks overthecounter weight loss product alli orlistat mg helps overweight adults lose weight preventing per cent dietary fat absorbed gut helps people lose per cent weight diet exercise alone alli launched us june since sold six million starter packs alli received positive opinion european medicines agency emea committee medicinal products human use january european commission granted nonprescription licence product vital alli marketed responsibly used right way need educate physicians dieticians pharmacists ensure alli sold appropriately patients receive right information treatment marketing emphasises using alli requires lifestyle changes including exercise lowfat diet produce right results without unwanted side effects safety efficacy profile orlistat well documented established data clinical studies set website wwwmyallicom provide support alli users enables people set targets track weight loss post success stories includes ready alli quiz asks potential users confirm commitment moderating diet taking exercise reading label carefully site also includes alli circles online moderated forum users share experiences help stay focused weight loss targets forum gives us valuable feedback patients effectiveness product monitor site reports adverse effects reported fda inappropriate content donated dress success dfs mark oneyear anniversary us launch alli dfs international nonprofit organisation provides business clothing career support disadvantaged women encourage alli users volunteer dfs donate clothing becomes big lose weight dfs far received pieces clothing alli users anderson j orlistat management overweight individuals obesity review potential mg overthecounter dosage expert opin pharmacother alli summary product characteristics spc jacob togerson j orlistat treatment beneficial primary care tertiary settings obesity reviews back top home responsibility ethical conduct qas corporate responsibility report qas respond questions raised stakeholders one company establish high standards ethical conduct industry approach required set high standards ethical conduct hope establish benchmark companies judged also work companies trade associations develop high ethical standards believe best interest patients pharmaceutical industry adopts common high standards ethical conduct also help improve trust industry among stakeholders lot gsk employees dismissed unethical conduct policies working employees dismissed agreed leave company voluntarily result policy violations unethical conduct occurs companies believe figures demonstrate effectiveness monitoring compliance programmes furthering ethical culture recruiting right people providing right training tools improving checks encouraging people speak enable us identify address unethical conduct consistent responsive manner gsk unduly influencing doctors take several approaches protect inappropriate influence doctors including regional marketing codes practice regular training monitoring policies apply employees agents commit us promotional practices ethical responsible principled patient centred prohibit kickbacks bribery inducements doctors promotion unapproved uses medicines sales force regularly trained supervised managers monitor educational events visits doctors expenses prevent offlabel promotion gsk employees dealing healthcare professionals undergo extensive training monitoring instructed full accurate information may provided approved uses medicine must based valid scientific evidence must accurate balanced fair objective unambiguous date questions doctors offlabel uses products must referred medical information department us additional processes place monitoring referrals help us ensure representatives promoting offlabel uses monitor volume letters responding questions types referrals made individual representatives example number referrals relating particular product particular offlabel use additionally internal audit department regularly audits sales marketing practices globally advertising standards authority ruled health claims horlicks advert shown uk unsubstantiated gsk involved false advertising gsk involved false advertising nepali tv bengalilanguage satellite channel aimed viewers indian subcontinent briefly aired advert homes uk however advert intended approved use india done without knowledge health claims advert appropriate uk claims advert relate specifically indian market indian diet advertising standards authority uk upheld complaint nepali tv broadcasting advert uk reprimand gsk uk office fair trading oft investigating whether supermarkets suppliers wrongly sharing information prices gsk consumer products involved uk office fair trading oft began investigation potential breaches comppaegteit ion olaf w companies including gsk oft looking claims data pricing passed rival companies suppliers asked gsk cooperation accused breaking law tolerate unethical behaviour corrupt anticompetitive behaviour undermines fair competition inhibits economic development bad economies business people code conduct sets expectations employees conduct training ensure operate within letter spirit law maintain high standards ethical business behaviour cooperating fully oft take disciplinary action dismissal gsk employee found breached policies law back tophome responsibility ethical conduct qas corporate responsibility report qas respond questions raised stakeholders one company establish high standards ethical conduct industry approach required set high standards ethical conduct hope establish benchmark companies judged also work companies trade associations develop high ethical standards believe best interest patients pharmaceutical industry adopts common high standards ethical conduct also help improve trust industry among stakeholders lot gsk employees dismissed unethical conduct policies working employees dismissed agreed leave company voluntarily result policy violations unethical conduct occurs companies believe figures demonstrate effectiveness monitoring compliance programmes furthering ethical culture recruiting right people providing right training tools improving checks encouraging people speak enable us identify address unethical conduct consistent responsive manner gsk unduly influencing doctors take several approaches protect inappropriate influence doctors including regional marketing codes practice regular training monitoring policies apply employees agents commit us promotional practices ethical responsible principled patient centred prohibit kickbacks bribery inducements doctors promotion unapproved uses medicines sales force regularly trained supervised managers monitor educational events visits doctors expenses prevent offlabel promotion gsk employees dealing healthcare professionals undergo extensive training monitoring instructed full accurate information may provided approved uses medicine must based valid scientific evidence must accurate balanced fair objective unambiguous date questions doctors offlabel uses products must referred medical information department us additional processes place monitoring referrals help us ensure representatives promoting offlabel uses monitor volume letters responding questions types referrals made individual representatives example number referrals relating particular product particular offlabel use additionally internal audit department regularly audits sales marketing practices globally advertising standards authority ruled health claims horlicks advert shown uk unsubstantiated gsk involved false advertising gsk involved false advertising nepali tv bengalilanguage satellite channel aimed viewers indian subcontinent briefly aired advert homes uk however advert intended approved use india done without knowledge health claims advert appropriate uk claims advert relate specifically indian market indian diet advertising standards authority uk upheld complaint nepali tv broadcasting advert uk reprimand gsk uk office fair trading oft investigating whether supermarkets suppliers wrongly sharing information prices gsk consumer products involved uk office fair trading oft began investigation potential breaches competition law companies including gsk oft looking claims data pricing passed rival companies suppliers asked gsk cooperation accused breaking law tolerate unethical behaviour corrupt anticompetitive behaviour undermines fair competition inhibits economic development bad economies business people code conduct sets expectations employees conduct training ensure operate within letter spirit law maintain high standards ethical business behaviour cooperating fully oft take disciplinary action dismissal gsk employee found breached policies law back top home responsibility ethical conduct qas corporate responsibility report qas respond questions raised stakeholders one company establish high standards ethical conduct industry approach required set high standards ethical conduct hope establish benchmark companies judged also work companies trade associations develop high ethical standards believe best interest patients pharmaceutical industry adopts common high standards ethical conduct also help improve trust industry among stakeholders lot gsk employees dismissed unethical conduct policies working employees dismissed agreed leave company voluntarily result policy violations unethical conduct occurs companies believe figures demonstrate effectiveness monitoring compliance programmes furthering ethical culture recruiting right people providing right training tools improving checks encouraging people speak enable us identify address unethical conduct consistent responsive manner gsk unduly influencing doctors take several approaches protect inappropriate influence doctors including regional marketing codes practice regular training monitoring policies apply employees agents commit us promotional practices ethical responsible principled patient centred prohibit kickbacks bribery inducements doctors promotion unapproved uses medicines sales force regularly trained supervised managers monitor educational events visits doctors expenses prevent offlabel promotion gsk employees dealing healthcare professionals undergo extensive training monitoring instructed full accurate information may provided approved uses medicine must based valid scientific evidence must accurate balanced fair objective unambiguous date questions doctors offlabel uses products must referred medical information department us additional processes place monitoring referrals help us ensure representatives promoting offlabel uses monitor volume letters responding questions types referrals made individual representatives example number referrals relating particular product particular offlabel use additionally internal audit department regularly audits sales marketing practices globally advertising standards authority ruled health claims horlicks advert shown uk unsubstantiated gsk involved false advertising gsk involved false advertising nepali tv bengalilanguage satellite channel aimed viewers indian subcontinent briefly aired advert homes uk however advert intended approved use india done without knowledge health claims advert appropriate uk claims advert relate specifically indian market indian diet advertising standards authority uk upheld complaint nepali tv broadcasting advert uk reprimand gsk uk office fair trading oft investigating whether supermarkets suppliers wrongly sharing information prices gsk consumer products involved uk office fair trading oft began investigation potential breaches competition law companies including gsk oft looking claims data pricing passed rival companies suppliers asked gsk cooperation accused breaking law tolerate unethical behaviour corrupt anticompetitive behaviour undermines fair competition inhibits economic development bad economies business people code conduct sets expectations employees conduct training ensure operate within letter spirit law maintain high standards ethical business behaviour cooperating fully oft take disciplinary action dismissal gsk employee found breached policies law back top home responsibility supply chain corporate responsibility report supply chain want source companies maintain high labour environmental standards inadequate environment health safety ehs human rights standards indicator poor management impact quality compromise patient safety impede continuity supply essential medicines association poorly performing suppliers could also damage reputation conduct detailed assessments new existing suppliers monitor performance ehs human rights issues work closely suppliers prevent disruptions supply key medicines counterfeit drugs pose serious threat patients build anticounterfeiting features products packaging take steps prevent criminals making distributing fake gsk products also working assess environment health safety impacts manufacturing suppliers supply chain number suppliers spend bn buy goods services around suppliers supply chain complex ranges strategic relationships suppliers manufacture active pharmaceutical ingredients intermediates raw materials packaging gsk medicines contracts goods services office equipment cleaning security home responsibility supply chain corporate responsibility report supply chain want source companies maintain high labour environmental standards inadequate environment health safety ehs human rights standards indicator poor management impact quality compromise patient safety impede continuity supply essential medicines association poorly performing suppliers could also damage reputation conduct detailed assessments new existing suppliers monitor performance ehs human rights issues work closely suppliers prevent disruptions supply key medicines counterfeit drugs pose serious threat patients build anticounterfeiting features products packaging take steps prevent criminals making distributing fake gsk products also working assess environment health safety impacts manufacturing suppliers supply chain number suppliers spend bn buy goods services around suppliers supply chain complex ranges strategic relationships suppliers manufacture active pharmaceutical ingredients intermediates raw materials packaging gsk medicines contracts goods services office equipment cleaning security home responsibility supply chain responsibility supply chain corporate responsibility report responsibility supply chain approach ensuring high standards global suppliers includes preassessments potential suppliers gather information help evaluation inclusion human rights clauses supplier contracts full environment health safety ehs requirements contracts critical suppliers review ehs human rights routine supplier engagements example business performance meetings ehs audits potential existing suppliers regular progress monitoring additional advice technical support supplier contracts supplier contracts contain ehs requirements based global ehs standards human rights clauses based international labour organization conventions uns universal declaration human rights companies must agree ehs human rights requirements included selection riskbased approach supply chain large complex use riskbased approach target efforts focus critical suppliers mostly based europe north america asia account approximately per cent supplier spend critical suppliers include contract manufacturers suppliers present greatest risk gsk one following issues relevance supply essential medicines threats continuity supply value affected products gsk regulatory requirements hazards associated manufacturing processes materials environmental impacts develop longterm relationships critical suppliers conduct regular monitoring support uninterrupted supply high quality materials services gsk training gsk procurement teams train new procurement employees standards requirements ehs human rights emphasises role promoting compliance standards key procurement employees including procurement managers receive ongoing training topics develop new sustainable procurement guidelines supporting training plans focus sourcing materials sustainable sources products recycled content energyefficient equipmenthome responsibility supply chain responsibility supply chain corporate responsibility report responsibility supply chain approach ensuring high standards global suppliers includes preassessments potential suppliers gather information help evaluation inclusion human rights clauses supplier contracts full environment health safety ehs requirements contracts critical suppliers review ehs human rights routine supplier engagements example business performance meetings ehs audits potential existing suppliers regular progress monitoring additional advice technical support supplier contracts supplier contracts contain ehs requirements based global ehs standards human rights clauses based international labour organization conventions uns universal declaration human rights companies must agree ehs human rights requirements included selection riskbased approach supply chain large complex use riskbased approach target efforts focus critical suppliers mostly based europe north america asia account approximately per cent supplier spend critical suppliers include contract manufacturers suppliers present greatest risk gsk one following issues relevance supply essential medicines threats continuity supply value affected products gsk regulatory requirements hazards associated manufacturing processes materials environmental impacts develop longterm relationships critical suppliers conduct regular monitoring support uninterrupted supply high quality materials services gsk training gsk procurement teams train new procurement employees standards requirements ehs human rights emphasises role promoting compliance standards key procurement employees including procurement managers receive ongoing training topics develop new sustainable procurement guidelines supporting training plans focus sourcing materials sustainable sources products recycled content energyefficient equipment home responsibility supply chain responsibility supply chain corporate responsibility report responsibility supply chain approach ensuring high standards global suppliers includes preassessments potential suppliers gather information help evaluation inclusion human rights clauses supplier contracts full environment health safety ehs requirements contracts critical suppliers review ehs human rights routine supplier engagements example business performance meetings ehs audits potential existing suppliers regular progress monitoring additional advice technical support supplier contracts supplier contracts contain ehs requirements based global ehs standards human rights clauses based international labour organization conventions uns universal declaration human rights companies must agree ehs human rights requirements included selection riskbased approach supply chain large complex use riskbased approach target efforts focus critical suppliers mostly based europe north america asia account approximately per cent supplier spend critical suppliers include contract manufacturers suppliers present greatest risk gsk one following issues relevance supply essential medicines threats continuity supply value affected products gsk regulatory requirements hazards associated manufacturing processes materials environmental impacts develop longterm relationships critical suppliers conduct regular monitoring support uninterrupted supply high quality materials services gsk training gsk procurement teams train new procurement employees standards requirements ehs human rights emphasises role promoting compliance standards key procurement employees including procurement managers receive ongoing training topics develop new sustainable procurement guidelines supporting training plans focus sourcing materials sustainable sources products recycled content energyefficient equipment home responsibility supply chain responsibility supply chain human rights clause corporate responsibility report human rights clause supplier contracts contain human rights clause based international labour organizations conventions uns universal declaration human rights may amend exact wording clause negotiations suppliers translation suit local law changes reduce contractual impact intent clause gsk standard contract clause ethical standards human rights unless otherwise required prohibited law supplier warrants best knowledge relation supply goods services terms agreement employ engage otherwise use child labour circumstances tasks performed child labour could reasonably foreseen cause either physical emotional impairment development child use forced labour form prison indentured bonded otherwise employees required lodge papers deposits starting work provides safe healthy workplace presenting immediate hazards employees housing provided supplier employees safe habitation supplier provides access clean water food emergency healthcare employees event accidents incidents supplier 's workplace discriminate employees ground including race religion disability gender engage support use corporal punishment mental physical sexual verbal abuse use cruel abusive disciplinary practices workplace pays employee least minimum wage fair representation prevailing industry wage whichever higher provides employee legally mandated benefits complies laws working hours employment rights countries operates respectful employees right join form independent trade unions freedom association supplier agrees responsible controlling supply chain shall encourage compliance ethical standards human rights subsequent supplier goods services used supplier performing obligations agreement supplier shall ensure ethical human rights policies appropriate complaints procedure deal breaches policies gsk reserves right upon reasonable notice unless inspection cause case notice shall necessary enter upon supplier 's premises monitor compliance supplier warranties set clause supplier shall subject compliance law furnish gsk relevant documents requested gsk relation thereto subsection required general right audit elsewhere within agreement back top home responsibility supply chain responsibility supply chain human rights clause corporate responsibility report human rights clause supplier contracts contain human rights clause based international labour organizations conventions uns universal declaration human rights may amend exact wording clause negotiations suppliers translation suit local law changes reduce contractual impact intent clause gsk standard contract clause ethical standards human rights unless otherwise required prohibited law supplier warrants best knowledge relation supply goods services terms agreement employ engage otherwise use child labour circumstances tasks performed child labour could reasonably foreseen cause either physical emotional impairment development child use forced labour form prison indentured bonded otherwise employees required lodge papers deposits starting work provides safe healthy workplace presenting immediate hazards employees housing provided supplier employees safe habitation supplier provides access clean water food emergency healthcare employees event accidents incidents supplier 's workplace discriminate employees ground including race religion disability gender engage support use corporal punishment mental physical sexual verbal abuse use cruel abusive disciplinary practices workplace pays employee least minimum wage fair representation prevailing industry wage whichever higher provides employee legally mandated benefits complies laws working hours employment rights countries operates respectful employees right join form independent trade unions freedom association supplier agrees responsible controlling supply chain shall encourage compliance ethical standards human rights subsequent supplier goods services used supplier performing obligations agreement supplier shall ensure ethical human rights policies appropriate complaints procedure deal breaches policies gsk reserves right upon reasonable notice unless inspection cause case notice shall necessary enter upon supplier 's premises monitor compliance supplier warranties set clause supplier shall subject compliance law furnish gsk relevant documents requested gsk relation thereto subsection required general right audit elsewhere within agreement back top home responsibility supply chain responsibility supply chain choosing suppliers corporate responsibility report choosing suppliers conduct detailed assessment critical suppliers selected critical suppliers include contract manufacturers suppliers present greatest risk gsk one key risk areas use questionnaires onsite reviews ehs audits assess performance health safety environmental human rights issues assess potential new critical suppliers ehs standards must achieve minimum audit score per cent standards join supply chain following audit many suppliers met requirements implement plans improve ehs performance monitor progress cases provide opportunities training technical support enable supplier achieve required standards also expect suppliers established supply arrangements us make improvements monitor progress reviews followup visits audits also include questions help us identify potential breaches human rights clauses included supplier contracts suppliers asked information policies practices relating age limits employees discrimination employees local population prevention abuse individuals wages benefits working hours whether meet legal minimum rights workers organise recognition worker organisations questions contribute ehs audit score may reason progress business supplier read audit programme ensures compliance quality standards back top home responsibility supply chain responsibility supply chain choosing suppliers corporate responsibility report choosing suppliers conduct detailed assessment critical suppliers selected critical suppliers include contract manufacturers suppliers present greatest risk gsk one key risk areas use questionnaires onsite reviews ehs audits assess performance health safety environmental human rights issues assess potential new critical suppliers ehs standards must achieve minimum audit score per cent standards join supply chain following audit many suppliers met requirements implement plans improve ehs performance monitor progress cases provide opportunities training technical support enable supplier achieve required standards also expect suppliers established supply arrangements us make improvements monitor progress reviews followup visits audits also include questions help us identify potential breaches human rights clauses included supplier contracts suppliers asked information policies practices relating age limits employees discrimination employees local population prevention abuse individuals wages benefits working hours whether meet legal minimum rights workers organise recognition worker organisations questions contribute ehs audit score may reason progress business supplier read audit programme ensures compliance quality standards back top home responsibility supply chain responsibility supply chain monitoring engagement corporate responsibility report monitoring engagement approach performance order maintain gsk standards supply chain routinely interact suppliers reviews followup visits procurement quality ehs staff consider ehs human rights issues interactions hold global regional supplier review meetings senior gsk managers interact suppliers key issues provide contract manufacturers information ehs risks associated gsk materials producing handling supplier booklet working gsk includes ethics policies requirements conduct regular ehs audits critical suppliers pharmaceutical consumer healthcare products focus higherrisk suppliers supplier facilities evaluated ehs standards must achieve score least per cent standards demonstrate acceptable performance support continuing supply arrangements suppliers develop improvement plans based audit findings follow monitor progress plans read case study helped supplier improve ehs performance provide feedback suppliers identify issues questions relating human rights require corrective action issues present potential breach human rights clause included supplier contracts suppliers promotional items many gift items indian business sourced within india industry higher risk use child labour conduct unannounced spot checks suppliers often night focus maintaining quality standards also used check suppliers using child labour spot checks conducted gsk procurement regional sales staff used findings programme india inform promotional supplier qualification process regions begun conduct detailed inspection assembly sites possible added extra checks regions child labour common back top home responsibility supply chain responsibility supply chain monitoring engagement corporate responsibility report monitoring engagement approach performance order maintain gsk standards supply chain routinely interact suppliers reviews followup visits procurement quality ehs staff consider ehs human rights issues interactions hold global regional supplier review meetings senior gsk managers interact suppliers key issues provide contract manufacturers information ehs risks associated gsk materials producing handling supplier booklet working gsk includes ethics policies requirements conduct regular ehs audits critical suppliers pharmaceutical consumer healthcare products focus higherrisk suppliers supplier facilities evaluated ehs standards must achieve score least per cent standards demonstrate acceptable performance support continuing supply arrangements suppliers develop improvement plans based audit findings follow monitor progress plans read case study helped supplier improve ehs performance provide feedback suppliers identify issues questions relating human rights require corrective action issues present potential breach human rights clause included supplier contracts suppliers promotional items many gift items indian business sourced within india industry higher risk use child labour conduct unannounced spot checks suppliers often night focus maintaining quality standards also used check suppliers using child labour spot checks conducted gsk procurement regional sales staff used findings programme india inform promotional supplier qualification process regions begun conduct detailed inspection assembly sites possible added extra checks regions child labour common back top home responsibility supply chain responsibility supply chain monitoring engagement corporate responsibility report monitoring engagement approach performance conducted supplier audits reviewsthe average audit score gsk ehs standards per cent highest score achieved percent lowest percent ehs audit scores key suppliers americas canada north america south america regions higher average scores north america europe contrast lower average scores asia largely related maturity ehs management supporting legislative framework enforcement regions broad range scores asia region reflects higher performing suppliers long term intervention gsk lower scores relate suppliers undertaken initial audits found significant deficiencies ehs management risk control five suppliers failed meet minimum requirement percent gsk ehs standards potential new suppliers scored minimum level either progressed work underway improve performance acceptable levels work existing suppliers ensure necessary improvements made within agreed timeframe gsk standards applied supply chain significant audit findings occurred mainly emerging economies included infrastructure fire protection poor emergency response capabilities absence fundamental risk controls process safety poor control exposure hazardous substances poor waste management environmental controls frequent regulatory findings significant issues identified relating human rights questions ask audits continued work number key suppliers help improve ehs performance included developing closer relationships two fulltime positions china india support work audited suppliers improve ehs performance work includes helping supppaligeer f develop improvement plans providing coaching opportunities read case study helped supplier improve ehs performance attending supplier forums rdbased pharmaceutical association committee rdpac industry consortium china forums provide opportunity gsk engage suppliers supplier companies take advantage training networking making progress pilot project strategic supplier achieve highly protected risk hpr status achieve hpr status best class insurance industry designation companies must adopt engineering approach minimising property supply chain risks plan extend strategic suppliers number type audits americas europe asia africa total type supplier primary raw materials intermediates active pharmaceutical ingredients pharmaceutical formulations consumer healthcare excipients actives raw materials type engagement audit review average audit score per cent number suppliers audited total cumulative total number americas europe asia africa number visits visits americas canada north america south america regions suppliers promotional items conducted five unannounced spot checks promotional goods suppliers india least one visit company supplying promotional goods indian business uncovered evidence child labourhome responsibility supply chain responsibility supply chain monitoring engagement corporate responsibility report monitoring engagement approach performance conducted supplier audits reviewsthe average audit score gsk ehs standards per cent highest score achieved percent lowest percent ehs audit scores key suppliers americas canada north america south america regions higher average scores north america europe contrast lower average scores asia largely related maturity ehs management supporting legislative framework enforcement regions broad range scores asia region reflects higher performing suppliers long term intervention gsk lower scores relate suppliers undertaken initial audits found significant deficiencies ehs management risk control five suppliers failed meet minimum requirement percent gsk ehs standards potential new suppliers scored minimum level either progressed work underway improve performance acceptable levels work existing suppliers ensure necessary improvements made within agreed timeframe gsk standards applied supply chain significant audit findings occurred mainly emerging economies included infrastructure fire protection poor emergency response capabilities absence fundamental risk controls process safety poor control exposure hazardous substances poor waste management environmental controls frequent regulatory findings significant issues identified relating human rights questions ask audits continued work number key suppliers help improve ehs performance included developing closer relationships two fulltime positions china india support work audited suppliers improve ehs performance work includes helping suppliers develop improvement plans providing coaching opportunities read case study helped supplier improve ehs performance attending supplier forums rdbased pharmaceutical association committee rdpac industry consortium china forums provide opportunity gsk engage suppliers supplier companies take advantage training networking making progress pilot project strategic supplier achieve highly protected risk hpr status achieve hpr status best class insurance industry designation companies must adopt engineering approach minimising property supply chain risks plan extend strategic suppliers number type audits americas europe asia africa total type supplier primary raw materials intermediates active pharmaceutical ingredients pharmaceutical formulations consumer healthcare excipients actives raw materials type engagement audit review average audit score per cent number suppliers audited total cumulative total number americas europe asia africa number visits visits americas canada north america south america regions suppliers promotional items conducted five unannounced spot checks promotional goods suppliers india least one visit company supplying promotional goods indian business uncovered evidence child labour home responsibility supply chain responsibility supply chain monitoring engagement corporate responsibility report monitoring engagement approach performance conducted supplier audits reviewsthe average audit score gsk ehs standards per cent highest score achieved percent lowest percent ehs audit scores key suppliers americas canada north america south america regions higher average scores north america europe contrast lower average scores asia largely related maturity ehs management supporting legislative framework enforcement regions broad range scores asia region reflects higher performing suppliers long term intervention gsk lower scores relate suppliers undertaken initial audits found significant deficiencies ehs management risk control five suppliers failed meet minimum requirement percent gsk ehs standards potential new suppliers scored minimum level either progressed work underway improve performance acceptable levels work existing suppliers ensure necessary improvements made within agreed timeframe gsk standards applied supply chain significant audit findings occurred mainly emerging economies included infrastructure fire protection poor emergency response capabilities absence fundamental risk controls process safety poor control exposure hazardous substances poor waste management environmental controls frequent regulatory findings significant issues identified relating human rights questions ask audits continued work number key suppliers help improve ehs performance included developing closer relationships two fulltime positions china india support work audited suppliers improve ehs performance work includes helping suppliers develop improvement plans providing coaching opportunities read case study helped supplier improve ehs performance attending supplier forums rdbased pharmaceutical association committee rdpac industry consortium china forums provide opportunity gsk engage suppliers supplier companies take advantage training networking making progress pilot project strategic supplier achieve highly protected risk hpr status achieve hpr status best class insurance industry designation companies must adopt engineering approach minimising property supply chain risks plan extend strategic suppliers number type audits americas europe asia africa total type supplier primary raw materials intermediates active pharmaceutical ingredients pharmaceutical formulations consumer healthcare excipients actives raw materials type engagement audit review average audit score per cent number suppliers audited total cumulative total number americas europe asia africa number visits visits americas canada north america south america regions suppliers promotional items conducted five unannounced spot checks promotional goods suppliers india least one visit company supplying promotional goods indian business uncovered evidence child labour home responsibility supply chain responsibility supply chain monitoring engagement corporate responsibility report monitoring engagement approach performance conducted supplier audits reviewsthe average audit score gsk ehs standards per cent highest score achieved percent lowest percent ehs audit scores key suppliers americas canada north america south america regions higher average scores north america europe contrast lower average scores asia largely related maturity ehs management supporting legislative framework enforcement regions broad range scores asia region reflects higher performing suppliers long term intervention gsk lower scores relate suppliers undertaken initial audits found significant deficiencies ehs management risk control five suppliers failed meet minimum requirement percent gsk ehs standards potential new suppliers scored minimum level either progressed work underway improve performance acceptable levels work existing suppliers ensure necessary improvements made within agreed timeframe gsk standards applied supply chain significant audit findings occurred mainly emerging economies included infrastructure fire protection poor emergency response capabilities absence fundamental risk controls process safety poor control exposure hazardous substances poor waste management environmental controls frequent regulatory findings significant issues identified relating human rights questions ask audits continued work number key suppliers help improve ehs performance included developing closer relationships two fulltime positions china india support work audited suppliers improve ehs performance work includes helping suppliers develop improvement plans providing coaching opportunities read case study helped supplier improve ehs performance attending supplier forums rdbased pharmaceutical association committee rdpac industry consortium china forums provide opportunity gsk engage suppliers supplier companies take advantage training networking making progress pilot project strategic supplier achieve highly protected risk hpr status achieve hpr status best class insurance industry designation companies must adopt engineering approach minimising property supply chain risks plan extend strategic suppliers number type audits americas europe asia africa total type supplier primary raw materials intermediates active pharmaceutical ingredients pharmaceutical formulations consumer healthcare excipients actives raw materials type engagement audit review average audit score per cent number suppliers audited total cumulative total number americas europe asia africa number visits visits americas canada north america south america regions suppliers promotional items conducted five unannounced spot checks promotional goods suppliers india least one visit company supplying promotional goods indian business uncovered evidence child labour home responsibility supply chain responsibility supply chain supplier diversity corporate responsibility report supplier diversity small minorityowned companies often underrepresented supply chains large companies response us government many large companies require suppliers source diverse companies broadbased black economic empowerment bill south africa includes similar requirements working increase diversity supply chain providing opportunities small diverse businesses provide us goods services helps diverse suppliers sustain businesses create jobs boost local economies business also benefits beyond complying regulations supplier diversity encourages innovation exposes us new perspectives fresh ideas us programme us dedicated team working create opportunities diverse suppliers work gsk channel procurement spend women minorityowned companies activities include participating national local diversity councils mentoring highpotential diverse suppliers providing improvement grants help expand business gsk corporations read case study sponsoring diverse business leaders attend executive programmes tuck school business kellogg school management sponsoring attending outreach networking conferences cosponsor congressional black caucus foundation cbcf nonprofit organisation supports african americans underserved communities us donating foundation provide training help make diverse businesses competitive also support initiative run cbcf help change federal policy restrict longterm relationships minority womenowned businesses major corporations sponsor roanoke online technology company hosts online database electronic sourcing system diverse suppliers gives large companies including gsk better access diverse suppliers corporations gain access large diverse pool contractors ultimately helps lower costs small diverse suppliers get chance grow businesses increased opportunities supply companies traditionally beyond reach part adopt neighbourhood development initiative procurement community relations teams work local communities durham north carolina philadelphia pennsylvania areas historically deprived often overlooked companies choosing locate businesses gsk provides annual grant support selfdevelopment within communities make areas attractive business locations outside us gsks dedicated supplier diversity team based us procurement employees worldwide responsible supporting diverse suppliers possible sponsor global link programme part role international advisory board us national minority supplier development council programme helps diverse suppliers develop partnerships local businesses around world collaboration two pharmaceutical companies paid ten usbased minorityowned companies visit south africa late companies met diverse south african businesses got chance form partnerships help compete globally also participated similar trips australia brazil china initiative enabled gsk invest local economies communities serve helps ensure supplier base reflects diversity communities gsk member new uk minority supplier development council council forms link corporations certified minority business enterprises aim increasing procurement business development opportunitieshome responsibility supply chain responsibility supply chain supplier diversity corporate responsibility report supplier diversity small minorityowned companies often underrepresented supply chains large companies response us government many large companies require suppliers source diverse companies broadbased black economic empowerment bill south africa includes similar requirements working increase diversity supply chain providing opportunities small diverse businesses provide us goods services helps diverse suppliers sustain businesses create jobs boost local economies business also benefits beyond complying regulations supplier diversity encourages innovation exposes us new perspectives fresh ideas us programme us dedicated team working create opportunities diverse suppliers work gsk channel procurement spend women minorityowned companies activities include participating national local diversity councils mentoring highpotential diverse suppliers providing improvement grants help expand business gsk corporations read case study sponsoring diverse business leaders attend executive programmes tuck school business kellogg school management sponsoring attending outreach networking conferences cosponsor congressional black caucus foundation cbcf nonprofit organisation supports african americans underserved communities us donating foundation provide training help make diverse businesses competitive also support initiative run cbcf help change federal policy restrict longterm relationships minority womenowned businesses major corporations sponsor roanoke online technology company hosts online database electronic sourcing system diverse suppliers gives large companies including gsk better access diverse suppliers corporations gain access large diverse pool contractors ultimately helps lower costs small diverse suppliers get chance grow businesses increased opportunities supply companies traditionally beyond reach part adopt neighbourhood development initiative procurement community relations teams work local communities durham north carolina philadelphia pennsylvania areas historically deprived often overlooked companies choosing locate businesses gsk provides annual grant support selfdevelopment within communities make areas attractive business locations outside us gsks dedicated supplier diversity team based us procurement employees worldwide responsible supporting diverse suppliers possible sponsor global link programme part role international advisory board us national minority supplier development council programme helps diverse suppliers develop partnerships local businesses around world collaboration two pharmaceutical companies paid ten usbased minorityowned companies visit south africa late companies met diverse south african businesses got chance form partnerships help compete globally also participated similar trips australia brazil china initiative enabled gsk invest local economies communities serve helps ensure supplier base reflects diversity communities gsk member new uk minority supplier development council council forms link corporations certified minority business enterprises aim increasing procurement business development opportunities home responsibility supply chain responsibility supply chain supplier diversity corporate responsibility report supplier diversity small minorityowned companies often underrepresented supply chains large companies response us government many large companies require suppliers source diverse companies broadbased black economic empowerment bill south africa includes similar requirements working increase diversity supply chain providing opportunities small diverse businesses provide us goods services helps diverse suppliers sustain businesses create jobs boost local economies business also benefits beyond complying regulations supplier diversity encourages innovation exposes us new perspectives fresh ideas us programme us dedicated team working create opportunities diverse suppliers work gsk channel procurement spend women minorityowned companies activities include participating national local diversity councils mentoring highpotential diverse suppliers providing improvement grants help expand business gsk corporations read case study sponsoring diverse business leaders attend executive programmes tuck school business kellogg school management sponsoring attending outreach networking conferences cosponsor congressional black caucus foundation cbcf nonprofit organisation supports african americans underserved communities us donating foundation provide training help make diverse businesses competitive also support initiative run cbcf help change federal policy restrict longterm relationships minority womenowned businesses major corporations sponsor roanoke online technology company hosts online database electronic sourcing system diverse suppliers gives large companies including gsk better access diverse suppliers corporations gain access large diverse pool contractors ultimately helps lower costs small diverse suppliers get chance grow businesses increased opportunities supply companies traditionally beyond reach part adopt neighbourhood development initiative procurement community relations teams work local communities durham north carolina philadelphia pennsylvania areas historically deprived often overlooked companies choosing locate businesses gsk provides annual grant support selfdevelopment within communities make areas attractive business locations outside us gsks dedicated supplier diversity team based us procurement employees worldwide responsible supporting diverse suppliers possible sponsor global link programme part role international advisory board us national minority supplier development council programme helps diverse suppliers develop partnerships local businesses around world collaboration two pharmaceutical companies paid ten usbased minorityowned companies visit south africa late companies met diverse south african businesses got chance form partnerships help compete globally also participated similar trips australia brazil china initiative enabled gsk invest local economies communities serve helps ensure supplier base reflects diversity communities gsk member new uk minority supplier development council council forms link corporations certified minority business enterprises aim increasing procurement business development opportunities home responsibility supply chain responsibility supply chain fair treatment suppliers corporate responsibility report fair treatment suppliers important foster relationships suppliers characterised mutual trust respect gsk established procurement policies require high standards ethical conduct integrity general terms conditions website part supplier review process two way dialogue identify areas mutual improvement provide environment suppliers discuss issues present new ideas support impartiality phases procurement cycle global electronic bid system ensures suppliers treated fairly equally vast majority suppliers provide goods services gsk registered system companies invited bid supply gsk receive information time example invitations compete specifications supplies required system managed bidding negotiationrelated events countries highly competitive goods services allow suppliers full transparency seeing bids rank competition payment suppliers september gsk changed standard payment terms uncontracted suppliers uk us days receipt invoice days review terms conditions contracted suppliers contract renewal earlier step taken part project reduce working capital recognise may impact cash flow suppliers however new day term brings us line practice industries faster terms set companies realise may cause genuine financial difficulty organisations evaluate implications casebycase basis home responsibility supply chain responsibility supply chain fair treatment suppliers corporate responsibility report fair treatment suppliers important foster relationships suppliers characterised mutual trust respect gsk established procurement policies require high standards ethical conduct integrity general terms conditions website part supplier review process two way dialogue identify areas mutual improvement provide environment suppliers discuss issues present new ideas support impartiality phases procurement cycle global electronic bid system ensures suppliers treated fairly equally vast majority suppliers provide goods services gsk registered system companies invited bid supply gsk receive information time example invitations compete specifications supplies required system managed bidding negotiationrelated events countries highly competitive goods services allow suppliers full transparency seeing bids rank competition payment suppliers september gsk changed standard payment terms uncontracted suppliers uk us days receipt invoice days review terms conditions contracted suppliers contract renewal earlier step taken part project reduce working capital recognise may impact cash flow suppliers however new day term brings us line practice industries faster terms set companies realise may cause genuine financial difficulty organisations evaluate implications casebycase basis home responsibility supply chain maintaining quality corporate responsibility report maintaining quality maintaining quality products make materials buy essential safety patients success business conduct quality assessments suppliers ingredients packaging materials used products agree specifications ingredients packaging materials suppliers apply set global auditing standards type ingredient packaging material buy use riskbased approach determine frequency audits conducted audits ingredient packaging material suppliers compared receipt gks sites samples taken testing performed according testing protocol samples tested identity every batch also tested quality specification examples additional measures place maintain quality supply chain prevent contamination include use dedicated transport use tamper evident seals use sophisticated analytical tools check authenticity materials receive helping suppliers meet quality standards conduct quality assessments potential suppliers enables us identify companies meet required standards well work make necessary improvements example identified one existing chemical suppliers asia expertise supply final active ingredient gsk product worked closely supplier help develop technical processes quality standards begin trial manufacturing included site visits advise configuration plan building modifications assistance preparing documentation required regulators us food drug administration conducted four day quality compliance inspection site resulted adverse findings approved site supply us market raising employee awareness commitment quality andrew witty gsks ceo endorsed new internal quality statement stresses importance quality across business activities including critical aspect product quality raised awareness statement discussion internal quality councils throughout business units new articles global intranet site mygsk posters display facilities quality statement quality heart activities support discovery supply marketing products patients customers quality critical building trust society therefore future business success andrew witty chief executive officer home responsibility supply chain maintaining quality corporate responsibility report maintaining quality maintaining quality products make materials buy essential safety patients success business conduct quality assessments suppliers ingredients packaging materials used products agree specifications ingredients packaging materials suppliers apply set global auditing standards type ingredient packaging material buy use riskbased approach determine frequency audits conducted audits ingredient packaging material suppliers compared receipt gks sites samples taken testing performed according testing protocol samples tested identity every batch also tested quality specification examples additional measures place maintain quality supply chain prevent contamination include use dedicated transport use tamper evident seals use sophisticated analytical tools check authenticity materials receive helping suppliers meet quality standards conduct quality assessments potential suppliers enables us identify companies meet required standards well work make necessary improvements example identified one existing chemical suppliers asia expertise supply final active ingredient gsk product worked closely supplier help develop technical processes quality standards begin trial manufacturing included site visits advise configuration plan building modifications assistance preparing documentation required regulators us food drug administration conducted four day quality compliance inspection site resulted adverse findings approved site supply us market raising employee awareness commitment quality andrew witty gsks ceo endorsed new internal quality statement stresses importance quality across business activities including critical aspect product quality raised awareness statement discussion internal quality councils throughout business units new articles global intranet site mygsk posters display facilities quality statement quality heart activities support discovery supply marketing products patients customers quality critical building trust society therefore future business success andrew witty chief executive officer home responsibility supply chain security supply corporate responsibility report security supply ensuring continuous supply high quality medicines essential patients depend products well success business vital security supply compromised stage distribution chain prepare major incidents may disrupt supply ranging largescale theft products natural manmade disasters near facility strategy directors therapy area overall responsibility security supply divisional heads meet procurement teams every month discuss potential issues gms manufacturing business implements contingency plans medically critical products define products medically critical lifesaving available patients likelihood serious detriment health known alternative plans defined productbyproduct basis may include holding sufficient stocks products active pharmaceutical ingredients work critical suppliers encourage implement contingency plans highrisk countries set joint ventures ensure maintain control distribution chain three global contracts suppliers deliver goods gsk facilities distribute products market conduct regular highlevel operational reviews suppliers include security elements read measures taking protect employees event pandemic flu outbreak ensure supply critical medicines disrupted home responsibility supply chain security supply corporate responsibility report security supply ensuring continuous supply high quality medicines essential patients depend products well success business vital security supply compromised stage distribution chain prepare major incidents may disrupt supply ranging largescale theft products natural manmade disasters near facility strategy directors therapy area overall responsibility security supply divisional heads meet procurement teams every month discuss potential issues gms manufacturing business implements contingency plans medically critical products define products medically critical lifesaving available patients likelihood serious detriment health known alternative plans defined productbyproduct basis may include holding sufficient stocks products active pharmaceutical ingredients work critical suppliers encourage implement contingency plans highrisk countries set joint ventures ensure maintain control distribution chain three global contracts suppliers deliver goods gsk facilities distribute products market conduct regular highlevel operational reviews suppliers include security elements read measures taking protect employees event pandemic flu outbreak ensure supply critical medicines disrupted home responsibility supply chain counterfeiting corporate responsibility report counterfeiting approach performance according world health organization less one per cent pharmaceutical products sold developed countries counterfeit developing world figure may higher per cent per cent countries counterfeit drugs come many variations may contain none legitimate active ingredient active ingredient reduced subtherapeutic amounts completely different andor inappropriate active ingredient impurities unapproved colourants microorganisms packaging falsifies product description expiry date counterfeit drugs subject quality control hygiene standards testing ingredients monitoring product specifications equipment counterfeiting threat public health potentially causing harm patients even death add anticounterfeiting features product packaging include holograms security seals complicated background patterns difficult photocopy scan well wide variety covert identifiers added using print technologies sophisticated markers help us identify counterfeits gather evidence offenders packing design technology security team uk carries forensic examinations suspected counterfeit gsk products sales representatives worldwide also play important role helping discover counterfeit products continual observation local market corporate security department investigates every potential case counterfeiting uses internal external investigators collect information assess report relevant government authorities set motion official law enforcement action well removing fake products market one primary aims trace products back source shut manufacturers partners example packaging printers distributors provide training regulatory authorities state food drug administration sfda china law enforcement agencies customs officers many parts world gsk works closely wider pharmaceutical industry investigate cases counterfeiting also raise awareness governments internationally pressing stricter laws severe penalties gsk founding member pharmaceutical security institute psi coordinates information collection investigations within industry internationally psi influential helping shape anti counterfeiting policy among national governments international organisations together psi gsk major contributor whos internationally represented anticounterfeiting working groups internet pharmacies evidence large number internet pharmacies involved sale counterfeit diverted medicines illegal generic substitutions switched time delivery requested brand name product internet pharmacies provide substandard product engage fraud customer using credit card information fraudulent activity ignore local laws regulations relating licences prescriptions patient information seemingly operating immunity prosecution internet pharmacies flourished past years likely rise continue provides lucrative lowrisk opportunity direct selling patients global largely unrestricted market uk medicines healthcare products regulatory agency estimated british patients purchased prescription medicines internet us fda reported pills purchased internet pharmacies month state kentucky alonehome responsibility supply chain counterfeiting corporate responsibility report counterfeiting approach performance according world health organization less one per cent pharmaceutical products sold developed countries counterfeit developing world figure may higher per cent per cent countries counterfeit drugs come many variations may contain none legitimate active ingredient active ingredient reduced subtherapeutic amounts completely different andor inappropriate active ingredient impurities unapproved colourants microorganisms packaging falsifies product description expiry date counterfeit drugs subject quality control hygiene standards testing ingredients monitoring product specifications equipment counterfeiting threat public health potentially causing harm patients even death add anticounterfeiting features product packaging include holograms security seals complicated background patterns difficult photocopy scan well wide variety covert identifiers added using print technologies sophisticated markers help us identify counterfeits gather evidence offenders packing design technology security team uk carries forensic examinations suspected counterfeit gsk products sales representatives worldwide also play important role helping discover counterfeit products continual observation local market corporate security department investigates every potential case counterfeiting uses internal external investigators collect information assess report relevant government authorities set motion official law enforcement action well removing fake products market one primary aims trace products back source shut manufacturers partners example packaging printers distributors provide training regulatory authorities state food drug administration sfda china law enforcement agencies customs officers many parts world gsk works closely wider pharmaceutical industry investigate cases counterfeiting also raise awareness governments internationally pressing stricter laws severe penalties gsk founding member pharmaceutical security institute psi coordinates information collection investigations within industry internationally psi influential helping shape anti counterfeiting policy among national governments international organisations together psi gsk major contributor whos internationally represented anticounterfeiting working groups internet pharmacies evidence large number internet pharmacies involved sale counterfeit diverted medicines illegal generic substitutions switched time delivery requested brand name product internet pharmacies provide substandard product engage fraud customer using credit card information fraudulent activity ignore local laws regulations relating licences prescriptions patient information seemingly operating immunity prosecution internet pharmacies flourished past years likely rise continue provides lucrative lowrisk opportunity direct selling patients global largely unrestricted market uk medicines healthcare products regulatory agency estimated british patients purchased prescription medicines internet us fda reported pills purchased internet pharmacies month state kentucky alone home responsibility supply chain counterfeiting corporate responsibility report counterfeiting approach performance according world health organization less one per cent pharmaceutical products sold developed countries counterfeit developing world figure may higher per cent per cent countries counterfeit drugs come many variations may contain none legitimate active ingredient active ingredient reduced subtherapeutic amounts completely different andor inappropriate active ingredient impurities unapproved colourants microorganisms packaging falsifies product description expiry date counterfeit drugs subject quality control hygiene standards testing ingredients monitoring product specifications equipment counterfeiting threat public health potentially causing harm patients even death add anticounterfeiting features product packaging include holograms security seals complicated background patterns difficult photocopy scan well wide variety covert identifiers added using print technologies sophisticated markers help us identify counterfeits gather evidence offenders packing design technology security team uk carries forensic examinations suspected counterfeit gsk products sales representatives worldwide also play important role helping discover counterfeit products continual observation local market corporate security department investigates every potential case counterfeiting uses internal external investigators collect information assess report relevant government authorities set motion official law enforcement action well removing fake products market one primary aims trace products back source shut manufacturers partners example packaging printers distributors provide training regulatory authorities state food drug administration sfda china law enforcement agencies customs officers many parts world gsk works closely wider pharmaceutical industry investigate cases counterfeiting also raise awareness governments internationally pressing stricter laws severe penalties gsk founding member pharmaceutical security institute psi coordinates information collection investigations within industry internationally psi influential helping shape anti counterfeiting policy among national governments international organisations together psi gsk major contributor whos internationally represented anticounterfeiting working groups internet pharmacies evidence large number internet pharmacies involved sale counterfeit diverted medicines illegal generic substitutions switched time delivery requested brand name product internet pharmacies provide substandard product engage fraud customer using credit card information fraudulent activity ignore local laws regulations relating licences prescriptions patient information seemingly operating immunity prosecution internet pharmacies flourished past years likely rise continue provides lucrative lowrisk opportunity direct selling patients global largely unrestricted market uk medicines healthcare products regulatory agency estimated british patients purchased prescription medicines internet us fda reported pills purchased internet pharmacies month state kentucky alone home responsibility supply chain counterfeiting performance corporate responsibility report counterfeiting approach performance reported cases counterfeiting gsk products resulted raids suspected counterfeiters arrested million worth counterfeit products found raids took place criminal manufacturing facilities wholesaledistribution outlets factories represent criminal operations capable mass production counterfeit medicines healthcare products raids facilities undoubtedly prevented huge amounts counterfeit product entering legitimate markets around world much million worth product found time raids reduction number reported cases counterfeiting see positive sign anticounterfeiting measures working number raids gsk risen per cent result proactive security investigations activity number raids directly related number reported cases counterfeits based intelligence security investigations activity gsk recognised leader industry combating counterfeit medicines currently chairs pharmaceutical security institute anticounterfeiting number value number reported number counterfeit cases raids products found arrests counterfeit raids million million million million home responsibility supply chain counterfeiting performance corporate responsibility report counterfeiting approach performance reported cases counterfeiting gsk products resulted raids suspected counterfeiters arrested million worth counterfeit products found raids took place criminal manufacturing facilities wholesaledistribution outlets factories represent criminal operations capable mass production counterfeit medicines healthcare products raids facilities undoubtedly prevented huge amounts counterfeit product entering legitimate markets around world much million worth product found time raids reduction number reported cases counterfeiting see positive sign anticounterfeiting measures working number raids gsk risen per cent result proactive security investigations activity number raids directly related number reported cases counterfeits based intelligence security investigations activity gsk recognised leader industry combating counterfeit medicines currently chairs pharmaceutical security institute anticounterfeiting number value number reported number counterfeit cases raids products found arrests counterfeit raids million million million million home responsibility supply chain case studies corporate responsibility report case studies mentoring diverse suppliers us callis construction services ccs minorityowned contracting company durham north carolina companys president jesse callis took part diverse supplier mentoring programme beginning helps suppliers form partnerships gsk large corporations part programme assessed ccss business processes identified issues preventing company becoming gsk preferred supplier concerns ranged management accessibility ability scale supply needs gsk company implemented improvements based recommendations enabled become preferred supplier win business worth around million success partnership enabled ccs contribute local community paid two employees attend local university mr callis developed training programme durham technical college prepares minority construction workers management positions major projects area asked relationship gsk mr callis said gsk wonderful mentor real leader commitment actions help diverse minority suppliers case provided assistance led significant growth business turn provided jobs others durham surrounding area ensuring monies paid gsk stay local communities win everyone involved helping improve supplier performance cases provide assistance suppliers fail meet minimum ehs quality standards improve performance enables companies improve work practices win business helps us develop supply chain need provide secure supply high quality medicines example provided support potential supplier active pharmaceutical ingredients india supplier received audit score per cent per cent minimum standard following audit made recommendations improvement provided coaching facilitated meetings supplier expert consultants supplier achieved audit score per cent accepted gsk supplier audit found company managing key risks effectively established detailed improvement programme continue monitor progress improvement plan success collaboration relied efforts gsk staff well willingness supplier recognise improvements needed resulted secure supply chain gsk safer working environment workers facility home responsibility supply chain case studies corporate responsibility report case studies mentoring diverse suppliers us callis construction services ccs minorityowned contracting company durham north carolina companys president jesse callis took part diverse supplier mentoring programme beginning helps suppliers form partnerships gsk large corporations part programme assessed ccss business processes identified issues preventing company becoming gsk preferred supplier concerns ranged management accessibility ability scale supply needs gsk company implemented improvements based recommendations enabled become preferred supplier win business worth around million success partnership enabled ccs contribute local community paid two employees attend local university mr callis developed training programme durham technical college prepares minority construction workers management positions major projects area asked relationship gsk mr callis said gsk wonderful mentor real leader commitment actions help diverse minority suppliers case provided assistance led significant growth business turn provided jobs others durham surrounding area ensuring monies paid gsk stay local communities win everyone involved helping improve supplier performance cases provide assistance suppliers fail meet minimum ehs quality standards improve performance enables companies improve work practices win business helps us develop supply chain need provide secure supply high quality medicines example provided support potential supplier active pharmaceutical ingredients india supplier received audit score per cent per cent minimum standard following audit made recommendations improvement provided coaching facilitated meetings supplier expert consultants supplier achieved audit score per cent accepted gsk supplier audit found company managing key risks effectively established detailed improvement programme continue monitor progress improvement plan success collaboration relied efforts gsk staff well willingness supplier recognise improvements needed resulted secure supply chain gsk safer working environment workers facility home responsibility supply chain qas corporate responsibility report qas respond questions raised stakeholders raise standards supply chain longterm relationships critical suppliers offer training support help raise standards monitoring process key part raising awareness expectations identifying areas suppliers need improve work suppliers help make necessary changes identified human rights risks supply chain gsks supply chain large complex like similar supply chains contains risk human rights violations risks vary considerably based type supplier goods service sourcing manufacturing ranpd suppliers employ skilled workers lower risk human rights violations ehs audits aim ensure good working conditions supplier facilities considerably higher human rights risks suppliers employ lowskilled workers example promotional goods suppliers conduct spot checks suppliers india supplier selection process aims ensure enter relationships suppliers respect human rights also include clauses contracts suppliers specify upholding human rights condition business gsk supply chain plan flu pandemic implemented contingency plan ensure operations supply medically critical products compromised flu pandemic encouraging critical suppliers implement contingency plans outsourcing manufacturing mean less control products increasing risk patients manufacture medicines vaccines closely controlled subject quality standards regardless whether produce outsource process contract manufacturers outsourcing stage manufacturing process confirm contractor carry required processes high standards contract manufacturers must also approved relevant regulatory authorities subject inspection gsk regulators home responsibility supply chain qas corporate responsibility report qas respond questions raised stakeholders raise standards supply chain longterm relationships critical suppliers offer training support help raise standards monitoring process key part raising awareness expectations identifying areas suppliers need improve work suppliers help make necessary changes identified human rights risks supply chain gsks supply chain large complex like similar supply chains contains risk human rights violations risks vary considerably based type supplier goods service sourcing manufacturing ranpd suppliers employ skilled workers lower risk human rights violations ehs audits aim ensure good working conditions supplier facilities considerably higher human rights risks suppliers employ lowskilled workers example promotional goods suppliers conduct spot checks suppliers india supplier selection process aims ensure enter relationships suppliers respect human rights also include clauses contracts suppliers specify upholding human rights condition business gsk supply chain plan flu pandemic implemented contingency plan ensure operations supply medically critical products compromised flu pandemic encouraging critical suppliers implement contingency plans outsourcing manufacturing mean less control products increasing risk patients manufacture medicines vaccines closely controlled subject quality standards regardless whether produce outsource process contract manufacturers outsourcing stage manufacturing process confirm contractor carry required processes high standards contract manufacturers must also approved relevant regulatory authorities subject inspection gsk regulators home responsibility environmental sustainability corporate responsibility report environmental sustainability sustainability defined meeting needs today without compromising ability future generations meet needs gsk embarking journey towards sustainability expect continue many years well benefiting environment sustainability efforts encourage innovation provides better outcome society help us reduce costs early environmental management programmes focused controlling emissions wastes operations treatment disposal systems approach sustainability change fundamental process reduce amount resource consumed avoiding waste source rather simply treating waste emissions arise already begun changing business developing innovative new manufacturing processes set initial sustainability goals double average efficiency convert raw materials finished products new products end baseline reduce energy climate change impact per unit sales levels per cent eliminate cfcs products equipment end examples sustainability initiatives include reducing amount material resources use raw materials fossil fuels minimising waste recycling unavoidable waste redesigning production processes eliminate production toxic materials reducing energy consumption associated carbon emissions manage environment health safety sustainability ehss programme according framework sets consistent standards employee health safety environmental protection sustainability framework acts internal regulatory system reflects understanding risks ensure operations comply laws regulations provides information tools training help everyone gsk meet standards includes targets set plan excellence address fundamental environmental sustainability impacts also work suppliers help become sustainable openness transparency fundamental sustainability performance continue engage stakeholders share views dilemmas back top home responsibility environmental sustainability corporate responsibility report environmental sustainability sustainability defined meeting needs today without compromising ability future generations meet needs gsk embarking journey towards sustainability expect continue many years well benefiting environment sustainability efforts encourage innovation provides better outcome society help us reduce costs early environmental management programmes focused controlling emissions wastes operations treatment disposal systems approach sustainability change fundamental process reduce amount resource consumed avoiding waste source rather simply treating waste emissions arise already begun changing business developing innovative new manufacturing processes set initial sustainability goals double average efficiency convert raw materials finished products new products end baseline reduce energy climate change impact per unit sales levels per cent eliminate cfcs products equipment end examples sustainability initiatives include reducing amount material resources use raw materials fossil fuels minimising waste recycling unavoidable waste redesigning production processes eliminate production toxic materials reducing energy consumption associated carbon emissions manage environment health safety sustainability ehss programme according framework sets consistent standards employee health safety environmental protection sustainability framework acts internal regulatory system reflects understanding risks ensure operations comply laws regulations provides information tools training help everyone gsk meet standards includes targets set plan excellence address fundamental environmental sustainability impacts also work suppliers help become sustainable openness transparency fundamental sustainability performance continue engage stakeholders share views dilemmas back top home responsibility environmental sustainability plan excellence corporate responsibility report plan excellence ehss plan excellence sets tenyear strategy improve environment health safety sustainability performance details developed concert business plan integrated business plans specific actions identified business plan reviewed every five years new targets set designed support gsks business plans consists three strategic priorities environment health safety fundamentals embedded business produce sustain high ehs performance need combine structured systems attitudes values create positive ehs culture achieve need embed awareness environment health safety concerns systems gsk activities environmental sustainability embrace environmental sustainability driver competitive advantage need define principles environmental sustainability progressively integrate business translating practical action open transparent external relations external stakeholders legitimate interest companys environment health safety sustainability affairs ready access relevant information opportunity dialogue issues concern building open relationships partnerships lead business opportunities failure engage may damage reputation strategic priorities supported plans performance targets key areas gsk worked external stakeholder panel help set plan review annual performance targets ehss plan excellence includes company targets improve environment health safety sustainability performance based site based practical improvement plans forecasts manufacturing operations read targets set view details company targets back top home responsibility environmental sustainability plan excellence corporate responsibility report plan excellence ehss plan excellence sets tenyear strategy improve environment health safety sustainability performance details developed concert business plan integrated business plans specific actions identified business plan reviewed every five years new targets set designed support gsks business plans consists three strategic priorities environment health safety fundamentals embedded business produce sustain high ehs performance need combine structured systems attitudes values create positive ehs culture achieve need embed awareness environment health safety concerns systems gsk activities environmental sustainability embrace environmental sustainability driver competitive advantage need define principles environmental sustainability progressively integrate business translating practical action open transparent external relations external stakeholders legitimate interest companys environment health safety sustainability affairs ready access relevant information opportunity dialogue issues concern building open relationships partnerships lead business opportunities failure engage may damage reputation strategic priorities supported plans performance targets key areas gsk worked external stakeholder panel help set plan review annual performance targets ehss plan excellence includes company targets improve environment health safety sustainability performance based site based practical improvement plans forecasts manufacturing operations read targets set view details company targets back top home responsibility environmental sustainability plan excellence targets corporate responsibility report targets set companywide targets drive continuous improvement managing significant environment health safety sustainability impacts see table compare proposals company targets put forward operations benchmarking information environment health safety professionals senior managers management teams throughout business closely review agree final target numbers believe important set achieve targets lower resource consumption less waste benefit environment gsk although track meet targets recognise difficult meet within time set explain progress targets discussions individual metrics read health safety targets targets progress progress target sustainability targets material efficiency new processes average period material efficiency actives achieved reduction per unit sales increased less energy operations transport baseline per sales cer climate change impact energy reduction per unit sales increased per sales operations transport baseline cer annual reduction reduced per sales water baseline per unit sales cer fundamental targets wastewater chemical oxygen annual reduction reduced per sales demand baseline per unit sales cer annual reduction reduced per sales solid waste baseline per unit sales cer elimination ozone depletion eliminated air emissions volatile organic annual reduction reduced per sales emissions baseline per unit sales cer average minimum average minimum ehs audit scores climate change impact measured co equivalent emissions includes ozone depletion potential production refrigeration losses targets performance normalised sales based constant exchange rate cer sgs verified back tophome responsibility environmental sustainability plan excellence targets corporate responsibility report targets set companywide targets drive continuous improvement managing significant environment health safety sustainability impacts see table compare proposals company targets put forward operations benchmarking information environment health safety professionals senior managers management teams throughout business closely review agree final target numbers believe important set achieve targets lower resource consumption less waste benefit environment gsk although track meet targets recognise difficult meet within time set explain progress targets discussions individual metrics read health safety targets targets progress progress target sustainability targets material efficiency new processes average period material efficiency actives achieved reduction per unit sales increased less energy operations transport baseline per sales cer climate change impact energy reduction per unit sales increased per sales operations transport baseline cer annual reduction reduced per sales water baseline per unit sales cer fundamental targets wastewater chemical oxygen annual reduction reduced per sales demand baseline per unit sales cer annual reduction reduced per sales solid waste baseline per unit sales cer elimination ozone depletion eliminated air emissions volatile organic annual reduction reduced per sales emissions baseline per unit sales cer average minimum average minimum ehs audit scores climate change impact measured co equivalent emissions includes ozone depletion potential production refrigeration losses targets performance normalised sales based constant exchange rate cer sgs verified back top home responsibility environmental sustainability plan excellence targets corporate responsibility report targets set companywide targets drive continuous improvement managing significant environment health safety sustainability impacts see table compare proposals company targets put forward operations benchmarking information environment health safety professionals senior managers management teams throughout business closely review agree final target numbers believe important set achieve targets lower resource consumption less waste benefit environment gsk although track meet targets recognise difficult meet within time set explain progress targets discussions individual metrics read health safety targets targets progress progress target sustainability targets material efficiency new processes average period material efficiency actives achieved reduction per unit sales increased less energy operations transport baseline per sales cer climate change impact energy reduction per unit sales increased per sales operations transport baseline cer annual reduction reduced per sales water baseline per unit sales cer fundamental targets wastewater chemical oxygen annual reduction reduced per sales demand baseline per unit sales cer annual reduction reduced per sales solid waste baseline per unit sales cer elimination ozone depletion eliminated air emissions volatile organic annual reduction reduced per sales emissions baseline per unit sales cer average minimum average minimum ehs audit scores climate change impact measured co equivalent emissions includes ozone depletion potential production refrigeration losses targets performance normalised sales based constant exchange rate cer sgs verified back top home responsibility environmental sustainability plan excellence journey sustainability corporate responsibility report journey sustainability james hagan vice president corporate environment health safety sustainability charts gsks history environmental management describes company making shift towards sustainability sustainability defined meeting needs today without compromising ability future generations meet needs gsk sustainable need efficient use resources including energy water raw materials need use renewable resources resources become scarce expensive sustainability cost closely linked ultimately means ability continue manufacture affordable medicines requires us address sustainability working towards sustainability since gsk formed similar industries time companies formed gsk started managing emissions waste using treatment disposal methods considered management waste necessary cost soon recognised bolton control measures essential ever incrementally improve impact waste achieve stepchange towards sustainability need make processes efficient prevent waste emissions produced first place fundamental change requires investment innovative solutions innovation create efficient processes use less resource reduce costs virtuous circle completed take portion sales reinvest innovation sustainability reflects builtin approach begin guiding business towards sustainability developed management framework set policy consistent standards everyone gsk follow produced plan outlined timetable achieving goals set framework set fiveyear improvement targets plan refreshed period plan identified manufacturing efficiency first area could make significant progress toward sustainability used material balance calculation looks amount produced compared amounts raw materials used measure material efficiency set improvement target double efficiency new products ecodesign toolkit supports development efficient manufacturing processes read process design already success new medicines think improve processes existing products well climate change one greatest challenges facing mankind key part sustainability strategy set targets almost halve amount energy use co produce per unit sales sustainability focus extends beyond manufacturing aspects business including rd sales activities also includes environmental product stewardship responsibility environmental impact medicines within gsk sustainability started take root example nutritional healthcare business comprehensive sustainability programme please read casestudy details working suppliers examine lifecycle biodiversity impacts raw materials used developing zero waste landfill manufacturing approach using recycled materials packaging developing innovative ways recover used bottles reverse vending consumer healthcare business also developed sustainability strategy called bright green includes packaging climate change water use product stewardship total supply chain goals although made progress nutritionals business certain areas achieving fundamental environmental improvement targets making progress toward sustainability continues challenge assess achieve targets course learn success failure year explain succeeded failed also continpuagee broaden view sustainability means gsk far focused attention sustainability rd manufacturing going forward know need broaden focus include sales force offices realise begun journey need commitment innovation succeed internal sustainability council composed senior managers leading efforts also external stakeholder panel gives feedback approach performance suggests improvement alternatives recognise value stakeholders bring welcome views approach please feel free let know thoughts emailing csrcontactgskcom back tophome responsibility environmental sustainability plan excellence journey sustainability corporate responsibility report journey sustainability james hagan vice president corporate environment health safety sustainability charts gsks history environmental management describes company making shift towards sustainability sustainability defined meeting needs today without compromising ability future generations meet needs gsk sustainable need efficient use resources including energy water raw materials need use renewable resources resources become scarce expensive sustainability cost closely linked ultimately means ability continue manufacture affordable medicines requires us address sustainability working towards sustainability since gsk formed similar industries time companies formed gsk started managing emissions waste using treatment disposal methods considered management waste necessary cost soon recognised bolton control measures essential ever incrementally improve impact waste achieve stepchange towards sustainability need make processes efficient prevent waste emissions produced first place fundamental change requires investment innovative solutions innovation create efficient processes use less resource reduce costs virtuous circle completed take portion sales reinvest innovation sustainability reflects builtin approach begin guiding business towards sustainability developed management framework set policy consistent standards everyone gsk follow produced plan outlined timetable achieving goals set framework set fiveyear improvement targets plan refreshed period plan identified manufacturing efficiency first area could make significant progress toward sustainability used material balance calculation looks amount produced compared amounts raw materials used measure material efficiency set improvement target double efficiency new products ecodesign toolkit supports development efficient manufacturing processes read process design already success new medicines think improve processes existing products well climate change one greatest challenges facing mankind key part sustainability strategy set targets almost halve amount energy use co produce per unit sales sustainability focus extends beyond manufacturing aspects business including rd sales activities also includes environmental product stewardship responsibility environmental impact medicines within gsk sustainability started take root example nutritional healthcare business comprehensive sustainability programme please read casestudy details working suppliers examine lifecycle biodiversity impacts raw materials used developing zero waste landfill manufacturing approach using recycled materials packaging developing innovative ways recover used bottles reverse vending consumer healthcare business also developed sustainability strategy called bright green includes packaging climate change water use product stewardship total supply chain goals although made progress nutritionals business certain areas achieving fundamental environmental improvement targets making progress toward sustainability continues challenge assess achieve targets course learn success failure year explain succeeded failed also continue broaden view sustainability means gsk far focused attention sustainability rd manufacturing going forward know need broaden focus include sales force offices realise begun journey need commitment innovation succeed internal sustainability council composed senior managers leading efforts also external stakeholder panel gives feedback approach performance suggests improvement alternatives recognise value stakeholders bring welcome views approach please feel free let know thoughts emailing csrcontactgskcom back top home responsibility environmental sustainability plan excellence journey sustainability corporate responsibility report journey sustainability james hagan vice president corporate environment health safety sustainability charts gsks history environmental management describes company making shift towards sustainability sustainability defined meeting needs today without compromising ability future generations meet needs gsk sustainable need efficient use resources including energy water raw materials need use renewable resources resources become scarce expensive sustainability cost closely linked ultimately means ability continue manufacture affordable medicines requires us address sustainability working towards sustainability since gsk formed similar industries time companies formed gsk started managing emissions waste using treatment disposal methods considered management waste necessary cost soon recognised bolton control measures essential ever incrementally improve impact waste achieve stepchange towards sustainability need make processes efficient prevent waste emissions produced first place fundamental change requires investment innovative solutions innovation create efficient processes use less resource reduce costs virtuous circle completed take portion sales reinvest innovation sustainability reflects builtin approach begin guiding business towards sustainability developed management framework set policy consistent standards everyone gsk follow produced plan outlined timetable achieving goals set framework set fiveyear improvement targets plan refreshed period plan identified manufacturing efficiency first area could make significant progress toward sustainability used material balance calculation looks amount produced compared amounts raw materials used measure material efficiency set improvement target double efficiency new products ecodesign toolkit supports development efficient manufacturing processes read process design already success new medicines think improve processes existing products well climate change one greatest challenges facing mankind key part sustainability strategy set targets almost halve amount energy use co produce per unit sales sustainability focus extends beyond manufacturing aspects business including rd sales activities also includes environmental product stewardship responsibility environmental impact medicines within gsk sustainability started take root example nutritional healthcare business comprehensive sustainability programme please read casestudy details working suppliers examine lifecycle biodiversity impacts raw materials used developing zero waste landfill manufacturing approach using recycled materials packaging developing innovative ways recover used bottles reverse vending consumer healthcare business also developed sustainability strategy called bright green includes packaging climate change water use product stewardship total supply chain goals although made progress nutritionals business certain areas achieving fundamental environmental improvement targets making progress toward sustainability continues challenge assess achieve targets course learn success failure year explain succeeded failed also continue broaden view sustainability means gsk far focused attention sustainability rd manufacturing going forward know need broaden focus include sales force offices realise begun journey need commitment innovation succeed internal sustainability council composed senior managers leading efforts also external stakeholder panel gives feedback approach performance suggests improvement alternatives recognise value stakeholders bring welcome views approach please feel free let know thoughts emailing csrcontactgskcom back top home responsibility environmental sustainability managing ehs sustainability corporate responsibility report managing environment health safety sustainability manage environment health safety sustainability issues using management system aligned recognised management system standards iso ohsas management system based structured framework starts vision policy policy supported standards guidance materials tools training recognition audits assist business manage environment health safety sustainability sites throughout key business operations systematic audits assess sites adoption management systems approach manage risks framework defines ehss vision policy set broad principles expect operations meet ehss standards outline specific requirements company based ehss risks meet exceed applicable laws regulations consistent international standards iso ohsas based management systems approach ehss guidelines support ehss standards providing information requirements standards setting approved approach achieving compliance incorporate good practice within outside gsk wide range information supplements ehss guidelines includes technical information training materials help employees understand implement ehss management system audits assess implementation management systems reward recognition recognises teams made outstanding progress towards achieving goals framework includes plan excellence sets strategy improve ehss performance improving efficiency greater integration horlicks manufacturing facility near delhi india certified international quality standard iso environmental standard iso safety standards iso ohsas site introduced integrated management system reduce burden complying separate standards new system improved efficiency cut costs plant reducing amount documentation required number audits employees use one instruction manual rather separate documents four standards project first place ceos ehs excellence awards initiativehealth safety category home responsibility environmental sustainability managing ehs sustainability corporate responsibility report managing environment health safety sustainability manage environment health safety sustainability issues using management system aligned recognised management system standards iso ohsas management system based structured framework starts vision policy policy supported standards guidance materials tools training recognition audits assist business manage environment health safety sustainability sites throughout key business operations systematic audits assess sites adoption management systems approach manage risks framework defines ehss vision policy set broad principles expect operations meet ehss standards outline specific requirements company based ehss risks meet exceed applicable laws regulations consistent international standards iso ohsas based management systems approach ehss guidelines support ehss standards providing information requirements standards setting approved approach achieving compliance incorporate good practice within outside gsk wide range information supplements ehss guidelines includes technical information training materials help employees understand implement ehss management system audits assess implementation management systems reward recognition recognises teams made outstanding progress towards achieving goals framework includes plan excellence sets strategy improve ehss performance improving efficiency greater integration horlicks manufacturing facility near delhi india certified international quality standard iso environmental standard iso safety standards iso ohsas site introduced integrated management system reduce burden complying separate standards new system improved efficiency cut costs plant reducing amount documentation required number audits employees use one instruction manual rather separate documents four standards project first place ceos ehs excellence awards initiativehealth safety category home responsibility environmental sustainability managing ehs sustainability ehss vision policy corporate responsibility report ehss vision policy vision gsks environment health safety sustainability ehss vision achieve sustainable competitive business advantage environmental sustainability leadership excellence ehss vision supports mission help people feel better live longer policy ehss policy describes employees external stakeholders want accomplish environment health safety sustainability sets aspiration global leadership excellence outlines broad scope plans achieved revised policy approved corporate executive team cet leadership continuous improvement culture leaders ehss performance protecting environment communities work enabling healthy motivated employees fully engaged success maintain culture continuous improvement ehs fundamentals risk impacts embed ehs fundamentals fabric business implementing management systems ehs governance risk management practices address risks impacts facilities processes contract research manufacturing organisations suppliers sustainability integrate sustainability principles aspects healthcare business working stakeholders operating within environmentally sustainable limits lowering ecological footprint enhancing social equity addressing future issues open ehss communication open transparent stakeholders efforts address ehss responsibilities ehss performance corporate executive team cet ensure risks tracked mitigated communication significant risks escalated within business management structure commensurate risks impacts involved cet ensure effective management involvement staff clearly assigned accountability responsibility back top home responsibility environmental sustainability managing ehs sustainability ehss vision policy corporate responsibility report ehss vision policy vision gsks environment health safety sustainability ehss vision achieve sustainable competitive business advantage environmental sustainability leadership excellence ehss vision supports mission help people feel better live longer policy ehss policy describes employees external stakeholders want accomplish environment health safety sustainability sets aspiration global leadership excellence outlines broad scope plans achieved revised policy approved corporate executive team cet leadership continuous improvement culture leaders ehss performance protecting environment communities work enabling healthy motivated employees fully engaged success maintain culture continuous improvement ehs fundamentals risk impacts embed ehs fundamentals fabric business implementing management systems ehs governance risk management practices address risks impacts facilities processes contract research manufacturing organisations suppliers sustainability integrate sustainability principles aspects healthcare business working stakeholders operating within environmentally sustainable limits lowering ecological footprint enhancing social equity addressing future issues open ehss communication open transparent stakeholders efforts address ehss responsibilities ehss performance corporate executive team cet ensure risks tracked mitigated communication significant risks escalated within business management structure commensurate risks impacts involved cet ensure effective management involvement staff clearly assigned accountability responsibility back top home responsibility environmental sustainability managing ehs sustainability training awareness corporate responsibility report training awareness provide detailed guidelines technical information part framework managing environment health safety sustainability ehss training awareness programmes based guidelines inform employees levels risks create culture ehss considerations integral way business help employees understand ehss issues specific jobs ehss training managed sites specific job roles ehss professionals receive induction training undertake regular training ensure aware latest technical information fields business leaders also receive training understand responsibilities reviewed training programme found opportunities improve standardise ehss training across gsk also include ehss competency part job grading programme employees ehss responsibilities read health safety training raise employee awareness environment health safety sustainability provide training support materials intranet regular internal publications events myehss intranet intranet becoming primary mechanism communicate within company several areas gsk intranet support ehss including main site known myehss myehss way news ehss programmes shared source supporting materials framework managing ehss policy standards guidelines training materials documents ehss myehss also basis information system collect data measuring ehss performance reporting results within gsk external stakeholders gsk sites use data manage ehss programmes risks measure progress publications ehss publications available electronically print publish articles environment health safety sustainability spirit internal magazine brief news stories internal web pages events sites participate earthweek annual voluntary programme raise awareness strategic environmental issues encourage integrating environmental concerns culture held june coincide world environment day earthweek encourages employees think impact environment employees sites countries took part earthweek sent information kits sites help develop activities including tree planting clearing litter local forest involving local school children drawing competitions environmental theme operations encouraged continue voluntary environmental activities longer organised centrally awards ceos ehs excellence award website vehicle sharing innovative ehs practices sites teams annual awards replaced website supporting ceos awards sustainability home responsibility environmental sustainability managing ehs sustainability training awareness corporate responsibility report training awareness provide detailed guidelines technical information part framework managing environment health safety sustainability ehss training awareness programmes based guidelines inform employees levels risks create culture ehss considerations integral way business help employees understand ehss issues specific jobs ehss training managed sites specific job roles ehss professionals receive induction training undertake regular training ensure aware latest technical information fields business leaders also receive training understand responsibilities reviewed training programme found opportunities improve standardise ehss training across gsk also include ehss competency part job grading programme employees ehss responsibilities read health safety training raise employee awareness environment health safety sustainability provide training support materials intranet regular internal publications events myehss intranet intranet becoming primary mechanism communicate within company several areas gsk intranet support ehss including main site known myehss myehss way news ehss programmes shared source supporting materials framework managing ehss policy standards guidelines training materials documents ehss myehss also basis information system collect data measuring ehss performance reporting results within gsk external stakeholders gsk sites use data manage ehss programmes risks measure progress publications ehss publications available electronically print publish articles environment health safety sustainability spirit internal magazine brief news stories internal web pages events sites participate earthweek annual voluntary programme raise awareness strategic environmental issues encourage integrating environmental concerns culture held june coincide world environment day earthweek encourages employees think impact environment employees sites countries took part earthweek sent information kits sites help develop activities including tree planting clearing litter local forest involving local school children drawing competitions environmental theme operations encouraged continue voluntary environmental activities longer organised centrally awards ceos ehs excellence award website vehicle sharing innovative ehs practices sites teams annual awards replaced website supporting ceos awards sustainability home responsibility environmental sustainability managing ehs sustainability training awareness corporate responsibility report training awareness provide detailed guidelines technical information part framework managing environment health safety sustainability ehss training awareness programmes based guidelines inform employees levels risks create culture ehss considerations integral way business help employees understand ehss issues specific jobs ehss training managed sites specific job roles ehss professionals receive induction training undertake regular training ensure aware latest technical information fields business leaders also receive training understand responsibilities reviewed training programme found opportunities improve standardise ehss training across gsk also include ehss competency part job grading programme employees ehss responsibilities read health safety training raise employee awareness environment health safety sustainability provide training support materials intranet regular internal publications events myehss intranet intranet becoming primary mechanism communicate within company several areas gsk intranet support ehss including main site known myehss myehss way news ehss programmes shared source supporting materials framework managing ehss policy standards guidelines training materials documents ehss myehss also basis information system collect data measuring ehss performance reporting results within gsk external stakeholders gsk sites use data manage ehss programmes risks measure progress publications ehss publications available electronically print publish articles environment health safety sustainability spirit internal magazine brief news stories internal web pages events sites participate earthweek annual voluntary programme raise awareness strategic environmental issues encourage integrating environmental concerns culture held june coincide world environment day earthweek encourages employees think impact environment employees sites countries took part earthweek sent information kits sites help develop activities including tree planting clearing litter local forest involving local school children drawing competitions environmental theme operations encouraged continue voluntary environmental activities longer organised centrally awards ceos ehs excellence award website vehicle sharing innovative ehs practices sites teams annual awards replaced website supporting ceos awards sustainability home responsibility environmental sustainability managing ehs sustainability audits compliance corporate responsibility report audits compliance approach performance regularly audit operations contract manufacturers key suppliers assess systems manage risks impacts compliance legislation implementation environment health safety sustainability standards audits also assess whether appropriate management systems place improve performance maintain compliance internal auditors certified lead auditors iso ohsas standards gsk manufacturing rd sites audited least every four years actual frequency determined level risk impacts sites performance managing risks audited sites began fouryear programme certify gsk pharmaceutical consumer healthcare manufacturing sites international environmental standard iso health safety standard ohsas certified three sites bringing total per cent pharmaceutical consumer healthcare manufacturing sites certified iso back top home responsibility environmental sustainability managing ehs sustainability audits compliance corporate responsibility report audits compliance approach performance regularly audit operations contract manufacturers key suppliers assess systems manage risks impacts compliance legislation implementation environment health safety sustainability standards audits also assess whether appropriate management systems place improve performance maintain compliance internal auditors certified lead auditors iso ohsas standards gsk manufacturing rd sites audited least every four years actual frequency determined level risk impacts sites performance managing risks audited sites began fouryear programme certify gsk pharmaceutical consumer healthcare manufacturing sites international environmental standard iso health safety standard ohsas certified three sites bringing total per cent pharmaceutical consumer healthcare manufacturing sites certified iso back top home responsibility environmental sustainability managing ehs sustainability audits compliance performance corporate responsibility report audits compliance approach performance audited gsk sites implementation ehs standards conducted follow visits average score per cent lowest score consider acceptable per cent site scored level lowest score per cent two sites achieved leadership scores per cent three achieved scores least per cent high audit scores indicate good management systems work practices sites achieve audit scores per cent higher considered leadership category receive certificates signed chief executive officer sites achieve per cent receive certificates achievement signed business heads critical findings related environment findings indicate high probability incidents potentially serious consequences two critical findings related health safety read performance health safety issues best performance environmental issues waste water management sites generally weakest assessment risks environment health safety twentysix pharmaceuticals consumer healthcare manufacturing sites certified iso ohsas standards four certified iso one consumer healthcare rd site certified standards one gsk vaccines site one pharmaceuticals rd site certified iso five sites confirmed certification audits early certified sites argentina australia brazil china egypt france germany india italy japan kenya mexico panama philippines poland saudi arabia spain turkey us uk iso certification important indicates good management systems place sites successfully certified found experience beneficial order achieve target certify pharmaceutical consumer healthcare manufacturing facilities upgrade level management systems implementation time embark planned expansion iso certification rd vaccines facilities compliance environmental fines penalties continuing compliance record however remain vigilant stay full compliance environmental laws regulations back top home responsibility environmental sustainability managing ehs sustainability audits compliance performance corporate responsibility report audits compliance approach performance audited gsk sites implementation ehs standards conducted follow visits average score per cent lowest score consider acceptable per cent site scored level lowest score per cent two sites achieved leadership scores per cent three achieved scores least per cent high audit scores indicate good management systems work practices sites achieve audit scores per cent higher considered leadership category receive certificates signed chief executive officer sites achieve per cent receive certificates achievement signed business heads critical findings related environment findings indicate high probability incidents potentially serious consequences two critical findings related health safety read performance health safety issues best performance environmental issues waste water management sites generally weakest assessment risks environment health safety twentysix pharmaceuticals consumer healthcare manufacturing sites certified iso ohsas standards four certified iso one consumer healthcare rd site certified standards one gsk vaccines site one pharmaceuticals rd site certified iso five sites confirmed certification audits early certified sites argentina australia brazil china egypt france germany india italy japan kenya mexico panama philippines poland saudi arabia spain turkey us uk iso certification important indicates good management systems place sites successfully certified found experience beneficial order achieve target certify pharmaceutical consumer healthcare manufacturing facilities upgrade level management systems implementation time embark planned expansion iso certification rd vaccines facilities compliance environmental fines penalties continuing compliance record however remain vigilant stay full compliance environmental laws regulations back top home responsibility environmental sustainability managing ehs sustainability reward recognition corporate responsibility report reward recognition ceos ehs excellence awards recognise reward gsk sites show leadership ehs sustainability highlight innovation examples good practice ehss management share sites winner receives trophy selects charity receive donation gsk individuals teams enter competition shortlist drawn internal review committee winners chosen panel includes experts academia government public interest groups awards divided three categories green chemistrygreen technology projects benefit environment health safety new efficient chemistry technology environmental initiative programmes demonstrate improvements environmental management performance occupational health safety initiatives programmes demonstrate improvements health safety management performance seventh year awards entries countries gsk businesses honours went eleven projects australia belgium india uk us read winning environmental projects throughout section winning health safety projects people section awards upgraded ceos awards sustainability new categories new judging criteria supporting increasing focus sustainability back top home responsibility environmental sustainability managing ehs sustainability reward recognition corporate responsibility report reward recognition ceos ehs excellence awards recognise reward gsk sites show leadership ehs sustainability highlight innovation examples good practice ehss management share sites winner receives trophy selects charity receive donation gsk individuals teams enter competition shortlist drawn internal review committee winners chosen panel includes experts academia government public interest groups awards divided three categories green chemistrygreen technology projects benefit environment health safety new efficient chemistry technology environmental initiative programmes demonstrate improvements environmental management performance occupational health safety initiatives programmes demonstrate improvements health safety management performance seventh year awards entries countries gsk businesses honours went eleven projects australia belgium india uk us read winning environmental projects throughout section winning health safety projects people section awards upgraded ceos awards sustainability new categories new judging criteria supporting increasing focus sustainability back top home responsibility environmental sustainability managing ehs sustainability management ehss corporate responsibility report management ehss overall responsibility environment health safety sustainability issues rests corporate executive team board chief executive officer represents issues board board chairman champion gsks climate change programme chief staff operational management responsibility ehss corporate executive team vice president corporate environment health safety sustainability cehss operational responsibility ehss reports directly chief staff dotted line reporting relationship president global manufacturing supply environment health safety sustainability activities overseen risk oversight compliance council corporate executive team audit corporate responsibility committees board directors committees regularly review ehss performance progress toward meeting ehss targets results ehss audits gsk operations suppliers consider issues sustainability social implications back top home responsibility environmental sustainability managing ehs sustainability management ehss corporate responsibility report management ehss overall responsibility environment health safety sustainability issues rests corporate executive team board chief executive officer represents issues board board chairman champion gsks climate change programme chief staff operational management responsibility ehss corporate executive team vice president corporate environment health safety sustainability cehss operational responsibility ehss reports directly chief staff dotted line reporting relationship president global manufacturing supply environment health safety sustainability activities overseen risk oversight compliance council corporate executive team audit corporate responsibility committees board directors committees regularly review ehss performance progress toward meeting ehss targets results ehss audits gsk operations suppliers consider issues sustainability social implications back top home responsibility environmental sustainability environmental fundamentals corporate responsibility report environmental fundamentals working reduce fundamental environmental impacts operations many years involves using treatment disposal systems control emissions wastes manufacturing facilities research laboratories numerous offices warehouses large fleet vehicles fundamental emissions include wastewater general solid hazardous waste ozone depleting substances released equipment production processes patients use inhaler products volatile organic compounds primarily solvents aim create culture fundamental environmental considerations part everyday business decisions continue manage fundamental emissions moving towards sustainability changing production business processes avoid waste source rather simply treating waste emissions arise back top home responsibility environmental sustainability environmental fundamentals corporate responsibility report environmental fundamentals working reduce fundamental environmental impacts operations many years involves using treatment disposal systems control emissions wastes manufacturing facilities research laboratories numerous offices warehouses large fleet vehicles fundamental emissions include wastewater general solid hazardous waste ozone depleting substances released equipment production processes patients use inhaler products volatile organic compounds primarily solvents aim create culture fundamental environmental considerations part everyday business decisions continue manage fundamental emissions moving towards sustainability changing production business processes avoid waste source rather simply treating waste emissions arise back top home responsibility environmental sustainability environmental fundamentals wastewater corporate responsibility report wastewater approach performance gsk sites discharge wastewater municipal treatment facilities large sites especially sites manufacture active pharmaceutical ingredients api onsite wastewater treatment systems sites permitted discharge wastewater direct sea assess quality wastewater measuring chemical oxygen demand cod oxygen required chemically oxidise compounds water lower cod cleaner water target improve cod levels three per cent year per unit sales give us reduction per cent end vast majority cod comes manufacturing api therefore wastewater domestic activities washrooms canteens included separated manufacturing activities sgs verified back top home responsibility environmental sustainability environmental fundamentals wastewater corporate responsibility report wastewater approach performance gsk sites discharge wastewater municipal treatment facilities large sites especially sites manufacture active pharmaceutical ingredients api onsite wastewater treatment systems sites permitted discharge wastewater direct sea assess quality wastewater measuring chemical oxygen demand cod oxygen required chemically oxidise compounds water lower cod cleaner water target improve cod levels three per cent year per unit sales give us reduction per cent end vast majority cod comes manufacturing api therefore wastewater domestic activities washrooms canteens included separated manufacturing activities sgs verified back top home responsibility environmental sustainability environmental fundamentals wastewater corporate responsibility report wastewater approach performance chemical oxygen demand wastewater targets performance normalised sales based constant exchange rate errors found data prior years corrected data may vary slightly earlier reports chemical oxygen demand per million sales corrected constant exchange rate cer decreased per cent baseline absolute chemical oxygen demand decreased per cent baseline million kilograms decrease line target decrease three per cent per year explanation trend quality wastewater discharged closely related types amount materials produced manufacture active pharmaceutical ingredient chemical oxygen demand wastewater decreased significantly decrease production antibiotic ingredients year production products increased chemical oxygen demand increased although still less site increased antibiotic production accounts per cent wastewater volume per cent wastewater cod concerned level pollution wastewater cause burden local municipal wastewater treatment facilities local receiving water bodies changes levels wastewater pollution year year due changes production waste minimisation continued improvements wastewater treatment example evaluating wastewater treatment technologies pharmaceutical ingredient manufacturing plant singapore planning reverse osmosis system pharmaceutical ingredient manufacturing plant india addition work improve manufacturing efficiency decrease wastewater pollution future generated million cubic metres wastewater compared million cubic metres volume wastewater per cent lower per cent lower baseline sgs verified back tophome responsibility environmental sustainability environmental fundamentals wastewater corporate responsibility report wastewater approach performance chemical oxygen demand wastewater targets performance normalised sales based constant exchange rate errors found data prior years corrected data may vary slightly earlier reports chemical oxygen demand per million sales corrected constant exchange rate cer decreased per cent baseline absolute chemical oxygen demand decreased per cent baseline million kilograms decrease line target decrease three per cent per year explanation trend quality wastewater discharged closely related types amount materials produced manufacture active pharmaceutical ingredient chemical oxygen demand wastewater decreased significantly decrease production antibiotic ingredients year production products increased chemical oxygen demand increased although still less site increased antibiotic production accounts per cent wastewater volume per cent wastewater cod concerned level pollution wastewater cause burden local municipal wastewater treatment facilities local receiving water bodies changes levels wastewater pollution year year due changes production waste minimisation continued improvements wastewater treatment example evaluating wastewater treatment technologies pharmaceutical ingredient manufacturing plant singapore planning reverse osmosis system pharmaceutical ingredient manufacturing plant india addition work improve manufacturing efficiency decrease wastewater pollution future generated million cubic metres wastewater compared million cubic metres volume wastewater per cent lower per cent lower baseline sgs verified back top home responsibility environmental sustainability environmental fundamentals wastewater corporate responsibility report wastewater approach performance chemical oxygen demand wastewater targets performance normalised sales based constant exchange rate errors found data prior years corrected data may vary slightly earlier reports chemical oxygen demand per million sales corrected constant exchange rate cer decreased per cent baseline absolute chemical oxygen demand decreased per cent baseline million kilograms decrease line target decrease three per cent per year explanation trend quality wastewater discharged closely related types amount materials produced manufacture active pharmaceutical ingredient chemical oxygen demand wastewater decreased significantly decrease production antibiotic ingredients year production products increased chemical oxygen demand increased although still less site increased antibiotic production accounts per cent wastewater volume per cent wastewater cod concerned level pollution wastewater cause burden local municipal wastewater treatment facilities local receiving water bodies changes levels wastewater pollution year year due changes production waste minimisation continued improvements wastewater treatment example evaluating wastewater treatment technologies pharmaceutical ingredient manufacturing plant singapore planning reverse osmosis system pharmaceutical ingredient manufacturing plant india addition work improve manufacturing efficiency decrease wastewater pollution future generated million cubic metres wastewater compared million cubic metres volume wastewater per cent lower per cent lower baseline sgs verified back top home responsibility environmental sustainability environmental fundamentals waste corporate responsibility report hazardous nonhazardous waste approach performance production research sales activities produce waste production hazardous wastes solvents chemicals rd quality control laboratories small amounts chemicals including products intermediates well broken glassware plastics offices paper standard commercial waste building renovations produce nonroutine waste obsolete equipment office furniture structural materials classify waste hazardous nonhazardous nonroutine waste construction demolition rubble significant proportion waste classified hazardous contains solvents chemicals used manufacture active pharmaceutical ingredients hazardous waste produce includes lubricants fluorescent lights carcasses animals used research non hazardous waste general material office waste paper kitchen waste nonhazardous substances used manufacturing approach aim eliminate waste reduce eliminate reuse materials possible recycle waste dispose remaining material sensitively separate hazardous wastes different categories efficient appropriate treatment regulations vary widely around world first choice solvents account hazardous waste reuse recycle used solvent recovered purified site reused original manufacturing process sold commercial reprocessing companies still included recycling statistics reuse recycling possible solvents mostly incinerated energy recovered wherever possible require disposal contractors comply ehs requirements local regulations sites audit waste contractors hire consultants carry audits target reduce nonhazardous waste disposed per unit sales one per cent per annum give us reduction four per cent end set target reduction hazardous waste target improve material efficiency efficiency convert raw materials finished products designed reduce hazardous waste amount nonhazardous waste disposed affected many factors amounts types products made year affect amount waste also ability recycle addition production changes sites actively aggressively working recycle much waste possible decrease disposal waste minimum levels focus eliminating waste sent landfill disposal hazardous waste affected way solvents managed mix products made year hazardous waste comes manufacture active pharmaceutical ingredients concentrate efforts collect hazardous waste data consumer manufacturing plants laboratories offices estimate sites may generate additional three per cent hazardous waste amount report sgs verified building trust environmental commitment manufacturing site boronia australia stepped environmental efforts ceo andrew witty recognised sites achievements awarding first prize environment initiative category environment health safety excellence awards achievements include establishing green team employee volunteers helped increase involvement sustainability activities result site reduced water use per cent levels energy use per cent levels waste tonnes diverted landfill per cent reduction co emissions product transport result switching air freight sea freight imports raw materials exports finished goods also saved facility estimated million million gbp anticipate savings increase million million gbp annually onwards introduction wastesaving measures cold chain distribution system including reusable cool boxes data loggers ice bricks new cold chain system manages temperature better even extreme conditions prevented polystyrene cool boxes temperature alert tags disposable ice bricks sent landfill also saves customers trouble waste disposal repack equipment collect project first place ceos ehs excellence awards initiativeenvironment category back tophome responsibility environmental sustainability environmental fundamentals waste corporate responsibility report hazardous nonhazardous waste approach performance production research sales activities produce waste production hazardous wastes solvents chemicals rd quality control laboratories small amounts chemicals including products intermediates well broken glassware plastics offices paper standard commercial waste building renovations produce nonroutine waste obsolete equipment office furniture structural materials classify waste hazardous nonhazardous nonroutine waste construction demolition rubble significant proportion waste classified hazardous contains solvents chemicals used manufacture active pharmaceutical ingredients hazardous waste produce includes lubricants fluorescent lights carcasses animals used research non hazardous waste general material office waste paper kitchen waste nonhazardous substances used manufacturing approach aim eliminate waste reduce eliminate reuse materials possible recycle waste dispose remaining material sensitively separate hazardous wastes different categories efficient appropriate treatment regulations vary widely around world first choice solvents account hazardous waste reuse recycle used solvent recovered purified site reused original manufacturing process sold commercial reprocessing companies still included recycling statistics reuse recycling possible solvents mostly incinerated energy recovered wherever possible require disposal contractors comply ehs requirements local regulations sites audit waste contractors hire consultants carry audits target reduce nonhazardous waste disposed per unit sales one per cent per annum give us reduction four per cent end set target reduction hazardous waste target improve material efficiency efficiency convert raw materials finished products designed reduce hazardous waste amount nonhazardous waste disposed affected many factors amounts types products made year affect amount waste also ability recycle addition production changes sites actively aggressively working recycle much waste possible decrease disposal waste minimum levels focus eliminating waste sent landfill disposal hazardous waste affected way solvents managed mix products made year hazardous waste comes manufacture active pharmaceutical ingredients concentrate efforts collect hazardous waste data consumer manufacturing plants laboratories offices estimate sites may generate additional three per cent hazardous waste amount report sgs verified building trust environmental commitment manufacturing site boronia australia stepped environmental efforts ceo andrew witty recognised sites achievements awarding first prize environment initiative category environment health safety excellence awards achievements include establishing green team employee volunteers helped increase involvement sustainability activities result site reduced water use per cent levels energy use per cent levels waste tonnes diverted landfill per cent reduction co emissions product transport result switching air freight sea freight imports raw materials exports finished goods also saved facility estimated million million gbp anticipate savings increase million million gbp annually onwards introduction wastesaving measures cold chain distribution system including reusable cool boxes data loggers ice bricks new cold chain system manages temperature better even extreme conditions prevented polystyrene cool boxes temperature alert tags disposable ice bricks sent landfill also saves customers trouble waste disposal repack equipment collect project first place ceos ehs excellence awards initiativeenvironment category back top home responsibility environmental sustainability environmental fundamentals waste corporate responsibility report hazardous nonhazardous waste approach performance production research sales activities produce waste production hazardous wastes solvents chemicals rd quality control laboratories small amounts chemicals including products intermediates well broken glassware plastics offices paper standard commercial waste building renovations produce nonroutine waste obsolete equipment office furniture structural materials classify waste hazardous nonhazardous nonroutine waste construction demolition rubble significant proportion waste classified hazardous contains solvents chemicals used manufacture active pharmaceutical ingredients hazardous waste produce includes lubricants fluorescent lights carcasses animals used research non hazardous waste general material office waste paper kitchen waste nonhazardous substances used manufacturing approach aim eliminate waste reduce eliminate reuse materials possible recycle waste dispose remaining material sensitively separate hazardous wastes different categories efficient appropriate treatment regulations vary widely around world first choice solvents account hazardous waste reuse recycle used solvent recovered purified site reused original manufacturing process sold commercial reprocessing companies still included recycling statistics reuse recycling possible solvents mostly incinerated energy recovered wherever possible require disposal contractors comply ehs requirements local regulations sites audit waste contractors hire consultants carry audits target reduce nonhazardous waste disposed per unit sales one per cent per annum give us reduction four per cent end set target reduction hazardous waste target improve material efficiency efficiency convert raw materials finished products designed reduce hazardous waste amount nonhazardous waste disposed affected many factors amounts types products made year affect amount waste also ability recycle addition production changes sites actively aggressively working recycle much waste possible decrease disposal waste minimum levels focus eliminating waste sent landfill disposal hazardous waste affected way solvents managed mix products made year hazardous waste comes manufacture active pharmaceutical ingredients concentrate efforts collect hazardous waste data consumer manufacturing plants laboratories offices estimate sites may generate additional three per cent hazardous waste amount report sgs verified building trust environmental commitment manufacturing site boronia australia stepped environmental efforts ceo andrew witty recognised sites achievements awarding first prize environment initiative category environment health safety excellence awards achievements include establishing green team employee volunteers helped increase involvement sustainability activities result site reduced water use per cent levels energy use per cent levels waste tonnes diverted landfill per cent reduction co emissions product transport result switching air freight sea freight imports raw materials exports finished goods also saved facility estimated million million gbp anticipate savings increase million million gbp annually onwards introduction wastesaving measures cold chain distribution system including reusable cool boxes data loggers ice bricks new cold chain system manages temperature better even extreme conditions prevented polystyrene cool boxes temperature alert tags disposable ice bricks sent landfill also saves customers trouble waste disposal repack equipment collect project first place ceos ehs excellence awards initiativeenvironment category back top home responsibility environmental sustainability environmental fundamentals waste corporate responsibility report hazardous nonhazardous waste approach performance nonhazardous waste nonhazardous waste disposed targets performance normalised sales based constant exchange rate errors found data prior years corrected data may vary slightly earlier reports destination nonhazardous waste targets performance normalised sales based constant exchange rate amount nonhazardous waste disposed per million sales corrected constant exchange rate cer decreased per cent baseline absolute nonhazardous waste decreased per cent baseline million kilograms significantly better one per cent per year improvement target explanation trend decrease nonhazardous waste disposed least partially due continuing efforts manage recycle waste especially pharmaceutical consumer manufacturing operations also due part decreased production products partially balanced increasing waste vaccines business continues grow target specific nonhazardous waste disposed also measure total nonhazardous waste generated includes nonhazardous waste disposed nonhazardous waste recycled generated million kilograms nonhazardous waste compared million kilograms million kilograms per cent recycled per cent disposed via landfill incineration reduced disposal nonhazardous waste pharmaceutical manufacturing sites per cent per cent pharmaceutical rd sites however per cent increase nonhazardous waste disposal vaccines business due continuing expansion resulted overall per cent decrease amount nonhazardous waste disposed gsk compared baseline met nonhazardous waste improvement target however ensure maintain improvement times production increases review improvement projects make sure continue reduce amount waste dispose particularly committed reducing amount waste sent landfill want minimise burden environment society landfill space becomes harder find cost sending waste landfill increases data include nonroutine waste construction demolition rubble similar material related daytoday operations continue look ways reduce waste undertaken waste management reviews many sites recycling nonhazardous waste paper cardboard glass plastic aluminium usually means sending reprocessing reused make new products addition waste reduction measures reductions likely due decreases volume production certain pharmaceutical consumer healthcare products examples projects reduced nonhazardous waste disposal two sites india stopped putting coal ash generate landfill instead sell raw material production construction material addition three nutritional drink manufacturing sites send process wastes barley husk use animal food others recycle canteen waste effluent treatment plant sludge converting biocompost sgs verified hazardous waste hazardous waste disposed targets performance normalised sales based constant exchange rate errors found data prior years corrected data may vary slightly earlier reports destination hazardous waste errors found data prior years corrected data may vary slightly earlier reports amount hazardous waste disposed per million sales corrected constant exchange rate cer decreased per cent baseline absolute hazardous waste decreased per cent baseline million kilograms explanation trend decrease hazardous waste disposed due continued efforts manage recycle hazardous waste especially solvents also due part decreased production products used significant quantities solvent outsourcing production amount hazardous waste disposed related types quantities products made amount solvent used factories manufacture active pharmaceutical ingredients solvent waste per cent hazardous waste generated per cent hazardous waste recycled four largest sites manufacture active pharmaceutical ingredients together account per cent solvent waste disposed set target reducing hazardous waste disposed instead focused attention improving manufacturing efficiency efficiency improvements mean less material used manufacturing process therefore less waste however efficiency improvements take time achieve meantime important minimise hazardous waste monitor improve way handle example recycling solvents sgs verified back tophome responsibility environmental sustainability environmental fundamentals waste corporate responsibility report hazardous nonhazardous waste approach performance nonhazardous waste nonhazardous waste disposed targets performance normalised sales based constant exchange rate errors found data prior years corrected data may vary slightly earlier reports destination nonhazardous waste targets performance normalised sales based constant exchange rate amount nonhazardous waste disposed per million sales corrected constant exchange rate cer decreased per cent baseline absolute nonhazardous waste decreased per cent baseline million kilograms significantly better one per cent per year improvement target explanation trend decrease nonhazardous waste disposed least partially due continuing efforts manage recycle waste especially pharmaceutical consumer manufacturing operations also due part decreased production products partially balanced increasing waste vaccines business continues grow target specific nonhazardous waste disposed also measure total nonhazardous waste generated includes nonhazardous waste disposed nonhazardous waste recycled generated million kilograms nonhazardous waste compared million kilograms million kilograms per cent recycled per cent disposed via landfill incineration reduced disposal nonhazardous waste pharmaceutical manufacturing sites per cent per cent pharmaceutical rd sites however per cent increase nonhazardous waste disposal vaccines business due continuing expansion resulted overall per cent decrease amount nonhazardous waste disposed gsk compared baseline met nonhazardous waste improvement target however ensure maintain improvement times production increases review improvement projects make sure continue reduce amount waste dispose particularly committed reducing amount waste sent landfill want minimise burden environment society landfill space becomes harder find cost sending waste landfill increases data include nonroutine waste construction demolition rubble similar material related daytoday operations continue look ways reduce waste undertaken waste management reviews many sites recycling nonhazardous waste paper cardboard glass plastic aluminium usually means sending reprocessing reused make new products addition waste reduction measures reductions likely due decreases volume production certain pharmaceutical consumer healthcare products examples projects reduced nonhazardous waste disposal two sites india stopped putting coal ash generate landfill instead sell raw material production construction material addition three nutritional drink manufacturing sites send process wastes barley husk use animal food others recycle canteen waste effluent treatment plant sludge converting biocompost sgs verified hazardous waste hazardous waste disposed targets performance normalised sales based constant exchange rate errors found data prior years corrected data may vary slightly earlier repoprtasge destination hazardous waste errors found data prior years corrected data may vary slightly earlier reports amount hazardous waste disposed per million sales corrected constant exchange rate cer decreased per cent baseline absolute hazardous waste decreased per cent baseline million kilograms explanation trend decrease hazardous waste disposed due continued efforts manage recycle hazardous waste especially solvents also due part decreased production products used significant quantities solvent outsourcing production amount hazardous waste disposed related types quantities products made amount solvent used factories manufacture active pharmaceutical ingredients solvent waste per cent hazardous waste generated per cent hazardous waste recycled four largest sites manufacture active pharmaceutical ingredients together account per cent solvent waste disposed set target reducing hazardous waste disposed instead focused attention improving manufacturing efficiency efficiency improvements mean less material used manufacturing process therefore less waste however efficiency improvements take time achieve meantime important minimise hazardous waste monitor improve way handle example recycling solvents sgs verified back tophome responsibility environmental sustainability environmental fundamentals waste corporate responsibility report hazardous nonhazardous waste approach performance nonhazardous waste nonhazardous waste disposed targets performance normalised sales based constant exchange rate errors found data prior years corrected data may vary slightly earlier reports destination nonhazardous waste targets performance normalised sales based constant exchange rate amount nonhazardous waste disposed per million sales corrected constant exchange rate cer decreased per cent baseline absolute nonhazardous waste decreased per cent baseline million kilograms significantly better one per cent per year improvement target explanation trend decrease nonhazardous waste disposed least partially due continuing efforts manage recycle waste especially pharmaceutical consumer manufacturing operations also due part decreased production products partially balanced increasing waste vaccines business continues grow target specific nonhazardous waste disposed also measure total nonhazardous waste generated includes nonhazardous waste disposed nonhazardous waste recycled generated million kilograms nonhazardous waste compared million kilograms million kilograms per cent recycled per cent disposed via landfill incineration reduced disposal nonhazardous waste pharmaceutical manufacturing sites per cent per cent pharmaceutical rd sites however per cent increase nonhazardous waste disposal vaccines business due continuing expansion resulted overall per cent decrease amount nonhazardous waste disposed gsk compared baseline met nonhazardous waste improvement target however ensure maintain improvement times production increases review improvement projects make sure continue reduce amount waste dispose particularly committed reducing amount waste sent landfill want minimise burden environment society landfill space becomes harder find cost sending waste landfill increases data include nonroutine waste construction demolition rubble similar material related daytoday operations continue look ways reduce waste undertaken waste management reviews many sites recycling nonhazardous waste paper cardboard glass plastic aluminium usually means sending reprocessing reused make new products addition waste reduction measures reductions likely due decreases volume production certain pharmaceutical consumer healthcare products examples projects reduced nonhazardous waste disposal two sites india stopped putting coal ash generate landfill instead sell raw material production construction material addition three nutritional drink manufacturing sites send process wastes barley husk use animal food others recycle canteen waste effluent treatment plant sludge converting biocompost sgs verified hazardous waste hazardous waste disposed targets performance normalised sales based constant exchange rate errors found data prior years corrected data may vary slightly earlier reports destination hazardous waste errors found data prior years corrected data may vary slightly earlier reports amount hazardous waste disposed per million sales corrected constant exchange rate cer decreased per cent baseline absolute hazardous waste decreased per cent baseline million kilograms explanation trend decrease hazardous waste disposed due continued efforts manage recycle hazardous waste especially solvents also due part decreased production products used significant quantities solvent outsourcing production amount hazardous waste disposed related types quantities products made amount solvent used factories manufacture active pharmaceutical ingredients solvent waste per cent hazardous waste generated per cent hazardous waste recycled four largest sites manufacture active pharmaceutical ingredients together account per cent solvent waste disposed set target reducing hazardous waste disposed instead focused attention improving manufacturing efficiency efficiency improvements mean less material used manufacturing process therefore less waste however efficiency improvements take time achieve meantime important minimise hazardous waste monitor improve way handle example recycling solvents sgs verified back tophome responsibility environmental sustainability environmental fundamentals waste corporate responsibility report hazardous nonhazardous waste approach performance nonhazardous waste nonhazardous waste disposed targets performance normalised sales based constant exchange rate errors found data prior years corrected data may vary slightly earlier reports destination nonhazardous waste targets performance normalised sales based constant exchange rate amount nonhazardous waste disposed per million sales corrected constant exchange rate cer decreased per cent baseline absolute nonhazardous waste decreased per cent baseline million kilograms significantly better one per cent per year improvement target explanation trend decrease nonhazardous waste disposed least partially due continuing efforts manage recycle waste especially pharmaceutical consumer manufacturing operations also due part decreased production products partially balanced increasing waste vaccines business continues grow target specific nonhazardous waste disposed also measure total nonhazardous waste generated includes nonhazardous waste disposed nonhazardous waste recycled generated million kilograms nonhazardous waste compared million kilograms million kilograms per cent recycled per cent disposed via landfill incineration reduced disposal nonhazardous waste pharmaceutical manufacturing sites per cent per cent pharmaceutical rd sites however per cent increase nonhazardous waste disposal vaccines business due continuing expansion resulted overall per cent decrease amount nonhazardous waste disposed gsk compared baseline met nonhazardous waste improvement target however ensure maintain improvement times production increases review improvement projects make sure continue reduce amount waste dispose particularly committed reducing amount waste sent landfill want minimise burden environment society landfill space becomes harder find cost sending waste landfill increases data include nonroutine waste construction demolition rubble similar material related daytoday operations continue look ways reduce waste undertaken waste management reviews many sites recycling nonhazardous waste paper cardboard glass plastic aluminium usually means sending reprocessing reused make new products addition waste reduction measures reductions likely due decreases volume production certain pharmaceutical consumer healthcare products examples projects reduced nonhazardous waste disposal two sites india stopped putting coal ash generate landfill instead sell raw material production construction material addition three nutritional drink manufacturing sites send process wastes barley husk use animal food others recycle canteen waste effluent treatment plant sludge converting biocompost sgs verified hazardous waste hazardous waste disposed targets performance normalised sales based constant exchange rate errors found data prior years corrected data may vary slightly earlier reports destination hazardous waste errors found data prior years corrected data may vary slightly earlier reports amount hazardous waste disposed per million sales corrected constant exchange rate cer decreased per cent baseline absolute hazardous waste decreased per cent baseline million kilograms explanation trend decrease hazardous waste disposed due continued efforts manage recycle hazardous waste especially solvents also due part decreased production products used significant quantities solvent outsourcing production amount hazardous waste disposed related types quantities products made amount solvent used factories manufacture active pharmaceutical ingredients solvent waste per cent hazardous waste generated per cent hazardous waste recycled four largest sites manufacture active pharmaceutical ingredients together account per cent solvent waste disposed set target reducing hazardous waste disposed instead focused attention improving manufacturing efficiency efficiency improvements mean less material used manufacturing process therefore less waste however efficiency improvements take time achieve meantime important minimise hazardous waste monitor improve way handle example recycling solvents sgs verified back top home responsibility environmental sustainability environmental fundamentals waste corporate responsibility report hazardous nonhazardous waste approach performance nonhazardous waste nonhazardous waste disposed targets performance normalised sales based constant exchange rate errors found data prior years corrected data may vary slightly earlier reports destination nonhazardous waste targets performance normalised sales based constant exchange rate amount nonhazardous waste disposed per million sales corrected constant exchange rate cer decreased per cent baseline absolute nonhazardous waste decreased per cent baseline million kilograms significantly better one per cent per year improvement target explanation trend decrease nonhazardous waste disposed least partially due continuing efforts manage recycle waste especially pharmaceutical consumer manufacturing operations also due part decreased production products partially balanced increasing waste vaccines business continues grow target specific nonhazardous waste disposed also measure total nonhazardous waste generated includes nonhazardous waste disposed nonhazardous waste recycled generated million kilograms nonhazardous waste compared million kilograms million kilograms per cent recycled per cent disposed via landfill incineration reduced disposal nonhazardous waste pharmaceutical manufacturing sites per cent per cent pharmaceutical rd sites however per cent increase nonhazardous waste disposal vaccines business due continuing expansion resulted overall per cent decrease amount nonhazardous waste disposed gsk compared baseline met nonhazardous waste improvement target however ensure maintain improvement times production increases review improvement projects make sure continue reduce amount waste dispose particularly committed reducing amount waste sent landfill want minimise burden environment society landfill space becomes harder find cost sending waste landfill increases data include nonroutine waste construction demolition rubble similar material related daytoday operations continue look ways reduce waste undertaken waste management reviews many sites recycling nonhazardous waste paper cardboard glass plastic aluminium usually means sending reprocessing reused make new products addition waste reduction measures reductions likely due decreases volume production certain pharmaceutical consumer healthcare products examples projects reduced nonhazardous waste disposal two sites india stopped putting coal ash generate landfill instead sell raw material production construction material addition three nutritional drink manufacturing sites send process wastes barley husk use animal food others recycle canteen waste effluent treatment plant sludge converting biocompost sgs verified hazardous waste hazardous waste disposed targets performance normalised sales based constant exchange rate errors found data prior years corrected data may vary slightly earlier reports destination hazardous waste errors found data prior years corrected data may vary slightly earlier reports amount hazardous waste disposed per million sales corrected constant exchange rate cer decreased per cent baseline absolute hazardous waste decreased per cent baseline million kilograms explanation trend decrease hazardous waste disposed due continued efforts manage recycle hazardous waste especially solvents also due part decreased production products used significant quantities solvent outsourcing production amount hazardous waste disposed related types quantities products made amount solvent used factories manufacture active pharmaceutical ingredients solvent waste per cent hazardous waste generated per cent hazardous waste recycled four largest sites manufacture active pharmaceutical ingredients together account per cent solvent waste disposed set target reducing hazardous waste disposed instead focused attention improving manufacturing efficiency efficiency improvements mean less material used manufacturing process therefore less waste however efficiency improvements take time achieve meantime important minimise hazardous waste monitor improve way handle example recycling solvents sgs verified back top home responsibility environmental sustainability environmental fundamentals contaminated land corporate responsibility report contaminated land handling practices chemicals used industries past longer followed caused contamination land groundwater land also become contaminated due accidental release materials involved number projects uk us remediate sites contaminated land identified five sites uk require remediation sites us work governments parties effect necessary remediation costs remediation shared parties involved five uk sites undergoing remediation two partially fully decommissioned gsk heritage companies spent million cleaning sites us last years continuing clean sites waste disposal sites gsk one several responsible parties figures included data verification explanation trend heritage companies formed gsk confronted number contaminated land sites undertook actions avoid similar problems occurring future first action audit commercial hazardous waste treatment disposal sites level performance financial solvency avoid inappropriate disposal second action minimise solvent use wherever possible changing solvent coating aqueous coating tablets third action initiate project improve material efficiency minimise eliminate hazardous persistent bioaccumulative toxic compounds also reviewed production operations determine past practices contaminated soil ground water problems discovered initiated site remediation back top home responsibility environmental sustainability environmental fundamentals contaminated land corporate responsibility report contaminated land handling practices chemicals used industries past longer followed caused contamination land groundwater land also become contaminated due accidental release materials involved number projects uk us remediate sites contaminated land identified five sites uk require remediation sites us work governments parties effect necessary remediation costs remediation shared parties involved five uk sites undergoing remediation two partially fully decommissioned gsk heritage companies spent million cleaning sites us last years continuing clean sites waste disposal sites gsk one several responsible parties figures included data verification explanation trend heritage companies formed gsk confronted number contaminated land sites undertook actions avoid similar problems occurring future first action audit commercial hazardous waste treatment disposal sites level performance financial solvency avoid inappropriate disposal second action minimise solvent use wherever possible changing solvent coating aqueous coating tablets third action initiate project improve material efficiency minimise eliminate hazardous persistent bioaccumulative toxic compounds also reviewed production operations determine past practices contaminated soil ground water problems discovered initiated site remediation back top home responsibility environmental sustainability environmental fundamentals emissions air corporate responsibility report emissions air approach performance plans ozone depletion ozone layer upper atmosphere essential human survival filters harmful ultra violet rays sun damaged ozone depleting substances odss mainly chlorofluorocarbons cfcs hydrochlorofluorocarbons hcfcs halons loss ozone upper atmosphere means ultravioletb radiation reaches earths surface affect health example causing skin cancer skin ageing eye disorders suppression immune system industrial use odss common negative effects realised past used cfcs propellant gas metered dose inhalers mdis deliver precise dose medication treat asthma sufferers people chronic obstructive pulmonary disease gas released patients use inhalers small amount escapes production montreal protocol bans production cfcs exempts number essential uses include mdis however support principles plan eliminate use cfcs products end less two per cent inhalers contain cfcs stopped using cfcs propellants inhalers made us european union offer selection alternatives countries eliminate cfcs products worldwide end main alternative propellant used hfa hydrofluoroalkane affect ozone layer global warming potential although significantly lower cfc contributing climate change also invested heavily dry powder delivery systems use propellants cfcs hfa suitable patients particularly children elderly contain propellants rely persons lung power active ingredients administered equipment production also use odss cooling systems ancillary uses gsk facilities contained inside systems released event leak maintenance switched using hydrofluorocarbons hfcs ammonia hydrocarbons ammonia contribute either ozone depletion climate change hydrocarbons small climate change impact aim eliminate cfcs hcfcs cooling systems way completely eliminate emissions equipment focusing removing larger pieces equipment service end intend replace equipment containing less one kilogram cfcs hcfcs prior planned replacement type equipment tends hermetically sealed less likely leak volatile organic compounds volatile organic compounds vocs react nitrogen oxides presence sunlight creating ozone lower atmosphere results smog factor human respiratory illness workplace exposure certain vocs also pose health risk emit vocs atmosphere mainly solvents used primary manufacturing operations rd pilot plants solvents also used coat tablets cleaning sterile operations use small quantities solvents laboratories measure emissions use target reduce volatile organic compound emissions air two per cent per year per unit sales give us reduction per cent end sgs verifiedhome responsibility environmental sustainability environmental fundamentals emissions air corporate responsibility report emissions air approach performance plans ozone depletion ozone layer upper atmosphere essential human survival filters harmful ultra violet rays sun damaged ozone depleting substances odss mainly chlorofluorocarbons cfcs hydrochlorofluorocarbons hcfcs halons loss ozone upper atmosphere means ultravioletb radiation reaches earths surface affect health example causing skin cancer skin ageing eye disorders suppression immune system industrial use odss common negative effects realised past used cfcs propellant gas metered dose inhalers mdis deliver precise dose medication treat asthma sufferers people chronic obstructive pulmonary disease gas released patients use inhalers small amount escapes production montreal protocol bans production cfcs exempts number essential uses include mdis however support principles plan eliminate use cfcs products end less two per cent inhalers contain cfcs stopped using cfcs propellants inhalers made us european union offer selection alternatives countries eliminate cfcs products worldwide end main alternative propellant used hfa hydrofluoroalkane affect ozone layer global warming potential although significantly lower cfc contributing climate change also invested heavily dry powder delivery systems use propellants cfcs hfa suitable patients particularly children elderly contain propellants rely persons lung power active ingredients administered equipment production also use odss cooling systems ancillary uses gsk facilities contained inside systems released event leak maintenance switched using hydrofluorocarbons hfcs ammonia hydrocarbons ammonia contribute either ozone depletion climate change hydrocarbons small climate change impact aim eliminate cfcs hcfcs cooling systems way completely eliminate emissions equipment focusing removing larger pieces equipment service end intend replace equipment containing less one kilogram cfcs hcfcs prior planned replacement type equipment tends hermetically sealed less likely leak volatile organic compounds volatile organic compounds vocs react nitrogen oxides presence sunlight creating ozone lower atmosphere results smog factor human respiratory illness workplace exposure certain vocs also pose health risk emit vocs atmosphere mainly solvents used primary manufacturing operations rd pilot plants solvents also used coat tablets cleaning sterile operations use small quantities solvents laboratories measure emissions use target reduce volatile organic compound emissions air two per cent per year per unit sales give us reduction per cent end sgs verified home responsibility environmental sustainability environmental fundamentals emissions air corporate responsibility report emissions air approach performance plans ozone depletion ozone layer upper atmosphere essential human survival filters harmful ultra violet rays sun damaged ozone depleting substances odss mainly chlorofluorocarbons cfcs hydrochlorofluorocarbons hcfcs halons loss ozone upper atmosphere means ultravioletb radiation reaches earths surface affect health example causing skin cancer skin ageing eye disorders suppression immune system industrial use odss common negative effects realised past used cfcs propellant gas metered dose inhalers mdis deliver precise dose medication treat asthma sufferers people chronic obstructive pulmonary disease gas released patients use inhalers small amount escapes production montreal protocol bans production cfcs exempts number essential uses include mdis however support principles plan eliminate use cfcs products end less two per cent inhalers contain cfcs stopped using cfcs propellants inhalers made us european union offer selection alternatives countries eliminate cfcs products worldwide end main alternative propellant used hfa hydrofluoroalkane affect ozone layer global warming potential although significantly lower cfc contributing climate change also invested heavily dry powder delivery systems use propellants cfcs hfa suitable patients particularly children elderly contain propellants rely persons lung power active ingredients administered equipment production also use odss cooling systems ancillary uses gsk facilities contained inside systems released event leak maintenance switched using hydrofluorocarbons hfcs ammonia hydrocarbons ammonia contribute either ozone depletion climate change hydrocarbons small climate change impact aim eliminate cfcs hcfcs cooling systems way completely eliminate emissions equipment focusing removing larger pieces equipment service end intend replace equipment containing less one kilogram cfcs hcfcs prior planned replacement type equipment tends hermetically sealed less likely leak volatile organic compounds volatile organic compounds vocs react nitrogen oxides presence sunlight creating ozone lower atmosphere results smog factor human respiratory illness workplace exposure certain vocs also pose health risk emit vocs atmosphere mainly solvents used primary manufacturing operations rd pilot plants solvents also used coat tablets cleaning sterile operations use small quantities solvents laboratories measure emissions use target reduce volatile organic compound emissions air two per cent per year per unit sales give us reduction per cent end sgs verified home responsibility environmental sustainability environmental fundamentals emissions air corporate responsibility report emissions air approach performance plans ozone depletion ozone depletion potential cfc equivalents targets performance normalised sales based constant exchange rate errors found data prior years corrected data may vary slightly earlier reports cfc ozone depletion potential reviewed refrigeration equipment inventories inventories incomplete estimated based inventories years also updated factors ozone depletion potential climate change emissions using wmo world meteorological organisation scientific assessment ozone depletion global ozone research monitoring projectreport pp geneva switzerland chapter estimated ozone depletion potential odp equipment production losses per million sales corrected constant exchange rate cer decreased per cent baseline absolute odp equipment production losses decreased per cent thousand kilograms indicates significant progress towards target eliminate losses cfcs hcfcs production equipment explanation trend thousand kilograms ozone depleting substance released production inhalers estimate less one thousand kilograms cfc equivalent emitted equipment thousand kilograms cfc propellant released patients used products ozone depletion potential patient use metered dose inhalers per cent lower production cfccontaining mdis decreases amount cfc lost production also declines maintain register significant pieces equipment contain refrigerants use register track progress towards target eliminate cfcs hcfcs refrigeration equipment pieces equipment containing cfcs amounting kilograms total items equipment contain odss odp kilograms cfc equivalent estimate using estimation factor per cent british refrigeration association kilograms cfc equivalent released equipment making progress towards target expect achieve sgs verified volatile organic compounds volatile organic compound emissions targets performance normalised sales based constant exchange rate errors found data prior years corrected data may vary slightly earlier reports amount volatile organic compound released air per million sales corrected constant exchange rate cer decreased per cent baseline absolute volatile organic compound emissions decreased per cent baseline million kilograms better two per cent per year target explanation trend emissions voc air affected management solvents mix products made year decreased production several products used significant quantities solvent outsourced several steps one product important reduce emissions voc benefits environment society gsk want reduce emissions even high production years continue identify projects reduce emissions one site installed carbon absorption unit reduce emission solvents two sites emission reduction projects planned anticipate achieving target plans material efficiency projects expected reduce amount solvent used see effects work reduced solvent emissions future meantime continue look ways reduce solvent use increase recycling achieve target two per cent annual reduction emissions resulting eight per cent improvement end two sites manufacture active pharmaceutical ingredients projects planned control emissions sgs verifiedhome responsibility environmental sustainability environmental fundamentals emissions air corporate responsibility report emissions air approach performance plans ozone depletion ozone depletion potential cfc equivalents targets performance normalised sales based constant exchange rate errors found data prior years corrected data may vary slightly earlier reports cfc ozone depletion potential reviewed refrigeration equipment inventories inventories incomplete estimated based inventories years also updated factors ozone depletion potential climate change emissions using wmo world meteorological organisation scientific assessment ozone depletion global ozone research monitoring projectreport pp geneva switzerland chapter estimated ozone depletion potential odp equipment production losses per million sales corrected constant exchange rate cer decreased per cent baseline absolute odp equipment production losses decreased per cent thousand kilograms indicates significant progress towards target eliminate losses cfcs hcfcs production equipment explanation trend thousand kilograms ozone depleting substance released production inhalers estimate less one thousand kilograms cfc equivalent emitted equipment thousand kilograms cfc propellant released patients used products ozone depletion potential patient use metered dose inhalers per cent lower production cfccontaining mdis decreases amount cfc lost production also declines maintain register significant pieces equipment contain refrigerants use register track progress towards target eliminate cfcs hcfcs refrigeration equipment pieces equipment containing cfcs amounting kilograms total items equipment contain odss odp kilograms cfc equivalent estimate using estimation factor per cent british refrigeration association kilograms cfc equivalent released equipment making progress towards target expect achieve sgs verified volatile organic compounds volatile organic compound emissions targets performance normalised sales based constant exchange rate errors found data prior years corrected data may vary slightly earlier reports amount volatile organic compound released air per million sales corrected constant exchange rate cer decreased per cent baseline absolute volatile organic compound emissions decreased per cent baseline million kilograms better two per cent per year target explanation trend emissions voc air affected management solvents mix products made year decreased production several products used significant quantities solvent outsourced several steps one product important reduce emissions voc benefits environment society gsk want reduce emissions even high production years continue identify projects reduce emissions one site installed carbon absorption unit reduce emission solvents two sites emission reduction projects planned anticipate achieving target plans material efficiency projects expected reduce amount solvent used see effects work reduced solvent emissions future meantime continue look ways reduce solvent use increase recycling achieve target two per cent annual reduction emissions resulting eight per cent improvement end two sites manufacture active pharmaceutical ingredients projects planned control emissions sgs verified home responsibility environmental sustainability environmental fundamentals emissions air corporate responsibility report emissions air approach performance plans ozone depletion ozone depletion potential cfc equivalents targets performance normalised sales based constant exchange rate errors found data prior years corrected data may vary slightly earlier reports cfc ozone depletion potential reviewed refrigeration equipment inventories inventories incomplete estimated based inventories years also updated factors ozone depletion potential climate change emissions using wmo world meteorological organisation scientific assessment ozone depletion global ozone research monitoring projectreport pp geneva switzerland chapter estimated ozone depletion potential odp equipment production losses per million sales corrected constant exchange rate cer decreased per cent baseline absolute odp equipment production losses decreased per cent thousand kilograms indicates significant progress towards target eliminate losses cfcs hcfcs production equipment explanation trend thousand kilograms ozone depleting substance released production inhalers estimate less one thousand kilograms cfc equivalent emitted equipment thousand kilograms cfc propellant released patients used products ozone depletion potential patient use metered dose inhalers per cent lower production cfccontaining mdis decreases amount cfc lost production also declines maintain register significant pieces equipment contain refrigerants use register track progress towards target eliminate cfcs hcfcs refrigeration equipment pieces equipment containing cfcs amounting kilograms total items equipment contain odss odp kilograms cfc equivalent estimate using estimation factor per cent british refrigeration association kilograms cfc equivalent released equipment making progress towards target expect achieve sgs verified volatile organic compounds volatile organic compound emissions targets performance normalised sales based constant exchange rate errors found data prior years corrected data may vary slightly earlier reports amount volatile organic compound released air per million sales corrected constant exchange rate cer decreased per cent baseline absolute volatile organic compound emissions decreased per cent baseline million kilograms better two per cent per year target explanation trend emissions voc air affected management solvents mix products made year decreased production several products used significant quantities solvent outsourced several steps one product important reduce emissions voc benefits environment society gsk want reduce emissions even high production years continue identify projects reduce emissions one site installed carbon absorption unit reduce emission solvents two sites emission reduction projects planned anticipate achieving target plans material efficiency projects expected reduce amount solvent used see effects work reduced solvent emissions future meantime continue look ways reduce solvent use increase recycling achieve target two per cent annual reduction emissions resulting eight per cent improvement end two sites manufacture active pharmaceutical ingredients projects planned control emissions sgs verified home responsibility environmental sustainability environmental fundamentals emissions air corporate responsibility report emissions air approach performance plans ozone depletion ozone depletion potential cfc equivalents targets performance normalised sales based constant exchange rate errors found data prior years corrected data may vary slightly earlier reports cfc ozone depletion potential reviewed refrigeration equipment inventories inventories incomplete estimated based inventories years also updated factors ozone depletion potential climate change emissions using wmo world meteorological organisation scientific assessment ozone depletion global ozone research monitoring projectreport pp geneva switzerland chapter estimated ozone depletion potential odp equipment production losses per million sales corrected constant exchange rate cer decreased per cent baseline absolute odp equipment production losses decreased per cent thousand kilograms indicates significant progress towards target eliminate losses cfcs hcfcs production equipment explanation trend thousand kilograms ozone depleting substance released production inhalers estimate less one thousand kilograms cfc equivalent emitted equipment thousand kilograms cfc propellant released patients used products ozone depletion potential patient use metered dose inhalers per cent lower production cfccontaining mdis decreases amount cfc lost production also declines maintain register significant pieces equipment contain refrigerants use register track progress towards target eliminate cfcs hcfcs refrigeration equipment pieces equipment containing cfcs amounting kilograms total items equipment contain odss odp kilograms cfc equivalent estimate using estimation factor per cent british refrigeration association kilograms cfc equivalent released equipment making progress towards target expect achieve sgs verified volatile organic compounds volatile organic compound emissions targets performance normalised sales based constant exchange rate errors found data prior years corrected data may vary slightly earlier reports amount volatile organic compound released air per million sales corrected constant exchange rate cer decreased per cent baseline absolute volatile organic compound emissions decreased per cent baseline million kilograms better two per cent per year target explanation trend emissions voc air affected management solvents mix products made year decreased production several products used significant quantities solvent outsourced several steps one product important reduce emissions voc benefits environment society gsk want reduce emissions even high production years continue identify projects reduce emissions one site installed carbon absorption unit reduce emission solvents two sites emission reduction projects planned anticipate achieving target plans material efficiency projects expected reduce amount solvent used see effects work reduced solvent emissions future meantime continue look ways reduce solvent use increase recycling achieve target two per cent annual reduction emissions resulting eight per cent improvement end two sites manufacture active pharmaceutical ingredients projects planned control emissions sgs verified home responsibility environmental sustainability environmental fundamentals ehss business processes corporate responsibility report ehss business processes describe embedding environment health safety sustainability ehss principles business processes new product development supply ehss milestone aligned process helps scientists identify address environment health safety sustainability issues new product development supply activities ensures scientists understand environment health safety sustainability impacts managed throughout products lifecycle new products processes developed harm people property environment opportunities identified process efficiencies elimination waste reduce environment health safety sustainability impacts improve product development supply acquisitions divestitures due diligence process acquiring divesting businesses ensures environment health safety sustainability issues considered contract negotiations adequate management systems place work acquired companies develop action plans align ehss practices gsks emergency response crisis management discovery development manufacture pharmaceutical consumer products involve use hazardous materials processes sites incorporate emergency response crisis management programmes management plans programmes ensure accidents effectively managed occur impact business local community environment minimised site conducts annual review internal emergency response programmes technical capabilities develops action plans address areas needing improvement procurement procurement activities support environment health safety sustainability ehss goals following areas sourcing renewable recycled materials appropriate choosing safe energyefficient equipment managing ehss risks supply chain capital project technical review process ensures consider environment health safety security loss prevention design new facilities processes identifying ehss issues early project engineer facilities processes efficient safe workers environment still cost effective read ehs procurement back top home responsibility environmental sustainability environmental fundamentals ehss business processes corporate responsibility report ehss business processes describe embedding environment health safety sustainability ehss principles business processes new product development supply ehss milestone aligned process helps scientists identify address environment health safety sustainability issues new product development supply activities ensures scientists understand environment health safety sustainability impacts managed throughout products lifecycle new products processes developed harm people property environment opportunities identified process efficiencies elimination waste reduce environment health safety sustainability impacts improve product development supply acquisitions divestitures due diligence process acquiring divesting businesses ensures environment health safety sustainability issues considered contract negotiations adequate management systems place work acquired companies develop action plans align ehss practices gsks emergency response crisis management discovery development manufacture pharmaceutical consumer products involve use hazardous materials processes sites incorporate emergency response crisis management programmes management plans programmes ensure accidents effectively managed occur impact business local community environment minimised site conducts annual review internal emergency response programmes technical capabilities develops action plans address areas needing improvement procurement procurement activities support environment health safety sustainability ehss goals following areas sourcing renewable recycled materials appropriate choosing safe energyefficient equipment managing ehss risks supply chain capital project technical review process ensures consider environment health safety security loss prevention design new facilities processes identifying ehss issues early project engineer facilities processes efficient safe workers environment still cost effective read ehs procurement back top home responsibility environmental sustainability environmental fundamentals supplier performance corporate responsibility report supplier performance want understand total environmental footprint processes used make products means measuring impacts suppliers active pharmaceutical ingredients packaged products well operations improvements hazardous waste air emissions due outsourcing production processes collect data suppliers know full impact production products future hope report combined environmental impacts manufacturing gsk facilities contract manufacturers gsk selects suppliers appropriate level ehs management systems control however past years proved difficult obtain environment health safety performance data suppliers products manufacture gsk surveyed suppliers received response per cent indicated preferred providing data first quarter year give time review input suppliers changed process energy data join carbon disclosure project cdp supplier initiative request energy climate change data large suppliers cdp collect water waste injury illness data suppliers second quarter using electronic system published data corporate responsibility report publish data report read gsks supply chain back top home responsibility environmental sustainability environmental fundamentals supplier performance corporate responsibility report supplier performance want understand total environmental footprint processes used make products means measuring impacts suppliers active pharmaceutical ingredients packaged products well operations improvements hazardous waste air emissions due outsourcing production processes collect data suppliers know full impact production products future hope report combined environmental impacts manufacturing gsk facilities contract manufacturers gsk selects suppliers appropriate level ehs management systems control however past years proved difficult obtain environment health safety performance data suppliers products manufacture gsk surveyed suppliers received response per cent indicated preferred providing data first quarter year give time review input suppliers changed process energy data join carbon disclosure project cdp supplier initiative request energy climate change data large suppliers cdp collect water waste injury illness data suppliers second quarter using electronic system published data corporate responsibility report publish data report read gsks supply chain back top home responsibility environmental sustainability sustainability corporate responsibility report sustainability traditional environmental programmes focus managing wastes generated business processes sustainable practices change business processes consume less natural resource switch renewable materials protect biodiversity generate less waste eliminate waste persistent toxic bioaccumulative lower costs approach benefits environment society gsk future generations high priority sustainability issues manufacturing efficiency reducing amount raw materials needed produce finished product climate change reducing climate impacts buildings equipment transport products water reducing amount water use product stewardship reducing use materials concern environmental impacts products use patient packaging reducing amount packaging use using recyclable recycled materials back top home responsibility environmental sustainability sustainability corporate responsibility report sustainability traditional environmental programmes focus managing wastes generated business processes sustainable practices change business processes consume less natural resource switch renewable materials protect biodiversity generate less waste eliminate waste persistent toxic bioaccumulative lower costs approach benefits environment society gsk future generations high priority sustainability issues manufacturing efficiency reducing amount raw materials needed produce finished product climate change reducing climate impacts buildings equipment transport products water reducing amount water use product stewardship reducing use materials concern environmental impacts products use patient packaging reducing amount packaging use using recyclable recycled materials back top home responsibility environmental sustainability sustainability materials efficiency corporate responsibility report materials efficiency approach performance aim increase efficiency convert raw materials finished products known materials efficiency helps reduce resources use waste generate cost production pharmaceutical processes often complex usually requiring large amounts solvents raw materials typically industry uses tonnes material every tonne active pharmaceutical ingredient api produced set target double average materials efficiency manufacturing processes new products introduced process design process design essential minimising environmental impacts determines chemicals processes used manufacturing well impacts production waste ehs team works process development teams incorporate ehs considerations process design materials sourcing identify potential ehs risks manufacturing new manufacturing technique cuts energy waste rd facility north carolina developed novel way manufacture diabetes drug currently phase clinical trials cutting environmental impacts costs replaces production method resourceintensive use large scale chemical development department found way synthesise molecule efficiently produce yield per cent greater new process uses fewer raw materials less half energy per cent less solvent also produces around per cent less wastewater new process save million year raw material waste disposal costs project first place ceos ehs excellence awards green chemistry technology category back top home responsibility environmental sustainability sustainability materials efficiency corporate responsibility report materials efficiency approach performance aim increase efficiency convert raw materials finished products known materials efficiency helps reduce resources use waste generate cost production pharmaceutical processes often complex usually requiring large amounts solvents raw materials typically industry uses tonnes material every tonne active pharmaceutical ingredient api produced set target double average materials efficiency manufacturing processes new products introduced process design process design essential minimising environmental impacts determines chemicals processes used manufacturing well impacts production waste ehs team works process development teams incorporate ehs considerations process design materials sourcing identify potential ehs risks manufacturing new manufacturing technique cuts energy waste rd facility north carolina developed novel way manufacture diabetes drug currently phase clinical trials cutting environmental impacts costs replaces production method resourceintensive use large scale chemical development department found way synthesise molecule efficiently produce yield per cent greater new process uses fewer raw materials less half energy per cent less solvent also produces around per cent less wastewater new process save million year raw material waste disposal costs project first place ceos ehs excellence awards green chemistry technology category back top home responsibility environmental sustainability sustainability materials efficiency corporate responsibility report materials efficiency approach performance mass productivity chart shows improve materials efficiency compounds move development stages early stages almost compounds less one per cent materials efficient last stage achieve two per cent three per cent one process achieving productivity per cent explanation trend improving manufacturing efficiency one important ways address sustainability meet fundamental environmental targets reducing disposal waste emissions air easy chemical processes make medicines complex spite difficulties remain committed improving efficiency new products review production processes transferred manufacturing determine additional improvements possible achieve target back top home responsibility environmental sustainability sustainability materials efficiency corporate responsibility report materials efficiency approach performance mass productivity chart shows improve materials efficiency compounds move development stages early stages almost compounds less one per cent materials efficient last stage achieve two per cent three per cent one process achieving productivity per cent explanation trend improving manufacturing efficiency one important ways address sustainability meet fundamental environmental targets reducing disposal waste emissions air easy chemical processes make medicines complex spite difficulties remain committed improving efficiency new products review production processes transferred manufacturing determine additional improvements possible achieve target back top home responsibility environmental sustainability sustainability climate change energy corporate responsibility report climate change energy approach performance plans widely acknowledged human activity primarily burning fossil fuels produce energy contributing climate change intergovernmental panel climate change ipcc worlds leading climate authority stated urgent action needed avoid effects dangerous climate change including frequent extreme weather events droughts floods hurricanes want part solution climate change committed reducing impact well benefiting environment taking action climate change helps us cut costs improves reputation stakeholders helps us prepare future legislation emissions read energy climate change position climate change programme following fourth assessment report intergovernmental panel climate change launched new climate change programme committed new targets includes commitment reducing climate change impact co equivalent emissions energy use operations transport levels per cent per unit sales based constant exchange rate per cent replaced target reduce energy use one per cent per year normalised sales achieve new targets making buildings equipment energy efficient installing onsite renewable technologies wind turbines photovoltaic panels buying electricity produced renewable sources reducing climate impact travel transport switching air sea freight transporting per load reduce number journeys needed corporate executive team approved central fund help finance energy saving projects climate change energy reduction team consulted gsk businesses identify potential energy saving projects projects completed expected result saving kwh gj energy per year thousand tonnes climate change emissions product climate impact also researching ways minimise amount greenhouse gases released propellant inhaler products used patients asthma chronic obstructive pulmonary disease account twothirds climate impact propellant inhalers contain either hydrofluoroalkanes hfas chlorofluorocarbons cfcs ensure consistent dose hfas times damaging climate co cfcs times damaging climate co cfcs also deplete ozone layer sgs assurance logo back tophome responsibility environmental sustainability sustainability climate change energy corporate responsibility report climate change energy approach performance plans widely acknowledged human activity primarily burning fossil fuels produce energy contributing climate change intergovernmental panel climate change ipcc worlds leading climate authority stated urgent action needed avoid effects dangerous climate change including frequent extreme weather events droughts floods hurricanes want part solution climate change committed reducing impact well benefiting environment taking action climate change helps us cut costs improves reputation stakeholders helps us prepare future legislation emissions read energy climate change position climate change programme following fourth assessment report intergovernmental panel climate change launched new climate change programme committed new targets includes commitment reducing climate change impact co equivalent emissions energy use operations transport levels per cent per unit sales based constant exchange rate per cent replaced target reduce energy use one per cent per year normalised sales achieve new targets making buildings equipment energy efficient installing onsite renewable technologies wind turbines photovoltaic panels buying electricity produced renewable sources reducing climate impact travel transport switching air sea freight transporting per load reduce number journeys needed corporate executive team approved central fund help finance energy saving projects climate change energy reduction team consulted gsk businesses identify potential energy saving projects projects completed expected result saving kwh gj energy per year thousand tonnes climate change emissions product climate impact also researching ways minimise amount greenhouse gases released propellant inhaler products used patients asthma chronic obstructive pulmonary disease account twothirds climate impact propellant inhalers contain either hydrofluoroalkanes hfas chlorofluorocarbons cfcs ensure consistent dose hfas times damaging climate co cfcs times damaging climate co cfcs also deplete ozone layer sgs assurance logo back top home responsibility environmental sustainability sustainability climate change energy corporate responsibility report climate change energy approach performance plans widely acknowledged human activity primarily burning fossil fuels produce energy contributing climate change intergovernmental panel climate change ipcc worlds leading climate authority stated urgent action needed avoid effects dangerous climate change including frequent extreme weather events droughts floods hurricanes want part solution climate change committed reducing impact well benefiting environment taking action climate change helps us cut costs improves reputation stakeholders helps us prepare future legislation emissions read energy climate change position climate change programme following fourth assessment report intergovernmental panel climate change launched new climate change programme committed new targets includes commitment reducing climate change impact co equivalent emissions energy use operations transport levels per cent per unit sales based constant exchange rate per cent replaced target reduce energy use one per cent per year normalised sales achieve new targets making buildings equipment energy efficient installing onsite renewable technologies wind turbines photovoltaic panels buying electricity produced renewable sources reducing climate impact travel transport switching air sea freight transporting per load reduce number journeys needed corporate executive team approved central fund help finance energy saving projects climate change energy reduction team consulted gsk businesses identify potential energy saving projects projects completed expected result saving kwh gj energy per year thousand tonnes climate change emissions product climate impact also researching ways minimise amount greenhouse gases released propellant inhaler products used patients asthma chronic obstructive pulmonary disease account twothirds climate impact propellant inhalers contain either hydrofluoroalkanes hfas chlorofluorocarbons cfcs ensure consistent dose hfas times damaging climate co cfcs times damaging climate co cfcs also deplete ozone layer sgs assurance logo back top home responsibility environmental sustainability sustainability climate change energy performance plans corporate responsibility report climate change energy approach performance plans gsks carbon footprint includes climate change impact greenhouse gases released cooling systems production inhaler products wastewater treatment processes errors found data prior years corrected data may vary slightly earlier reports climate change impact operations energy transport targets performance normalised sales based constant exchange rate errors found data prior years corrected data may vary slightly earlier reports use greenhouse gas protocol calculations co emissions energy use also updated factors climate change emissions propellants refrigerants using wmo world meteorological organisation scientific assessment ozone depletion global ozone repsaegae rch oaf nd monitoring projectreport pp geneva switzerland chapter carbon footprint equivalent million tonnes co compared million tonnes majority emissions come use inhalers patients respiratory disease decrease use cfc inhalers simultaneous increase use hfa inhalers meant climate change emissions patient use inhalers change significantly remaining million metric tonnes co exclude use inhalers carbon footprint reduced million tonnes co million tonnes reflecting emissions greenhouse gas inhaler manufacturing decreased million tonnes million tonnes explanation trend recognise products climate change impact energy consumption rd scientists working develop alternatives hfa propellant candidate inhaled products emissions operations energy transport co emissions operations energy transport per million sales corrected constant exchange rate increased per cent baseline absolute climate change emissions increased less per cent baseline million tonnes due increased energy use growing vaccines business overshadowed energy savings pharmaceutical consumer manufacturing operations increase use coal india energy use operations transport co emissions based decreased less one per cent million gigajoules sgs verified energy performance energy consumption facilities processes targets performance normalised sales based constant exchange rate errors found data prior years corrected data may vary slightly earlier reports seventynine per cent energy use attributed energy operations facilities processes energy use per million sales corrected constant exchange rate cer increased less one per cent baseline absolute energy use decreased less one per cent baseline million gigajoules equivalent energy used uk households explanation trend set aggressive targets reduce energy use related climate change emissions moving towards although progress slower expected continue present course expect achieve improvement eight per cent per unit sales taken steps accelerate implementation energy reduction projects diverting engineering resources support also expect projects initiated begin deliver energy carbon savings sustained addition business changes site closures resulting efficient use existing facilities may help us achieve target therefore remain committed target per cent improvement energy use decreased four per cent pharmaceutical consumer manufacturing organisation pharmaceutical rd organisation however increased per cent vaccines organisation due continuing growth additional enlarged buildings new products pharmaceutical consumer manufacturing vaccines manufacturing research group pharmaceuticals rd group accounted per cent per cent per cent energy use respectively energy efficiency programme achieved incremental gains energy efficiency focusing operational changes included optimisation equipment use resetting thermostats changing energy efficient lighting since parts business continued make incremental gains energy efficiency growth vaccines business associated increases energy use partially offset efficiency gains mid revised climate change programme include challenging targets covering energy operations facilities processes transport products employees fund set encourage energy projects potential projects identified support fund projects completed million spent projects expected save million kilowatt hours energy thousand metric tonnes climate change emissions majority projects completed towards end full benefit projects realised currently working projects significant proportion completed around projects identified support abandoned following detailed investigations determine business benefit plans gsk identified potential projects support climate change fund pharmaceutical consumer healthcare manufacturing business created centre excellence support implementation projects particular emphasis given implementing combined heat power chp projects chp simultaneous generation usable heat power usually electricity single process typically chp uses gas turbine engine steam turbine drive alternator produce electricity heat produced recovered usually heat recovery boiler provide steam hot water even cooling right equipment chp systems use heat produced electricity generation process achieve overall efficiencies excess per cent point use conventional power plants efficiencies less per cent excess heat generate normally wasted additional losses occur transmission distribution another key area focus identify energy saving opportunities associated heating ventilation cooling hvac equipment needed maintain correct environmental conditions within production areas manufacture products however responsible per cent operational energy consume energy reduction also identified key objective business remuneration senior managers linked achievement energy reduction targets energy consumption also identified key business metric tracked throughout corporate executive team using canal water sustainable cooling december gsk unveiled energysaving scheme partnership british waterways organisation charge uks canal network initiative gsk house brentford use water nearby canal rather energyintensive air conditioning cool computer data centres reduce carbon dioxide emissions around tonnes per year also lower energy bills annually recovering costs project within five years back tophome responsibility environmental sustainability sustainability climate change energy performance plans corporate responsibility report climate change energy approach performance plans gsks carbon footprint includes climate change impact greenhouse gases released cooling systems production inhaler products wastewater treatment processes errors found data prior years corrected data may vary slightly earlier reports climate change impact operations energy transport targets performance normalised sales based constant exchange rate errors found data prior years corrected data may vary slightly earlier reports use greenhouse gas protocol calculations co emissions energy use also updated factors climate change emissions propellants refrigerants using wmo world meteorological organisation scientific assessment ozone depletion global ozone research monitoring projectreport pp geneva switzerland chapter carbon footprint equivalent million tonnes co compared million tonnes majority emissions come use inhalers patients respiratory disease decrease use cfc inhalers simultaneous increase use hfa inhalers meant climate change emissions patient use inhalers change significantly remaining million metric tonnes co exclude use inhalers carbon footprint reduced million tonnes co million tonnes reflecting emissions greenhouse gas inhaler manufacturing decreased million tonnes million tonnes explanation trend recognise products climate change impact energy consumption rd scientists working develop alternatives hfa propellant candidate inhaled products emissions operations energy transport co emissions operations energy transport per million sales corrected constant exchange rate increased per cent baseline absolute climate change emissions increased less per cent baseline million tonnes due increased energy use growing vaccines business overshadowed energy savings pharmaceutical consumer manufacturing operations increase use coal india energy use operations transport co emissions based decreased less one per cent million gigajoules sgs verified energy performance energy consumption facilities processes targets performance normalised sales based constant exchange rate errors found data prior years corrected data may vary slightly earlier reports seventynine per cent energy use attributed energy operations facilities processes energy use per million sales corrected constant exchange rate cer increased less one per cent baseline absolute energy use decreased less one per cent baseline million gigajoules equivalent energy used uk houspeahgoe lds explanation trend set aggressive targets reduce energy use related climate change emissions moving towards although progress slower expected continue present course expect achieve improvement eight per cent per unit sales taken steps accelerate implementation energy reduction projects diverting engineering resources support also expect projects initiated begin deliver energy carbon savings sustained addition business changes site closures resulting efficient use existing facilities may help us achieve target therefore remain committed target per cent improvement energy use decreased four per cent pharmaceutical consumer manufacturing organisation pharmaceutical rd organisation however increased per cent vaccines organisation due continuing growth additional enlarged buildings new products pharmaceutical consumer manufacturing vaccines manufacturing research group pharmaceuticals rd group accounted per cent per cent per cent energy use respectively energy efficiency programme achieved incremental gains energy efficiency focusing operational changes included optimisation equipment use resetting thermostats changing energy efficient lighting since parts business continued make incremental gains energy efficiency growth vaccines business associated increases energy use partially offset efficiency gains mid revised climate change programme include challenging targets covering energy operations facilities processes transport products employees fund set encourage energy projects potential projects identified support fund projects completed million spent projects expected save million kilowatt hours energy thousand metric tonnes climate change emissions majority projects completed towards end full benefit projects realised currently working projects significant proportion completed around projects identified support abandoned following detailed investigations determine business benefit plans gsk identified potential projects support climate change fund pharmaceutical consumer healthcare manufacturing business created centre excellence support implementation projects particular emphasis given implementing combined heat power chp projects chp simultaneous generation usable heat power usually electricity single process typically chp uses gas turbine engine steam turbine drive alternator produce electricity heat produced recovered usually heat recovery boiler provide steam hot water even cooling right equipment chp systems use heat produced electricity generation process achieve overall efficiencies excess per cent point use conventional power plants efficiencies less per cent excess heat generate normally wasted additional losses occur transmission distribution another key area focus identify energy saving opportunities associated heating ventilation cooling hvac equipment needed maintain correct environmental conditions within production areas manufacture products however responsible per cent operational energy consume energy reduction also identified key objective business remuneration senior managers linked achievement energy reduction targets energy consumption also identified key business metric tracked throughout corporate executive team using canal water sustainable cooling december gsk unveiled energysaving scheme partnership british waterways organisation charge uks canal network initiative gsk house brentford use water nearby canal rather energyintensive air conditioning cool computer data centres reduce carbon dioxide emissions around tonnes per year also lower energy bills annually recovering costs project within five years back tophome responsibility environmental sustainability sustainability climate change energy performance plans corporate responsibility report climate change energy approach performance plans gsks carbon footprint includes climate change impact greenhouse gases released cooling systems production inhaler products wastewater treatment processes errors found data prior years corrected data may vary slightly earlier reports climate change impact operations energy transport targets performance normalised sales based constant exchange rate errors found data prior years corrected data may vary slightly earlier reports use greenhouse gas protocol calculations co emissions energy use also updated factors climate change emissions propellants refrigerants using wmo world meteorological organisation scientific assessment ozone depletion global ozone research monitoring projectreport pp geneva switzerland chapter carbon footprint equivalent million tonnes co compared million tonnes majority emissions come use inhalers patients respiratory disease decrease use cfc inhalers simultaneous increase use hfa inhalers meant climate change emissions patient use inhalers change significantly remaining million metric tonnes co exclude use inhalers carbon footprint reduced million tonnes co million tonnes reflecting emissions greenhouse gas inhaler manufacturing decreased million tonnes million tonnes explanation trend recognise products climate change impact energy consumption rd scientists working develop alternatives hfa propellant candidate inhaled products emissions operations energy transport co emissions operations energy transport per million sales corrected constant exchange rate increased per cent baseline absolute climate change emissions increased less per cent baseline million tonnes due increased energy use growing vaccines business overshadowed energy savings pharmaceutical consumer manufacturing operations increase use coal india energy use operations transport co emissions based decreased less one per cent million gigajoules sgs verified energy performance energy consumption facilities processes targets performance normalised sales based constant exchange rate errors found data prior years corrected data may vary slightly earlier reports seventynine per cent energy use attributed energy operations facilities processes energy use per million sales corrected constant exchange rate cer increased less one per cent baseline absolute energy use decreased less one per cent baseline million gigajoules equivalent energy used uk households explanation trend set aggressive targets reduce energy use related climate change emissions moving towards although progress slower expected continue present course expect achieve improvement eight per cent per unit sales taken steps accelerate implementation energy reduction projects diverting engineering resources support also expect projects initiated begin deliver energy carbon savings sustained addition business changes site closures resulting efficient use existing facilities may help us achieve target therefore remain committed target per cent improvement energy use decreased four per cent pharmaceutical consumer manufacturing organisation pharmaceutical rd organisation however increased per cent vaccines organisation due continuing growth additional enlarged buildings new products pharmaceutical consumer manufacturing vaccines manufacturing research group pharmaceuticals rd group accounted per cent per cent per cent energy use respectively energy efficiency programme achieved incremental gains energy efficiency focusing operational changes included optimisation equipment use resetting thermostats changing energy efficient lighting since parts business continued make incremental gains energy efficiency growth vaccines business associated increases energy use partially offset efficiency gains mid revised climate change programme include challenging targets covering energy operations facilities processes transport products employees fund set encourage energy projects potential projects identified support fund projects completed million spent projects expected save million kilowatt hours energy thousand metric tonnes climate change emissions majority projects completed towards end full benefit projects realised currently working projects significant proportion completed around projects identified support abandoned following detailed investigations determine business benefit plans gsk identified potential projects support climate change fund pharmaceutical consumer healthcare manufacturing business created centre excellence support implementation projects particular emphasis given implementing combined heat power chp projects chp simultaneous generation usable heat power usually electricity single process typically chp uses gas turbine engine steam turbine drive alternator produce electricity heat produced recovered usually heat recovery boiler provide steam hot water even cooling right equipment chp systems use heat produced electricity generation process achieve overall efficiencies excess per cent point use conventional power plants efficiencies less per cent excess heat generate normally wasted additional losses occur transmission distribution another key area focus identify energy saving opportunities associated heating ventilation cooling hvac equipment needed maintain correct environmental conditions within production areas manufacture products however responsible per cent operational energy consume energy reduction also identified key objective business remuneration senior managers linked achievement energy reduction targets energy consumption also identified key business metric tracked throughout corporate executive team using canal water sustainable cooling december gsk unveiled energysaving scheme partnership british waterwapyasge organisation charge uks canal network initiative gsk house brentford use water nearby canal rather energyintensive air conditioning cool computer data centres reduce carbon dioxide emissions around tonnes per year also lower energy bills annually recovering costs project within five years back tophome responsibility environmental sustainability sustainability climate change energy performance plans corporate responsibility report climate change energy approach performance plans gsks carbon footprint includes climate change impact greenhouse gases released cooling systems production inhaler products wastewater treatment processes errors found data prior years corrected data may vary slightly earlier reports climate change impact operations energy transport targets performance normalised sales based constant exchange rate errors found data prior years corrected data may vary slightly earlier reports use greenhouse gas protocol calculations co emissions energy use also updated factors climate change emissions propellants refrigerants using wmo world meteorological organisation scientific assessment ozone depletion global ozone research monitoring projectreport pp geneva switzerland chapter carbon footprint equivalent million tonnes co compared million tonnes majority emissions come use inhalers patients respiratory disease decrease use cfc inhalers simultaneous increase use hfa inhalers meant climate change emissions patient use inhalers change significantly remaining million metric tonnes co exclude use inhalers carbon footprint reduced million tonnes co million tonnes reflecting emissions greenhouse gas inhaler manufacturing decreased million tonnes million tonnes explanation trend recognise products climate change impact energy consumption rd scientists working develop alternatives hfa propellant candidate inhaled products emissions operations energy transport co emissions operations energy transport per million sales corrected constant exchange rate increased per cent baseline absolute climate change emissions increased less per cent baseline million tonnes due increased energy use growing vaccines business overshadowed energy savings pharmaceutical consumer manufacturing operations increase use coal india energy use operations transport co emissions based decreased less one per cent million gigajoules sgs verified energy performance energy consumption facilities processes targets performance normalised sales based constant exchange rate errors found data prior years corrected data may vary slightly earlier reports seventynine per cent energy use attributed energy operations facilities processes energy use per million sales corrected constant exchange rate cer increased less one per cent baseline absolute energy use decreased less one per cent baseline million gigajoules equivalent energy used uk households explanation trend set aggressive targets reduce energy use related climate change emissions moving towards although progress slower expected continue present course expect achieve improvement eight per cent per unit sales taken steps accelerate implementation energy reduction projects diverting engineering resources support also expect projects initiated begin deliver energy carbon savings sustained addition business changes site closures resulting efficient use existing facilities may help us achieve target therefore remain committed target per cent improvement energy use decreased four per cent pharmaceutical consumer manufacturing organisation pharmaceutical rd organisation however increased per cent vaccines organisation due continuing growth additional enlarged buildings new products pharmaceutical consumer manufacturing vaccines manufacturing research group pharmaceuticals rd group accounted per cent per cent per cent energy use respectively energy efficiency programme achieved incremental gains energy efficiency focusing operational changes included optimisation equipment use resetting thermostats changing energy efficient lighting since parts business continued make incremental gains energy efficiency growth vaccines business associated increases energy use partially offset efficiency gains mid revised climate change programme include challenging targets covering energy operations facilities processes transport products employees fund set encourage energy projects potential projects identified support fund projects completed million spent projects expected save million kilowatt hours energy thousand metric tonnes climate change emissions majority projects completed towards end full benefit projects realised currently working projects significant proportion completed around projects identified support abandoned following detailed investigations determine business benefit plans gsk identified potential projects support climate change fund pharmaceutical consumer healthcare manufacturing business created centre excellence support implementation projects particular emphasis given implementing combined heat power chp projects chp simultaneous generation usable heat power usually electricity single process typically chp uses gas turbine engine steam turbine drive alternator produce electricity heat produced recovered usually heat recovery boiler provide steam hot water even cooling right equipment chp systems use heat produced electricity generation process achieve overall efficiencies excess per cent point use conventional power plants efficiencies less per cent excess heat generate normally wasted additional losses occur transmission distribution another key area focus identify energy saving opportunities associated heating ventilation cooling hvac equipment needed maintain correct environmental conditions within production areas manufacture products however responsible per cent operational energy consume energy reduction also identified key objective business remuneration senior managers linked achievement energy reduction targets energy consumption also identified key business metric tracked throughout corporate executive team using canal water sustainable cooling december gsk unveiled energysaving scheme partnership british waterways organisation charge uks canal network initiative gsk house brentford use water nearby canal rather energyintensive air conditioning cool computer data centres reduce carbon dioxide emissions around tonnes per year also lower energy bills annually recovering costs project within five years back top home responsibility environmental sustainability sustainability climate change energy performance plans corporate responsibility report climate change energy approach performance plans gsks carbon footprint includes climate change impact greenhouse gases released cooling systems production inhaler products wastewater treatment processes errors found data prior years corrected data may vary slightly earlier reports climate change impact operations energy transport targets performance normalised sales based constant exchange rate errors found data prior years corrected data may vary slightly earlier reports use greenhouse gas protocol calculations co emissions energy use also updated factors climate change emissions propellants refrigerants using wmo world meteorological organisation scientific assessment ozone depletion global ozone research monitoring projectreport pp geneva switzerland chapter carbon footprint equivalent million tonnes co compared million tonnes majority emissions come use inhalers patients respiratory disease decrease use cfc inhalers simultaneous increase use hfa inhalers meant climate change emissions patient use inhalers change significantly remaining million metric tonnes co exclude use inhalers carbon footprint reduced million tonnes co million tonnes reflecting emissions greenhouse gas inhaler manufacturing decreased million tonnes million tonnes explanation trend recognise products climate change impact energy consumption rd scientists working develop alternatives hfa propellant candidate inhaled products emissions operations energy transport co emissions operations energy transport per million sales corrected constant exchange rate increased per cent baseline absolute climate change emissions increased less per cent baseline million tonnes due increased energy use growing vaccines business overshadowed energy savings pharmaceutical consumer manufacturing operations increase use coal india energy use operations transport co emissions based decreased less one per cent million gigajoules sgs verified energy performance energy consumption facilities processes targets performance normalised sales based constant exchange rate errors found data prior years corrected data may vary slightly earlier reports seventynine per cent energy use attributed energy operations facilities processes energy use per million sales corrected constant exchange rate cer increased less one per cent baseline absolute energy use decreased less one per cent baseline million gigajoules equivalent energy used uk households explanation trend set aggressive targets reduce energy use related climate change emissions moving towards although progress slower expected continue present course expect achieve improvement eight per cent per unit sales taken steps accelerate implementation energy reduction projects diverting engineering resources support also expect projects initiated begin deliver energy carbon savings sustained addition business changes site closures resulting efficient use existing facilities may help us achieve target therefore remain committed target per cent improvement energy use decreased four per cent pharmaceutical consumer manufacturing organisation pharmaceutical rd organisation however increased per cent vaccines organisation due continuing growth additional enlarged buildings new products pharmaceutical consumer manufacturing vaccines manufacturing research group pharmaceuticals rd group accounted per cent per cent per cent energy use respectively energy efficiency programme achieved incremental gains energy efficiency focusing operational changes included optimisation equipment use resetting thermostats changing energy efficient lighting since parts business continued make incremental gains energy efficiency growth vaccines business associated increases energy use partially offset efficiency gains mid revised climate change programme include challenging targets covering energy operations facilities processes transport products employees fund set encourage energy projects potential projects identified support fund projects completed million spent projects expected save million kilowatt hours energy thousand metric tonnes climate change emissions majority projects completed towards end full benefit projects realised currently working projects significant proportion completed around projects identified support abandoned following detailed investigations determine business benefit plans gsk identified potential projects support climate change fund pharmaceutical consumer healthcare manufacturing business created centre excellence support implementation projects particular emphasis given implementing combined heat power chp projects chp simultaneous generation usable heat power usually electricity single process typically chp uses gas turbine engine steam turbine drive alternator produce electricity heat produced recovered usually heat recovery boiler provide steam hot water even cooling right equipment chp systems use heat produced electricity generation process achieve overall efficiencies excess per cent point use conventional power plants efficiencies less per cent excess heat generate normally wasted additional losses occur transmission distribution another key area focus identify energy saving opportunities associated heating ventilation cooling hvac equipment needed maintain correct environmental conditions within production areas manufacture products however responsible per cent operational energy consume energy reduction also identified key objective business remuneration senior managers linked achievement energy reduction targets energy consumption also identified key business metric tracked throughout corporate executive team using canal water sustainable cooling december gsk unveiled energysaving scheme partnership british waterways organisation charge uks canal network initiative gsk house brentford use water nearby canal rather energyintensive air conditioning cool computer data centres reduce carbon dioxide emissions around tonnes per year also lower energy bills annually recovering costs project within five years back top home responsibility environmental sustainability sustainability climate change energy climate change emissions since corporate responsibility report climate change emissions since gsk climate change emissions inhaler products significantly greater climate change emissions operational energy transport climate change emissions increased per cent sales inhalers chlorofluorocarbon cfc propellants increased phase cfc propellants began result montreal protocol aimed eliminate ozone depleting compounds cfcs impact ozone depletion climate change replaced inhalers using hydrofluoroalkane hfa propellants dry powder inhalers use propellants climate change emissions improved dramatically hfas much lower climate change impact cfcs currently per cent inhalers either using hfa propellants dry power propellantfree inhalers climate change emissions per cent lower levels emissions expected grow coming years sales inhalers hfa propellants continue grow emissions inhalers energy back estimated based energy cfc data public reports back heritage smithkline beecham heritage glaxowellcome actual data inhalers energy available sales data used factors applied estimate climate change emissions climate change emission factors cfc hfc revised years used current factors world meteorological organisation published global warming potential energy transport inhaler use httpwwwepagovozonescienceodsclassonehtml wmo world meteorological organisation scientific assessment ozone depletion global ozone research monitoring projectreport pp geneva switzerland chapter explanation trend montreal protocol called elimination cfcs effect ozone layer invested billion develop alternatives including devices use hfa replacement propellant hfa ozone depleting potential lower effect climate change cfc therefore cfc propellants phased hfa phased significant decline climate change impact products estimated climate change emissions back calculated improvement per cent compares per cent reduction kyoto protocol requires uk kyoto protocol include climate change emissions cfc include hfa back top home responsibility environmental sustainability sustainability climate change energy climate change emissions since corporate responsibility report climate change emissions since gsk climate change emissions inhaler products significantly greater climate change emissions operational energy transport climate change emissions increased per cent sales inhalers chlorofluorocarbon cfc propellants increased phase cfc propellants began result montreal protocol aimed eliminate ozone depleting compounds cfcs impact ozone depletion climate change replaced inhalers using hydrofluoroalkane hfa propellants dry powder inhalers use propellants climate change emissions improved dramatically hfas much lower climate change impact cfcs currently per cent inhalers either using hfa propellants dry power propellantfree inhalers climate change emissions per cent lower levels emissions expected grow coming years sales inhalers hfa propellants continue grow emissions inhalers energy back estimated based energy cfc data public reports back heritage smithkline beecham heritage glaxowellcome actual data inhalers energy available sales data used factors applied estimate climate change emissions climate change emission factors cfc hfc revised years used current factors world meteorological organisation published global warming potential energy transport inhaler use httpwwwepagovozonescienceodsclassonehtml wmo world meteorological organisation scientific assessment ozone depletion global ozone research monitoring projectreport pp geneva switzerland chapter explanation trend montreal protocol called elimination cfcs effect ozone layer invested billion develop alternatives including devices use hfa replacement propellant hfa ozone depleting potential lower effect climate change cfc therefore cfc propellants phased hfa phased significant decline climate change impact products estimated climate change emissions back calculated improvement per cent compares per cent reduction kyoto protocol requires uk kyoto protocol include climate change emissions cfc include hfa back top home responsibility environmental sustainability sustainability climate change energy emissions trading corporate responsibility report emissions trading number uk sites participate uk governments voluntary climate change agreement programme provides companies energy tax rebates meet agreed energyefficiency targets gsk reported compliance agreements participating gsk sites found comply climate change agreements several gsk sites participated european union emissions trading scheme eu ets collectively sites emitted specified co allowances generating surplus carbon credits proceeds sale carbon credits invested energysaving projects back top home responsibility environmental sustainability sustainability climate change energy emissions trading corporate responsibility report emissions trading number uk sites participate uk governments voluntary climate change agreement programme provides companies energy tax rebates meet agreed energyefficiency targets gsk reported compliance agreements participating gsk sites found comply climate change agreements several gsk sites participated european union emissions trading scheme eu ets collectively sites emitted specified co allowances generating surplus carbon credits proceeds sale carbon credits invested energysaving projects back top home responsibility environmental sustainability sustainability climate change energy transport impact corporate responsibility report transport impact estimate transport products employees accounted million kilograms co compared million kilograms equivalent per cent climate change impact energy travelrelated co emissions consisted business air travel per cent global sales fleet per cent transport products manufacturing plants distributors per cent air freight per cent options reducing impact transporting products include consolidating freight shipments reducing number shipping points making use round tripping managing inbound freight trucks return empty switching air sea transport possible travelling work green travel plans number sites encourage employees reduce environmental impact travel work example gsk house brentford uk reserved parking spaces given carsharers drivers fuelefficient cars provide changing rooms showers cyclists well discounts bicycle equipment repairs philadelphia office cost public transportation subsidised back top home responsibility environmental sustainability sustainability climate change energy transport impact corporate responsibility report transport impact estimate transport products employees accounted million kilograms co compared million kilograms equivalent per cent climate change impact energy travelrelated co emissions consisted business air travel per cent global sales fleet per cent transport products manufacturing plants distributors per cent air freight per cent options reducing impact transporting products include consolidating freight shipments reducing number shipping points making use round tripping managing inbound freight trucks return empty switching air sea transport possible travelling work green travel plans number sites encourage employees reduce environmental impact travel work example gsk house brentford uk reserved parking spaces given carsharers drivers fuelefficient cars provide changing rooms showers cyclists well discounts bicycle equipment repairs philadelphia office cost public transportation subsidised back top home responsibility environmental sustainability sustainability water use corporate responsibility report water use approach performance plans clean water valuable resource needs conserved protected pollution aim minimise amount water use environmental impact water discharge gsk uses water manufacturing processes products cooling cleaning general site uses including drinking food services sanitation sites manufacture active pharmaceutical ingredients use large amounts water rd sites offices use less water standard requires sites minimise water use reuse water whenever feasible ensure wastewater treated discharged way minimises adverse environmental impacts target reduce water consumption two per cent per annum per unit sales give us eight per cent water saving end sgs verified back top home responsibility environmental sustainability sustainability water use corporate responsibility report water use approach performance plans clean water valuable resource needs conserved protected pollution aim minimise amount water use environmental impact water discharge gsk uses water manufacturing processes products cooling cleaning general site uses including drinking food services sanitation sites manufacture active pharmaceutical ingredients use large amounts water rd sites offices use less water standard requires sites minimise water use reuse water whenever feasible ensure wastewater treated discharged way minimises adverse environmental impacts target reduce water consumption two per cent per annum per unit sales give us eight per cent water saving end sgs verified back top home responsibility environmental sustainability sustainability water use corporate responsibility report water use approach performance plans water consumption targets performance normalised sales based constant exchange rate errors found data prior years corrected data may vary slightly earlier reports amount water used per million sales corrected constant exchange rate cer decreased per cent baseline absolute water use decreased per cent baseline million cubic metres significantly better two per cent per year target explanation trend reduction achieved maintenance facilities process changes smaller improvements achieved ongoing conservation measures particularly waterstressed locations example pharmaceutical manufacturing plant boronia australia located water stressed area ongoing campaign save water since reduced water usage per cent increasing production per cent staff per cent saving average million litres water year water savings accomplished recovering wastewater using cooling towers amenities maintenance capturing storm water communicating employees saving water believe achieve target plans gsk endorsed un global compacts ceo water mandate un estimates billion people access clean water billion people lack basic sanitation necessary health wellbeing water stress expected worsen many parts world result factors including urbanization population growth increasing food production changing consumption patterns industrialization water pollution climate change joined mandate recognise water important valuable resource needs managed responsibly committed taking action developing comprehensive approach six areas identified mandate direct operations supply chain watershed management collective action public policy community engagement transparency many areas already taken action example targets water conservation reported water usage operations plans place collect report water usage sample key suppliers work local communities conserve pwaagete r onfd preserve wetlands educate employees water conservation understand connection water public health philanthropic project known phase educate people developing countries importance hand washing meet requirements mandate build existing efforts manage single programme team representatives across business formed determine key priorities objectives sgs verified back tophome responsibility environmental sustainability sustainability water use corporate responsibility report water use approach performance plans water consumption targets performance normalised sales based constant exchange rate errors found data prior years corrected data may vary slightly earlier reports amount water used per million sales corrected constant exchange rate cer decreased per cent baseline absolute water use decreased per cent baseline million cubic metres significantly better two per cent per year target explanation trend reduction achieved maintenance facilities process changes smaller improvements achieved ongoing conservation measures particularly waterstressed locations example pharmaceutical manufacturing plant boronia australia located water stressed area ongoing campaign save water since reduced water usage per cent increasing production per cent staff per cent saving average million litres water year water savings accomplished recovering wastewater using cooling towers amenities maintenance capturing storm water communicating employees saving water believe achieve target plans gsk endorsed un global compacts ceo water mandate un estimates billion people access clean water billion people lack basic sanitation necessary health wellbeing water stress expected worsen many parts world result factors including urbanization population growth increasing food production changing consumption patterns industrialization water pollution climate change joined mandate recognise water important valuable resource needs managed responsibly committed taking action developing comprehensive approach six areas identified mandate direct operations supply chain watershed management collective action public policy community engagement transparency many areas already taken action example targets water conservation reported water usage operations plans place collect report water usage sample key suppliers work local communities conserve water preserve wetlands educate employees water conservation understand connection water public health philanthropic project known phase educate people developing countries importance hand washing meet requirements mandate build existing efforts manage single programme team representatives across business formed determine key priorities objectives sgs verified back top home responsibility environmental sustainability sustainability water use corporate responsibility report water use approach performance plans water consumption targets performance normalised sales based constant exchange rate errors found data prior years corrected data may vary slightly earlier reports amount water used per million sales corrected constant exchange rate cer decreased per cent baseline absolute water use decreased per cent baseline million cubic metres significantly better two per cent per year target explanation trend reduction achieved maintenance facilities process changes smaller improvements achieved ongoing conservation measures particularly waterstressed locations example pharmaceutical manufacturing plant boronia australia located water stressed area ongoing campaign save water since reduced water usage per cent increasing production per cent staff per cent saving average million litres water year water savings accomplished recovering wastewater using cooling towers amenities maintenance capturing storm water communicating employees saving water believe achieve target plans gsk endorsed un global compacts ceo water mandate un estimates billion people access clean water billion people lack basic sanitation necessary health wellbeing water stress expected worsen many parts world result factors including urbanization population growth increasing food production changing consumption patterns industrialization water pollution climate change joined mandate recognise water important valuable resource needs managed responsibly committed taking action developing comprehensive approach six areas identified mandate direct operations supply chain watershed management collective action public policy community engagement transparency many areas already taken action example targets water conservation reported water usage operations plans place collect report water usage sample key suppliers work local communities conserve water preserve wetlands educate employees water conservation understand connection water public health philanthropic project known phase educate people developing countries importance hand washing meet requirements mandate build existing efforts manage single programme team representatives across business formed determine key priorities objectives sgs verified back top home responsibility environmental sustainability sustainability product stewardship corporate responsibility report product stewardship take environment account across entire lifecycle products begins process design continues manufacturing use patients eventual disposal wastes used solvents reused raw material another industry paint stripping cradle cradle section focus several aspects product stewardship pharmaceuticals environment portion active pharmaceutical ingredients substances make medicines work may eventually excreted humans enter environment conduct tests risk assessments evaluate potential effects pharmaceutical products environment materials concern materials concern chemicals scientific evidence shows probable serious longterm effects humans environment existing potential future legislation may restrict use process development teams develop strategies eliminate substitute use materials genetically modified organisms use genetically modified organisms gmos research development new therapeutic agents manufacture certain medical products vaccines work gmos controlled strictest national international regulations apply best practice across facilities reach continued work reduce risks continuity supply chemicals presented introduction eus registration evaluation authorisation restriction chemicals reach legislation global harmonisation continue prepare impending changes classification labelling hazards part uns globally harmonised system classification labelling chemicals regulation home responsibility environmental sustainability sustainability product stewardship corporate responsibility report product stewardship take environment account across entire lifecycle products begins process design continues manufacturing use patients eventual disposal wastes used solvents reused raw material another industry paint stripping cradle cradle section focus several aspects product stewardship pharmaceuticals environment portion active pharmaceutical ingredients substances make medicines work may eventually excreted humans enter environment conduct tests risk assessments evaluate potential effects pharmaceutical products environment materials concern materials concern chemicals scientific evidence shows probable serious longterm effects humans environment existing potential future legislation may restrict use process development teams develop strategies eliminate substitute use materials genetically modified organisms use genetically modified organisms gmos research development new therapeutic agents manufacture certain medical products vaccines work gmos controlled strictest national international regulations apply best practice across facilities reach continued work reduce risks continuity supply chemicals presented introduction eus registration evaluation authorisation restriction chemicals reach legislation global harmonisation continue prepare impending changes classification labelling hazards part uns globally harmonised system classification labelling chemicals regulation home responsibility environmental sustainability sustainability product stewardship pharmaceuticals environment corporate responsibility report pharmaceuticals environment portion active pharmaceutical ingredients apis substances make medicines work may eventually excreted humans enter environment wastewater treatment removes pharmaceutical residues small concentrations end rivers sea low concentrations pharmaceuticals occasionally found drinking water countries wastewater treated higher concentrations may enter environment conduct tests risk assessments evaluate potential effects pharmaceutical products environment date indicate products appear pose risk humans environment based current risk assessment methodologies information conduct retrospective analysis environmental data refine testing methodology assessment models recently revised material testing strategies include chronic testing determine impact products environment long term mode action analysis identify sensitive species meet new regulatory guidelines improve understanding possible environmental effects committed transparency data collect make environmental data publicly available assessments environmental data individual apis provided online safety data sheets data also available swedish doctors prescribing guide see make information pharmaceuticals environment available public publishing results risk assessments scientific journals read public position statement pharmaceuticals environment eu us environmental risk assessments part approval process producing marketing new medicines allow regulatory agencies assess potential environmental impacts drugs pending approval work regulatory agencies ensure potential environmental impacts pharmaceuticals understood minimised continue monitor latest scientific studies findings improve risk assessment methodology addition conduct contribute environmental research area recently completed study submitted scientific paper assessing potential impacts human health environmental exposures around apis included gsk pharmaceuticals also beginning study possible impacts mixtures various compounds household wastewater extremely low concentrations include pharmaceuticals well pharmaceuticals household products although main source pharmaceuticals environment patients excreting medicines taken gsk established limits active pharmaceutical ingredients wastewater manufacturing sites based studies establish safe levels api based demonstration risk assess process waste concentrations established levels treat wastewater required ensure safe levels achieved subsequent environmental risk industry collaboration work pharmaceutical companies universities research groups activities around pharmaceuticals environment also collaborate joint projects industry groups sponsor academic studies example submit environmental data products part swedish classification system pharmaceuticals collaboration swedish pharmaceutical association swedish government voluntary transparency initiative making information environmental risks available public doctors scientists participate technical working groups pharmaceuticals environment sponsored industry group pharmaceutical research manufacturers america phrma phrma association british pharmaceutical industry continually engage regulatory scientistpsa gfreo tohf e us environmental protection agency us food drug administration uk environment agency back tophome responsibility environmental sustainability sustainability product stewardship pharmaceuticals environment corporate responsibility report pharmaceuticals environment portion active pharmaceutical ingredients apis substances make medicines work may eventually excreted humans enter environment wastewater treatment removes pharmaceutical residues small concentrations end rivers sea low concentrations pharmaceuticals occasionally found drinking water countries wastewater treated higher concentrations may enter environment conduct tests risk assessments evaluate potential effects pharmaceutical products environment date indicate products appear pose risk humans environment based current risk assessment methodologies information conduct retrospective analysis environmental data refine testing methodology assessment models recently revised material testing strategies include chronic testing determine impact products environment long term mode action analysis identify sensitive species meet new regulatory guidelines improve understanding possible environmental effects committed transparency data collect make environmental data publicly available assessments environmental data individual apis provided online safety data sheets data also available swedish doctors prescribing guide see make information pharmaceuticals environment available public publishing results risk assessments scientific journals read public position statement pharmaceuticals environment eu us environmental risk assessments part approval process producing marketing new medicines allow regulatory agencies assess potential environmental impacts drugs pending approval work regulatory agencies ensure potential environmental impacts pharmaceuticals understood minimised continue monitor latest scientific studies findings improve risk assessment methodology addition conduct contribute environmental research area recently completed study submitted scientific paper assessing potential impacts human health environmental exposures around apis included gsk pharmaceuticals also beginning study possible impacts mixtures various compounds household wastewater extremely low concentrations include pharmaceuticals well pharmaceuticals household products although main source pharmaceuticals environment patients excreting medicines taken gsk established limits active pharmaceutical ingredients wastewater manufacturing sites based studies establish safe levels api based demonstration risk assess process waste concentrations established levels treat wastewater required ensure safe levels achieved subsequent environmental risk industry collaboration work pharmaceutical companies universities research groups activities around pharmaceuticals environment also collaborate joint projects industry groups sponsor academic studies example submit environmental data products part swedish classification system pharmaceuticals collaboration swedish pharmaceutical association swedish government voluntary transparency initiative making information environmental risks available public doctors scientists participate technical working groups pharmaceuticals environment sponsored industry group pharmaceutical research manufacturers america phrma phrma association british pharmaceutical industry continually engage regulatory scientists us environmental protection agency us food drug administration uk environment agency back top home responsibility environmental sustainability sustainability product stewardship pharmaceuticals environment corporate responsibility report pharmaceuticals environment portion active pharmaceutical ingredients apis substances make medicines work may eventually excreted humans enter environment wastewater treatment removes pharmaceutical residues small concentrations end rivers sea low concentrations pharmaceuticals occasionally found drinking water countries wastewater treated higher concentrations may enter environment conduct tests risk assessments evaluate potential effects pharmaceutical products environment date indicate products appear pose risk humans environment based current risk assessment methodologies information conduct retrospective analysis environmental data refine testing methodology assessment models recently revised material testing strategies include chronic testing determine impact products environment long term mode action analysis identify sensitive species meet new regulatory guidelines improve understanding possible environmental effects committed transparency data collect make environmental data publicly available assessments environmental data individual apis provided online safety data sheets data also available swedish doctors prescribing guide see make information pharmaceuticals environment available public publishing results risk assessments scientific journals read public position statement pharmaceuticals environment eu us environmental risk assessments part approval process producing marketing new medicines allow regulatory agencies assess potential environmental impacts drugs pending approval work regulatory agencies ensure potential environmental impacts pharmaceuticals understood minimised continue monitor latest scientific studies findings improve risk assessment methodology addition conduct contribute environmental research area recently completed study submitted scientific paper assessing potential impacts human health environmental exposures around apis included gsk pharmaceuticals also beginning study possible impacts mixtures various compounds household wastewater extremely low concentrations include pharmaceuticals well pharmaceuticals household products although main source pharmaceuticals environment patients excreting medicines taken gsk established limits active pharmaceutical ingredients wastewater manufacturing sites based studies establish safe levels api based demonstration risk assess process waste concentrations established levels treat wastewater required ensure safe levels achieved subsequent environmental risk industry collaboration work pharmaceutical companies universities research groups activities around pharmaceuticals environment also collaborate joint projects industry groups sponsor academic studies example submit environmental data products part swedish classification system pharmaceuticals collaboration swedish pharmaceutical association swedish government voluntary transparency initiative making information environmental risks available public doctors scientists participate technical working groups pharmaceuticals environment sponsored industry group pharmaceutical research manufacturers america phrma phrma association british pharmaceutical industry continually engage regulatory scientists us environmental protection agency us food drug administration uk environment agency back top home responsibility environmental sustainability sustainability product stewardship materials concern gmos nanomaterials corporate responsibility report materials concern gmos nanomaterials materials concern materials concern chemicals scientific evidence shows probable serious longterm effects humans environment existing potential future legislation may restrict use compounds include called pbts substances persist environment bioaccumulate animals plants toxic life carcinogens mutagens reproductive toxins substances known cause asthma endocrine disrupting chemicals ozone depleting substances ehs team works process development teams help develop strategies eliminate substitute use thesematerials read position paper hazardous chemicals management performance used metric tonnes materials concern per cent accounted five solvents solvent waste production destroyed incineration although recycled part work pilot plants also examined use materials concern across phases development determined substances used identified replaced development genetically modified organisms use genetically modified organisms gmos research development new therapeutic agents manufacture certain medical products vaccines use gmos identify genetic targets causes disease develop new antibiotics drugs conditions heart disease diabetes depression use number different gmos predominantly harmless organisms disabled strains bacterium ecoli eukaryotic cells culture also manufacture number products derived genetically modified materials hepatitis b vaccine produce plan produce products contain viable organisms work gmos controlled strictest national international regulations apply best practice across facilities work gmos subject full risk assessment ensuring safe use storage disposal processes performed closed vessels minimising risk release largescale fermentation propagation gmos always undertaken fully contained systems research performed containment laboratories appropriate risk materials handled work controlled written procedures carry regular maintenance checks treat waste gmo operations ensure release viable gmos contained processes environment gmos deactivated prior disposal chemical heat treatment routinely undertake research development involving cultivation genetically modified plant species nanomaterials nanotechnology area science involves controlling nanomaterial materials atomic molecular scale nanotechnology may future used develop new medicines participated responsible nano code consultation development code conduct businesses use nanotechnology responsible nano code collaboration royal society insight investment nanotechnology industries association estimate begin using nanotechnology around back tophome responsibility environmental sustainability sustainability product stewardship materials concern gmos nanomaterials corporate responsibility report materials concern gmos nanomaterials materials concern materials concern chemicals scientific evidence shows probable serious longterm effects humans environment existing potential future legislation may restrict use compounds include called pbts substances persist environment bioaccumulate animals plants toxic life carcinogens mutagens reproductive toxins substances known cause asthma endocrine disrupting chemicals ozone depleting substances ehs team works process development teams help develop strategies eliminate substitute use thesematerials read position paper hazardous chemicals management performance used metric tonnes materials concern per cent accounted five solvents solvent waste production destroyed incineration although recycled part work pilot plants also examined use materials concern across phases development determined substances used identified replaced development genetically modified organisms use genetically modified organisms gmos research development new therapeutic agents manufacture certain medical products vaccines use gmos identify genetic targets causes disease develop new antibiotics drugs conditions heart disease diabetes depression use number different gmos predominantly harmless organisms disabled strains bacterium ecoli eukaryotic cells culture also manufacture number products derived genetically modified materials hepatitis b vaccine produce plan produce products contain viable organisms work gmos controlled strictest national international regulations apply best practice across facilities work gmos subject full risk assessment ensuring safe use storage disposal processes performed closed vessels minimising risk release largescale fermentation propagation gmos always undertaken fully contained systems research performed containment laboratories appropriate risk materials handled work controlled written procedures carry regular maintenance checks treat waste gmo operations ensure release viable gmos contained processes environment gmos deactivated prior disposal chemical heat treatment routinely undertake research development involving cultivation genetically modified plant species nanomaterials nanotechnology area science involves controlling nanomaterial materials atomic molecular scale nanotechnology may future used develop new medicines participated responsible nano code consultation development code conduct businesses use nanotechnology responsible nano code collaboration royal society insight investment nanotechnology industries association estimate begin using nanotechnology around back top home responsibility environmental sustainability sustainability product stewardship materials concern gmos nanomaterials corporate responsibility report materials concern gmos nanomaterials materials concern materials concern chemicals scientific evidence shows probable serious longterm effects humans environment existing potential future legislation may restrict use compounds include called pbts substances persist environment bioaccumulate animals plants toxic life carcinogens mutagens reproductive toxins substances known cause asthma endocrine disrupting chemicals ozone depleting substances ehs team works process development teams help develop strategies eliminate substitute use thesematerials read position paper hazardous chemicals management performance used metric tonnes materials concern per cent accounted five solvents solvent waste production destroyed incineration although recycled part work pilot plants also examined use materials concern across phases development determined substances used identified replaced development genetically modified organisms use genetically modified organisms gmos research development new therapeutic agents manufacture certain medical products vaccines use gmos identify genetic targets causes disease develop new antibiotics drugs conditions heart disease diabetes depression use number different gmos predominantly harmless organisms disabled strains bacterium ecoli eukaryotic cells culture also manufacture number products derived genetically modified materials hepatitis b vaccine produce plan produce products contain viable organisms work gmos controlled strictest national international regulations apply best practice across facilities work gmos subject full risk assessment ensuring safe use storage disposal processes performed closed vessels minimising risk release largescale fermentation propagation gmos always undertaken fully contained systems research performed containment laboratories appropriate risk materials handled work controlled written procedures carry regular maintenance checks treat waste gmo operations ensure release viable gmos contained processes environment gmos deactivated prior disposal chemical heat treatment routinely undertake research development involving cultivation genetically modified plant species nanomaterials nanotechnology area science involves controlling nanomaterial materials atomic molecular scale nanotechnology may future used develop new medicines participated responsible nano code consultation development code conduct businesses use nanotechnology responsible nano code collaboration royal society insight investment nanotechnology industries association estimate begin using nanotechnology around back top home responsibility environmental sustainability sustainability product stewardship reach corporate responsibility report reach continued work reduce risks continuity supply chemicals presented introduction eus registration evaluation authorisation restriction chemicals reach legislation involved using site inventories eu international sites identify chemicals sourced eu suppliers imported manufactured gsk contacting companies supply gsk chemicals covered reach assess plans management potential risks continuity supply gsk involved evaluation suppliers preregistering phasein material manufactured imported gsk volumes one tonne per year registering new substances manufacture import volumes less one tonne per year read position reach gskcom plans start gather information use materials ehs hazard data required meet first reach registration milestone november phasein substances also continue work suppliers ensure meet reach obligations collaborate companies via substance information exchange forums sief share hazard data substances mutual interest require reach registration back top home responsibility environmental sustainability sustainability product stewardship reach corporate responsibility report reach continued work reduce risks continuity supply chemicals presented introduction eus registration evaluation authorisation restriction chemicals reach legislation involved using site inventories eu international sites identify chemicals sourced eu suppliers imported manufactured gsk contacting companies supply gsk chemicals covered reach assess plans management potential risks continuity supply gsk involved evaluation suppliers preregistering phasein material manufactured imported gsk volumes one tonne per year registering new substances manufacture import volumes less one tonne per year read position reach gskcom plans start gather information use materials ehs hazard data required meet first reach registration milestone november phasein substances also continue work suppliers ensure meet reach obligations collaborate companies via substance information exchange forums sief share hazard data substances mutual interest require reach registration back top home responsibility environmental sustainability sustainability product stewardship global harmonisation corporate responsibility report global harmonisation continue prepare impending changes classification labelling hazards part uns globally harmonised system classification labelling chemicals ghs regulation includes changing way produce safety data sheets ensure compliance initiating process reclassifying substances manufacture import following ghs rules developing training employees new hazard warning symbols labels introduced part ghs read position paper hazardous chemicals management plans work gsk operations evaluate hazard labelling solutions facilitate production ghs compliant labels based upon revised classifications developed back top home responsibility environmental sustainability sustainability product stewardship global harmonisation corporate responsibility report global harmonisation continue prepare impending changes classification labelling hazards part uns globally harmonised system classification labelling chemicals ghs regulation includes changing way produce safety data sheets ensure compliance initiating process reclassifying substances manufacture import following ghs rules developing training employees new hazard warning symbols labels introduced part ghs read position paper hazardous chemicals management plans work gsk operations evaluate hazard labelling solutions facilitate production ghs compliant labels based upon revised classifications developed back top home responsibility environmental sustainability sustainability packaging corporate responsibility report packaging working reduce environmental impact packaging pharmaceutical consumer healthcare products green packaging guide provides guidance evaluating selecting packaging allows designers managers benchmark new existing packaging designs using five metrics manufacturing impacts mass material biodegradability pvc content resource depletion petrochemical feedstocks one example reducing impact packaging use per cent recycled plastic ribena bottles achieved despite challenge sourcing sufficient quantities recycled plastic ribena packaging nutritionals business embedded sustainability every aspect business evidenced work done ribena work biodiversity farmers grow berries work towards goal zero waste landfill manufacturing ribena use per cent recycled materials bottles actions realised benefits sustainability benefits environment customers business work done bottling one example approach produce hundreds millions bottles ribena lucozade year bottles made type plastic known pet estimate packaging form much per cent nutritional healthcare products environmental impact launched uk europes first per cent recycled recyclable drinks bottle ribena squash readytodrink products previously packaged ribena bottle made per cent recycled material filled million new bottles ribena using per cent recycled material avoided emission tonnes co prevented total tonnes waste sent landfill bottles also recycled consumers use trying understand would make people recycle away home trialling reverse vending machines major shopping centres people put used drinks bottles machines crush compact ready collection recycling new bottles contribute towards targets gsk nutritional healthcare products use per cent less packaging use packaging made average per cent recycled materials project vanguard award ceos ehs excellence awards back top home responsibility environmental sustainability sustainability packaging corporate responsibility report packaging working reduce environmental impact packaging pharmaceutical consumer healthcare products green packaging guide provides guidance evaluating selecting packaging allows designers managers benchmark new existing packaging designs using five metrics manufacturing impacts mass material biodegradability pvc content resource depletion petrochemical feedstocks one example reducing impact packaging use per cent recycled plastic ribena bottles achieved despite challenge sourcing sufficient quantities recycled plastic ribena packaging nutritionals business embedded sustainability every aspect business evidenced work done ribena work biodiversity farmers grow berries work towards goal zero waste landfill manufacturing ribena use per cent recycled materials bottles actions realised benefits sustainability benefits environment customers business work done bottling one example approach produce hundreds millions bottles ribena lucozade year bottles made type plastic known pet estimate packaging form much per cent nutritional healthcare products environmental impact launched uk europes first per cent recycled recyclable drinks bottle ribena squash readytodrink products previously packaged ribena bottle made per cent recycled material filled million new bottles ribena using per cent recycled material avoided emission tonnes co prevented total tonnes waste sent landfill bottles also recycled consumers use trying understand would make people recycle away home trialling reverse vending machines major shopping centres people put used drinks bottles machines crush compact ready collection recycling new bottles contribute towards targets gsk nutritional healthcare products use per cent less packaging use packaging made average per cent recycled materials project vanguard award ceos ehs excellence awards back top home responsibility environmental sustainability open transparent relations corporate responsibility report open transparent relations aim transparent open environmental impacts products processes helps us build trust stakeholders provides assurance managing environment health safety sustainability ehss risks report progress ehss objectives annual corporate responsibility report respond specific requests information throughout year also engage formally stakeholders gather feedback approach performance address concerns home responsibility environmental sustainability open transparent relations corporate responsibility report open transparent relations aim transparent open environmental impacts products processes helps us build trust stakeholders provides assurance managing environment health safety sustainability ehss risks report progress ehss objectives annual corporate responsibility report respond specific requests information throughout year also engage formally stakeholders gather feedback approach performance address concerns home responsibility environmental sustainability open transparent relations stakeholder engagement corporate responsibility report stakeholder engagement engage stakeholders corporate local level inform plans approach managing ehss help identify emerging issues includes ad hoc meetings formalised feedback stakeholder panel uk created ehs stakeholder workshop held us first time expanded role uk panel provide input sustainability council council composed senior gsk managers formed consider sustainability issues important gsk recommend actions component gsks larger effort address public concerns conduct business engage regulators help develop controls protect environment safeguarding development launch new medicines read engage stakeholders feedback receive see fare benchmarks back top home responsibility environmental sustainability open transparent relations stakeholder engagement corporate responsibility report stakeholder engagement engage stakeholders corporate local level inform plans approach managing ehss help identify emerging issues includes ad hoc meetings formalised feedback stakeholder panel uk created ehs stakeholder workshop held us first time expanded role uk panel provide input sustainability council council composed senior gsk managers formed consider sustainability issues important gsk recommend actions component gsks larger effort address public concerns conduct business engage regulators help develop controls protect environment safeguarding development launch new medicines read engage stakeholders feedback receive see fare benchmarks back top home responsibility environmental sustainability open transparent relations ehss reporting corporate responsibility report ehss reporting primary objective collecting ehss performance data help operations manage ehss issues done ehs manager webbased information management system focus external reporting environmental issues relevant gsk interest stakeholders read overall approach corporate responsibility reporting read approach health safety health safety performance back top home responsibility environmental sustainability open transparent relations ehss reporting corporate responsibility report ehss reporting primary objective collecting ehss performance data help operations manage ehss issues done ehs manager webbased information management system focus external reporting environmental issues relevant gsk interest stakeholders read overall approach corporate responsibility reporting read approach health safety health safety performance back top home responsibility environmental sustainability open transparent relations assurance corporate responsibility report assurance sgs assurance statement sgs united kingdom ltds report environment health safety data glaxosmithkline corporate responsibility report nature scope assurance sgs united kingdom ltd commissioned glaxosmithkline gsk conduct independent assurance environmental health safety data corporate responsibility cr report scope assurance based sgs sustainability report assurance methodology included data contained following sections report waste water injury illness rates waste injury illness causes emissions air fatalities serious injuries climate change ergonomics energy driver safety transport impact health safety data table water use environment data table information gsk cr report presentation responsibility directors management gsk sgs united kingdom ltd involved preparation material included cr report responsibility express opinion data graphs statements within scope verification financial data drawn directly independently audited financial accounts checked back source part assurance process sgs group developed set protocols assurance sustainability reports based best practice guidance provided global reporting initiative sustainability reporting guidelines aa assurance standard protocols follow differing levels assurance depending reporting history capabilities reporting organisation report assured content veracity assurance comprised combination interviews relevant employees documentation record review nineteen gsk locations end reporting year follows interim site visits october france evreux notre dame de bondeville saintamandles eaux india nabha italy verona gms rd nigeria agbara uk slough stevenage rd ware gms worthing usa clifton memphis research triangle park rd end year site visits january february india nashik thane ireland cork uk irvine ulverston corporate csr function london sites selected included submitting high proportions key data included parts gsk business statement independence competence sgs group companies world leader inspection testing verification operating countries providing services including management systems service certification quality environmental social ethical auditing training environmental social sustainability report assurance sgs united kingdom ltd affirm independence gsk free bias conflicts interest organisation subsidiaries stakeholders assurance team assembled based knowledge experience qualifications assignment comprised auditors assurors registered irca iema emas verifiers assurance opinion basis methodology described verification work performed satisfied environmental health safety data contained within gsk corporate responsibility report reliable provides fair balanced representation gsks environmental health safety activities believe gsk chosen appropriate level assurance stage reporting key areas improvement data collection submission manipulation identified assurance process far possible addressed incorporate improvements report improvement opportunities outlined enable review establish need system process changes future reporting cycles data points collated centrally year end fully reviewed identify anomalies leading inconsistent approach estimating missing data several data points calculated using new emissions factors previous years data restated using calculation allow yearonyear comparison important ensure restated information fully explained references factors used remain current significant contributors selected data points failed submit required information calculation methodology ozone depleting substances patient use inhalers updated one production site remaining sites noted reported data previous years may change slightly due obtaining additional data submissions updating estimates publication date anomalies identified data submitted reviewing site level data comparing previous years submissions included examples data entered twice following change database improvement opportunities identified site visits mainly site specific common observations focussing around following areas manual transfer data opportunity mistakes variations roundings transfer utilising benefits improvement regular review internal checks data accuracy formalising secondary review manual transfers rather end year checks extension monthly reporting rather quarterly annual improvements identified previous reporting period started implemented follows specific reports ehs manager begun implemented energy module reduce need additional data transfer spreadsheets site level may additional opportunities extend areas waste data provided key subcontractor site visits conducted noted staff well prepared able provide required evidence auditors majority cases particularly sites undergone previous visits addition required changes generally made promptly possible data ancillary services site activities started included explanation provided comments section ehs manager however site visits identified remain missing items review data submissions indicated increase monthly reporting rather annual quarterly allowing regular review update data entries also indicating discrepancies clearly majority site visits conducted last quarter enabled issues concern identified dealt earlier assurance process key areas improvement data verification process identified follows sites selected visits identified earliest opportunity order enable visits completed alongside isoohsas certification audits possible recommended site visits completed last quarter enable followup required completed end year verification performed recommend selection key indicators full review calculation methodologies across major contributors example voc cod emissions hazardous waste disposal primary sites recommend site visits include detailed review source evidence ozone depleting substances equipment recommend sites selected visits include sample sites manufacturing inhalers order verify data back source sample sites significant contributions failed submit data sample sites significant changes occurred reflected data submitted signed behalf sgs united kingdom ltd pauline earl managing director february wwwsgscom back tophome responsibility environmental sustainability open transparent relations assurance corporate responsibility report assurance sgs assurance statement sgs united kingdom ltds report environment health safety data glaxosmithkline corporate responsibility report nature scope assurance sgs united kingdom ltd commissioned glaxosmithkline gsk conduct independent assurance environmental health safety data corporate responsibility cr report scope assurance based sgs sustainability report assurance methodology included data contained following sections report waste water injury illness rates waste injury illness causes emissions air fatalities serious injuries climate change ergonomics energy driver safety transport impact health safety data table water use environment data table information gsk cr report presentation responsibility directors management gsk sgs united kingdom ltd involved preparation material included cr report responsibility express opinion data graphs statements within scope verification financial data drawn directly independently audited financial accounts checked back source part assurance process sgs group developed set protocols assurance sustainability reports based best practice guidance provided global reporting initiative sustainability reporting guidelines aa assurance standard protocols follow differing levels assurance depending reporting history capabilities reporting organisation report assured content veracity assurance comprised combination interviews relevant employees documentation record review nineteen gsk locations end reporting year follows interim site visits october france evreux notre dame de bondeville saintamandles eaux india nabha italy verona gms rd nigeria agbara uk slough stevenage rd ware gms worthing usa clifton memphis research triangle park rd end year site visits january february india nashik thane ireland cork uk irvine ulverston corporate csr function london sites selected included submitting high proportions key data included parts gsk business statement independence competence sgs group companies world leader inspection testing verification operating countries providing services including management systems service certification quality environmental social ethical auditing training environmental social sustainability report assurance sgs united kingdom ltd affirm independence gsk free bias conflicts interest organisation subsidiaries stakeholders assurance team assembled based knowledge experience qualifications assignment comprised auditors assurors registered irca iema emas verifiers assurance opinion basis methodology described verification work performed satisfied environmental health safety data contained within gsk corporate responsibility report reliable provides fair balanced representation gsks environmental health safety activities believe gsk chosen appropriate level assurance stage reporting key areas improvement data collection submission manipulation identified assurance process far possible addressed incorporate improvements report improvement opportunities outlined enable review establish need system process changes future reporting cycles data points collated centrally year end fully reviewed identify anomalies leading inconsistent approach estimating missing data several data points calculated using new emissions factors previous years data restated using calculation allow yearonyear comparison important ensure restated information fully explained references factors used remain current significant contributors selected data points failed submit required information calculation methodology ozone depleting substances patient use inhalers updated one production site remaining sites noted reported data previous years may change slightly due obtaining additional data submissions updating estimates publication date anomalies identified data submitted reviewing site level data comparing previous years submissions included examples data entered twice following change database improvement opportunities identified site visits mainly site specific common observations focussing around following areas manual transfer data opportunity mistakes variations roundings transfer utilising benefits improvement regular review internal checks data accuracy formalising secondary review manual transfers rather end year checks extension monthly reporting rather quarterly annual improvements identified previous reporting period started implemented follows specific reports ehs manager begun implemented energy module reduce need additional data transfer spreadsheets site level may additional opportunities extend areas waste data provided key subcontractor site visits conducted noted staff well prepared able provide required evidence auditors majority cases particularly sites undergone previous visits addition required changes generally made promptly possible data ancillary services site activities started included explanation provided comments section ehs manager however site visits identified remain missinpagg eit em sof review data submissions indicated increase monthly reporting rather annual quarterly allowing regular review update data entries also indicating discrepancies clearly majority site visits conducted last quarter enabled issues concern identified dealt earlier assurance process key areas improvement data verification process identified follows sites selected visits identified earliest opportunity order enable visits completed alongside isoohsas certification audits possible recommended site visits completed last quarter enable followup required completed end year verification performed recommend selection key indicators full review calculation methodologies across major contributors example voc cod emissions hazardous waste disposal primary sites recommend site visits include detailed review source evidence ozone depleting substances equipment recommend sites selected visits include sample sites manufacturing inhalers order verify data back source sample sites significant contributions failed submit data sample sites significant changes occurred reflected data submitted signed behalf sgs united kingdom ltd pauline earl managing director february wwwsgscom back tophome responsibility environmental sustainability open transparent relations assurance corporate responsibility report assurance sgs assurance statement sgs united kingdom ltds report environment health safety data glaxosmithkline corporate responsibility report nature scope assurance sgs united kingdom ltd commissioned glaxosmithkline gsk conduct independent assurance environmental health safety data corporate responsibility cr report scope assurance based sgs sustainability report assurance methodology included data contained following sections report waste water injury illness rates waste injury illness causes emissions air fatalities serious injuries climate change ergonomics energy driver safety transport impact health safety data table water use environment data table information gsk cr report presentation responsibility directors management gsk sgs united kingdom ltd involved preparation material included cr report responsibility express opinion data graphs statements within scope verification financial data drawn directly independently audited financial accounts checked back source part assurance process sgs group developed set protocols assurance sustainability reports based best practice guidance provided global reporting initiative sustainability reporting guidelines aa assurance standard protocols follow differing levels assurance depending reporting history capabilities reporting organisation report assured content veracity assurance comprised combination interviews relevant employees documentation record review nineteen gsk locations end reporting year follows interim site visits october france evreux notre dame de bondeville saintamandles eaux india nabha italy verona gms rd nigeria agbara uk slough stevenage rd ware gms worthing usa clifton memphis research triangle park rd end year site visits january february india nashik thane ireland cork uk irvine ulverston corporate csr function london sites selected included submitting high proportions key data included parts gsk business statement independence competence sgs group companies world leader inspection testing verification operating countries providing services including management systems service certification quality environmental social ethical auditing training environmental social sustainability report assurance sgs united kingdom ltd affirm independence gsk free bias conflicts interest organisation subsidiaries stakeholders assurance team assembled based knowledge experience qualifications assignment comprised auditors assurors registered irca iema emas verifiers assurance opinion basis methodology described verification work performed satisfied environmental health safety data contained within gsk corporate responsibility report reliable provides fair balanced representation gsks environmental health safety activities believe gsk chosen appropriate level assurance stage reporting key areas improvement data collection submission manipulation identified assurance process far possible addressed incorporate improvements report improvement opportunities outlined enable review establish need system process changes future reporting cycles data points collated centrally year end fully reviewed identify anomalies leading inconsistent approach estimating missing data several data points calculated using new emissions factors previous years data restated using calculation allow yearonyear comparison important ensure restated information fully explained references factors used remain current significant contributors selected data points failed submit required information calculation methodology ozone depleting substances patient use inhalers updated one production site remaining sites noted reported data previous years may change slightly due obtaining additional data submissions updating estimates publication date anomalies identified data submitted reviewing site level data comparing previous years submissions included examples data entered twice following change database improvement opportunities identified site visits mainly site specific common observations focussing around following areas manual transfer data opportunity mistakes variations roundings transfer utilising benefits improvement regular review internal checks data accuracy formalising secondary review manual transfers rather end year checks extension monthly reporting rather quarterly annual improvements identified previous reporting period started implemented follows specific reports ehs manager begun implemented energy module reduce need additional data transfer spreadsheets site level may additional opportunities extend areas waste data provided key subcontractor site visits conducted noted staff well prepared able provide required evidence auditors majority cases particularly sites undergone previous visits addition required changes generally made promptly possible data ancillary services site activities started included explanation provided comments section ehs manager however site visits identified remain missing items review data submissions indicated increase monthly reporting rather annual quarterly allowing regular review update data entries also indicating discrepancies clearly majority site visits conducted last quarter enabled issues concern identified dealt earlier assurance process key areas improvement data verification process identified follows sites selected visits identified earliest opportunity order enable visits completed alongside isoohsas certification audits possible recommended site visits completed last quarter enable followup required completed end year verification performed recommend selection key indicators full review calculation methodologies across major contributors example voc cod emissions hazardous waste disposal primary sites recommend site visits include detailed review source evidence ozone depleting substances equipment recommend sites selected visits include sample sites manufacturing inhalers order verify data back source sample sites significant contributions failed submit data sample sites significant changes occurred reflected data submitted signed behalf sgs united kingdom ltd pauline earl managing director february wwwsgscom back top home responsibility environmental sustainability open transparent relations assurance corporate responsibility report assurance sgs assurance statement sgs united kingdom ltds report environment health safety data glaxosmithkline corporate responsibility report nature scope assurance sgs united kingdom ltd commissioned glaxosmithkline gsk conduct independent assurance environmental health safety data corporate responsibility cr report scope assurance based sgs sustainability report assurance methodology included data contained following sections report waste water injury illness rates waste injury illness causes emissions air fatalities serious injuries climate change ergonomics energy driver safety transport impact health safety data table water use environment data table information gsk cr report presentation responsibility directors management gsk sgs united kingdom ltd involved preparation material included cr report responsibility express opinion data graphs statements within scope verification financial data drawn directly independently audited financial accounts checked back source part assurance process sgs group developed set protocols assurance sustainability reports based best practice guidance provided global reporting initiative sustainability reporting guidelines aa assurance standard protocols follow differing levels assurance depending reporting history capabilities reporting organisation report assured content veracity assurance comprised combination interviews relevant employees documentation record review nineteen gsk locations end reporting year follows interim site visits october france evreux notre dame de bondeville saintamandles eaux india nabha italy verona gms rd nigeria agbara uk slough stevenage rd ware gms worthing usa clifton memphis research triangle park rd end year site visits january february india nashik thane ireland cork uk irvine ulverston corporate csr function london sites selected included submitting high proportions key data included parts gsk business statement independence competence sgs group companies world leader inspection testing verification operating countries providing services including management systems service certification quality environmental social ethical auditing training environmental social sustainability report assurance sgs united kingdom ltd affirm independence gsk free bias conflicts interest organisation subsidiaries stakeholders assurance team assembled based knowledge experience qualifications assignment comprised auditors assurors registered irca iema emas verifiers assurance opinion basis methodology described verification work performed satisfied environmental health safety data contained within gsk corporate responsibility report reliable provides fair balanced representation gsks environmental health safety activities believe gsk chosen appropriate level assurance stage reporting key areas improvement data collection submission manipulation identified assurance process far possible addressed incorporate improvements report improvement opportunities outlined enable review establish need system process changes future reporting cycles data points collated centrally year end fully reviewed identify anomalies leading inconsistent approach estimating missing data several data points calculated using new emissions factors previous years data restated using calculation allow yearonyear comparison important ensure restated information fully explained references factors used remain current significant contributors selected data points failed submit required information calculation methodology ozone depleting substances patient use inhalers updated one production site remaining sites noted reported data previous years may change slightly due obtaining additional data submissions updating estimates publication date anomalies identified data submitted reviewing site level data comparing previous years submissions included examples data entered twice following change database improvement opportunities identified site visits mainly site specific common observations focussing around following areas manual transfer data opportunity mistakes variations roundings transfer utilising benefits improvement regular review internal checks data accuracy formalising secondary review manual transfers rather end year checks extension monthly reporting rather quarterly annual improvements identified previous reporting period started implemented follows specific reports ehs manager begun implemented energy module reduce need additional data transfer spreadsheets site level may additional opportunities extend areas waste data provided key subcontractor site visits conducted noted staff well prepared able provide required evidence auditors majority cases particularly sites undergone previous visits addition required changes generally made promptly possible data ancillary services site activities started included explanation provided comments section ehs manager however site visits identified remain missing items review data submissions indicated increase monthly reporting rather annual quarterly allowing regular review update data entries also indicating discrepancies clearly majority site visits conducted last quarter enabled issues concern identified dealt earlier assurance process key areas improvement data verification process identified follows sites selected visits identified earliest opportunity order enable visits completed alongside isoohsas certification audits possible recommended site visits completed last quarter enable followup required completed end year verification performed recommend selection key indicators full review calculation methodologies across major contributors example voc cod emissions hazardous waste disposal primary sites recommend site visits include detailed review source evidence ozone depleting substances equipment recommend sites selected visits include sample sites manufacturing inhalers order verify data back source sample sites significant contributions failed submit data sample sites significant changes occurred reflected data submitted signed behalf sgs united kingdom ltd pauline earl managing director february wwwsgscom back top home responsibility environmental sustainability open transparent relations gsk response assurance corporate responsibility report gsk response assurance gsk response sgs march third year sgs reviewed data environment injury illness data people section corporate responsibility report verification complex due large amount data covered every year sgs auditors suggest improvements based findings unbiased view data processes valuable adopted suggestions result quality systems data continued improve years sgs selects sites review based magnitude contribution sites overall gsk performance types operations degree difficulty sites seem reporting believe site evaluations valuable learning experiences site personnel data included corporate responsibility report used individual sites monitor improve environmental programmes health safety programmes therefore sgs data verification assures veracity data corporate responsibility report also improves accuracy therefore usefulness data sites still find challenges collecting complete accurate data timely fashion committed continuing improve record reach goal able provide accurate data public website real time responses specific key areas improvement year selecting sites reviewed part iso certification sites already selected review verified combination iso certifications take place year site visits completed last quarter sites notified selection verification visits first quarter visits take place last quarter conjunction iso certification visits earlier year selection key indicators full review calculation methodologies work sites manufacture active pharmaceutical ingredients principal contributors voc cod emissions hazardous waste review calculation methods course site visits include detailed review source evidence ozone depleting substances equipment prepare reports refrigeration equipment register sgs include site reviews sites selected visits include manufacturers inhalers sites failed submit data sites significant changes data submitted sites selected review fully represent groups including large sales groups submitted incomplete late data injuries illnesses sites businesses regions made significant data errors look forward improvements attention areas bring james hagan vice president corporate environment health safety sustainability back top home responsibility environmental sustainability open transparent relations gsk response assurance corporate responsibility report gsk response assurance gsk response sgs march third year sgs reviewed data environment injury illness data people section corporate responsibility report verification complex due large amount data covered every year sgs auditors suggest improvements based findings unbiased view data processes valuable adopted suggestions result quality systems data continued improve years sgs selects sites review based magnitude contribution sites overall gsk performance types operations degree difficulty sites seem reporting believe site evaluations valuable learning experiences site personnel data included corporate responsibility report used individual sites monitor improve environmental programmes health safety programmes therefore sgs data verification assures veracity data corporate responsibility report also improves accuracy therefore usefulness data sites still find challenges collecting complete accurate data timely fashion committed continuing improve record reach goal able provide accurate data public website real time responses specific key areas improvement year selecting sites reviewed part iso certification sites already selected review verified combination iso certifications take place year site visits completed last quarter sites notified selection verification visits first quarter visits take place last quarter conjunction iso certification visits earlier year selection key indicators full review calculation methodologies work sites manufacture active pharmaceutical ingredients principal contributors voc cod emissions hazardous waste review calculation methods course site visits include detailed review source evidence ozone depleting substances equipment prepare reports refrigeration equipment register sgs include site reviews sites selected visits include manufacturers inhalers sites failed submit data sites significant changes data submitted sites selected review fully represent groups including large sales groups submitted incomplete late data injuries illnesses sites businesses regions made significant data errors look forward improvements attention areas bring james hagan vice president corporate environment health safety sustainability back top home responsibility environmental sustainability open transparent relations gsk response assurance corporate responsibility report gsk response assurance gsk response sgs march third year sgs reviewed data environment injury illness data people section corporate responsibility report verification complex due large amount data covered every year sgs auditors suggest improvements based findings unbiased view data processes valuable adopted suggestions result quality systems data continued improve years sgs selects sites review based magnitude contribution sites overall gsk performance types operations degree difficulty sites seem reporting believe site evaluations valuable learning experiences site personnel data included corporate responsibility report used individual sites monitor improve environmental programmes health safety programmes therefore sgs data verification assures veracity data corporate responsibility report also improves accuracy therefore usefulness data sites still find challenges collecting complete accurate data timely fashion committed continuing improve record reach goal able provide accurate data public website real time responses specific key areas improvement year selecting sites reviewed part iso certification sites already selected review verified combination iso certifications take place year site visits completed last quarter sites notified selection verification visits first quarter visits take place last quarter conjunction iso certification visits earlier year selection key indicators full review calculation methodologies work sites manufacture active pharmaceutical ingredients principal contributors voc cod emissions hazardous waste review calculation methods course site visits include detailed review source evidence ozone depleting substances equipment prepare reports refrigeration equipment register sgs include site reviews sites selected visits include manufacturers inhalers sites failed submit data sites significant changes data submitted sites selected review fully represent groups including large sales groups submitted incomplete late data injuries illnesses sites businesses regions made significant data errors look forward improvements attention areas bring james hagan vice president corporate environment health safety sustainability back top home responsibility environmental sustainability qas corporate responsibility report qas respond questions raised stakeholders inhaler products large environmental impact phasing cfcs inhaler products last years replacing gases hfas lower climate change impact per cent cfcs less two per cent inhalers contain cfcs committed complete phaseout part new climate strategy exploring ways reduce amount hfas released inhaler products looking alternative propellants also offer dry powder inhalers asthma sufferers contain greenhouse gases suitable patients particularly children elderly contain propellants rely persons lung power active ingredients administered pharmaceutical manufacturing process made efficient making medicines highly regulated complicated due number process steps required know need improve efficiency set target double average materials efficiency manufacturing processes new products introduced pharmaceutical residues present drinking water risk humans studies shown gsk pharmaceutical products either present watercourses present low concentrations risk assessments demonstrate concentrations pose risk human health environment complacent continually monitor latest scientific studies findings improve risk assessment methodology back top home responsibility environmental sustainability qas corporate responsibility report qas respond questions raised stakeholders inhaler products large environmental impact phasing cfcs inhaler products last years replacing gases hfas lower climate change impact per cent cfcs less two per cent inhalers contain cfcs committed complete phaseout part new climate strategy exploring ways reduce amount hfas released inhaler products looking alternative propellants also offer dry powder inhalers asthma sufferers contain greenhouse gases suitable patients particularly children elderly contain propellants rely persons lung power active ingredients administered pharmaceutical manufacturing process made efficient making medicines highly regulated complicated due number process steps required know need improve efficiency set target double average materials efficiency manufacturing processes new products introduced pharmaceutical residues present drinking water risk humans studies shown gsk pharmaceutical products either present watercourses present low concentrations risk assessments demonstrate concentrations pose risk human health environment complacent continually monitor latest scientific studies findings improve risk assessment methodology back top home responsibility environmental sustainability environmental metrics corporate responsibility report environmental metrics metric energy use energy operations million gigajoules natural gas fuels coal steam imported electricity imported energy transport million gigajoules sales force air travel product logistics electricity sustainable sources climate change impact co equivalents total climate change impact million kilograms co equivalent co equivalents operations energy million kilograms natural gas fuels coal steam imported electricity imported co equivalents transport million page kilograms sales force air travel product logistics co equivalents production activities million kilograms inhaler production losses equipment containing greater kg refrigerant co methane nitrous oxide production waste treatment sources co equivalents use inhalers patients million kilograms cfc inhalers cfc inhalers hfaa inhalers water use discharge water million cubic metres municipal wells boreholes water wastewater volume million cubic metres wastewater recycling wastewater municipal sewer wastewater water bodies cod onsite treatment million kilograms cod recycled water cod municipal sewer cod water bodies waste generated disposed hazardous waste generated million kilograms hazardous waste recycled hazardous waste disposed hazardous waste incinerated energy recovery hazardous waste incinerated energy recovery hazardous waste landfill nonhazardous waste generated million kilograms nonhazardous waste recycled nonhazardous waste disposed nonhazardous waste incinerated energy recovery nonhazardous waste incinerated energy recovery nonhazardous waste landfill nonroutine waste generated million kilograms nonroutine waste recycled nonroutine waste disposed nonroutine waste incinerated energy recovery nonroutine waste incinerated energy recovery nonroutine waste landfill volatile organic compound emissions volatile organic compound emissions million kilograms top six solvents released air million kilograms acetone dichloromethane methanol ethanol isopropanol toluene ozone depleting substances ods releases production thousand kilograms cfc releases production cfc releases production ozone depletion potential refrigerants released eqauipment thousand kilograms cfc equivalent cfc releases equipment cfc releases equipment ods equipment ods released patient use inhalers cfc patient use cfc patient use odp refrigerants contined equipment thousand kilograms cfc equivalent estimated costs investments operations maintenance cost million capital investment million footnotes energy climate change impact travel transport air land sea calculated using greenhouse gas protocol starting distance travelled directly fuel use years collect categories freight transport employee business travel transport data estimated may capture routes employee air travel climate change impact calculated co equivalent using greenhouse gas protocol developed world resources institute world business council sustainable development year review co factors update data years appropriate greatest changes generally updated factors electricity reviewed refrigeration equipment inventories inventories incomplete estimated based inventories years also updated factors ozone depletion potential climate change emissions using wmo world meteorological organisation scientific assessment ozone depletion global ozone research monitoring projectreport pp geneva switzerland chapter calculate probable releases using factor british refrigeration association enough information calculate climate change impact inhaler use water sources includes recycled sources focus collection wastewater chemical oxygen demand data primarily major contributors primary manufacturing operations pilot plants coating activities sterile operations sanitary wastewater streams included separated production wastewater streams significant chemical oxygen demand cod measure water pollution measured wastewater leaves sites following onsite treatment consider waste hazardous properties defined basel convention radioactive bioengineered biohazardous basel convention properties include flammability explosivity water air reactivity corrosivity oxidising potential acute chronic toxicity ecotoxicity infection biological waste rendered nonhazardous treatment considered nonhazardous waste focus collection hazardous waste major contributors primary manufacturing operations pilot plants coating activities sterile operations incineration energy recovery means burning material using resulting energy nonroutine waste includes construction demolition rubble included hazardous non hazardous waste calculations focus collection volatile organic compound emissions major contributors primary manufacturing operations pilot plants coating activities sterile operations used wmo world meteorological organisation scientific assessment ozone depletion global ozone research monitoring projectreport pp geneva switzerland chapter ozone depletion potential climate change emissions factors information inhalers produced asia included odp gwp calculations information amounts refrigerants contained equipment back tophome responsibility environmental sustainability environmental metrics corporate responsibility report environmental metrics metric energy use energy operations million gigajoules natural gas fuels coal steam imported electricity imported energy transport million gigajoules sales force air travel product logistics electricity sustainable sources climate change impact co equivalents total climate change impact million kilograms co equivalent co equivalents operations energy million kilograms natural gas fuels coal steam imported electricity imported co equivalents transport million kilograms sales force air travel product logistics co equivalents production activities million kilograms inhaler production losses equipment containing greater kg refrigerant co methane nitrous oxide production waste treatment sources co equivalents use inhalers patients million kilograms cfc inhalers cfc inhalers hfaa inhalers water use discharge water million cubic metres municipal wells boreholes water wastewater volume million cubic metres wastewater recycling wastewater municipal sewer wastewater water bodies cod onsite treatment million kilograms cod recycled water cod municipal sewer page cod water bodies waste generated disposed hazardous waste generated million kilograms hazardous waste recycled hazardous waste disposed hazardous waste incinerated energy recovery hazardous waste incinerated energy recovery hazardous waste landfill nonhazardous waste generated million kilograms nonhazardous waste recycled nonhazardous waste disposed nonhazardous waste incinerated energy recovery nonhazardous waste incinerated energy recovery nonhazardous waste landfill nonroutine waste generated million kilograms nonroutine waste recycled nonroutine waste disposed nonroutine waste incinerated energy recovery nonroutine waste incinerated energy recovery nonroutine waste landfill volatile organic compound emissions volatile organic compound emissions million kilograms top six solvents released air million kilograms acetone dichloromethane methanol ethanol isopropanol toluene ozone depleting substances ods releases production thousand kilograms cfc releases production cfc releases production ozone depletion potential refrigerants released eqauipment thousand kilograms cfc equivalent cfc releases equipment cfc releases equipment ods equipment ods released patient use inhalers cfc patient use cfc patient use odp refrigerants contined equipment thousand kilograms cfc equivalent estimated costs investments operations maintenance cost million capital investment million footnotes energy climate change impact travel transport air land sea calculated using greenhouse gas protocol starting distance travelled directly fuel use years collect categories freight transport employee business travel transport data estimated may capture routes employee air travel climate change impact calculated co equivalent using greenhouse gas protocol developed world resources institute world business council sustainable development year review co factors update data years appropriate greatest changes generally updated factors electricity reviewed refrigeration equipment inventories inventories incomplete estimated based inventories years also updated factors ozone depletion potential climate change emissions using wmo world meteorological organisation scientific assessment ozone depletion global ozone research monitoring projectreport pp geneva switzerland chapter calculate probable releases using factor british refrigeration association enough information calculate climate change impact inhaler use water sources includes recycled sources focus collection wastewater chemical oxygen demand data primarily major contributors primary manufacturing operations pilot plants coating activities sterile operations sanitary wastewater streams included separated production wastewater streams significant chemical oxygen demand cod measure water pollution measured wastewater leaves sites following onsite treatment consider waste hazardous properties defined basel convention radioactive bioengineered biohazardous basel convention properties include flammability explosivity water air reactivity corrosivity oxidising potential acute chronic toxicity ecotoxicity infection biological waste rendered nonhazardous treatment considered nonhazardous waste focus collection hazardous waste major contributors primary manufacturing operations pilot plants coating activities sterile operations incineration energy recovery means burning material using resulting energy nonroutine waste includes construction demolition rubble included hazardous non hazardous waste calculations focus collection volatile organic compound emissions major contributors primary manufacturing operations pilot plants coating activities sterile operations used wmo world meteorological organisation scientific assessment ozone depletion global ozone research monitoring projectreport pp geneva switzerland chapter ozone depletion potential climate change emissions factors information inhalers produced asia included odp gwp calculations information amounts refrigerants contained equipment back tophome responsibility environmental sustainability environmental metrics corporate responsibility report environmental metrics metric energy use energy operations million gigajoules natural gas fuels coal steam imported electricity imported energy transport million gigajoules sales force air travel product logistics electricity sustainable sources climate change impact co equivalents total climate change impact million kilograms co equivalent co equivalents operations energy million kilograms natural gas fuels coal steam imported electricity imported co equivalents transport million kilograms sales force air travel product logistics co equivalents production activities million kilograms inhaler production losses equipment containing greater kg refrigerant co methane nitrous oxide production waste treatment sources co equivalents use inhalers patients million kilograms cfc inhalers cfc inhalers hfaa inhalers water use discharge water million cubic metres municipal wells boreholes water wastewater volume million cubic metres wastewater recycling wastewater municipal sewer wastewater water bodies cod onsite treatment million kilograms cod recycled water cod municipal sewer cod water bodies waste generated disposed hazardous waste generated million kilograms hazardous waste recycled hazardous waste disposed hazardous waste incinerated energy recovery hazardous waste incinerated energy recovery hazardous waste landfill nonhazardous waste generated million kilograms nonhazardous waste recycled nonhazardous waste disposed nonhazardous waste incinerated energy recovery nonhazardous waste incinerated energy recovery nonhazardous waste landfill nonroutine waste generated million kilograms nonroutine waste recycled nonroutine waste disposed nonroutine waste incinerated energy recovery nonroutine waste incinerated energy recovery nonroutine waste landfill volatile organic compound emissions volatile organic compound emissions million kilograms top six solvents released air million kilograms acetone dichloromethane methanol ethanol isopropanol toluene ozone depleting substances ods releases production thousand kilograms cfc releases production cfc releases production ozone depletion potential refrigerants released eqauipment thousand kilograms cfc equivalent cfc releases equipment cfc releases equipment ods equipment ods released patient use inhalers cfc patient use cfc patient use odp refrigerants contined equipment thousand kilograms cfc equivalent estimated costs investments operations maintenance cost million capital investment million footnotes energy climate change impact travel transport air land sea calculated using greenhouse gas protocol starting distance travelled directly fuel use years collect categories freight transport employee business travel transport data estimated may capture routes employee air travel climate change impact calculated co equivalent using greenhouse gas protocol developed world resources institute world business council sustainable development year review co factors update data years appropriate greatest changes generally updated factors electricity reviewed refrigeration equipment inventories inventories incomplete estimated based inventories years also updated factors ozone depletion potential climate change emissions using wmo world meteorological organisation scientific assessment ozone depletion global ozone research monitoring projectreport pp geneva switzerland chapter calculate probable releases using factor british refrigeration association enough information calculate climate change impact inhaler use water sources includes recycled sources focus collection wastewater chemical oxygen demand data primarily major contributors primary manufacturing operations pilot plants coating activities sterile operations sanitary wastewater streams included separated production wastewater streams significant chemical oxygen demand cod measure water pollution measured wastewater leaves sites following onsite treatment consider waste hazardous properties defined basel convention radioactive bioengineered biohazardous basel convention properties include flammability explosivity water air reactivity corrosivity oxidising potential acute chronic toxicity ecotoxicity infection biological waste rendered nonhazardous treatment considered nonhazardous waste focus collection hazardous waste major contributors primary manufacturing operations pilot plants coating activities sterile operations incineration energy recovery means burning material using resulting energy nonroutine waste includes construction demolition rubble included hazardous non hazardous waste calculations focus collection volatile organic compound emissions major contributors primary manufacturing operations pilot plants coating activities sterile operations used wmo world meteorological organisation scientific assessment ozone depletion global ozone research monitoring projectreport pp geneva switzerland chapter ozone depletion potential climate change emissions factors information inhalers produced asia included odp gwp calculations information amounts refrigerants contained equipment back tophome responsibility environmental sustainability environmental metrics corporate responsibility report environmental metrics metric energy use energy operations million gigajoules natural gas fuels coal steam imported electricity imported energy transport million gigajoules sales force air travel product logistics electricity sustainable sources climate change impact co equivalents total climate change impact million kilograms co equivalent co equivalents operations energy million kilograms natural gas fuels coal steam imported electricity imported co equivalents transport million kilograms sales force air travel product logistics co equivalents production activities million kilograms inhaler production losses equipment containing greater kg refrigerant co methane nitrous oxide production waste treatment sources co equivalents use inhalers patients million kilograms cfc inhalers cfc inhalers hfaa inhalers water use discharge water million cubic metres municipal wells boreholes water wastewater volume million cubic metres wastewater recycling wastewater municipal sewer wastewater water bodies cod onsite treatment million kilograms cod recycled water cod municipal sewer cod water bodies waste generated disposed hazardous waste generated million kilograms hazardous waste recycled hazardous waste disposed hazardous waste incinerated energy recovery hazardous waste incinerated energy recovery hazardous waste landfill nonhazardous waste generated million kilograms nonhazardous waste recycled nonhazardous waste disposed nonhazardous waste incinerated energy recovery nonhazardous waste incinerated energy recovery nonhazardous waste landfill nonroutine waste generated million kilograms nonroutine waste recycled nonroutine waste disposed nonroutine waste incinerated energy recovery nonroutine waste incinerated energy recovery nonroutine waste landfill volatile organic compound emissions volatile organic compound emissions million kilograms top six solvents released air million kilograms acetone dichloromethane methanol ethanol isopropanol toluene ozone depleting substances ods releases production thousand kilograms cfc releases production cfc releases production ozone depletion potential refrigerants released eqauipment thousand kilograms cfc equivalent cfc releases equipment cfc releases equipment ods equipment ods released patient use inhalers cfc patient use cfc patient use odp refrigerants contined equipment thousand kilograms cfc equivalent estimated costs investments operations maintenance cost million capital investment million footnotes energy climate change impact travel transport air land sea calculated using greenhouse gas protocol starting distance travelled directly fuel use years collect categories freight transport employee business travel transport data estimated may capture routes employee air travel climate change impact calculated co equivalent using greenhouse gas protocol developed world resources institute world business council sustainable development year review co factors update data years appropriate greatest changes generally updated factors electricity reviewed refrigeration equipment inventories inventories incomplete estimated based inventories years also updated factors ozone depletion potential climate change emissions using wmo world meteorological organisation scientific assessment ozone depletion global ozone research monitoring projectreport pp geneva switzerland chapter calculate probable releases using factor british refrigeration association enough information calculate climate change impact inhaler use water sources includes recycled sources focus collection wastewater chemical oxygen demand data primarily major contributors primary manufacturing operations pilot plants coating activities sterile operations sanitary wastewater streams included separated production wastewater streams significant chemical oxygen demand cod measure water pollution measured wastewater leaves sites following onsite treatment consider waste hazardous properties defined basel convention radioactive bioengineered biohazardous basel convention properties include flammability explosivity water air reactivity corrosivity oxidising potential acute chronic toxicity ecotoxicity infection biological waste rendered nonhazardous treatment considered nonhazardous waste focus collection hazardous waste major contributors primary manufacturing operations pilot plants coating activities sterile operations incineration energy recovery means burning material using resulting energy nonroutine waste includes construction demolition rubble included hazardous non hazardous waste calculations focus collection volatile organic compound emissions major contributors primary manufacturing operations pilot plants coating activities sterile operations used wmo world meteorological organisation scientific assessment ozone depletion global ozone research monitoring projectreport pp geneva switzerland chapter ozone depletion potential climate change emissions factors information inhalers produced asia included odp gwp calculations information amounts refrigerants contained equipment back tophome responsibility environmental sustainability environmental metrics corporate responsibility report environmental metrics metric energy use energy operations million gigajoules natural gas fuels coal steam imported electricity imported energy transport million gigajoules sales force air travel product logistics electricity sustainable sources climate change impact co equivalents total climate change impact million kilograms co equivalent co equivalents operations energy million kilograms natural gas fuels coal steam imported electricity imported co equivalents transport million kilograms sales force air travel product logistics co equivalents production activities million kilograms inhaler production losses equipment containing greater kg refrigerant co methane nitrous oxide production waste treatment sources co equivalents use inhalers patients million kilograms cfc inhalers cfc inhalers hfaa inhalers water use discharge water million cubic metres municipal wells boreholes water wastewater volume million cubic metres wastewater recycling wastewater municipal sewer wastewater water bodies cod onsite treatment million kilograms cod recycled water cod municipal sewer cod water bodies waste generated disposed hazardous waste generated million kilograms hazardous waste recycled hazardous waste disposed hazardous waste incinerated energy recovery hazardous waste incinerated energy recovery hazardous waste landfill nonhazardous waste generated million kilograms nonhazardous waste recycled nonhazardous waste disposed nonhazardous waste incinerated energy recovery nonhazardous waste incinerated energy recovery nonhazardous waste landfill nonroutine waste generated million kilograms nonroutine waste recycled nonroutine waste disposed nonroutine waste incinerated energy recovery nonroutine waste incinerated energy recovery nonroutine waste landfill volatile organic compound emissions volatile organic compound emissions million kilograms top six solvents released air million kilograms acetone dichloromethane methanol ethanol isopropanol toluene ozone depleting substances ods releases production thousand kilograms cfc releases production cfc releases production ozone depletion potential refrigerants released eqauipment thousand kilograms cfc equivalent cfc releases equipment cfc releases equipment ods equipment ods released patient use inhalers cfc patient use cfc patient use odp refrigerants contined equipment thousand kilograms cfc equivalent estimated costs investments operations maintenance cost million capital investment million footnotes energy climate change impact travel transport air land sea calculated using greenhouse gas protocol starting distance travelled directly fuel use years collect categories freight transport employee business travel transport data estimated may capture routes employee air travel climate change impact calculated co equivalent using greenhouse gas protocol developed world resources institute world business council sustainable development year review co factors update data years appropriate greatest changes generally updated factors electricity reviewed refrigeration equipment inventories inventories incomplete estimated based inventories years also updated factors ozone depletion potential climate change emissions using wmo world meteorological organisation scientific assessment ozone depletion global ozone research monitoring projectreport pp geneva switzerland chapter calculate probable releases using factor british refrigeration association enough information calculate climate change impact inhaler use water sources includes recycled sources focus collection wastewater chemical oxygen demand data primarily major contributors primary manufacturing operations pilot plants coating activities sterile operations sanitary wastewater streams included separated production wastewater streams significant chemical oxygen demand cod measure water pollution measured wastewater leaves sites following onsite treatment consider waste hazardous properties defined basel convention radioactive bioengineered biohazardous basel convention properties include flammability explosivity water air reactivity corrosivity oxidising potential acute chronic toxicity ecotoxicity infection biological waste rendered nonhazardous treatment considered nonhazardous waste focus collection hazardous waste major contributors primary manufacturing operations pilot plants coating activities sterile operations incineration energy recovery means burning material using resulting energy nonroutine waste includes construction demolition rubble included hazardous non hazardous waste calculations focus collection volatile organic compound emissions major contributors primary manufacturing operations pilot plants coating activities sterile operations used wmo world meteorological organisation scientific assessment ozone depletion global ozone research monitoring projectreport pp geneva switzerland chapter ozone depletion potential climate change emissions factors information inhalers produced asia included odp gwp calculations information amounts refrigerants contained equipment back top home responsibility environmental sustainability environmental metrics corporate responsibility report environmental metrics metric energy use energy operations million gigajoules natural gas fuels coal steam imported electricity imported energy transport million gigajoules sales force air travel product logistics electricity sustainable sources climate change impact co equivalents total climate change impact million kilograms co equivalent co equivalents operations energy million kilograms natural gas fuels coal steam imported electricity imported co equivalents transport million kilograms sales force air travel product logistics co equivalents production activities million kilograms inhaler production losses equipment containing greater kg refrigerant co methane nitrous oxide production waste treatment sources co equivalents use inhalers patients million kilograms cfc inhalers cfc inhalers hfaa inhalers water use discharge water million cubic metres municipal wells boreholes water wastewater volume million cubic metres wastewater recycling wastewater municipal sewer wastewater water bodies cod onsite treatment million kilograms cod recycled water cod municipal sewer cod water bodies waste generated disposed hazardous waste generated million kilograms hazardous waste recycled hazardous waste disposed hazardous waste incinerated energy recovery hazardous waste incinerated energy recovery hazardous waste landfill nonhazardous waste generated million kilograms nonhazardous waste recycled nonhazardous waste disposed nonhazardous waste incinerated energy recovery nonhazardous waste incinerated energy recovery nonhazardous waste landfill nonroutine waste generated million kilograms nonroutine waste recycled nonroutine waste disposed nonroutine waste incinerated energy recovery nonroutine waste incinerated energy recovery nonroutine waste landfill volatile organic compound emissions volatile organic compound emissions million kilograms top six solvents released air million kilograms acetone dichloromethane methanol ethanol isopropanol toluene ozone depleting substances ods releases production thousand kilograms cfc releases production cfc releases production ozone depletion potential refrigerants released eqauipment thousand kilograms cfc equivalent cfc releases equipment cfc releases equipment ods equipment ods released patient use inhalers cfc patient use cfc patient use odp refrigerants contined equipment thousand kilograms cfc equivalent estimated costs investments operations maintenance cost million capital investment million footnotes energy climate change impact travel transport air land sea calculated using greenhouse gas protocol starting distance travelled directly fuel use years collect categories freight transport employee business travel transport data estimated may capture routes employee air travel climate change impact calculated co equivalent using greenhouse gas protocol developed world resources institute world business council sustainable development year review co factors update data years appropriate greatest changes generally updated factors electricity reviewed refrigeration equipment inventories inventories incomplete estimated based inventories years also updated factors ozone depletion potential climate change emissions using wmo world meteorological organisation scientific assessment ozone depletion global ozone research monitoring projectreport pp geneva switzerland chapter calculate probable releases using factor british refrigeration association enough information calculate climate change impact inhaler use water sources includes recycled sources focus collection wastewater chemical oxygen demand data primarily major contributors primary manufacturing operations pilot plants coating activities sterile operations sanitary wastewater streams included separated production wastewater streams significant chemical oxygen demand cod measure water pollution measured wastewater leaves sites following onsite treatment consider waste hazardous properties defined basel convention radioactive bioengineered biohazardous basel convention properties include flammability explosivity water air reactivity corrosivity oxidising potential acute chronic toxicity ecotoxicity infection biological waste rendered nonhazardous treatment considered nonhazardous waste focus collection hazardous waste major contributors primary manufacturing operations pilot plants coating activities sterile operations incineration energy recovery means burning material using resulting energy nonroutine waste includes construction demolition rubble included hazardous non hazardous waste calculations focus collection volatile organic compound emissions major contributors primary manufacturing operations pilot plants coating activities sterile operations used wmo world meteorological organisation scientific assessment ozone depletion global ozone research monitoring projectreport pp geneva switzerland chapter ozone depletion potential climate change emissions factors information inhalers produced asia included odp gwp calculations information amounts refrigerants contained equipment back top home responsibility people corporate responsibility report people good employment practices essential achieve business strategy goal best place best people best work employ people countries across world essential characteristics good workplace integrity diversity inclusion development creativity integrity critical everything gsk spirit defines culture behaviours expect employees failures integrity risk damaging longterm success diversity inclusion workforce demonstrate commitment equal opportunities enhance business diversity inclusion help us attract best people countries operate give us wide range perspectives draw enhance understanding local market needs development employees means likely stay gsk contribute best success encourage employees achieve full potential training programmes thejob development offer supportive safe work environment competitive reward packages creativity fostered best work environments aim gsk workplaces empower people creative innovative work benefit company shareholders customers patients employment awards selection employment awards gsk uk ranked fourth britains top employers survey crf international published guardian books best class engineering science shortlisted best graduate employer target awards voted graduates postgraduates received times employers choice research development award based results undergraduate interviews ranked th times top graduate employers survey list organisations new graduates want work first employee benefits award effective use employee financial education workplace awarded employee benefits magazine highly commended pricewaterhousecoopers building public trust awards people reporting category based disclosure strength human capital management employee practices us awarded perfect score per cent corporate equality human rights campaign foundation listed one best places work gay lesbian bisexual transgender equality named one best companies working mother magazine th consecutive year awarded platinum honours workplace lifestyle programmes national business group health identified leader providing healthy workplace promoting healthy lifestyle employees families home responsibility people corporate responsibility report people good employment practices essential achieve business strategy goal best place best people best work employ people countries across world essential characteristics good workplace integrity diversity inclusion development creativity integrity critical everything gsk spirit defines culture behaviours expect employees failures integrity risk damaging longterm success diversity inclusion workforce demonstrate commitment equal opportunities enhance business diversity inclusion help us attract best people countries operate give us wide range perspectives draw enhance understanding local market needs development employees means likely stay gsk contribute best success encourage employees achieve full potential training programmes thejob development offer supportive safe work environment competitive reward packages creativity fostered best work environments aim gsk workplaces empower people creative innovative work benefit company shareholders customers patients employment awards selection employment awards gsk uk ranked fourth britains top employers survey crf international published guardian books best class engineering science shortlisted best graduate employer target awards voted graduates postgraduates received times employers choice research development award based results undergraduate interviews ranked th times top graduate employers survey list organisations new graduates want work first employee benefits award effective use employee financial education workplace awarded employee benefits magazine highly commended pricewaterhousecoopers building public trust awards people reporting category based disclosure strength human capital management employee practices us awarded perfect score per cent corporate equality human rights campaign foundation listed one best places work gay lesbian bisexual transgender equality named one best companies working mother magazine th consecutive year awarded platinum honours workplace lifestyle programmes national business group health identified leader providing healthy workplace promoting healthy lifestyle employees families home responsibility people corporate responsibility report people good employment practices essential achieve business strategy goal best place best people best work employ people countries across world essential characteristics good workplace integrity diversity inclusion development creativity integrity critical everything gsk spirit defines culture behaviours expect employees failures integrity risk damaging longterm success diversity inclusion workforce demonstrate commitment equal opportunities enhance business diversity inclusion help us attract best people countries operate give us wide range perspectives draw enhance understanding local market needs development employees means likely stay gsk contribute best success encourage employees achieve full potential training programmes thejob development offer supportive safe work environment competitive reward packages creativity fostered best work environments aim gsk workplaces empower people creative innovative work benefit company shareholders customers patients employment awards selection employment awards gsk uk ranked fourth britains top employers survey crf international published guardian books best class engineering science shortlisted best graduate employer target awards voted graduates postgraduates received times employers choice research development award based results undergraduate interviews ranked th times top graduate employers survey list organisations new graduates want work first employee benefits award effective use employee financial education workplace awarded employee benefits magazine highly commended pricewaterhousecoopers building public trust awards people reporting category based disclosure strength human capital management employee practices us awarded perfect score per cent corporate equality human rights campaign foundation listed one best places work gay lesbian bisexual transgender equality named one best companies working mother magazine th consecutive year awarded platinum honours workplace lifestyle programmes national business group health identified leader providing healthy workplace promoting healthy lifestyle employees families home responsibility people culture behaviours corporate responsibility report culture behaviours mission improve quality human life enabling people feel better live longer place great emphasis achieve also deliver achievements integrity critical everything gsk spirit defines culture behaviours expect employees culture passionate people patientfocused performance integrity behaviours innovative thinking engaging developing others leading people achieving excellence mission spirit help employees deal new challenges maintain clear focus raise awareness gsk spirit help employees understand adopt principles workshops team meetings presentations awards working individually empower employees empowerment means trusting employees recognising rewarding achieving objectives helps encourage innovation entrepreneurship good employee morale empowered employees take responsibility tasks able prioritise better make decisions quickly effectively achieving culture individual empowerment across gsk motivate staff make us effective improve ability deal challenges home responsibility people culture behaviours corporate responsibility report culture behaviours mission improve quality human life enabling people feel better live longer place great emphasis achieve also deliver achievements integrity critical everything gsk spirit defines culture behaviours expect employees culture passionate people patientfocused performance integrity behaviours innovative thinking engaging developing others leading people achieving excellence mission spirit help employees deal new challenges maintain clear focus raise awareness gsk spirit help employees understand adopt principles workshops team meetings presentations awards working individually empower employees empowerment means trusting employees recognising rewarding achieving objectives helps encourage innovation entrepreneurship good employee morale empowered employees take responsibility tasks able prioritise better make decisions quickly effectively achieving culture individual empowerment across gsk motivate staff make us effective improve ability deal challenges home responsibility people restructuring corporate responsibility report restructuring october announced threeyear operational excellence programme improve effectiveness productivity operations launched programme response challenging business environment forecast would deliver annual pretax savings million february announced expansion restructuring programme realise increased pretax annual savings billion savings restructuring mitigate decline expect gross margin due product mix changes higher percentage sales generated vaccines consumer healthcare emerging markets support investment behind strategic priorities programme includes initiatives streamline manufacturing adapt selling model improve efficiency rd conscious effect programme inevitably employees options exist achieve financial goals preserve jobs everything consult employees representatives implement measures affect outsourcing site closures staff reductions always speak affected employees first except local regulations allow works councils trade unions employee representatives appropriate aim treat employees dignity respect offer wide range support affected employees includes competitive severance package outplacement support assistance finding alternative employment career counselling retraining also work hard maintain morale employees gsk home responsibility people restructuring corporate responsibility report restructuring october announced threeyear operational excellence programme improve effectiveness productivity operations launched programme response challenging business environment forecast would deliver annual pretax savings million february announced expansion restructuring programme realise increased pretax annual savings billion savings restructuring mitigate decline expect gross margin due product mix changes higher percentage sales generated vaccines consumer healthcare emerging markets support investment behind strategic priorities programme includes initiatives streamline manufacturing adapt selling model improve efficiency rd conscious effect programme inevitably employees options exist achieve financial goals preserve jobs everything consult employees representatives implement measures affect outsourcing site closures staff reductions always speak affected employees first except local regulations allow works councils trade unions employee representatives appropriate aim treat employees dignity respect offer wide range support affected employees includes competitive severance package outplacement support assistance finding alternative employment career counselling retraining also work hard maintain morale employees gsk home responsibility people consultation corporate responsibility report consultation europe staff works councils european employee consultation forum meet regularly providing opportunity employees company management discuss key issues developments business also recognise trade unions consultation collective bargaining many countries worldwide european employee consultation forum includes employee representatives eu countries works alongside national consultation processes governed uk law operating subcommittee six employee representatives meet four times year six management representatives receive updates review proposals affecting structure business extraordinary operating subcommittee meetings called need arise whole forum meets year annual meeting receive business update senior gsk executives eddie gray president gsk pharmaceuticals europe business leaders spoke opportunities presented new products rd pipeline challenge growth within europe gsks vision developing consumer healthcare business also discuss issues national consultation forums example uk information consultation ic forum consists gsk elected employee representatives seven managers meets three times year ic forum reviewed amended number gsks uk policies including driving company business education special leave forum also continued review ukwide redeployment selection guidelines redundancy proposals handle pension legislation changes taking effect april forum received presentations strategy senior managers within global manufacturing supply rd home responsibility people consultation corporate responsibility report consultation europe staff works councils european employee consultation forum meet regularly providing opportunity employees company management discuss key issues developments business also recognise trade unions consultation collective bargaining many countries worldwide european employee consultation forum includes employee representatives eu countries works alongside national consultation processes governed uk law operating subcommittee six employee representatives meet four times year six management representatives receive updates review proposals affecting structure business extraordinary operating subcommittee meetings called need arise whole forum meets year annual meeting receive business update senior gsk executives eddie gray president gsk pharmaceuticals europe business leaders spoke opportunities presented new products rd pipeline challenge growth within europe gsks vision developing consumer healthcare business also discuss issues national consultation forums example uk information consultation ic forum consists gsk elected employee representatives seven managers meets three times year ic forum reviewed amended number gsks uk policies including driving company business education special leave forum also continued review ukwide redeployment selection guidelines redundancy proposals handle pension legislation changes taking effect april forum received presentations strategy senior managers within global manufacturing supply rd home responsibility people communication corporate responsibility report communication approach performance plans good twoway communication employees vital aim keep everyone well informed involved company activities provide opportunities get feedback internal communications channels include facetoface communications example town hall style meetings lunches corporate executive team conferences team meetings gsk experience programme new starters mandatory twoday induction programme teaches new employees uk us gsk feedback indicates programme helps feel valued involved countries arrange induction programmes locally spirit internal magazine print distribute copies throughout company four times year spirit also published intranet mygsk reaching broader audience print alone allowing employees easily give us feedback articles read global intranet site mygsk provides updates company industry news large range information resources employees mygsk several features employees including myceo dedicated part intranet staff pose questions chief executive officer ceo members corporate executive team employees ask approximately questions month ceos answers posted regularly site ambassador intranet community provides reference materials information tools employees use reference including presentations facts figures interactive intranet feature story allows employees share stories inspires impacts work company email cascade system messages sent business leaders share employees example details latest financial results surveys enable us monitor employee engagement help us track impact internal communications home responsibility people communication corporate responsibility report communication approach performance plans good twoway communication employees vital aim keep everyone well informed involved company activities provide opportunities get feedback internal communications channels include facetoface communications example town hall style meetings lunches corporate executive team conferences team meetings gsk experience programme new starters mandatory twoday induction programme teaches new employees uk us gsk feedback indicates programme helps feel valued involved countries arrange induction programmes locally spirit internal magazine print distribute copies throughout company four times year spirit also published intranet mygsk reaching broader audience print alone allowing employees easily give us feedback articles read global intranet site mygsk provides updates company industry news large range information resources employees mygsk several features employees including myceo dedicated part intranet staff pose questions chief executive officer ceo members corporate executive team employees ask approximately questions month ceos answers posted regularly site ambassador intranet community provides reference materials information tools employees use reference including presentations facts figures interactive intranet feature story allows employees share stories inspires impacts work company email cascade system messages sent business leaders share employees example details latest financial results surveys enable us monitor employee engagement help us track impact internal communications home responsibility people communication corporate responsibility report communication approach performance plans internal communications ways communicated employees ceo communications ceo designate andrew witty held nine employee forums employees across world help inform strategic priorities gsk ceo andrew witty hosted three global employee broadcasts recorded live front employee audience broadcasts available employees view throughout year video demand via online video library gsktv ceo advisory board also established act informal sounding board ideas board filled employees across company communicating senior leaders held meetings senior leaders april september support alignment different parts business new strategic priorities attended leaders respectively online communications launched several new features company intranet mygsk including new myceo discussion forum called lets talk designed support transition new ceo received comments employees may december employees also sent questions myceo qa facility online version employee magazine spirit september also redesigned magazine print per cent recycled chlorinefree paper gsktv online multimedia library allows employees view download range videos across organisation new internal website provides employees information event flu pandemic read gsks flu pandemic preparedness business communications business units communicate directly employees intranet town hall meetings facetoface meetings broadcasts video messages many members corporate executive team also run live web chats host qa sessions intranet communities ensuring aware areas concern within regions business units functional areas employee surveys conducted global leadership surveys every two years track management views range issues next survey run measure managers perceptions progress towards achieving new strategic priorities introduced plans continually reviewing effectiveness communications improve employees encouraged ask questions comment information provide thep age communication channels use technology updated easier us encourage direct communication discussion employees expand use technology social media tools encourage greater collaboration communication across gsk breaking traditional communication barriershome responsibility people communication corporate responsibility report communication approach performance plans internal communications ways communicated employees ceo communications ceo designate andrew witty held nine employee forums employees across world help inform strategic priorities gsk ceo andrew witty hosted three global employee broadcasts recorded live front employee audience broadcasts available employees view throughout year video demand via online video library gsktv ceo advisory board also established act informal sounding board ideas board filled employees across company communicating senior leaders held meetings senior leaders april september support alignment different parts business new strategic priorities attended leaders respectively online communications launched several new features company intranet mygsk including new myceo discussion forum called lets talk designed support transition new ceo received comments employees may december employees also sent questions myceo qa facility online version employee magazine spirit september also redesigned magazine print per cent recycled chlorinefree paper gsktv online multimedia library allows employees view download range videos across organisation new internal website provides employees information event flu pandemic read gsks flu pandemic preparedness business communications business units communicate directly employees intranet town hall meetings facetoface meetings broadcasts video messages many members corporate executive team also run live web chats host qa sessions intranet communities ensuring aware areas concern within regions business units functional areas employee surveys conducted global leadership surveys every two years track management views range issues next survey run measure managers perceptions progress towards achieving new strategic priorities introduced plans continually reviewing effectiveness communications improve employees encouraged ask questions comment information provide communication channels use technology updated easier us encourage direct communication discussion employees expand use technology social media tools encourage greater collaboration communication across gsk breaking traditional communication barriers home responsibility people communication corporate responsibility report communication approach performance plans internal communications ways communicated employees ceo communications ceo designate andrew witty held nine employee forums employees across world help inform strategic priorities gsk ceo andrew witty hosted three global employee broadcasts recorded live front employee audience broadcasts available employees view throughout year video demand via online video library gsktv ceo advisory board also established act informal sounding board ideas board filled employees across company communicating senior leaders held meetings senior leaders april september support alignment different parts business new strategic priorities attended leaders respectively online communications launched several new features company intranet mygsk including new myceo discussion forum called lets talk designed support transition new ceo received comments employees may december employees also sent questions myceo qa facility online version employee magazine spirit september also redesigned magazine print per cent recycled chlorinefree paper gsktv online multimedia library allows employees view download range videos across organisation new internal website provides employees information event flu pandemic read gsks flu pandemic preparedness business communications business units communicate directly employees intranet town hall meetings facetoface meetings broadcasts video messages many members corporate executive team also run live web chats host qa sessions intranet communities ensuring aware areas concern within regions business units functional areas employee surveys conducted global leadership surveys every two years track management views range issues next survey run measure managers perceptions progress towards achieving new strategic priorities introduced plans continually reviewing effectiveness communications improve employees encouraged ask questions comment information provide communication channels use technology updated easier us encourage direct communication discussion employees expand use technology social media tools encourage greater collaboration communication across gsk breaking traditional communication barriers home responsibility people diversity inclusion corporate responsibility report diversity inclusion approach performance plans gsk recognise value different perspectives experiences bring gsk aim recruit diverse range employees global workforce respect employees include talented people workforce regardless race gender sexuality age religion belief disability require medical testing prerequisite employment aim adopt inclusive work practices create environment employees feel individually collectively empowered develop contribute business full potential diverse inclusive business helps gsk recruit retain best people job also enables us understand meet needs diverse patients customers consumers global diversity policy commitment set global diversity policy corporate executive team endorses policy related activities annual multicultural marketing diversity awards employees expected comply policy allegations discrimination taken extremely seriously fully investigated findings acted upon business diversity champions employees promote diversity issues uk us diversity inclusion di steering committees made human resources managers line managers specific responsibility diversity inclusion committees run diversity awareness campaigns training sessions gsk also monitors reports gender diversity management uk us employee networks employee networks important element diversity inclusion programme support professional growth provide forum people similar interests backgrounds meet discuss shared experiences address problem areas helps engage empower employees networks important source expertise diversity issues gsk managers engage networks improve understanding employees different backgrounds networks also help media marketing teams understand diverse customers stakeholders gsk networks asian african american hispanic gay lesbian bisexual transgender employees also networks mature employees employees early career women leadership veterans network executive sponsor helps set achieve goals obtain resources promote networks objectives among senior management disability work ensure people disabilities access full range recruitment career opportunities gsk uk partner employers forum disability strive disability confident organisation disability confidence concept developed employers forum describe companies create culture inclusion remove barriers access make adjustments enable individuals disabilities contribute employees customers partners hold two ticks symbol jobcentreplus demonstrates gsks commitment employing disabled people read information approach diversity inclusion positively managing hiv workplace discriminate prospective current employees based hiv status require testing prerequisite employment maintain medical confidentiality times provide information training staff hivaids prevention addressing problems stigma relating disease provide hivaids testing voluntary counselling treatment programmes employees families countries easily available via government healthcare programmes also offer preferentially priced antiretrovirals equivalent notforprofit arrangements employers subsahara africa workplace clinicshome responsibility people diversity inclusion corporate responsibility report diversity inclusion approach performance plans gsk recognise value different perspectives experiences bring gsk aim recruit diverse range employees global workforce respect employees include talented people workforce regardless race gender sexuality age religion belief disability require medical testing prerequisite employment aim adopt inclusive work practices create environment employees feel individually collectively empowered develop contribute business full potential diverse inclusive business helps gsk recruit retain best people job also enables us understand meet needs diverse patients customers consumers global diversity policy commitment set global diversity policy corporate executive team endorses policy related activities annual multicultural marketing diversity awards employees expected comply policy allegations discrimination taken extremely seriously fully investigated findings acted upon business diversity champions employees promote diversity issues uk us diversity inclusion di steering committees made human resources managers line managers specific responsibility diversity inclusion committees run diversity awareness campaigns training sessions gsk also monitors reports gender diversity management uk us employee networks employee networks important element diversity inclusion programme support professional growth provide forum people similar interests backgrounds meet discuss shared experiences address problem areas helps engage empower employees networks important source expertise diversity issues gsk managers engage networks improve understanding employees different backgrounds networks also help media marketing teams understand diverse customers stakeholders gsk networks asian african american hispanic gay lesbian bisexual transgender employees also networks mature employees employees early career women leadership veterans network executive sponsor helps set achieve goals obtain resources promote networks objectives among senior management disability work ensure people disabilities access full range recruitment career opportunities gsk uk partner employers forum disability strive disability confident organisation disability confidence concept developed employers forum describe companies create culture inclusion remove barriers access make adjustments enable individuals disabilities contribute employees customers partners hold two ticks symbol jobcentreplus demonstrates gsks commitment employing disabled people read information approach diversity inclusion positively managing hiv workplace discriminate prospective current employees based hiv status require testing prerequisite employment maintain medical confidentiality times provide information training staff hivaids prevention addressing problems stigma relating disease provide hivaids testing voluntary counselling treatment programmes employees families countries easily available via government healthcare programmes also offer preferentially priced antiretrovirals equivalent notforprofit arrangements employers subsahara africa workplace clinics home responsibility people diversity inclusion corporate responsibility report diversity inclusion approach performance plans gsk recognise value different perspectives experiences bring gsk aim recruit diverse range employees global workforce respect employees include talented people workforce regardless race gender sexuality age religion belief disability require medical testing prerequisite employment aim adopt inclusive work practices create environment employees feel individually collectively empowered develop contribute business full potential diverse inclusive business helps gsk recruit retain best people job also enables us understand meet needs diverse patients customers consumers global diversity policy commitment set global diversity policy corporate executive team endorses policy related activities annual multicultural marketing diversity awards employees expected comply policy allegations discrimination taken extremely seriously fully investigated findings acted upon business diversity champions employees promote diversity issues uk us diversity inclusion di steering committees made human resources managers line managers specific responsibility diversity inclusion committees run diversity awareness campaigns training sessions gsk also monitors reports gender diversity management uk us employee networks employee networks important element diversity inclusion programme support professional growth provide forum people similar interests backgrounds meet discuss shared experiences address problem areas helps engage empower employees networks important source expertise diversity issues gsk managers engage networks improve understanding employees different backgrounds networks also help media marketing teams understand diverse customers stakeholders gsk networks asian african american hispanic gay lesbian bisexual transgender employees also networks mature employees employees early career women leadership veterans network executive sponsor helps set achieve goals obtain resources promote networks objectives among senior management disability work ensure people disabilities access full range recruitment career opportunities gsk uk partner employers forum disability strive disability confident organisation disability confidence concept developed employers forum describe companies create culture inclusion remove barriers access make adjustments enable individuals disabilities contribute employees customers partners hold two ticks symbol jobcentreplus demonstrates gsks commitment employing disabled people read information approach diversity inclusion positively managing hiv workplace discriminate prospective current employees based hiv status require testing prerequisite employment maintain medical confidentiality times provide information training staff hivaids prevention addressing problems stigma relating disease provide hivaids testing voluntary counselling treatment programmes employees families countries easily available via government healthcare programmes also offer preferentially priced antiretrovirals equivalent notforprofit arrangements employers subsahara africa workplace clinics home responsibility people diversity inclusion corporate responsibility report diversity inclusion approach performance plans gender diversity pleased percentage women management increased incrementally last five years however still lot room improvement gender diversity management per cent positions held women worldwide corporate executive team senior vice presidents vice presidents director grade manager grade management positions gender equality workplace affected many factors external gsk including requirements family life flexible working policies help employees balance demands work home life particularly beneficial caring family responsibilities example offer parttime working job sharing remote working read programmes encouraging women science women science events scientific womens scholarship programme ethnic diversity us minorities defined blacks hispanics asians pacific islanders american indians alaskan natives made per cent workforce compared per cent per cent per cent uk ethnic minorities accounted per cent employees compared per cent per cent per cent ethnic minorities accounted per cent uk population england wales last uk census use uk commission racial equality definition ethnic minorities includes anyone identify white british means people identified white irish north american european included minorities also measure diversity uk counting number employees define non white per cent employees defined nonwhite compared per cent per cent per cent ethnic minorities us ethnic minorities uk multicultural marketing diversity awards annual multicultural marketing diversity awards aim inspire employees find creative ways reach broader range potential employees customers communities awards given categories employee attraction development retention multicultural marketing sales community outreach diversity ambassador awards recognised project teams five individuals awardwinning projects included initiative four years increased representation diverse subjects us clinical trials per cent per cent slightly higher overall us minority population literacy programme teach indian manufacturing employees sign names official documents instead using thumb print read case study literacy programme plans plan simplify approach diversity inclusion ensuring maximises employee empowermenthome responsibility people diversity inclusion corporate responsibility report diversity inclusion approach performance plans gender diversity pleased percentage women management increased incrementally last five years however still lot room improvement gender diversity management per cent positions held women worldwide corporate executive team senior vice presidents vice presidents director grade manager grade management positions gender equality workplace affected many factors external gsk including requirements family life flexible working policies help employees balance demands work home life particularly beneficial caring family responsibilities example offer parttime working job sharing remote working read programmes encouraging women science women science events scientific womens scholarship programme ethnic diversity us minorities defined blacks hispanics asians pacific islanders american indians alaskan natives made per cent workforce compared per cent per cent per cent uk ethnic minorities accounted per cent employees compared per cent per cent per cent ethnic minorities accounted per cent uk population england wales last uk census use uk commission racial equality definition ethnic minorities includes anyone identify white british means people identified white irish north american european included minorities also measure diversity uk counting number employees define non white per cent employees defined nonwhite compared per cent per cent per cent ethnic minorities us ethnic minorities uk multicultural marketing diversity awards annual multicultural marketing diversity awards aim inspire employees find creative ways reach broader range potential employees customers communities awards given categories employee attraction development retention multicultural marketing sales community outreach diversity ambassador awards recognised project teams five individuals awardwinning projects included initiative four years increased representation diverse subjects us clinical trials per cent per cent slightly higher overall us minority population literacy programme teach indian manufacturing employees sign names official documents instead using thumb print read case study literacy programme plans plan simplify approach diversity inclusion ensuring maximises employee empowerment home responsibility people diversity inclusion corporate responsibility report diversity inclusion approach performance plans gender diversity pleased percentage women management increased incrementally last five years however still lot room improvement gender diversity management per cent positions held women worldwide corporate executive team senior vice presidents vice presidents director grade manager grade management positions gender equality workplace affected many factors external gsk including requirements family life flexible working policies help employees balance demands work home life particularly beneficial caring family responsibilities example offer parttime working job sharing remote working read programmes encouraging women science women science events scientific womens scholarship programme ethnic diversity us minorities defined blacks hispanics asians pacific islanders american indians alaskan natives made per cent workforce compared per cent per cent per cent uk ethnic minorities accounted per cent employees compared per cent per cent per cent ethnic minorities accounted per cent uk population england wales last uk census use uk commission racial equality definition ethnic minorities includes anyone identify white british means people identified white irish north american european included minorities also measure diversity uk counting number employees define non white per cent employees defined nonwhite compared per cent per cent per cent ethnic minorities us ethnic minorities uk multicultural marketing diversity awards annual multicultural marketing diversity awards aim inspire employees find creative ways reach broader range potential employees customers communities awards given categories employee attraction development retention multicultural marketing sales community outreach diversity ambassador awards recognised project teams five individuals awardwinning projects included initiative four years increased representation diverse subjects us clinical trials per cent per cent slightly higher overall us minority population literacy programme teach indian manufacturing employees sign names official documents instead using thumb print read case study literacy programme plans plan simplify approach diversity inclusion ensuring maximises employee empowerment home responsibility people training development corporate responsibility report training development approach performance plans training development opportunities help employees feel valued engaged work gsk provides workrelated training courses employees leadership training managers focus providing people right behaviours expertise jobs skills needed apply knowledge effectively goal individual achieve potential contribute fully company performance conduct regular appraisals identify training needs help employees set achieve development objectives operate degree assessments top managers ensure receive objective feedback performance employees manage colleagues work well manager training carried within business function online example mylearning intranet site us uk also offer project secondments help employees learn new skills leadership development identify highperforming employees potential leaders business function annual talent management cycle managers accountable developing talent successors top priority every leader process ensures diverse highperforming talent required deliver business strategy reflect global growth gsk talented people participate leadership programmes connect senior management programmes chief executive forum leadership framework helps employees fulfil potential become leaders field contribute fully business performance specifically helps develop behaviours distinguish highperforming leaders include innovative thinking engaging developing others leading people achieving excellence work understand behaviour take personal responsibility actions continue perform integrity enhance expertise including technical functional skills broader knowledge contribute directly gsks overall performance likely unique position role function employee effectively use apply processes practices within gsk also provide extensive health safety environment training employees home responsibility people training development corporate responsibility report training development approach performance plans training development opportunities help employees feel valued engaged work gsk provides workrelated training courses employees leadership training managers focus providing people right behaviours expertise jobs skills needed apply knowledge effectively goal individual achieve potential contribute fully company performance conduct regular appraisals identify training needs help employees set achieve development objectives operate degree assessments top managers ensure receive objective feedback performance employees manage colleagues work well manager training carried within business function online example mylearning intranet site us uk also offer project secondments help employees learn new skills leadership development identify highperforming employees potential leaders business function annual talent management cycle managers accountable developing talent successors top priority every leader process ensures diverse highperforming talent required deliver business strategy reflect global growth gsk talented people participate leadership programmes connect senior management programmes chief executive forum leadership framework helps employees fulfil potential become leaders field contribute fully business performance specifically helps develop behaviours distinguish highperforming leaders include innovative thinking engaging developing others leading people achieving excellence work understand behaviour take personal responsibility actions continue perform integrity enhance expertise including technical functional skills broader knowledge contribute directly gsks overall performance likely unique position role function employee effectively use apply processes practices within gsk also provide extensive health safety environment training employees home responsibility people training development corporate responsibility report training development approach performance plans majority employees receive annual performance appraisal performance development planning pdp programme compliance requirement measured local level know twothirds employees received appraisal pdp programme assesses well employees implemented gsk business principles work appraisals impact bonus payments future career development focused embedding leadership framework included following training initiatives hot topics training focused lead times transformational change nearly managers senior leaders attended workshops teach gsk leaders importance coaching staff techniques effectively managers took part workshops online development resources available englishspeaking employees providing variety steps take build leadership skills also offered learning programmes gsk employees via online learning management system plans leadership organisation development function work support gsks strategic priorities plans include forecasting delivering capabilities needed future growth success gsk addition leadership development continue area focus including refining behaviours necessary successful leadership supporting prescribed learning development opportunities experiences home responsibility people training development corporate responsibility report training development approach performance plans majority employees receive annual performance appraisal performance development planning pdp programme compliance requirement measured local level know twothirds employees received appraisal pdp programme assesses well employees implemented gsk business principles work appraisals impact bonus payments future career development focused embedding leadership framework included following training initiatives hot topics training focused lead times transformational change nearly managers senior leaders attended workshops teach gsk leaders importance coaching staff techniques effectively managers took part workshops online development resources available englishspeaking employees providing variety steps take build leadership skills also offered learning programmes gsk employees via online learning management system plans leadership organisation development function work support gsks strategic priorities plans include forecasting delivering capabilities needed future growth success gsk addition leadership development continue area focus including refining behaviours necessary successful leadership supporting prescribed learning development opportunities experiences home responsibility people reward recognition corporate responsibility report reward recognition offer employees competitive salary based industry benchmarks well performancerelated incentives benefits helps us attract retain best people particularly reward employees innovation good performance reward leaders empower staff pay strategy managers based programme called totalreward helps us recognise good performance enables managers share gsks success use feedback managers identify types reward prefer components totalreward include cash including salary bonuses incentives including longterm incentives eligible employees recognition awards salaries allocated within defined bands different employment levels savings choices pension provision share schemes lifestyle benefits example healthcare childcare support employee car ownership programmes totalreward applies gsk managers around world although component parts employees package differ country accordance local legislation best practice share ownership share ownership schemes help create culture ownership among employees countries share ownership opportunities exist open employees high level participation example uk per cent employees participate sharesave scheme per cent sharereward scheme home responsibility people reward recognition corporate responsibility report reward recognition offer employees competitive salary based industry benchmarks well performancerelated incentives benefits helps us attract retain best people particularly reward employees innovation good performance reward leaders empower staff pay strategy managers based programme called totalreward helps us recognise good performance enables managers share gsks success use feedback managers identify types reward prefer components totalreward include cash including salary bonuses incentives including longterm incentives eligible employees recognition awards salaries allocated within defined bands different employment levels savings choices pension provision share schemes lifestyle benefits example healthcare childcare support employee car ownership programmes totalreward applies gsk managers around world although component parts employees package differ country accordance local legislation best practice share ownership share ownership schemes help create culture ownership among employees countries share ownership opportunities exist open employees high level participation example uk per cent employees participate sharesave scheme per cent sharereward scheme home responsibility people health safety wellbeing corporate responsibility report health safety wellbeing keeping employees contractors healthy safe priority rigorous management system reduces risk harm employees helps stay healthy part broader environment health safety sustainability ehss programme well right thing improves business performance increasing attendance improving productivity reducing healthcare insurance costs home responsibility people health safety wellbeing corporate responsibility report health safety wellbeing keeping employees contractors healthy safe priority rigorous management system reduces risk harm employees helps stay healthy part broader environment health safety sustainability ehss programme well right thing improves business performance increasing attendance improving productivity reducing healthcare insurance costs home responsibility people health safety wellbeing health safety management corporate responsibility report health safety management manage health safety integrated environment health safety sustainability ehss management system incorporates ehs sustainability vision policy associated standards ehss plan excellence includes strategy improving ehss performance employ health safety professionals across sites within business units global level manage health safety risks across gsk read ehss management system occupational health safety data independently assured assurance include personal health wellbeing programmes data audits performance part overall environment health safety sustainability audit programme conduct occupational health safety audits sites every one four years frequency depends current risks past performance carry frequent visits sites based degree risk site health safety performance issues raised previous audits audit results presented audit committee board directors occupational health safety target link environmental sustainabilityplan excellencetargets reduce reportable injuries illnesses five per cent year placed within top quartile comparable industry ratings systematically assess manage occupational health safety risks performance incidents happen identify root causes take action prevent reoccurrence believe addressing causes incidents help eliminate risks hazards prevent future occupational injuries illnesses audited gsk sites implementation occupational health safety standards part overall environment health safety sustainability audits average audit score per cent compares target per cent best performance seen fire prevention site management commitment occupational health safety investigation reporting injuries illnesses emergency planning response sites generally weakest resilience mental wellbeing control chemical agents use work equipment risk assessment permit work systems noise control ergonomics auditors found two critical findings indicate high probability incidents potentially serious consequences first related deficiencies controlling risk falls construction project second related risk fire inadequate management highly flammable liquids issues monitored ensure appropriate actions taken mitigate risks ensure ongoing compliance one active pharmaceutical ingredients manufacturing sites fined uk regulator hse process safety incident occurred serious explosion occurred irvine uk site involving placebo batch used test plant conditions controls two operators injured event thoroughly investigated learnings shared improvements made reported corporate responsibility report site us received fine south carolina state occupational safety health administration osha violations forklift regulations concerns addressed site ohsas certification twentysix pharmaceuticals consumer healthcare manufacturing sites one consumer healthcare rd site certified international health safety standard ohsas set goal manufacturing sites jointly certified ohsas environmental standard iso end three new sites certified certified sites argentina australia brazil china egypt france germany india japan kenya mexico panama philippines poland saudi arabia spain turkey us ukhome responsibility people health safety wellbeing health safety management corporate responsibility report health safety management manage health safety integrated environment health safety sustainability ehss management system incorporates ehs sustainability vision policy associated standards ehss plan excellence includes strategy improving ehss performance employ health safety professionals across sites within business units global level manage health safety risks across gsk read ehss management system occupational health safety data independently assured assurance include personal health wellbeing programmes data audits performance part overall environment health safety sustainability audit programme conduct occupational health safety audits sites every one four years frequency depends current risks past performance carry frequent visits sites based degree risk site health safety performance issues raised previous audits audit results presented audit committee board directors occupational health safety target link environmental sustainabilityplan excellencetargets reduce reportable injuries illnesses five per cent year placed within top quartile comparable industry ratings systematically assess manage occupational health safety risks performance incidents happen identify root causes take action prevent reoccurrence believe addressing causes incidents help eliminate risks hazards prevent future occupational injuries illnesses audited gsk sites implementation occupational health safety standards part overall environment health safety sustainability audits average audit score per cent compares target per cent best performance seen fire prevention site management commitment occupational health safety investigation reporting injuries illnesses emergency planning response sites generally weakest resilience mental wellbeing control chemical agents use work equipment risk assessment permit work systems noise control ergonomics auditors found two critical findings indicate high probability incidents potentially serious consequences first related deficiencies controlling risk falls construction project second related risk fire inadequate management highly flammable liquids issues monitored ensure appropriate actions taken mitigate risks ensure ongoing compliance one active pharmaceutical ingredients manufacturing sites fined uk regulator hse process safety incident occurred serious explosion occurred irvine uk site involving placebo batch used test plant conditions controls two operators injured event thoroughly investigated learnings shared improvements made reported corporate responsibility report site us received fine south carolina state occupational safety health administration osha violations forklift regulations concerns addressed site ohsas certification twentysix pharmaceuticals consumer healthcare manufacturing sites one consumer healthcare rd site certified international health safety standard ohsas set goal manufacturing sites jointly certified ohsas environmental standard iso end three new sites certified certified sites argentina australia brazil china egypt france germany india japan kenya mexico panama philippines poland saudi arabia spain turkey us uk home responsibility people health safety wellbeing health safety management corporate responsibility report health safety management manage health safety integrated environment health safety sustainability ehss management system incorporates ehs sustainability vision policy associated standards ehss plan excellence includes strategy improving ehss performance employ health safety professionals across sites within business units global level manage health safety risks across gsk read ehss management system occupational health safety data independently assured assurance include personal health wellbeing programmes data audits performance part overall environment health safety sustainability audit programme conduct occupational health safety audits sites every one four years frequency depends current risks past performance carry frequent visits sites based degree risk site health safety performance issues raised previous audits audit results presented audit committee board directors occupational health safety target link environmental sustainabilityplan excellencetargets reduce reportable injuries illnesses five per cent year placed within top quartile comparable industry ratings systematically assess manage occupational health safety risks performance incidents happen identify root causes take action prevent reoccurrence believe addressing causes incidents help eliminate risks hazards prevent future occupational injuries illnesses audited gsk sites implementation occupational health safety standards part overall environment health safety sustainability audits average audit score per cent compares target per cent best performance seen fire prevention site management commitment occupational health safety investigation reporting injuries illnesses emergency planning response sites generally weakest resilience mental wellbeing control chemical agents use work equipment risk assessment permit work systems noise control ergonomics auditors found two critical findings indicate high probability incidents potentially serious consequences first related deficiencies controlling risk falls construction project second related risk fire inadequate management highly flammable liquids issues monitored ensure appropriate actions taken mitigate risks ensure ongoing compliance one active pharmaceutical ingredients manufacturing sites fined uk regulator hse process safety incident occurred serious explosion occurred irvine uk site involving placebo batch used test plant conditions controls two operators injured event thoroughly investigated learnings shared improvements made reported corporate responsibility report site us received fine south carolina state occupational safety health administration osha violations forklift regulations concerns addressed site ohsas certification twentysix pharmaceuticals consumer healthcare manufacturing sites one consumer healthcare rd site certified international health safety standard ohsas set goal manufacturing sites jointly certified ohsas environmental standard iso end three new sites certified certified sites argentina australia brazil china egypt france germany india japan kenya mexico panama philippines poland saudi arabia spain turkey us uk home responsibility people health safety wellbeing hazard assessment communication corporate responsibility report hazard assessment communication assessment understanding intrinsic hazards materials produce use research development manufacturing important first step enable us effectively manage health safety risks prevent damage environment occupational toxicologists environmental scientists assess materials hazards throughout product development increasingly use computerbased modelling vitro methods instead animal tests use hazard information assign occupational environmental exposure limits help guide design systems used protect employees health protect environment chemical contamination hazard assessments help us meet regulatory requirements new eu registration evaluation authorisation chemicals reach legislation communication provide hazard information enable employees contract manufacturing partners customers handle dispose materials products safely develop safety data sheets new materials products progress development process ensures health safety information readily available staff handle chemicals customers product launched distribute safety data sheets using webbased system provides safety information nearly gsk materials key manufacturing process chemicals also includes safety data sheets pharmaceutical biological consumer healthcare products information regularly updated available english french german italian portuguese spanish safety data sheets products available website also communicated directly customers via fax demand customer response centres safe transport materials part normal business operations transport materials require special handling chemicals biological radioactive materials finished products network highly trained employees oversee transportationrelated activities ensure materials transported safe effective manner complies national international laws conventions ensures employees public environment kept safe use two systems support tracking classification emergency information transportation chemical biological radioactive materials hazclass system available use rd sites manufacturing sites use sap system manage transport materials products understanding fire explosion risks inhouse fire explosion laboratory conducts tests determine fire explosion properties materials handled research development manufacturing work primarily driven requirements eu regulations explosive atmospheres directive ec atex manufacturing sites receive hazard data laboratories undertake risk assessments design work practices eliminate reduce risk fires dust explosions home responsibility people health safety wellbeing hazard assessment communication corporate responsibility report hazard assessment communication assessment understanding intrinsic hazards materials produce use research development manufacturing important first step enable us effectively manage health safety risks prevent damage environment occupational toxicologists environmental scientists assess materials hazards throughout product development increasingly use computerbased modelling vitro methods instead animal tests use hazard information assign occupational environmental exposure limits help guide design systems used protect employees health protect environment chemical contamination hazard assessments help us meet regulatory requirements new eu registration evaluation authorisation chemicals reach legislation communication provide hazard information enable employees contract manufacturing partners customers handle dispose materials products safely develop safety data sheets new materials products progress development process ensures health safety information readily available staff handle chemicals customers product launched distribute safety data sheets using webbased system provides safety information nearly gsk materials key manufacturing process chemicals also includes safety data sheets pharmaceutical biological consumer healthcare products information regularly updated available english french german italian portuguese spanish safety data sheets products available website also communicated directly customers via fax demand customer response centres safe transport materials part normal business operations transport materials require special handling chemicals biological radioactive materials finished products network highly trained employees oversee transportationrelated activities ensure materials transported safe effective manner complies national international laws conventions ensures employees public environment kept safe use two systems support tracking classification emergency information transportation chemical biological radioactive materials hazclass system available use rd sites manufacturing sites use sap system manage transport materials products understanding fire explosion risks inhouse fire explosion laboratory conducts tests determine fire explosion properties materials handled research development manufacturing work primarily driven requirements eu regulations explosive atmospheres directive ec atex manufacturing sites receive hazard data laboratories undertake risk assessments design work practices eliminate reduce risk fires dust explosions home responsibility people health safety wellbeing hazard assessment communication corporate responsibility report hazard assessment communication assessment understanding intrinsic hazards materials produce use research development manufacturing important first step enable us effectively manage health safety risks prevent damage environment occupational toxicologists environmental scientists assess materials hazards throughout product development increasingly use computerbased modelling vitro methods instead animal tests use hazard information assign occupational environmental exposure limits help guide design systems used protect employees health protect environment chemical contamination hazard assessments help us meet regulatory requirements new eu registration evaluation authorisation chemicals reach legislation communication provide hazard information enable employees contract manufacturing partners customers handle dispose materials products safely develop safety data sheets new materials products progress development process ensures health safety information readily available staff handle chemicals customers product launched distribute safety data sheets using webbased system provides safety information nearly gsk materials key manufacturing process chemicals also includes safety data sheets pharmaceutical biological consumer healthcare products information regularly updated available english french german italian portuguese spanish safety data sheets products available website also communicated directly customers via fax demand customer response centres safe transport materials part normal business operations transport materials require special handling chemicals biological radioactive materials finished products network highly trained employees oversee transportationrelated activities ensure materials transported safe effective manner complies national international laws conventions ensures employees public environment kept safe use two systems support tracking classification emergency information transportation chemical biological radioactive materials hazclass system available use rd sites manufacturing sites use sap system manage transport materials products understanding fire explosion risks inhouse fire explosion laboratory conducts tests determine fire explosion properties materials handled research development manufacturing work primarily driven requirements eu regulations explosive atmospheres directive ec atex manufacturing sites receive hazard data laboratories undertake risk assessments design work practices eliminate reduce risk fires dust explosions home responsibility people health safety wellbeing safety programmes corporate responsibility report safety programmes operate number programmes keep employees contractors safe chemical exposure rigorous procedures controls place ensure employees involved developing manufacturing products protected exposure chemicals goal make per cent operations involving handling hazardous compounds respirator free means employees need wear respiratory protective equipment routine production tasks instead sites install technology prevents release hazardous compounds work environment example installed contained powder transfer systems glovebox technology pilot plant facility cork ireland special containment system new penicillin facility pakistan also developed proprietary manufacturing technology greatly reduces operator exposure medicines manufactured gsk site monitors air quality assess exposure hazardous compounds implements controls protect employees achieve respirator free goal occupational hygienists employee health staff engineers work together site regional global levels reduce employees exposure chemicals end per cent operations achieved respirator free level engineering control based least occupational hygiene monitoring results continue upgrade engineering controls achieve respirator free levels control situations engineering controls possible employees remain protected appropriate respiratory protective equipment process safety many products begin formulation processing hazardous materials flammable solvents combustible powders scientists look opportunities eliminate use hazardous materials green chemistry green technology programmes substitution elimination option process safety programme aims ensure safety built manufacturing research development processes employees receive training understand risks implement appropriate controls engineers use online assessment system develop safer processes plant maintenance strategies share hazard information control strategies across gsk reviewed updated process safety strategy two employees injured explosion factory irvine uk using results review continuing update integrate process safety management system psms ehss management systems gsk sites includes design code containing new engineering standards process safety assessments new engineering standards gap analyses upgraded risk assessments remediation processes process safety indicators steps embed process safety overall safety culture new training competence programmes process safety tools also appointed new director process safety safety engineering safety engineering programme focuses improving construction plant safety ensuring effective emergency response systems developed safety engineering guides managing risk fire explosion provide guidance machine guarding electrical hazards webbased guides provide standardised approach managing safety risks across gsk also ensure safety built maintained sites worldwide following programmes risk assessment control processes construction contractor safety programme capital project ehs review process emergency response programmes ergonomics musculoskeletal illnesses repetitive strain injuries leading causes time away work corporate executive team set target reduce number illnesses injuries five per cent year good workplace job design known ergonomics helps employees jobs effectively reducing risk musculoskeletal illnesses injuries ergonomic improvement teams working across gsk businesses assess manage ergonomic risks existing operations planned projects teams include members areas manufacturing quality safety health medical services perform work teams work together identify risks develop solutions share best practice globally dedicated ergonomics community intranet addition trained facilitators throughout business help manage computerbased ergonomic risk assessments employees assessments identify steps reduce discomfort injury relating computer use information ergonomics best practice also available employees intranet site efforts contributed per cent improvement ergonomicsrelated injury illness short target annual five percent improvement equivalent per cent improvement order meet exceed target increase effort resources area cost productivity gains manufacturing operations example nabha site india manual handling task improved resulting simplified work process reduced risk injury reduction number employees needed perform task three people one person allowed two workers focus tasks reducing risk injury workers improved audit scores implementation ergonomic improvement processes example kuala lumpur improved ergonomics management risks score per cent per cent result implementing ergonomics improvement process improved overall audit score significant impacts introduction new ergonomics improvement teams example tianjin facility china six major ergonomic improvements initiated new team first months resulted per cent reduction reports discomfortinjury improved morale gsk ergonomic improvement teams given special recognition european safety health council part europe widefocus improving manual handling internal recognition global ergonomic community team process example new ways working gsk shared global resources spanning functions businesses cultures team award cross sector multicultural marketing diversity awards driver safety sales representatives spend significant amounts time driving therefore risk involved road traffic incidents aim reduce risk much possible worldwide driver safety programme includes instructions guidelines driver training vehicle selection risk assessment accident reporting motorbike rider safety manual employees countries provide motorbikes scooters around threequarters gsks commercial businesses extensive driver safety programmes place including driving licence checks guidance use mobile phones safety training tracking reporting incidents plan extend sites common cause fatalities serious injuries remains driving accidents per cent injuries lost time due motor vehicle accidents per cent injuries without lost time two road traffic accidents caused death two employees see fatalities serious injuries defibrillator programme six people resuscitated using automated external defibrillators aeds aed safe easy use portable medical device analyses heart rhythm delivers electric shocks victims ventricular fibrillation order restore victims heart rhythm normal began expanding number sites aeds used saving several lives us uk key personnel trained use aeds emergency situations equipment installed estimated gsk sites belgium brazil canada egypt france germany india italy japan mexico puerto rico singapore south africa spain us used risk assessment decide sites aeds based factors including heart disease risks among employees hazards site chemicals energised circuits could cause cardiac arrest ambulance response timeshome responsibility people health safety wellbeing safety programmes corporate responsibility report safety programmes operate number programmes keep employees contractors safe chemical exposure rigorous procedures controls place ensure employees involved developing manufacturing products protected exposure chemicals goal make per cent operations involving handling hazardous compounds respirator free means employees need wear respiratory protective equipment routine production tasks instead sites install technology prevents release hazardous compounds work environment example installed contained powder transfer systems glovebox technology pilot plant facility cork ireland special containment system new penicillin facility pakistan also developed proprietary manufacturing technology greatly reduces operator exposure medicines manufactured gsk site monitors air quality assess exposure hazardous compounds implements controls protect employees achieve respirator free goal occupational hygienists employee health staff engineers work together site regional global levels reduce employees exposure chemicals end per cent operations achieved respirator free level engineering control based least occupational hygiene monitoring results continue upgrade engineering controls achieve respirator free levels control situations engineering controls possible employees remain protected appropriate respiratory protective equipment process safety many products begin formulation processing hazardous materials flammable solvents combustible powders scientists look opportunities eliminate use hazardous materials green chemistry green technology programmes substitution elimination option process safety programme aims ensure safety built manufacturing research development processes employees receive training understand risks implement appropriate controls engineers use online assessment system develop safer processes plant maintenance strategies share hazard information control strategies across gsk reviewed updated process safety strategy two employees injured explosion factory irvine uk using results review continuing update integrate process safety management system psms ehss management systems gsk sites includes design code containing new engineering standards process safety assessments new engineering standards gap analyses upgraded risk assessments remediation processes process safety indicators steps embed process safety overall safety culture new training competence programmes process safety tools also appointed new director process safety safety engineering safety engineering programme focuses improving construction plant safety ensuring effective emergency response systems developed safety engineering guides managing risk fire explosion provide guidance machine guarding electrical hazards webbased guides provide standardised approach managing safety risks across gsk also ensure safety built maintained sites worldwide following programmes risk assessment control processes construction contractor safety programme capital project ehs review process emergency response programmes ergonomics musculoskeletal illnesses repetitive strain injuries leading causes time away work corporate executive team set target reduce number illnesses injuries five per cent year good workplace job design known ergonomics helps employees jobs effectively reducing risk musculoskeletal illnesses injuries ergonomic improvement teams working across gsk businesses assess manage ergonomic risks existing operations planned projects teams include members areas manufacturing quality safety health medical services perform work teams work together identify risks develop solutions share best practice globally dedicated ergonomics community intranet addition trained facilitators throughout business help manage computerbased ergonomic risk assessments employees assessments identify steps reduce discomfort injury relating computer use information ergonomics best practice also available employees intranet site efforts contributed per cent improvement ergonomicsrelated injury illness short target annual five percent improvement equivalent per cent improvement order meet exceed target increase effort resources area cost productivity gains manufacturing operations example nabha site india manual handling task improved resulting simplified work process reduced risk injury reduction number employees needed perform task three people one person allowed two workers focus tasks reducing risk injury workers improved audit scores implementation ergonomic improvement processes example kuala lumpur improved ergonomics management risks score per cent per cent result implementing ergonomics improvement process improved overall audit score significant impacts introduction new ergonomics improvement teams example tianjin facility china six major ergonomic improvements initiated new team first months resulted per cent reduction reports discomfortinjury improved morale gsk ergonomic improvement teams given special recognition european safety health council part europe widefocus improving manual handling internal recognition global ergonomic community team process example new ways working gsk shared global resources spanning functions businesses cultures team award cross sector multicultural marketing diversity awards driver safety sales representatives spend significant amounts time driving therefore risk involved road traffic incidents aim reduce risk much possible worldwide driver safety programme includes instructions guidelines driver training vehicle selection risk assessment accident reporting motorbike rider safety manual employees countries provide motorbikes scooters around threequarters gsks commercial businesses extensive driver safety programmes place including driving licence checks guidance use mobile phones safety training tracking reporting incidents plan extend sites common cause fatalities serious injuries remains driving accidents per cent injuries lost time due motor vehicle accidents per cent injuries without lost time two road traffic accidents caused death two employees see fatalities serious injuries defibrillator programme six people resuscitated using automated external defibrillators aeds aed safe easy use portable medical device analyses heart rhythm delivers electric shocks victims ventricular fibrillation order restore victims heart rhythm normal began expanding number sites aeds used saving several lives us uk key personnel trained use aeds emergency situations equipment installed estimated gsk sites belgium brazil canada egypt france germany india italy japan mexico puerto rico singapore south africa spain us used risk assessment decide sites aeds based factors including heart disease risks among employees hazards site chemicals energised circuits could cause cardiac arrest ambulance response timeshome responsibility people health safety wellbeing safety programmes corporate responsibility report safety programmes operate number programmes keep employees contractors safe chemical exposure rigorous procedures controls place ensure employees involved developing manufacturing products protected exposure chemicals goal make per cent operations involving handling hazardous compounds respirator free means employees need wear respiratory protective equipment routine production tasks instead sites install technology prevents release hazardous compounds work environment example installed contained powder transfer systems glovebox technology pilot plant facility cork ireland special containment system new penicillin facility pakistan also developed proprietary manufacturing technology greatly reduces operator exposure medicines manufactured gsk site monitors air quality assess exposure hazardous compounds implements controls protect employees achieve respirator free goal occupational hygienists employee health staff engineers work together site regional global levels reduce employees exposure chemicals end per cent operations achieved respirator free level engineering control based least occupational hygiene monitoring results continue upgrade engineering controls achieve respirator free levels control situations engineering controls possible employees remain protected appropriate respiratory protective equipment process safety many products begin formulation processing hazardous materials flammable solvents combustible powders scientists look opportunities eliminate use hazardous materials green chemistry green technology programmes substitution elimination option process safety programme aims ensure safety built manufacturing research development processes employees receive training understand risks implement appropriate controls engineers use online assessment system develop safer processes plant maintenance strategies share hazard information control strategies across gsk reviewed updated process safety strategy two employees injured explosion factory irvine uk using results review continuing update integrate process safety management system psms ehss management systems gsk sites includes design code containing new engineering standards process safety assessments new engineering standards gap analyses upgraded risk assessments remediation processes process safety indicators steps embed process safety overall safety culture new training competence programmes process safety tools also appointed new director process safety safety engineering safety engineering programme focuses improving construction plant safety ensuring effective emergency response systems developed safety engineering guides managing risk fire explosion provide guidance machine guarding electrical hazards webbased guides provide standardised approach managing safety risks across gsk also ensure safety built maintained sites worldwide following programmes risk assessment control processes construction contractor safety programme capital project ehs review process emergency response programmes ergonomics musculoskeletal illnesses repetitive strain injuries leading causes time away work corporate executive team set target reduce number illnesses injuries five per cent year good workplace job design known ergonomics helps employees jobs effectively reducing risk musculoskeletal illnesses injuries ergonomic improvement teams working across gsk businesses assess manage ergonomic risks existing operations planned projects teams include members areas manufacturing quality safety health medical services perform work teams work together identify risks develop solutions share best practice globally dedicated ergonomics community intranet addition trained facilitators throughout business help manage computerbased ergonomic risk assessments employees assessments identify steps reduce discomfort injury relating computer use information ergonomics best practice also available employees intranet site efforts contributed per cent improvement ergonomicsrelated injury illness short target annual five percent improvement equivalent per cent improvement order meet exceed target increase effort resources area cost productivity gains manufacturing operations example nabha site india manual handling task improved resulting simplified work process reduced risk injury reduction number employees needed perform task three people one person allowed two workers focus tasks reducing risk injury workers improved audit scores implementation ergonomic improvement processes example kuala lumpur improved ergonomics management risks score per cent per cent result implementing ergonomics improvement process improved overall audit score significant impacts introduction new ergonomics improvement teams example tianjin facility china six major ergonomic improvements initiated new team first months resulted per cent reduction reports discomfortinjury improved morale gsk ergonomic improvement teams given special recognition european safety health council part europe widefocus improving manual handling internal recognition global ergonomic community team process example new ways working gsk shared global resources spanning functions businesses cultures team award cross sector multicultural marketing diversity awards driver safety sales representatives spend significant amounts time driving therefore risk involved road traffic incidents aim reduce risk much possible worldwide driver safety programme includes instructions guidelines driver training vehicle selection risk assessment accident reporting motorbike rider safety manual employees countries provide motorbikes scooters around threequarters gsks commercial businesses extensive driver safety programmes place including driving licence checks guidance use mobile phones safety training tracking reporting incidents plan extend sites common cause fatalities serious injuries remains driving accidents per cent injuries lost time due motor vehicle accidents per cent injuries without lost time two road traffic accidents caused death two employees see fatalities serious injuries defibrillator programme six people resuscitated using automated external defibrillators aeds aed safe easy use portable medical device analyses heart rhythm delivers electric shocks victims ventricular fibrillation order restore victims heart rhythm normal began expanding number sites aeds used saving several lives us uk key personnel trained use aeds emergency situations equipment installed estimated gsk sites belgium brazil canada egypt france germany india italy japan mexico puerto rico singapore south africa spain us used risk assessment decide sites aeds based factors including heart disease risks among employees hazards site chemicals energised circuits could cause cardiac arrest ambulance response times home responsibility people health safety wellbeing safety programmes corporate responsibility report safety programmes operate number programmes keep employees contractors safe chemical exposure rigorous procedures controls place ensure employees involved developing manufacturing products protected exposure chemicals goal make per cent operations involving handling hazardous compounds respirator free means employees need wear respiratory protective equipment routine production tasks instead sites install technology prevents release hazardous compounds work environment example installed contained powder transfer systems glovebox technology pilot plant facility cork ireland special containment system new penicillin facility pakistan also developed proprietary manufacturing technology greatly reduces operator exposure medicines manufactured gsk site monitors air quality assess exposure hazardous compounds implements controls protect employees achieve respirator free goal occupational hygienists employee health staff engineers work together site regional global levels reduce employees exposure chemicals end per cent operations achieved respirator free level engineering control based least occupational hygiene monitoring results continue upgrade engineering controls achieve respirator free levels control situations engineering controls possible employees remain protected appropriate respiratory protective equipment process safety many products begin formulation processing hazardous materials flammable solvents combustible powders scientists look opportunities eliminate use hazardous materials green chemistry green technology programmes substitution elimination option process safety programme aims ensure safety built manufacturing research development processes employees receive training understand risks implement appropriate controls engineers use online assessment system develop safer processes plant maintenance strategies share hazard information control strategies across gsk reviewed updated process safety strategy two employees injured explosion factory irvine uk using results review continuing update integrate process safety management system psms ehss management systems gsk sites includes design code containing new engineering standards process safety assessments new engineering standards gap analyses upgraded risk assessments remediation processes process safety indicators steps embed process safety overall safety culture new training competence programmes process safety tools also appointed new director process safety safety engineering safety engineering programme focuses improving construction plant safety ensuring effective emergency response systems developed safety engineering guides managing risk fire explosion provide guidance machine guarding electrical hazards webbased guides provide standardised approach managing safety risks across gsk also ensure safety built maintained sites worldwide following programmes risk assessment control processes construction contractor safety programme capital project ehs review process emergency response programmes ergonomics musculoskeletal illnesses repetitive strain injuries leading causes time away work corporate executive team set target reduce number illnesses injuries five per cent year good workplace job design known ergonomics helps employees jobs effectively reducing risk musculoskeletal illnesses injuries ergonomic improvement teams working across gsk businesses assess manage ergonomic risks existing operations planned projects teams include members areas manufacturing quality safety health medical services perform work teams work together identify risks develop solutions share best practice globally dedicated ergonomics community intranet addition trained facilitators throughout business help manage computerbased ergonomic risk assessments employees assessments identify steps reduce discomfort injury relating computer use information ergonomics best practice also available employees intranet site efforts contributed per cent improvement ergonomicsrelated injury illness short target annual five percent improvement equivalent per cent improvement order meet exceed target increase effort resources area cost productivity gains manufacturing operations example nabha site india manual handling task improved resulting simplified work process reduced risk injury reduction number employees needed perform task three people one person allowed two workers focus tasks reducing risk injury workers improved audit scores implementation ergonomic improvement processes example kuala lumpur improved ergonomics management risks score per cent per cent result implementing ergonomics improvement process improved overall audit score significant impacts introduction new ergonomics improvement teams example tianjin facility china six major ergonomic improvements initiated new team first months resulted per cent reduction reports discomfortinjury improved morale gsk ergonomic improvement teams given special recognition european safety health council part europe widefocus improving manual handling internal recognition global ergonomic community team process example new ways working gsk shared global resources spanning functions businesses cultures team award cross sector multicultural marketing diversity awards driver safety sales representatives spend significant amounts time driving therefore risk involved road traffic incidents aim reduce risk much possible worldwide driver safety programme includes instructions guidelines driver training vehicle selection risk assessment accident reporting motorbike rider safety manual employees countries provide motorbikes scooters around threequarters gsks commercial businesses extensive driver safety programmes place including driving licence checks guidance use mobile phones safety training tracking reporting incidents plan extend sites common cause fatalities serious injuries remains driving accidents per cent injuries lost time due motor vehicle accidents per cent injuries without lost time two road traffic accidents caused death two employees see fatalities serious injuries defibrillator programme six people resuscitated using automated external defibrillators aeds aed safe easy use portable medical device analyses heart rhythm delivers electric shocks victims ventricular fibrillation order restore victims heart rhythm normal began expanding number sites aeds used saving several lives us uk key personnel trained use aeds emergency situations equipment installed estimated gsk sites belgium brazil canada egypt france germany india italy japan mexico puerto rico singapore south africa spain us used risk assessment decide sites aeds based factors including heart disease risks among employees hazards site chemicals energised circuits could cause cardiac arrest ambulance response times home responsibility people health safety wellbeing health wellbeing programmes corporate responsibility report health wellbeing programmes gsk offers programmes boost employee health wellbeing create sustain energy engagement work turn helps improve business performance gsk helps improve employee wellbeing offering flexible working options health wellbeing initiatives include health risk appraisals screening diabetes hypertension smoking control support fitness nutritional advice immunisations prevention screening initiatives focus leading causes illness disability among employees include depression nonwork related injuries heart disease stroke respiratory infections increasingly also focusing ways encourage team personal energy resilience times high pressure many employee health wellbeing programmes national awards excellence platinum awards national business group health nbgh us health promotion board singapore team resilience programme received award nbgh innovation commitment providing lifestyle improvement programmes designed improve healthier lifestyles employees energy resilience define resilience describe skills traits necessary success highpressure working environment skills behaviours also help prevent mental illness due stress leading cause ill health disability work energy performance employees energy focus better perform tasks efficiently energy performance ep programme designed boost energy levels help employees invest energy right way work home uptake good employees participated ep workshops employees countries attended ep workshops end per cent reported significant improvement physical mental performance emotional energy participants found performance improvements persisted least months workshop personal resilience run workshops employees want enhance build personal resilience focusing improving work home life programme aims help employees increase focus energy confidence also helping reduce tension anxiety fatigue since programme started employees participated programme team resilience healthy collaborative motivated teams critical business success team resilience programme helps employees managers identify sources pressure teams process complexity lack workplace flexibility accountability teams work together agree action plans address concerns programme helps teams take control work eliminate manage sources pressure lead ill health inefficiency since programme began completed teams countries comprising employees end participants report per cent reduction workplace pressures per cent drop worklife conflict per cent increase satisfaction gsk employer wellbeing worklife balance gsk offers programmes improve health employees families find increases employee commitment productivity reduces absenteeism cost ill health support varies countries according local needs sites use public health gsk data identify high risk areas investments lead significant health cost improvements programmes often include benefits onsite health fitness centres flexible working arrangements immunisations regular medical checkups assistance stop smoking disease screening management family support services health education also assist employees suffering chronic diseases ensure access correct longterm treatment support programmes help local healthcare services focusing health education prevention awareness management current conditions created network gsk employee health professionals share health wellbeing best practice gsk also supports key public health efforts world aids day world health organizations health day tobacco free day global handwashing day back tophome responsibility people health safety wellbeing health wellbeing programmes corporate responsibility report health wellbeing programmes gsk offers programmes boost employee health wellbeing create sustain energy engagement work turn helps improve business performance gsk helps improve employee wellbeing offering flexible working options health wellbeing initiatives include health risk appraisals screening diabetes hypertension smoking control support fitness nutritional advice immunisations prevention screening initiatives focus leading causes illness disability among employees include depression nonwork related injuries heart disease stroke respiratory infections increasingly also focusing ways encourage team personal energy resilience times high pressure many employee health wellbeing programmes national awards excellence platinum awards national business group health nbgh us health promotion board singapore team resilience programme received award nbgh innovation commitment providing lifestyle improvement programmes designed improve healthier lifestyles employees energy resilience define resilience describe skills traits necessary success highpressure working environment skills behaviours also help prevent mental illness due stress leading cause ill health disability work energy performance employees energy focus better perform tasks efficiently energy performance ep programme designed boost energy levels help employees invest energy right way work home uptake good employees participated ep workshops employees countries attended ep workshops end per cent reported significant improvement physical mental performance emotional energy participants found performance improvements persisted least months workshop personal resilience run workshops employees want enhance build personal resilience focusing improving work home life programme aims help employees increase focus energy confidence also helping reduce tension anxiety fatigue since programme started employees participated programme team resilience healthy collaborative motivated teams critical business success team resilience programme helps employees managers identify sources pressure teams process complexity lack workplace flexibility accountability teams work together agree action plans address concerns programme helps teams take control work eliminate manage sources pressure lead ill health inefficiency since programme began completed teams countries comprising employees end participants report per cent reduction workplace pressures per cent drop worklife conflict per cent increase satisfaction gsk employer wellbeing worklife balance gsk offers programmes improve health employees families find increases employee commitment productivity reduces absenteeism cost ill health support varies countries according local needs sites use public health gsk data identify high risk areas investments lead significant health cost improvements programmes often include benefits onsite health fitness centres flexible working arrangements immunisations regular medical checkups assistance stop smoking disease screening management family support services health education also assist employees suffering chronic diseases ensure access correct longterm treatment support programmes help local healthcare services focusing health education prevention awareness management current conditions created network gsk employee health professionals share health wellbeing best practice gsk also supports key public health efforts world aids day world health organizations health day tobacco free day global handwashing day back top home responsibility people health safety wellbeing health wellbeing programmes corporate responsibility report health wellbeing programmes gsk offers programmes boost employee health wellbeing create sustain energy engagement work turn helps improve business performance gsk helps improve employee wellbeing offering flexible working options health wellbeing initiatives include health risk appraisals screening diabetes hypertension smoking control support fitness nutritional advice immunisations prevention screening initiatives focus leading causes illness disability among employees include depression nonwork related injuries heart disease stroke respiratory infections increasingly also focusing ways encourage team personal energy resilience times high pressure many employee health wellbeing programmes national awards excellence platinum awards national business group health nbgh us health promotion board singapore team resilience programme received award nbgh innovation commitment providing lifestyle improvement programmes designed improve healthier lifestyles employees energy resilience define resilience describe skills traits necessary success highpressure working environment skills behaviours also help prevent mental illness due stress leading cause ill health disability work energy performance employees energy focus better perform tasks efficiently energy performance ep programme designed boost energy levels help employees invest energy right way work home uptake good employees participated ep workshops employees countries attended ep workshops end per cent reported significant improvement physical mental performance emotional energy participants found performance improvements persisted least months workshop personal resilience run workshops employees want enhance build personal resilience focusing improving work home life programme aims help employees increase focus energy confidence also helping reduce tension anxiety fatigue since programme started employees participated programme team resilience healthy collaborative motivated teams critical business success team resilience programme helps employees managers identify sources pressure teams process complexity lack workplace flexibility accountability teams work together agree action plans address concerns programme helps teams take control work eliminate manage sources pressure lead ill health inefficiency since programme began completed teams countries comprising employees end participants report per cent reduction workplace pressures per cent drop worklife conflict per cent increase satisfaction gsk employer wellbeing worklife balance gsk offers programmes improve health employees families find increases employee commitment productivity reduces absenteeism cost ill health support varies countries according local needs sites use public health gsk data identify high risk areas investments lead significant health cost improvements programmes often include benefits onsite health fitness centres flexible working arrangements immunisations regular medical checkups assistance stop smoking disease screening management family support services health education also assist employees suffering chronic diseases ensure access correct longterm treatment support programmes help local healthcare services focusing health education prevention awareness management current conditions created network gsk employee health professionals share health wellbeing best practice gsk also supports key public health efforts world aids day world health organizations health day tobacco free day global handwashing day back top home responsibility people health safety wellbeing health business continuity corporate responsibility report health business continuity developed contingency plans protect employees business event natural disasters manmade emergencies flu pandemic plans aim ensure business continue function continue supply critical medicines patients also developed implemented programmes protect staff dependants key complementary workers countries event pandemic offer employees annual seasonal flu vaccination per cent markets well travel health programmes stockpile multiple antiviral medicines used prevent treat pandemic flu include prepandemic vaccines administered pandemic started pandemic flu vaccine available six months exact pandemic flu strain identified event outbreak implement special rules prevent disease spreading among workforce example nonessential services close facetoface meetings held special cleaning personal protective programmes implemented restrict business travel access gsk sites employees encouraged work home developed special website accessible intranet externally acts single source global local flu information across gsk home responsibility people health safety wellbeing health business continuity corporate responsibility report health business continuity developed contingency plans protect employees business event natural disasters manmade emergencies flu pandemic plans aim ensure business continue function continue supply critical medicines patients also developed implemented programmes protect staff dependants key complementary workers countries event pandemic offer employees annual seasonal flu vaccination per cent markets well travel health programmes stockpile multiple antiviral medicines used prevent treat pandemic flu include prepandemic vaccines administered pandemic started pandemic flu vaccine available six months exact pandemic flu strain identified event outbreak implement special rules prevent disease spreading among workforce example nonessential services close facetoface meetings held special cleaning personal protective programmes implemented restrict business travel access gsk sites employees encouraged work home developed special website accessible intranet externally acts single source global local flu information across gsk home responsibility people health safety wellbeing training awareness corporate responsibility report training awareness training helps create workplace culture occupational health safety taken seriously employees responsible managing occupational health safety issues sites business units receive regular training turn instruct employees safe working give training environment health safety sustainability ehss standards well programmes process safety chemical exposure protection identifying risk auditing ergonomics sites develop conduct training based local needs capabilities use internal learning tools commercially available training programmes locally available government university sponsored training programmes developed training framework identifies gaps employees knowledge health safety provides inhouse external training courses health safety professionals share knowledge best practice via teleconferences intranet communities training programmes discussion forums raise awareness employee health safety issues employee bulletins announcements myehs community intranet sites ceos ehs excellence awards programme health safety week held october coincide european health safety week event encourages employees address potential risks work home employees sites countries took part health safety week activities read training environment health safety issues health safety worthing ehs challenge competition gsks penicillin manufacturing facility worthing uk ran four competitions improve employees knowledge ehs issues month ehs team sent five questions staff topics fire evacuation first aid respond penicillin exposure sites ehs targets following month questions posed five employees work unit points awarded correct responses team published league table month every quarter winning team awarded charity choice total competition winners gave charity following success worthing competition introduced sites uk france china india project second place ceos ehs excellence awards safety initiative category back top home responsibility people health safety wellbeing training awareness corporate responsibility report training awareness training helps create workplace culture occupational health safety taken seriously employees responsible managing occupational health safety issues sites business units receive regular training turn instruct employees safe working give training environment health safety sustainability ehss standards well programmes process safety chemical exposure protection identifying risk auditing ergonomics sites develop conduct training based local needs capabilities use internal learning tools commercially available training programmes locally available government university sponsored training programmes developed training framework identifies gaps employees knowledge health safety provides inhouse external training courses health safety professionals share knowledge best practice via teleconferences intranet communities training programmes discussion forums raise awareness employee health safety issues employee bulletins announcements myehs community intranet sites ceos ehs excellence awards programme health safety week held october coincide european health safety week event encourages employees address potential risks work home employees sites countries took part health safety week activities read training environment health safety issues health safety worthing ehs challenge competition gsks penicillin manufacturing facility worthing uk ran four competitions improve employees knowledge ehs issues month ehs team sent five questions staff topics fire evacuation first aid respond penicillin exposure sites ehs targets following month questions posed five employees work unit points awarded correct responses team published league table month every quarter winning team awarded charity choice total competition winners gave charity following success worthing competition introduced sites uk france china india project second place ceos ehs excellence awards safety initiative category back top home responsibility people health safety wellbeing performance corporate responsibility report performance performance data table injury illness rates main health safety measure reportable injury illness rate also measure number injuries illnesses result lost days well number days lost injuries illnesses provides indication severity incidents although rough guide set targets improve injury illness rates injury illness targets injury illness target progress reduce reportable injury illness improved per cent rate per cent year end reduce reportable musculoskeletal improved per cent illness injury rate per cent year end rank first quartile industry improved ranking one place remaining benchmark group third quartile data cover gsk employees contract workers directly supervise report separately data contractors work gsk sites supervise staff data table contractors data externally verified injury illness data collected pharmaceutical consumer healthcare nutritionals manufacturing sites vaccines sites one site yet operation pharmaceutical consumer healthcare research development sites two sites considered new start reporting us uk headquarters sites eighteen offices sales groups one million hours worked smaller offices distribution centres sales office sites report injury illness data estimate approximately three per cent data missing due one large sales group reported injury illness injury illness rates reportable injury illness rate continues improve average rate five per cent per year across gsk injuries illnesses total reportable injury illness rate reportable injuries illnesses per hours worked improvement per cent baseline exceeding target reportable ergonomicsrelated injury illness rate improved percent short target annual five percent improvement equivalent per cent improvement order meet exceed target increase effort resources area pharmaceutical consumer healthcare manufacturing organisation injury illness rates included managers objectives rate improved per cent machinery safety projects many manufacturing sites projects encouraging employee safety awareness examples initiatives contributing improvement rate losttime injuries illnesses improved per cent losttime injuries illnesses per hours worked however days lost per hours improved per cent indicating lower number days lost per incident possibly indicator less severe injuries illnesses injury illness performance places us third quartile benchmark industry group means need improve target top quartile comparable industry ratings read case study site improved safety shutdown sgs verified injury illness causes frequent types incident overall ergonomic mainly musculoskeletal illnesses repetitive strain injuries accounting per cent injuries illnesses continue expand ergonomics programmes address cause injury illness frequent reportable injuries slips trips falls account per cent injuries illnesses team assigned look ways address type injury injuries due machinery accounted per cent injuries illnesses manufacturing sites renewing focus machine safety continue improvements area road traffic accidents accounted per cent injuries illnesses two fatalities detailed belowdriver safety continuing area focus especially sales force mental ill health accounts per cent injuries illnesses cases result highest number days lost days per case average per cent total number days lost injuries illnesses addressed resilience programme sgs verified fatalities serious injuries employee fatalities five year trend employee fatalities one sales employees killed fatal road traffic accident philippines three passengers also killed accident one sales employees india killed fell bicycle path oncoming motorized threewheeler front tire bicycle punctured two gsk employees seriously injured another road traffic accident india vehicle transported contract driver struck another vehicle killing two people five amputations serious finger injury due accidents moving machinery three employees amputations fingers finger tips one employee sustained amputation foot one contract worker amputation forearm employee us injured foot caught powered rollers reconstructive surgery proved unsuccessful foot amputated contract worker india reached clothes dryer rotating remove article clothing resulting amputation forearm employee south africa slipped wet floor grabbed piece equipment keep falling weight caused valve close hand amputating finger top joint badly crushing two fingers severed finger reattached crushed fingers could saved amputated engineering mechanic pakistan placed hand operating piece machinery tube holder struck finger inflicting severe damage resulting amputation employee us clearing jam assemblypacking machine placed hand part machine closed finger amputating finger tip fitter australia suffered serious lacerations finger installing cutter blister pack machine hospital treatment required amputation avoided amputations resulted renewed emphasis machine guarding programmes sites sgs verified injury illness milestones gsk operations strive work without experiencing losttime injuries illnesses issue certificates signed business heads sites reach one million hours worked without losttime injury illness sites reach two million hours worked without losttime injury illness awarded certificates signed chief executive officer small sites attain level one million hours worked three year period obtain certificate three years worked without losttime injury illness milestones achieved hours worked without lost time injury illness million hours sites million hours site million hours sites million hours site million hours site years site years sites back tophome responsibility people health safety wellbeing performance corporate responsibility report performance performance data table injury illness rates main health safety measure reportable injury illness rate also measure number injuries illnesses result lost days well number days lost injuries illnesses provides indication severity incidents although rough guide set targets improve injury illness rates injury illness targets injury illness target progress reduce reportable injury illness improved per cent rate per cent year end reduce reportable musculoskeletal improved per cent illness injury rate per cent year end rank first quartile industry improved ranking one place remaining benchmark group third quartile data cover gsk employees contract workers directly supervise report separately data contractors work gsk sites supervise staff data table contractors data externally verified injury illness data collected pharmaceutical consumer healthcare nutritionals manufacturing sites vaccines sites one site yet operation pharmaceutical consumer healthcare research development sites two sites considered new start reporting us uk headquarters sites eighteen offices sales groups one million hours worked smaller offices distribution centres sales office sites report injury illness data estimate approximately three per cent data missing due one large sales group reported injury illness injury illness rates reportable injury illness rate continues improve average rate five per cent per year across gsk injuries illnesses total reportable injury illness rate reportable injuries illnesses per hours worked improvement per cent baseline exceeding target reportable ergonomicsrelated injury illness rate improved percent short target annual five percent improvement equivalent per cent improvement order meet exceed target increase effort resources area pharmaceutical consumer healthcare manufacturing organisation injury illness rates included managers objectives rate improved per cent machinery safety projects many manufacturing sites projects encouraging employee safety awareness examples initiatives contributing improvement rate losttime injuries illnesses improved per cent losttime injuries illnesses per hours worked however days lost per hours improved per cent indicating lower number days lost per incident possibly indicator less severe injuries illnesses injury illness performance places us third quartile benchmark industry group means need improve target top quartile comparable industry ratings read case study site improved safety shutdown sgs verified injury illness causes frequent types incident overall ergonomic mainly musculoskeletal illnesses repetitive strain injuries accounting per cent injuries illnesses continue expand ergonomics programmes address cause injury illness frequent reportable injuries slips trips falls account per cent injuries illnesses team assigned look ways address type injury injuries due machinery accounted per cent injuries illnesses manufacturing sites renewing focus machine safety continue improvements area road traffic accidents accounted per cent injuries illnesses two fatalities detailed belowdriver safety continuing area focus especially sales force mental ill health accounts per cent injuries illnesses cases result highest number days lost days per case average per cent total number days lost injuries illnesses addressed resilience programme sgs verified fatalities serious injuries employee fatalities five year trend employee fatalities one sales employees killed fatal road traffic accident philippines three passengers also killed accident one sales employees india killed fell bicycle path oncoming motorized threewheeler front tire bicycle punctured two gsk employees seriously injured another road traffic accident india vehicle transported contract driver struck another vehicle killing two people five amputations serious finger injury due accidents moving machinery three employees amputations fingers finger tips one employee sustained amputation foot one contract worker amputation forearm employee us injured foot caught powered rollers reconstructive surgery proved unsuccessful foot amputated contract worker india reached clothes dryer rotating remove article clothing resulting amputation forearm employee south africa slipped wet floor grabbed piece equipment keep falling weight caused valve close hand amputating finger top joint badly crushing two fingers severed finger reattached crushed fingers could saved amputated engineering mechanic pakistan placed hand operating piece machinery tube holder struck finger inflicting severe damage resulting amputation employee us clearing jam assemblypacking machine placed hand part machine closed finger amputating finger tip fitter australia suffered serious lacerations finger installing cutter blister pack machine hospital treatment required amputation avoided amputations resulted renewed emphasis machine guarding programmes sites sgs verified injury illness milestones gsk operations strive work without experiencing losttime injuries illnesses issue certificates signed business heads sites reach one million hours worked without losttime injury illness sites reach two million hours worked without losttime injury illness awarded certificates signed chief executive officer small sites attain level one million hours worked three year period obtain certificate three years worked without losttime injury illness milestones achieved hours worked without lost time injury illness million hours sites million hours site million hours sites million hours site million hours site years site years sites back tophome responsibility people health safety wellbeing performance corporate responsibility report performance performance data table injury illness rates main health safety measure reportable injury illness rate also measure number injuries illnesses result lost days well number days lost injuries illnesses provides indication severity incidents although rough guide set targets improve injury illness rates injury illness targets injury illness target progress reduce reportable injury illness improved per cent rate per cent year end reduce reportable musculoskeletal improved per cent illness injury rate per cent year end rank first quartile industry improved ranking one place remaining benchmark group third quartile data cover gsk employees contract workers directly supervise report separately data contractors work gsk sites supervise staff data table contractors data externally verified injury illness data collected pharmaceutical consumer healthcare nutritionals manufacturing sites vaccines sites one site yet operation pharmaceutical consumer healthcare research development sites two sites considered new start reporting us uk headquarters sites eighteen offices sales groups one million hours worked smaller offices distribution centres sales office sites report injury illness data estimate approximately three per cent data missing due one large sales group reported injury illness injury illness rates reportable injury illness rate continues improve average rate five per cent per year across gsk injuries illnesses total reportable injury illness rate reportable injuries illnesses per hours worked improvement per cent baseline exceeding target reportable ergonomicsrelated injury illness rate improved percent short target annual five percent improvement equivalent per cent improvement order meet exceed target increase effort resources area pharmaceutical consumer healthcare manufacturing organisation injury illness rates included managers objectives rate improved per cent machinery safety projects many manufacturing sites projects encouraging employee safety awareness examples initiatives contributing improvement rate losttime injuries illnesses improved per cent losttime injuries illnesses per hours worked however days lost per hours improved per cent indicating lower number days lost per incident possibly indicator less severe injuries illnesses injury illness performance places us third quartile benchmark industry group means need improve target top quartile comparable industry ratings read case study site improved safety shutdown sgs verified injury illness causes frequent types incident overall ergonomic mainly musculoskeletal illnesses repetitive strain injuries accounting per cent injuries illnesses continue expand ergonomics programmes address cause injury illness frequent reportable injuries slips trips falls account per cent injuries illnesses team assigned look ways address type injury injuries due machinery accounted per cent injuries illnesses manufacturing sites renewing focus machine safety continue improvements area road traffic accidents accounted per cent injuries illnesses two fatalities detailed belowdriver safety continuing area focus especially sales force mental ill health accounts per cent injuries illnesses cases result highest number days lost days per case average per cent total number days lost injuries illnesses addressed resilience programme sgs verified fatalities serious injuries employee fatalities five year trend employee fatalities one sales employees killed fatal road traffic accident philippines three passengers also killed accident one sales employees india killed fell bicycle path oncoming motorized threewheeler front tire bicycle punctured two gsk employees seriously injured another road traffic accident india vehicle transported contract driver struck another vehicle killing two people five amputations serious finger injury due accidents moving machinery three employees amputations fingers finger tips one employee sustained amputation foot one contract worker amputation forearm employee us injured foot caught powered rollers reconstructive surgery proved unsuccessful foot amputated contract worker india reached clothes dryer rotating remove article clothing resulting amputation forearm employee south africa slipped wet floor grabbed piece equipment keep falling weight caused valve close hand amputating finger top joint badly crushing two fingers severed finger reattached crushed fingers could saved amputated engineering mechanic pakistan placed hand operating piece machinery tube holder struck finger inflicting severe damage resulting amputation employee us clearing jam assemblypacking machine placed hand part machine closed finger amputating finger tip fitter australia suffered serious lacerations finger installing cutter blister pack machine hospital treatment required amputation avoided amputations resulted renewed emphasis machine guarding programmes sites sgs verified injury illness milestones gsk operations strive work without experiencing losttime injuries illnesses issue certificates signed business heads sites reach one million hours worked without losttime injury illness sites reach two million hours worked without losttime injury illness arpea agew ard oef certificates signed chief executive officer small sites attain level one million hours worked three year period obtain certificate three years worked without losttime injury illness milestones achieved hours worked without lost time injury illness million hours sites million hours site million hours sites million hours site million hours site years site years sites back tophome responsibility people health safety wellbeing performance corporate responsibility report performance performance data table injury illness rates main health safety measure reportable injury illness rate also measure number injuries illnesses result lost days well number days lost injuries illnesses provides indication severity incidents although rough guide set targets improve injury illness rates injury illness targets injury illness target progress reduce reportable injury illness improved per cent rate per cent year end reduce reportable musculoskeletal improved per cent illness injury rate per cent year end rank first quartile industry improved ranking one place remaining benchmark group third quartile data cover gsk employees contract workers directly supervise report separately data contractors work gsk sites supervise staff data table contractors data externally verified injury illness data collected pharmaceutical consumer healthcare nutritionals manufacturing sites vaccines sites one site yet operation pharmaceutical consumer healthcare research development sites two sites considered new start reporting us uk headquarters sites eighteen offices sales groups one million hours worked smaller offices distribution centres sales office sites report injury illness data estimate approximately three per cent data missing due one large sales group reported injury illness injury illness rates reportable injury illness rate continues improve average rate five per cent per year across gsk injuries illnesses total reportable injury illness rate reportable injuries illnesses per hours worked improvement per cent baseline exceeding target reportable ergonomicsrelated injury illness rate improved percent short target annual five percent improvement equivalent per cent improvement order meet exceed target increase effort resources area pharmaceutical consumer healthcare manufacturing organisation injury illness rates included managers objectives rate improved per cent machinery safety projects many manufacturing sites projects encouraging employee safety awareness examples initiatives contributing improvement rate losttime injuries illnesses improved per cent losttime injuries illnesses per hours worked however days lost per hours improved per cent indicating lower number days lost per incident possibly indicator less severe injuries illnesses injury illness performance places us third quartile benchmark industry group means need improve target top quartile comparable industry ratings read case study site improved safety shutdown sgs verified injury illness causes frequent types incident overall ergonomic mainly musculoskeletal illnesses repetitive strain injuries accounting per cent injuries illnesses continue expand ergonomics programmes address cause injury illness frequent reportable injuries slips trips falls account per cent injuries illnesses team assigned look ways address type injury injuries due machinery accounted per cent injuries illnesses manufacturing sites renewing focus machine safety continue improvements area road traffic accidents accounted per cent injuries illnesses two fatalities detailed belowdriver safety continuing area focus especially sales force mental ill health accounts per cent injuries illnesses cases result highest number days lost days per case average per cent total number days lost injuries illnesses addressed resilience programme sgs verified fatalities serious injuries employee fatalities five year trend employee fatalities one sales employees killed fatal road traffic accident philippines three passengers also killed accident one sales employees india killed fell bicycle path oncoming motorized threewheeler front tire bicycle punctured two gsk employees seriously injured another road traffic accident india vehicle transported contract driver struck another vehicle killing two people five amputations serious finger injury due accidents moving machinery three employees amputations fingers finger tips one employee sustained amputation foot one contract worker amputation forearm employee us injured foot caught powered rollers reconstructive surgery proved unsuccessful foot amputated contract worker india reached clothes dryer rotating remove article clothing resulting amputation forearm employee south africa slipped wet floor grabbed piece equipment keep falling weight caused valve close hand amputating finger top joint badly crushing two fingers severed finger reattached crushed fingers could saved amputated engineering mechanic pakistan placed hand operating piece machinery tube holder struck finger inflicting severe damage resulting amputation employee us clearing jam assemblypacking machine placed hand part machine closed finger amputating finger tip fitter australia suffered serious lacerations finger installing cutter blister pack machine hospital treatment required amputation avoided amputations resulted renewed emphasis machine guarding programmes sites sgs verified injury illness milestones gsk operations strive work without experiencing losttime injuries illnesses issue certificates signed business heads sites reach one million hours worked without losttime injury illness sites reach two million hours worked without losttime injury illness awarded certificates signed chief executive officer small sites attain level one million hours worked three year period obtain certificate three years worked without losttime injury illness milestones achieved hours worked without lost time injury illness million hours sites million hours site million hours sites million hours site million hours site years site years sites back top home responsibility people health safety wellbeing performance corporate responsibility report performance performance data table injury illness rates main health safety measure reportable injury illness rate also measure number injuries illnesses result lost days well number days lost injuries illnesses provides indication severity incidents although rough guide set targets improve injury illness rates injury illness targets injury illness target progress reduce reportable injury illness improved per cent rate per cent year end reduce reportable musculoskeletal improved per cent illness injury rate per cent year end rank first quartile industry improved ranking one place remaining benchmark group third quartile data cover gsk employees contract workers directly supervise report separately data contractors work gsk sites supervise staff data table contractors data externally verified injury illness data collected pharmaceutical consumer healthcare nutritionals manufacturing sites vaccines sites one site yet operation pharmaceutical consumer healthcare research development sites two sites considered new start reporting us uk headquarters sites eighteen offices sales groups one million hours worked smaller offices distribution centres sales office sites report injury illness data estimate approximately three per cent data missing due one large sales group reported injury illness injury illness rates reportable injury illness rate continues improve average rate five per cent per year across gsk injuries illnesses total reportable injury illness rate reportable injuries illnesses per hours worked improvement per cent baseline exceeding target reportable ergonomicsrelated injury illness rate improved percent short target annual five percent improvement equivalent per cent improvement order meet exceed target increase effort resources area pharmaceutical consumer healthcare manufacturing organisation injury illness rates included managers objectives rate improved per cent machinery safety projects many manufacturing sites projects encouraging employee safety awareness examples initiatives contributing improvement rate losttime injuries illnesses improved per cent losttime injuries illnesses per hours worked however days lost per hours improved per cent indicating lower number days lost per incident possibly indicator less severe injuries illnesses injury illness performance places us third quartile benchmark industry group means need improve target top quartile comparable industry ratings read case study site improved safety shutdown sgs verified injury illness causes frequent types incident overall ergonomic mainly musculoskeletal illnesses repetitive strain injuries accounting per cent injuries illnesses continue expand ergonomics programmes address cause injury illness frequent reportable injuries slips trips falls account per cent injuries illnesses team assigned look ways address type injury injuries due machinery accounted per cent injuries illnesses manufacturing sites renewing focus machine safety continue improvements area road traffic accidents accounted per cent injuries illnesses two fatalities detailed belowdriver safety continuing area focus especially sales force mental ill health accounts per cent injuries illnesses cases result highest number days lost days per case average per cent total number days lost injuries illnesses addressed resilience programme sgs verified fatalities serious injuries employee fatalities five year trend employee fatalities one sales employees killed fatal road traffic accident philippines three passengers also killed accident one sales employees india killed fell bicycle path oncoming motorized threewheeler front tire bicycle punctured two gsk employees seriously injured another road traffic accident india vehicle transported contract driver struck another vehicle killing two people five amputations serious finger injury due accidents moving machinery three employees amputations fingers finger tips one employee sustained amputation foot one contract worker amputation forearm employee us injured foot caught powered rollers reconstructive surgery proved unsuccessful foot amputated contract worker india reached clothes dryer rotating remove article clothing resulting amputation forearm employee south africa slipped wet floor grabbed piece equipment keep falling weight caused valve close hand amputating finger top joint badly crushing two fingers severed finger reattached crushed fingers could saved amputated engineering mechanic pakistan placed hand operating piece machinery tube holder struck finger inflicting severe damage resulting amputation employee us clearing jam assemblypacking machine placed hand part machine closed finger amputating finger tip fitter australia suffered serious lacerations finger installing cutter blister pack machine hospital treatment required amputation avoided amputations resulted renewed emphasis machine guarding programmes sites sgs verified injury illness milestones gsk operations strive work without experiencing losttime injuries illnesses issue certificates signed business heads sites reach one million hours worked without losttime injury illness sites reach two million hours worked without losttime injury illness awarded certificates signed chief executive officer small sites attain level one million hours worked three year period obtain certificate three years worked without losttime injury illness milestones achieved hours worked without lost time injury illness million hours sites million hours site million hours sites million hours site million hours site years site years sites back top home responsibility people health safety wellbeing performance corporate responsibility report performance performance data table metric injury illness gsk employees hours worked millions fatalities number injuries lost time calendar days lost injuries number illnesses lost time calendar days lost illnesses number injuries without lost time number illnesses without lost time reportable injury illness rate reportable ergonomic injury illness rate losttime injury illness rate injury illness nongsk employees hours worked million fatalities number injuries illnesses lost time calendar days lost number injuries illnesses without lost time occupational health safety data cover employees contract workers directly supervised gsk employees report snapshot injury illness performance year cases may added end year prior years may change losttime injuries illnesses workrelated injuries illnesses serious enough result one days away work lost calendar days calendar days including weekends employees could work workrelated injuries illnesses helps provide measure severity injuries illnesses reportable injuries illnesses without lost time incidents result time away work lost time serious first aid serious enough result lost time sgs verified back tophome responsibility people health safety wellbeing performance corporate responsibility report performance performance data table metric injury illness gsk employees hours worked millions fatalities number injuries lost time calendar days lost injuries number illnesses lost time calendar days lost illnesses number injuries without lost time number illnesses without lost time reportable injury illness rate reportable ergonomic injury illness rate losttime injury illness rate injury illness nongsk employees hours worked million fatalities number injuries illnesses lost time calendar days lost number injuries illnesses without lost time occupational health safety data cover employees contract workers directly supervised gsk employees report snapshot injury illness performance year cases may added end year prior years may change losttime injuries illnesses workrelated injuries illnesses serious enough result one days away work lost calendar days calendar days including weekends employees could work workrelated injuries illnesses helps provide measure severity injuries illnesses reportable injuries illnesses without lost time incidents result time away work lost time serious first aid serious enough result lost time sgs verified back top home responsibility people health safety wellbeing performance corporate responsibility report performance performance data table metric injury illness gsk employees hours worked millions fatalities number injuries lost time calendar days lost injuries number illnesses lost time calendar days lost illnesses number injuries without lost time number illnesses without lost time reportable injury illness rate reportable ergonomic injury illness rate losttime injury illness rate injury illness nongsk employees hours worked million fatalities number injuries illnesses lost time calendar days lost number injuries illnesses without lost time occupational health safety data cover employees contract workers directly supervised gsk employees report snapshot injury illness performance year cases may added end year prior years may change losttime injuries illnesses workrelated injuries illnesses serious enough result one days away work lost calendar days calendar days including weekends employees could work workrelated injuries illnesses helps provide measure severity injuries illnesses reportable injuries illnesses without lost time incidents result time away work lost time serious first aid serious enough result lost time sgs verified back top home responsibility people case studies corporate responsibility report case studies diversity inclusion women science event created global programme within gsk rd encourages celebrates women science women science event wise programme started uk bringing women scientists together daylong event networking education knowledgesharing opportunities since developed scope attendance annual event held simultaneously sites stevenage north carolina series speakers workshops simultaneous broadcast keynote speaker internationally renowned female scientist sites held events uk two us sites north carolina delaware keynote speaker networking opportunities plan hold event late additional speaking networking events arranged throughout year uk us featuring leading female scientists gsk scientific womens scholarship programme scientific womens scholarship programme place since programme offered unique combination scholarships mentor relationships professional women scientists supported endowment fund programme open us colleges universities women scholars selected participate programme gsk research triangle park north carolina fiftyfive gsk mentors worked scholars pass dedication energy passion science new generation students scholars paired professional women scientists gsk serve mentors women take scholars wing provide expert advice share experiences lessons learned years gsk volunteer mentors also work secure internship funding opportunities scholars internships offer insight careers give scholars handson experience pharmaceutical industry supporting adult literacy manufacturing sites nabha rajamundy india taking action improve literacy rates among employees beginning around ten per cent workers could read write use thumb print instead signing name sites set goal employees able sign name employees nabha factory took nearly hours training total including sessions read write punjabi english result initiative people learned read write employees able sign name sessions also included areas family relations aids awareness good health practices domestic safety budgeting project received honourable mention employee attraction development retention category multicultural marketing diversity awards occupational health safety contractor competition improves safety shutdown gsks slough site makes lucozade horlicks powders holds annual shutdown clean maintain manufacturing equipment sites ehs team developed programme reduce number accidents occurring shutdown time increased risk employees contractors undertake nonroutine engineering activities short period time team reviewed log accidents nearmisses previous shutdowns held briefing meetings supervisors contractors raise awareness risks ran competition identify reward contractors best safety performance initiative contributed reduction minor accidents shutdown reportable incidents since competition began project third place ceos ehs excellence awards safety initiative categoryhome responsibility people case studies corporate responsibility report case studies diversity inclusion women science event created global programme within gsk rd encourages celebrates women science women science event wise programme started uk bringing women scientists together daylong event networking education knowledgesharing opportunities since developed scope attendance annual event held simultaneously sites stevenage north carolina series speakers workshops simultaneous broadcast keynote speaker internationally renowned female scientist sites held events uk two us sites north carolina delaware keynote speaker networking opportunities plan hold event late additional speaking networking events arranged throughout year uk us featuring leading female scientists gsk scientific womens scholarship programme scientific womens scholarship programme place since programme offered unique combination scholarships mentor relationships professional women scientists supported endowment fund programme open us colleges universities women scholars selected participate programme gsk research triangle park north carolina fiftyfive gsk mentors worked scholars pass dedication energy passion science new generation students scholars paired professional women scientists gsk serve mentors women take scholars wing provide expert advice share experiences lessons learned years gsk volunteer mentors also work secure internship funding opportunities scholars internships offer insight careers give scholars handson experience pharmaceutical industry supporting adult literacy manufacturing sites nabha rajamundy india taking action improve literacy rates among employees beginning around ten per cent workers could read write use thumb print instead signing name sites set goal employees able sign name employees nabha factory took nearly hours training total including sessions read write punjabi english result initiative people learned read write employees able sign name sessions also included areas family relations aids awareness good health practices domestic safety budgeting project received honourable mention employee attraction development retention category multicultural marketing diversity awards occupational health safety contractor competition improves safety shutdown gsks slough site makes lucozade horlicks powders holds annual shutdown clean maintain manufacturing equipment sites ehs team developed programme reduce number accidents occurring shutdown time increased risk employees contractors undertake nonroutine engineering activities short period time team reviewed log accidents nearmisses previous shutdowns held briefing meetings supervisors contractors raise awareness risks ran competition identify reward contractors best safety performance initiative contributed reduction minor accidents shutdown reportable incidents since competition began project third place ceos ehs excellence awards safety initiative category home responsibility people case studies corporate responsibility report case studies diversity inclusion women science event created global programme within gsk rd encourages celebrates women science women science event wise programme started uk bringing women scientists together daylong event networking education knowledgesharing opportunities since developed scope attendance annual event held simultaneously sites stevenage north carolina series speakers workshops simultaneous broadcast keynote speaker internationally renowned female scientist sites held events uk two us sites north carolina delaware keynote speaker networking opportunities plan hold event late additional speaking networking events arranged throughout year uk us featuring leading female scientists gsk scientific womens scholarship programme scientific womens scholarship programme place since programme offered unique combination scholarships mentor relationships professional women scientists supported endowment fund programme open us colleges universities women scholars selected participate programme gsk research triangle park north carolina fiftyfive gsk mentors worked scholars pass dedication energy passion science new generation students scholars paired professional women scientists gsk serve mentors women take scholars wing provide expert advice share experiences lessons learned years gsk volunteer mentors also work secure internship funding opportunities scholars internships offer insight careers give scholars handson experience pharmaceutical industry supporting adult literacy manufacturing sites nabha rajamundy india taking action improve literacy rates among employees beginning around ten per cent workers could read write use thumb print instead signing name sites set goal employees able sign name employees nabha factory took nearly hours training total including sessions read write punjabi english result initiative people learned read write employees able sign name sessions also included areas family relations aids awareness good health practices domestic safety budgeting project received honourable mention employee attraction development retention category multicultural marketing diversity awards occupational health safety contractor competition improves safety shutdown gsks slough site makes lucozade horlicks powders holds annual shutdown clean maintain manufacturing equipment sites ehs team developed programme reduce number accidents occurring shutdown time increased risk employees contractors undertake nonroutine engineering activities short period time team reviewed log accidents nearmisses previous shutdowns held briefing meetings supervisors contractors raise awareness risks ran competition identify reward contractors best safety performance initiative contributed reduction minor accidents shutdown reportable incidents since competition began project third place ceos ehs excellence awards safety initiative category home responsibility people qas corporate responsibility report qas respond questions raised stakeholders reduce workforce ensure remaining employees faced additional stress jobs recognise stress work important issue established programmes help individuals teams deal stress offer support onsite health fitness centres flexible working arrangements family support services health education gsk aims simplify operating model create culture individual empowerment employee takes responsibility work simplifying work removing processes structures reduces amount work areas result fewer people required empowering individuals make decisions carry work without layers bureaucracy support operational excellence programme affect employees regrettably operational excellence programme result job losses everything support affected employees including providing competitive severance package providing outplacement support assistance identifying alternative employment career counselling retraining also work hard ensure programme negative impact morale staff produced guide managers information support employees uncertainty anxiety stress encountered major organisational change still relatively women senior management gsk pleased percentage women management increased incrementally last four years however recognise still room improvement especially senior management positions roles within historically maledominated disciplines science engineering aim attract women gsk support career development existing employees flexible working programmes help employees balance demands personal professional lives also diversity champions business unit well employee networks support career development women minority groups gsk health safety performance industry average needs improve know need improve performance area assessment project identified ergonomics attitudes health safety workplace among main causes injuries illnesses target awareness training programmes based results year also launched toolkit help sites assess risks identify interventions adopted pharmaceutical manufacturing business behaviourbased safety programmes planned sites progress made toward respiratorfree target results baseline monitoring level exposure chemicals workplace used define new upgraded engineering controls needed meet target employees operations able work without needing wear respiratory protection reached operations achieved level engineering control pending completion full verification monitoring continue upgrade engineering controls achieve respirator free levels control situations engineering controls possible make sure appropriate respiratory protective equipment used home responsibility people qas corporate responsibility report qas respond questions raised stakeholders reduce workforce ensure remaining employees faced additional stress jobs recognise stress work important issue established programmes help individuals teams deal stress offer support onsite health fitness centres flexible working arrangements family support services health education gsk aims simplify operating model create culture individual empowerment employee takes responsibility work simplifying work removing processes structures reduces amount work areas result fewer people required empowering individuals make decisions carry work without layers bureaucracy support operational excellence programme affect employees regrettably operational excellence programme result job losses everything support affected employees including providing competitive severance package providing outplacement support assistance identifying alternative employment career counselling retraining also work hard ensure programme negative impact morale staff produced guide managers information support employees uncertainty anxiety stress encountered major organisational change still relatively women senior management gsk pleased percentage women management increased incrementally last four years however recognise still room improvement especially senior management positions roles within historically maledominated disciplines science engineering aim attract women gsk support career development existing employees flexible working programmes help employees balance demands personal professional lives also diversity champions business unit well employee networks support career development women minority groups gsk health safety performance industry average needs improve know need improve performance area assessment project identified ergonomics attitudes health safety workplace among main causes injuries illnesses target awareness training programmes based results year also launched toolkit help sites assess risks identify interventions adopted pharmaceutical manufacturing business behaviourbased safety programmes planned sites progress made toward respiratorfree target results baseline monitoring level exposure chemicals workplace used define new upgraded engineering controls needed meet target employees operations able work without needing wear respiratory protection reached operations achieved level engineering control pending completion full verification monitoring continue upgrade engineering controls achieve respirator free levels control situations engineering controls possible make sure appropriate respiratory protective equipment used home responsibility people qas corporate responsibility report qas respond questions raised stakeholders reduce workforce ensure remaining employees faced additional stress jobs recognise stress work important issue established programmes help individuals teams deal stress offer support onsite health fitness centres flexible working arrangements family support services health education gsk aims simplify operating model create culture individual empowerment employee takes responsibility work simplifying work removing processes structures reduces amount work areas result fewer people required empowering individuals make decisions carry work without layers bureaucracy support operational excellence programme affect employees regrettably operational excellence programme result job losses everything support affected employees including providing competitive severance package providing outplacement support assistance identifying alternative employment career counselling retraining also work hard ensure programme negative impact morale staff produced guide managers information support employees uncertainty anxiety stress encountered major organisational change still relatively women senior management gsk pleased percentage women management increased incrementally last four years however recognise still room improvement especially senior management positions roles within historically maledominated disciplines science engineering aim attract women gsk support career development existing employees flexible working programmes help employees balance demands personal professional lives also diversity champions business unit well employee networks support career development women minority groups gsk health safety performance industry average needs improve know need improve performance area assessment project identified ergonomics attitudes health safety workplace among main causes injuries illnesses target awareness training programmes based results year also launched toolkit help sites assess risks identify interventions adopted pharmaceutical manufacturing business behaviourbased safety programmes planned sites progress made toward respiratorfree target results baseline monitoring level exposure chemicals workplace used define new upgraded engineering controls needed meet target employees operations able work without needing wear respiratory protection reached operations achieved level engineering control pending completion full verification monitoring continue upgrade engineering controls achieve respirator free levels control situations engineering controls possible make sure appropriate respiratory protective equipment used home responsibility human rights corporate responsibility report human rights committed upholding un universal declaration human rights oecd guidelines multinational enterprises core labour standards set international labour organization signatory un global compact voluntary global standard human rights labour environment anticorruption believe governments responsibility define enforce legal framework human rights accordance international laws agreements universal declaration human rights businesses also responsibilities work hard uphold human rights within sphere influence includes employees suppliers communities society direct control human rights operations also influence supply chain wider society marketer medicines strive make widely available possible running business sustainable way high standards human rights important gsk help us get best employees support relationships communities near sites ensure supplier contracts run smoothly provide reliable supply highquality products protect reputation human rights relevant many issues covered report section gives overview approach information gsk human rights see human rights clauses included contracts suppliers read supply chain read efforts improve access medicines read investment local communities read employment practices read position statement convention biological diversity home responsibility human rights corporate responsibility report human rights committed upholding un universal declaration human rights oecd guidelines multinational enterprises core labour standards set international labour organization signatory un global compact voluntary global standard human rights labour environment anticorruption believe governments responsibility define enforce legal framework human rights accordance international laws agreements universal declaration human rights businesses also responsibilities work hard uphold human rights within sphere influence includes employees suppliers communities society direct control human rights operations also influence supply chain wider society marketer medicines strive make widely available possible running business sustainable way high standards human rights important gsk help us get best employees support relationships communities near sites ensure supplier contracts run smoothly provide reliable supply highquality products protect reputation human rights relevant many issues covered report section gives overview approach information gsk human rights see human rights clauses included contracts suppliers read supply chain read efforts improve access medicines read investment local communities read employment practices read position statement convention biological diversity home responsibility human rights employees corporate responsibility report employees employment standards issues diversity equal opportunities health safety protect employees human rights employer committed providing fair salary good employment conditions committed providing healthy safe secure workplace employees contractors opposed discrimination work committed promoting respect diversitys committed promoting personal development dignity every employee respectful employees right join independent trade union freedom association opposed forms slavery exploitative child labour work appropriate partners address problem responsibly wherever encounter employees report concerns supervisor line manager human resources ethics compliance office also use global confidential reporting line read employment practices home responsibility human rights employees corporate responsibility report employees employment standards issues diversity equal opportunities health safety protect employees human rights employer committed providing fair salary good employment conditions committed providing healthy safe secure workplace employees contractors opposed discrimination work committed promoting respect diversitys committed promoting personal development dignity every employee respectful employees right join independent trade union freedom association opposed forms slavery exploitative child labour work appropriate partners address problem responsibly wherever encounter employees report concerns supervisor line manager human resources ethics compliance office also use global confidential reporting line read employment practices home responsibility human rights suppliers corporate responsibility report suppliers buyer raw materials manufactured goods services around world require suppliers contractors business partners meet standards human rights gsk knowingly use suppliers responsible human rights infringements conduct regular audits existing suppliers engage new suppliers meet expectations human rights clauses included contracts consider human rights issues routine interactions critical suppliers contract manufacturers suppliers present greatest risk gsk one key risk areas ehs audits potential new existing critical suppliers also include questions help us identify potential breaches human rights clauses included supplier contracts suppliers asked information policies practices relating age limits employees discrimination employees local population prevention abuse individuals wages benefits working hours whether meet legal minimum rights workers organise recognition worker organisations questions contribute ehs audit score may reason progress business supplier read supply chain home responsibility human rights suppliers corporate responsibility report suppliers buyer raw materials manufactured goods services around world require suppliers contractors business partners meet standards human rights gsk knowingly use suppliers responsible human rights infringements conduct regular audits existing suppliers engage new suppliers meet expectations human rights clauses included contracts consider human rights issues routine interactions critical suppliers contract manufacturers suppliers present greatest risk gsk one key risk areas ehs audits potential new existing critical suppliers also include questions help us identify potential breaches human rights clauses included supplier contracts suppliers asked information policies practices relating age limits employees discrimination employees local population prevention abuse individuals wages benefits working hours whether meet legal minimum rights workers organise recognition worker organisations questions contribute ehs audit score may reason progress business supplier read supply chain home responsibility human rights communities corporate responsibility report communities respect promote rights communities near operations example local communities gsk aims good relationships communities around sites operate ways infringe human rights seek minimise impacts local environment operate sites safely aim bring social economic benefits areas presence read investment local communities un convention biological diversity cbd convention biological diversity provides framework conservation sustainable use biodiversity also promotes fair equitable sharing benefits arising use genetic resources gsk supports cbds role currently involved bioprospecting activity result access benefit sharing agreements place possible future may undertake development work using natural genetic resources indigenous particular country instance access resources would obtained accordance cbd reflected local laws would ensure relevant parties received agreed benefits use resources example monetary payments read position statement convention biological diversity read position protecting biodiversity home responsibility human rights communities corporate responsibility report communities respect promote rights communities near operations example local communities gsk aims good relationships communities around sites operate ways infringe human rights seek minimise impacts local environment operate sites safely aim bring social economic benefits areas presence read investment local communities un convention biological diversity cbd convention biological diversity provides framework conservation sustainable use biodiversity also promotes fair equitable sharing benefits arising use genetic resources gsk supports cbds role currently involved bioprospecting activity result access benefit sharing agreements place possible future may undertake development work using natural genetic resources indigenous particular country instance access resources would obtained accordance cbd reflected local laws would ensure relevant parties received agreed benefits use resources example monetary payments read position statement convention biological diversity read position protecting biodiversity home responsibility human rights society corporate responsibility report society un declaration human rights states everyone right standard living adequate health wellbeing family including medical care improving healthcare one greatest challenges face particularly developing world gsk contributes healthcare developing world discovering new treatments vaccines also make wide range products affordable developing countries preferential pricing voluntary licence agreements generic manufacturers engage governments multilateral agencies ngos pharmaceutical companies help improve access medicines read efforts improve access medicines community investment initiatives home responsibility human rights society corporate responsibility report society un declaration human rights states everyone right standard living adequate health wellbeing family including medical care improving healthcare one greatest challenges face particularly developing world gsk contributes healthcare developing world discovering new treatments vaccines also make wide range products affordable developing countries preferential pricing voluntary licence agreements generic manufacturers engage governments multilateral agencies ngos pharmaceutical companies help improve access medicines read efforts improve access medicines community investment initiatives home responsibility human rights activities sensitive countries corporate responsibility report activities sensitive countries stakeholders concerned gsks business activity countries poor human rights records burma myanmar north korea sudan share uns belief see box people denied access medicines regime operating country aim provide medicines vaccines countries need wish purchase observe trading controls required law countries operate many nations longstanding commitment presence predate oppressive regimes subsequent introduction measures trade embargoes periods governmentimposed trade embargoes continued operations subject specific legal restrictions due need products sensitive countries countries operate support committed upholding universal declaration human rights core standards set international labour organization observe local laws regulations un statement right highest attainable standard health paragraphs relating access medicines sensitive countries paragraph health facilities goods services must accessible everyone without discrimination within jurisdiction state party paragraph parties refrain times imposing embargoes similar measures restricting supply another state adequate medicines medical equipment restrictions goods never used instrument political economic pressure paragraph states parties covenant thus ultimately accountable compliance members society individuals including health professionals families local communities intergovernmental nongovernmental organizations civil society organizations well private business sector responsibilities regarding realization right health state parties therefore provide environment facilitates discharge responsibilities read full un statement right highest attainable standard health home responsibility human rights activities sensitive countries corporate responsibility report activities sensitive countries stakeholders concerned gsks business activity countries poor human rights records burma myanmar north korea sudan share uns belief see box people denied access medicines regime operating country aim provide medicines vaccines countries need wish purchase observe trading controls required law countries operate many nations longstanding commitment presence predate oppressive regimes subsequent introduction measures trade embargoes periods governmentimposed trade embargoes continued operations subject specific legal restrictions due need products sensitive countries countries operate support committed upholding universal declaration human rights core standards set international labour organization observe local laws regulations un statement right highest attainable standard health paragraphs relating access medicines sensitive countries paragraph health facilities goods services must accessible everyone without discrimination within jurisdiction state party paragraph parties refrain times imposing embargoes similar measures restricting supply another state adequate medicines medical equipment restrictions goods never used instrument political economic pressure paragraph states parties covenant thus ultimately accountable compliance members society individuals including health professionals families local communities intergovernmental nongovernmental organizations civil society organizations well private business sector responsibilities regarding realization right health state parties therefore provide environment facilitates discharge responsibilities read full un statement right highest attainable standard health home responsibility public policy patient advocacy corporate responsibility report public policy patient advocacy pharmaceutical industry highly regulated government policy legislation significant impact business important engage governments stakeholders legislative policy process public policy activity work towards legislation policy encourage scientific innovation balance interests business stakeholders also work patient groups help give members voice healthcare debate believe conduct advocacy work responsibly make valuable contribution debate public policy issues impact business particularly relating research development use pharmaceuticals healthcare aim increase stakeholder trust gsk transparent lobbying public policy work address concerns stakeholders pharmaceutical industry strong influence governments publish annual public policy activity website report memberships trade associations political contributions us lobbying expenditures also publish information work patient groups including details funding provide provide information approach working doctors healthcare professionals research practices ethical conduct sections website back top home responsibility public policy patient advocacy corporate responsibility report public policy patient advocacy pharmaceutical industry highly regulated government policy legislation significant impact business important engage governments stakeholders legislative policy process public policy activity work towards legislation policy encourage scientific innovation balance interests business stakeholders also work patient groups help give members voice healthcare debate believe conduct advocacy work responsibly make valuable contribution debate public policy issues impact business particularly relating research development use pharmaceuticals healthcare aim increase stakeholder trust gsk transparent lobbying public policy work address concerns stakeholders pharmaceutical industry strong influence governments publish annual public policy activity website report memberships trade associations political contributions us lobbying expenditures also publish information work patient groups including details funding provide provide information approach working doctors healthcare professionals research practices ethical conduct sections website back top home responsibility public policy patient advocacy approach external affairs corporate responsibility report approach external affairs employees involved public policy work must abide employee guide business conduct based three principles partnership committed working governments regulatory authorities constructive way communication well giving views take board concerns external audiences enables us assess improve business practices integrity base public policy work research analysis facts respect opinions look constructive solutions external affairs work must line code conduct relevant policies including related competition law preventing corrupt practices political contributions external affairs teams major regions monitor proposed legislative reforms policy developments meet regularly government officials stakeholders example multilateral organisations ngos explain views range public policy issues tailor approach suit different cultures political traditions countries engage public policy process ensuring position discussions fully consistent public policy statements ensure standards set guide business conduct applied globally lobbying issues affecting whole pharmaceutical industry sometimes conducted trade associations may also hire professional lobbyists support public policy work political contributions policy governing contributions political candidates parties trade associations gsk member many trade industry organisations including association british pharmaceutical industry abpi bioindustry association bia biotechnology industry organization bio british pharma group bpg confederation british industry cbi european federation pharmaceutical industries efpia international chamber commerce icc intellectual property owners association ipo international federation pharmaceutical manufacturers associations ifpma japan pharmaceutical manufacturers association jpma organisation pharmaceutical producers india oppi organization international investment ofii pharmaceutical research manufacturers america phrma important lobbying conducted trade associations reflects policies values work members help set policies may also attend lobbying meetings governments stakeholders sometimes share views particular issue members trade association trade association adopts public policy position agree participate advocacy activity related subject senior gsk managers sit boards majority industry trade associations members raise concerns may particular advocacy position back tophome responsibility public policy patient advocacy approach external affairs corporate responsibility report approach external affairs employees involved public policy work must abide employee guide business conduct based three principles partnership committed working governments regulatory authorities constructive way communication well giving views take board concerns external audiences enables us assess improve business practices integrity base public policy work research analysis facts respect opinions look constructive solutions external affairs work must line code conduct relevant policies including related competition law preventing corrupt practices political contributions external affairs teams major regions monitor proposed legislative reforms policy developments meet regularly government officials stakeholders example multilateral organisations ngos explain views range public policy issues tailor approach suit different cultures political traditions countries engage public policy process ensuring position discussions fully consistent public policy statements ensure standards set guide business conduct applied globally lobbying issues affecting whole pharmaceutical industry sometimes conducted trade associations may also hire professional lobbyists support public policy work political contributions policy governing contributions political candidates parties trade associations gsk member many trade industry organisations including association british pharmaceutical industry abpi bioindustry association bia biotechnology industry organization bio british pharma group bpg confederation british industry cbi european federation pharmaceutical industries efpia international chamber commerce icc intellectual property owners association ipo international federation pharmaceutical manufacturers associations ifpma japan pharmaceutical manufacturers association jpma organisation pharmaceutical producers india oppi organization international investment ofii pharmaceutical research manufacturers america phrma important lobbying conducted trade associations reflects policies values work members help set policies may also attend lobbying meetings governments stakeholders sometimes share views particular issue members trade association trade association adopts public policy position agree participate advocacy activity related subject senior gsk managers sit boards majority industry trade associations members raise concerns may particular advocacy position back top home responsibility public policy patient advocacy approach external affairs corporate responsibility report approach external affairs employees involved public policy work must abide employee guide business conduct based three principles partnership committed working governments regulatory authorities constructive way communication well giving views take board concerns external audiences enables us assess improve business practices integrity base public policy work research analysis facts respect opinions look constructive solutions external affairs work must line code conduct relevant policies including related competition law preventing corrupt practices political contributions external affairs teams major regions monitor proposed legislative reforms policy developments meet regularly government officials stakeholders example multilateral organisations ngos explain views range public policy issues tailor approach suit different cultures political traditions countries engage public policy process ensuring position discussions fully consistent public policy statements ensure standards set guide business conduct applied globally lobbying issues affecting whole pharmaceutical industry sometimes conducted trade associations may also hire professional lobbyists support public policy work political contributions policy governing contributions political candidates parties trade associations gsk member many trade industry organisations including association british pharmaceutical industry abpi bioindustry association bia biotechnology industry organization bio british pharma group bpg confederation british industry cbi european federation pharmaceutical industries efpia international chamber commerce icc intellectual property owners association ipo international federation pharmaceutical manufacturers associations ifpma japan pharmaceutical manufacturers association jpma organisation pharmaceutical producers india oppi organization international investment ofii pharmaceutical research manufacturers america phrma important lobbying conducted trade associations reflects policies values work members help set policies may also attend lobbying meetings governments stakeholders sometimes share views particular issue members trade association trade association adopts public policy position agree participate advocacy activity related subject senior gsk managers sit boards majority industry trade associations members raise concerns may particular advocacy position back top home responsibility public policy patient advocacy public policy activity corporate responsibility report public policy activity engage governments stakeholders wide range issues affect industry key issues engaged access healthcare disease prevention research practices patient safety intellectual property pricing competitiveness publish position key issues relating corporate responsibility including access medicines developing countries research development intellectual property environment public health competitiveness pricing reimbursement market access happy discuss position issues legitimate parties contact corporate responsibility team csrcontactgskcom back top home responsibility public policy patient advocacy public policy activity corporate responsibility report public policy activity engage governments stakeholders wide range issues affect industry key issues engaged access healthcare disease prevention research practices patient safety intellectual property pricing competitiveness publish position key issues relating corporate responsibility including access medicines developing countries research development intellectual property environment public health competitiveness pricing reimbursement market access happy discuss position issues legitimate parties contact corporate responsibility team csrcontactgskcom back top home responsibility public policy patient advocacy public policy activity advocacy healthcare disease prevention corporate responsibility report advocacy healthcare disease prevention global activity safeguarding timely unrestricted access influenza viruses organisations engaged world health organization key developed developing country governments including countries affected hn strain eu institutions industry associations involved efpia evm ifpma ivs phrma gsk position influenza virus unstable mutate quickly governments must remain vigilant emergence new strains virus must share virus strains freely governments free sharing viruses best interests global public health enables governments develop vaccines may prevent influenza pandemic whos global influenza surveillance network recommends content influenza vaccines twice year act global alert mechanism event pandemic international community unconditionally support network relies receiving information virus strains governments despite importance timely unrestricted access viruses indonesia stopped sharing influenza viruses insisting access benefits exchange viruses international community including vaccine industry spent much finding way help developing countries prepare pandemic progress made towards agreeing effective solution intergovernmental meeting geneva december gsk hopeful solution ensure speedy access pandemic virus assuring developing countries support require secure access prepandemic pandemic vaccines agreed next igm may us activity investment chronic disease prevention treatment organisations engaged us department health human services office first lady us congress white house state legislators governors offices various state health agencies industry associations involved phrma gsk position chronic diseases diabetes heart disease lung disease account three quarters healthcare spending relatively little invested prevention even though many chronic diseases costly complications preventable increasingly manageable advocating threepart approach achieving lowercost higherquality healthcare increasing prevention improving treatment accelerating research better treatments chronic disease healthcare providers need incentives promote preventative services address major causes chronic disease obesity smoking healthcare policy needs reform better encourage reward medical research improved treatments costly unmet medical needs alzheimers disease preventing better managing chronic diseases reduce overall healthcare costs long term supporting petition protect americans fraudulent weight loss claims organisations engaged us food drug administration industry associations involved none see healthcare associations involved gsk position us twothirds adults overweight obese increasing risk illnesses cancer heart disease type diabetes dozens dietary supplements market us manufacturers claim help people lose weight claims reviewed food drug administrationp afged oaf nd supported credible scientific evidence ineffective weight loss products prevent people getting support need lose weight us federal trade commissions consumer fraud survey recently highlighted victims fraudulent weightloss products million american consumers frauds covered survey gsk manufactures alli overthecounter weight loss product gained fda approval safety efficacy april gsk three research advocacy organisations american dietetic association obesity society shaping americas health submitted citizens petition fda asking provide greater protection americans fraudulent weight loss claims petition requests fda treats weight loss claims way unsubstantiated claims efficacy disease permitted dietary supplement health education act petition calls fda require rigorous scientific evidence claims also aims raise awareness educate public issue fraudulent weight loss products separate development january fda demanded recall large number weightloss supplement products warned number companies may liable criminal charges among fdas complaints supplement products us illegal inclusion regulated unapproved withdrawn prescription pharmaceuticals including sibutramine rimonabant weight loss phenytoin antiseizure phenolphthalein laxative previously withdrawn fda due carcinogenicity gsk supports continue work fda help protect public false unsubstantiated weight loss claims possibly unsafe products back tophome responsibility public policy patient advocacy public policy activity advocacy healthcare disease prevention corporate responsibility report advocacy healthcare disease prevention global activity safeguarding timely unrestricted access influenza viruses organisations engaged world health organization key developed developing country governments including countries affected hn strain eu institutions industry associations involved efpia evm ifpma ivs phrma gsk position influenza virus unstable mutate quickly governments must remain vigilant emergence new strains virus must share virus strains freely governments free sharing viruses best interests global public health enables governments develop vaccines may prevent influenza pandemic whos global influenza surveillance network recommends content influenza vaccines twice year act global alert mechanism event pandemic international community unconditionally support network relies receiving information virus strains governments despite importance timely unrestricted access viruses indonesia stopped sharing influenza viruses insisting access benefits exchange viruses international community including vaccine industry spent much finding way help developing countries prepare pandemic progress made towards agreeing effective solution intergovernmental meeting geneva december gsk hopeful solution ensure speedy access pandemic virus assuring developing countries support require secure access prepandemic pandemic vaccines agreed next igm may us activity investment chronic disease prevention treatment organisations engaged us department health human services office first lady us congress white house state legislators governors offices various state health agencies industry associations involved phrma gsk position chronic diseases diabetes heart disease lung disease account three quarters healthcare spending relatively little invested prevention even though many chronic diseases costly complications preventable increasingly manageable advocating threepart approach achieving lowercost higherquality healthcare increasing prevention improving treatment accelerating research better treatments chronic disease healthcare providers need incentives promote preventative services address major causes chronic disease obesity smoking healthcare policy needs reform better encourage reward medical research improved treatments costly unmet medical needs alzheimers disease preventing better managing chronic diseases reduce overall healthcare costs long term supporting petition protect americans fraudulent weight loss claims organisations engaged us food drug administration industry associations involved none see healthcare associations involved gsk position us twothirds adults overweight obese increasing risk illnesses cancer heart disease type diabetes dozens dietary supplements market us manufacturers claim help people lose weight claims reviewed food drug administration fda supported credible scientific evidence ineffective weight loss products prevent people getting support need lose weight us federal trade commissions consumer fraud survey recently highlighted victims fraudulent weightloss products million american consumers frauds covered survey gsk manufactures alli overthecounter weight loss product gained fda approval safety efficacy april gsk three research advocacy organisations american dietetic association obesity society shaping americas health submitted citizens petition fda asking provide greater protection americans fraudulent weight loss claims petition requests fda treats weight loss claims way unsubstantiated claims efficacy disease permitted dietary supplement health education act petition calls fda require rigorous scientific evidence claims also aims raise awareness educate public issue fraudulent weight loss products separate development january fda demanded recall large number weightloss supplement products warned number companies may liable criminal charges among fdas complaints supplement products us illegal inclusion regulated unapproved withdrawn prescription pharmaceuticals including sibutramine rimonabant weight loss phenytoin antiseizure phenolphthalein laxative previously withdrawn fda due carcinogenicity gsk supports continue work fda help protect public false unsubstantiated weight loss claims possibly unsafe products back top home responsibility public policy patient advocacy public policy activity advocacy healthcare disease prevention corporate responsibility report advocacy healthcare disease prevention global activity safeguarding timely unrestricted access influenza viruses organisations engaged world health organization key developed developing country governments including countries affected hn strain eu institutions industry associations involved efpia evm ifpma ivs phrma gsk position influenza virus unstable mutate quickly governments must remain vigilant emergence new strains virus must share virus strains freely governments free sharing viruses best interests global public health enables governments develop vaccines may prevent influenza pandemic whos global influenza surveillance network recommends content influenza vaccines twice year act global alert mechanism event pandemic international community unconditionally support network relies receiving information virus strains governments despite importance timely unrestricted access viruses indonesia stopped sharing influenza viruses insisting access benefits exchange viruses international community including vaccine industry spent much finding way help developing countries prepare pandemic progress made towards agreeing effective solution intergovernmental meeting geneva december gsk hopeful solution ensure speedy access pandemic virus assuring developing countries support require secure access prepandemic pandemic vaccines agreed next igm may us activity investment chronic disease prevention treatment organisations engaged us department health human services office first lady us congress white house state legislators governors offices various state health agencies industry associations involved phrma gsk position chronic diseases diabetes heart disease lung disease account three quarters healthcare spending relatively little invested prevention even though many chronic diseases costly complications preventable increasingly manageable advocating threepart approach achieving lowercost higherquality healthcare increasing prevention improving treatment accelerating research better treatments chronic disease healthcare providers need incentives promote preventative services address major causes chronic disease obesity smoking healthcare policy needs reform better encourage reward medical research improved treatments costly unmet medical needs alzheimers disease preventing better managing chronic diseases reduce overall healthcare costs long term supporting petition protect americans fraudulent weight loss claims organisations engaged us food drug administration industry associations involved none see healthcare associations involved gsk position us twothirds adults overweight obese increasing risk illnesses cancer heart disease type diabetes dozens dietary supplements market us manufacturers claim help people lose weight claims reviewed food drug administration fda supported credible scientific evidence ineffective weight loss products prevent people getting support need lose weight us federal trade commissions consumer fraud survey recently highlighted victims fraudulent weightloss products million american consumers frauds covered survey gsk manufactures alli overthecounter weight loss product gained fda approval safety efficacy april gsk three research advocacy organisations american dietetic association obesity society shaping americas health submitted citizens petition fda asking provide greater protection americans fraudulent weight loss claims petition requests fda treats weight loss claims way unsubstantiated claims efficacy disease permitted dietary supplement health education act petition calls fda require rigorous scientific evidence claims also aims raise awareness educate public issue fraudulent weight loss products separate development january fda demanded recall large number weightloss supplement products warned number companies may liable criminal charges among fdas complaints supplement products us illegal inclusion regulated unapproved withdrawn prescription pharmaceuticals including sibutramine rimonabant weight loss phenytoin antiseizure phenolphthalein laxative previously withdrawn fda due carcinogenicity gsk supports continue work fda help protect public false unsubstantiated weight loss claims possibly unsafe products back top home responsibility public policy patient advocacy public policy activity advocacy research practices corporate responsibility report advocacy research practices regularly engage policy makers stakeholders issues relating research practices research environment read research practices global activity advocacy revisions declaration helsinki organisations engaged world medical association american medical association industry associations involved bio ifpma phrma gsk position declaration helsinki sets ethical principles conduct research human subjects declaration revised world medical association urged world medical association resist changes make document detailed prescriptive believe create confusion conflict detailed guidance ich guidance good clinical practice shaping scope international regime access benefit sharing organisations engaged secretariat convention biological diversity cbd ad hoc working group access benefit sharing uk defra dg trade european commission national european governments us government industry associations involved bio bpg efpia icc ifpma phrma gsk position convention biological diversity cbd signed three main goals including fair equitable sharing benefits arising use genetic resources gsk believes best way achieve cbds access benefitsharing objectives countries introduce national laws governing access genetic resources mutually agreed contracts define benefits arising use shared approach allows national governments flexibility develop guidelines best serve national interests enables users guidelines reach agreements appropriate individual case notwithstanding gsks support national legislation recognise cbds mandate elaborate negotiate international regime access benefitsharing believe resulting regime currently discussion within cbd consistent cbds treaty objectives create new obligations cbd signatories applied retrospectively provide guidance governments cbd members achieve access benefitsharing objectives rather prescribing rules adopt sectoral approach seek enforce one size fits solution industries apply genetic resources defined cbd broader class materials extend human genetic resources derivatives pathogens read position statement convention biological diversity european activity advocacy european animal directive organisations engaged european commission industry associations involved abpi efpia gsk position european animal directive originally introduced governs use animals experimental scientific purposes aims establish framework animal research activities within eu european commission published draft revision directive controls use laboratory animals sets minimum standards housing care gsk welcomes review directive recognises need revised reflect advances animal welfare science welcome many recommendations draft revision many already integrated current practices example welcome rules relating replacement reduction refinement use animals research known rs need permanent standing ethic review body establishments use animals research essential legislative changes achieve high animal welfare standards supporting environment allows research leads new medicines vaccines meet patients needs regard number concerns related restrictions use nonhuman primates diseases considered lifethreatening seriously debilitating reuse surgically instrumented animals likely result increased number animals procedures mild moderate read position statement use nonhuman primates research supporting new approach pharmacovigilance eu organisations engaged european commission european medicines agency uk government industry associations involved abpi efpia gsk position gsk seeks new approach pharmacovigilance regulation eu allow pharmaceutical companies regulators focus resources safety evaluation activities instead compliance unclear complex regulatory demands new pharmacovigilance legislation contain clear concise provisions simplify strengthen provide legal certainty eu legislative framework pharmacovigilance specifically contain single set simplified rules single reporting point adverse drug reactions eu require reporting serious cases electronic reporting system implemented contain clear flexible provisions allow individual companies appoint number qualified persons pharmacovigilance qppvs require provide consistent standards inspections company pharmacovigilance departments emea eu member state authorities back tophome responsibility public policy patient advocacy public policy activity advocacy research practices corporate responsibility report advocacy research practices regularly engage policy makers stakeholders issues relating research practices research environment read research practices global activity advocacy revisions declaration helsinki organisations engaged world medical association american medical association industry associations involved bio ifpma phrma gsk position declaration helsinki sets ethical principles conduct research human subjects declaration revised world medical association urged world medical association resist changes make document detailed prescriptive believe create confusion conflict detailed guidance ich guidance good clinical practice shaping scope international regime access benefit sharing organisations engaged secretariat convention biological diversity cbd ad hoc working group access benefit sharing uk defra dg trade european commission national european governments us government industry associations involved bio bpg efpia icc ifpma phrma gsk position convention biological diversity cbd signed three main goals including fair equitable sharing benefits arising use genetic resources gsk believes best way achieve cbds access benefitsharing objectives countries introduce national laws governing access genetic resources mutually agreed contracts define benefits arising use shared approach allows national governments flexibility develop guidelines best serve national interests enables users guidelines reach agreements appropriate individual case notwithstanding gsks support national legislation recognise cbds mandate elaborate negotiate international regime access benefitsharing believe resulting regime currently discussion within cbd consistent cbds treaty objectives create new obligations cbd signatories applied retrospectively provide guidance governments cbd members achieve access benefitsharing objectives rather prescribing rules adopt sectoral approach seek enforce one size fits solution industries apply genetic resources defined cbd broader class materials extend human genetic resources derivatives pathogens read position statement convention biological diversity european activity advocacy european animal directive organisations engaged european commission industry associations involved abpi efpia gsk position european animal directive originally introduced governs use animals experimental scientific purposes aims establish framework animal research activities within eu european commission published draft revision directive controls use laboratory animals sets minimum standards housing care gsk welcomes review directive recognises need revised reflect advances animal welfare science welcome many recommendations draft revision many already integrated current practices example welcome rules relating replacement reduction refinement use animals research known rs need permanent standing ethic review body establishments use animals research essential legislative changes achieve high animal welfare standards supporting environment allows research leads new medicines vaccines meet patients needs regard number concerns related restrictions use nonhuman primates diseases considered lifethreatening seriously debilitating reuse surgically instrumented animals likely result increased number animals procedures mild moderate read position statement use nonhuman primates research supporting new approach pharmacovigilance eu organisations engaged european commission european medicines agency uk government industry associations involved abpi efpia gsk position gsk seeks new approach pharmacovigilance regulation eu allow pharmaceutical companies regulators focus resources safety evaluation activities instead compliance unclear complex regulatory demands new pharmacovigilance legislation contain clear concise provisions simplify strengthen provide legal certainty eu legislative framework pharmacovigilance specifically contain single set simplified rules single reporting point adverse drug reactions eu require reporting serious cases electronic reporting system implemented contain clear flexible provisions allow individual companies appoint number qualified persons pharmacovigilance qppvs require provide consistent standards inspections company pharmacovigilance departments emea eu member state authorities back top home responsibility public policy patient advocacy public policy activity advocacy research practices corporate responsibility report advocacy research practices regularly engage policy makers stakeholders issues relating research practices research environment read research practices global activity advocacy revisions declaration helsinki organisations engaged world medical association american medical association industry associations involved bio ifpma phrma gsk position declaration helsinki sets ethical principles conduct research human subjects declaration revised world medical association urged world medical association resist changes make document detailed prescriptive believe create confusion conflict detailed guidance ich guidance good clinical practice shaping scope international regime access benefit sharing organisations engaged secretariat convention biological diversity cbd ad hoc working group access benefit sharing uk defra dg trade european commission national european governments us government industry associations involved bio bpg efpia icc ifpma phrma gsk position convention biological diversity cbd signed three main goals including fair equitable sharing benefits arising use genetic resources gsk believes best way achieve cbds access benefitsharing objectives countries introduce national laws governing access genetic resources mutually agreed contracts define benefits arising use shared approach allows national governments flexibility develop guidelines best serve national interests enables users guidelines reach agreements appropriate individual case notwithstanding gsks support national legislation recognise cbds mandate elaborate negotiate international regime access benefitsharing believe resulting regime currently discussion within cbd consistent cbds treaty objectives create new obligations cbd signatories applied retrospectively provide guidance governments cbd members achieve access benefitsharing objectives rather prescribing rules adopt sectoral approach seek enforce one size fits solution industries apply genetic resources defined cbd broader class materials extend human genetic resources derivatives pathogens read position statement convention biological diversity european activity advocacy european animal directive organisations engaged european commission industry associations involved abpi efpia gsk position european animal directive originally introduced governs use animals experimental scientific purposes aims establish framework animal research activities within eu european commission published draft revision directive controls use laboratory animals sets minimum standards housing care gsk welcomes review directive recognises need revised reflect advances animal welfare science welcome many recommendations draft revision many already integrated current practices example welcome rules relating replacement reduction refinement use animals research known rs need permanent standing ethic review body establishments use animals research essential legislative changes achieve high animal welfare standards supporting environment allows research leads new medicines vaccines meet patients needs regard number concerns related restrictions use nonhuman primates diseases considered lifethreatening seriously debilitating reuse surgically instrumented animals likely result increased number animals procedures mild moderate read position statement use nonhuman primates research supporting new approach pharmacovigilance eu organisations engaged european commission european medicines agency uk government industry associations involved abpi efpia gsk position gsk seeks new approach pharmacovigilance regulation eu allow pharmaceutical companies regulators focus resources safety evaluation activities instead compliance unclear complex regulatory demands new pharmacovigilance legislation contain clear concise provisions simplify strengthen provide legal certainty eu legislative framework pharmacovigilance specifically contain single set simplified rules single reporting point adverse drug reactions eu require reporting serious cases electronic reporting system implemented contain clear flexible provisions allow individual companies appoint number qualified persons pharmacovigilance qppvs require provide consistent standards inspections company pharmacovigilance departments emea eu member state authorities back top home responsibility public policy patient advocacy public policy activity advocacy patient safety corporate responsibility report advocacy patient safety us activity legislation prescription medicine imports organisations engaged us department health human services food drug administration fda us congress state boards pharmacy state legislators governors offices industry associations involved bio phrma gsk position current us law prevents prescription medicines imported us unless safety cost savings certifications secretary health human services pending legislation would remove safety savings certification requirements making easier legally import medicines would undermine fdas ability protect us distribution system counterfeit unsafe medicines could harm patients also guarantee consumers would save money department health human services found thirdparty payers insurance companies likely benefit gsk supports safer alternatives help patients afford medicines partnership prescription assistance ppa example gives access public private patient assistance programmes patients lack prescription drug coverage read gsks patient assistance programs back top home responsibility public policy patient advocacy public policy activity advocacy patient safety corporate responsibility report advocacy patient safety us activity legislation prescription medicine imports organisations engaged us department health human services food drug administration fda us congress state boards pharmacy state legislators governors offices industry associations involved bio phrma gsk position current us law prevents prescription medicines imported us unless safety cost savings certifications secretary health human services pending legislation would remove safety savings certification requirements making easier legally import medicines would undermine fdas ability protect us distribution system counterfeit unsafe medicines could harm patients also guarantee consumers would save money department health human services found thirdparty payers insurance companies likely benefit gsk supports safer alternatives help patients afford medicines partnership prescription assistance ppa example gives access public private patient assistance programmes patients lack prescription drug coverage read gsks patient assistance programs back top home responsibility public policy patient advocacy public policy activity advocacy intellectual property corporate responsibility report advocacy intellectual property us activity us patent system reform federal legislation organisations engaged patent trademark office pto us congress industry associations involved bio coalition st century patent reform phrma gsk position patent law framework provides business certainty long period promotes investment essential researchbased pharmaceutical industry wide range manufacturers long lead times research market us congress considering patent reform legislation could negative effect current framework specifically proposals fail strike appropriate balance areas restricting abuse inequitable conduct doctrine encourages infringers try prove litigation patent improperly obtained completely valid patent may held unenforceable allocation damages infringement addition giving pto substantive rulemaking authority removes responsibility establishing substantive patent law congress innovation policy public debate gsk working coalition researchbased companies manufacturers universities small inventors promote us patent reform stimulates investment research strengthens patent system support patent reforms clear provide business certainty improve quality patents remove subjectivity litigation issues asian activity compulsory licensing thailand organisations engaged thai government including thai ministry public health academics ngos members business community thailand world health organization international ngos us eu member state industry associations involved bpg efpia ifpma phrma prema gsk position late thai government issued compulsory licences three pharmaceutical products four compulsory licenses oncology products announced prior previously elected government leaving office early two implemented support thai governments public health goals want help improve health outcomes people thailand compulsory licences legitimate policy option thai government used routine policy tool commercial purposes rather unilaterally using compulsory licences increase access medicines believe effective engage dialogue industry stakeholders find sustainable ways address healthcare issues including access medicines hope reinforce dialogue governments stakeholders future healthcare intellectual property india organisations engaged relevant agencies indian government members pharmaceutical industry wider business community india indian academics civil society representatives us eu member state governments european commission industry associations involved bpg efpia oppi phrma gsk position believe indias tremendous strengths science pharmaceuticals coupled rapid economic growth offer government opportunity tackle fundamental characteristics healthcare system policy base improvements indias intellectual property ip regime level provided eu us could encourage investment collaborative rd issues poafg iep rig ohf ts fundamental barrier access healthcare believe reform increased investment indian healthcare system priority want active partners addressing challenges back tophome responsibility public policy patient advocacy public policy activity advocacy intellectual property corporate responsibility report advocacy intellectual property us activity us patent system reform federal legislation organisations engaged patent trademark office pto us congress industry associations involved bio coalition st century patent reform phrma gsk position patent law framework provides business certainty long period promotes investment essential researchbased pharmaceutical industry wide range manufacturers long lead times research market us congress considering patent reform legislation could negative effect current framework specifically proposals fail strike appropriate balance areas restricting abuse inequitable conduct doctrine encourages infringers try prove litigation patent improperly obtained completely valid patent may held unenforceable allocation damages infringement addition giving pto substantive rulemaking authority removes responsibility establishing substantive patent law congress innovation policy public debate gsk working coalition researchbased companies manufacturers universities small inventors promote us patent reform stimulates investment research strengthens patent system support patent reforms clear provide business certainty improve quality patents remove subjectivity litigation issues asian activity compulsory licensing thailand organisations engaged thai government including thai ministry public health academics ngos members business community thailand world health organization international ngos us eu member state industry associations involved bpg efpia ifpma phrma prema gsk position late thai government issued compulsory licences three pharmaceutical products four compulsory licenses oncology products announced prior previously elected government leaving office early two implemented support thai governments public health goals want help improve health outcomes people thailand compulsory licences legitimate policy option thai government used routine policy tool commercial purposes rather unilaterally using compulsory licences increase access medicines believe effective engage dialogue industry stakeholders find sustainable ways address healthcare issues including access medicines hope reinforce dialogue governments stakeholders future healthcare intellectual property india organisations engaged relevant agencies indian government members pharmaceutical industry wider business community india indian academics civil society representatives us eu member state governments european commission industry associations involved bpg efpia oppi phrma gsk position believe indias tremendous strengths science pharmaceuticals coupled rapid economic growth offer government opportunity tackle fundamental characteristics healthcare system policy base improvements indias intellectual property ip regime level provided eu us could encourage investment collaborative rd issues ip rights fundamental barrier access healthcare believe reform increased investment indian healthcare system priority want active partners addressing challenges back top home responsibility public policy patient advocacy public policy activity advocacy intellectual property corporate responsibility report advocacy intellectual property us activity us patent system reform federal legislation organisations engaged patent trademark office pto us congress industry associations involved bio coalition st century patent reform phrma gsk position patent law framework provides business certainty long period promotes investment essential researchbased pharmaceutical industry wide range manufacturers long lead times research market us congress considering patent reform legislation could negative effect current framework specifically proposals fail strike appropriate balance areas restricting abuse inequitable conduct doctrine encourages infringers try prove litigation patent improperly obtained completely valid patent may held unenforceable allocation damages infringement addition giving pto substantive rulemaking authority removes responsibility establishing substantive patent law congress innovation policy public debate gsk working coalition researchbased companies manufacturers universities small inventors promote us patent reform stimulates investment research strengthens patent system support patent reforms clear provide business certainty improve quality patents remove subjectivity litigation issues asian activity compulsory licensing thailand organisations engaged thai government including thai ministry public health academics ngos members business community thailand world health organization international ngos us eu member state industry associations involved bpg efpia ifpma phrma prema gsk position late thai government issued compulsory licences three pharmaceutical products four compulsory licenses oncology products announced prior previously elected government leaving office early two implemented support thai governments public health goals want help improve health outcomes people thailand compulsory licences legitimate policy option thai government used routine policy tool commercial purposes rather unilaterally using compulsory licences increase access medicines believe effective engage dialogue industry stakeholders find sustainable ways address healthcare issues including access medicines hope reinforce dialogue governments stakeholders future healthcare intellectual property india organisations engaged relevant agencies indian government members pharmaceutical industry wider business community india indian academics civil society representatives us eu member state governments european commission industry associations involved bpg efpia oppi phrma gsk position believe indias tremendous strengths science pharmaceuticals coupled rapid economic growth offer government opportunity tackle fundamental characteristics healthcare system policy base improvements indias intellectual property ip regime level provided eu us could encourage investment collaborative rd issues ip rights fundamental barrier access healthcare believe reform increased investment indian healthcare system priority want active partners addressing challenges back top home responsibility public policy patient advocacy public policy activity advocacy pricing competitiveness corporate responsibility report advocacy pricing competitiveness european activity guiding principles relative effectiveness assessments pricing organisations engaged eu member states european commission stakeholder representatives participating eus high level pharmaceutical forum industry associations involved efpia europabio gsk position government funding decisions often based assessment medicines clinical cost effectiveness believe value assessments conducted transparently timely manner key stakeholders able submit evidence assessments governments allow greater pricing flexibility longterm value medicine certain launch gsk representing efpia strongly supported good practice principles relative effectiveness assessments developed within framework eus high level pharmaceutical forum hlpf adopted along guiding principles good practices implementing pricing reimbursement policy efpias health technology assessments principles industry previous adopted gsk helped develop aligned principles adopted hlpf improving regulations impact pharmaceutical industrys competitiveness uk organisations engaged uk government european commission industry associations involved abpi cbi institute directors gsk position pharmaceutical industry one highly regulated industries europe gsk supports strong regulation working uk government european commission propose ways simplify regulations achieving policy goal aligns aims uk government european commission reduce regulatory burden placed industry gsk submitted series proposals uk government simplification existing regulations also made similar submission commission focusing regulations originate european level back top home responsibility public policy patient advocacy public policy activity advocacy pricing competitiveness corporate responsibility report advocacy pricing competitiveness european activity guiding principles relative effectiveness assessments pricing organisations engaged eu member states european commission stakeholder representatives participating eus high level pharmaceutical forum industry associations involved efpia europabio gsk position government funding decisions often based assessment medicines clinical cost effectiveness believe value assessments conducted transparently timely manner key stakeholders able submit evidence assessments governments allow greater pricing flexibility longterm value medicine certain launch gsk representing efpia strongly supported good practice principles relative effectiveness assessments developed within framework eus high level pharmaceutical forum hlpf adopted along guiding principles good practices implementing pricing reimbursement policy efpias health technology assessments principles industry previous adopted gsk helped develop aligned principles adopted hlpf improving regulations impact pharmaceutical industrys competitiveness uk organisations engaged uk government european commission industry associations involved abpi cbi institute directors gsk position pharmaceutical industry one highly regulated industries europe gsk supports strong regulation working uk government european commission propose ways simplify regulations achieving policy goal aligns aims uk government european commission reduce regulatory burden placed industry gsk submitted series proposals uk government simplification existing regulations also made similar submission commission focusing regulations originate european level back top home responsibility public policy patient advocacy political contributions lobbying expenditures corporate responsibility report political contributions lobbying expenditures late december gsk announced new global policy voluntarily stop corporate political contributions prior gsk made political contributions corporate funds countries authorised law culturally appropriate us canada new policy ensures contributions made future contributions political parties political organisations european union prohibited gsk policy prior change see corporate governance section annual report information prior policy change contributed political organisations us canada rest world contributions rare low monetary value contributions agreed local management approved gsks international legal operations corporate government affairs department contributions made compliance local laws customs contributions us us corporate contributions party affiliated committees candidates running federal office prohibited law state local political campaigns financed variety sources including contributions companies individuals ngos local campaign committees supporting pro business candidates corporate contributions accepted legal means corporations voice political debate however ensure implication whatsoever contributions provide gsk special privileges company changed policy late december prohibit corporate contributions political candidates contributions state candidates prior change policy gsk donated candidates stateheld offices contributions made permitted law made basis political party contributions made candidates support environment appropriately rewards highrisk highinvestment industries work preserve free market principles intellectual property rights made approximately per cent contributions republican candidates per cent democratic candidates states publish information disclosing names contributors amount contributions established threshold political action committee contributions accordance federal election campaign act gsk established political action committee pac facilitates voluntary political contributions eligible employees pac controlled gsk decisions amount recipients contributions made participating employees exercising legal right pool resources make political contributions pac contributions voluntary contributions subject strict limitations example gsk pac may contribute per election individual candidate federal office pac run governing board participating gsk employees across company required law pac contributions reported federal elections commission fec gsk employees pac contributed per cent republicans per cent democrats two per cent unaffiliated party candidates running state federal offices contributions canada gsk donated canada political candidates provinces legal lobbying expenditure europe december gsk signed european commissions new code conduct voluntary register organisations working influence european union institutions transparency register interest declared costs associated lobbying eu institutions range includes running brussels advocacy office salaries external events educational materials figure takes account proportion employee time spent interest representation us report us lobbying expenditures us congress accordance lobbying disclosure act spent million federal lobbying activities us includes costs salaries benefits employees registered lobby us government use lobbying consultants support lobbying contacts planning activities research running gsk washington dc government affairs office support staff portion trade association fees associated federal lobbying also report state lobbying expenses line applicable state laws contributions policy groups gsk contributes various groups provide forum policy analysis debate includes think tanks number countries `` organisations ushome responsibility public policy patient advocacy political contributions lobbying expenditures corporate responsibility report political contributions lobbying expenditures late december gsk announced new global policy voluntarily stop corporate political contributions prior gsk made political contributions corporate funds countries authorised law culturally appropriate us canada new policy ensures contributions made future contributions political parties political organisations european union prohibited gsk policy prior change see corporate governance section annual report information prior policy change contributed political organisations us canada rest world contributions rare low monetary value contributions agreed local management approved gsks international legal operations corporate government affairs department contributions made compliance local laws customs contributions us us corporate contributions party affiliated committees candidates running federal office prohibited law state local political campaigns financed variety sources including contributions companies individuals ngos local campaign committees supporting pro business candidates corporate contributions accepted legal means corporations voice political debate however ensure implication whatsoever contributions provide gsk special privileges company changed policy late december prohibit corporate contributions political candidates contributions state candidates prior change policy gsk donated candidates stateheld offices contributions made permitted law made basis political party contributions made candidates support environment appropriately rewards highrisk highinvestment industries work preserve free market principles intellectual property rights made approximately per cent contributions republican candidates per cent democratic candidates states publish information disclosing names contributors amount contributions established threshold political action committee contributions accordance federal election campaign act gsk established political action committee pac facilitates voluntary political contributions eligible employees pac controlled gsk decisions amount recipients contributions made participating employees exercising legal right pool resources make political contributions pac contributions voluntary contributions subject strict limitations example gsk pac may contribute per election individual candidate federal office pac run governing board participating gsk employees across company required law pac contributions reported federal elections commission fec gsk employees pac contributed per cent republicans per cent democrats two per cent unaffiliated party candidates running state federal offices contributions canada gsk donated canada political candidates provinces legal lobbying expenditure europe december gsk signed european commissions new code conduct voluntary register organisations working influence european union institutions transparency register interest declared costs associated lobbying eu institutions range includes running brussels advocacy office salaries external events educational materials figure takes account proportion employee time spent interest representation us report us lobbying expenditures us congress accordance lobbying disclosure act spent million federal lobbying activities us includes costs salaries benefits employees registered lobby us government use lobbying consultants support lobbying contacts planning activities research running gsk washington dc government affairs office support staff portion trade association fees associated federal lobbying also report state lobbying expenses line applicable state laws contributions policy groups gsk contributes various groups provide forum policy analysis debate includes think tanks number countries `` organisations us home responsibility public policy patient advocacy political contributions lobbying expenditures corporate responsibility report political contributions lobbying expenditures late december gsk announced new global policy voluntarily stop corporate political contributions prior gsk made political contributions corporate funds countries authorised law culturally appropriate us canada new policy ensures contributions made future contributions political parties political organisations european union prohibited gsk policy prior change see corporate governance section annual report information prior policy change contributed political organisations us canada rest world contributions rare low monetary value contributions agreed local management approved gsks international legal operations corporate government affairs department contributions made compliance local laws customs contributions us us corporate contributions party affiliated committees candidates running federal office prohibited law state local political campaigns financed variety sources including contributions companies individuals ngos local campaign committees supporting pro business candidates corporate contributions accepted legal means corporations voice political debate however ensure implication whatsoever contributions provide gsk special privileges company changed policy late december prohibit corporate contributions political candidates contributions state candidates prior change policy gsk donated candidates stateheld offices contributions made permitted law made basis political party contributions made candidates support environment appropriately rewards highrisk highinvestment industries work preserve free market principles intellectual property rights made approximately per cent contributions republican candidates per cent democratic candidates states publish information disclosing names contributors amount contributions established threshold political action committee contributions accordance federal election campaign act gsk established political action committee pac facilitates voluntary political contributions eligible employees pac controlled gsk decisions amount recipients contributions made participating employees exercising legal right pool resources make political contributions pac contributions voluntary contributions subject strict limitations example gsk pac may contribute per election individual candidate federal office pac run governing board participating gsk employees across company required law pac contributions reported federal elections commission fec gsk employees pac contributed per cent republicans per cent democrats two per cent unaffiliated party candidates running state federal offices contributions canada gsk donated canada political candidates provinces legal lobbying expenditure europe december gsk signed european commissions new code conduct voluntary register organisations working influence european union institutions transparency register interest declared costs associated lobbying eu institutions range includes running brussels advocacy office salaries external events educational materials figure takes account proportion employee time spent interest representation us report us lobbying expenditures us congress accordance lobbying disclosure act spent million federal lobbying activities us includes costs salaries benefits employees registered lobby us government use lobbying consultants support lobbying contacts planning activities research running gsk washington dc government affairs office support staff portion trade association fees associated federal lobbying also report state lobbying expenses line applicable state laws contributions policy groups gsk contributes various groups provide forum policy analysis debate includes think tanks number countries `` organisations us home responsibility public policy patient advocacy patient advocacy corporate responsibility report patient advocacy patient groups nonprofit organisations founded patients caregivers family members health professionals provide members information condition guidance live disease engage healthcare providers governments media promote improved treatment services patients campaign change issues affect patients carers lives carry vital research causes potential treatments specific conditions gsk works wide range patient groups disease areas cancer asthma diabetes alzheimers disease multiple sclerosis hivaids gsk patient groups share common concern healthcare systems focus preventing treating managing disease parties believe patients access quality medicines services information disease patient groups important stakeholders gsk engage part commitment patient focused company relationships patient groups mutually beneficial help us better understand patient needs illnesses work patient groups strengthen support patients throughout illness diagnosis chronic treatment endoflife care also help groups give patients ability voice heard healthcare debate alongside stakeholders approach support patient groups across world number different ways include providing core funding support daytoday running group oneoff donations help patient groups conduct specific event activity example breast cancer awareness day educational support training staff management skills disease education working together disease awarenessprevention projects relationship patient group defined written agreement specifying group use funding benefit members stakeholders concerned pharmaceutical companies use patient groups way marketing products support patient groups bigger agendas dictate whether new medicines made available patients whether patients access kind treatments need committed maintaining highest ethical standards transparency area developed detailed guidance standard operating procedures sop employees major regions policies used conjunction gsks patient advocacy manual ensure gsk employees work patient groups comply applicable laws regulations standards read summary sop employees outside agencies working gsk likely interact patient groups must abide guidelines sops provide training employees understand requirements example around marketing employees us attended webinar guidelines sops patient advocacy teams europe asia pacific japan emerging market region coordinate interaction patient groups adherence policies global principles us patient advocacy decentralised across number functions including state government affairs rd communications marketing coordinated state government affairs group employees regions access patient advocacy resource intranet site europe also publish newsletter raise employee awareness internal external developments relating patient groups conducted review departments relationships patient groups us led development interactive patient group database tracks relationships patient advocacy groups projects support enable employees learn past interactions patient groups type projects supported help us allocate resources patient groups efficiently database launched encouraging independence believe patient groups independent encourage seek financial support wide range organisations possible ensure funding give patient groups appropriate size guidelines state gsk funding make per cent groups overall income vast majority instances actual percentage much lower allow exemptions per cent cap groups supported limited incomes small donation example would exceed limit groups difficulty attracting funding nature activity example providing needle exchange drug users cases must approved general manager local operating company also encourage patient groups seek funding multiple sources hold workshops make funding applicationshome responsibility public policy patient advocacy patient advocacy corporate responsibility report patient advocacy patient groups nonprofit organisations founded patients caregivers family members health professionals provide members information condition guidance live disease engage healthcare providers governments media promote improved treatment services patients campaign change issues affect patients carers lives carry vital research causes potential treatments specific conditions gsk works wide range patient groups disease areas cancer asthma diabetes alzheimers disease multiple sclerosis hivaids gsk patient groups share common concern healthcare systems focus preventing treating managing disease parties believe patients access quality medicines services information disease patient groups important stakeholders gsk engage part commitment patient focused company relationships patient groups mutually beneficial help us better understand patient needs illnesses work patient groups strengthen support patients throughout illness diagnosis chronic treatment endoflife care also help groups give patients ability voice heard healthcare debate alongside stakeholders approach support patient groups across world number different ways include providing core funding support daytoday running group oneoff donations help patient groups conduct specific event activity example breast cancer awareness day educational support training staff management skills disease education working together disease awarenessprevention projects relationship patient group defined written agreement specifying group use funding benefit members stakeholders concerned pharmaceutical companies use patient groups way marketing products support patient groups bigger agendas dictate whether new medicines made available patients whether patients access kind treatments need committed maintaining highest ethical standards transparency area developed detailed guidance standard operating procedures sop employees major regions policies used conjunction gsks patient advocacy manual ensure gsk employees work patient groups comply applicable laws regulations standards read summary sop employees outside agencies working gsk likely interact patient groups must abide guidelines sops provide training employees understand requirements example around marketing employees us attended webinar guidelines sops patient advocacy teams europe asia pacific japan emerging market region coordinate interaction patient groups adherence policies global principles us patient advocacy decentralised across number functions including state government affairs rd communications marketing coordinated state government affairs group employees regions access patient advocacy resource intranet site europe also publish newsletter raise employee awareness internal external developments relating patient groups conducted review departments relationships patient groups us led development interactive patient group database tracks relationships patient advocacy groups projects support enable employees learn past interactions patient groups type projects supported help us allocate resources patient groups efficiently database launched encouraging independence believe patient groups independent encourage seek financial support wide range organisations possible ensure funding give patient groups appropriate size guidelines state gsk funding make per cent groups overall income vast majority instances actual percentage much lower allow exemptions per cent cap groups supported limited incomes small donation example would exceed limit groups difficulty attracting funding nature activity example providing needle exchange drug users cases must approved general manager local operating company also encourage patient groups seek funding multiple sources hold workshops make funding applications home responsibility public policy patient advocacy patient advocacy corporate responsibility report patient advocacy patient groups nonprofit organisations founded patients caregivers family members health professionals provide members information condition guidance live disease engage healthcare providers governments media promote improved treatment services patients campaign change issues affect patients carers lives carry vital research causes potential treatments specific conditions gsk works wide range patient groups disease areas cancer asthma diabetes alzheimers disease multiple sclerosis hivaids gsk patient groups share common concern healthcare systems focus preventing treating managing disease parties believe patients access quality medicines services information disease patient groups important stakeholders gsk engage part commitment patient focused company relationships patient groups mutually beneficial help us better understand patient needs illnesses work patient groups strengthen support patients throughout illness diagnosis chronic treatment endoflife care also help groups give patients ability voice heard healthcare debate alongside stakeholders approach support patient groups across world number different ways include providing core funding support daytoday running group oneoff donations help patient groups conduct specific event activity example breast cancer awareness day educational support training staff management skills disease education working together disease awarenessprevention projects relationship patient group defined written agreement specifying group use funding benefit members stakeholders concerned pharmaceutical companies use patient groups way marketing products support patient groups bigger agendas dictate whether new medicines made available patients whether patients access kind treatments need committed maintaining highest ethical standards transparency area developed detailed guidance standard operating procedures sop employees major regions policies used conjunction gsks patient advocacy manual ensure gsk employees work patient groups comply applicable laws regulations standards read summary sop employees outside agencies working gsk likely interact patient groups must abide guidelines sops provide training employees understand requirements example around marketing employees us attended webinar guidelines sops patient advocacy teams europe asia pacific japan emerging market region coordinate interaction patient groups adherence policies global principles us patient advocacy decentralised across number functions including state government affairs rd communications marketing coordinated state government affairs group employees regions access patient advocacy resource intranet site europe also publish newsletter raise employee awareness internal external developments relating patient groups conducted review departments relationships patient groups us led development interactive patient group database tracks relationships patient advocacy groups projects support enable employees learn past interactions patient groups type projects supported help us allocate resources patient groups efficiently database launched encouraging independence believe patient groups independent encourage seek financial support wide range organisations possible ensure funding give patient groups appropriate size guidelines state gsk funding make per cent groups overall income vast majority instances actual percentage much lower allow exemptions per cent cap groups supported limited incomes small donation example would exceed limit groups difficulty attracting funding nature activity example providing needle exchange drug users cases must approved general manager local operating company also encourage patient groups seek funding multiple sources hold workshops make funding applications home responsibility public policy patient advocacy patient advocacy transparency corporate responsibility report transparency believe transparent support patient groups helps build trust stakeholders including groups publish information work patient groups europe asia pacific japan emerging markets regions well information support patient groups working globally including details funding received see details funding patient organisations first pharmaceutical company publish level information goes beyond industry codes practice require list groups funded detailed information gsk australia canada found websites us february report educational charitable grants provided healthrelated organisations including hospitals teaching institutions patient advocacy groups report updated quarterly see details funding patient organisations working patient groups standard operating procedures state involvement patient organisation must declared transparent gsk must neither seek patient organisation endorsement medicines pay patient groups endorse gsk services medicines must promoted patient organisations gsk must create patient organisations must sole funding sponsor patient organisation provide per cent funding patient organisations exceptions may allowed case rare disease focus startup funding per cent however must agreed directly local country region general manager head regional government affairs gsk must seek direct return investment funding patient organisation information gsk pipeline compounds must factual nonpromotional provided patient organisations part scientific dialogue acceptable gsk clinical trials medical personnel work patient organisations ensure optimal clinical trial recruitment consult clinical trial design protocols gsk must directly sponsor patient organisation representatives attend medical congresses conferences healthcare professional events exceptions include representative invited speak conference medical congress specific workstream designed patients gsk may sponsor representatives attend nonmedical congresses gsk may pay modest honorarium speaker fee patient organisation advisory board member speaker represents third party working gsk given project must fully transparent relationship interacting patient group project back top home responsibility public policy patient advocacy patient advocacy transparency corporate responsibility report transparency believe transparent support patient groups helps build trust stakeholders including groups publish information work patient groups europe asia pacific japan emerging markets regions well information support patient groups working globally including details funding received see details funding patient organisations first pharmaceutical company publish level information goes beyond industry codes practice require list groups funded detailed information gsk australia canada found websites us february report educational charitable grants provided healthrelated organisations including hospitals teaching institutions patient advocacy groups report updated quarterly see details funding patient organisations working patient groups standard operating procedures state involvement patient organisation must declared transparent gsk must neither seek patient organisation endorsement medicines pay patient groups endorse gsk services medicines must promoted patient organisations gsk must create patient organisations must sole funding sponsor patient organisation provide per cent funding patient organisations exceptions may allowed case rare disease focus startup funding per cent however must agreed directly local country region general manager head regional government affairs gsk must seek direct return investment funding patient organisation information gsk pipeline compounds must factual nonpromotional provided patient organisations part scientific dialogue acceptable gsk clinical trials medical personnel work patient organisations ensure optimal clinical trial recruitment consult clinical trial design protocols gsk must directly sponsor patient organisation representatives attend medical congresses conferences healthcare professional events exceptions include representative invited speak conference medical congress specific workstream designed patients gsk may sponsor representatives attend nonmedical congresses gsk may pay modest honorarium speaker fee patient organisation advisory board member speaker represents third party working gsk given project must fully transparent relationship interacting patient group project back top home responsibility public policy patient advocacy patient advocacy understanding patients corporate responsibility report understanding patients help us better understand patient needs set advisory boards us europe include representatives wide range patient groups advisory boards independent chairs meet regularly attended senior gsk managers boards enable voice patients heard highest levels gsk also allow us access views patient groups seek feedback subjects clinical trials pharmacogenetics information provided patients ethical issues regions invite speakers patient groups meet gsk employees including scientists researchers marketers discuss issues affecting members well improving understanding patient needs shows gsk employees difference work make peoples lives read focus patient initiative helping us better understand patient needs develop better medicines also engage patient groups patient advocacy leaders summits pals bring groups together discuss health policy concerns develop new skills andor ways expand influence pals also give patient groups opportunity learn gsk tell company better support work involved running total summits nine european countries one japan throughout us discussions pals focused broad range issues including efforts establish patientcentred healthcare japan availability medicines role patients patient organisations netherlands clinical trials germany healthcare political priority healthcare funding impacts patients estonia healthcare system reform patient rights czech republic healthcare financing patient access healthcare economic downturn latvia patient input national strategy cancer bulgaria communications strategies patient associations france importance innovation intervention prevention health care reform us gsk cosponsored european patient forums annual conference brussels pharmaceutical company pfizer brought together approximately patient groups stakeholders exchange ideas improving healthcare role patient organisations intend hold pals summits us europe support similar number pals also plan several regional pals meetings asia pacific emerging markets regions back top home responsibility public policy patient advocacy patient advocacy understanding patients corporate responsibility report understanding patients help us better understand patient needs set advisory boards us europe include representatives wide range patient groups advisory boards independent chairs meet regularly attended senior gsk managers boards enable voice patients heard highest levels gsk also allow us access views patient groups seek feedback subjects clinical trials pharmacogenetics information provided patients ethical issues regions invite speakers patient groups meet gsk employees including scientists researchers marketers discuss issues affecting members well improving understanding patient needs shows gsk employees difference work make peoples lives read focus patient initiative helping us better understand patient needs develop better medicines also engage patient groups patient advocacy leaders summits pals bring groups together discuss health policy concerns develop new skills andor ways expand influence pals also give patient groups opportunity learn gsk tell company better support work involved running total summits nine european countries one japan throughout us discussions pals focused broad range issues including efforts establish patientcentred healthcare japan availability medicines role patients patient organisations netherlands clinical trials germany healthcare political priority healthcare funding impacts patients estonia healthcare system reform patient rights czech republic healthcare financing patient access healthcare economic downturn latvia patient input national strategy cancer bulgaria communications strategies patient associations france importance innovation intervention prevention health care reform us gsk cosponsored european patient forums annual conference brussels pharmaceutical company pfizer brought together approximately patient groups stakeholders exchange ideas improving healthcare role patient organisations intend hold pals summits us europe support similar number pals also plan several regional pals meetings asia pacific emerging markets regions back top home responsibility public policy patient advocacy patient advocacy developing industry standards corporate responsibility report developing industry standards taking leadership approach developing industry standards engaging patient groups us working industry trade group phrma develop guidelines members working patient groups launched may also helped national health council develop guidelines patient groups follow working companies patient group members council required follow guidelines launched update august since publication report work phrma develop guidelines working patient groups stopped companies agree need develop industry wide guidelines however phrma supports national health council guidelines patient groups working companies gsk remains committed developing industry standards engaging patient groups europe closely involved development first efpia code practice relationships patient organisations came effect july code bears close resemblance gsks policies working patient groups senior gsk manager chaired efpia patient relations network originally developed code efpia code contains many requirements gsks policies states companies promote medicines patient groups must written agreements place interactions patient groups companies must list patient groups work describe nature support involved training companies prepare implement code european level locally countries including finland germany back top home responsibility public policy patient advocacy patient advocacy developing industry standards corporate responsibility report developing industry standards taking leadership approach developing industry standards engaging patient groups us working industry trade group phrma develop guidelines members working patient groups launched may also helped national health council develop guidelines patient groups follow working companies patient group members council required follow guidelines launched update august since publication report work phrma develop guidelines working patient groups stopped companies agree need develop industry wide guidelines however phrma supports national health council guidelines patient groups working companies gsk remains committed developing industry standards engaging patient groups europe closely involved development first efpia code practice relationships patient organisations came effect july code bears close resemblance gsks policies working patient groups senior gsk manager chaired efpia patient relations network originally developed code efpia code contains many requirements gsks policies states companies promote medicines patient groups must written agreements place interactions patient groups companies must list patient groups work describe nature support involved training companies prepare implement code european level locally countries including finland germany back top home responsibility public policy patient advocacy patient advocacy advocacy corporate responsibility report advocacy activity describe advocacy activities undertook partnership patient groups global recruitment lung cancer vaccine clinical trial partner global lung cancer coalition glcc body comprising notforprofit groups around world promotes understanding lung cancer advocates patients right early detection better treatment supportive care glcc members also committed campaigning lung cancer research increase enrolment patients clinical trials many new therapy trials glcc network helped us recruitment patients phase lll clinical trial therapeutic lung cancer vaccine raised awareness trial glcc members disseminated information lung cancer patients calling recently undergone surgery ask doctors entering study hope vaccine given lung cancer patients surgery could help stop tumours returning reduce effect disease chronic hepatitis b asia pacific continued campaign asia pacific raise awareness chronic hepatitis b increase number people tested diagnosed improve compliance antiviral medication around million people region live disease gsk patient consortium developed patient engagement programme created resources support healthcare professionals encourage patients adhere treatment regimes including sms service reminds patients manage condition piloted programme resources korea roll across ten countries world hepatitis day may raising awareness breast cancer treatment times canada partnership canadian breast cancer network cbcn gsk helped raise awareness unacceptable treatment waiting times differences access breast cancer care across canadas provinces cbcn published report revealed waiting times five years initial application manufacturer patients could access new breast cancer drug report provoked extensive national media coverage strong call action policy makers politicians concerned organisations individuals work together address issues back top home responsibility public policy patient advocacy patient advocacy advocacy corporate responsibility report advocacy activity describe advocacy activities undertook partnership patient groups global recruitment lung cancer vaccine clinical trial partner global lung cancer coalition glcc body comprising notforprofit groups around world promotes understanding lung cancer advocates patients right early detection better treatment supportive care glcc members also committed campaigning lung cancer research increase enrolment patients clinical trials many new therapy trials glcc network helped us recruitment patients phase lll clinical trial therapeutic lung cancer vaccine raised awareness trial glcc members disseminated information lung cancer patients calling recently undergone surgery ask doctors entering study hope vaccine given lung cancer patients surgery could help stop tumours returning reduce effect disease chronic hepatitis b asia pacific continued campaign asia pacific raise awareness chronic hepatitis b increase number people tested diagnosed improve compliance antiviral medication around million people region live disease gsk patient consortium developed patient engagement programme created resources support healthcare professionals encourage patients adhere treatment regimes including sms service reminds patients manage condition piloted programme resources korea roll across ten countries world hepatitis day may raising awareness breast cancer treatment times canada partnership canadian breast cancer network cbcn gsk helped raise awareness unacceptable treatment waiting times differences access breast cancer care across canadas provinces cbcn published report revealed waiting times five years initial application manufacturer patients could access new breast cancer drug report provoked extensive national media coverage strong call action policy makers politicians concerned organisations individuals work together address issues back top home responsibility public policy patient advocacy qas corporate responsibility report qas make sure lobbying activity doesnt contradict undermine corporate responsibility work corporate responsibility central business aim ensure lobbying activity reflects values set report well sensitive views stakeholders employees involved public policy must abide employee guide business conduct commits acting honesty integrity wellestablished public policy positions developed wide consultation approved corporate executive team employees lobby gsk closely involved developing positions believe transparency key building trust stakeholders disclose public policy positions website gsk make political contributions socalled organisations yes support number organisations new democratic network gsk influence organisations use gsk contributions however support enables organisations develop advocate policy positions us participate functions debate discuss important issues gsk organisations public policy makers contributions organisations defined political contributions subject policy stop corporate political contributions isnt support patient groups another marketing tool gsk neither promotes medicines patient groups would ever ask patient group endorse gsk medicine work patient groups number areas including improving clinical trials run disease awareness initiatives bigger agenda ensuring new medicines made available patients gsk provides funding trying buy favours patient organisation never ask endorsement medicines return investment support careful support organisation compromise independence based trust mutual respect complies highest standards code conduct groups maintain independence receive significant funding companies gsk encourage patient groups diversify funding sources public private sector patient groups never become dependent one funder either sector guidelines state provide per cent groups overall income except exceptional home responsibility public policy patient advocacy qas corporate responsibility report qas make sure lobbying activity doesnt contradict undermine corporate responsibility work corporate responsibility central business aim ensure lobbying activity reflects values set report well sensitive views stakeholders employees involved public policy must abide employee guide business conduct commits acting honesty integrity wellestablished public policy positions developed wide consultation approved corporate executive team employees lobby gsk closely involved developing positions believe transparency key building trust stakeholders disclose public policy positions website gsk make political contributions socalled organisations yes support number organisations new democratic network gsk influence organisations use gsk contributions however support enables organisations develop advocate policy positions us participate functions debate discuss important issues gsk organisations public policy makers contributions organisations defined political contributions subject policy stop corporate political contributions isnt support patient groups another marketing tool gsk neither promotes medicines patient groups would ever ask patient group endorse gsk medicine work patient groups number areas including improving clinical trials run disease awareness initiatives bigger agenda ensuring new medicines made available patients gsk provides funding trying buy favours patient organisation never ask endorsement medicines return investment support careful support organisation compromise independence based trust mutual respect complies highest standards code conduct groups maintain independence receive significant funding companies gsk encourage patient groups diversify funding sources public private sector patient groups never become dependent one funder either sector guidelines state provide per cent groups overall income except exceptional home responsibility work communities corporate responsibility report work communities donate money time medicines equipment support communities around world programmes long term focus addressing healthcare challenges increasing access medicines also invest improving education especially science education provide support art environment initiatives believe contributing profits benefit communities part responsible company community investment also brings us longterm business benefits improving reputation boosting employee morale helping us build good relations governments use community investment way generating sales invest innovative projects prevent disease build capacity community organisations promote education particularly science focus community investment areas relevant business skills people bring benefit communities gsk investment made nonprofit organisations experts healthcare education organisations best placed understand local community needs target resources effectively donations made company level individual sites healthcare support major public health initiatives developing world example founding member global alliance eliminate lymphatic filariasis gaelf committed donating many albendazole tablets needed eliminate lymphatic filariasis elephantiasis disabling parasitic disease threatens billion people onefifth worlds population countries positive action programme works communities reduce stigma improve capacity hiv prevention treatment african malaria partnership supports mobilising malaria advocacy initiative generate political commitment funding combat malaria phase personal hygiene sanitation education handwashing programme children prevent diarrhoearelated disease improve school attendance donate essential antibiotics medicines disaster relief underserved communities around world specific programmes support lowincome uninsured patients us education support education programmes link supporting science education uk us inspire young people science improve understanding science encourage pursue sciencerelated career programmes enable young people make informed decisions sciencerelated issues meet everyday life healthy eating vaccinations value medicines measuring impact ask partner organisations larger programmes report annually progress projects supported gsk ensure money give greatest possible impact review results partners identify changes required achieve programmes objectiveshome responsibility work communities corporate responsibility report work communities donate money time medicines equipment support communities around world programmes long term focus addressing healthcare challenges increasing access medicines also invest improving education especially science education provide support art environment initiatives believe contributing profits benefit communities part responsible company community investment also brings us longterm business benefits improving reputation boosting employee morale helping us build good relations governments use community investment way generating sales invest innovative projects prevent disease build capacity community organisations promote education particularly science focus community investment areas relevant business skills people bring benefit communities gsk investment made nonprofit organisations experts healthcare education organisations best placed understand local community needs target resources effectively donations made company level individual sites healthcare support major public health initiatives developing world example founding member global alliance eliminate lymphatic filariasis gaelf committed donating many albendazole tablets needed eliminate lymphatic filariasis elephantiasis disabling parasitic disease threatens billion people onefifth worlds population countries positive action programme works communities reduce stigma improve capacity hiv prevention treatment african malaria partnership supports mobilising malaria advocacy initiative generate political commitment funding combat malaria phase personal hygiene sanitation education handwashing programme children prevent diarrhoearelated disease improve school attendance donate essential antibiotics medicines disaster relief underserved communities around world specific programmes support lowincome uninsured patients us education support education programmes link supporting science education uk us inspire young people science improve understanding science encourage pursue sciencerelated career programmes enable young people make informed decisions sciencerelated issues meet everyday life healthy eating vaccinations value medicines measuring impact ask partner organisations larger programmes report annually progress projects supported gsk ensure money give greatest possible impact review results partners identify changes required achieve programmes objectives home responsibility work communities corporate responsibility report work communities donate money time medicines equipment support communities around world programmes long term focus addressing healthcare challenges increasing access medicines also invest improving education especially science education provide support art environment initiatives believe contributing profits benefit communities part responsible company community investment also brings us longterm business benefits improving reputation boosting employee morale helping us build good relations governments use community investment way generating sales invest innovative projects prevent disease build capacity community organisations promote education particularly science focus community investment areas relevant business skills people bring benefit communities gsk investment made nonprofit organisations experts healthcare education organisations best placed understand local community needs target resources effectively donations made company level individual sites healthcare support major public health initiatives developing world example founding member global alliance eliminate lymphatic filariasis gaelf committed donating many albendazole tablets needed eliminate lymphatic filariasis elephantiasis disabling parasitic disease threatens billion people onefifth worlds population countries positive action programme works communities reduce stigma improve capacity hiv prevention treatment african malaria partnership supports mobilising malaria advocacy initiative generate political commitment funding combat malaria phase personal hygiene sanitation education handwashing programme children prevent diarrhoearelated disease improve school attendance donate essential antibiotics medicines disaster relief underserved communities around world specific programmes support lowincome uninsured patients us education support education programmes link supporting science education uk us inspire young people science improve understanding science encourage pursue sciencerelated career programmes enable young people make informed decisions sciencerelated issues meet everyday life healthy eating vaccinations value medicines measuring impact ask partner organisations larger programmes report annually progress projects supported gsk ensure money give greatest possible impact review results partners identify changes required achieve programmes objectives home responsibility work communities community investment corporate responsibility report community investment global community investment million million compared restated million increase per cent half comprises product donations first year valued donations using cost average cost goods rather wholesale acquisition price wac new approach valuing donations accurate reflection true cost gsk therefore transparent believe first pharmaceutical company adopt practice continue also report wac value donations benchmarking purposes belong uks london benchmarking group lbg us committee encouraging corporate philanthropy cecp lbg guidelines report product donations cost whereas cecp guidelines report product donations market value comparative purposes total value giving using wac products would million million compared million million giving figure built following way method giving million breakdown cash giving product donations made three main programmes patient assistance programmes support lowincome patients us totalling million cost humanitarian product donations underserved communities countries including people affected natural disasters burma china totalling cost donation million albendazole tablets lymphatic filariasis lf elimination programme announced would double manufacturing capacity albendazole tablets million tablets per year current million meet growth lf programme especially india result donations albendazole tablets increase significantly onwards already publish data charitable grants made patient groups european emerging markets asia pacific regions increasing transparency publishing details charitable grants find grants gsk one companies manufacturing company awarded new communitymark following independent assessment outstanding community investment mark created business community endorsed uk government voluntary sector leaders given work local national level uk well larger international programmeshome responsibility work communities community investment corporate responsibility report community investment global community investment million million compared restated million increase per cent half comprises product donations first year valued donations using cost average cost goods rather wholesale acquisition price wac new approach valuing donations accurate reflection true cost gsk therefore transparent believe first pharmaceutical company adopt practice continue also report wac value donations benchmarking purposes belong uks london benchmarking group lbg us committee encouraging corporate philanthropy cecp lbg guidelines report product donations cost whereas cecp guidelines report product donations market value comparative purposes total value giving using wac products would million million compared million million giving figure built following way method giving million breakdown cash giving product donations made three main programmes patient assistance programmes support lowincome patients us totalling million cost humanitarian product donations underserved communities countries including people affected natural disasters burma china totalling cost donation million albendazole tablets lymphatic filariasis lf elimination programme announced would double manufacturing capacity albendazole tablets million tablets per year current million meet growth lf programme especially india result donations albendazole tablets increase significantly onwards already publish data charitable grants made patient groups european emerging markets asia pacific regions increasing transparency publishing details charitable grants find grants gsk one companies manufacturing company awarded new communitymark following independent assessment outstanding community investment mark created business community endorsed uk government voluntary sector leaders given work local national level uk well larger international programmes home responsibility work communities community investment corporate responsibility report community investment global community investment million million compared restated million increase per cent half comprises product donations first year valued donations using cost average cost goods rather wholesale acquisition price wac new approach valuing donations accurate reflection true cost gsk therefore transparent believe first pharmaceutical company adopt practice continue also report wac value donations benchmarking purposes belong uks london benchmarking group lbg us committee encouraging corporate philanthropy cecp lbg guidelines report product donations cost whereas cecp guidelines report product donations market value comparative purposes total value giving using wac products would million million compared million million giving figure built following way method giving million breakdown cash giving product donations made three main programmes patient assistance programmes support lowincome patients us totalling million cost humanitarian product donations underserved communities countries including people affected natural disasters burma china totalling cost donation million albendazole tablets lymphatic filariasis lf elimination programme announced would double manufacturing capacity albendazole tablets million tablets per year current million meet growth lf programme especially india result donations albendazole tablets increase significantly onwards already publish data charitable grants made patient groups european emerging markets asia pacific regions increasing transparency publishing details charitable grants find grants gsk one companies manufacturing company awarded new communitymark following independent assessment outstanding community investment mark created business community endorsed uk government voluntary sector leaders given work local national level uk well larger international programmes home responsibility work communities preventing disease corporate responsibility report preventing disease infectious diseases kill millions people developing world year cause misery cost billions dollars slow economic growth preventing infection effective treatment significant social economic benefits vaccines play significant role preventing disease gsk supports innovative community approaches disease prevention tailored local settings needs marked two significant milestones support community disease prevention ten years since made commitment eliminate lymphatic filariasis lf worldwide since launched handwashing programme phase prevent diarrhoearelated disease also support wide range local programmes help prevent disease communities operate home responsibility work communities preventing disease corporate responsibility report preventing disease infectious diseases kill millions people developing world year cause misery cost billions dollars slow economic growth preventing infection effective treatment significant social economic benefits vaccines play significant role preventing disease gsk supports innovative community approaches disease prevention tailored local settings needs marked two significant milestones support community disease prevention ten years since made commitment eliminate lymphatic filariasis lf worldwide since launched handwashing programme phase prevent diarrhoearelated disease also support wide range local programmes help prevent disease communities operate home responsibility work communities preventing disease eliminating lymphatic filariasis corporate responsibility report eliminating lymphatic filariasis lf committed donating many tablets albendazole antiparasitic drug needed eliminate lf lf disfiguring disease prevalent tropical subtropical countries transmitted mosquitoes lead severe swelling arms legs breasts genitals thickening skin lf one worlds leading causes permanent disability billion people countries approximately onefifth worlds population risk infection gsk donated million albendazole treatments countries included million tablets india country largest lf burden economic cost lf india estimated exceed us million due treatment costs reduced working time since programme began donated one billion tablets million people treated least albendazole estimate end million babies born treated regions spared risk contracting lf study published journal public library science neglected tropical diseases confirmed progress already made towards eliminating lf year decided double annual manufacturing capacity albendazole tablets million tablets per year opening new production line nashik western india additional benefit albendazole tablets given lf programme also treat intestinal worms parasites particularly affect children causing anaemia malnutrition stunting growth estimate since beginning lf programme million albendazole treatments administered children million women childbearing age positive impact overall health infected intestinal worms country aiming eliminate lf must treat atrisk people year least five years far egypt several pacific island countries sri lanka zanzibar completed five annual mass drug administrations mdas countries monitoring populations evaluate impact programme disease assessments conducted egypt vanuatu pacific island nation showed lf eliminated areas countries programmes tanzania madagascar burkina faso also reported unexpected benefit mdas beyond reducing infection rates countries patients already infected lf describing alleviation symptoms mdas including reduced leg swelling reduction frequency length acute attacks spells feverishness loss energy acute attacks incapacitating symptom lf read approach lf patients living disease home responsibility work communities preventing disease eliminating lymphatic filariasis corporate responsibility report eliminating lymphatic filariasis lf committed donating many tablets albendazole antiparasitic drug needed eliminate lf lf disfiguring disease prevalent tropical subtropical countries transmitted mosquitoes lead severe swelling arms legs breasts genitals thickening skin lf one worlds leading causes permanent disability billion people countries approximately onefifth worlds population risk infection gsk donated million albendazole treatments countries included million tablets india country largest lf burden economic cost lf india estimated exceed us million due treatment costs reduced working time since programme began donated one billion tablets million people treated least albendazole estimate end million babies born treated regions spared risk contracting lf study published journal public library science neglected tropical diseases confirmed progress already made towards eliminating lf year decided double annual manufacturing capacity albendazole tablets million tablets per year opening new production line nashik western india additional benefit albendazole tablets given lf programme also treat intestinal worms parasites particularly affect children causing anaemia malnutrition stunting growth estimate since beginning lf programme million albendazole treatments administered children million women childbearing age positive impact overall health infected intestinal worms country aiming eliminate lf must treat atrisk people year least five years far egypt several pacific island countries sri lanka zanzibar completed five annual mass drug administrations mdas countries monitoring populations evaluate impact programme disease assessments conducted egypt vanuatu pacific island nation showed lf eliminated areas countries programmes tanzania madagascar burkina faso also reported unexpected benefit mdas beyond reducing infection rates countries patients already infected lf describing alleviation symptoms mdas including reduced leg swelling reduction frequency length acute attacks spells feverishness loss energy acute attacks incapacitating symptom lf read approach lf patients living disease home responsibility work communities preventing disease personal hygiene sanitation education corporate responsibility report personal hygiene sanitation education phase every year two million people die diarrhoearelated disease mostly children developing countries deaths often easily prevented better handwashing sanitation phase schoolbased programme helps reduce diarrhoearelated disease encouraging school children wash hands established phase since invested million million programme phase run partnership amref save children earth institute columbia university well ministries health education countries programme operates programme impressive results bangladesh example partnership save children introduced phase schools one countrys poorest areas helping improve lives young children families threeyear period programmes funding schools handwashing facilities increased per cent per cent leading increase hand washing soap schoolchildren per cent per cent latrines made available schools latrines constructed childrens homes resulting marked decrease open defecation per cent population per cent healthier children school attendance rates increased per cent per cent period july success phase nasirnagar bangladesh led decision expand programme include schools brahmanbaria district save children working health education ministers prepare scaleup committed funding three years extend programme slum areas mumbai india partner pratham phase operates countries reached children aim programme reach one million children next year supporting millennium development goals world leaders agreed millennium development goals mdgs meet needs worlds poorest people mdgs include targets halve extreme poverty hunger improve education health gender equality environmental sustainability introduced phase two millennium villages malawi senegal millennium villages research projects african communities designed find practical ways meet mdgs global handwashing day first global handwashing day held marked week activities encouraging millions children adults around world wash hands aim improving hygiene health phase partners arranged range activities promote handwashing reached around people read phase global handwashing day home responsibility work communities preventing disease personal hygiene sanitation education corporate responsibility report personal hygiene sanitation education phase every year two million people die diarrhoearelated disease mostly children developing countries deaths often easily prevented better handwashing sanitation phase schoolbased programme helps reduce diarrhoearelated disease encouraging school children wash hands established phase since invested million million programme phase run partnership amref save children earth institute columbia university well ministries health education countries programme operates programme impressive results bangladesh example partnership save children introduced phase schools one countrys poorest areas helping improve lives young children families threeyear period programmes funding schools handwashing facilities increased per cent per cent leading increase hand washing soap schoolchildren per cent per cent latrines made available schools latrines constructed childrens homes resulting marked decrease open defecation per cent population per cent healthier children school attendance rates increased per cent per cent period july success phase nasirnagar bangladesh led decision expand programme include schools brahmanbaria district save children working health education ministers prepare scaleup committed funding three years extend programme slum areas mumbai india partner pratham phase operates countries reached children aim programme reach one million children next year supporting millennium development goals world leaders agreed millennium development goals mdgs meet needs worlds poorest people mdgs include targets halve extreme poverty hunger improve education health gender equality environmental sustainability introduced phase two millennium villages malawi senegal millennium villages research projects african communities designed find practical ways meet mdgs global handwashing day first global handwashing day held marked week activities encouraging millions children adults around world wash hands aim improving hygiene health phase partners arranged range activities promote handwashing reached around people read phase global handwashing day home responsibility work communities preventing disease local programmes corporate responsibility report local programmes support wide range programmes help prevent disease communities operate fund programmes corporate local levels local programme examples australia helping aborigines tackle diabetes indigenous australians poorer heath life expectancy years less rest australian population due rapid increase socalled lifestyle diseases including type diabetes could wipe indigenous populations years gsk working unity first people australia far north western australia diabetes management care program programme aims arrest rising incidence diabetes aboriginal communities encouraging local people take responsibility communitys health health providers much without active support uk improving sexual health services disabled people donated three years leonard cheshire disability fund project give young disabled people better access sexual health services project addresses knowledge understanding gaps relating disabled peoples sexual health issues threeyear period organisation run focus groups workshops identify key issues develop range materials support sexual health workers deal disabled people uk promoting sport children consumer healthcare business support access sport organisation encourages young people uk keep fit participate sport access sport held three sports jam events bristol bath london children took part sporting activities provided funding employees volunteered time held fundraising events example employees raised money cycling lands end john ogroats future gsk staff also support access sport volunteering local sports clubs annual employee volunteering day preventing childhood obesity us us support zone health initiative helps schools strengthen policies programmes nutrition physical activity aims improve health children following successful pilot zone health expanded gsk announced support fitu programme washington dc area benefit young people three years home responsibility work communities preventing disease local programmes corporate responsibility report local programmes support wide range programmes help prevent disease communities operate fund programmes corporate local levels local programme examples australia helping aborigines tackle diabetes indigenous australians poorer heath life expectancy years less rest australian population due rapid increase socalled lifestyle diseases including type diabetes could wipe indigenous populations years gsk working unity first people australia far north western australia diabetes management care program programme aims arrest rising incidence diabetes aboriginal communities encouraging local people take responsibility communitys health health providers much without active support uk improving sexual health services disabled people donated three years leonard cheshire disability fund project give young disabled people better access sexual health services project addresses knowledge understanding gaps relating disabled peoples sexual health issues threeyear period organisation run focus groups workshops identify key issues develop range materials support sexual health workers deal disabled people uk promoting sport children consumer healthcare business support access sport organisation encourages young people uk keep fit participate sport access sport held three sports jam events bristol bath london children took part sporting activities provided funding employees volunteered time held fundraising events example employees raised money cycling lands end john ogroats future gsk staff also support access sport volunteering local sports clubs annual employee volunteering day preventing childhood obesity us us support zone health initiative helps schools strengthen policies programmes nutrition physical activity aims improve health children following successful pilot zone health expanded gsk announced support fitu programme washington dc area benefit young people three years home responsibility work communities building community capacity corporate responsibility report building community capacity lack healthcare infrastructure including clinics trained healthcare professionals cultural attitudes significant barriers treatment many developing countries global programmes positive action working communities affected hiv aids african malaria partnership improving prevention access malaria treatment support local initiatives help overcome stigma build capacity communities provide healthcare combat disease also provide humanitarian relief times emergency natural disasters home responsibility work communities building community capacity corporate responsibility report building community capacity lack healthcare infrastructure including clinics trained healthcare professionals cultural attitudes significant barriers treatment many developing countries global programmes positive action working communities affected hiv aids african malaria partnership improving prevention access malaria treatment support local initiatives help overcome stigma build capacity communities provide healthcare combat disease also provide humanitarian relief times emergency natural disasters home responsibility work communities building community capacity combating hivaids positive action corporate responsibility report combating hivaids positive action positive action works community organisations build capacity counter ignorance stigma surrounding hiv outreach education advocacy since established provided million funding projects countries across africa asia latin america eastern europe positive action gsk pioneered support vulnerable communities including men sex men intravenous drug users sex workers migrants young people orphans vulnerable children marginilised poor rural women groups limited human rights public voice thus excluded playing role developing mainstream programming essential work groups expect make difference epidemic supported positive action programmes countries key projects include fighting stigma discrimination mexico among vulnerable sectors population bringing hiv education vulnerable women india selfhelp groups helping communities asia understand prepare treatment programmes improving access treatment kenya promoting greater understanding involvement communities update august july announced creation new positive action children fund fund make million million available ten years help prevent mothertochild transmission hiv support orphans vulnerable children positive action programmes involve grass roots organisations able continue support communities projects come end year principal sponsor global village community space international aids conference held mexico city also hosted community forums allow delegates share experience fight hivaids read positive action home responsibility work communities building community capacity combating hivaids positive action corporate responsibility report combating hivaids positive action positive action works community organisations build capacity counter ignorance stigma surrounding hiv outreach education advocacy since established provided million funding projects countries across africa asia latin america eastern europe positive action gsk pioneered support vulnerable communities including men sex men intravenous drug users sex workers migrants young people orphans vulnerable children marginilised poor rural women groups limited human rights public voice thus excluded playing role developing mainstream programming essential work groups expect make difference epidemic supported positive action programmes countries key projects include fighting stigma discrimination mexico among vulnerable sectors population bringing hiv education vulnerable women india selfhelp groups helping communities asia understand prepare treatment programmes improving access treatment kenya promoting greater understanding involvement communities update august july announced creation new positive action children fund fund make million million available ten years help prevent mothertochild transmission hiv support orphans vulnerable children positive action programmes involve grass roots organisations able continue support communities projects come end year principal sponsor global village community space international aids conference held mexico city also hosted community forums allow delegates share experience fight hivaids read positive action home responsibility work communities building community capacity combating malaria africa malaria partnership corporate responsibility report combating malaria africa malaria partnership every year million people affected malaria one million die mostly young children africa disease prevented controlling breeding mosquitoes using low cost measures insecticidetreated nets malaria cured treated promptly effective medicines established african malaria partnership improve prevention access treatment malaria subsaharan africa since invested million initiatives combat disease final year threeyear grant support mobilising malaria advocacy initiative generate greater awareness political commitment sustained funding malaria europe africa national coalitions malaria launched uk belgium france ethiopia cameroon bringing together advocates activists public sector ngos media private sector political academic scientific communities part initiative award innovation grants civil society organisations africa boost advocacy efforts inspire african civil society organisations media become leaders fight malaria countries grants awarded civil organisations nigeria tanzania ghana mozambique democratic republic congo burkina faso supported journalist competition run guardian british newspaper raise awareness issues faced people malaria lf global web site attracted unique visitors winning stories published two dedicated supplements read malaria programmes home responsibility work communities building community capacity combating malaria africa malaria partnership corporate responsibility report combating malaria africa malaria partnership every year million people affected malaria one million die mostly young children africa disease prevented controlling breeding mosquitoes using low cost measures insecticidetreated nets malaria cured treated promptly effective medicines established african malaria partnership improve prevention access treatment malaria subsaharan africa since invested million initiatives combat disease final year threeyear grant support mobilising malaria advocacy initiative generate greater awareness political commitment sustained funding malaria europe africa national coalitions malaria launched uk belgium france ethiopia cameroon bringing together advocates activists public sector ngos media private sector political academic scientific communities part initiative award innovation grants civil society organisations africa boost advocacy efforts inspire african civil society organisations media become leaders fight malaria countries grants awarded civil organisations nigeria tanzania ghana mozambique democratic republic congo burkina faso supported journalist competition run guardian british newspaper raise awareness issues faced people malaria lf global web site attracted unique visitors winning stories published two dedicated supplements read malaria programmes home responsibility work communities building community capacity local programmes corporate responsibility report local programmes support wide range programmes build healthcare capacity communities operate fund programmes corporate local levels local programme examples training midwives vietnam support project train birth attendants bring maternal healthcare services rural villages vietnam project aims reduce childbirth complications decrease newborn fatality unacceptably high level per cent trainees housed residential training centre built gsk tu du hospital ho chi minh city supported hospital staff spend four months gaining practical knowledge maternal child healthcare first phase project midwives representing vietnams ethnic groups graduated governmentrecognised qualification midwives return villages equipped medical pack also provided motor scooter assist access remote areas phase two project launched involves hospital staff visiting villages provide additional training midwives provide basic pregnancy reproductive health education community members palliative care children romania last three years working partnership hospice casa sperentei romania beacon hope project improve level care available terminally ill children balkans huge progress achieved helping change attitudes towards dying patients region project received acclaim romanian government began partnership hospice view creating national plan palliative care key achievements include establishment childrens palliative care unit brasov mobile nursing team network care providers across region project developed regional centre excellence whole southeastern europe provides palliative care training health workers volunteers result childrens palliative care services set neighbouring moldova new fund childrens hospital philadelphia october announced million donation childrens hospital philadelphia help young people cancer us hospital runs one worlds largest paediatric cancer programmes contribution together matched donation hospital form glaxosmithkline hope families fund fund permanent endowment enable children young adults suffering relapsed hardtocure cancers access innovative therapies help cover travel accommodation costs patients families often must stay near hospital extended periods healthcare homeless pittsburgh gsk supports pittsburgh mercy foundations operation safety net street medicine outreach programme enables pittsburghs homeless access free healthcare programme includes mobile medical unit dropin clinic teams clinicians care workers walk streets offering medical examinations treatment homeless people rewarding community healthcare organisation uk year gsk impact awards recognise voluntary organisations significantly improved health local communities ten winning charities receive overall winner awarded extra uk impact awards programme introduced initiative managers winning organisations trained leadership networking fundraising skills help strengthen small charities often unable afford vital skills training gsk impact awards also run philadelphia us read gsk impact awards winning organisationshome responsibility work communities building community capacity local programmes corporate responsibility report local programmes support wide range programmes build healthcare capacity communities operate fund programmes corporate local levels local programme examples training midwives vietnam support project train birth attendants bring maternal healthcare services rural villages vietnam project aims reduce childbirth complications decrease newborn fatality unacceptably high level per cent trainees housed residential training centre built gsk tu du hospital ho chi minh city supported hospital staff spend four months gaining practical knowledge maternal child healthcare first phase project midwives representing vietnams ethnic groups graduated governmentrecognised qualification midwives return villages equipped medical pack also provided motor scooter assist access remote areas phase two project launched involves hospital staff visiting villages provide additional training midwives provide basic pregnancy reproductive health education community members palliative care children romania last three years working partnership hospice casa sperentei romania beacon hope project improve level care available terminally ill children balkans huge progress achieved helping change attitudes towards dying patients region project received acclaim romanian government began partnership hospice view creating national plan palliative care key achievements include establishment childrens palliative care unit brasov mobile nursing team network care providers across region project developed regional centre excellence whole southeastern europe provides palliative care training health workers volunteers result childrens palliative care services set neighbouring moldova new fund childrens hospital philadelphia october announced million donation childrens hospital philadelphia help young people cancer us hospital runs one worlds largest paediatric cancer programmes contribution together matched donation hospital form glaxosmithkline hope families fund fund permanent endowment enable children young adults suffering relapsed hardtocure cancers access innovative therapies help cover travel accommodation costs patients families often must stay near hospital extended periods healthcare homeless pittsburgh gsk supports pittsburgh mercy foundations operation safety net street medicine outreach programme enables pittsburghs homeless access free healthcare programme includes mobile medical unit dropin clinic teams clinicians care workers walk streets offering medical examinations treatment homeless people rewarding community healthcare organisation uk year gsk impact awards recognise voluntary organisations significantly improved health local communities ten winning charities receive overall winner awarded extra uk impact awards programme introduced initiative managers winning organisations trained leadership networking fundraising skills help strengthen small charities often unable afford vital skills training gsk impact awards also run philadelphia us read gsk impact awards winning organisations home responsibility work communities building community capacity local programmes corporate responsibility report local programmes support wide range programmes build healthcare capacity communities operate fund programmes corporate local levels local programme examples training midwives vietnam support project train birth attendants bring maternal healthcare services rural villages vietnam project aims reduce childbirth complications decrease newborn fatality unacceptably high level per cent trainees housed residential training centre built gsk tu du hospital ho chi minh city supported hospital staff spend four months gaining practical knowledge maternal child healthcare first phase project midwives representing vietnams ethnic groups graduated governmentrecognised qualification midwives return villages equipped medical pack also provided motor scooter assist access remote areas phase two project launched involves hospital staff visiting villages provide additional training midwives provide basic pregnancy reproductive health education community members palliative care children romania last three years working partnership hospice casa sperentei romania beacon hope project improve level care available terminally ill children balkans huge progress achieved helping change attitudes towards dying patients region project received acclaim romanian government began partnership hospice view creating national plan palliative care key achievements include establishment childrens palliative care unit brasov mobile nursing team network care providers across region project developed regional centre excellence whole southeastern europe provides palliative care training health workers volunteers result childrens palliative care services set neighbouring moldova new fund childrens hospital philadelphia october announced million donation childrens hospital philadelphia help young people cancer us hospital runs one worlds largest paediatric cancer programmes contribution together matched donation hospital form glaxosmithkline hope families fund fund permanent endowment enable children young adults suffering relapsed hardtocure cancers access innovative therapies help cover travel accommodation costs patients families often must stay near hospital extended periods healthcare homeless pittsburgh gsk supports pittsburgh mercy foundations operation safety net street medicine outreach programme enables pittsburghs homeless access free healthcare programme includes mobile medical unit dropin clinic teams clinicians care workers walk streets offering medical examinations treatment homeless people rewarding community healthcare organisation uk year gsk impact awards recognise voluntary organisations significantly improved health local communities ten winning charities receive overall winner awarded extra uk impact awards programme introduced initiative managers winning organisations trained leadership networking fundraising skills help strengthen small charities often unable afford vital skills training gsk impact awards also run philadelphia us read gsk impact awards winning organisations home responsibility work communities building community capacity responding disasters around world corporate responsibility report responding disasters around world gsk provides humanitarian assistance form cash product donations times emergency natural disasters part ongoing programme provided humanitarian relief many areas including china burma zimbabwe following cyclone burma worked americares one partners specialising rapid response delivery supply gskdonated medicines also made donation save children charity established presence burma contribution supported recovery efforts including provision shelter child protection food nutrition emergency health services children families earthquake hit sichuan province china may left dead million people displaced homeless gsk hong kongchina gave cash donation million yuan approximately million china red cross donated supplies basic medicines provided funds british red cross mass sanitation module provide emergency sanitation facilities hygiene education people times crisis helps avoid outbreaks disease deployed december zimbabwe help stem cholera outbreak continued support communities affected indian ocean tsunami caused huge damage coastal areas across south asia sri lanka helping establish mobile clinics increase access quality healthcare isolated communities affected tsunami conflict country mobile clinics set different locations providing reliable healthcare services areas clinics treated nearly patients total gave healthcare education messages patients people accompanying working leonard cheshire disability create inclusive barrierfree rightsbased society people disabilities affected tsunami galle sri lanka new resource centre established support people disabilities providing rehabilitation services mainstream education livelihood opportunities support longterm relief efforts affected areas chennai india providing nursing training young women poor villages well boosting healthcare services area training enables women support financially becoming nursing assistants women trained thailand helping boost economies six coastal villages local fishing industry destroyed tsunami raks thai foundation support initiatives provide business loans organise youth activities efforts improve local environment also gave funding help ngo francois xavier bagnoud fxb introduce concept model village lowcost sustainable communitybased programme successful helping families achieve self sufficiency back top home responsibility work communities building community capacity responding disasters around world corporate responsibility report responding disasters around world gsk provides humanitarian assistance form cash product donations times emergency natural disasters part ongoing programme provided humanitarian relief many areas including china burma zimbabwe following cyclone burma worked americares one partners specialising rapid response delivery supply gskdonated medicines also made donation save children charity established presence burma contribution supported recovery efforts including provision shelter child protection food nutrition emergency health services children families earthquake hit sichuan province china may left dead million people displaced homeless gsk hong kongchina gave cash donation million yuan approximately million china red cross donated supplies basic medicines provided funds british red cross mass sanitation module provide emergency sanitation facilities hygiene education people times crisis helps avoid outbreaks disease deployed december zimbabwe help stem cholera outbreak continued support communities affected indian ocean tsunami caused huge damage coastal areas across south asia sri lanka helping establish mobile clinics increase access quality healthcare isolated communities affected tsunami conflict country mobile clinics set different locations providing reliable healthcare services areas clinics treated nearly patients total gave healthcare education messages patients people accompanying working leonard cheshire disability create inclusive barrierfree rightsbased society people disabilities affected tsunami galle sri lanka new resource centre established support people disabilities providing rehabilitation services mainstream education livelihood opportunities support longterm relief efforts affected areas chennai india providing nursing training young women poor villages well boosting healthcare services area training enables women support financially becoming nursing assistants women trained thailand helping boost economies six coastal villages local fishing industry destroyed tsunami raks thai foundation support initiatives provide business loans organise youth activities efforts improve local environment also gave funding help ngo francois xavier bagnoud fxb introduce concept model village lowcost sustainable communitybased programme successful helping families achieve self sufficiency back top home responsibility work communities supporting science education corporate responsibility report supporting science education uk us numbers young people choosing science subjects falling many students lack proficiency either reading mathematics result countries face significant skills shortage success business relies us able recruit talented individuals particularly science qualifications also want young people make sound decisions sciencerelated issues meet everyday life education programmes help make science relevant young people uk us stimulating interest science supports training development science teachers uk project enthuse half secondary school science teachers uk subject training within past five years project enthuse launched improve continuing professional development science teachers provide latest techniques rekindle interest science teachers assistants technicians apply enthuse award help study national science learning centre university york award cover course fees cost covering teachers roles course travel accommodation teachers year schools also receive small amount money help implement ideas back classroom committed million initiative helping create million fund support uk government wellcome trust eight industry partners crest star investigators afterschool clubs help broaden interests experiences young people often focus sports arts rather science crest star investigators developed british association advancement science funded gsk aims redress balance engage year olds sciencebased activities ukwide programme offers activity packs schools organisations brownies cubs use afterschool clubs activities encourage children solve scientific problems exciting practical investigations pack contains activities three different difficulty levels children awarded certificate complete stage far almost packs distributed nearly schools aim schools children taking part us institute competitive workforce icw building gsks leadership state local levels related reform improvement public schools gsk led effort create icw national level result national movement businesseducation partnerships focused improved academic achievement public school system order help ensure qualified workforce american businesses future science summer support science summer free education programme designed get young people pittsburgh pennsylvania greater philadelphia north carolina interested science classes held local libraries give children chance take part handson experiments take courses ranging genetics oceanography programme began gsk invested across sites children participated programme north carolina new schools project gsk partners north carolina new schools project initiative aims transform teaching learning high school students graduate ready college workplace gsk helping fund development science technology programmes ten north carolinas lowperforming high schools initiative aims improve schools test results graduation rates gsk also funds review state curricula benefits shared widelyhome responsibility work communities supporting science education corporate responsibility report supporting science education uk us numbers young people choosing science subjects falling many students lack proficiency either reading mathematics result countries face significant skills shortage success business relies us able recruit talented individuals particularly science qualifications also want young people make sound decisions sciencerelated issues meet everyday life education programmes help make science relevant young people uk us stimulating interest science supports training development science teachers uk project enthuse half secondary school science teachers uk subject training within past five years project enthuse launched improve continuing professional development science teachers provide latest techniques rekindle interest science teachers assistants technicians apply enthuse award help study national science learning centre university york award cover course fees cost covering teachers roles course travel accommodation teachers year schools also receive small amount money help implement ideas back classroom committed million initiative helping create million fund support uk government wellcome trust eight industry partners crest star investigators afterschool clubs help broaden interests experiences young people often focus sports arts rather science crest star investigators developed british association advancement science funded gsk aims redress balance engage year olds sciencebased activities ukwide programme offers activity packs schools organisations brownies cubs use afterschool clubs activities encourage children solve scientific problems exciting practical investigations pack contains activities three different difficulty levels children awarded certificate complete stage far almost packs distributed nearly schools aim schools children taking part us institute competitive workforce icw building gsks leadership state local levels related reform improvement public schools gsk led effort create icw national level result national movement businesseducation partnerships focused improved academic achievement public school system order help ensure qualified workforce american businesses future science summer support science summer free education programme designed get young people pittsburgh pennsylvania greater philadelphia north carolina interested science classes held local libraries give children chance take part handson experiments take courses ranging genetics oceanography programme began gsk invested across sites children participated programme north carolina new schools project gsk partners north carolina new schools project initiative aims transform teaching learning high school students graduate ready college workplace gsk helping fund development science technology programmes ten north carolinas lowperforming high schools initiative aims improve schools test results graduation rates gsk also funds review state curricula benefits shared widely home responsibility work communities supporting science education corporate responsibility report supporting science education uk us numbers young people choosing science subjects falling many students lack proficiency either reading mathematics result countries face significant skills shortage success business relies us able recruit talented individuals particularly science qualifications also want young people make sound decisions sciencerelated issues meet everyday life education programmes help make science relevant young people uk us stimulating interest science supports training development science teachers uk project enthuse half secondary school science teachers uk subject training within past five years project enthuse launched improve continuing professional development science teachers provide latest techniques rekindle interest science teachers assistants technicians apply enthuse award help study national science learning centre university york award cover course fees cost covering teachers roles course travel accommodation teachers year schools also receive small amount money help implement ideas back classroom committed million initiative helping create million fund support uk government wellcome trust eight industry partners crest star investigators afterschool clubs help broaden interests experiences young people often focus sports arts rather science crest star investigators developed british association advancement science funded gsk aims redress balance engage year olds sciencebased activities ukwide programme offers activity packs schools organisations brownies cubs use afterschool clubs activities encourage children solve scientific problems exciting practical investigations pack contains activities three different difficulty levels children awarded certificate complete stage far almost packs distributed nearly schools aim schools children taking part us institute competitive workforce icw building gsks leadership state local levels related reform improvement public schools gsk led effort create icw national level result national movement businesseducation partnerships focused improved academic achievement public school system order help ensure qualified workforce american businesses future science summer support science summer free education programme designed get young people pittsburgh pennsylvania greater philadelphia north carolina interested science classes held local libraries give children chance take part handson experiments take courses ranging genetics oceanography programme began gsk invested across sites children participated programme north carolina new schools project gsk partners north carolina new schools project initiative aims transform teaching learning high school students graduate ready college workplace gsk helping fund development science technology programmes ten north carolinas lowperforming high schools initiative aims improve schools test results graduation rates gsk also funds review state curricula benefits shared widely home responsibility work communities plans corporate responsibility report plans volunteering expand volunteering programme every gsk employee spend least one day year helping community employees select local organisations support undertake variety work ranging manual jobs fundraising include supporting employees wish visit schools encourage science education also launching international assignment programme enable select number employees use professional skills support nonprofit partners extended periods positive action agreed extend three larger hiv programmes zingatia maisha kenya vida digna mexico reach india additional year ensure sustainability working ubuntu education fund south africa expand programme called living positively programme work men older boys port elizabeth township challenge gender roles exacerbate hiv infection exclude men hiv services working aids action europe provide networking hivaids ngos across eastern europe central asia improved hiv policy advocacy programming support facing hiv crisis working american foundation aids research amfar expand initiative provide prevention care support services men sex men asia pacific also work aids patient groups philippines increase members understanding health issues phase partner pratham implementing phase programme slum areas mumbai india also extend phase new districts uganda advocate incorporation phase national policy enabling sustainability replication project nationwide lf increasing manufacturing capacity albendazole tablets million tablets per year enable us increase fourfold number tablets donated us continuing provide leadership support childrens health fund chf referral management initiative increase access specialist healthcare homeless uninsured american families also supporting pilot telemedicine project help patients access specialist care chfs new memphis regional childrens health project serve pilot site link approximately rural patients specialists memphis hospital using stateoftheart videoconferencing technology europe emerging markets asia pacific regions several new programmes implemented example greece helping introduce concept homebased nursing services children living cancer netherlands supporting national programme promote healthy behaviours among young people helping make informed decisions eat encourage regular physical activity also seek new partnerships improve community healthcare social venture anpda ge enterprise projects preparing funding stops programmes run number years recognising takes time build change start plan happen end funding work hard community organisations bring results life project usually around three years help organisations win funding sources continue work start require partners work budget make sure funding spent effectively produces right results also ask partners demonstrate achievements producing annual progress report reports show evidence success crucial part attracting new donorshome responsibility work communities plans corporate responsibility report plans volunteering expand volunteering programme every gsk employee spend least one day year helping community employees select local organisations support undertake variety work ranging manual jobs fundraising include supporting employees wish visit schools encourage science education also launching international assignment programme enable select number employees use professional skills support nonprofit partners extended periods positive action agreed extend three larger hiv programmes zingatia maisha kenya vida digna mexico reach india additional year ensure sustainability working ubuntu education fund south africa expand programme called living positively programme work men older boys port elizabeth township challenge gender roles exacerbate hiv infection exclude men hiv services working aids action europe provide networking hivaids ngos across eastern europe central asia improved hiv policy advocacy programming support facing hiv crisis working american foundation aids research amfar expand initiative provide prevention care support services men sex men asia pacific also work aids patient groups philippines increase members understanding health issues phase partner pratham implementing phase programme slum areas mumbai india also extend phase new districts uganda advocate incorporation phase national policy enabling sustainability replication project nationwide lf increasing manufacturing capacity albendazole tablets million tablets per year enable us increase fourfold number tablets donated us continuing provide leadership support childrens health fund chf referral management initiative increase access specialist healthcare homeless uninsured american families also supporting pilot telemedicine project help patients access specialist care chfs new memphis regional childrens health project serve pilot site link approximately rural patients specialists memphis hospital using stateoftheart videoconferencing technology europe emerging markets asia pacific regions several new programmes implemented example greece helping introduce concept homebased nursing services children living cancer netherlands supporting national programme promote healthy behaviours among young people helping make informed decisions eat encourage regular physical activity also seek new partnerships improve community healthcare social venture enterprise projects preparing funding stops programmes run number years recognising takes time build change start plan happen end funding work hard community organisations bring results life project usually around three years help organisations win funding sources continue work start require partners work budget make sure funding spent effectively produces right results also ask partners demonstrate achievements producing annual progress report reports show evidence success crucial part attracting new donors